

From: (b)(6); (b)(7)(C)
Sent: 27 Jul 2018 14:14:27 +0000
To: (b)(6); (b)(7)(C)
Subject: FW: ALMAZAN
Attachments: ALMAZAN DDR Medical Narrative - Glades County Detention Center.docx, ALMAZAN DDR Medical Narrative - Krome North Service Processing Center.docx, ALMAZAN DDR Medical Narrative Polk County Adult Detention Center.docx

FYI

From: (b)(6); (b)(7)(C)
Sent: Wednesday, July 25, 2018 4:50 PM
To: (b)(6); (b)(7)(C)
Subject: ALMAZAN

(b)(6);
(b)(7)(C)

(b)(6);
(b)(7)(C) didn't do timelines but instead, did three separate narratives. Here they are. Please give me a call when you have a chance.

(b)(6); (b)(7)(C)

Detainee Death Review: ALMAZAN-Ruiz, Felipe A028866428
Medical Compliance Analysis
Glades County Detention Center
Moore Haven, Florida

Medical Staffing

Armor Correctional Health Services (ACHS), with headquarters in Miami, Florida has provided 24-hour medical care since the facility's activation in June 2007. GCDC earned their most recent accreditation through the National Commission on Correctional Healthcare (NCCHC) in May 2017, and at the current time, eight medical employees have earned status as Certified Correctional Health Professionals (CCHP)¹. Full time positions include the Director of Nurses (DON), a licensed clinical social worker, the Administrative Assistant, and the Health Services Administrator (HSA), the latter of whom is not a clinician but has a health services administration background. Three part time registered nurses (RN) provide a total of 56 hours per week, and 13 part time licensed practical nurses (LPN) provide 460 hours per week. Other part time positions include a mental health physician assistant, two licensed mental health professionals, a dentist, and a dental assistant. The Clinical Director, a CCHP is licensed in Puerto Rico and Florida, with certification to work in critical need areas. He is available on site for clinical services four days per week. Staffing numbers were found to be sufficient for the provision of detainee healthcare, in accordance with the NDS, and all professional licenses were present, current and primary source verified.

Summary of Events

On Saturday, **August 12, 2017**, at 3:15 a.m. [REDACTED] LPN documented the medical intake screening, noting there were no barriers to communication, and responding "Yes" to ALMAZAN's ability to "Understand English". During interview she denied her personal ability to speak Spanish and when questioned about the level of ALMAZAN's English proficiency, she replied, "If I did the intake, he spoke English. We would use Interpretalk (*Language Service*) otherwise." When questioned about the frequency of Interpretalk use over a week period, she estimated, "maybe once or twice." Regarding Creative Correction's observation that all consent and agreement forms were in English, LPN [REDACTED] stated she was unaware of Spanish version forms. During interview [REDACTED], HSA stated Spanish forms are available for sick call requests and medical consents and agreed the Spanish versions should have been used for ALMAZAN. The intake screening documentation did not mention review of the medical summary sent by the Krome North Service Processing Center (KNSPC), with resulting failure to

¹ A CCHP is a medical person who has demonstrated, through NCCHC testing, the possession, application, and interpretation of knowledge necessary for professional practice in correctional health care.

list current diagnoses and treatment. Vitals signs were recorded within normal limits (*See Appendix I for vital signs table*). The health questionnaire included a subjective history of liver cirrhosis², vision problems, and depression. He admitted to having tried or seriously considered killing or hurting himself, “Six times, about three years ago”, but he denied current suicidal thinking. A chest x-ray was scheduled for tuberculosis³ clearance, although there is no report evidencing this was done. He was noted, however, to have had a normal chest x-ray on July 12, 2017, while at KNSPC, having remained in continual ICE custody. He was assigned to chronic care clinic, referred to a provider on an urgent basis, and cleared for general population. The intake screen was electronically approved by (b)(6); (b)(7)(C) RN, DON on August 15, 2017.

Two days later on Monday, **August 14, 2017**, at 10:26 a.m. (b)(6); (b)(7)(C) conducted the intake mental health screening, noting ALMAZAN’s diagnoses of liver cirrhosis, depression, and anxiety. He reported a history of alcohol dependence, having last used three months ago when he was arrested. He stated he had been prescribed trazadone⁴ for the past three months while incarcerated in Metro West, Dade County. He was described as cooperative, with a calm demeanor, while presenting sadness and mild anxiety. He denied audiovisual hallucinations⁵, delusions⁶, and suicidal and homicidal ideations but reported bouts of depression and crying over the past three months. He attributed his sadness and anxiety to stress of his current situation, and having been divorced five years ago due to his alcohol problem. He reported his drinking worsened until he was incarcerated, having since suffered guilt, sadness and loss, using prayer and faith to manage his feelings. He admitted having, “tried to commit suicide many times by drinking excessively,” but denied current intention, ideation, or plan. His mental health status was described as alert, appropriate in behavior, cooperative, fully oriented, neat, well-groomed, and appearing older than his stated age. His affect was good, and judgment was fair. He reported both sleep and appetite were within normal limits. The past medical history section of the assessment noted the only hospitalization was related to liver cirrhosis. His medications accurately reflected the pill line medications listed on the Krome medical summary, as listed:

Medication	Purpose
Clotrimazole 1%	Antifungal cream for athlete’s foot
Ducosate Sodium 100 mg	Stool softener used to treat constipation
Folic Acid 1 mg	B vitamin used to enhance red blood cell production
Hydrocortisone 1%	Steroid used to treat skin conditions
Lactulose 10 GM/15 ml solution	Type of sugar solution used to treat chronic constipation

² Liver cirrhosis is a chronic liver disease in which liver cells become inflamed and begin dying, causing scar tissue to form. Alcohol abuse is a common cause of cirrhosis.

³ Tuberculosis is a serious bacterial infection which mostly affects the lungs.

⁴ Trazadone is a sedative medication which can treat depression.

⁵ Hallucinations are perceptions of having seen, heard, touched, tasked or smelled something that was not actually there, commonly a symptom of mental illness.

⁶ Delusions are beliefs or altered reality persistently held despite evidence or agreement to the contrary, commonly a symptom of mental illness.

	and to reduce the amount of ammonia in the blood of patients with liver disease.
Maalox 30 cc	Antacid which neutralizes stomach acidity
Multivitamin	Nutritional supplement
Omeprazole 20 mg	Treatment of heartburn and esophageal reflux disease (GERD) ⁷
Proctosol 2.5%	Treatment of itching or swelling caused by hemorrhoids
Sertraline Hcl 100 mg	Treatment for depression and anxiety
Spironolactone 25 mg	Treatment for high blood pressure and fluid retention.
Trazodone 50 mg	Treatment for depression and sleep difficulty
Triamcinolone Acetonide 0.1%	Treatment for psoriasis
Rifaximin 550 mg	Treatment for irritable bowel syndrome with diarrhea

The mental health assessment findings were listed as depression, generalized anxiety disorder, and alcohol dependence, in remission. The plan was, “Appointment electronically created for patient to see psychiatrist as soon as possible.” He was deemed eligible for program participation and job placement and was assigned to general population without segregation.

On the same day, at 10:27 a.m. (b)(6); (b)(7)(C) MD conducted the initial chronic care clinic for cirrhosis, stating during interview he communicated with ALMAZAN in Spanish and was unaware of the detainee’s English proficiency. He documented, “51 year old male with history of liver cirrhosis, GERD, possible portal hypertension⁸, constipation here today for initial clinical evaluation, the patient diagnosed seven years ago and he’s been on treatment since then.” ALMAZAN’s personal risk factors were identified as smoking, “two per day”, and “a lot” of alcohol. He denied past surgeries or hospitalizations. He was described as appearing well, in no acute distress, obese, well developed, and well nourished. He complained of external hemorrhoids⁹, dry itchy skin and eyes, and headaches. He denied chest pain, abdominal pain, and nausea and vomiting. The review of systems revealed no abnormal findings, and the vital signs were all within normal limits. The abdominal assessment was described as, “Positive bowel sounds, non-tender, no hepatosplenomegaly¹⁰, no masses¹¹.” The assessment listing included 1) liver cirrhosis/fatty liver; 2) GERD; 3) possible portal hypertension; 4) IBS¹², and 5) eczema¹³. There was no reference to pancytopenia¹⁴, as was noted in the last chronic care clinic

⁷ GERD is short for gastroesophageal reflux disease, also known as acid reflux, is a digestive disease in which stomach acid or bile irritates the food pipe lining (esophagus).

⁸ Portal hypertension refers to high blood pressure in the system of veins coming from the stomach, intestine, spleen, and pancreas which merge into the portal area before traveling through the liver.

⁹ Hemorrhoids are swollen and inflamed veins in the rectum and anus which can cause discomfort and bleeding.

¹⁰ Hepatosplenomegaly refers to abnormal enlargement of the liver and spleen.

¹¹ Masses are any localized enlargement or swelling in the human body.

¹² IBS, short for irritable bowel syndrome is an intestinal disorder causing pain in the belly, gas, diarrhea, and constipation.

¹³ Eczema is a condition in which the skin becomes inflamed and itchy.

at the Krome North SPC (KNSPC). When questioned about his suspicion of portal hypertension in the absence of KNSPC's previous diagnoses, he explained that once he was aware of the cirrhosis diagnosis he considered all possible outcomes and conducted laboratory testing to rule it out. He further stated there were no varices¹⁵ or spider webbing¹⁶ noted during the abdominal assessment. The plan included 1) Triamcinolone Acetonide 0.1% cream twice daily for 60 days; 2) PT¹⁷, PTT¹⁸, INR¹⁹, psa²⁰, cmp²¹, cbc²², lipid panel²³, h pylori test²⁴, ammonia level²⁵ tomorrow; 3) follow-up Thursday with lab results; 4) increase fluid intake; 5) continue with all other meds for 30 days; 6) please renew when finishing; 7) follow-up in 90 days; 8) Proctosol 2.5% topical cream twice daily for 30 days. During interview (b)(6); (b)(7)(C) explained that a nurse works directly with him to ensure his orders are carried out.

According to the laboratory report, the blood collection took place on August 17, 2017, with receipt in the lab and complete report forwarded on the following day, August 18, 2017. (b)(6) (b)(6); viewed the laboratory results, electronically noted as "Observation Report Date", on the same day as receipt. Questioned during interview, he stated that although the results were concerning, he knew ALMAZAN was scheduled for his follow-up clinic in two weeks, and because the PT and PTT were only slightly elevated, he felt comfortable waiting until the next appointment to address the seriously low platelet count²⁶ of 41. He further offered his opinion that he places urgency on levels lower than 30, at which time he transfers the patient to the hospital for treatment. On questioning whether he was aware of the pancytopenia condition previously diagnosed at KNSPC, he, along with (b)(6);, Regional Vice President of ACHS, expressed surprise and disbelief, voicing they had not been aware of the diagnosis, nor the

¹⁴ Pancytopenia is a medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets.

¹⁵ Varices are abnormal veins in the lower part of the tube running from the throat to the stomach.

¹⁶ Spider webbing, otherwise known as Spider angiomas, refers to surfaced veins, which have a local spot and radiating vessels to appear web-like, commonly caused by advanced liver disease.

¹⁷ PT is short for prothrombin test, a blood test to determine how quickly the blood clots.

¹⁸ PTT is short for partial thromboplastin time, a blood test which measures the time it takes for blood to clot.

¹⁹ INR is short for international normalized ration, a blood test which evaluates blood clotting.

²⁰ PSA is short for prostate specific antigen, a substance produced by the prostate gland, which is measure to determine prostate disease.

²¹ CMP is short for comprehensive metabolic panel which tests blood glucose level, electrolytes levels, kidney function, liver function, and nutritional problems.

²² CBC is short for complete blood count, which tests levels of all types of blood cells to determine presence of disease.

²³ Lipid panel is a series of lab tests, which determine levels of fats and cholesterol in the blood.

²⁴ H-pylori test is short for helicobacter pylori, bacteria that causes infection in the stomach, such as ulcers.

²⁵ An ammonia level test determines the amount of ammonia produced by bacteria in the intestines. Ammonia is normally converted by the liver, producing urea which is eliminated in the urine. With liver disease, ammonia levels can rise due to the inability for the liver to convert it.

²⁶ A platelet count is the number of clot-producing cells in the blood.

significantly low platelet count of 37. Regarding his treatment plan, [REDACTED] stated he believed he did the right thing in trying to excrete the excess ammonia in ALMAZAN's system. He further offered if he had been the physician at KNSPC and had known ICE was going to move him with his current medical condition, he would not have approved the transfer. When asked if a two to three hour flight transfer would have been appropriate considering the current medical condition, he stated, "I might say no", basing his statement on the fact that because it is not known why the platelets are so low, the detainee might have an embolism.

Detainee ALMAZAN submitted an initial sick call request for vision problems, dated **August 16, 2017**, writing, "I Need See The Doctor be Cause He Tool mi I have 2 Apoimenes, Monday and Tuesday I ron't Recib Notin in My Dormitory Please Because I ron't See Noting and He Told my y Need Test for My Ayees PLEASE The Doctor is [REDACTED] Please Help Mv I conT Read Noting Please Help My" (See Appendix II for sick call table). [REDACTED] LPN documented receipt of the sick call request at 9:00 p.m. on August 17, 2017, referring him to nurse sick call. [REDACTED] LPN documented a sick call encounter, using "Nursing Protocol – Eyes, Ears, Nose, Teeth, and Throat." The date of **August 18, 2017**, was stamped at the top of the first page; however the note was not signed off until October 15, 2017, suggesting the note could have been written or altered at any time during that time. There was no reference to barriers of communication, language preference, or use of interpretation assistance. Vital signs were all recorded within normal limits, and his vision test showed 20/20 in the right eye and 20/200 in the left eye. Of note, the eye examination conducted by KNSPC on July 19, 2017, showed 20/100 in the left eye and 20/200 in the right eye, and the vision testing done during this physical assessment on August 24, 2017, showed 20/200 in both eyes, suggesting the 20/20 recording was erroneous. The nursing assessment diagnosis was disturbed sensory perception: rule out visual disturbance, and the plan, based on "not acute" vision disturbance was to allow ALMAZAN to obtain his glasses from home and to use proper lighting. Documentation failed to show inquiry into the current location of his glasses or what his home situation was. As was documented in the August 22, 2017, provider assessment, he had his glasses while at Krome and believed they were in his property. Consequently, LPN [REDACTED] failed to adequately address his complaint, which remained unresolved. Creative Correction notes that the provided medical record did not include a copy of this sick call encounter; but rather, it was provided just prior to the review close-out. Consequently, LPN [REDACTED] was not interviewed.

A second Inmate/Detainee Request was dated **August 20, 2017**, in which ALMAZAN wrote, "DR – I need You Help Because My Medicates AHORA NO SEE MEDICIN I TAKE EVRY DA [REDACTED] I fillin My EYES DRY. PLEASE I need My GLASES Please When I go To Court They Give to mi but I canT SEE NOTHING My EYES I filling Burning and MY HEAD I HAVE PAIN So I need My GLASES Please [REDACTED]. The sick call response was left blank, but the request was signed as received by LPN [REDACTED] on **August 21, 2017**. During interview [REDACTED] reviewed the medical record and verified a sick call encounter was not present, stating that he was not seen in nursing sick call because he had a pending appointment with the provider for this evaluation.

(b)(6); (b)(7)(C)

Advanced Registered Nurse Practitioner (ARNP) conducted a provider assessment on **August 22, 2017**, at 3:17 p.m. to address ALMAZAN's complaints of, "I am having a lot of pain in my joints. I cannot see, either. I had glasses at Krome but they say they are not in my property here. My vision is very bad. The medication is helping some, but I still can only sleep two to three hours." There is no documentation of barriers to communication, language preference, or use of interpretation assistance. NP (b)(6); (b)(7)(C) documented his extensive history of alcohol dependence, and noted he was currently taking Zoloft and trazodone with some benefit. He was described as cooperative with a congruent affect²⁷, logical thought process, anxious mood, and a restless and fidgety manner. There is no objective assessment, including vital signs. The treatment plan was to continue Zoloft 100 mg daily and increase trazodone to 75 mg nightly to improve his insomnia. A Specific Authorization for Psychotropic Medications form was signed by ALMAZAN, but the specific medication was not indicated with a check mark. The treatment plan did not address the complaint of vision difficulty. He was electronically scheduled for follow-up in 60 days. As NP (b)(6); (b)(7)(C) no longer works for GCDC, an interview could not be conducted to clarify if the encounter was intended to serve only as a mental health follow-up, as opposed to a sick call assessment.

The initial health assessment was conducted by (b)(6); (b)(7)(C) RN on **August 24, 2017**, at 2:33 p.m., with review and approved electronic signature of (b)(6); (b)(7)(C) on September 5, 2017. A review of the training and credentials file showed RN (b)(6); (b)(7)(C) as trained for conducting initial medical and dental assessments on January 12, 2016 and on August 22, 2017. Detainee ALMAZAN identified current complaints as right knee pain and vision difficulty. He denied blood in his sputum, blood in his stools, or black tarry stools²⁸. His vital signs and physical assessment were all within normal limits, including the abdomen, which was described as having normal bowel sounds and no masses or tenderness. Tremors were not observed, and his gait and coordination were normal. Examination of his skin showed no rashes, lesions²⁹ or infestations³⁰. ALMAZAN's visual acuity using the Snellen Eye Chart measured 20/200 in the right eye, 20/200 in the left eye, and 20/200 in both eyes, without correction, for which he was referred to the doctor for visual disturbance. The dental screening found no missing teeth and "four upper implants per patient."

A third sick call request was submitted on **August 27, 2017**, in which ALMAZAN wrote, "I NEED SEE THE DOCTOR BECAUSE I have To Much Pain in My Bond's I Want Somthin XXXike Bengay is Hard THE PA A and I want A see The doctor THE LAST Went I see HE PuT in THE Sistem For Examen in My Eyes I Need glases PLE! I can'T Read NoThing I need Realy The Glases". The Triage Decision By Nursing Staff noted referral to nurse sick call and was signed two days later on **August 29, 2017**, at 9:00 p.m. by (b)(6); (b)(7)(C) PN

²⁷ Congruent affect means a person's emotions are appropriate for the situation.

²⁸ Black tarry stools can indicate bleeding in the upper portion of the digestive tract.

²⁹ Lesions are regions of an organ or tissue which have suffered damage through injury or disease, such as a wound, ulcer or tumor.

³⁰ Infestations refer to a state of being invaded or overrun with pests or parasites.

(b)(6); (b)(7)(C) LPN, CCHP conducted a sick call assessment on **August 30, 2017**, at 2:24 p.m. to address ALMAZAN's complaint of pain in both shoulders and both knees. The pain was described as moderate, constant and worsening. A pain scale was not used to determine pain level. Vital signs were all recorded within normal limits. The general examination noted an uncomfortable appearance with tenderness on palpation. There was no swelling or gait abnormality. The nursing assessment was Alteration in Comfort in joints. The plan was to provide ibuprofen 400 mg twice daily for five days as needed in accordance with the Nursing Protocol on Muscular Skeletal problems. LPN (b)(6); (b)(7)(C) noted, "NO history of bleeding ulcers." He was provided patient education and instructed to return to sick call if symptoms worsen or persist more than seven days. Documentation fails to address ALMAZAN's complaint of vision difficulty was addressed. During interview, LPN (b)(6); (b)(7)(C) who triaged this sick call request, offered that nurses allow only one complaint per sick call request and that the detainees are expected to submit an individual request for each complaint they have, with the sick call nurse prioritizing the issues. HSA (b)(6); (b)(7)(C) and VP (b)(6); (b)(7)(C) both agreed during interview that the two issues absolutely should have been addressed in a single visit. RN (b)(6); (b)(7)(C) electronically approved the sick call assessment on August 31, 2017.

On September 1, 2017, ALMAZAN completed a fourth sick call request, stating, "I Need See The Doctor The Name of (b)(6); (b)(7)(C). I wan'T To Se because I ned Glases THE Nurse OnLY No GIME Apoimen For OpticoI I have Pain in MvV Head and My EYES in My EYES I fell likefire and The People I see Strange (b)(6); (b)(7)(C) Nothing Please I need See THE DOCTOR For My ApoinmenT an Medicinefo EYES LiKe Vicine SO<Thin DROPS for My Eyes THANK YOU". (b)(6); (b)(7)(C) LPN documented receipt of the request the same day at 0:00 n.m. and referred him to nurse sick call. On **September 2, 2017**, at 4:56 p.m. (b)(6); (b)(7)(C)

(b)(6); (b)(7)(C) LPN conducted a sick call assessment to address ALMAZAN's complaint of having difficulty seeing, as things look blurry. He stated he had an appointment scheduled with an optometrist prior to entering the facility. Vital signs were all recorded within normal limits and his vision remained at 20/200 in both eyes. The assessment was disturbed sensory perception: Rule out visual disturbance. The plan included a "Routine referral to (b)(6); (b)(7)(C) within five days secondary to patient having difficulty seeing, may need glasses. Made same complaint during initial health assessment." The note was electronically approved by (b)(6); (b)(7)(C) on September 5, 2017.

Four days later on Wednesday, **September 6, 2017**, at 9:48 a.m. (b)(6); (b)(7)(C) initiated a sick call visit for complaints of visual disturbance, along with a thirty-day chronic care evaluation. Forty-six laboratory results, completed on August 18, 2017, were addressed, along with additional results provided the following day. Only the abnormal levels are included below, with comparisons of those that had also been done at Krome:

Test	Krome Result	Glades Result	Normal Limits
Bilirubin ³¹	1.6	1.7	0.0-1.2

Alkaline Phosphatase ³²	157	162	20-130
Hemoglobin ³³	10.5	11.3	13-18
Red Blood Cells ³⁴	3.28	3.65	4.5-5.9
Hematocrit ³⁵	29.3	34	40-52
White Blood Cells ³⁶	2.0	3.0	3.6-11
Platelets	37	41	150-400
Lymphocytes ³⁷	0.4	0.7	1.1-4.7
Ammonia		108	11-35
Activated PTT		41.6	50-89

ALMAZAN's general appearance and physical assessment findings were all within normal limits, with exception of the abdominal assessment, which described pain in the mid-epigastric area radiating to the chest. Bowel sounds were normal, and there was no tenderness, masses, or hepatosplenomegaly on palpation. The plan was written as follows:

1—I will increase lactulose doses and will continue with the current meds. CBC weekly the follow-up ++see below prednisone 100 mg X3 days then 0 mg x 3 days then 60 mg po x 3 days then 50 mg x 3 days the 40 mg x 3 days then 30 mg x 3 days then 20 mg x 3 days the 10 mg x 2 days then 5 mg x 2 days the 2.5 mg x 2 days then d/c.

2—FERROUS SULFATE, 325 mg #90, Sig: 1 time per day for 90 days

3—+++++cbc weekly x 4 weeks+++++

4—d/c dulcolax

5—lactulose 40 ml po daily x 90 days

6—FOLIC ACID, 1 MG #90, Sig: Take 1 Tablet by mouth 1 time per day for 90 days

7—MULTIVITAMIN, #90, Sig: Take 1 Tablet by mouth 1 time per day for 90 days

8—SPIRONOLACTONE, 25 MG #180, Sig: Take 1 Tablet by mouth 2 times per day for 90 days.

9—Xifaxan 550 mg po bid x 90 days

10—Patient c/o visual disturbance

11—OS 20/200 OD 20/200

12—ammonia level Q2 WEEK X 8 WEEKS

13—Renal diet x 180 days

14—cbc cmp lipid panel in 82 days

³¹ Bilirubin is an orange, yellow pigment produced by the liver.

³² Alkaline phosphatase is an enzyme found throughout the body, which can be elevated in liver disease.

³³ Hemoglobin is the protein molecule in the red blood cells that carries oxygen from the lungs to the body's tissues and returns carbon dioxide from the body back to the lungs.

³⁴ Red blood cells are the blood cells that contain hemoglobin and carry oxygen.

³⁵ Hematocrit is a volume percentage of red blood cells in the blood, usually at 47% in men.

³⁶ White blood cells are the cells involved in protecting the body against infection.

³⁷ Lymphocytes are a form of white blood cells that produce antibodies to fight infection.

14==follow==up in 90 days

15==OMEPRAZOLE 40 MG #90, Sig: Take 1 Capsule by mouth 1 time per day for 90 days.”

(b)(6); (b)(7)(C)


signed off his note at 10:23 a.m. on the same day. Creative Corrections notes there was no referral to the optometrist for ALMAZAN’s serious vision impairment. Without eyeglasses his ability to read written instructions, consents, or patient education was seriously declined. His frustration was clearly expressed in his sick call requests. Following is documentation of sick call requests and complaints during clinical encounters.

Date and Mode of Request	Date of Encounter Who Conducted	Treatment Plan	Completed
August 16, 2017 Sick Call Request	August 18, 2017 LPN	Approved to have glasses from home sent in.	No, as his glasses were not at his home
August 20, 2017 Sick Call Request	No sick call scheduled	None, as triage nurse believed detainee was scheduled for MD	No, as a provider failed to address the complaint.
August 22, 2017 Complained during encounter.	August 22, 2017 ARNP	None. Complaint was not addressed.	NA
August 24, 2017 during initial physical assessment.	August 24, 2017 RN	Referred to MD	No
August 27, 2017 Sick call	August 30, 2017 LPN	None, as only one of two complaints were addressed.	N/A
September 1, 2017 Chronic Care	September 1, 2017 MD	None, as not addressed in plan	N/A

The ACHS Medical policy J-E-07 Non-emergency Health Care Requests and Services, mirroring the NCCHC Standard of the same number and title, instructs that any patient who has been seen in sick call more than twice in 30 days for the same complaint, but who has not yet been seen by a practitioner will be scheduled for the clinician’s clinic. Although the sick call nurses’ dispositions were followed by provider assessments, the focus was limited to chronic care and mental health issues, leaving the vision problem unaddressed. A review of the commissary showed reading glasses were available for purchase, but with a maximum of \$10.00 in his account at any given time, he would not have been able to pay the cost of \$11.55. There is no indication that any attempts were made to obtain reading glasses for him, although according to HS (b)(6); (b)(7)(C), an optometry appointment was pending but not completed because of his transfer.

According to custody logs, ALMAZAN was transferred to Polk County Texas in emergency response to hurricane Irma on September 7, 2017. The Transfer Summary, documented by RN (b)(6); (b)(7)(C) the same day as his departure, medically cleared him for travel. The listed diagnoses included only cirrhosis of the liver without alcohol, generalized anxiety disorder, and depression. The additional serious chronic care diagnoses of portal hypertension, pancytopenia, and irritable bowel syndrome were not listed, and with no accompanying medical records, to include

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical Compliance Review – Glades County Detention Center



laboratory results, most recent chronic care assessment, and pending specialty services, these diagnoses were unknown on his arrival to PC. It remains unexplained why the cirrhosis diagnosis was erroneously changed to “cirrhosis without alcohol”, but the diagnosis followed him to Polk on September 8, 2017 and to the hospital where he died nine days later.


APPENDIX I Vital Signs

DATE	TEMPERATURE	PULSE	RESPIRATIONS	BLOOD PRESSURE	WEIGHT
August 12, 2017	98.1	66	18	106/70	168
August 14, 2017	98.3	62	18	101/66	165
August 16, 2017	97.0	59	18	104/70	164
August 24, 2017	98.4	65	16	112/78	163
August 30, 2017	98.6	74	18	106/68	165
September 2, 2017	98.3	83	18	113/77	166
September 6, 2017	97.6	80	18	122/76	170

APPENDIX II Sick Call Requests

DATE SUBMITTED	COMPLAINT	DATE TRIAGED	DATE OF ASSESSMENT	TREATMENT PROVIDED
August 16, 2017	Vision difficulty	August 17, 2017	August 17, 2017	Instructed to get glasses sent in from home. Vision difficulty unresolved.
August 20, 2017	Vision difficulty with headache	August 21, 2017	August 24, 2017	Referred to the doctor. Not evaluated by MD for vision difficulty until September 6, 2017.
August 27, 2017	General body pain Vision difficulty	August 29, 2017	August 30, 2017	Ibuprofen provided for pain. Vision difficulty remained unresolved.
September 1, 2017	Vision difficulty with headache	September 1, 2017	September 2, 2017	Routine referral to (b)(6); (b)(7)(C) within five days. Was seen for vision difficulty during chronic care clinic on September 6, but no MD order written for optometry. Transferred same day due to hurricane.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical Compliance Review – Glades County Detention Center



Compliance Findings

There were no NDS deficiencies found. Identified areas of concern are as follows:

- Sick call requests, consents for medical care and psychiatric medication use, and keep-on-person agreements were not provided in Spanish version. As evidenced during interviews, not all nurses were aware of the availability of Spanish version forms.
- There was no reference to barriers of communication, language preference, or use of interpretation assistance during most nursing and provider encounters. Throughout interviews with staff from all three facilities in which detainee ALMAZAN was detained, there is strong evidence he was not English proficient.
- A nursing note by a sick call LPN was not signed at the time of her August 16, 2017, encounter, but rather it was signed two months later on October 15, 2017. From a legal standpoint it cannot be determined the note was not initiated and/or altered immediately prior to the sign-off on the latter date.
- During the August 16, 2017, encounter the LPN failed to inquire about the location of the detainee's eyeglasses, which were not at his home, resulting in an unresolved issue. Creative Corrections considered this misinformation might have been a result of a preventable communication barrier related to the detainee's inability to proficiently speak and understand English.
- Multiple complaints on the same request form are not always addressed and nurses reported a practice of one complaint per request form, with prioritization of the complaint at the time of the sick call encounter.
- In spite of the detainee's early and repeated complaint of serious vision impairment, a request for optometry to get eyeglasses was never processed.
- Possibly related to the hurried nature of the hurricane evacuation, the transfer summary failed to ensure adequate continuity of care to by failing to include all relevant health information.

Detainee Death Review: ALMAZAN-Ruiz, Felipe A028866428
Medical Compliance Analysis
Krome North Service Processing Center (KNSPC)
Miami, Florida

Medical Staffing

KNSPC's primary health care provider is ICE Health Service Corps (IHSC), supported by contractor InGenesis Medical Staffing based in San Antonio, Texas. InGenesis Medical Staffing sub-contracts STG International, Incorporated. Medical services are provided 24 hours a day, seven days a week. The staffing plan includes 21 commissioned Public Health Service officers, five GS employees, and 31 contract employees. Additionally, there are four casual nurses. The commissioned officers include the Health Services Administrator (HSA), assistant HSA, Clinical Director, three mental health professionals, dentist, pharmacist, three mid level providers, nurse manager, program manager, and eight registered nurses (RN). The GS employees include three medical records technicians, a dental assistant, and a radiology technician. The contract positions include a staff physician, two mental health professionals, psychiatrist, two pharmacy technicians, one midlevel provider, ten RNs, nine psychiatric RNs, three licensed practical nurses (LPN), one medical records technician, and an administrative assistant. A casual pool of three contract RNs and one contract LPN supplement the staffing model. According to the HSA (b)(6); (b)(7)(C) vacancies at the time of ALMAZAN's detention included five RNs and a radiology technician. Credential files were reviewed and found to be current and primary source verified.

IHSC's electronic medical record system, e-Clinical Works (eCW), is used at KNSPC. It is noted that unless indicated, the times of medical encounters identified in this report are the times nurses and providers electronically entered their notes, per system-produced timestamps. The times encounters were actually conducted is not available unless documented in the notes.

Summary of Events

LT (b)(6); (b)(7)(C) RN conducted a pre-screen at 5:47 p.m. on **July 12, 2017**, noting that detainee ALMARAZ arrived to the facility at 1500 hours. Creative Corrections believes the nurse's documented time is in error, as processing officers confirm arrival times with double checks prior to the pre-screen, which they recorded as 5:00 p.m. Interpretation assistance was not provided, as, "Detainee speaks English fluently," and there were no barriers to communication identified. During interview (b)(6); (b)(7)(C) stated she does not speak Spanish but, "If I say do you have any medical questions and I can see he is struggling with my questions, I can get an interpreter." It was noted ALMAZAN had not transferred from another facility. He was noted to have current, unspecified health problems and was taking medication. He was

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical Compliance Review – Krome North Service Processing Center



placed on a Priority 2 status, which according to LT (b)(6); (b)(7)(C) means a provider must evaluate the detainee within 24 hours because of a chronic condition or if he is taking medications.

At 9:39 p.m. (b)(6); (b)(7)(C) RN, InGenesis, conducted the intake screen, noting that Detainee ALMAZAN was Spanish speaking, for which interpretation assistance was provided. Inconsistent with LT (b)(6); (b)(7)(C) note, RN (b)(6); (b)(7)(C) stated he had transferred from another facility, having arriving with a transfer summary. Attempts to locate a transfer form, however, found no evidence of its existence. Detainee ALMAZAN stated he was feeling fine and was not in pain. He offered his previous diagnosis of cirrhosis¹ and that he was on medication. The only medication listed, however, was sertraline (Zoloft), a medication to treat depression. When asked if he was now or ever had been treated by a doctor for a medical condition, he replied no. He denied symptoms of tuberculosis infection, and his chest x-ray was negative. He denied drug abuse but admitted to drinking 12 to 15 beers a day, having last used on April 1, 2017. He also admitted to being a smoker, smoking two cigarettes per night. The examination, mental health screening, and vital signs were all within normal limits (*See Appendix I for vitals*). A Spanish version of the consent for medical treatment was signed. He was noted to have an abnormal intake screening and was referred to a medical provider. He was medically cleared for custody.

(b)(6); (b)(7)(C) RN documented a sick call visit on **July 16, 2017**, at 3:34 p.m. to assess an unspecified skin irritation. An interpreter was not used, as, “Detainee speaks English fluently.” When questioned during interview as to how she determines when interpretation assistance is needed, she replied that she is able to understand the issue, sometimes using “sign language” and since this visit occurred on a Sunday, “We probably had a Spanish speaking person to translate, and I didn’t document it.” Vital signs were all within normal limits, and ALMAZAN’s general appearance was described as well developed, well nourished, and in no acute distress. In spite of the complaint of skin irritation, the skin was documented only as normal, warm and dry. His heart was regular in rate and rhythm, and his lungs were normal. Treatment included Clotrimazole cream², with application to the affected area twice a day for seven days, as keep-on-person (KOP) medication and hydrocortisone cream³ with application to the affected area, externally, twice a day for seven days, also as a KOP medication. An English version of a KOP agreement was signed by ALMAZAN. Treatment notes refer only to “RN Guidelines for Foot Fungus”, while a reference to a nursing guideline authorizing use of hydrocortisone cream was not filed. During interview, RN (b)(6); (b)(7)(C) admitted her failure to document the complete physical assessment and was unable to recall why she ordered the hydrocortisone cream, stating, “If I treated him, there was a reason I treated him”.

Seven days following intake, on **July 19, 2017**, at 5:34 a.m., LCDR (b)(6); (b)(7)(C) NP, conducted an initial physical examination, noting that the intake screen was reviewed. An

¹ Cirrhosis is liver damage from a variety of causes, such as alcohol abuse, leading to scarring and liver failure.

² Clotrimazole cream is an antifungal medication, commonly used to treat athlete’s foot.

³ Hydrocortisone cream is a steroid used to treat skin conditions.

interpretation service was used, with the Language Line identification number recorded. During interview NP (b)(6); (b)(7)(C) stated, “Even if they say they speak a little bit of English, I use the service to make sure they understand.” Detainee ALMAZAN denied all medical and dental complaints, with the exception of hepatitis and depression. He admitted to suicidal ideation one year ago but denied any attempts. NP (b)(6); (b)(7)(C) narrative states detainee ALMAZAN was taking medication for cirrhosis while in Metrowest Detention Center (MDC)⁴. He stated he felt fine, was eating and sleeping well, and had regular bowel movements. He denied homicidal or suicidal ideations or thoughts of potential for violence towards others. He denied chest pain, shortness of breath, nausea or vomiting, fever or chills, abdominal pain, diarrhea, constipation or any other complaints or concerns at that time. His vital signs were all within normal limits. His eye test showed a visual impairment⁵ of 20/200 in the left eye, 20/100 in the right eye, and 20/70 in both eyes, without glasses. The general examination found him to be in no acute distress, well developed, well nourished, and calm and relaxed. He was noted to be asymptomatic⁶ and clinically stable. The assessment diagnoses were alcoholic cirrhosis of liver without ascites⁷ and visual disturbance. The treatment plan included renewal of sertraline, follow up with mental health, comprehensive laboratory studies on July 28, 2017, referral to ophthalmology⁸, and referral to radiology for an ultrasound⁹ of the liver. A medical consent was sent to MDC to obtain medical and medication records. Detainee ALMAZAN was provided patient instructions and preventive health information.

The initial mental health screen was conducted on **July 20, 2017**, at 2:18 p.m. (b)(6); (b)(7)(C) Psychologist, STG recalled conducting the encounter in Spanish and was not aware of what ALMAZAN’s level of English proficiency was. During questioning ALMAZAN verbalized that the father of a 43 year-old woman he had been dating was angry that he was going out with his daughter and later accused him of sexual assault. His past psychiatric history included hospitalization at Jackson Memorial Hospital (JMH) for alcohol abuse four years ago, but was later referred to mental health while at the hospital. He reported that he was drinking heavily due to depression and stress. He said he would experience sadness, crying spells, and had suicidal ideations. He said he felt this way because of not having a wife or significant other, not having his parents, having a sibling pass away, and losing his job. He reported that while at JMH he was seen by a psychiatrist who prescribed medication, which helped him significantly, but he did not recall the name of it. As per medical records, he was taking Zoloft (*sertraline*) 100 mg. He reported a history of suicidal ideations prior to his hospitalization, having had thoughts of jumping off a building, but he did not follow through as he began to think about his family, and

⁴ MDC is a Dade County prison in Doral, Florida

⁵ A visual impairment refers to loss of vision and decreased ability to see. Normal vision is 20/20, while 20/200 is a significant vision loss.

⁶ Asymptomatic means an absence of symptoms.

⁷ Ascites is an abnormal accumulation of fluid in the abdominal cavity.

⁸ Ophthalmology refers to a specialty in eye disease.

⁹ An Ultrasound is a diagnostic tool using sound waves to produce images of inside the body.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical Compliance Review – Krome North Service Processing Center



he started to read the Bible. He also reported suicidal ideations three years ago with thoughts of cutting himself with a knife, but focusing on his faith, he did not follow through. He denied current suicidal/homicidal ideation, intent or plans. He also denied a history of perceptual disturbances or delusions. The substance abuse history noted detainee ALMAZAN had been convicted for driving under the influence of alcohol and participated in in-patient alcohol treatment. The assessment findings were 1. Major depressive disorder¹⁰, recurrent, mild; and 2. Alcohol abuse, uncomplicated. Treatment included follow-up in two to three weeks and referral to (b)(6); (b)(7)(C) for medication management.

On **July 24, 2017**, at 5:46 p.m., LCDR (b)(6); (b)(7)(C) RN documented a progress note related to a sick call refusal, stating, "Patient called for sick call on evening shift but refused. Multiple calls were placed by PHS desk officer with no result. Will continue to monitor." (b)(6); (b)(7)(C) explained that detainees are typically seen in sick call between 8:00 a.m. to 3:00 p.m. every day, but in the event of a spill over, a list is made of those not seen, and the detainees who are returned to the housing until after 3:00 p.m. are called back on the evening shift of the same day. Prior to the sick call visit, nurses do not know the nature of the request. Three days later on **July 27, 2017**, at 12:19 p.m., (b)(6); (b)(7)(C) RN documented a late entry for a sick call visit conducted on July 26, 2017. An interpretation service was not used as "Detainee speaks English fluently." Detainee ALMAZAN stated he had been taking pills for his liver but had not yet received them." He denied pain, and his vital signs were all within normal limits. The nursing plan was to send a telephone encounter to a medical provider. The following day of July 28, 2017, at 12:00 p.m., RN (b)(6); (b)(7)(C) documented another sick call visit for complaint of respiratory symptoms and sore throat. An interpreter was not used for his visit as, "Detainee speaks English fluently." Detainee ALMAZAN denied pain, and his vital signs were all within normal limits. He stated his cold symptoms were mild and had been present for a few days. His general appearance was described as pleasant, in no acute distress. His throat appeared normal, and his respirations were even and unlabored. He was instructed to do salt water gargles three times daily for three days and was returned to the dorm.

(b)(6); (b)(7)(C) RN, InGenesis documented a sick call assessment for complaint of skin itching on **August 2, 2017** at 1:39 p.m. An interpreter was not used, as, "Detainee speaks English fluently." Detainee ALMAZAN denied pain, and his vital signs were all within normal limits. He described moderate itchiness over his whole body, having started weeks ago. He was observed to be persistently scratching. His general examination found him to be alert, well hydrated, and in no acute distress. There were no suspicious lesions, and psychologically he was alert, oriented, cooperative with the exam, and showed intact cognitive¹¹ functioning. The nursing treatment plan included application of hydrocortisone cream to the affected areas twice daily, start polyvinyl alcohol ophthalmic solution¹² to the eyes four times daily, and patient

¹⁰ Major depressive disorder is a mental health disorder characterized by persistently depressed mood or loss of interest in activities, causing a significant impairment in daily life.

¹¹ Cognitive refers to the process of knowing and perceiving.

instructions regarding bathing, avoidance of irritants, and increase of water intake. Following repeated requests for a RN Guideline addressing itching to verify the prescribed treatment of hydrocortisone cream, it was never produced.

(b)(6); (b)(7)(C) documented a follow-up mental health assessment on **August 4, 2017**, at 12:29 p.m., noting the conversation was in Spanish. Vital signs conducted by (b)(6); (b)(7)(C) RN were all within normal limits, and detainee ALMAZAN denied pain. He expressed having symptoms of depressed mood, but they were decreased from those previously reported. He stated he was participating in recreational activities and socializing with his peers. He presented as psychiatrically stable and was able to remain housed in the general population. He reported he had been complying with his psychiatric medication, with improvement in his level of sadness, energy, and motivation. His mood and attitude seemed better, and he no longer felt tearful. He offered he had talked to his sister who told him she was in the process of legalizing her stay in the U.S. and therefore did not want contact with him. He also discussed having gone to court the previous day, at which time the judge asked him if he found a lawyer with the list given to him. He said he informed the judge that no one returned his call. The judge asked him if he wanted to proceed with the case on his own which he replied yes to. An appointment was pending with (b)(6); (b)(7)(C) Psychologist on August 11, 2017, and he was scheduled for follow-up with Dr. (b)(6); (b)(7)(C) in three to four weeks.

At 2:32 p.m. the same day, (b)(6); (b)(7)(C) PA, STG documented a provider visit to review laboratory studies with detainee ALMARAZ. According to the laboratory reports, the blood samples were drawn and forwarded to the laboratory on July 28, 2017, results were received on July 31, 2017, and (b)(6); (b)(7)(C) reviewed them on August 3, 2017, noting, “MLP will discuss with patient tomorrow”. Interpretation services were not used for this encounter, as (b)(6); (b)(7)(C) speaks fluent Spanish. Detainee ALMAZAN reported that he takes pills for his liver and had not received them as yet. He stated he occasionally feels weak and tired, had been eating and sleeping well and was better adjusted in general population. He listed his medications as rifaximin¹³ 550 mg twice daily, Folic acid¹⁴ 1 mg once daily, docusate¹⁵ 100 mg twice daily, multivitamin¹⁶ one tablet daily, Aspirin¹⁷ 81 mg once daily, and omeprazole¹⁸ 20 mg once daily. He explained he had been taking rifaximin for six to seven years. He denied any bruises, bleeding, or abdominal pain. As over 50 laboratory values were obtained, only the abnormal levels are listed:

¹² Polyvinyl alcohol ophthalmic solution is also known as artificial tears, a treatment for dry eyes.

¹³ Rifaximin is a type of antibiotic, which treats traveler’s diarrhea and irritable bowel syndrome with diarrhea.

¹⁴ Folic acid is a B vitamin used to enhance red blood cell production.

¹⁵ Docusate is a stool softener used to treat constipation.

¹⁶ Multivitamin is a nutritional supplement.

¹⁷ Aspirin is a pain reliever.

¹⁸ Omeprazole is a medication used to treat heartburn and esophageal reflux disease (GERD).

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical Compliance Review – Krome North Service Processing Center



Test	Normal Range	Result
Hemoglobin A1c ¹⁹	4.8-5.6	4.4
Prothrombin Time ²⁰	9.1-12.0	12.3
Hepatitis A Antibody ²¹	Positive	Negative
Hepatitis B Core Antibody ²²	Positive	Negative
Bilirubin ²³	1.6	0.0-1.2
Albumin, Serum ²⁴	3.4	3.5-5.5
BUN/Creatinine Ratio ²⁵	23	9-20
Creatinine, Serum	0.57	0.76-1.27
Alkaline Phosphatase ²⁶	157	39-117
Serum Lipase ²⁷	67	0-59
Neutrophils ²⁸	1.3	1.4-7.0
Hemoglobin ²⁹	10.5	12.6-17.7
Red Blood Cells ³⁰	3.28	4.14-5.8
Hematocrit ³¹	29.3	37.5-51.0
White Blood Cells ³²	2.0	3.4-10.8
Platelets ³³	37	150-379
Lymphocytes ³⁴	0.4	0.7-3.1

¹⁹ Hemoglobin A1c is a test, which provides an average of blood sugar over a two-month period.

²⁰ Prothrombin time is a blood test to determine how quickly the blood clots.

²¹ Hepatitis A antibody is a protein which if present in the blood, signifies past exposure to hepatitis A.

²² Hepatitis B core antibody is a protein, which if present in the blood, indicates previous or ongoing infection with hepatitis B

²³ Bilirubin is an orange, yellow pigment produced by the liver.

²⁴ Serum albumin is the most abundant protein in the blood and is also the major carrier of fatty acids in the blood.

²⁵ BUN (blood urea nitrogen)/Creatinine (a waste product from muscle breakdown) ratio is a test to check kidney function.

²⁶ Alkaline phosphatase is an enzyme found in the blood. Abnormal values can help determine the level of liver dysfunction.

²⁷ Serum lipase is an enzyme, which can be found in abnormally high levels in the blood when the pancreas is damaged.

²⁸ Neutrophils are a type of white blood cells, which help fight infection by ingesting microorganisms

²⁹ Hemoglobin is the protein molecule in the red blood cells that carries oxygen from the lungs to the body's tissues and returns carbon dioxide from the body back to the lungs.

³⁰ Red blood cells are the blood cells that contain hemoglobin and carry oxygen.

³¹ Hematocrit is a volume percentage of red blood cells in the blood, usually at 47% in males.

³² White blood cells are the cells involved in protecting the body against infection.

³³ Platelets, also called thrombocytes, are a component of blood whose function is to stop bleeding by clumping and clotting blood vessel injuries.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
 Medical Compliance Review – Krome North Service Processing Center



(b)(6); (b)(7)(C)

(b)(6); (b)(7)(C)

MD, STG noted lab results would be discussed with detainee ALMAZAN. (b)(6); (b)(7)(C) stated the assessment findings as 1) Alcoholic cirrhosis of liver without ascites; 2) Other pancytopenia³⁵, and 3) Hepatitis B carrier. Creative Corrections notes that according to the CDC website, the hepatitis B results indicate immunity due to natural disease and do not indicate carrier status as diagnosed by (b)(6); (b)(7)(C). Treatment ordered for liver disease included rifaximin 550 mg twice daily; folic acid 1 mg daily; docusate 100 mg twice daily; multivitamin, one tablet daily; enteric coated³⁶ aspirin 81 mg daily; and omeprazole 20 mg daily. Follow-up laboratory studies were ordered to include serum uric acid³⁷, CBC³⁸ with differential³⁹, serum lipase, serum amylase, thyroid panel⁴⁰ with thyroid stimulating hormone⁴¹, and GGT⁴². Rifaximin was non-formulary, so a request for authorization was completed. A referral was submitted for hematology⁴³, pending approval. Detainee ALMAZAN was cleared for custody and scheduled for follow-up “as scheduled or sooner as needed.”

On **August 9, 2017**, at 9:38 a.m., NP (b)(6); (b)(7)(C) conducted a follow-up assessment for pancytopenia and review of lab results. An interpreter was not used during this visit. Questioned about why interpretation assistance was not used, as she had voiced its importance at the time of the initial physical examination, she stated, “Maybe I forgot to note the interpreter was used, because as I said, if they only speak a little English, I get an interpreter.” Detainee ALMAZAN denied pain and his vital signs were all within normal limits. He requested medication for skin itching, especially over his back. He also requested an eye appointment and medication for gas. He reported he had been eating and sleeping well and was doing well in general population. He denied any bruising, bleeding, or abdominal pain at that time. The general examination noted no acute distress, well developed, well nourished, and calm and relaxed. His skin was warm and dry with good turgor⁴⁴, and there was no bruising, hematomas⁴⁵,

³⁴ Lymphocytes are a form of white blood cells that produce antibodies to fight infection.

³⁵ Pancytopenia is a medical condition in which there is a reduction in the number of red blood cells, white blood cells, and platelets.

³⁶ Enteric-coating is a polymer barrier applied on oral medication, which prevents its disintegration in the stomach.

³⁷ Serum uric acid is the chemical found in the blood when the body breaks down foods containing organic compounds called purines. If too much uric acid is being produced or if the kidneys are not able to remove it from the blood normally, the level increases, potentially causing solid crystals to form within the joints, causing gout.

³⁸ CBC, short for complete blood count tests levels of all types of blood cells to determine the presence of disease.

³⁹ A blood differential test measure the percentage of each type of white blood cells.

⁴⁰ Thyroid panel is a series of tests used to evaluate thyroid function and help diagnose hypo- or hyperthyroidism.

⁴¹ Thyroid stimulating hormone is a hormone produced by the pituitary gland, which stimulates the thyroid gland to produce and release hormones into the blood.

⁴² GGT is short for gamma-glutamyl transferase, which is elevated in some forms of liver disease.

⁴³ Hematology is the branch of medicine concerned with the study of the cause, diagnosis, treatment, and prevention of blood related diseases.

⁴⁴ Turgor is the degree of elasticity of the skin, assessment of which can determine the extent of dehydration of

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical Compliance Review – Krome North Service Processing Center



bleeding, or fragile capillaries. His heart assessment was normal. He was alert, oriented, and cooperative, demonstrating intact cognitive functioning and good eye contact. His gait was normal. The assessment diagnoses were 1) Other pancytopenia and 2) Tinea pedis⁴⁶. Treatment for pancytopenia included lactulose⁴⁷ solution twice daily, Spironolactone 25 mg twice daily, hematology referral pending approval, and ophthalmology referral pending approval. Orders for tinea pedis included clotrimazole cream twice daily for seven days and hydrocortisone cream twice daily for seven days. Aluminum-magnesium-simethicone suspension⁴⁸ 400 mg was ordered four times a day for seven days.

(b)(6); (b)(7)(C) MD, Psychiatrist conducted a psychiatric evaluation on **August 11, 2017**, at 9:40 a.m., noting that an interpretation service was not used as, "Detainee speaks English fluently." (b)(6); (b)(7)(C) noted she obtained her subjective information from the initial mental health intake, and following the narrative, documented, "Patient concurred with the above information. He currently denied any depressive, manic, psychotic, or anxiety symptoms, no suicidal ideation/homicidal ideation. He reports insomnia. Risks, benefits, and side effect of Trazodone were discussed with patient who consented." Creative Corrections observed English consent forms were signed for both (b)(6); (b)(7)(C) on July 19, 2017, and for Trazodone at the time of this encounter, suggesting that ALMAZAN may not have fully understood the indication and side effects of the medication. Vital signs conducted by RN (b)(6); (b)(7)(C) were all within normal limits, with the exception of a mildly elevated body temperature of 99.3. The diagnosis was major depressive disorder, recurrent, mild, for which trazodone⁴⁹ 50 mg was ordered. Follow-up was scheduled for four weeks. As (b)(6); (b)(7)(C) was no longer employed at KNSPC at the time of the review.

At 4:23 p.m, RN (b)(6); (b)(7)(C) documented a transfer summary for ALMAZAN's departure to Glades County Detention Center (GCDC) the same day. There were no special needs or medical, dental, or mental health reasons listed that would affect his transportation, nor were there any restrictions or special equipment required for travel. The disposition was "medically cleared for custody". The document included all current medications, but the only medical history listed was cirrhosis for eight years. There was no reference to pancytopenia, depression, or tinea pedis, all of which had been identified since his intake. Additionally, there was no reference to pending referrals for hematology, ophthalmology, and radiology for a liver ultrasound; nor were copies of laboratory studies and most current chronic care clinic records sent with the transfer summary to

fluid loss in the body.

⁴⁵ A hematoma is a solid swelling of clotted blood within the tissues.

⁴⁶ Tinea pedis, also known as athlete's foot, is a fungal infection of the feet, usually beginning between the toes.

⁴⁷ Lactulose is a type of sugar solution used to treat chronic constipation and to reduce the amount of ammonia in the blood of patients with liver disease.

⁴⁸ Aluminum-magnesium-simethicone is

⁴⁹ Trazodone is a medication used to treat depression and sleep difficulty.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical Compliance Review – Krome North Service Processing Center



ensure efficient continuity of care by the receiving facility. The medical documentation failed to include a medical hold to ensure provider review prior to transfer.

During interview, CAPT (b)(6); (b)(7)(C) MD, Clinical Director addressed the adverse findings related to ALMAZAN's medical care, emphasizing that he had not rendered care so was "only looking at other things as the clinical director." He cited his main concern as the flow of appointments related to pancytopenia, chronic liver problems, and cirrhosis caused by abuse of alcohol. He described the platelet count of 37 as, "very low, he didn't have the building blocks for coagulation," adding that there was definitely a risk for bleeding and infections, but it may have been going on for years. Questioned about the length of time it took for the hematology referral, he replied, "We have no control," explaining that certain consulting specialties are difficult to access, and that it basically is no different from being seen in the community, which can take three to four weeks. With his specialty as a flight surgeon, (b)(6); (b)(7)(C) stated low platelets would not affect clearance for air travel, and even with a low hemoglobin level of 10.5, "I would still clear someone at those levels to fly." In discussion of the transfer summary, which omitted serious diagnoses, (b)(6); (b)(7)(C) explained if providers failed to update the problem list, the conditions will not show at the time the nurse prepares the summary, agreeing that the problem list was not current and in addition to pancytopenia and depression, should have included varices⁵⁰ and portal hypertension⁵¹. He stated it would not be impossible to send applicable copies of the medical record with the summary, although, "It would take more work to include it." He did agree, however, that it would be helpful to include the last chronic care clinic. Regarding a medical hold, he stated there would not be a need for a medical hold if the receiving institution was aware of and followed up with the medical condition. He added that he would have no problem telling ICE a detainee can not go if there were pending consults, however, adding, "Whether it would have made a difference in the outcome, hard to say." He voiced his opinion that GCDC was an appropriate facility to send a stabilized case, and that they had not any any significant issues with them.

APPENDIX I Vital Signs

DATE	TEMPERATURE	PULSE	RESPIRATIONS	BLOOD PRESSURE	WEIGHT
July 12, 2017	98.1	74	16	114/68	171
July 16, 2017	97.6	74	16	107/66	170
July 19, 2017	98.5	69	16	110/70	175
July 20, 2017	97.9	68	16	101/61	175
July 27, 2017	98.1	73	16	115/61	170

⁵⁰ Varices are abnormal veins in the lower part of the tube running from the throat to the stomach.

⁵¹ Portal hypertension refers to high blood pressure in the system of veins coming from the stomach, intestine, spleen, and pancreas which merge into the portal area before traveling through the liver.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical Compliance Review – Krome North Service Processing Center



August 2, 2017	98.2	82	16	105/63	170
August 4, 2017	98.1	72	16	100/63	172
August 8, 2017	98.4	71	16	102/64	165
August 11, 2017	99.3	74	16	97/57	170

CONCLUSIONS

Medical

Compliance Findings

Creative Corrections finds the care provided to Filipe ALMAZAN-Ruiz by the Krome North Service Processing Center did not meet all requirements of the 2016-revised ICE PBNDS 2011, Medical Care. Deficiencies were identified in the following components of the standard:

ICE PBNDS 2016, Medical Care, section (V)(E), which states, “Each facility shall provide appropriate interpretation and language services for LEP detainees related to medical and mental health care. Where appropriate staff interpretation is not available, facilities will make use of professional interpretation services.”

- On July 16, 2017, at 3:34 p.m. to assess an unspecified skin irritation. An interpreter was not used, as, “Detainee speaks English fluently.”
- The keep-on-person agreement form signed on July 16, 2017, was in English and may not have ensured his full understanding.
- Consent forms for psychotropic medications were not provided in Spanish version to ensure full understanding of the indication and side effects of the medication.
- Nursing sick call encounters conducted on July 26, 2017, July 27, 2017, and August 2, 2017, failed to use interpretation assistance to ensure full and accurate information gathering and clear understanding of instructions provided.
- On August 9, 2017, a non-Spanish-speaking provider conducted a laboratory results follow-up encounter in the absence of interpretation assistance.

ICE PBNDS 2016, Medical Care, section (V)(G)(3), which states, “Each detention facility shall have and comply with written policy and procedures for the management of pharmaceuticals, to include: 3) prescription practices, including requirements that medications are prescribed only when clinically indicated, and that prescriptions are reviewed before being renewed.”

- July 16, 2017, hydrocortisone cream was issued in the absence of assessment findings.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
 Medical Compliance Review – Krome North Service Processing Center



- On August 2, 2017, hydrocortisone cream was again issued as a KOP in the absence of a RN Guideline.

ICE PBNDS 2016, Medical Care, section (V)(M), which states, “Each facility’s health care provider shall conduct a comprehensive health assessment, including a physical examination and mental health screening, on each detainee within 14 days of the detainee’s arrival unless more immediate attention is required due to an acute or identifiable chronic condition.” Additionally: **NCCHC J-E-04 (Essential), section (5)**, which states, “Inmates identified with *clinically significant findings* as the result of a comprehensive receiving screening receive an initial health assessment as soon as possible, but no later than 2 working days after admission.”

- Although the intake assessment identified cirrhosis, the initial physical assessment was not completed until one week following intake.

ICE PBNDS 2016, Medical Care, section (V)(N), which states, “Where a detainee has a serious medical or mental health condition or otherwise requires special or close medical care, medical staff shall complete a Medical/Psychiatric Alert form (IHSC-834) or equivalent, and file the form in the detainee’s medical record. Where medical staff furthermore determine the condition to be serious enough to require medical clearance of the detainee prior to transfer or removal, medical staff shall also place a medical hold on the detainee using the Medical/Psychiatric Alert form (IHSC-834) or equivalent, which serves to prevent ICE from transferring or removing the detainee without the prior clearance of medical staff at the facility. The facility administrator shall receive notice of all medical/psychiatric alerts or holds, and shall be responsible for notifying ICE/ERO of any medical alerts or holds placed on a detainee that is to be transferred. Potential health conditions meriting the completion of a Medical/Psychiatric Alert form may include, but are not limited to medical conditions requiring ongoing therapy, such as a.) active TB, b) infectious diseases, and c) chronic conditions.”

- Medical documentation failed to include a medical hold to ensure provider review prior to transfer.

ICE PBNDS 2016, Medical Care, section (V)(W), which states, “Consistent with Standard 4.8 ‘Disability Identification, Assessment, and Accommodation’ and the IHSC Detainee Covered Services Package, detainees will be provided medical prosthetic devices or other impairment aids, such as eyeglasses, hearing aids, or wheelchairs.”

- Significant vision impairment identified one week following intake failed to result in the issuing of reading or prescription eyeglasses. Additionally, because the pending ophthalmology referral was not forwarded to the receiving facility during transfer, the detainee never received glasses during his remaining detention period.

ICE PBNDS 2016, Medical Care, section (V)(X)(1), which states, “The facility administrator and clinical medical authority shall ensure that the Field Office Director is notified as soon as practicable of any detainee housed at the facility who is determined to have a serious physical or mental illness or to be pregnant, or have medical complications related to advanced age, but no

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical Compliance Review – Krome North Service Processing Center



later than 72 hours after such determination. The notification shall become part of the detainee's health record file.”

- The medical record did not include a notification to the Field Office Director regarding the condition of potentially advanced cirrhosis and pancytopenia.

ICE PBNDS 2016, Medical Care, section (V)(Z), which states, “The facility HSA must ensure that a plan is developed that provides for continuity of medical care in the event of a change in detention placement or status. The detainee’s medical needs shall be taken into account prior to any transfer of the detainee to another facility. Alternatives to transfer shall be considered, taking into account the disruption that a transfer will cause to a detainee receiving medical care.”

- The transfer summary dated August 11, 2017, failed to include the serious chronic diagnoses of pancytopenia and depression. Additionally, there was no reference to pending referrals for hematology, ophthalmology, and radiology for a liver ultrasound; nor were copies of laboratory studies and most current chronic care clinic.

Areas of Note

In addition to the above deficiencies, Creative Corrections notes the following:

- Providers failed maintain a current problem list of serious illnesses, to include pancytopenia and depression, resulting in delayed continuity of care following transfer to another ICE facility.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical Compliance Review – Krome North Service Processing Center



Detainee Death Review: ALMAZAN-Ruiz, Felipe A028866428
Medical Compliance Analysis
Polk County Adult Detention Center (PCADC)
West Livingston, Texas

Medical Staffing

MTC Medical, with headquarters in Houston, Texas provides 24-hour nursing coverage seven days per week. The facility earned reaccreditation by the American Correctional Association on January 23, 2017. Although the facility is contracted under the NDS, MTC policies and procedures address the elevated standards of PBNDS 2011. The HSA, a registered nurse (RN) who has worked with MTC since April 2016, assumed her administrative role in September 2017. The Clinical Director is a contract MD who has worked at PCADC for about ten years. He delivers on-site medical services one six-hour day per week. For medical reasons, (b)(6); (b)(6); MD was not available during the three days detainee ALMAZAN was at the facility, and therefore he was unfamiliar with the case. He was not interviewed during this review. A part time certified physician assistant is on site from 6:00 p.m. to 7:00 p.m. on Mondays, Tuesdays, and Thursdays. On call coverage is shared between the two providers. A licensed professional counselor provides full time services, and an MTC psychiatrist is available via telemedicine four to six hours a week. Nursing staff includes a full time director of nurses (DON), three fulltime RNs and six licensed vocational nurses (LVN), all assigned twelve-hour shifts from six to six. Two medical assistants and one pharmacy technician provide clinical and administrative support. There were no vacancies at the time of the review. ODO finds staffing adequate to provide basic medical services for all detainees. A credential review found all professional licenses current and primary source verified.

PCADC uses hard copy medical records, with the exception of chronic care appointment scheduling and electronic medication administration records. Detainees access sick call by filling out paper requests and depositing them into a locked box. Sick call request forms and deposit boxes were inconveniently located outside the locked cells in C Unit, where detainee ALMAZAN was housed. According to detainees who were residing in the same cell with detainee ALMAZAN, they request sick call forms from an officer and when completed put it up to the window so the officer who is making rounds can retrieve the requests. This practice does not ensure the confidentiality of detainees who request appointments for sensitive medical problems. According to the detainee handbook, "Detainees desiring routine medical care will fill out a sick call request which will be picked up daily by the nursing staff." Officer rounds are conducted through window observation only; however, intercoms are available in those units for contacting officers on duty.


Summary of Events

(b)(6); (b)(7)(C) RN, (b)(6); (b)(7)(C) conducted the medical intake screening on **September 8, 2017**, at 11:30 p.m., noting that 51 year old detainee ALMAZAN spoke English and therefore an interpreter was not used. During interview, however, RN (b)(6); (b)(7)(C) stated he spoke very little English but there was a medical person available who interpreted for her. She was unable to ascertain who provided this assistance. (b)(6); (b)(7)(C), Detention Officer who worked intake during the arrival of the Florida-evacuated detainees, recalled detainee ALMAZAN only spoke Spanish, requiring another intake officer to provide language assistance (b)(6); (b)(7)(C) Detention Officer who was working in the detainee's unit, also stated detainee ALMAZAN spoke no English and that because he himself was fluent in Spanish, he provided interpretation assistance. Throughout interviews, other custody staff having had direct contact with detainee ALMAZAN also described his minimal ability to speak and understand English.

At five feet, one inch tall, detainee ALMAZAN weighed 170 pounds. A pain level of four on a scale of zero to ten was reported at the time of arrival, as he complained of general joint pain and discomfort in the upper right quadrant of his abdomen. The reviewer notes that pain in this location is common in liver cirrhosis. Vital signs were recorded within normal limits with the exception of a significantly elevated blood pressure of 180/109 (*See Appendix I*). Rechecks at unrecorded times noted a decrease in blood pressure to 164/100 and finally to 152/86, levels that remained abnormally high (*See Appendix II*). (b)(6); (b)(7)(C) stated during interview she did not contact the provider regarding these blood pressures, as detainee ALMAZAN told her he had not received his medication for an undetermined period of time. According to the MTC nursing protocol a blood pressure read of 160/100 requires provider contact, which (b)(6); (b)(7)(C) stated she was aware of. When questioned if he would have wanted to be notified of the abnormal read, (b)(6); (b)(7)(C) PA-C stated that considering the diagnoses of cirrhosis and probable portal hypertension, it would have been important for him to know. (b)(6); (b)(7)(C) stated during interview that she was not aware what the interval period was between rechecks of the blood pressure, but she explained that she had administered his medication prior to the second and third check. However, (b)(6); (b)(7)(C) LVN, who said she was present at the time of detainee ALMAZAN's intake screen, stated during interview that she personally pulled him out of the screening area to help him relax and conducted the second and third blood pressure rechecks. When asked if she administered his medication prior to the rechecks, she stated she did not believe the meds had been given. A review of the medication administration record (MAR) does not indicate any of his medications were given until the 5:30 a.m. pill line the following morning. The MAR does indicate prescribed medications were regularly administered from that time until his hospital transfer. Of note, the next blood pressure check was not recorded until three days later prior to hospital transport.

Detainee ALMAZAN signed and dated a Spanish version of consent for medical treatment. He was noted to have had a chest x-ray on July 12, 2017, which was negative for tuberculosis, and he denied a history or current symptoms of infectious disease. Chronic medical issues, as supported by those listed on the medical summary from Glades County Detention Center

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical Compliance Review – Polk County Adult Detention Center



(GCDC), included cirrhosis of the liver, depression, and generalized anxiety disorder (GAD). Other diagnoses established at both previous facilities, Krome Service Processing Center (KSPC) and GCDC but not listed on the medical summary, included portal hypertension¹, varices², pancytopenia³, irritable bowel syndrome⁴, and gastro-esophageal reflux disease⁵. The medical summary from GCDC also failed to include pending referrals initiated while he was detained at KSPC, including an abdominal ultrasound and specialty consults for hematology and ophthalmology. According to medical records received from KSPC and GCDC, the referrals were never completed; nor were there references to the pending state of these referrals on the transfer summary forwarded from KSPC and received by GCDC.

Detainee ALMAZAN reported not being a smoker, but admitted to a significant history of alcohol abuse, stating he used “mucho” beer and tequila, last using about three months ago. He had been hospitalized and went through “the program”. He was noted to have tremors, which was listed as a withdrawal symptom, and he admitted to having gone through a period of withdrawal at the time of his hospitalization. His mental health assessment was all shown to be normal, although following a “no” response to the question if he ever tried to harm himself, RN (b)(6); noted, “passive suicidal intent”. When asked to clarify what this meant, she stated in the past he had thoughts of wanting to die. His mood and behavior were found to be appropriate. RN (b)(6); completed MTC’s “Treatment Plan: Special Needs and Restrictions” form, excusing him from a work program assignment for medical reasons. He was placed on no restrictions for the disciplinary process, and “chronically ill” was checked for special needs. Routine referrals were checked for mental health, medical doctor, and special diet (renal). He was assigned to a low bunk in handicap housing unit C-20.

(b)(6); (b)(7)(C) RN, HSA documented a verbal order from (b)(6); (b)(7)(C) PA to continue all medications as ordered by the previous facility. The transfer summary from GCDC listed his medication as follows:

Medication	Dosage	Indications
Sertraline	100 mg daily	Depression and anxiety
Trazadone	75 mg daily at bedtime	Depression and anxiety
Folic Acid	1 mg daily	Vitamin B folic acid deficiency related to liver disease.
Omeprazole	40 mg daily	Gastro-esophageal reflux disease (GERD)

¹ Portal hypertension is an increase in the blood pressure within a system of veins called the portal venous system. Veins coming from the stomach, intestine, spleen, and pancreas merge into the portal vein, which branches into small vessels and travels through the liver. When a sick liver is unable to accommodate the blood, it pools back, causing vessel enlargement and weakness (varices).


² Varices are abnormal veins in the lower part of the esophagus and stomach.

³ Pancytopenia is a deficiency of all three cellular components of the blood (red cells, white cells, and platelets)

⁴ Irritable bowel syndrome is an intestinal disorder causing stomach pain, gas, diarrhea, and constipation.

⁵ Gastro-esophageal reflux disease is a digestive disease in which stomach acid or bile irritated the lining of the esophagus and stomach.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
 Medical Compliance Review – Polk County Adult Detention Center



Prednisone	100 mg daily for three days.	Steroid to treat inflammation
Spirolactone	25 mg twice daily	High blood pressure and fluid retention

The medications submitted on the MAR included a taper⁶ on the prednisone, the addition of lactulose 30 ml twice daily, and the addition of Xifaxan⁷ 550 mg twice daily. According to RN (b)(6); (b)(7)(C) she reconciled the medication summary with the bottle labels, correcting the dosages documented by GCDC on the medication summary. Of note, (b)(6); (b)(7)(C) MD from GCDC added and/or adjusted medications on September 6, 2017. Neither the medication bottles nor the order information was forwarded to or received by PCADC. Specifically, he had increased lactulose to 40 ml, started ferrous sulfate (iron) 325 mg one time daily, and added a multivitamin, one daily. It was noted that detainee ALMAZAN had never been prescribed a beta-blocker⁸ as an important adjunct in his cirrhosis treatment. (b)(6); (b)(7)(C) reported during interview he had questioned if a beta-blocker had been prescribed by the previous facilities and was surprised it was not been. According to an article published by the gastroenterology department of the National Institutes of Health, related to the use of non-selective beta-blockers (NSBB)⁹, they remain the cornerstone of therapy in cirrhotic patients with portal hypertension. In primary prophylaxis (disease prevention), patients with high-risk small varices or large/medium varices should receive primary prophylaxis with NSBB, except when contraindication to these drugs exist, in which case ligation¹⁰ should be performed.

(b)(6); (b)(7)(C) Licensed Professional Counselor, documented a mental health assessment following the referral for depression. Detainee ALMAZAN was described as clean, cooperative, fully oriented, and having normal speech. His mood was described as depressed, his affect was congruent, his thought process was logical, and he had no hallucinations or suicidal intent. His judgment and insight were fair. The narrative note stated, “Processed thoughts and feelings regarding being incarcerated. Discussed the importance of positive coping skills. Established skills he could use while incarcerated. Informed how to access mental health services. Will refer to psychiatrist for med management.” He was not found to be a danger to himself or others. During interview, LPC (b)(6); (b)(7)(C) did not recall detainee ALMAZAN ever discussing his medical condition, including any possibility that he had been vomiting or coughing up blood since his arrival.


⁶ Drug tapering is the gradual discontinuation or reduction of a therapeutic dose of a particular drug required by a patient over a prolonged period of time, as a means of reducing potentially severe side effects. Tapered doses for detainee ALMAZAN were: 100mg, 80mg, 60mg, 50 mg, 40 mg, 30 mg, 20 mg, each for three days; then 10 mg, 5 mg, 2.5 mg each for two days, then discontinue.

⁷ Xifaxin is a medication used to treat irritable bowel syndrome and can help prevent certain liver problems.

⁸ Beta-blockers are a class of drug commonly used to treat high blood pressure. Nonselective beta-blockers are a subclass of beta-blockers, commonly used to treat portal hypertension.

⁹ Gianelli V, Lattanzi B, Merli, M, Beta-blockers in liver cirrhosis, *Annals of Gastroenterology*. 2014;27(1):20-26.

¹⁰ Surgically tying off varices.




According to MTC’s policy addressing intake health screening, “When a referral for medical follow-up is initiated, the resident shall receive a health evaluation no later than two working days from the date of assessment.” HSA (b)(6); (b)(7)(C) produced an electronic chronic care roster document, indicating that detainee ALMAZAN’s chronic care clinic was pending at an unspecified date. He was transported to the hospital on Monday, September 11, the first working day since his arrival.

At 7:45 p.m. (b)(6); (b)(7)(C) LVN completed an emergency assessment form, noting, “Nurse called to tank C-20 because detainee was reportedly vomiting blood.” Detainee ALMAZAN’s vital signs were recorded as normal, with the exception of an abnormally elevated blood pressure of 151/95 and an abnormally rapid heart rate of 106. He was fully oriented to person, place, and time. He complained of pain in his mid chest. ERAU’s review of the housing unit video clearly showed a second nurse responded to the unit when the call came through. This nurse was identified as (b)(6); (b)(7)(C) LVN. When questioned during interview as to why she did not document a note, she explained that LVN (b)(6); (b)(7)(C) was taking charge of the situation. She did report assisting with the detainee’s transfer from the bed to the wheelchair, however. According to the “Provider Progress Notes/Orders”, PA (b)(6); (b)(7)(C) completed his evaluation of detainee ALMAZAN at 9:57 p.m. During interview PA (b)(6); (b)(7)(C) reported he incorrectly recorded the military time, intending to have signed off at 7:57 p.m. According to the note, he was brought to medical with complaints of vomiting blood, similar to an incident he reported having occurred seven years ago. He was believed to have cirrhosis with varices, information that was extracted from the chart, (b)(6); (b)(7)(C) determined, “Pt [patient] poor historian”. When questioned as to how he arrived at this description, (b)(6); (b)(7)(C) stated that detainee ALMAZAN offered no medical history, as if he did not want medical to know how sick he was. When directly questioned about his cirrhosis, however, he then admitted it. (b)(6); (b)(7)(C) voiced his opinion that the detainee did not speak English and that (b)(6); (b)(7)(C) Medical Assistant, provided interpretation. He was described as alert and oriented and appeared to be in no acute distress. PA (b)(6); (b)(7)(C) stated there were no symptoms or patient behaviors at the time of assessment to suggest this was an emergency situation. Bright red blood was observed on both the inside and outside his mouth, but there was no blood on his shirt or pants. He was diagnosed with gastrointestinal bleed of five days duration and was sent to the emergency room for evaluation on a stat basis, but not via 911.

A “Timeline/Checklist – Depart from the Facility” form was completed by an unidentified medical staff member at 8:42 p.m. According to this document (b)(6); (b)(7)(C) was notified of the need to transport detainee ALMAZAN to CHI St. Luke’s via van with security escort. Hospital updates were recorded daily, as follows:

Reporting Nurse, Date, and Time	Report Summary
(b)(6); (b)(7)(C) September 12, 2017	Stable at this time. Most recent vitals: Blood pressure 99/58, pulse 75, and respirations 17. Pulse oxygen 97. Temperature remains normal. Two units of platelets given due to critical platelet level of 27. Post transfusion level is up to 55. All other labs remain within

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
 Medical Compliance Review – Polk County Adult Detention Center



	normal limits. Scheduled to have EGD ¹¹ in the morning. Previously receiving cardene drip ¹² via external jugular line. Has been stopped and is now receiving oral lisinopril ¹³ .
(b)(6); (b)(7)(C) LVN September 13, 2017 5:35 p.m.	Alert and oriented. Blood pressure 117/58, pulse 88, R 19, Temperature 98.3, pulse oxygen 100. Received two units of platelets. Hemoglobin is 11.2, and platelets are 27.
(b)(6); (b)(7)(C) September 14, 2017 6:41 a.m.	Alert and oriented. Blood pressure 101/51, pulse 69, respirations 14, temperature 98.3, pulse oxygen 99. Continues lisinopril orally. Denied pain throughout the night.
(b)(6); (b)(7)(C), RN September 14, 2017 6:31 p.m.	Alert and oriented. Blood pressure 125/73, pulse 79, respirations 18, temperature 98.7, and pulse oxygen 99. Continues oral lisinopril. Pain is eight of ten, reporting severe GERD. Moved to medical-surgical unit.
(b)(6); (b)(7)(C) September 15, 2017 5:40 a.m.	Remains stable. Removed from ICU room 18 to medical surgical floor, room 141. Blood pressure 93/54, temperature 98.1, pulse 72, respirations 18, pulse oxygen 97.
(b)(6); (b)(7)(C) RN September 16, 2017 7:24 p.m.	Remains stable. Blood pressure 106/65, temperature 98.2, pulse 72, respirations 16, pulse oxygen 98. Had a normal cardiac stress test earlier in the day. Medications remain Zoloft, folic acid, metoprolol ¹⁴ , Protonix ¹⁵ , lactulose, and aldactone. Possible discharge Sunday after seen by doctor.
(b)(6); (b)(7)(C) September 17, 2017 2:32 a.m.	At about 1:00 a.m. patient coded and is now critical and has been moved to ICU, room 36. He is on life support and is intubated with agonal ¹⁶ breathing. When able to get a blood pressure, it is in the 50s by palpation ¹⁷ . Hemoglobin is 5. Blood being given. Warden Stacks has notified ICE personnel (b)(6); (b)(7)(C)

The death certificate and autopsy are pending.

¹¹ An EGD, short for esophagogastroduodenoscopy is a scope used to examine the lining of the esophagus, stomach, and duodenum (upper part of the small intestine)

¹² A cardene drip is an intravenous therapy infused with medication to treat high blood pressure.

¹³ Lisinopril is a medication to treat hypertension.


¹⁴ Metoprolol is a beta-blocker to treat high blood pressure.

¹⁵ Protonix is a treatment for GERD.

¹⁶ Agonal breathing is abnormal respirations characterized by gasping, and labored breathing.

¹⁷ Palpation is a method of examining the body using the hands.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical Compliance Review – Polk County Adult Detention Center



APPENDIX I

Vital Signs

DATE	TEMPERATURE	PULSE	RESPIRATIONS	BLOOD PRESSURE	Oxygen
September 8, 2017	97.0	98	14	180/109	98
				164/100	
				152/86	
September 11, 2017	97.5	106	18	151/95	100

APPENDIX II

American Heart Association Blood Pressure Parameter


Blood Pressure Category	Systolic (Upper number)		Diastolic (Lower number)
Normal Blood Pressure	Less than 120	and	Less than 80
Prehypertension	120-139	or	80-89
Stage One Hypertension	140-159	or	90-99
Stage Two Hypertension	160 or higher	or	100 or higher
Hypertension Crisis	Higher than 180	or	Higher than 110

CONCLUSIONS

Medical Compliance Findings

Medical Care, Section (III)(D), which states, “Non-English speaking detainees and detainees who are deaf or hard of hearing will be provided interpretation or translation services or other assistance as needed for medical care activities. Language assistance may be provided by another staff member competent in the language or by a professional service, such as a telephone translation service.”

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical Compliance Review – Polk County Adult Detention Center



- During the intake screening [REDACTED] noted ALMAZAN spoke English and therefore did not require language assistance. During interview, however [REDACTED] stated he “spoke very little English” but that an unidentified medical person provided interpretation. There was no documentation to substantiate this. [REDACTED] Intake Detention Officer recalled detainee ALMAZAN only spoke Spanish, requiring another intake officer to provide language assistance. [REDACTED] Detention Officer who was working in the detainee’s unit, also stated detainee ALMAZAN spoke no English and required interpretation assistance. There is no telephone access in the medical intake area.

Medical Care, Section (III)(D), which states, “Medical and mental health interviews and examinations shall be conducted in settings that respect detainees’ privacy.”

- Curtain dividers and ceiling-mounted acoustic boards in the medical intake screening areas do not fully protect privacy to fully and comfortably discuss sensitive medical information.

Medical Care, Section (III)(D), which states, “The clinical medical authority shall be responsible for review of all health screening forms within 24 hours or next business day to assess the priority for treatment (for example Urgent, Today, or Routine).”

- The intake screen does not include a signature of review by the clinical medical authority. Of note, the evening detainee ALMAZAN was transferred to the hospital was the first business day for that review.

Medical Care, Section (III)(B), which states, “Health care personnel perform duties for which they are credentialed by training, licensure, certification, job descriptions, and/or written standing or direct orders by personnel authorized by law to give such orders.”


- A seriously elevated blood pressure of 180/102 was not reported to a provider in accordance with MTC’s Nursing Protocols. Additionally, regular blood pressure monitoring was not done during the three days detainee ALMAZAN was detained at PCADC.

Areas of Concern

Creative Corrections has also identified the following areas of concern:

- Sick call forms and deposit boxes are inconveniently placed in the hallway outside the locked unit. Detainees reported they access them when they go to recreation, and after completion they hold them to the window when the officer conducts minute rounds. The officer then takes the request and deposits it in the locked box. This practice does not

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical Compliance Review – Polk County Adult Detention Center




protect the privacy and confidentiality of the detainees. Detainee ALMAZAN did not request a sick call appointment during his detention.

(b)(6); (b)(7)(C)

*Medical Subject Matter Expert
Creative Corrections, LLC*

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical Compliance Review – Polk County Adult Detention Center



Detainee Death Review: ALMAZAN-Ruiz, Felipe A028866428
Healthcare and Security Compliance Analysis
Krome North Service Processing Center, Miami, Florida
Glades County Detention Center, Moore Haven, Florida
Polk County Adult Detention Center, West Livingston, Texas

As requested by the ICE Office of Professional Responsibility, Office of Detention Oversight (ODO), Creative Corrections participated in a review of the death of detainee Sergio Alonso LOPEZ who had been detained at the Krome Service Processing Center (KSPC) from July 12 to August 11, 2017, Glades County Detention Center (GCDC) from August 11 to September 8, 2017, and Polk County Adult Detention Center (PCADC) from September 8 until his death on September 17, 2017. Site visits were conducted at each of these facilities by members of a review team comprised of (b)(6); (b)(7)(C) External Reviews and Analysis Unit, and Management and Program

(b)(6); (b)(7)(C) , accompanied by Creative Corrections contract personnel (b)(6); (b)(7)(C) Security Subject (b)(6); (b)(7)(C) Healthcare Subject Matter


Expert. Creative Corrections' participation was requested to determine compliance with the National Detention standards at GCDC and PCADC and the 2016-revised 2011 Performance Based National Detention Standards (PBNDS) at KNSPC. The reviews were conducted from October 17-19, 2017, at IAH/PCADC, from December 4-5, 2017, at Krome North Service Processing Center (KNSPC) and from December 6-7, 2017, at Glades County Detention Center (GCDC).

The information and findings herein are based on analysis of detainee LOPEZ' medical record and detention file, tour of housing units and the medical area, interviews of staff, and review of facility policy, video surveillance footage, hospital records, and supporting documentation.

Synopsis

Per the ERO Form 213, Felipe ALMAZAN entered the United States on or around May 4, 1985, at or near San Ysidro, CA, without having been admitted by an immigration officer. Once in the United States he acquired an extensive criminal history which included convictions for Larceny in August 1994, and July 1998, Indecent Exposure in July 1998, and Driving under the Influence of Liquor in May 2001. Per the Miami-Dade Police booking form, ALMAZAN was arrested at 10:20 p.m. on April 14, 2017, for alcoholic beverages/drinking in public and engaging in sexual act with a familial child. On **July 10, 2017**, he was convicted of two counts of Child Abuse/Aggravated/Great Bodily Harm and Torture and sentenced to 15 years of probation. The Miami Dade Probation Office notified the Miami Fugitive Operations Team about his case on **July 12, 2017**, and he was taken into custody at the Miami Dade Probation Office in Miami, FL and transported to Krome North Service Processing Center (KNSPC) for processing.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



Detainee ALMAZAN had an extensive criminal history and was placed on probation for a term of 15 years after being convicted of child abuse aggravated, causing great bodily harm and torture. ERO transported him from the Miami-Dade probation office to KNSPC on July 12, 2017. He was detained at KNSPC for 30 days. During his stay there he made no phone calls, had no visits and had no disciplinary issues.

He was next transferred to GCDC. While there, he completed three phone calls and worked for five days as a trustee in the food service area earning \$1.00 per day. After 26 days at GCDC, he was transferred to the Folkston Processing Center in anticipation of the approaching Hurricane Irma. One day later he was transported to the PCADC when the projected path of Hurricane Irma changed. He was housed at IAH/PCADC from September 8 to September 11, 2017. During that time he filed no grievances, had no disciplinary violations and made no phone calls. A review of the video surveillance footage from inside his housing pod showed that he slept almost all of the time and ate very little from his food trays.

On September 11, 2017, other detainees in his housing unit alerted the officer that detainee ALMAZAN was vomiting blood. Both security and medical staff responded and the provider ordered him to be sent to the hospital. He was transported to a local hospital and then transported a day later to a regional medical center for treatment of cirrhosis of the liver. On September 17, 2017 he coded and was transferred to the Intensive Care Unit where he was placed on life support. He was declared dead at 5:15 a.m. on the same date.

There were minor security deficiencies noted at two of the three facilities detainee ALMAZAN was housed at. None of these issues contributed to his death.


Krome North Service Processing Center

Facility Description

KNSPC is owned by ICE and managed by ERO, Miami Field Office. The facility has a capacity of 581. While female detainees are temporarily brought to KNSPC for court, only male detainees are detained overnight. On September 12, 2017, the population was 608. There are approximately 90 ICE employees on staff at the facility. Contractors Akima Global Services (AGS), with regional headquarters in Herndon, Virginia, and AKAL Security, with corporate headquarters in Espanola, New Mexico, provide security and armed transportation services. AGS officers are not weapons certified and supervise detainees in areas such as housing units and the cafeteria inside the facility. AKAL officers are weapons certified and work the processing/intake area, transport detainees and provide vigils when detainees are at one of the three hospitals used by KNSPC. There are 177 AKAL contract security staff. All officers involved in this event were AKAL staff.

Healthcare Services

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



KNSPC's primary health care provider is ICE Health Service Corps (IHSC), supported by contractor InGenesis Medical Staffing based in San Antonio, Texas. InGenesis Medical Staffing sub-contracts STG International, Incorporated. Medical services are provided 24 hours a day, seven days a week. The staffing plan includes 21 commissioned Public Health Service officers, five GS employees, and 31 contract employees. Additionally, there are four casual nurses. The commissioned officers include the Health Services Administrator (HSA), assistant HSA, Clinical Director, three mental health professionals, dentist, pharmacist, three mid level providers, nurse manager, program manager, and eight registered nurses (RN). The GS employees include three medical records technicians, a dental assistant, and a radiology technician. (b)(7)(E)

(b)(7)(E)

(b)(7)(E)

A casual pool of three contract RNs and one contract LPN supplement the staffing model. According to the HSA (b)(6); (b)(7)(C) vacancies at the time of ALMAZAN's detention included five RNs and a radiology technician. Credential files were reviewed and found to be current and primary source verified. KNSPC achieved American Correctional Association accreditation in August 2015, and National Commission on Correctional Health Care accreditation in April 2015.

IHSC's electronic medical record system, e-Clinical Works (eCW), is used at KNSPC. It is noted that unless indicated, the times of medical encounters identified in this report are the times nurses and providers electronically entered their notes, per system-produced timestamps. The times encounters were actually conducted are not available unless documented in the notes.

Detention Summary


Detention Officer (b)(6); (b)(7)(C) processed detainee ALMAZAN into KNSPC, documenting that the detainee's primary language was Spanish. Officer (b)(6); (b)(7)(C) acknowledged he does not speak Spanish and he stated that he typically obtains assistance from a bilingual fellow officer when processing the detainee into the facility. On interview, Officer (b)(6); (b)(7)(C) stated he had only slight recollection of this detainee but would have followed his usual practice when processing him. He initially pat searches each detainee when they arrive and he completed a Record of Search form confirming no contraband was found on detainee ALMAZAN. Officer (b)(6); (b)(7)(C) stated he would next provide the detainee the opportunity to shower and then send the detainee to be classified. Detainee ALMAZAN's classification review was completed by other members of the processing team and he was appropriately classified as medium high. The classification level was approved by a supervisor on the same date.

Once classified, detainee ALMAZAN was sent back to Office (b)(6); (b)(7)(C) so the proper color uniforms could be issued as well as facility linens, hygiene supplies and other clothing. The detainee would have next been sent to property to have his personal property inventoried and his funds placed into an account. The detainee's inventory form documents he arrived with one

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz

Medical and Security Compliance Review

December 4-5, 2017



billfold, one pair of jeans, two pairs of shorts, some personal papers, two pairs of shoes, one pair of sunglasses, two t-shirts and valuables that were not identified. These items were placed in property bin #3666037. A receipt for the property was signed by the detainee. The detainee also arrived with a check for \$9.00 and the funds were deposited into the kiosk system for his use at commissary. Detainee ALMAZAN was issued facility clothing, linens and hygiene supplies and he signed a receipt for these items. Detainee ALMAZAN did not provide the facility with a forwarding address and signed a form documenting this. He also signed a form acknowledging he received a copy of the local and national handbooks. Per Officer (b)(6);
(b)(7)(C) the detainee was then sent to medical for intake screening. Officer (b)(6);
(b)(7)(C) recalled that detainee ALMAZAN moved slowly.

During his stay at KNSPC, detainee ALMAZAN was assigned to units four, five and six in building eight. Building eight houses high and medium high detainees and contains six units; units one through three on the lower level and units four through six on the upper level. On each floor there is a control pod in the center with an officer assigned at all times. Another officer is assigned to each pod for direct supervision of the detainees. On the upper level, pods four through six are located clockwise around the control center. Each pod is essentially identical with small variations in the unit set up.


Pod four has a capacity for 60 detainees with 30 bunk beds in the center of the unit. Upon entry to the unit, the officer's station is located to the left and there are a bank of phones along the left wall. To the right of the entry way is a kiosk for ordering commissary and sending requests or grievances. There are also numerous chairs for detainees to use while viewing the TV located on that wall. A second TV is mounted on the ceiling near the center of the unit. Along the right wall at the rear of the unit is a shower and toilet area separated from the open area by a half wall. There are long, narrow windows along the left and rear walls which allows natural light into the unit. There are four ceiling mounted cameras in the unit; appropriately none with a view of the bathroom area.

EARM documents that the detainee was originally on a manifest to transfer to Glades County Detention Center (GCDC) in Moore Haven, FL on **July 13, 2017**; however, he was removed from that trip for unknown reasons.

There is no record of any requests, visits, phone calls or unusual incidents involving detainee ALMAZAN during his stay at KNSPC. On August 11, 2017, detainee ALMAZAN's personal property was again inventoried for transfer to GCDC. A receipt for \$9.00 in funds was signed by the detainee and a check was issued at 3:08 p.m. per the Resident Transaction Receipt. The check notes, "Release Glades". Detainee ALAZAN was provided with the address and phone number of GCDC and he signed a form acknowledging that he received the information. Per EARM, he was transferred out of KNSPC at 7:30 p.m.

Summary of Events

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



(b)(6); (b)(7)(C)

RN documented a pre-screen at 5:47 p.m. on **July 12, 2017**, noting that detainee ALMARAZ arrived to the facility at 1500 hours, the latter time believed to be in error. Lieutenant (b)(6); (b)(7)(C) stated during interview he is alerted whenever detainees arrive. After verifying the detainee's name, nationality and date of birth on the Order to Detain or Release Alien 203 form, he stated it is his common practice to then ask the officer at the desk to tell him the time from the computer screen, and he notes the time on the form. In this case, the arrival time noted was 5:00 p.m. When asked if the time he documented could have been an error as medical had noted a medical screening was done at 3:00 p.m. the Lieutenant replied that he did not think that was possible as the time of arrival is verified by the officer at the desk. In addition, the EARM records document the detainee arrived at 5:00 p.m.

Interpretation assistance was not provided at the time of the pre-screen, as, "Detainee speaks English fluently," and there were no barriers to communication identified. (b)(6); (b)(7)(C) advised she does not speak Spanish but, "If I say do you have any medical questions and I can see he is struggling with my questions, I can get an interpreter." It was noted ALMAZAN had not transferred from another facility. He was noted to have current, unspecified health problems and was taking medication. He was placed on a Priority 2 status, which according to (b)(6); (b)(7)(C) means a provider must evaluate the detainee within 24 hours because of a chronic condition or if he is taking medications.

At 9:39 p.m. (b)(6); (b)(7)(C) RN, InGenesis, conducted the intake screen, noting that Detainee ALMAZAN was Spanish speaking, for which interpretation assistance was provided. Inconsistent with LT (b)(6); (b)(7)(C) note, RN (b)(6); (b)(7)(C) stated he had transferred from another facility, having arriving with a transfer summary. Attempts to locate a transfer form, however, found no evidence of its existence. Detainee ALMAZAN stated he was feeling fine and was not in pain. He offered his previous diagnosis of cirrhosis¹ and that he was on medication. The only medication listed, however, was sertraline (Zoloft), a medication to treat depression. When asked if he was now or ever had been treated by a doctor for a medical condition, he replied no. He denied symptoms of tuberculosis infection, and his chest x-ray was negative. He denied drug abuse but admitted to drinking 12 to 15 beers a day, having last used on April 1, 2017. He also admitted to being a smoker, smoking two cigarettes per night. The examination, mental health screening, and vital signs were all within normal limits (*See Appendix I for vitals*). A Spanish version of the consent for medical treatment was signed. He was noted to have an abnormal intake screening and was referred to a medical provider. He was medically cleared for custody.

LT (b)(6); (b)(7)(C) RN documented a sick call visit on **July 16, 2017**, at 3:34 p.m. to assess an unspecified skin irritation. An interpreter was not used, as, "Detainee speaks English fluently." When questioned during interview as to how she determines when interpretation assistance is needed, she replied that she is able to understand the issue, sometimes using "sign

¹ Cirrhosis is liver damage from a variety of causes, such as alcohol abuse, leading to scarring and liver failure.

language” and since this visit occurred on a Sunday, “We probably had a Spanish speaking person to translate, and I didn’t document it.” Vital signs were all within normal limits, and ALMAZAN’s general appearance was described as well developed, well nourished, and in no acute distress. In spite of the complaint of skin irritation, the skin was documented only as normal, warm and dry. His heart was regular in rate and rhythm, and his lungs were normal. Treatment included Clotrimazole cream², with application to the affected area twice a day for seven days, as keep-on-person (KOP) medication and hydrocortisone cream³ with application to the affected area, externally, twice a day for seven days, also as a KOP medication. An English version of a KOP agreement was signed by ALMAZAN. Treatment notes refer only to “RN Guidelines for Foot Fungus”, while a reference to a nursing guideline authorizing use of hydrocortisone cream was not filed. During interview, (b)(6); (b)(7)(C) admitted her failure to document the complete physical assessment and was unable to recall why she ordered the hydrocortisone cream, stating, “If I treated him, there was a reason I treated him”.

Seven days following intake, on **July 19, 2017**, at 5:34 a.m., LCDR (b)(6); (b)(7)(C) NP, conducted an initial physical examination, noting that the intake screen was reviewed. An interpretation service was used, with the Language Line identification number recorded. During interview NP (b)(6); (b)(7)(C) stated, “Even if they say they speak a little bit of English, I use the service to make sure they understand.” Detainee ALMAZAN denied all medical and dental complaints, with the exception of hepatitis and depression. He admitted to suicidal ideation one year ago but denied any attempts. NP (b)(6); (b)(7)(C) narrative states detainee ALMAZAN was taking medication for cirrhosis while in Metrowest Detention Center (MDC)⁴. He stated he felt fine, was eating and sleeping well, and had regular bowel movements. He denied homicidal or suicidal ideations or thoughts of potential for violence towards others. He denied chest pain, shortness of breath, nausea or vomiting, fever or chills, abdominal pain, diarrhea, constipation or any other complaints or concerns at that time. His vital signs were all within normal limits. His eye test showed a visual impairment⁵ of 20/200 in the left eye, 20/100 in the right eye, and 20/70 in both eyes, without glasses. The general examination found him to be in no acute distress, well developed, well nourished, and calm and relaxed. He was noted to be asymptomatic⁶ and clinically stable. The assessment diagnoses were alcoholic cirrhosis of liver without ascites⁷ and visual disturbance. The treatment plan included renewal of sertraline, follow up with mental health, comprehensive laboratory studies on July 28, 2017, referral to ophthalmology⁸, and referral to radiology for an ultrasound⁹ of the liver. A medical consent was sent to MDC to obtain medical and medication

² Clotrimazole cream is an antifungal medication, commonly used to treat athlete’s foot.

³ Hydrocortisone cream is a steroid used to treat skin conditions.

⁴ MDC is a Dade County prison in Doral, Florida


⁵ A visual impairment refers to loss of vision and decreased ability to see. Normal vision is 20/20, while 20/200 is a significant vision loss.

⁶ Asymptomatic means an absence of symptoms.

⁷ Ascites is an abnormal accumulation of fluid in the abdominal cavity.

⁸ Ophthalmology refers to a specialty in eye disease.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



records. Detainee ALMAZAN was provided patient instructions and preventive health information.


The initial mental health screen was conducted on **July 20, 2017**, at 2:18 p.m. (b)(6); (b)(7)(C) Psychologist, STG recalled conducting the encounter in Spanish and was not aware of what ALMAZAN's level of English proficiency was. During questioning ALMAZAN verbalized that the father of a 43 year-old woman he had been dating was angry that he was going out with his daughter and later accused him of sexual assault. His past psychiatric history included hospitalization at Jackson Memorial Hospital (JMH) for alcohol abuse four years ago, but was later referred to mental health while at the hospital. He reported that he was drinking heavily due to depression and stress. He said he would experience sadness, crying spells, and had suicidal ideations. He said he felt this way because of not having a wife or significant other, not having his parents, having a sibling pass away, and losing his job. He reported that while at JMH he was seen by a psychiatrist who prescribed medication, which helped him significantly, but he did not recall the name of it. As per medical records, he was taking Zoloft (*sertraline*) 100 mg. He reported a history of suicidal ideations prior to his hospitalization, having had thoughts of jumping off a building, but he did not follow through as he began to think about his family, and he started to read the Bible. He also reported suicidal ideations three years ago with thoughts of cutting himself with a knife, but focusing on his faith, he did not follow through. He denied current suicidal/homicidal ideation, intent or plans. He also denied a history of perceptual disturbances or delusions. The substance abuse history noted detainee ALMAZAN had been convicted for driving under the influence of alcohol and participated in in-patient alcohol treatment. The assessment findings were 1. Major depressive disorder¹⁰, recurrent, mild; and 2. Alcohol abuse, uncomplicated. Treatment included follow-up in two to three weeks and referral to (b)(6); (b)(7)(C) for medication management.

On **July 24, 2017**, at 5:46 p.m., LCDR (b)(6); (b)(7)(C) RN documented a progress note related to a sick call refusal, stating, "Patient called for sick call on evening shift but refused. Multiple calls were placed by PHS desk officer with no result. Will continue to monitor." RN (b)(6); (b)(7)(C) explained that detainees are typically seen in sick call between 8:00 a.m. to 3:00 p.m. every day, but in the event of a spill over, a list is made of those not seen, and the detainees who are returned to the housing until after 3:00 p.m. are called back on the evening shift of the same day. Prior to the sick call visit, nurses do not know the nature of the request. Three days later on **July 27, 2017**, at 12:19 p.m. (b)(6); (b)(7)(C) RN documented a late entry for a sick call visit conducted on July 26, 2017. An interpretation service was not used as "Detainee speaks English fluently." Detainee ALMAZAN stated he had been taking pills for his liver but had not yet received them." He denied pain, and his vital signs were all within normal limits. The nursing plan was to send a telephone encounter to a medical provider. The following day of July 28, 2017, at 12:00 p.m., RN (b)(6); (b)(7)(C)

⁹ An Ultrasound is a diagnostic tool using sound waves to produce images of inside the body.

¹⁰ Major depressive disorder is a mental health disorder characterized by persistently depressed mood or loss of interest in activities, causing a significant impairment in daily life.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



documented another sick call visit for complaint of respiratory symptoms and sore throat. An interpreter was not used for his visit as, "Detainee speaks English fluently." Detainee ALMAZAN denied pain, and his vital signs were all within normal limits. He stated his cold symptoms were mild and had been present for a few days. His general appearance was described as pleasant, in no acute distress. His throat appeared normal, and his respirations were even and unlabored. He was instructed to do salt water gargles three times daily for three days and was returned to the dorm.

(b)(6); (b)(7)(C)

RN, InGenesis documented a sick call assessment for complaint of skin itching on **August 2, 2017** at 1:39 p.m. An interpreter was not used, as, "Detainee speaks English fluently." Detainee ALMAZAN denied pain, and his vital signs were all within normal limits. He described moderate itchiness over his whole body, having started weeks ago. He was observed to be persistently scratching. His general examination found him to be alert, well hydrated, and in no acute distress. There were no suspicious lesions, and psychologically he was alert, oriented, cooperative with the exam, and showed intact cognitive¹¹ functioning. The nursing treatment plan included application of hydrocortisone cream to the affected areas twice daily, start polyvinyl alcohol ophthalmic solution¹² to the eyes four times daily, and patient instructions regarding bathing, avoidance of irritants, and increase of water intake. Following repeated requests for a RN Guideline addressing itching to verify the prescribed treatment of hydrocortisone cream, it was never produced.

(b)(6); (b)(7)(C)

documented a follow-up mental health assessment on **August 4, 2017**, at 12:29 p.m., noting the conversation was in Spanish. Vital signs conducted (b)(6); (b)(7)(C) RN were all within normal limits, and detainee ALMAZAN denied pain. He expressed having symptoms of depressed mood, but they were decreased from those previously reported. He stated he was participating in recreational activities and socializing with his peers. He presented as psychiatrically stable and was able to remain housed in the general population. He reported he had been complying with his psychiatric medication, with improvement in his level of sadness, energy, and motivation. His mood and attitude seemed better, and he no longer felt tearful. He offered he had talked to his sister who told him she was in the process of legalizing her stay in the U.S. and therefore did not want contact with him. He also discussed having gone to court the previous day, at which time the judge asked him if he found a lawyer with the list given to him. He said he informed the judge that no one returned his call. The judge asked him if he wanted to **proceed with** the case on his own which he replied yes to. An appointment was **pending with** (b)(6); (b)(7)(C) Psychologist on August 11, 2017, and he was scheduled for follow-up with (b)(6); (b)(7)(C) in three to four weeks.

At 2:32 p.m. the same day, (b)(6); (b)(7)(C) PA, STG documented a provider visit to review laboratory studies with detainee ALMARAZ. According to the laboratory reports, the blood samples were drawn and forwarded to the laboratory on July 28, 2017, results were received on

¹¹ Cognitive refers to the process of knowing and perceiving.

¹² Polyvinyl alcohol ophthalmic solution is also known as artificial tears, a treatment for dry eyes.

July 31, 2017, and [REDACTED] reviewed them on August 3, 2017, noting, “MLP will discuss with patient tomorrow”. Interpretation services were not used for this encounter, as PA Mederos-Perez speaks fluent Spanish. Detainee ALMAZAN reported that he takes pills for his liver and had not received them as yet. He stated he occasionally feels weak and tired, had been eating and sleeping well and was better adjusted in general population. He listed his medications as rifaximin¹³ 550 mg twice daily, Folic acid¹⁴ 1 mg once daily, docusate¹⁵ 100 mg twice daily, multivitamin¹⁶ one tablet daily, Aspirin¹⁷ 81 mg once daily, and omeprazole¹⁸ 20 mg once daily. He explained he had been taking rifaximin for six to seven years. He denied any bruises, bleeding, or abdominal pain. As over 50 laboratory values were obtained, only the abnormal levels are listed:

Test	Normal Range	Result
Hemoglobin A1c ¹⁹	4.8-5.6	4.4
Prothrombin Time ²⁰	9.1-12.0	12.3
Hepatitis A Antibody ²¹	Positive	Negative
Hepatitis B Core Antibody ²²	Positive	Negative
Bilirubin ²³	1.6	0.0-1.2
Albumin, Serum ²⁴	3.4	3.5-5.5
BUN/Creatinine Ratio ²⁵	23	9-20
Creatinine, Serum	0.57	0.76-1.27
Alkaline Phosphatase ²⁶	157	39-117
Serum Lipase ²⁷	67	0-59

¹³ Rifaximin is a type of antibiotic, which treats traveler’s diarrhea and irritable bowel syndrome with diarrhea.

¹⁴ Folic acid is a B vitamin used to enhance red blood cell production.

¹⁵ Docusate is a stool softener used to treat constipation.

¹⁶ Multivitamin is a nutritional supplement.

¹⁷ Aspirin is a pain reliever.

¹⁸ Omeprazole is a medication used to treat heartburn and esophageal reflux disease (GERD).

¹⁹ Hemoglobin A1c is a test, which provides an average of blood sugar over a two-month period.

²⁰ Prothrombin time is a blood test to determine how quickly the blood clots.

²¹ Hepatitis A antibody is a protein which if present in the blood, signifies past exposure to hepatitis A.

²² Hepatitis B core antibody is a protein, which if present in the blood, indicates previous or ongoing infection with hepatitis B

²³ Bilirubin is an orange, yellow pigment produced by the liver.

²⁴ Serum albumin is the most abundant protein in the blood and is also the major carrier of fatty acids in the blood.


²⁵ BUN (blood urea nitrogen)/Creatinine (a waste product from muscle breakdown) ratio is a test to check kidney function.

²⁶ Alkaline phosphatase is an enzyme found in the blood. Abnormal values can help determine the level of liver dysfunction.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz

Medical and Security Compliance Review

December 4-5, 2017



Neutrophils ²⁸	1.3	1.4-7.0
Hemoglobin ²⁹	10.5	12.6-17.7
Red Blood Cells ³⁰	3.28	4.14-5.8
Hematocrit ³¹	29.3	37.5-51.0
White Blood Cells ³²	2.0	3.4-10.8
Platelets ³³	37	150-379
Lymphocytes ³⁴	0.4	0.7-3.1

(b)(6); (b)(7)(C) MD, STG noted lab results would be discussed with detainee ALMAZAN. (b)(6); (b)(7)(C) listed the assessment findings as 1) Alcoholic cirrhosis of liver without ascites; 2) Other pancytopenia³⁵, and 3) Hepatitis B carrier. Creative Corrections notes that according to the CDC website, the hepatitis B results indicate immunity due to natural disease and do not indicate carrier status as diagnosed by (b)(6); (b)(7)(C). Treatment ordered for liver disease included rifaximin 550 mg twice daily; folic acid 1 mg daily; docusate 100 mg twice daily; multivitamin, one tablet daily; enteric coated³⁶ aspirin 81 mg daily; and omeprazole 20 mg daily. Follow-up laboratory studies were ordered to include serum uric acid³⁷, CBC³⁸ with differential³⁹, serum lipase, serum amylase, thyroid panel⁴⁰ with thyroid stimulating hormone⁴¹, and GGT⁴². Rifaximin was non-formulary, so a request for authorization was completed. A referral was

²⁷ Serum lipase is an enzyme, which can be found in abnormally high levels in the blood when the pancreas is damaged.

²⁸ Neutrophils are a type of white blood cells, which help fight infection by ingesting microorganisms

²⁹ Hemoglobin is the protein molecule in the red blood cells that carries oxygen from the lungs to the body's tissues and returns carbon dioxide from the body back to the lungs.

³⁰ Red blood cells are the blood cells that contain hemoglobin and carry oxygen.

³¹ Hematocrit is a volume percentage of red blood cells in the blood, usually at 47% in males.

³² White blood cells are the cells involved in protecting the body against infection.

³³ Platelets, also called thrombocytes, are a component of blood whose function is to stop bleeding by clumping and clotting blood vessel injuries.

³⁴ Lymphocytes are a form of white blood cells that produce antibodies to fight infection.

³⁵ Pancytopenia is a medical condition in which there is a reduction in the number of red blood cells, white blood cells, and platelets.

³⁶ Enteric-coating is a polymer barrier applied on oral medication, which prevents its disintegration in the stomach.

³⁷ Serum uric acid is the chemical found in the blood when the body breaks down foods containing organic compounds called purines. If too much uric acid is being produced or if the kidneys are not able to remove it from the blood normally, the level increases, potentially causing solid crystals to form within the joints, causing gout.

³⁸ CBC, short for complete blood count tests levels of all types of blood cells to determine the presence of disease.


³⁹ A blood differential test measure the percentage of each type of white blood cells.

⁴⁰ Thyroid panel is a series of tests used to evaluate thyroid function and help diagnose hypo- or hyperthyroidism.

⁴¹ Thyroid stimulating hormone is a hormone produced by the pituitary gland, which stimulates the thyroid gland to produce and release hormones into the blood.

⁴² GGT is short for gamma-glutamyl transferase, which is elevated in some forms of liver disease.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
 Medical and Security Compliance Review
 December 4-5, 2017



submitted for hematology⁴³, pending approval. Detainee ALMAZAN was cleared for custody and scheduled for follow-up “as scheduled or sooner as needed.”

On **August 9, 2017**, at 9:38 a.m., NP (b)(6);
(b)(7)(C) conducted a follow-up assessment for pancytopenia and review of lab results. An interpreter was not used during this encounter. Questioned about why interpretation assistance was not used, as she had earlier voiced its importance at the time of the initial physical examination, she stated, “Maybe I forgot to note the interpreter was used, because as I said, if they only speak a little English, I get an interpreter.” Detainee ALMAZAN denied pain and his vital signs were all within normal limits. He requested medication for skin itching, especially over his back. He also requested an eye appointment and medication for gas. He reported he had been eating and sleeping well and was doing well in general population. He denied any bruising, bleeding, or abdominal pain at that time. The general examination noted no acute distress, well developed, well nourished, and calm and relaxed. His skin was warm and dry with good turgor⁴⁴, and there was no bruising, hematomas⁴⁵, bleeding, or fragile capillaries. His heart assessment was normal. He was alert, oriented, and cooperative, demonstrating intact cognitive functioning and good eye contact. His gait was normal. The assessment diagnoses were 1) Other pancytopenia and 2) Tinea pedis⁴⁶. Treatment for pancytopenia included lactulose⁴⁷ solution twice daily, Spironolactone 25 mg twice daily, hematology referral pending approval, and ophthalmology referral pending approval. Orders for tinea pedis included clotrimazole cream twice daily for seven days and hydrocortisone cream twice daily for seven days. Aluminum-magnesium-simethicone suspension⁴⁸ 400 mg was ordered four times a day for seven days.

(b)(6); (b)(7)(C) MD, Psychiatrist conducted a psychiatric evaluation on **August 11, 2017**, at 9:40 a.m., noting that an interpretation service was not used as, “Detainee speaks English fluently.” (b)(6);
(b)(7)(C) noted she obtained her subjective information from the initial mental health intake, and following the narrative, documented, “Patient concurred with the above information. He currently denied any depressive, manic, psychotic, or anxiety symptoms, no suicidal ideation/homicidal ideation. He reports insomnia. Risks, benefits, and side effect of Trazodone were discussed with patient who consented.” Creative Corrections observed English consent forms were signed for both Zoloft on July 19, 2017, and for Trazodone at the time of this encounter, suggesting that ALMAZAN may not have fully understood the indication and side effects of the medication. Vital signs conducted by RN (b)(6);
(b)(7)(C) were all within normal limits, with the exception of a mildly

⁴³ Hematology is the branch of medicine concerned with the study of the cause, diagnosis, treatment, and prevention of blood related diseases.

⁴⁴ Turgor is the degree of elasticity of the skin, assessment of which can determine the extent of dehydration of fluid loss in the body.

⁴⁵ A hematoma is a solid swelling of clotted blood within the tissues.

⁴⁶ Tinea pedis, also known as athlete’s foot, is a fungal infection of the feet, usually beginning between the toes.

⁴⁷ Lactulose is a type of sugar solution used to treat chronic constipation and to reduce the amount of ammonia in the blood of patients with liver disease.

⁴⁸ Aluminum-magnesium-simethicone is

elevated body temperature of 99.3. The diagnosis was major depressive disorder, recurrent, mild, for which trazodone⁴⁹ 50 mg was ordered. Follow-up was scheduled for four weeks. As Dr. (b)(6); (b)(7)(C) was no longer employed at KNSPC at the time of the review.

At 4:23 p.m., RN (b)(6); (b)(7) documented a transfer summary for ALMAZAN's departure to Glades County Detention Center (GCDC) the same day. There were no special needs or medical, dental, or mental health reasons listed that would affect his transportation, nor were there any restrictions or special equipment required for travel. The disposition was "medically cleared for custody". The document included all current medications, but the only medical history listed was cirrhosis for eight years. There was no reference to pancytopenia, depression, or tinea pedis, all of which had been identified since his intake. Additionally, there was no reference to pending referrals for hematology, ophthalmology, and radiology for a liver ultrasound; nor were copies of laboratory studies and most current chronic care clinic records sent with the transfer summary to ensure efficient continuity of care by the receiving facility. The medical documentation failed to include a medical hold to ensure provider review prior to transfer.

During interview, CAPT (b)(6); (b)(7)(C) MD, Clinical Director addressed the adverse findings related to ALMAZAN's medical care, emphasizing that he had not rendered care so was "only looking at other things as the clinical director." He cited his main concern as the flow of appointments related to pancytopenia, chronic liver problems, and cirrhosis caused by abuse of alcohol. He described the platelet count of 37 as, "very low, he didn't have the building blocks for coagulation," adding that there was definitely a risk for bleeding and infections, but it may have been going on for years. Questioned about the length of time it took for the hematology referral, he replied, "We have no control," explaining that certain consulting specialties are difficult to access, and that it basically is no different from being seen in the community, which can take three to four weeks. With his specialty as a flight surgeon (b)(6); (b)(7)(C) stated low platelets would not affect clearance for air travel, and even with a low hemoglobin level of 10.5, "I would still clear someone at those levels to fly." In discussion of the transfer summary, which omitted serious diagnoses, (b)(6); (b)(7)(C) explained if providers failed to update the problem list, the conditions will not show at the time the nurse prepares the summary, agreeing that the problem list was not current and in addition to pancytopenia and depression, should have included varices⁵⁰ and portal hypertension⁵¹. He stated it would not be impossible to send applicable copies of the medical record with the summary, although, "It would take more work to include it." He did agree, however, that it would be helpful to include the last chronic care clinic. Regarding a medical hold, he stated there would not be a need for a medical hold if the receiving institution was aware of and followed up with the medical condition. He added that he would have no problem telling ICE a detainee can not go if there were pending consults, however, adding, "Whether it would have made a difference in the outcome,

⁴⁹ Trazodone is a medication used to treat depression and sleep difficulty.

⁵⁰ Varices are abnormal veins in the lower part of the tube running from the throat to the stomach.

⁵¹ Portal hypertension refers to high blood pressure in the system of veins coming from the stomach, intestine, spleen, and pancreas which merge into the portal area before traveling through the liver.

hard to say.” He voiced his opinion that GCDC was an appropriate facility to send a stabilized case, and that they had not any any significant issues with them.

APPENDIX I Vital Signs

DATE	TEMPERATURE	PULSE	RESPIRATIONS	BLOOD PRESSURE	WEIGHT
July 12, 2017	98.1	74	16	114/68	171
July 16, 2017	97.6	74	16	107/66	170
July 19, 2017	98.5	69	16	110/70	175
July 20, 2017	97.9	68	16	101/61	175
July 27, 2017	98.1	73	16	115/61	170
August 2, 2017	98.2	82	16	105/63	170
August 4, 2017	98.1	72	16	100/63	172
August 8, 2017	98.4	71	16	102/64	165
August 11, 2017	99.3	74	16	97/57	170

CONCLUSIONS


Medical Compliance Findings

Creative Corrections finds the care provided to Filipe ALMAZAN-Ruiz by the Krome North Service Processing Center did not meet all requirements of the 2016-revised ICE PBNDS 2011, Medical Care. Deficiencies were identified in the following components of the standard:

ICE PBNDS 2016, Medical Care, section (V)(E), which states, “Each facility shall provide appropriate interpretation and language services for LEP detainees related to medical and mental health care. Where appropriate staff interpretation is not available, facilities will make use of professional interpretation services.”

- On July 16, 2017, at 3:34 p.m. to assess an unspecified skin irritation. An interpreter was not used, as, “Detainee speaks English fluently.”
- The keep-on-person agreement form signed on July 16, 2017, was in English and may not have ensured his full understanding.
- Consent forms for psychotropic medications were not provided in Spanish version to ensure full understanding of the indication and side effects of the medication.
- Nursing sick call encounters conducted on July 26, 2017, July 27, 2017, and August 2, 2017, failed to use interpretation assistance to ensure full and accurate information gathering and clear understanding of instructions provided.
- On August 9, 2017, a non-Spanish-speaking provider conducted a laboratory results follow-up encounter in the absence of interpretation assistance.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



ICE PBNDS 2016, Medical Care, section (V)(G)(3), which states, “Each detention facility shall have and comply with written policy and procedures for the management of pharmaceuticals, to include: 3) prescription practices, including requirements that medications are prescribed only when clinically indicated, and that prescriptions are reviewed before being renewed.”

- July 16, 2017, hydrocortisone cream was issued in the absence of assessment findings.
- On August 2, 2017, hydrocortisone cream was again issued as a KOP in the absence of a RN Guideline.

ICE PBNDS 2016, Medical Care, section (V)(M), which states, “Each facility’s health care provider shall conduct a comprehensive health assessment, including a physical examination and mental health screening, on each detainee within 14 days of the detainee’s arrival unless more immediate attention is required due to an acute or identifiable chronic condition.” Additionally: **NCCHC J-E-04 (Essential), section (5)**, which states, “Inmates identified with *clinically significant findings* as the result of a comprehensive receiving screening receive an initial health assessment as soon as possible, but no later than 2 working days after admission.”

- Although the intake assessment identified cirrhosis, the initial physical assessment was not completed until one week following intake.

ICE PBNDS 2016, Medical Care, section (V)(N), which states, “Where a detainee has a serious medical or mental health condition or otherwise requires special or close medical care, medical staff shall complete a Medical/Psychiatric Alert form (IHSC-834) or equivalent, and file the form in the detainee’s medical record. Where medical staff furthermore determine the condition to be serious enough to require medical clearance of the detainee prior to transfer or removal, medical staff shall also place a medical hold on the detainee using the Medical/Psychiatric Alert form (IHSC-834) or equivalent, which serves to prevent ICE from transferring or removing the detainee without the prior clearance of medical staff at the facility. The facility administrator shall receive notice of all medical/psychiatric alerts or holds, and shall be responsible for notifying ICE/ERO of any medical alerts or holds placed on a detainee that is to be transferred.


Potential health conditions meriting the completion of a Medical/Psychiatric Alert form may include, but are not limited to medical conditions requiring ongoing therapy, such as a.) active TB, b) infectious diseases, and c) chronic conditions.”

- Medical documentation failed to include a medical hold to ensure provider review prior to transfer.

ICE PBNDS 2016, Medical Care, section (V)(W), which states, “Consistent with Standard 4.8 ‘Disability Identification, Assessment, and Accommodation’ and the IHSC Detainee Covered Services Package, detainees will be provided medical prosthetic devices or other impairment aids, such as eyeglasses, hearing aids, or wheelchairs.”

- Significant vision impairment identified one week following intake failed to result in the issuing of reading or prescription eyeglasses. Additionally, because the pending

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



ophthalmology referral was not forwarded to the receiving facility during transfer, the detainee never received glasses during his remaining detention period.

ICE PBNDS 2016, Medical Care, section (V)(X)(1), which states, “The facility administrator and clinical medical authority shall ensure that the Field Office Director is notified as soon as practicable of any detainee housed at the facility who is determined to have a serious physical or mental illness or to be pregnant, or have medical complications related to advanced age, but no later than 72 hours after such determination. The notification shall become part of the detainee’s health record file.”

- The medical record did not include a notification to the Field Office Director regarding the condition of potentially advanced cirrhosis and pancytopenia.

ICE PBNDS 2016, Medical Care, section (V)(Z), which states, “The facility HSA must ensure that a plan is developed that provides for continuity of medical care in the event of a change in detention placement or status. The detainee’s medical needs shall be taken into account prior to any transfer of the detainee to another facility. Alternatives to transfer shall be considered, taking into account the disruption that a transfer will cause to a detainee receiving medical care.”

- The transfer summary dated August 11, 2017, failed to include the serious chronic diagnoses of pancytopenia and depression. Additionally, there was no reference to pending referrals for hematology, ophthalmology, and radiology for a liver ultrasound; nor were copies of laboratory studies and most current chronic care clinic.

Areas of Note

In addition to the above deficiencies, Creative Corrections notes the following:


- Providers failed maintain a current problem list of serious illnesses, to include pancytopenia and depression, resulting in delayed continuity of care following transfer to another ICE facility.

Glades County Detention Center

Facility Description

GCDC is operated by the Glades County Sheriff’s Office and houses county inmates as well as United States Marshall Service (USMS) and ICE male and female detainees. The facility, which opened in 2007, houses medium, medium high and high custody detainees and has a capacity of 540. On September 5, 2017, the facility count was 429 and was comprised of 369 ICE detainees

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



(298 male and 71 female), 40 county inmates (30 male and 10 female) and 20 male USMS detainees.

All staff with direct supervision responsibilities over detainees are sworn law enforcement officers. Officers must attend 500 hours of training at an academy to be certified by the state of Florida.

There are two main dormitory-style housing areas at GCDC – Dorm 1 and Dorm 2. There is also a 20 bed Special Management Unit. Detainee ALMAZAN was housed in Dorm 1 throughout his stay at GCDC. Per the Movement History, detainee ALMAZAN was assigned to Dorm 1, pod C, at 3:57 a.m. Dorm 1 has a capacity for 378 and is used primarily for ICE detainees. The dorm is comprised of four separate pods, A through D, each of which houses between 92 and 96 detainees. The pods encircle an elevated observation control center which is staffed by a civilian clerk who manages the doors to each pod and has no direct contact with detainees. A sergeant and officers are assigned to the dorm floor and provide supervision to the four separate pods. The housing pods are each two stories with eight four-bunk open bays on each level. A bathroom and shower area is on each level. The upper tier is accessed by a staircase on the left side of the pod. On the lower level are tables, a television and a video terminal for visitation.

Healthcare Services

Armor Correctional Health Services (ACHS), with headquarters in Miami, Florida has provided 24-hour medical care since the facility's activation in June 2007. GCDC earned their most recent accreditation through the National Commission on Correctional Healthcare (NCCCHC) in May 2017, and at the current time, eight medical employees have earned status as Certified Correctional Health Professionals (CCHP)⁵². Full time positions include the Director of Nurses (DON), a licensed clinical social worker, the Administrative Assistant, and the Health Services Administrator (HSA), the latter of whom is not a clinician but has a health services administration background. Three part time registered nurses (RN) provide a total of 56 hours per week, and 13 part time licensed practical nurses (LPN) provide 460 hours per week. Other part time positions include a mental health physician assistant, two licensed mental health professionals, a dentist, and a dental assistant. The Clinical Director, a CCHP is licensed in Puerto Rico and Florida, with certification to work in critical need areas. He is available on site for clinical services four days per week. Staffing numbers were found to be sufficient for the provision of detainee healthcare, in accordance with the NDS, and all professional licenses were present, current and primary source verified.

The GCDC medical clinic houses a multi-workspace nursing station with a pass-through window connecting to an 18-chair waiting room. A custody officer's desk is located inside the waiting room providing direct supervision. The clinic houses four examination/treatment rooms, a

⁵² A CCHP is a medical person who has demonstrated, through NCCCHC testing, the possession, application, and interpretation of knowledge necessary for professional practice in correctional health care.

pharmacy, a one-chair dental suite, a specimen collection room, two administrative offices, and four medical observation rooms, three of which have negative air pressure capability for respiratory isolation. GCDC's electronic medical record (EMR) CorrecTek has been in place since May 2014, and language assistance for detainees with limited English proficiency is provided by Interpretalk Interpretive Services.

Detention Summary

EARM records document detainee ALMAZAN arrived at GCDC in Moore Haven, FL at 8:29 p.m. on **August 11, 2017**. At 9:28 p.m., detainee ALMAZAN was booked into the GCDC per the facility records. Upon arrival, detainee ALMAZAN was searched and photographed by Officer (b)(6); (b)(7)(C) and booked in by Officer (b)(6); (b)(7)(C) per the GCDC booking information form. When interviewed, Officer (b)(6); (b)(7)(C) did not recall the detainee but stated his typical process is to pat search the incoming detainee, issue them facility clothing and take their photograph. (Note: **Maio** (b)(6); (b)(7)(C) the Facility Administrator sat in on the interviews with officer staff.) Officer (b)(6); (b)(7)(C) stated on interview that he did recall the detainee because he was quiet and respectful to staff. Officer (b)(6); (b)(7)(C) speaks Spanish and stated he uses the 216 Record of Persons and Property Transferred form to confirm the classification level as determined by ERO. In this case, the 216 form designated detainee ALMAZAN as medium high. The detainee's housing level was then marked as, "Close Observation" and he was approved for placement in general population with visits allowed.


On Saturday, **August 12, 2017**, at 2:28 a.m. his property was inventoried and he was allowed to retain possession of miscellaneous legal papers, a Bible, four pairs of underwear and a grey shirt and pants. The other items were placed in property bag 396. A property receipt was generated and signed by both the detainee and two officers at 2:45 a.m. on August 12, 2017. The \$9.00 in personal funds he brought from KNSPC were placed into a commissary account he could access through a kiosk to buy phone time, snacks and personal care items. The detainee also signed an acknowledgement that he had received both the NDS and facility handbooks, PREA information and that he participated in the facility orientation program.

At 8:10 p.m. on **August 13, 2017**, detainee ALMAZAN made his free three-minute phone call per the Audio File List from GCDC. On **August 17, 2017**, an immigration judge ordered ALMAZAN removed to Mexico.

On **August 23, 2017**, detainee ALMAZAN purchased \$5.00 in phone time per his account summary. At 3:23 p.m. on August 25, 2017, he completed a seven minute and 58 second phone call per the call record. This was the last phone call the detainee made while at GCDC.

On **August 30, 2017**, detainee ALMAZAN submitted a request asking for a job at the facility in the dorm or kitchen. He received medical clearance the following day to become a trustee and work at the facility. On the same date, he was moved to pod D. On **September 6, 2017**, he moved

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



to pod A. It is unclear when he began work in the food service area but both security and medical staff reported he served as a trustee and delivered meal trays into the medical unit. The account records confirm he was later paid for five days of work.

According to an email dated September 17, 2017 from Deputy Field Office Director (b)(6); (b)(7)(C) in anticipation of approaching Hurricane Irma, ERO transferred detainee ALMAZAN by bus to Folkston Processing Center (FPC) in Folkston, GA, on **September 7, 2017**, at 3:43 a.m. (Note: EARM records document the time of departure from GCDC as 2:56 p.m. with arrival at FPC at 9:00 p.m.) The balance of \$4.00 in his account was issued to him by check.

Following detainee ALMAZAN's transfer from GCDC, he received payroll for the five days he worked and \$5.00 was deposited into his account at GCDC on September 13, 2017. These funds remained at GCDC and were still in his account during the review team's site visit. The issue was brought to the attention of Deportation Officer (b)(6); (b)(7)(C) who stated he would ensure the funds were transferred to ERO staff at IAH/PCDC for inclusion with the property stored there to be sent to the detainee's next of kin.


Detainee ALMAZAN remained at FPC for less than 24 hours and departed that facility for IAH/PCADC at 5:59 p.m. on **September 8, 2017**, per EARM records.

Summary of Events

At 3:15 a.m., on **August 12, 2017**, (b)(6); (b)(7)(C) LPN documented the medical intake screening, noting there were no barriers to communication, and responding "Yes" to ALMAZAN's ability to "Understand English". During interview she denied her personal ability to speak Spanish and when questioned about the level of ALMAZAN's English proficiency, she replied, "If I did the intake, he spoke English. We would use Interpretalk (*Language Service*) otherwise." When questioned about the frequency of Interpretalk use over a week period, she estimated, "maybe once or twice." Regarding Creative Correction's observation that all consent and agreement forms were in English, LPN (b)(6); (b)(7)(C) stated she was unaware of Spanish version forms. During interview (b)(6); (b)(7)(C) HSA stated Spanish forms are available for sick call requests and medical consents and agreed the Spanish versions should have been used for ALMAZAN. The intake screening documentation did not mention review of the medical summary sent by the Krome North Service Processing Center (KNSPC), with resulting failure to list current diagnoses and treatment. Vitals signs were recorded within normal limits (*See Appendix I for vital signs table*). The health questionnaire included a subjective history of liver cirrhosis⁵³, vision problems, and depression. He admitted to having tried or seriously considered killing or hurting himself, "Six times, about three years ago", but he denied current suicidal thinking. A chest x-ray was scheduled for tuberculosis⁵⁴ clearance, although there is no report evidencing this was done. He was noted,

⁵³ Liver cirrhosis is a chronic liver disease in which liver cells become inflamed and begin dying, causing scar tissue to form. Alcohol abuse is a common cause of cirrhosis.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



however, to have had a normal chest x-ray on July 12, 2017, while at KNSPC, having remained in continual ICE custody. He was assigned to chronic care clinic, referred to a provider on an urgent basis, and cleared for general population. The intake screen was electronically approved by

(b)(6); (b)(7)(C) RN, DON on August 15, 2017.

Two days later on Monday, **August 14, 2017**, at 10:26 a (b)(6); (b)(7)(C) conducted the intake mental health screening, noting ALMAZAN's diagnoses of liver cirrhosis, depression, and anxiety. He reported a history of alcohol dependence, having last used three months ago when he was arrested. He stated he had been prescribed trazadone⁵⁵ for the past three months while incarcerated in Metro West, Dade County. He was described as cooperative, with a calm demeanor, while presenting sadness and mild anxiety. He denied audiovisual hallucinations⁵⁶, delusions⁵⁷, and suicidal and homicidal ideations but reported bouts of depression and crying over the past three months. He attributed his sadness and anxiety to stress of his current situation, and having been divorced five years ago due to his alcohol problem. He reported his drinking worsened until he was incarcerated, having since suffered guilt, sadness and loss, using prayer and faith to manage his feelings. He admitted having, "tried to commit suicide many times by drinking excessively," but denied current intention, ideation, or plan. His mental health status was described as alert, appropriate in behavior, cooperative, fully oriented, neat, well-groomed, and appearing older than his stated age. His affect was good, and judgment was fair. He reported both sleep and appetite were within normal limits. The past medical history section of the assessment noted the only hospitalization was related to liver cirrhosis. His medications accurately reflected the pill line medications listed on the Krome medical summary, as listed:

Medication	Purpose
Clotrimazole 1%	Antifungal cream for athlete's foot
Ducosate Sodium 100 mg	Stool softener used to treat constipation
Folic Acid 1 mg	B vitamin used to enhance red blood cell production
Hydrocortisone 1%	Steroid used to treat skin conditions
Lactulose 10 GM/15 ml solution	Type of sugar solution used to treat chronic constipation and to reduce the amount of ammonia in the blood of patients with liver disease.
Maalox 30 cc	Antacid which neutralizes stomach acidity
Multivitamin	Nutritional supplement
Omeprazole 20 mg	Treatment of heartburn and esophageal reflux disease (GERD) ⁵⁸


⁵⁴ Tuberculosis is a serious bacterial infection which mostly affects the lungs.

⁵⁵ Trazadone is a sedative medication which can treat depression.

⁵⁶ Hallucinations are perceptions of having seen, heard, touched, tasted or smelled something that was not actually there, commonly a symptom of mental illness.

⁵⁷ Delusions are beliefs or altered reality persistently held despite evidence or agreement to the contrary, commonly a symptom of mental illness.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
 Medical and Security Compliance Review
 December 4-5, 2017



Proctosol 2.5%	Treatment of itching or swelling caused by hemorrhoids
Sertraline Hcl 100 mg	Treatment for depression and anxiety
Spirolactone 25 mg	Treatment for high blood pressure and fluid retention.
Trazodone 50 mg	Treatment for depression and sleep difficulty
Triamcinolone Acetonide 0.1%	Treatment for psoriasis
Rifaximin 550 mg	Treatment for irritable bowel syndrome with diarrhea

The mental health assessment findings were listed as depression, generalized anxiety disorder, and alcohol dependence, in remission. The plan was, "Appointment electronically created for patient to see psychiatrist as soon as possible." He was deemed eligible for program participation and job placement and was assigned to general population without segregation.

On the same day, at 10:27 a.m. (b)(6); (b)(7)(C) MD conducted the initial chronic care clinic for cirrhosis, stating during interview he communicated with ALMAZAN in Spanish and was unaware of the detainee's English proficiency. He documented, "51 year old male with history of liver cirrhosis, GERD, possible portal hypertension⁵⁹, constipation here today for initial clinical evaluation, the patient diagnosed seven years ago and he's been on treatment since then." ALMAZAN's personal risk factors were identified as smoking, "two per day", and "a lot" of alcohol. He denied past surgeries or hospitalizations. He was described as appearing well, in no acute distress, obese, well developed, and well nourished. He complained of external hemorrhoids⁶⁰, dry itchy skin and eyes, and headaches. He denied chest pain, abdominal pain, and nausea and vomiting. The review of systems revealed no abnormal findings, and the vital signs were all within normal limits. The abdominal assessment was described as, "Positive bowel sounds, non-tender, no hepatosplenomegaly⁶¹, no masses⁶²." The assessment listing included 1) liver cirrhosis/fatty liver; 2) GERD; 3) possible portal hypertension; 4) IBS⁶³, and 5) eczema⁶⁴. There was no reference to pancytopenia⁶⁵, as was noted in the last chronic care clinic at the Krome North SPC (KCSPC). When questioned about his suspicion of portal hypertension in the absence of KNSPC's previous diagnoses, he explained that once he was aware of the cirrhosis diagnosis he considered all possible outcomes and conducted laboratory testing to rule it out. He further

⁵⁸ GERD is short for gastroesophageal reflux disease, also known as acid reflux, is a digestive disease in which stomach acid or bile irritates the food pipe lining (esophagus).

⁵⁹ Portal hypertension refers to high blood pressure in the system of veins coming from the stomach, intestine, spleen, and pancreas which merge into the portal area before traveling through the liver.

⁶⁰ Hemorrhoids are swollen and inflamed veins in the rectum and anus which can cause discomfort and bleeding.

⁶¹ Hepatosplenomegaly refers to abnormal enlargement of the liver and spleen.


⁶² Masses are any localized enlargement or swelling in the human body.

⁶³ IBS, short for irritable bowel syndrome is an intestinal disorder causing pain in the belly, gas, diarrhea, and constipation.

⁶⁴ Eczema is a condition in which the skin becomes inflamed and itchy.

⁶⁵ Pancytopenia is a medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
 Medical and Security Compliance Review
 December 4-5, 2017



stated there were no varices⁶⁶ or spider webbing⁶⁷ noted during the abdominal assessment. The plan included 1) Triamcinolone Acetonide 0.1% cream twice daily for 60 days; 2) PT⁶⁸, PTT⁶⁹, INR⁷⁰, psa⁷¹, cmp⁷², cbc⁷³, lipid panel⁷⁴, h pylori test⁷⁵, ammonia level⁷⁶ tomorrow; 3) follow-up Thursday with lab results; 4) increase fluid intake; 5) continue with all other meds for 30 days; 6) please renew when finishing; 7) follow-up in 90 days; 8) Proctosol 2.5% topical cream twice daily for 30 days. During interview [REDACTED] explained that a nurse works directly with him to ensure his orders are carried out.

According to the laboratory report, the blood collection took place on August 17, 2017, with receipt in the lab and complete report forwarded on the following day, August 18, 2017. [REDACTED] reviewed the laboratory results, electronically noted as "Observation Report Date", on the same day as receipt. Questioned during interview, he stated that although the results were concerning, he knew ALMAZAN was scheduled for his follow-up clinic in two weeks, and because the PT and PTT were only slightly elevated, he felt comfortable waiting until the next appointment to address the seriously low platelet count⁷⁷ of 41. He further offered his opinion that he places urgency on levels lower than 30, at which time he transfers the patient to the hospital for treatment. On questioning whether he was aware of the pancytopenia condition previously diagnosed at KNSPC, he, along with Davies, Regional Vice President of ACHS, expressed surprise and disbelief, voicing they had not been aware of the diagnosis, nor the significantly low platelet count of 37. Regarding his treatment plan [REDACTED] stated he believed he did the right thing in trying to excrete the excess ammonia in ALMAZAN's system. He further offered if he had been the physician at KNSPC and had known ICE was going to move him with his current medical condition, he would not have approved the transfer. When asked if a two to three hour flight

⁶⁶ Varices are abnormal veins in the lower part of the tube running from the throat to the stomach.

⁶⁷ Spider webbing, otherwise known as Spider angiomas, refers to surfaced veins, which have a local spot and radiating vessels to appear web-like, commonly caused by advanced liver disease.

⁶⁸ PT is short for prothrombin test, a blood test to determine how quickly the blood clots.

⁶⁹ PTT is short for partial thromboplastin time, a blood test which measures the time it takes for blood to clot.

⁷⁰ INR is short for international normalized ration, a blood test which evaluates blood clotting.

⁷¹ PSA is short for prostate specific antigen, a substance produced by the prostate gland, which is measure to determine prostate disease.

⁷² CMP is short for comprehensive metabolic panel which tests blood glucose level, electrolytes levels, kidney function, liver function, and nutritional problems.

⁷³ CBC is short for complete blood count, which tests levels of all types of blood cells to determine presence of disease.


⁷⁴ Lipid panel is a series of lab tests, which determine levels of fats and cholesterol in the blood.

⁷⁵ H-pylori test is short for helicobacter pylori, bacteria that causes infection in the stomach, such as ulcers.

⁷⁶ An ammonia level test determines the amount of ammonia produced by bacteria in the intestines. Ammonia is normally converted by the liver, producing urea which is eliminated in the urine. With liver disease, ammonia levels can rise due to the inability for the liver to convert it.

⁷⁷ A platelet count is the number of clot-producing cells in the blood.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017




transfer would have been appropriate considering the current medical condition, he stated, “I might say no”, basing his statement on the fact that because it is not known why the platelets are so low, the detainee might have an embolism.

Detainee ALMAZAN submitted an initial sick call request for vision problems, dated **August 16, 2017**, writing, “I Need See The Doctor be Cause He Tool mi I have 2 Apoimenes, Monday and Tuesday I ron’t Recib Notin in My Dormitory Please Because I ron’t See Noting and He Told my y Need Test for My Ayees PLEASE The Doctor is (b)(6); (b)(7)(C) Please Help My I conT Read Noting Please Help My” (See Appendix II for sick call table). (b)(6); (b)(7)(C) LPN documented receipt of the sick call request at 9:00 p.m. on August 17, 2017, referring him to nurse sick ca (b)(6); (b)(7)(C) LPN documented a sick call encounter, using “Nursing Protocol – Eyes, Ears, Nose, Teeth, and Throat.” The date of August 18, 2017, was stamped at the top of the first page; however the note was not signed off until October 15, 2017, suggesting the note could have been written or altered at any time during that time. There was no reference to barriers of communication, language preference, or use of interpretation assistance. Vital signs were all recorded within normal limits, and his vision test showed 20/20 in the right eye and 20/200 in the left eye. Of note, the eye examination conducted by KNSPC on July 19, 2017, showed 20/100 in the left eye and 20/200 in the right eye, and the vision testing done during this physical assessment on August 24, 2017, showed 20/200 in both eyes, suggesting the 20/20 recording was erroneous. The nursing assessment diagnosis was disturbed sensory perception: rule out visual disturbance, and the plan, based on “not acute” vision disturbance was to allow ALMAZAN to obtain his glasses from home and to use proper lighting. Documentation failed to show inquiry into the current location of his glasses or what his home situation was. As was documented in the August 22, 2017, provider assessment, he had his glasses while at Krome and believed they were in his property. Consequently, (b)(6); (b)(7)(C) failed to adequately address his complaint, which remained unresolved. Creative Correction notes that the provided medical record did not include a copy of this sick call encounter; but rather, it was provided just prior to the review close-out. Consequently, I (b)(6); (b)(7)(C) as not interviewed.

A second Inmate/Detainee Request was dated **August 20, 2017**, in which ALMAZAN wrote, “DR – I need You Help Because My Medicates AHORA NO SEE MEDICIN I TAKE EVRY DA DR- (b)(6); (b)(7)(C) I fillin My EYES DRY. PLEASE I need My GLASES Please When I go To Court They Give to mi but I canT SEE NOTHING My EYES I filling Burning and MY HEAD I HAVE PAIN So I need My GLASES Please (b)(6); (b)(7)(C) The sick call response was left blank, but the request was signed as received by (b)(6); (b)(7)(C) on **August 21, 2017**. During interview LPN (b)(6); (b)(7)(C) reviewed the medical record and verified a sick call encounter was not present, stating that he was not seen in nursing sick call because he had a pending appointment with the provider for this evaluation.

(b)(6); (b)(7)(C) Advanced Registered Nurse Practitioner (ARNP) conducted a provider assessment on **August 22, 2017**, at 3:17 p.m. to address ALMAZAN’s complaints of, “I am having a lot of pain in my joints. I cannot see, either. I had glasses at Krome but they say they are not in my

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



property here. My vision is very bad. The medication is helping some, but I still can only sleep two to three hours.” There is no documentation of barriers to communication, language preference, or use of interpretation assistance. (b)(6); (b)(7)(C) documented his extensive history of alcohol dependence, and noted he was currently taking Zoloft and trazodone with some benefit. He was described as cooperative with a congruent affect⁷⁸, logical thought process, anxious mood, and a restless and fidgety manner. There is no objective assessment, including vital signs. The treatment plan was to continue Zoloft 100 mg daily and increase trazodone to 75 mg nightly to improve his insomnia. A Specific Authorization for Psychotropic Medications form was signed by ALMAZAN, but the specific medication was not indicated with a check mark. The treatment plan did not address the complaint of vision difficulty. He was electronically scheduled for follow-up in 60 days. As NP (b)(6); (b)(7)(C) no longer works for GCDC, an interview could not be conducted to clarify if the encounter was intended to serve only as a mental health follow-up, as opposed to a sick call assessment.

The initial health assessment was conducted by (b)(6); (b)(7)(C) RN on **August 24, 2017**, at 2:33 p.m., with review and approved electronic signature of (b)(6); on September 5, 2017. A review of the training and credentials file showed RN Bonner was trained for conducting initial medical and dental assessments on January 12, 2016 and on August 22, 2017. Detainee ALMAZAN identified current complaints as right knee pain and vision difficulty. He denied blood in his sputum, blood in his stools, or black tarry stools⁷⁹. His vital signs and physical assessment were all within normal limits, including the abdomen, which was described as having normal bowel sounds and no masses or tenderness. Tremors were not observed, and his gait and coordination were normal. Examination of his skin showed no rashes, lesions⁸⁰ or infestations⁸¹. ALMAZAN’s visual acuity using the Snellen Eye Chart measured 20/200 in the right eye, 20/200 in the left eye, and 20/200 in both eyes, without correction, for which he was referred to the doctor for visual disturbance. The dental screening found no missing teeth and “four upper implants per patient.”

A third sick call request was submitted on **August 27, 2017**, in which ALMAZAN wrote, “I NEED SEE THE DOCTOR BECAUSE I have To Much Pain in My Bond’s I Want Somthin XXXike Bengay is Hard THE PA A and I want A see The doctor THE LAST Went I see HE PuT in THE Sistem For Examen in My Eyes I Need glasses PLE! I can’T Read NoThing I need Realy The Glasses”. The Triage Decision By Nursing Staff noted referral to nurse sick call and was signed two days later on **August 29, 2017**, at 9:00 p.m. by (b)(6); (b)(7)(C) LPN

⁷⁸ Congruent affect means a person’s emotions are appropriate for the situation.

⁷⁹ Black tarry stools can indicate bleeding in the upper portion of the digestive tract.

⁸⁰ Lesions are regions of an organ or tissue which have suffered damage through injury or disease, such as a wound, ulcer or tumor.

⁸¹ Infestations refer to a state of being invaded or overrun with pests or parasites.

(b)(6); (b)(7)(C) LPN, CCHP conducted a sick call assessment on **August 30, 2017**, at 2:24 p.m. to address ALMAZAN's complaint of pain in both shoulders and both knees. The pain was described as moderate, constant and worsening. A pain scale was not used to determine pain level. Vital signs were all recorded within normal limits. The general examination noted an uncomfortable appearance with tenderness on palpation. There was no swelling or gait abnormality. The nursing assessment was Alteration in Comfort in joints. The plan was to provide ibuprofen 400 mg twice daily for five days as needed in accordance with the Nursing Protocol on Muscular Skeletal problems. LPN (b)(6); (b)(7)(C) noted, "NO history of bleeding ulcers." He was provided patient education and instructed to return to sick call if symptoms worsen or persist more than seven days. Documentation fails to show ALMAZAN's complaint of vision difficulty was addressed. During interview, LPN (b)(6); (b)(7)(C) who triaged this sick call request, offered that nurses allow only one complaint per sick call request and that the detainees are expected to submit an individual request for each complaint they have, with the sick call nurse prioritizing the issues. HSA (b)(6); (b)(7)(C) and VI (b)(6); (b)(7)(C) both agreed during interview that the two issues absolutely should have been addressed in a single visit. RN (b)(6); (b)(7)(C) electronically approved the sick call assessment on August 31, 2017.

On September 1, 2017, ALMAZAN completed a fourth sick call request, stating, "I Need See The Doctor The Name of (b)(6); (b)(7)(C) I wan'T To Se because I ned Glases THE Nurse OnLY No GIME Apoimen For Opticol I have Pain in Myy Head and My EYES in My EYES I fell likefire and The People I see Strange Aron'T Read Nothing Please I need See THE DOCTOR For My ApoinmenT an Medicinefo EYES LiKe Vicine SO<Thin DROPS for My Eyes THANK YOU (b)(6); (b)(7)(C) LPN documented receipt of the request the same day at 9:00 p.m. and referred him to nurse sick call. On **September 2, 2017**, at 4:56 p.m. (b)(6); (b)(7)(C) LPN conducted a sick call assessment to address ALMAZAN's complaint of having difficulty seeing, as things look blurry. He stated he had an appointment scheduled with an optometrist prior to entering the facility. Vital signs were all recorded within normal limits and his vision remained at 20/200 in both eyes. The assessment was disturbed sensory perception: Rule out visual disturbance. The plan included a "Routine referral to (b)(6); (b)(7)(C) within five days secondary to patient having difficulty seeing, may need glasses. Made same complaint during initial health assessment." The note was electronically approved by (b)(6); (b)(7)(C) on September 5, 2017.

Four days later on Wednesday, **September 6, 2017**, at 9:48 a.m. (b)(6); (b)(7)(C) initiated a sick call visit for complaints of visual disturbance, along with a thirty-day chronic care evaluation. Forty-six laboratory results, completed on August 18, 2017, were addressed, along with additional results provided the following day. Only the abnormal levels are included below, with comparisons of those that had also been done at Krome:

Test	Krome Result	Glades Result	Normal Limits
Bilirubin ⁸²	1.6	1.7	0.0-1.2

⁸² Bilirubin is an orange, yellow pigment produced by the liver.

Alkaline Phosphatase ⁸³	157	162	20-130
Hemoglobin ⁸⁴	10.5	11.3	13-18
Red Blood Cells ⁸⁵	3.28	3.65	4.5-5.9
Hematocrit ⁸⁶	29.3	34	40-52
White Blood Cells ⁸⁷	2.0	3.0	3.6-11
Platelets	37	41	150-400
Lymphocytes ⁸⁸	0.4	0.7	1.1-4.7
Ammonia		108	11-35
Activated PTT		41.6	50-89

ALMAZAN's general appearance and physical assessment findings were all within normal limits, with exception of the abdominal assessment, which described pain in the mid-epigastric area radiating to the chest. Bowel sounds were normal, and there was no tenderness, masses, or hepatosplenomegaly on palpation. The plan was written as follows:

1—I will increase lactulose doses and will continue with the current meds. CBC weekly the follow-up ++see below prednisone 100 mg X3 days then 0 mg x 3 days then 60 mg po x 3 days then 50 mg x 3 days the 40 mg x 3 days then 30 mg x 3 days then 20 mg x 3 days the 10 mg x 2 days then 5 mg x 2 days the 2.5 mg x 2 days then d/c.

2—FERROUS SULFATE, 325 mg #90, Sig: 1 time per day for 90 days

3—+++++cbc weekly x 4 weeks+++++

4—d/c dulcolax

5—lactulose 40 ml po daily x 90 days

6—FOLIC ACID, 1 MG #90, Sig: Take 1 Tablet by mouth 1 time per day for 90 days

7—MULTIVITAMIN, #90, Sig: Take 1 Tablet by mouth 1 time per day for 90 days

8—SPIRONOLACTONE, 25 MG #180, Sig: Take 1 Tablet by mouth 2 times per day for 90 days.

9—Xifaxan 550 mg po bid x 90 days

10—Patient c/o visual disturbance

11—OS 20/200 OD 20/200

12—ammonia level Q2 WEEK X 8 WEEKS

13—Renal diet x 180 days

14—cbc cmp lipid panel in 82 days

⁸³ Alkaline phosphatase is an enzyme found throughout the body, which can be elevated in liver disease.

⁸⁴ Hemoglobin is the protein molecule in the red blood cells that carries oxygen from the lungs to the body's tissues and returns carbon dioxide from the body back to the lungs.

⁸⁵ Red blood cells are the blood cells that contain hemoglobin and carry oxygen.

⁸⁶ Hematocrit is a volume percentage of red blood cells in the blood, usually at 47% in men.


⁸⁷ White blood cells are the cells involved in protecting the body against infection.

⁸⁸ Lymphocytes are a form of white blood cells that produce antibodies to fight infection.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz

Medical and Security Compliance Review

December 4-5, 2017



14==follow==up in 90 days

15==OMEPRAZOLE 40 MG #90, Sig: Take 1 Capsule by mouth 1 time per day for 90 days.”


(b)(6); (b)(7)(C) signed off his note at 10:23 a.m. on the same day. Creative Corrections notes there was no referral to the optometrist for ALMAZAN’s serious vision impairment. Without eyeglasses his ability to read written instructions, consents, or patient education was seriously declined. His frustration was clearly expressed in his sick call requests. Following is documentation of sick call requests and complaints during clinical encounters.

Date and Mode of Request	Date of Encounter Who Conducted	Treatment Plan	Completed
August 16, 2017 Sick Call Request	August 18, 2017 LPN	Approved to have glasses from home sent in.	No, as his glasses were not at his home
August 20, 2017 Sick Call Request	No sick call scheduled	None, as triage nurse believed detainee was scheduled for MD	No, as a provider failed to address the complaint.
August 22, 2017 Complained during encounter.	August 22, 2017 ARNP	None. Complaint was not addressed.	NA
August 24, 2017 during initial physical assessment.	August 24, 2017 RN	Referred to MD	No
August 27, 2017 Sick call	August 30, 2017 LPN	None, as only one of two complaints were addressed.	N/A
September 1, 2017 Chronic Care	September 1, 2017 MD	None, as not addressed in plan	N/A

The ACHS Medical policy J-E-07 Non-emergency Health Care Requests and Services, mirroring the NCCHC Standard of the same number and title, instructs that any patient who has been seen in sick call more than twice in 30 days for the same complaint, but who has not yet been seen by a practitioner will be scheduled for the clinician’s clinic. Although the sick call nurses’ dispositions were followed by provider assessments, the focus was limited to chronic care and mental health issues, leaving the vision problem unaddressed. A review of the commissary showed reading glasses were available for purchase, but with a maximum of \$10.00 in his account at any given time, he would not have been able to pay the cost of \$11.55. There is no indication that any attempts were made to obtain reading glasses for him, although according to HSA (b)(6); (b)(7)(C), an optometry appointment was pending but not completed because of his transfer.

The Transfer Summary, documented by (b)(6); (b)(7)(C) the same day as his departure, medically cleared him for travel. The listed diagnoses included only cirrhosis of the liver without alcohol, generalized anxiety disorder, and depression. The additional serious chronic care diagnoses of portal hypertension, pancytopenia, and irritable bowel syndrome were not listed, and with no accompanying medical records, to include laboratory results, most recent chronic care assessment,

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



and pending specialty services, these diagnoses were unknown on his arrival to PC. It remains unexplained why the cirrhosis diagnosis was erroneously changed to “cirrhosis without alcohol”, but the diagnosis followed him to Polk on **September 8, 2017**, and to the hospital where he died nine days later.


APPENDIX I Vital Signs

DATE	TEMPERATURE	PULSE	RESPIRATIONS	BLOOD PRESSURE	WEIGHT
August 12, 2017	98.1	66	18	106/70	168
August 14, 2017	98.3	62	18	101/66	165
August 16, 2017	97.0	59	18	104/70	164
August 24, 2017	98.4	65	16	112/78	163
August 30, 2017	98.6	74	18	106/68	165
September 2, 2017	98.3	83	18	113/77	166
September 6, 2017	97.6	80	18	122/76	170

APPENDIX II Sick Call Requests

DATE SUBMITTED	COMPLAINT	DATE TRIAGED	DATE OF ASSESSMENT	TREATMENT PROVIDED
August 16, 2017	Vision difficulty	August 17, 2017	August 17, 2017	Instructed to get glasses sent in from home. Vision difficulty unresolved.
August 20, 2017	Vision difficulty with headache	August 21, 2017	August 24, 2017	Referred to the doctor. Not evaluated by MD for vision difficulty until September 6, 2017.
August 27, 2017	General body pain Vision difficulty	August 29, 2017	August 30, 2017	Ibuprofen provided for pain. Vision difficulty remained unresolved.
September 1, 2017	Vision difficulty with headache	September 1, 2017	September 2, 2017	Routine referral to (b)(6); (b)(7)(C) within five days. Was seen for vision difficulty during chronic care clinic on September 6, but no MD order written for optometry. Transferred same day due to hurricane.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



CONCLUSION

Medical Compliance Findings

There were no NDS deficiencies found. Identified areas of concern are as follows:

- Sick call requests, consents for medical care and psychiatric medication use, and keep-on-person agreements were not provided in Spanish version. As evidenced during interviews, not all nurses were aware of the availability of Spanish version forms.
- There was no reference to barriers of communication, language preference, or use of interpretation assistance during most nursing and provider encounters. Throughout interviews with staff from all three facilities in which detainee ALMAZAN was detained, there is strong evidence he was not English proficient.
- A nursing note by a sick call LPN was not signed at the time of her August 16, 2017, encounter, but rather it was signed two months later on October 15, 2017. From a legal standpoint it cannot be determined the note was not initiated and/or altered immediately prior to the sign-off on the latter date.
- During the August 16, 2017, encounter the LPN failed to inquire about the location of the detainee's eyeglasses, which were not at his home, resulting in an unresolved issue. Creative Corrections considered this misinformation might have been a result of a preventable communication barrier related to the detainee's inability to proficiently speak and understand English.
- Multiple complaints on the same request form are not always addressed and nurses reported a practice of one complaint per request form, with prioritization of the complaint at the time of the sick call encounter.
- In spite of the detainee's early and repeated complaint of serious vision impairment, a request for optometry to get eyeglasses was never processed.
- Possibly related to the hurried nature of the hurricane evacuation, the transfer summary failed to ensure adequate continuity of care to by failing to include all relevant health information.


Security Compliance Findings

Creative Corrections cites the following deficiencies in relevant components of facility policies and post orders.

The GCDC Detainee Handbook, page 12 states, "Prior to departing the facility, any funds you have remaining will be returned to you."

Funds earned by the detainee were paid on September 13, 2017 following his transfer out of GCDC. However, no effort was made to forward the funds to the detainee at his next facility and the funds remained at GCDC during the site visit on December 7, 2017.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



IAH/PCADC

Facility Description

IAH/PCADC is located in Livingston, TX, approximately 74 miles northeast of Houston, TX. The facility is operated by the Management and Training Corporation (MTC) of Centerville, Utah. According to their website, MTC entered the field of corrections in 1987 and now oversees more than 25,000 offenders and detainees at 21 facilities. The IAH/PCADC was established in January 2006. The original design was for 524 adult detainees. In July 2007, IAH/PCADC added an additional 528 beds to bring it to the current capacity of 1052. On September 17 2017, the date of detainee ALMAZAN's death, the population was 26 USMS male detainees and 337 male ICE detainees for a total population of 363. The IAH/PCADC received American Correctional Association accreditation on January 23, 2017.

A double fence with two rolls of razor wire along the top and five rolls between the fences encircles the facility. Visitors must enter through a secure external sallyport with both gates operated by central control. Once inside the gates, visitors must display identification before passing through a metal detector and being permitted to pass through a secure door into the facility. Video surveillance cameras are used throughout the facility, including in the housing units to monitor and record events.


Per the officers interviewed, upon hire they receive 40 hours of classroom training and 40 hours of on the job training with a veteran officer before they are approved to work on their own. Additional training is provided for specific job duties when the officer is assigned to a post.

On September 7, 2017, IAH/PCADC had 261 ICE detainees. On September 8, 2017, IAH/PCADC received 127 detainees due to Hurricane Irma approaching the Florida area and the population surged to 388 ICE detainees. On September 9, 2017, an additional 124 detainees were received and the population rose to 512 ICE detainees. Over 48 hours, the detainee population almost doubled.

Healthcare Services

MTC Medical, with headquarters in Houston, Texas provides 24-hour nursing coverage seven days per week. The facility earned reaccreditation by the American Correctional Association on January 23, 2017. Although the facility is contracted under the NDS, MTC policies and procedures address the elevated standards of PBNDS 2011. The HSA, a registered nurse (RN) who has worked with MTC since April 2016, assumed her administrative role in September 2017. The Clinical Director is a contract MD who has worked at PCADC for about ten years. He delivers on-site medical services one six-hour day per week. For medical reasons, (b)(6); (b)(7)(C)

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



MD was not available during the three days detainee ALMAZAN was at the facility, and therefore he was unfamiliar with the case. He was not interviewed during this review. A part time certified physician assistant is on site from 6:00 p.m. to 7:00 p.m. on Mondays, Tuesdays, and Thursdays. On call coverage is shared between the two providers. A licensed professional counselor provides full time services, and an MTC psychiatrist is available via telemedicine four to six hours a week. Nursing staff includes a full time director of nurses (DON), three fulltime RNs and six licensed vocational nurses (LVN), all assigned twelve-hour shifts from six to six. Two medical assistants and one pharmacy technician provide clinical and administrative support. There were no vacancies at the time of the review. ODO finds staffing adequate to provide basic medical services for all detainees. A credential review found all professional licenses current and primary source verified. CHI St. Lukes in Livingston, approximately six minutes from PCADC and Conroe Hospital, approximately 50 miles are used for emergency and specialty care beyond the scope of services


The PCADC medical department consists of two examination rooms, a medical records room, x-ray room, medication room with a pill pass window, and a health services administrator (HSA) office. There are four medical observation cells, one suicide watch cell, and an infection control room with negative airflow. The detention officer's desk is located in the hallway, affording correctional supervision in the clinic. The clinic was found to be clean and adequately sized and equipped.

PCADC uses hard copy medical records, with the exception of chronic care appointment scheduling and electronic medication administration records. Detainees access sick call by filling out paper requests and depositing them into a locked box. Sick call request forms and deposit boxes were inconveniently located outside the locked cells in C Unit, where detainee ALMAZAN was housed. According to detainees who were residing in the same cell with detainee ALMAZAN, they request sick call forms from an officer and when completed put it up to the window so the officer who is making rounds can retrieve the requests. This practice does not ensure the confidentiality of detainees who request appointments for sensitive medical problems. According to the detainee handbook, "Detainees desiring routine medical care will fill out a sick call request which will be picked up daily by the nursing staff." Officer rounds are conducted through window observation only; however, intercoms are available in those units for contacting officers on duty.

Detention Summary

Detainee ALMAZAN arrived at IAH/PCADC on **Friday, September 8, 2017**. An I-203 Order to Detain form was present in the detention file but incorrectly listed the detainee's name as "Alaman" and his date of birth as June 6, 1966, rather than the correct date of June 26, 1966. Intake Officer (b)(6); (b)(7)(C) stated on interview that his main concern is ensuring the A numbers match and in this case they did. The IAH/PCADC records document the detainee arrived at 4:00 p.m. However, Officer (b)(6); (b)(7)(C) stated the document would have indicated the time the information was entered into the system, rather than the actual time of arrival. He was on duty the night the detainee arrived and recalled the bus arrived later in the evening. Video surveillance footage from

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



the vehicle sallyport shows the first of four buses arrived at 10:19 p.m. Detainees and their property were removed from the buses between the hours of 10:19 p.m. and 11:10 p.m.


The intake processing area contains a long bench with a curtain that can be drawn across the middle of the room. On the opposite side of the curtain are two folding tables and chairs. Acoustic boards for sound baffling have been added to the ceiling. Video surveillance footage from the intake area was reviewed. At 1:04 a.m. detainee ALMAZAN can be seen seated on the bench partially obscured by a curtain. At 1:21 a.m. a nurse arrives, sits next to him and appears to take his blood pressure. At 1:23 a.m. a blood pressure machine is wheeled to the detainee and his blood pressure is again taken. At 1:25 a.m. the detainee leaves the intake area.

The detention file contained intake screening forms for suicide and medical or mental impairments as well as screening for risk of victimization and abusiveness. Detainee ALMAZAN's classification review was completed on this date by Officer (b)(6); (b)(7)(C). It was documented that the detainee's primary language was Spanish. Officer (b)(6); (b)(7)(C) acknowledged he does not speak Spanish and he recalled that a fellow intake officer who does sat with him and went over the intake process in Spanish with detainee ALMAZAN. The officer appropriately rated detainee ALMAZAN high custody based on the severity of his charge, his serious offense history and his prior convictions. This rating was approved by Reception and Discharge Supervisor (b)(6); (b)(7)(C) (b)(6); (b)(7)(C) the same day.

On September 8, 2017, the clothing the detainee was wearing was inventoried. He had one pair of shoes, socks, underwear, sweatpants and one sweatshirt. Detainee ALMAZAN was issued facility clothing, linens and hygiene supplies. Neither the incoming property inventory form nor the facility property issued form were signed by the detainee. Officer (b)(6); (b)(7)(C) stated that because there was such a large influx of detainees on this date, medical staff took half of the group and the officers took the other half. When the property was inventoried, the detainee was with the medical staff and was not available to sign the forms. Detainee ALMAZAN did sign a form acknowledging he received a copy of the facility handbook and PREA information form and that he viewed the ICE orientation video. Documentation confirms he was also fingerprinted. The detainee financial transaction history report shows he had no funds on arrival. It is unknown what happened to the \$4.00 check sent with the detainee from GCDC.

Office (b)(6); (b)(7)(C) stated that additional property arrived in red mesh bags clearly marked with each detainee's name and A#. However, no property inventory had been completed by the sending facility. Per N (b)(6); (b)(7)(C) ERO instructed staff not to inventory and distribute property from the mesh bags until the facility knew if the detainees would be retained at IAH/PCADC. (b)(6); (b)(7)(C) stated that 28 detainees stayed at IAH/PCADC and their mesh bags were inventoried and allowable property distributed to those detainees. All other mesh bags were stored and then transferred with the detainees when they left IAH/PCADC after their temporary stay.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017




Detainee ALMAZAN was assigned to Dorm C, Bed 20-04. The log maintained by the officers assigned to this unit documented the detainee's placement in cell C-20 at 2:40 a.m. on **September 9, 2017**. Cell C-20 is a four person handicap accessible unit. The unit is accessed through a sallyport with two steel doors. The doors are opened remotely from central control when an intercom is pressed and staff are identified. Inside the unit, four single metal bunks are welded to the floor with one on the left wall, two on the back wall and one on the right wall. In the middle of the unit is a picnic style metal table with a bench on each side. A TV is mounted on the wall on the left side. Detainee ALMAZAN's bunk was directly under the TV on the left wall. Two phones are on the wall by the entry door as is a camera which is mounted near the ceiling. A single handicap shower is located behind a curtain and a stainless steel toilet and sink with grab bars are located behind a partial partition on the right hand wall which blocks the camera view of the bathroom facilities. An intercom on the inside of the unit by the door alerts in central control. A large window in the hallway provides a direct view into the unit.

IAH/PCADC utilizes indirect supervision with an officer assigned to the hallway outside the dorm. Dorm officer post orders require that a security round be conducted twice per hour at irregular intervals with no more than 40 minutes elapsing between rounds. The officers are not required to enter each dorm during these rounds. Officers do enter the dorms during the seven official counts conducted daily and to distribute and retrieve trays for all meals. Indoor recreation is offered in an area directly across from the dorm. There is also a large recreation field outside. Detainees are permitted one hour of recreation daily.

Video surveillance footage from inside Dorm C for detainee ALMAZAN's detention period was viewed. At 2:44 a.m. on September 9, 2017, detainee ALMAZAN entered the dorm carrying a bag of property. Detainee ALMAZAN took a seat at the table and spoke to another detainee. At 2:50 a.m. an officer entered the unit and handed detainee ALMAZAN a mattress and pillow. Detainee ALMAZAN, with the assistance of the detainee he was speaking with, made up his bed. Detainee ALMAZAN then placed his property in his assigned property storage box and laid down at 2:57 a.m. Between 3:00 a.m. and 6:30 a.m. detainee ALMAZAN went to the bathroom four times. Other than that, he laid on his bunk. At 6:36 a.m. he showered. At 6:43 a.m. breakfast trays were delivered by an officer. Detainee ALMAZAN did not eat but rather gave his tray to the other detainees. Throughout the morning, detainee ALMAZAN slept, only rising to use the bathroom or watch TV for a few minutes. When the lunch tray was delivered at 11:45 a.m., detainee ALMAZAN sat on his bunk eating a portion of the meal and then handed his tray to the other three detainees for them to share the remaining food.

Detainee ALMAZAN slept, laid on his bunk and went to the bathroom throughout the afternoon. At 6:07 p.m. he walked to the unit door. As the door is obscured by a wall, it is not known if the detainee left the unit but it is surmised he did, perhaps for pill call. At 6:17 p.m. an officer delivered meal trays to the unit. Detainee ALMAZAN returned to his bunk at 6:27 p.m., appeared to take an item off of his food tray and then handed the tray with the remaining food items on it to the

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



other detainees who were seated at the table eating. Those detainees took and shared the food from the tray.

Throughout the evening, the other detainees played checkers, watched TV and read. Detainee ALMAZAN did not participate in any of these activities and simply laid on his bunk or went to the bathroom.

On **September 10, 2017**, detainee ALMAZAN went to the unit door at 5:53 a.m. and returned to his bunk at 6:03 a.m. Again, he ate some food from his meal tray while seated on his bunk but brought the tray to the other detainees to share the remaining food. Again, he slept and went to the bathroom numerous times. At 10:13 a.m. he sat up on his bunk and ate what appeared to be a piece of fruit. At 11:34 a.m. the lunch trays were delivered and he ate some food while sitting on his bunk and then placed some items from the tray into a brown paper sack which he retained by his bunk. He then took the tray to the other detainees who shared the remaining items. Between 8:00 a.m. and 4:30 p.m. he went to the bathroom area nine times.


Dinner trays were delivered at 6:40 p.m. and again, detainee ALMAZAN ate some items from the tray at his bunk and gave the remaining items away to the other detainees. At 8:01 p.m. he went to the door of the unit and returned to his bunk at 8:16 p.m. Throughout the evening, he slept or went to the bathroom.

On **September 11, 2017**, at 5:31 a.m. detainee ALMAZAN went to the unit door. He returned to his bunk at 5:42 a.m. carrying his breakfast tray. Again, he sat on his bunk eating and then brought the tray to the three detainees seated at the table eating. They could be seen taking food items off the tray. Between 5:00 a.m. and 11:00 a.m., he went to the bathroom four times. At 11:54 a.m. lunch trays were delivered and the detainee ate on his bunk. He placed some items from his tray in a separate container and then offered the remaining food items to the other detainees. At 12:12 p.m. another detainee walked to detainee ALMAZAN's bunk and appeared to offer him some food. Detainee ALMAZAN did not take the food item and the other detainee walked away.

At 1:43 p.m. detainee ALMAZAN went to the unit door and returned to the unit at 1:48 p.m. He stood up speaking with another detainee until he returned to his bunk at 2:05 p.m. For the next several hours he sat or laid on his bunk, went through his property bin or went to the bathroom. At 6:11 p.m. he went to the unit door and returned to his bunk at 6:36 p.m. carrying some paperwork which he placed under his mattress.

At 7:04 p.m. the dinner trays arrived and another detainee offered detainee ALMAZAN a tray but he did not take it. At 7:28 p.m. Officer (b)(6); (b)(7)(C) entered the unit and a detainee spoke with the officer. The officer and the detainee then went to detainee ALMAZAN's bunk and appeared to speak with him while he remained laying down. Detainee ALMAZAN handed the officer his identification card and the officer walked away. A minute later, the officer returned to the

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



detainee's bunk and spoke with him again. The officer then walked toward the unit door while speaking on his handheld radio.

At 7:32 p.m. Officer (b)(6); (b)(7)(C) returned to the unit with Officer (b)(6); (b)(7)(C). At 7:33 p.m. LVN's (b)(6); (b)(7)(C) arrived in the unit pushing a wheelchair. The six staff surrounded detainee ALMAZAN's bunk so the view of the detainee from the camera was blocked. At 7:34 p.m. it appeared the detainee was helped into a sitting position on his bunk and at 7:35 p.m. he was assisted into the wheelchair. At 7:35 p.m. the detainee was wheeled off the unit by the nurses. The video surveillance footage from other cameras throughout the facility showed the detainee was wheeled into the medical unit at 7:38 p.m. and was taken to the vehicle sallyport at 8:38 p.m. for transport to the hospital.


Two of the three detainees who were housed with detainee ALMAZAN during his detention at IAH/PCADC were still housed at the facility during this review and were interviewed. Detainee (b)(6); (b)(7)(C) recalled detainee ALMAZAN and stated he was a "little sick" when he arrived. He stated detainee ALMAZAN did not eat or drink much and slept most of the time and that he declined soup or other foods when offered. Detainee (b)(6); (b)(7)(C) stated detainee ALMAZAN didn't want to do anything and he thought he was sad or depressed. Detainee (b)(6); (b)(7)(C) recalled that on September 11, 2017, detainee ALMAZAN vomited three or four times. When he observed drops of blood on the floor and some dried blood around the mouth of detainee ALMAZAN he stated he alerted the dorm officer.

Detainee (b)(6); (b)(7)(C) recalled detainee ALMAZAN was always sleeping and that he would only eat a few bites of his meal tray. He and the other detainees in the dorm would try to get detainee ALMAZAN to attend recreation or to play cards or chess in the dorm but he refused. Detainee (b)(6); (b)(7)(C) noted that if another detainee is not open to mingling with other detainees, they cannot force it. While he did not observe detainee ALMAZAN vomit up blood on September 11, 2017, he did observe dried blood around the detainee's mouth.

Both detainees noted that once the officer arrived and assessed the situation, he called an emergency on his radio. They estimated that security and medical staff arrived within two or three minutes and detainee ALMAZAN was removed from the dorm in a wheelchair.

Officer (b)(6); (b)(7)(C) was assigned to Dorm C hallway for the 2:00 p.m. to 10:00 p.m. shift on September 11, 2017. Officer (b)(6); (b)(7)(C) recalled that he had pulled detainee ALMAZAN from the dorm to the medication pill window at 5:15 p.m. and the detainee was walking slow and appeared dizzy. He asked the detainee if he was okay and detainee ALMAZAN responded that his stomach hurt. Officer (b)(6); (b)(7)(C) served dinner trays at 6:00 p.m. When he later picked up the dinner trays he was told by the other detainees in Dorm C that detainee ALMAZAN had been vomiting up blood. Officer (b)(6); (b)(7)(C) who speaks Spanish, noted that detainee ALMAZAN did not speak English. He went to detainee ALMAZAN's bunk and asked him if he had been vomiting up blood. The detainee responded that he did not know because he just flushed the toilet after he vomited

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



without looking. Officer (b)(6); (b)(7)(C) observed blood on the detainee's lip and called a medical emergency on his radio.

The C Dorm logbook documents that the detainee was pulled for pill call at 6:14 p.m. At 7:00 p.m. dinner trays were served and at 7:30 p.m. one detainee was sent to medical. The C Dorm logbook had no entries related to this emergency, including the response of medical and security personnel. When asked, Officer N (b)(6); (b)(7)(C) acknowledged his error in not documenting the medical emergency. He stated that since this event he has been recording any unusual incidents in the logbook. As for an incident report, Officer (b)(6); (b)(7)(C) stated he was told by an unknown supervisor that medical would document the incident and he did not need to do so.

Upon hearing the emergency call, Sergeant (b)(6); (b)(7)(C) responded first along with Lieutenant (b)(6); (b)(7)(C) followed by the two nurses with a wheelchair and emergency medical bag. Sergeant (b)(6); (b)(7)(C) stated that no staff observed the detainee vomiting blood so he was sent to medical to be evaluated.


(b)(6); (b)(7)(C) responded to the emergency medical call to Dorm C. (b)(6); (b)(7)(C) stated on interview that she observed dried blood on the detainee's lips. She recalled the detainee stated his chest hurt. Officer (b)(6); (b)(7)(C) translated for the medical staff and they had him ask detainee ALMAZAN how long he had been vomiting blood. (b)(6); (b)(7)(C) recalled the detainee responded that it had been five days. The detainee was then assisted into the wheelchair and wheeled to medical.

Physician's Assistant (b)(6); (b)(7)(C) was on duty and both (b)(6); (b)(7)(C) stated they wheeled detainee ALMAZAN right in to the provider for examination. PA (b)(6); (b)(7)(C) ordered a blood draw. LVN (b)(6); (b)(7)(C) stated the detainee was able to transfer himself from the wheelchair to the chair for the blood draw. She took his blood pressure and recalled it was elevated but was lower the second time she took it. PA (b)(6); (b)(7)(C) then found out detainee ALMAZAN had cirrhosis so he cancelled the blood draw and said the detainee needed to go to the emergency room. PA (b)(6); (b)(7)(C) determined an ambulance wasn't necessary and he could go by facility van. (b)(6); (b)(7)(C) recalled the detainee was able to transfer himself from the chair back to the wheelchair for transport to the facility vehicle.

(b)(6); (b)(7)(C) recalled on interview that the detainee was reluctant to tell him anything. (b)(6); (b)(7)(C) surmised the detainee didn't want staff to know he was sick and believed if he went to the hospital he wouldn't get to go home. (b)(6); (b)(7)(C) stated he observed blood around the detainee's mouth and the detainee reported he had been vomiting blood for five days. (b)(6); (b)(7)(C) stated it was "obvious" to him that the detainee had varicies.

(b)(6); (b)(7)(C) was no longer employed at IAH/PCADC at the time of this review and was therefore not available to be interviewed. According to the critical incident report completed by (b)(6); (b)(7)(C) the medical emergency was called at 7:52 p.m. and the Warden was notified at 7:53 p.m. Lt. (b)(6); (b)(7)(C) documented that upon arrival at C-20, detainee ALMAZAN was "lying in bed moaning".

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



After he was brought to medical and examined by Doctor (b)(6); (b)(7)(C) the doctor determined the detainee needed to be transported to CHI St. Luke's Health Memorial Hospital.

The Stationary Guard Roster report documented that on September 11, 2017, at 8:45 p.m. Officers (b)(6); (b)(7)(C) transported detainee ALMAZAN to CHI St. Luke's Health Memorial Hospital in Livingston, TX, a distance of 7 miles. They arrived at 9:00 p.m. On interview, Officer (b)(6); (b)(7)(C) stated that she assisted detainee ALMAZAN into the van because he was wearing leg irons, handcuffs and a waist belt. As with all detainees who are transported in restraints, she stated a crate was used for the detainee to step up on to safely enter the van. She recalled the detainee was quiet and cooperative during the transport. Officer (b)(6); (b)(7)(C) carried the weapon and drove the van. Upon arrival at the hospital, she dropped the detainee and Officer (b)(6); (b)(7)(C) at the door where they were met by hospital staff with a wheelchair. The detainee was wheeled into the ER for treatment and Officer (b)(6); (b)(7)(C) parked the van. Officer (b)(6); (b)(7)(C) recalled the hospital staff had trouble getting an IV into detainee ALMAZAN's arm. The Hospital Activity Log the officers completed noted permission was received from the shift supervisor to remove one handcuff and the belly chain and to restrain the detainee with one cuff attached to the bed. These officers were relieved at 11:00 p.m. and returned to the facility at 11:15 p.m.


Officer (b)(6); (b)(7)(C) assumed vigil duty at 11:00 p.m. and documented that the detainee received an IV and the doctor informed them at 1:10 a.m. that the detainee needed to be transferred to another hospital. These officers stayed with the detainee until 6:15 a.m. on **September 12, 2017**. At 6:00 a.m. Officer (b)(6); (b)(7)(C) reported for vigil duty and relieved Officer (b)(6); (b)(7)(C)

A Texan EMS LLC report documents a paramedic and EMT responded to CHI St. Luke's Health Memorial Hospital at 6:45 a.m. to transport detainee ALMAZAN to Conroe Regional Medical Center (CRMC) in Conroe, TX for treatment of "upper GI bleed noticed when pt began vomiting blood @ 12 hours ago". The report noted detainee ALMAZAN was ambulatory and was able to walk to the stretcher. He was assessed and no abnormalities were found. It was documented he was being transported by ambulance due to the need to administer IV medications and oxygen en route. Upon arrival at CRMC at 8:13 a.m., EMS staff documented the detainee was able to ambulate to a chair and his care was turned over to staff at CRMC.

According to Sergeant (b)(6); (b)(7)(C) he is weapons certified so he followed the ambulance in the facility van while Officer (b)(6); (b)(7)(C) rode in the ambulance. Sergeant (b)(6); (b)(7)(C) stated the trip usually takes an hour but it took 90 minutes due to heavy traffic. They logged an arrival time of 8:13 a.m. at CRMC and noted the detainee was admitted to the ICU. Sergeant (b)(6); (b)(7)(C) recalled that the detainee was alert when not sleeping, ate his meals and was able to sit up to urinate. The officers logged that they were relieved at 4:40 p.m.

⁸⁹ Officer (b)(6); (b)(7)(C) has since been promoted to sergeant at PCADC. She will be referred to as officer throughout this report.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



Relieving Sergeant (b)(6); (b)(7)(C) were Officers (b)(6); (b)(7)(C) who arrived at 4:32 p.m. They documented in the Hospital Activity Log that technicians were in the room performing an EKG and an X-Ray at 5:10 p.m. As medical staff were having trouble with the IV in the detainee's neck, the officers requested and received permission from the facility to remove the handcuffs from the detainee so an IV could be placed in his arm.

Officer (b)(6); (b)(7)(C) were relieved by (b)(6); (b)(7)(C) at 10:30 p.m. They documented that during their shift nursing staff checked the detainee's IV, changed his bedding, drew blood and assisted him to the restroom throughout the night.


On **September 13, 2017** Officers (b)(6); (b)(7)(C) reported for vigil duty at 6:26 a.m. Throughout their shift, they logged the detainee went for a procedure at 7:37 a.m. and returned to his room at 7:43 a.m. Staff logged that nursing staff changed his linens, brought him food and delivered pain medication throughout the shift. Officers (b)(6); (b)(7)(C) were relieved at 8:14 p.m. by Officers (b)(6); (b)(7)(C) throughout their shift, they logged that nursing staff gave the detainee medication, walked him to the restroom, and checked his vital signs.

An email from Commander (b)(6); (b)(7)(C) sent this date to ERO officials inquired as to the plan for detainee ALMAZAN upon discharge from the hospital. She noted, "His condition is chronic and will only get worse with time. GI bleeds can happen suddenly and can vary in severity depending on where the bleed occurs".

In written statements dated September 25, 2017 and submitted to SDD (b)(6); (b)(7)(C) and AFOD (b)(6); (b)(7)(C) documented a visit they made to the CRMC on September 13, 2017. They documented that upon their arrival, detainee ALMAZAN was asleep but he woke up while they were talking with MTC vigil officers. The deportation officers spoke with detainee ALMAZAN about the status of his immigration case and the detainee informed them he intended to appeal his case and had a petition pending. They then discussed with him whether he had family in the United States and he stated he had family in Florida and possibly New York. They then concluded their interview of detainee ALMAZAN. The deportation officers' statements do not document the time of their visit. The MTC hospital log does not document any visit to detainee ALMAZAN by ERO officers.

On **September 14, 2017** at 6:20 a.m. Officers (b)(6); (b)(7)(C) reported for vigil duty. They logged that nursing staff checked the detainee's vital signs and at 8:10 a.m. Doctor (b)(6); (b)(7)(C) informed the nurse the detainee should be moved from the ICU to a "regular room". At 1:15 p.m. officers logged the detainee was "complaining of chest pain". At 2:20 p.m. the detainee stated he "had gas". At 2:40 p.m. the detainee was moved from the ICU to room 141. At 3:15 p.m. the detainee reported he had pain. He was given Mylanta and other unknown medications per the log. At 6:56 p.m. Officers (b)(6); (b)(7)(C) reported for vigil duty. They logged nursing staff checked vitals, gave pain medication and took a blood sample during their shift. Also on

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



this date, AFOD (b)(6); (b)(7)(C) noted in an email to Commander (b)(6); (b)(7)(C) that the detainee, when discharged, would be moved to HCDF until he could be moved back to Florida.

On **September 15, 2017** at 6:20 a.m. Officers (b)(6); (b)(7)(C) reported for vigil duty. Throughout their shift they logged that nursing staff checked the detainee's blood pressure and gave him medication. They also noted the detainee took a shower at 2:00 p.m. These officers were relieved at 6:37 p.m. by Officer (b)(6); (b)(7)(C)

Commander (b)(6); (b)(7)(C) in an email this date to various ERO officials provided a medical update on detainee ALMAZAN. In the email, Commander (b)(6); (b)(7)(C) noted that a cardiac stress test was being scheduled and it was possible the detainee would be discharged in time to make a flight back to KNSPC scheduled for September 17, 2017. If the detainee was not released in time for the Sunday flight, Commander (b)(6); (b)(7)(C) recommended that he be moved, when discharged, to "Houston CDF due to his combined chronic medical issues".

Officers (b)(6); (b)(7)(C) who had assumed vigil duty logged that nursing staff met with the detainee at 7:04 p.m. to review paperwork with the detainee authorizing a stress test scheduled for the following day. At 5:38 a.m. on **September 16, 2017** the detainee signed the paperwork. At 6:40 a.m. Officers (b)(6); (b)(7)(C) arrived for vigil duty. At 9:18 a.m. they logged that the detainee went for his heart stress test and returned at 10:49 a.m.

Officer (b)(6); (b)(7)(C) reported for vigil duty at 6:10 p.m. They logged that three nurses and a doctor entered the room at 00:34 a.m. on **September 17, 2017**. At 00:55 officers contacted the warden to receive permission to remove handcuffs for "blood gas testing" and noted it was an "emergency". At 1:04 a.m. the detainee was moved to the ICU and a chest X-Ray and blood samples were taken. At 2:01 a.m. officers called the facility to report the detainee was on life support. At 2:11 a.m. chest X-rays were again taken. At 2:31 a.m. the cuffs and belly chain were noted as removed after permission was received by a shift sergeant. At 3:23 a.m. (b)(6); (b)(7)(C)


(b)(6); (b)(7)(C) entered to check on the detainee and searched for veins for IV picks. At 4:41 a.m. nursing staff asked if the facility could notify detainee ALMAZAN's next of kin to "prepare for the worst". At 4:57 a.m. the detainee went into cardiac arrest and nurses started CPR. At 5:15 a.m. the detainee was pronounced dead. At 5:18 a.m. Warden David Stacks was notified by the vigil officers of the detainee's death.

Per an email from Assistant Officer in Charge (b)(6); (b)(7)(C) at KNSPC, at 8:04 a.m. EST he notified the detainee's sister (b)(6); (b)(7)(C) that her brother had passed away.

Vigil duties were performed as follows:

Date	Officers	Arrival	Departure
September 12, 2017	(b)(6); (b)(7)(C)	4:32 p.m. 10:30 p.m.	10:47 p.m. 7:15a.m.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017




September 13, 2017	(b)(6); (b)(7)(C)	6:26 a.m.	8:34 p.m.
September 14, 2017		8:14 p.m.	6:35 a.m.
September 15, 2017		6:20 a.m.	7:25 p.m.
September 16, 2017		6:56 p.m.	6:28 a.m.
September 17, 2017		6:20 a.m.	6:55 p.m.
September 17, 2017		6:37 p.m.	7:23 a.m.
		6:40 a.m.	6:22 p.m.
		6:10 p.m.	7:20 a.m.
		6:01 a.m.	7:02 a.m.

Warden Stacks completed a Critical Incident Report on September 17, 2017. In the report he noted that detainee ALMAZAN had been transported to IAH/PCADC at approximately 11:00 p.m. on September 8, 2017, “due to expected imminent damage and dangers from Hurricane Irma to the state of Florida”. Warden Stack also documented that the detainee arrived at the facility, “with noticeable jaundice skin”. Warden Stacks’ report lists the initial apparent cause of death as a heart attack. An autopsy was ordered by Precinct Judge Wayne Mack through Texas Ranger (b)(6); (b)(7)(C) per the Warden’s report.

On **September 18, 2017**, Detainee ALMAZAN’s personal property was inventoried and photographed by Officer (b)(6); (b)(7)(C). The property consisted of one pair of pants, four shirts, 11 pairs of socks, one sweatpants, two t-shirts, eight pairs of underwear, three pairs of shoes, one wash rag, one ID card, one wristband, books, legal paperwork, a Bible, a watch, necklace, wallet, sunglasses, a homemade ring, one clear cup and \$2.10 in coins. Multiple hygiene items and multiple medications were also marked. (b)(6); (b)(7)(C) noted on interview that the shirt with elephants on it which the detainee was wearing upon admission to Krome and for his intake photo as well as a pair of his shorts had small spots on them with a “moldy, reddish tint” that may have been blood. (b)(6); (b)(7)(C) stated the property was turned over to Supervisory Detention and Deportation Officer (SDDO) (b)(6); (b)(7)(C).

Per SDDO (b)(6); (b)(7)(C) upon receipt of the property, it was taped shut in a cardboard box and secured in his office with the inventory sheet taped on top. The box was opened by the SDDO for the reviewers on October 18, 2017 and the contents were inspected. The various clothing items were reviewed and the elephant shirt and one pair of shorts did appear to have small spots of blood on them. The clothes he had worn on the trip from Folkston to IAH/PCADC were inspected and no blood was observed on the orange pants or cream colored t-shirt he wore during that trip.

Assistant Field Office Director (b)(6); (b)(7)(C) documented in an email dated September 18, 2017 that he was contacted that date by the brother of detainee ALMAZAN requesting that ERO assist with the payment to ship the body back to Florida.



On September 18, 2017, Texas Ranger (b)(6); (b)(7)(C) from Livingston, TX sent an email to AFOD (b)(6); (b)(7)(C) stating he had been contacted by Montgomery County Justice of the Peace (b)(6); (b)(7)(C) Judge Mack advised Ranger (b)(6); (b)(7)(C) that he had ordered an inquest into the death of detainee ALMAZAN (incorrectly identified as Ruiz in the email) and requested that Ranger (b)(6); (b)(7)(C) conduct the investigation. Upon speaking with AFOD (b)(6); (b)(7)(C) and being informed that an investigation into the death of the detainee was being conducted (b)(6); (b)(7)(C) sent the email to confirm with AFOD Canales that he was not conducting an investigation into the death.

The transportation of the body was funded by ERO and coordinated through All Faith's Mortuary per an invoice and purchase card transaction worksheet. The body was shipped via commercial air to Miami, FL on September 20, 2017. On the same date, the Field Office Director from the Houston Field Office notified the detainee's sister in writing of the death.


On September 20, 2017 the State of Texas issued a Certificate of Death which listed the cause of death as "pending".

Summary of Events

(b)(6); (b)(7)(C) conducted the medical intake screening at 11:30 p.m., noting that 51 year old detainee ALMAZAN spoke English, and therefore an interpreter was not used. During interview, however, (b)(6); (b)(7)(C) stated he spoke very little English but there was a medical person available who interpreted for her. She was unable to ascertain who provided this assistance. (b)(6); (b)(7)(C) Detention Officer who worked intake during the arrival of the Florida-evacuated detainees, recalled detainee ALMAZAN only spoke Spanish, requiring another intake officer to provide language assistance. (b)(6); (b)(7)(C) Detention Officer who was working in the detainee's unit, also stated detainee ALMAZAN spoke no English and that because he himself was fluent in Spanish, he provided interpretation assistance. Throughout interviews, other custody staff having had direct contact with detainee ALMAZAN also described his minimal ability to speak and understand English.

At five feet, one inch tall, detainee ALMAZAN weighed 170 pounds. A pain level of four on a scale of zero to ten was reported at the time of arrival, as he complained of general joint pain and discomfort in the upper right quadrant of his abdomen. The reviewer notes that pain in this location is common in liver cirrhosis. Vital signs were recorded within normal limits with the exception of a significantly elevated blood pressure of 180/109 (*See Appendix I*). Rechecks at unrecorded times noted a decrease in blood pressure to 164/100 and finally to 152/86, levels that remained abnormally high (*See Appendix II*). (b)(6); (b)(7)(C) stated during interview she did not contact the provider regarding these blood pressures, as detainee ALMAZAN told her he had not received his medication for an undetermined period of time. According to the MTC nursing protocol a blood pressure read of 160/100 requires provider contact, which (b)(6); (b)(7)(C) stated she was aware of. When questioned if he would have wanted to be notified of the abnormal read, (b)(6); (b)(7)(C) P-A-

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



C stated that considering the diagnoses of cirrhosis and probable portal hypertension, it would have been important for him to know. (b)(6); (b)(7)(C) stated during interview that she was not aware what the interval period was between rechecks of the blood pressure, but she explained that she had administered his medication prior to the second and third check. However, (b)(6); (b)(7)(C) LVN, who said she was present at the time of detainee ALMAZAN's intake screen, stated during interview that she personally pulled him out of the screening area to help him relax and conducted the second and third blood pressure rechecks. When asked if she administered his medication prior to the rechecks, she stated she did not believe the meds had been given. A review of the medication administration record (MAR) does not indicate any of his medications were given until the 5:30 a.m. pill line the following morning. The MAR does indicated prescribed medications were regularly administered from that time until his hospital transfer. Of note, the next blood pressure check was not recorded until three days later prior to hospital transport.

Detainee ALMAZAN signed and dated a Spanish version of consent for medical treatment. He was noted to have had a chest x-ray on July 12, 2017, negative for tuberculosis, and he denied a history or current symptoms of infectious disease. Chronic medical issues, as supported by those listed on the medical summary from Glades County Detention Center (GCDC), included cirrhosis of the liver, depression, and generalized anxiety disorder (GAD). Other diagnoses established at both previous facilities, Krome Service Processing Center (KSPC) and GCDC but not listed on the medical summary, included portal hypertension⁹⁰, varices⁹¹, pancytopenia⁹², irritable bowel syndrome⁹³, and gastro-esophageal reflux disease⁹⁴. The medical summary from GCDC also failed to include pending referrals initiated while he was detained at KSPC, including an abdominal ultrasound and specialty consults for hematology and ophthalmology. According to medical records received from KSPC and GCDC, the referrals were never completed; nor were there references to the pending state of these referrals on the transfer summary forwarded from KSPC and received by GCDC.

Detainee ALMAZAN reported not being a smoker, but admitted to a significant history of alcohol abuse, stating he used "mucho" beer and tequila, last using about three months ago. He had been hospitalized and went through "the program". He was noted to have tremors, which was listed as a withdrawal symptom, and he admitted to having gone through a period of withdrawal at the time of his hospitalization. His mental health assessment was all shown to be normal although following a "no" response to the question if he ever tried to harm himself, (b)(6); (b)(7)(C) noted,

⁹⁰ Portal hypertension is an increase in the blood pressure within a system of veins called the portal venous system. Veins coming from the stomach, intestine, spleen, and pancreas merge into the portal vein, which branches into small vessels and travels through the liver. When a sick liver is unable to accommodate the blood, it pools back, causing vessel enlargement and weakness (varices).


⁹¹ Varices are abnormal veins in the lower part of the esophagus and stomach.

⁹² Pancytopenia is a deficiency of all three cellular components of the blood (red cells, white cells, and platelets)

⁹³ Irritable bowel syndrome is an intestinal disorder causing stomach pain, gas, diarrhea, and constipation.

⁹⁴ Gastro-esophageal reflux disease is a digestive disease in which stomach acid or bile irritated the lining of the esophagus and stomach.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



“passive suicidal intent”. When asked to clarify what this meant, she stated in the past he had thoughts of wanting to die. His mood and behavior were found to be appropriate. (b)(6); (b)(7)(C) completed MTC’s “Treatment Plan: Special Needs and Restrictions” form, excusing him from a work program assignment for medical reasons. He was placed on no restrictions for the disciplinary process, and “chronically ill” was checked for special needs. Routine referrals were checked for mental health, medical doctor, and special diet (renal). He was assigned to a low bunk in handicap housing unit C-20.

(b)(6); (b)(7)(C) RN, HSA documented a verbal order from (b)(6); (b)(7)(C) PA to continue all medications as ordered by the previous facility. The transfer summary from GCDC listed his medication as follows:

Medication	Dosage	Indications
Sertraline	100 mg daily	Depression and anxiety
Trazadone	75 mg daily at bedtime	Depression and anxiety
Folic Acid	1 mg daily	Vitamin B folic acid deficiency related to liver disease.
Omeprazole	40 mg daily	Gastro-esophageal reflux disease (GERD)
Prednisone	100 mg daily for three days. Tapered doses: (100mg, 80mg, 60mg, 50 mg, 40 mg, 30 mg, 20 mg, each for three days; then 10 mg, 5 mg, 2.5 mg each for two days, then discontinue.	Steroid to treat inflammation
Spironolactone	25 mg twice daily	High blood pressure and fluid retention

The medications submitted on the MAR included a taper⁹⁵ on the prednisone, the addition of lactulose 30 mg twice daily, and the addition of Xifaxan 550 mg twice daily. Of note, Dr. (b)(6); (b)(7)(C) MD from GCDC added and/or adjusted medications on September 6, 2017. Neither the medication bottles nor the order information was forwarded to or received by PCADC. Specifically, he had increased lactulose to 40 ml, started ferrous sulfate (iron) 325 mg one time daily, and added a multivitamin, one daily. (b)(6); (b)(7)(C) Advanced Registered Nurse Practitioner from GCDC ordered an increase of trazodone to 75 mg nightly on August 22, 2017. The dosage on the medical summary was 50 mg, but during interview (b)(6); (b)(7)(C) explained she reconciled the medication labels and noted the current dosage. The reviewer observed that detainee ALMAZAN had never been prescribed a beta-blocker⁹⁶ as an important adjunct in his cirrhosis treatment. PA

⁹⁵ Drug tapering is the gradual discontinuation or reduction of a therapeutic dose of a particular drug required by a patient over a prolonged period of time, as a means of reducing potentially severe side effects.

(b)(6); (b)(7)(C) reported during interview he had questioned if he was receiving a beta-blocker and was surprised he was not. According to an article published by the gastroenterology department of the National Institutes of Health, related to the use of non-selective beta-blockers (NSBB)⁹⁷, they remain the cornerstone of therapy in cirrhotic patients with portal hypertension. In primary prophylaxis, patients with high-risk small varices or large/medium varices should receive primary prophylaxis with NSBB, except when contraindication to these drugs exist, in which case endoscopic band ligation should be performed.

IAH/PCADC utilizes indirect supervision with an officer assigned to the hallway outside the dorm. Dorm officer post orders require that a security round be conducted twice per hour at irregular intervals with no more than 40 minutes elapsing between rounds. The officers are not required to enter each dorm during these rounds. Officers do enter the dorms during the seven official counts conducted daily and to distribute and retrieve trays for all meals. Indoor recreation is offered in an area directly across from the dorm. There is also a large recreation field outside. Detainees are permitted one hour of recreation daily.

(b)(6); (b)(7)(C) Licensed Professional Counselor, documented a mental health assessment following the referral for depression. Detainee ALMAZAN was described as clean, cooperative, fully oriented, and having normal speech. His mood was described as depressed, his affect was congruent, his thought process was logical, and he had no hallucinations or suicidal intent. His judgment and insight were fair. The narrative note stated, "Processed thoughts and feelings regarding being incarcerated. Discussed the importance of positive coping skills. Established skills he could use while incarcerated. Informed how to access mental health services. Will refer to psychiatrist for med management." He was not found to be a danger to himself or others. During interview, (b)(6); (b)(7)(C) did not recall detainee ALMAZAN ever discussing his medical condition, including any possibility that he had been vomiting or coughing up blood since his arrival.


According to MTC's policy addressing intake health screening, "When a referral for medical follow-up is initiated, the resident shall receive a health evaluation no later than two working days from the date of assessment." HSA (b)(6); (b)(7)(C) produced an electronic chronic care roster document, indicating that detainee ALMAZAN's chronic care clinic was pending at an unspecified date. He was transported to the hospital on Monday, September 11, the first working day since his arrival.

At 7:45 p.m. (b)(6); (b)(7)(C) LVN completed an emergency assessment form, noting, "Nurse called to tank C-20 because detainee was reportedly vomiting blood." Detainee ALMAZAN's vital signs were recorded as normal, with the exception of an abnormally elevated blood pressure of 151/95 and an abnormally rapid heart rate of 106. He was fully oriented to person, place, and time. He complained of pain in his mid chest. ERAU's review of the housing unit video clearly showed a

⁹⁶ Beta-blockers are a class of drug commonly used to treat high blood pressure. Nonselective beta-blockers are a subclass of beta-blockers, commonly used to treat portal hypertension.

⁹⁷ Gianelli V, Lattanzi B, Merli, M, Beta-blockers in liver cirrhosis, *Annals of Gastroenterology*. 2014;27(1):20-26.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



second nurse responded to the unit when the call came through. This nurse was identified as (b)(6); (b)(7)(C) LVN. When questioned during interview as to why she did not document a note, she explained that (b)(6); (b)(7)(C) was taking charge of the situation. She did report assisting with the detainee's transfer from the bed to the wheelchair, however. According to the "Provider Progress Notes/Orders" (b)(6); (b)(7)(C) completed his evaluation of detainee ALMAZAN at 9:57 p.m. During interview (b)(6); (b)(7)(C) reported he incorrectly recorded the military time, intending to have signed off at 7:57 p.m. According to the note, he was brought to medical with complaints of vomiting blood, similar to an incident he reported having occurred seven years ago. He was believed to have cirrhosis with varices, information that was extracted from the chart, as (b)(6); (b)(7)(C) determined, "Pt [patient] poor historian". When questioned as to how he arrived at this description, (b)(6); (b)(7)(C) stated that detainee ALMAZAN offered no medical history, as if he did not want medical to know how sick he was. When directly questioned about his cirrhosis, however, he then admitted it. (b)(6); (b)(7)(C) voiced his opinion that the detainee did not speak English and that (b)(6); (b)(7)(C) Medical Assistant, provided interpretation. He was described as alert and oriented and appeared to be in no acute distress (b)(6); (b)(7)(C) stated there were no symptoms or patient behaviors at the time of assessment to suggest this was an emergency situation. Bright red blood was observed on both the inside and outside his mouth, but there was no blood on his shirt or pants. He was diagnosed with gastrointestinal bleed of five days duration and was sent to the emergency room for evaluation on a stat basis, but not via 911.

A "Timeline/Checklist – Depart from the Facility" form was completed by an unidentified medical staff member at 8:42 p.m. According to this document, (b)(6); (b)(7)(C) was notified of the need to transport detainee ALMAZAM to CHI St. Luke's via van with security escort. Hospital updates were recorded daily, as follows:


Reporting Nurse, Date, Time	Report Summary
(b)(6); (b)(7)(C) September 12, 2017	Stable at this time. Most recent vitals: Blood pressure 99/58, pulse 75, and respirations 17. Pulse oxygen 97. Temperature remains normal. Two units of platelets given due to critical platelet level of 27. Post transfusion level is up to 55. All other labs remain within normal limits. Scheduled to have EGD ⁹⁸ in the morning. Previously receiving cardene drip ⁹⁹ via external jugular line. Has been stopped and is now receiving oral lisinopril ¹⁰⁰ .
(b)(6); (b)(7)(C) LVN September 13, 2017 5:35 p.m.	Alert and oriented. Blood pressure 117/58, pulse 88, R 19, Temperature 98.3, pulse oxygen 100. Received two units of platelets. Hemoglobin is 11.2, and platelets are 27.
LVN Pena	Alert and oriented. Blood pressure 101/51, pulse 69, respirations 14,

⁹⁸ An EGD, short for esophagogastroduodenoscopy is a scope used to examine the lining of the esophagus, stomach, and duodenum (upper part of the small intestine)

⁹⁹ A cardene drip is an intravenous therapy infused with medication to treat high blood pressure.

¹⁰⁰ Lisinopril is a medication to treat hypertension.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



September 14, 2017 6:41 a.m.		temperature 98.3, pulse oxygen 99. Continues lisinopril orally. Denied pain throughout the night.
(b)(6); (b)(7)(C)	N	Alert and oriented. Blood pressure 125/73, pulse 79, respirations 18, temperature 98.7, and pulse oxygen 99. Continues oral lisinopril. Pain is eight of ten, reporting severe GERD. Moved to medical-surgical unit.
September 14, 2017 6:31 p.m.		
(b)(6); (b)(7)(C)		Remains stable. Removed from ICU room 18 to medical surgical floor, room 141. Blood pressure 93/54, temperature 98.1, pulse 72, respirations 18, pulse oxygen 97.
September 15, 2017 5:40 a.m.		
(b)(6); (b)(7)(C)	RN	Remains stable. Blood pressure 1006/65, temperature 98.2, pulse 72, respirations 16, pulse oxygen 98. Had a normal cardiac stress test earlier in the day. Medications remain Zoloft, folic acid, metoprolol ¹⁰¹ , Protonix ¹⁰² , lactulose, and aldactone. Possible discharge Sunday after seen by doctor.
September 16, 2017 7:24 p.m.		
(b)(6); (b)(7)(C)		At about 1:00 a.m. patient coded and is now critical and has been moved to ICU, room 36. He is on life support and is intubated with agonal ¹⁰³ breathing. When able to get a blood pressure, it is in the 50s by palpation ¹⁰⁴ . Hemoglobin is 5. Blood being given. Warden Stacks has notified ICE personnel (b)(6); (b)(7)(C)
September 17, 2017 2:32 a.m.		

On September 20, 2017 the State of Texas issued a Certificate of Death which listed the cause of death as “pending”.

APPENDIX I

Vital Signs

DATE	TEMPERATURE	PULSE	RESPIRATIONS	BLOOD PRESSURE	Oxygen
September 8, 2017	97.0	98	14	180/109	98
				164/100	
				152/86	
September 11, 2017	97.5	106	18	151/95	100

APPENDIX II


¹⁰¹ Metoprolol is a beta-blocker to treat high blood pressure.

¹⁰² Protonix is a treatment for GERD.

¹⁰³ Agonal breathing is abnormal respirations characterized by gasping, and labored breathing.

¹⁰⁴ Palpation is a method of examining the body using the hands.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



American Heart Association Blood Pressure Parameter

Blood Pressure Category	Systolic (Upper number)		Diastolic (Lower number)
Normal Blood Pressure	Less than 120	and	Less than 80
Prehypertension	120-139	or	80-89
Stage One Hypertension	140-159	or	90-99
Stage Two Hypertension	160 or higher	or	100 or higher
Hypertension Crisis	Higher than 180	or	Higher than 110

CONCLUSIONS


Medical Compliance Findings

Medical Care, Section (III)(D), which states, “Non-English speaking detainees and detainees who are deaf or hard of hearing will be provided interpretation or translation services or other assistance as needed for medical care activities. Language assistance may be provided by another staff member competent in the language or by a professional service, such as a telephone translation service.”

- During the intake screening (b)(6); (b)(7)(C) noted ALMAZAN spoke English and therefore did not require language assistance. During interview, however, (b)(6); (b)(7)(C) stated he “spoke very little English” but that an unidentified medical person provided interpretation. There was no documentation to substantiate this. (b)(6); (b)(7)(C) Intake Detention Officer recalled detainee ALMAZAN only spoke Spanish, requiring another intake officer to provide language assistance. (b)(6); (b)(7)(C), Detention Officer who was working in the detainee’s unit, also stated detainee ALMAZAN spoke no English and required interpretation assistance. There is no telephone access in the medical intake area.

Medical Care, Section (III)(D), which states, “Medical and mental health interviews and examinations shall be conducted in settings that respect detainees’ privacy.”

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
 Medical and Security Compliance Review
 December 4-5, 2017



- Curtain dividers and ceiling-mounted acoustic boards do not fully protect a detainee's privacy to fully and comfortably discuss sensitive medical information.

Medical Care, Section (III)(D), which states, "The clinical medical authority shall be responsible for review of all health screening forms within 24 hours or next business day to assess the priority for treatment (for example Urgent, Today, or Routine).

- The intake screen does not include a signature of review by the clinical medical authority. Of note, the evening detainee ALMAZAN was transferred to the hospital was the first business day for that review.

Medical Care, Section (III)(B), which states, "Health care personnel perform duties for which they are credentialed by training, licensure, certification, job descriptions, and/or written standing or direct orders by personnel authorized by law to give such orders."

- A seriously elevated blood pressure of 180/102 was not reported to a provider in accordance with MTC's Nursing Protocols. Additionally, regular blood pressure monitoring was not done during the three days detainee ALMAZAN was detained at PCADC.

Areas of Concern

- Sick call forms and deposit boxes are inconveniently placed in the hallway outside the locked unit. Detainees reported they access them when they go to recreation and after completion, hold them to the window when the officer passes by doing rounds. The officer then takes the request and deposits it in the locked box. This practice does not protect the privacy and confidentiality of the detainees. Detainee ALMAZAN did not request a sick call appointment during his detention.


Safety and Security Compliance Findings

Creative Corrections cites the following deficiencies in relevant components of facility policies and post orders.

Dorm Officer Post Orders, section III 8. Post Activity Log Entries requires unusual incidents to be recorded in the log.

- The medical emergency called to the detainee's dorm and the response of both security and medical staff was not logged.


DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



Stationary Guard Medical Officer Post Orders, section II, 9.B requires the assigned officer to maintain a daily log of activities to include visits by physicians, nurses, room attendants, and any other relevant information.

- Assigned vigil officers did not log the visit by two deportation officers to detainee ALMAZAN while he was hospitalized.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



From: (b)(6); (b)(7)(C)
Sent: 23 Jul 2018 17:33:53 +0000
To: (b)(6); (b)(7)(C)
Subject: FW: ALMAZAN
Attachments: ALMAZAN DDR Merged Report.docx

(b)(6); (b)(7)(C)

Management & Program Analyst
ICE/OPR/ERAU

950 L'Enfant Plaza SW (b)(6); (b)(7)(C)
Washington, DC 20536
202-7 (b)(6); (b)(7)(C) desk)
202-2 (b)(6); (b)(7)(C) cell)

From: (b)(6); (b)(7)(C)
Sent: Monday, February 05, 2018 11:06 AM
To: (b)(6); (b)(7)(C) gov>
Subject: FW: ALMAZAN

From: (b)(6); (b)(7)(C)
Sent: Friday, February 02, 2018 3:50 PM
To: (b)(6); (b)(7)(C)
Subject: ALMAZAN

Detainee Death Review: ALMAZAN-Ruiz, Felipe A028866428
Healthcare and Security Compliance Analysis
Krome North Service Processing Center, Miami, Florida
Glades County Detention Center, Moore Haven, Florida
Polk County Adult Detention Center, West Livingston, Texas

As requested by the ICE Office of Professional Responsibility, Office of Detention Oversight (ODO), Creative Corrections participated in a review of the death of detainee Sergio Alonso LOPEZ who had been detained at the Krome Service Processing Center (KSPC) from July 12 to August 11, 2017, Glades County Detention Center (GCDC) from August 11 to September 8, 2017, and Polk County Adult Detention Center (PCADC) from September 8 until his death on September 17, 2017. Site visits were conducted at each of these facilities by members of a review team comprised of (b)(6); (b)(7)(C) External Reviews and Analysis Unit, and Management and Program

(b)(6); (b)(7)(C) accompanied by Creative Corrections contract personnel

(b)(6); (b)(7)(C), Security Subject (b)(6); (b)(7)(C) healthcare Subject Matter


Expert. Creative Corrections' participation was requested to determine compliance with the National Detention standards at GCDC and PCADC and the 2016-revised 2011 Performance Based National Detention Standards (PBNDS) at KNSPC. The reviews were conducted from October 17-19, 2017, at IAH/PCADC, from December 4-5, 2017, at Krome North Service Processing Center (KNSPC) and from December 6-7, 2017, at Glades County Detention Center (GCDC).

The information and findings herein are based on analysis of detainee LOPEZ' medical record and detention file, tour of housing units and the medical area, interviews of staff, and review of facility policy, video surveillance footage, hospital records, and supporting documentation.

Synopsis

Per the ERO Form 213, Felipe ALMAZAN entered the United States on or around May 4, 1985, at or near San Ysidro, CA, without having been admitted by an immigration officer. Once in the United States he acquired an extensive criminal history which included convictions for Larceny in August 1994, and July 1998, Indecent Exposure in July 1998, and Driving under the Influence of Liquor in May 2001. Per the Miami-Dade Police booking form, ALMAZAN was arrested at 10:20 p.m. on April 14, 2017, for alcoholic beverages/drinking in public and engaging in sexual act with a familial child. On **July 10, 2017**, he was convicted of two counts of Child Abuse/Aggravated/Great Bodily Harm and Torture and sentenced to 15 years of probation. The Miami Dade Probation Office notified the Miami Fugitive Operations Team about his case on **July 12, 2017**, and he was taken into custody at the Miami Dade Probation Office in Miami, FL and transported to Krome North Service Processing Center (KNSPC) for processing.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



Detainee ALMAZAN had an extensive criminal history and was placed on probation for a term of 15 years after being convicted of child abuse aggravated, causing great bodily harm and torture. ERO transported him from the Miami-Dade probation office to KNSPC on July 12, 2017. He was detained at KNSPC for 30 days. During his stay there he made no phone calls, had no visits and had no disciplinary issues.

He was next transferred to GCDC. While there, he completed three phone calls and worked for five days as a trustee in the food service area earning \$1.00 per day. After 26 days at GCDC, he was transferred to the Folkston Processing Center in anticipation of the approaching Hurricane Irma. One day later he was transported to the PCADC when the projected path of Hurricane Irma changed. He was housed at IAH/PCADC from September 8 to September 11, 2017. During that time he filed no grievances, had no disciplinary violations and made no phone calls. A review of the video surveillance footage from inside his housing pod showed that he slept almost all of the time and ate very little from his food trays.

On September 11, 2017, other detainees in his housing unit alerted the officer that detainee ALMAZAN was vomiting blood. Both security and medical staff responded and the provider ordered him to be sent to the hospital. He was transported to a local hospital and then transported a day later to a regional medical center for treatment of cirrhosis of the liver. On September 17, 2017 he coded and was transferred to the Intensive Care Unit where he was placed on life support. He was declared dead at 5:15 a.m. on the same date.

There were minor security deficiencies noted at two of the three facilities detainee ALMAZAN was housed at. None of these issues contributed to his death.


Krome North Service Processing Center

Facility Description

KNSPC is owned by ICE and managed by ERO, Miami Field Office. The facility has a capacity of 581. While female detainees are temporarily brought to KNSPC for court, only male detainees are detained overnight. On September 12, 2017, the population was 608. There are approximately 90 ICE employees on staff at the facility. Contractors Akima Global Services (AGS), with regional headquarters in Herndon, Virginia, and AKAL Security, with corporate headquarters in Espanola, New Mexico, provide security and armed transportation services. AGS officers are not weapons certified and supervise detainees in areas such as housing units and the cafeteria inside the facility. AKAL officers are weapons certified and work the processing/intake area, transport detainees and provide vigils when detainees are at one of the three hospitals used by KNSPC. There are 177 AKAL contract security staff. All officers involved in this event were AKAL staff.

Healthcare Services

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



KNSPC's primary health care provider is ICE Health Service Corps (IHSC), supported by contractor InGenesis Medical Staffing based in San Antonio, Texas. InGenesis Medical Staffing sub-contracts STG International, Incorporated. Medical services are provided 24 hours a day, seven days a week. The staffing plan includes 21 commissioned Public Health Service officers, five GS employees, and 31 contract employees. Additionally, there are four casual nurses. The commissioned officers include the Health Services Administrator (HSA), assistant HSA, Clinical Director, three mental health professionals, dentist, pharmacist, three mid level providers, nurse manager, program manager, and eight registered nurses (RN). The GS employees include three medical records technicians, a dental assistant, and a radiology technician. (b)(7)(E)

(b)(7)(E)

(b)(7)(E) A casual pool of three contract RNs and one contract LPN supplement the staffing model. According to the (b)(6); (b)(7)(C) vacancies at the time of ALMAZAN's detention included five RNs and a radiology technician. Credential files were reviewed and found to be current and primary source verified. KNSPC achieved American Correctional Association accreditation in August 2015, and National Commission on Correctional Health Care accreditation in April 2015.


IHSC's electronic medical record system, e-Clinical Works (eCW), is used at KNSPC. It is noted that unless indicated, the times of medical encounters identified in this report are the times nurses and providers electronically entered their notes, per system-produced timestamps. The times encounters were actually conducted are not available unless documented in the notes.

Detention Summary

Detention Officer (b)(6); (b)(7)(C) processed detainee ALMAZAN into KNSPC, documenting that the detainee's primary language was Spanish. Officer (b)(6); (b)(7)(C) acknowledged he does not speak Spanish and he stated that he typically obtains assistance from a bilingual fellow officer when processing the detainee into the facility. On interview, Officer (b)(6); (b)(7)(C) stated he had only slight recollection of this detainee but would have followed his usual practice when processing him. He initially pat searches each detainee when they arrive and he completed a Record of Search form confirming no contraband was found on detainee ALMAZAN. Officer (b)(6); (b)(7)(C) stated he would next provide the detainee the opportunity to shower and then send the detainee to be classified. Detainee ALMAZAN's classification review was completed by other members of the processing team and he was appropriately classified as medium high. The classification level was approved by a supervisor on the same date.

Once classified, detainee ALMAZAN was sent back to Officer (b)(6); (b)(7)(C) so the proper color uniforms could be issued as well as facility linens, hygiene supplies and other clothing. The detainee would have next been sent to property to have his personal property inventoried and his funds placed into an account. The detainee's inventory form documents he arrived with one

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



billfold, one pair of jeans, two pairs of shorts, some personal papers, two pairs of shoes, one pair of sunglasses, two t-shirts and valuables that were not identified. These items were placed in property bin #3666037. A receipt for the property was signed by the detainee. The detainee also arrived with a check for \$9.00 and the funds were deposited into the kiosk system for his use at commissary. Detainee ALMAZAN was issued facility clothing, linens and hygiene supplies and he signed a receipt for these items. Detainee ALMAZAN did not provide the facility with a forwarding address and signed a form documenting this. He also signed a form acknowledging he received a copy of the local and national handbooks. Per Officer (b)(6); (b)(7)(C) the detainee was then sent to medical for intake screening. Officer (b)(6); (b)(7)(C) recalled that detainee ALMAZAN moved slowly.

During his stay at KNSPC, detainee ALMAZAN was assigned to units four, five and six in building eight. Building eight houses high and medium high detainees and contains six units; units one through three on the lower level and units four through six on the upper level. On each floor there is a control pod in the center with an officer assigned at all times. Another officer is assigned to each pod for direct supervision of the detainees. On the upper level, pods four through six are located clockwise around the control center. Each pod is essentially identical with small variations in the unit set up.


Pod four has a capacity for 60 detainees with 30 bunk beds in the center of the unit. Upon entry to the unit, the officer's station is located to the left and there are a bank of phones along the left wall. To the right of the entry way is a kiosk for ordering commissary and sending requests or grievances. There are also numerous chairs for detainees to use while viewing the TV located on that wall. A second TV is mounted on the ceiling near the center of the unit. Along the right wall at the rear of the unit is a shower and toilet area separated from the open area by a half wall. There are long, narrow windows along the left and rear walls which allows natural light into the unit. There are four ceiling mounted cameras in the unit; appropriately none with a view of the bathroom area.

EARM documents that the detainee was originally on a manifest to transfer to Glades County Detention Center (GCDC) in Moore Haven, FL on **July 13, 2017**; however, he was removed from that trip for unknown reasons.

There is no record of any requests, visits, phone calls or unusual incidents involving detainee ALMAZAN during his stay at KNSPC. On August 11, 2017, detainee ALMAZAN's personal property was again inventoried for transfer to GCDC. A receipt for \$9.00 in funds was signed by the detainee and a check was issued at 3:08 p.m. per the Resident Transaction Receipt. The check notes, "Release Glades". Detainee ALAZAN was provided with the address and phone number of GCDC and he signed a form acknowledging that he received the information. Per EARM, he was transferred out of KNSPC at 7:30 p.m.

Summary of Events

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



(b)(6); (b)(7)(C)

RN documented a pre-screen at 5:47 p.m. on **July 12, 2017**, noting that detainee ALMARAZ arrived to the facility at 1500 hours, the latter time believed to be in error. Lieutenant (b)(6); (b)(7)(C) stated during interview he is alerted whenever detainees arrive. After verifying the detainee's name, nationality and date of birth on the Order to Detain or Release Alien 203 form, he stated it is his common practice to then ask the officer at the desk to tell him the time from the computer screen, and he notes the time on the form. In this case, the arrival time noted was 5:00 p.m. When asked if the time he documented could have been an error as medical had noted a medical screening was done at 3:00 p.m. the Lieutenant replied that he did not think that was possible as the time of arrival is verified by the officer at the desk. In addition, the EARM records document the detainee arrived at 5:00 p.m.

Interpretation assistance was not provided at the time of the pre-screen as "Detainee speaks English fluently," and there were no barriers to communication identified. (b)(6); (b)(7)(C) advised she does not speak Spanish but, "If I say do you have any medical questions and I can see he is struggling with my questions, I can get an interpreter." It was noted ALMAZAN had not transferred from another facility. He was noted to have current, unspecified health problems and was taking medication. He was placed on a Priority 2 status, which according to (b)(6); (b)(7)(C) means a provider must evaluate the detainee within 24 hours because of a chronic condition or if he is taking medications.

At 9:39 p.m. (b)(6); (b)(7)(C) InGenesis, conducted the intake screen, noting that Detainee ALMAZAN was Spanish speaking for which interpretation assistance was provided. Inconsistent with (b)(6); (b)(7)(C)'s note, (b)(6); (b)(7)(C) stated he had transferred from another facility, having arriving with a transfer summary. Attempts to locate a transfer form, however, found no evidence of its existence. Detainee ALMAZAN stated he was feeling fine and was not in pain. He offered his previous diagnosis of cirrhosis¹ and that he was on medication. The only medication listed, however, was sertraline (Zoloft), a medication to treat depression. When asked if he was now or ever had been treated by a doctor for a medical condition, he replied no. He denied symptoms of tuberculosis infection, and his chest x-ray was negative. He denied drug abuse but admitted to drinking 12 to 15 beers a day, having last used on April 1, 2017. He also admitted to being a smoker, smoking two cigarettes per night. The examination, mental health screening, and vital signs were all within normal limits (*See Appendix I for vitals*). A Spanish version of the consent for medical treatment was signed. He was noted to have an abnormal intake screening and was referred to a medical provider. He was medically cleared for custody.

LT (b)(6); (b)(7)(C) RN documented a sick call visit on **July 16, 2017**, at 3:34 p.m. to assess an unspecified skin irritation. An interpreter was not used, as, "Detainee speaks English fluently." When questioned during interview as to how she determines when interpretation assistance is needed, she replied that she is able to understand the issue, sometimes using "sign

¹ Cirrhosis is liver damage from a variety of causes, such as alcohol abuse, leading to scarring and liver failure.

language” and since this visit occurred on a Sunday, “We probably had a Spanish speaking person to translate, and I didn’t document it.” Vital signs were all within normal limits, and ALMAZAN’s general appearance was described as well developed, well nourished, and in no acute distress. In spite of the complaint of skin irritation, the skin was documented only as normal, warm and dry. His heart was regular in rate and rhythm, and his lungs were normal. Treatment included Clotrimazole cream², with application to the affected area twice a day for seven days, as keep-on-person (KOP) medication and hydrocortisone cream³ with application to the affected area, externally, twice a day for seven days, also as a KOP medication. An English version of a KOP agreement was signed by ALMAZAN. Treatment notes refer only to “RN Guidelines for Foot Fungus”, while a reference to a nursing guideline authorizing use of hydrocortisone cream was not filed. During interview, (b)(6); (b)(7)(C) admitted her failure to document the complete physical assessment and was unable to recall why she ordered the hydrocortisone cream, stating, “If I treated him, there was a reason I treated him”.

Seven days following intake, on **July 19, 2017**, at 5:34 a.m., LCDR (b)(6); (b)(7)(C) NP, conducted an initial physical examination, noting that the intake screen was reviewed. An interpretation service was used, with the Language Line identification number recorded. During interview NP (b)(6); (b)(7)(C) stated, “Even if they say they speak a little bit of English, I use the service to make sure they understand.” Detainee ALMAZAN denied all medical and dental complaints, with the exception of hepatitis and depression. He admitted to suicidal ideation one year ago but denied any attempts. NP (b)(6); (b)(7)(C) narrative states detainee ALMAZAN was taking medication for cirrhosis while in Metrowest Detention Center (MDC)⁴. He stated he felt fine, was eating and sleeping well, and had regular bowel movements. He denied homicidal or suicidal ideations or thoughts of potential for violence towards others. He denied chest pain, shortness of breath, nausea or vomiting, fever or chills, abdominal pain, diarrhea, constipation or any other complaints or concerns at that time. His vital signs were all within normal limits. His eye test showed a visual impairment⁵ of 20/200 in the left eye, 20/100 in the right eye, and 20/70 in both eyes, without glasses. The general examination found him to be in no acute distress, well developed, well nourished, and calm and relaxed. He was noted to be asymptomatic⁶ and clinically stable. The assessment diagnoses were alcoholic cirrhosis of liver without ascites⁷ and visual disturbance. The treatment plan included renewal of sertraline, follow up with mental health, comprehensive laboratory studies on July 28, 2017, referral to ophthalmology⁸, and referral to radiology for an ultrasound⁹ of the liver. A medical consent was sent to MDC to obtain medical and medication

² Clotrimazole cream is an antifungal medication, commonly used to treat athlete’s foot.

³ Hydrocortisone cream is a steroid used to treat skin conditions.

⁴ MDC is a Dade County prison in Doral, Florida

⁵ A visual impairment refers to loss of vision and decreased ability to see. Normal vision is 20/20, while 20/200 is a significant vision loss.

⁶ Asymptomatic means an absence of symptoms.


⁷ Ascites is an abnormal accumulation of fluid in the abdominal cavity.

⁸ Ophthalmology refers to a specialty in eye disease.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz

Medical and Security Compliance Review

December 4-5, 2017



records. Detainee ALMAZAN was provided patient instructions and preventive health information.


The initial mental health screen was conducted on **July 20, 2017**, at 2:18 p.m. (b)(6); (b)(7)(C) Psychologist, STG recalled conducting the encounter in Spanish and was not aware of what ALMAZAN's level of English proficiency was. During questioning ALMAZAN verbalized that the father of a 43 year-old woman he had been dating was angry that he was going out with his daughter and later accused him of sexual assault. His past psychiatric history included hospitalization at Jackson Memorial Hospital (JMH) for alcohol abuse four years ago, but was later referred to mental health while at the hospital. He reported that he was drinking heavily due to depression and stress. He said he would experience sadness, crying spells, and had suicidal ideations. He said he felt this way because of not having a wife or significant other, not having his parents, having a sibling pass away, and losing his job. He reported that while at JMH he was seen by a psychiatrist who prescribed medication, which helped him significantly, but he did not recall the name of it. As per medical records, he was taking Zoloft (*sertraline*) 100 mg. He reported a history of suicidal ideations prior to his hospitalization, having had thoughts of jumping off a building, but he did not follow through as he began to think about his family, and he started to read the Bible. He also reported suicidal ideations three years ago with thoughts of cutting himself with a knife, but focusing on his faith, he did not follow through. He denied current suicidal/homicidal ideation, intent or plans. He also denied a history of perceptual disturbances or delusions. The substance abuse history noted detainee ALMAZAN had been convicted for driving under the influence of alcohol and participated in in-patient alcohol treatment. The assessment findings were 1. Major depressive disorder¹⁰, recurrent, mild; and 2. Alcohol abuse, uncomplicated. Treatment included follow-up in two to three weeks and referral to (b)(6); (b)(7)(C) for medication management.

On **July 24, 2017**, at 5:46 p.m., LCDR (b)(6); (b)(7)(C) RN documented a progress note related to a sick call refusal, stating, "Patient called for sick call on evening shift but refused (b)(6); (b)(7)(C) multiple calls were placed by PHS desk officer with no result. Will continue to monitor." RN (b)(6); (b)(7)(C) explained that detainees are typically seen in sick call between 8:00 a.m. to 3:00 p.m. every day, but in the event of a spill over, a list is made of those not seen, and the detainees who are returned to the housing until after 3:00 p.m. are called back on the evening shift of the same day. Prior to the sick call visit, nurses do not know the nature of the request. Three days later on **July 27, 2017**, at 12:19 p.m., (b)(6); (b)(7)(C) RN documented a late entry for a sick call visit conducted on July 26, 2017. An interpretation service was not used as "Detainee speaks English fluently." Detainee ALMAZAN stated he had been taking pills for his liver but had not yet received them." He denied pain, and his vital signs were all within normal limits. The nursing plan was to send a telephone encounter to a medical provider. The following day of July 28, 2017, at 12:00 p.m., RN (b)(6); (b)(7)(C)

⁹ An Ultrasound is a diagnostic tool using sound waves to produce images of inside the body.

¹⁰ Major depressive disorder is a mental health disorder characterized by persistently depressed mood or loss of interest in activities, causing a significant impairment in daily life.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



documented another sick call visit for complaint of respiratory symptoms and sore throat. An interpreter was not used for his visit as, "Detainee speaks English fluently." Detainee ALMAZAN denied pain, and his vital signs were all within normal limits. He stated his cold symptoms were mild and had been present for a few days. His general appearance was described as pleasant, in no acute distress. His throat appeared normal, and his respirations were even and unlabored. He was instructed to do salt water gargles three times daily for three days and was returned to the dorm.

(b)(6); (b)(7)(C) RN, InGenesis documented a sick call assessment for complaint of skin itching on **August 2, 2017** at 1:39 p.m. An interpreter was not used, as, "Detainee speaks English fluently." Detainee ALMAZAN denied pain, and his vital signs were all within normal limits. He described moderate itchiness over his whole body, having started weeks ago. He was observed to be persistently scratching. His general examination found him to be alert, well hydrated, and in no acute distress. There were no suspicious lesions, and psychologically he was alert, oriented, cooperative with the exam, and showed intact cognitive¹¹ functioning. The nursing treatment plan included application of hydrocortisone cream to the affected areas twice daily, start polyvinyl alcohol ophthalmic solution¹² to the eyes four times daily, and patient instructions regarding bathing, avoidance of irritants, and increase of water intake. Following repeated requests for a RN Guideline addressing itching to verify the prescribed treatment of hydrocortisone cream, it was never produced.

(b)(6); (b)(7)(C) documented a follow-up mental health assessment on **August 4, 2017**, at 12:29 p.m., noting the conversation was in Spanish. Vital signs conducted by (b)(6); (b)(7)(C) RN were all within normal limits, and detainee ALMAZAN denied pain. He expressed having symptoms of depressed mood, but they were decreased from those previously reported. He stated he was participating in recreational activities and socializing with his peers. He presented as psychiatrically stable and was able to remain housed in the general population. He reported he had been complying with his psychiatric medication, with improvement in his level of sadness, energy, and motivation. His mood and attitude seemed better, and he no longer felt tearful. He offered he had talked to his sister who told him she was in the process of legalizing her stay in the U.S. and therefore did not want contact with him. He also discussed having gone to court the previous day, at which time the judge asked him if he found a lawyer with the list given to him. He said he informed the judge that no one returned his call. The judge asked him if he wanted to proceed with the case on his own which he replied yes to. An appointment was pending with (b)(6); (b)(7)(C) Psychologist on August 11, 2017, and he was scheduled for follow-up with (b)(6); (b)(7)(C) in three to four weeks.

At 2:32 p.m. the same day, (b)(6); (b)(7)(C) PA, STG documented a provider visit to review laboratory studies with detainee ALMARAZ. According to the laboratory reports, the blood samples were drawn and forwarded to the laboratory on July 28, 2017, results were received on

¹¹ Cognitive refers to the process of knowing and perceiving.

¹² Polyvinyl alcohol ophthalmic solution is also known as artificial tears, a treatment for dry eyes.

July 31, 2017, and (b)(6); (b)(7)(C) reviewed them on August 3, 2017, noting, “MI P will discuss with patient tomorrow”. Interpretation services were not used for this encounter, a (b)(6); (b)(7)(C)

(b)(6); (b)(7)(C) speaks fluent Spanish. Detainee ALMAZAN reported that he takes pills for his liver and had not received them as yet. He stated he occasionally feels weak and tired, had been eating and sleeping well and was better adjusted in general population. He listed his medications as rifaximin¹³ 550 mg twice daily, Folic acid¹⁴ 1 mg once daily, docusate¹⁵ 100 mg twice daily, multivitamin¹⁶ one tablet daily, Aspirin¹⁷ 81 mg once daily, and omeprazole¹⁸ 20 mg once daily. He explained he had been taking rifaximin for six to seven years. He denied any bruises, bleeding, or abdominal pain. As over 50 laboratory values were obtained, only the abnormal levels are listed:

Test	Normal Range	Result
Hemoglobin A1c ¹⁹	4.8-5.6	4.4
Prothrombin Time ²⁰	9.1-12.0	12.3
Hepatitis A Antibody ²¹	Positive	Negative
Hepatitis B Core Antibody ²²	Positive	Negative
Bilirubin ²³	1.6	0.0-1.2
Albumin, Serum ²⁴	3.4	3.5-5.5
BUN/Creatinine Ratio ²⁵	23	9-20
Creatinine, Serum	0.57	0.76-1.27
Alkaline Phosphatase ²⁶	157	39-117
Serum Lipase ²⁷	67	0-59

¹³ Rifaximin is a type of antibiotic, which treats traveler’s diarrhea and irritable bowel syndrome with diarrhea.

¹⁴ Folic acid is a B vitamin used to enhance red blood cell production.

¹⁵ Docusate is a stool softener used to treat constipation.

¹⁶ Multivitamin is a nutritional supplement.

¹⁷ Aspirin is a pain reliever.

¹⁸ Omeprazole is a medication used to treat heartburn and esophageal reflux disease (GERD).

¹⁹ Hemoglobin A1c is a test, which provides an average of blood sugar over a two-month period.

²⁰ Prothrombin time is a blood test to determine how quickly the blood clots.

²¹ Hepatitis A antibody is a protein which if present in the blood, signifies past exposure to hepatitis A.

²² Hepatitis B core antibody is a protein, which if present in the blood, indicates previous or ongoing infection with hepatitis B


²³ Bilirubin is an orange, yellow pigment produced by the liver.

²⁴ Serum albumin is the most abundant protein in the blood and is also the major carrier of fatty acids in the blood.

²⁵ BUN (blood urea nitrogen)/Creatinine (a waste product from muscle breakdown) ratio is a test to check kidney function.

²⁶ Alkaline phosphatase is an enzyme found in the blood. Abnormal values can help determine the level of liver dysfunction.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
 Medical and Security Compliance Review
 December 4-5, 2017



Neutrophils ²⁸	1.3	1.4-7.0
Hemoglobin ²⁹	10.5	12.6-17.7
Red Blood Cells ³⁰	3.28	4.14-5.8
Hematocrit ³¹	29.3	37.5-51.0
White Blood Cells ³²	2.0	3.4-10.8
Platelets ³³	37	150-379
Lymphocytes ³⁴	0.4	0.7-3.1

(b)(6); (b)(7)(C) MD, STG noted lab results would be discussed with detainee ALMAZAN. (b)(6); (b)(7)(C) listed the assessment findings as 1) Alcoholic cirrhosis of liver without ascites; 2) Other pancytopenia³⁵, and 3) Hepatitis B carrier. Creative Corrections notes that according to the CDC website, the hepatitis B results indicate immunity due to natural disease and do not indicate carrier status as diagnosed by (b)(6); (b)(7)(C). Treatment ordered for liver disease included rifaximin 550 mg twice daily; folic acid 1 mg daily; docusate 100 mg twice daily; multivitamin, one tablet daily; enteric coated³⁶ aspirin 81 mg daily; and omeprazole 20 mg daily. Follow-up laboratory studies were ordered to include serum uric acid³⁷, CBC³⁸ with differential³⁹, serum lipase, serum amylase, thyroid panel⁴⁰ with thyroid stimulating hormone⁴¹, and GGT⁴². Rifaximin was non-formulary, so a request for authorization was completed. A referral was

²⁷ Serum lipase is an enzyme, which can be found in abnormally high levels in the blood when the pancreas is damaged.

²⁸ Neutrophils are a type of white blood cells, which help fight infection by ingesting microorganisms

²⁹ Hemoglobin is the protein molecule in the red blood cells that carries oxygen from the lungs to the body's tissues and returns carbon dioxide from the body back to the lungs.

³⁰ Red blood cells are the blood cells that contain hemoglobin and carry oxygen.

³¹ Hematocrit is a volume percentage of red blood cells in the blood, usually at 47% in males.

³² White blood cells are the cells involved in protecting the body against infection.

³³ Platelets, also called thrombocytes, are a component of blood whose function is to stop bleeding by clumping and clotting blood vessel injuries.

³⁴ Lymphocytes are a form of white blood cells that produce antibodies to fight infection.

³⁵ Pancytopenia is a medical condition in which there is a reduction in the number of red blood cells, white blood cells, and platelets.

³⁶ Enteric-coating is a polymer barrier applied on oral medication, which prevents its disintegration in the stomach.

³⁷ Serum uric acid is the chemical found in the blood when the body breaks down foods containing organic compounds called purines. If too much uric acid is being produced or if the kidneys are not able to remove it from the blood normally, the level increases, potentially causing solid crystals to form within the joints, causing gout.

³⁸ CBC, short for complete blood count tests levels of all types of blood cells to determine the presence of disease.

³⁹ A blood differential test measure the percentage of each type of white blood cells.

⁴⁰ Thyroid panel is a series of tests used to evaluate thyroid function and help diagnose hypo- or hyperthyroidism.


⁴¹ Thyroid stimulating hormone is a hormone produced by the pituitary gland, which stimulates the thyroid gland to produce and release hormones into the blood.

⁴² GGT is short for gamma-glutamyl transferase, which is elevated in some forms of liver disease.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz

Medical and Security Compliance Review

December 4-5, 2017



submitted for hematology⁴³, pending approval. Detainee ALMAZAN was cleared for custody and scheduled for follow-up “as scheduled or sooner as needed.”

On **August 9, 2017**, at 9:38 a.m. (b)(6); (b)(7)(C) conducted a follow-up assessment for pancytopenia and review of lab results. An interpreter was not used during this encounter. Questioned about why interpretation assistance was not used, as she had earlier voiced its importance at the time of the initial physical examination, she stated, “Maybe I forgot to note the interpreter was used, because as I said, if they only speak a little English, I get an interpreter.” Detainee ALMAZAN denied pain and his vital signs were all within normal limits. He requested medication for skin itching, especially over his back. He also requested an eye appointment and medication for gas. He reported he had been eating and sleeping well and was doing well in general population. He denied any bruising, bleeding, or abdominal pain at that time. The general examination noted no acute distress, well developed, well nourished, and calm and relaxed. His skin was warm and dry with good turgor⁴⁴, and there was no bruising, hematomas⁴⁵, bleeding, or fragile capillaries. His heart assessment was normal. He was alert, oriented, and cooperative, demonstrating intact cognitive functioning and good eye contact. His gait was normal. The assessment diagnoses were 1) Other pancytopenia and 2) Tinea pedis⁴⁶. Treatment for pancytopenia included lactulose⁴⁷ solution twice daily, Spironolactone 25 mg twice daily, hematology referral pending approval, and ophthalmology referral pending approval. Orders for tinea pedis included clotrimazole cream twice daily for seven days and hydrocortisone cream twice daily for seven days. Aluminum-magnesium-simethicone suspension⁴⁸ 400 mg was ordered four times a day for seven days.

(b)(6); (b)(7)(C) MD, Psychiatrist conducted a psychiatric evaluation on **August 11, 2017**, at 9:40 a.m., noting that an interpretation service was not used as, “Detainee speaks English fluently.” (b)(6) (b)(6); noted she obtained her subjective information from the initial mental health intake, and following the narrative, documented, “Patient concurred with the above information. He currently denied any depressive, manic, psychotic, or anxiety symptoms, no suicidal ideation/homicidal ideation. He reports insomnia. Risks, benefits, and side effect of Trazodone were discussed with patient who consented.” Creative Corrections observed English consent forms were signed for both Zoloft on July 19, 2017, and for Trazodone at the time of this encounter, suggesting that ALMAZAN may not have fully understood the indication and side effects of the medication. Vital signs conducted by (b)(6); (b)(7)(C) were all within normal limits, with the exception of a mildly

⁴³ Hematology is the branch of medicine concerned with the study of the cause, diagnosis, treatment, and prevention of blood related diseases.

⁴⁴ Turgor is the degree of elasticity of the skin, assessment of which can determine the extent of dehydration of fluid loss in the body.

⁴⁵ A hematoma is a solid swelling of clotted blood within the tissues.

⁴⁶ Tinea pedis, also known as athlete’s foot, is a fungal infection of the feet, usually beginning between the toes.

⁴⁷ Lactulose is a type of sugar solution used to treat chronic constipation and to reduce the amount of ammonia in the blood of patients with liver disease.

⁴⁸ Aluminum-magnesium-simethicone is

elevated body temperature of 99.3. The diagnosis was major depressive disorder, recurrent, mild, for which trazodone⁴⁹ 50 mg was ordered. Follow-up was scheduled for four weeks. A (b)(6); (b)(7)(C) was no longer employed at KNSPC at the time of the review.

At 4:23 p.m. (b)(6); (b)(7)(C) documented a transfer summary for ALMAZAN's departure to Glades County Detention Center (GCDC) the same day. There were no special needs or medical, dental, or mental health reasons listed that would affect his transportation, nor were there any restrictions or special equipment required for travel. The disposition was "medically cleared for custody". The document included all current medications, but the only medical history listed was cirrhosis for eight years. There was no reference to pancytopenia, depression, or tinea pedis, all of which had been identified since his intake. Additionally, there was no reference to pending referrals for hematology, ophthalmology, and radiology for a liver ultrasound; nor were copies of laboratory studies and most current chronic care clinic records sent with the transfer summary to ensure efficient continuity of care by the receiving facility. The medical documentation failed to include a medical hold to ensure provider review prior to transfer.

During interview, CAPT (b)(6); (b)(7)(C) MD, Clinical Director addressed the adverse findings related to ALMAZAN's medical care, emphasizing that he had not rendered care so was "only looking at other things as the clinical director." He cited his main concern as the flow of appointments related to pancytopenia, chronic liver problems, and cirrhosis caused by abuse of alcohol. He described the platelet count of 37 as, "very low, he didn't have the building blocks for coagulation," adding that there was definitely a risk for bleeding and infections, but it may have been going on for years. Questioned about the length of time it took for the hematology referral, he replied, "We have no control," explaining that certain consulting specialties are difficult to access, and that it basically is no different from being seen in the community, which can take three to four weeks. With his specialty as a flight surgeon, (b)(6); (b)(7)(C) stated low platelets would not affect clearance for air travel, and even with a low hemoglobin level of 10.5, "I would still clear someone at those levels to fly." In discussion of the transfer summary, which omitted serious diagnoses (b)(6); (b)(7)(C) explained if providers failed to update the problem list, the conditions will not show at the time the nurse prepares the summary, agreeing that the problem list was not current and in addition to pancytopenia and depression, should have included varices⁵⁰ and portal hypertension⁵¹. He stated it would not be impossible to send applicable copies of the medical record with the summary, although, "It would take more work to include it." He did agree, however, that it would be helpful to include the last chronic care clinic. Regarding a medical hold, he stated there would not be a need for a medical hold if the receiving institution was aware of and followed up with the medical condition. He added that he would have no problem telling ICE a detainee can not go if there were pending consults, however, adding, "Whether it would have made a difference in the outcome,

⁴⁹ Trazodone is a medication used to treat depression and sleep difficulty.

⁵⁰ Varices are abnormal veins in the lower part of the tube running from the throat to the stomach.

⁵¹ Portal hypertension refers to high blood pressure in the system of veins coming from the stomach, intestine, spleen, and pancreas which merge into the portal area before traveling through the liver.

hard to say.” He voiced his opinion that GCDC was an appropriate facility to send a stabilized case, and that they had not any any significant issues with them. (b)(6)

(b)(6);
(b)(7)(C)

(b)(6);
(b)(7)(C)

APPENDIX I Vital Signs

DATE	TEMPERATURE	PULSE	RESPIRATIONS	BLOOD PRESSURE	WEIGHT
July 12, 2017	98.1	74	16	114/68	171
July 16, 2017	97.6	74	16	107/66	170
July 19, 2017	98.5	69	16	110/70	175
July 20, 2017	97.9	68	16	101/61	175
July 27, 2017	98.1	73	16	115/61	170
August 2, 2017	98.2	82	16	105/63	170
August 4, 2017	98.1	72	16	100/63	172
August 8, 2017	98.4	71	16	102/64	165
August 11, 2017	(b)(6); (b)(7)(C)	74	16	97/57	170

CONCLUSIONS


Medical Compliance Findings

Creative Corrections finds the care provided to Filipe ALMAZAN-Ruiz by the Krome North Service Processing Center did not meet all requirements of the 2016-revised ICE PBNDS 2011, Medical Care. Deficiencies were identified in the following components of the standard: (b)(6); (b)(7)(C)

ICE PBNDS 2016, Medical Care, section (V)(E), which states, “Each facility shall provide appropriate interpretation and language services for LEP detainees related to medical and mental health care. Where appropriate staff interpretation is not available, facilities will make use of professional interpretation services.” (b)(6); (b)(7)(C)

- On July 16, 2017, at 3:34 p.m. to assess an unspecified skin irritation. An interpreter was not used, as, “Detainee speaks English fluently.”
- The keep-on-person agreement form signed on July 16, 2017, was in English and may not have ensured his full understanding.
- Consent forms for psychotropic medications were not provided in Spanish version to ensure full understanding of the indication and side effects of the medication.
- Nursing sick call encounters conducted on July 26, 2017, July 27, 2017, and August 2, 2017, failed to use interpretation assistance to ensure full and accurate information gathering and clear understanding of instructions provided.
- On August 9, 2017, a non-Spanish-speaking provider conducted a laboratory results follow-up encounter in the absence of interpretation assistance.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



ICE PBNDS 2016, Medical Care, section (V)(G)(3), which states, “Each detention facility shall have and comply with written policy and procedures for the management of pharmaceuticals, to include: 3) prescription practices, including requirements that medications are prescribed only when clinically indicated, and that prescriptions are reviewed before being renewed.”

- July 16, 2017, hydrocortisone cream was issued in the absence of assessment findings.
- On August 2, 2017, hydrocortisone cream was again issued as a KOP in the absence of a RN Guideline.

ICE PBNDS 2016, Medical Care, section (V)(M), which states, “Each facility’s health care provider shall conduct a comprehensive health assessment, including a physical examination and mental health screening, on each detainee within 14 days of the detainee’s arrival unless more immediate attention is required due to an acute or identifiable chronic condition.” Additionally: **NCCHC J-E-04 (Essential), section (5)**, which states, “Inmates identified with *clinically significant findings* as the result of a comprehensive receiving screening receive an initial health assessment as soon as possible, but no later than 2 working days after admission.”

- Although the intake assessment identified cirrhosis, the initial physical assessment was not completed until one week following intake.

ICE PBNDS 2016, Medical Care, section (V)(N), which states, “Where a detainee has a serious medical or mental health condition or otherwise requires special or close medical care, medical staff shall complete a Medical/Psychiatric Alert form (IHSC-834) or equivalent, and file the form in the detainee’s medical record. Where medical staff furthermore determine the condition to be serious enough to require medical clearance of the detainee prior to transfer or removal, medical staff shall also place a medical hold on the detainee using the Medical/Psychiatric Alert form (IHSC-834) or equivalent, which serves to prevent ICE from transferring or removing the detainee without the prior clearance of medical staff at the facility. The facility administrator shall receive notice of all medical/psychiatric alerts or holds, and shall be responsible for notifying ICE/ERO of any medical alerts or holds placed on a detainee that is to be transferred.


Potential health conditions meriting the completion of a Medical/Psychiatric Alert form may include, but are not limited to medical conditions requiring ongoing therapy, such as a.) active TB, b) infectious diseases, and c) chronic conditions.”

- Medical documentation failed to include a medical hold to ensure provider review prior to transfer.

ICE PBNDS 2016, Medical Care, section (V)(W), which states, “Consistent with Standard 4.8 ‘Disability Identification, Assessment, and Accommodation’ and the IHSC Detainee Covered Services Package, detainees will be provided medical prosthetic devices or other impairment aids, such as eyeglasses, hearing aids, or wheelchairs.”

- Significant vision impairment identified one week following intake failed to result in the issuing of reading or prescription eyeglasses. Additionally, because the pending

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



ophthalmology referral was not forwarded to the receiving facility during transfer, the detainee never received glasses during his remaining detention period.

ICE PBNDS 2016, Medical Care, section (V)(X)(1), which states, “The facility administrator and clinical medical authority shall ensure that the Field Office Director is notified as soon as practicable of any detainee housed at the facility who is determined to have a serious physical or mental illness or to be pregnant, or have medical complications related to advanced age, but no later than 72 hours after such determination. The notification shall become part of the detainee’s health record file.”

- The medical record did not include a notification to the Field Office Director regarding the condition of potentially advanced cirrhosis and pancytopenia.

ICE PBNDS 2016, Medical Care, section (V)(Z), which states, “The facility HSA must ensure that a plan is developed that provides for continuity of medical care in the event of a change in detention placement or status. The detainee’s medical needs shall be taken into account prior to any transfer of the detainee to another facility. Alternatives to transfer shall be considered, taking into account the disruption that a transfer will cause to a detainee receiving medical care.”

- The transfer summary dated August 11, 2017, failed to include the serious chronic diagnoses of pancytopenia and depression. Additionally, there was no reference to pending referrals for hematology, ophthalmology, and radiology for a liver ultrasound; nor were copies of laboratory studies and most current chronic care clinic.

Areas of Note

In addition to the above deficiencies, Creative Corrections notes the following:


- Providers failed maintain a current problem list of serious illnesses, to include pancytopenia and depression, resulting in delayed continuity of care following transfer to another ICE facility.

Glades County Detention Center

Facility Description

GCDC is operated by the Glades County Sheriff’s Office and houses county inmates as well as United States Marshall Service (USMS) and ICE male and female detainees. The facility, which opened in 2007, houses medium, medium high and high custody detainees and has a capacity of 540. On September 5, 2017, the facility count was 429 and was comprised of 369 ICE detainees

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



(298 male and 71 female), 40 county inmates (30 male and 10 female) and 20 male USMS detainees.

All staff with direct supervision responsibilities over detainees are sworn law enforcement officers. Officers must attend 500 hours of training at an academy to be certified by the state of Florida.

There are two main dormitory-style housing areas at GCDC – Dorm 1 and Dorm 2. There is also a 20 bed Special Management Unit. Detainee ALMAZAN was housed in Dorm 1 throughout his stay at GCDC. Per the Movement History, detainee ALMAZAN was assigned to Dorm 1, pod C, at 3:57 a.m. Dorm 1 has a capacity for 378 and is used primarily for ICE detainees. The dorm is comprised of four separate pods, A through D, each of which houses between 92 and 96 detainees. The pods encircle an elevated observation control center which is staffed by a civilian clerk who manages the doors to each pod and has no direct contact with detainees. A sergeant and officers are assigned to the dorm floor and provide supervision to the four separate pods. The housing pods are each two stories with eight four-bunk open bays on each level. A bathroom and shower area is on each level. The upper tier is accessed by a staircase on the left side of the pod. On the lower level are tables, a television and a video terminal for visitation.

Healthcare Services

Armor Correctional Health Services (ACHS), with headquarters in Miami, Florida has provided 24-hour medical care since the facility's activation in June 2007. GCDC earned their most recent accreditation through the National Commission on Correctional Healthcare (NCCHC) in May 2017, and at the current time, eight medical employees have earned status as Certified Correctional Health Professionals (CCHP)⁵². Full time positions include the Director of Nurses (DON), a licensed clinical social worker, the Administrative Assistant, and the Health Services Administrator (HSA), the latter of whom is not a clinician but has a health services administration background. Three part time registered nurses (RN) provide a total of 56 hours per week, and 13 part time licensed practical nurses (LPN) provide 460 hours per week. Other part time positions include a mental health physician assistant, two licensed mental health professionals, a dentist, and a dental assistant. The Clinical Director, a CCHP is licensed in Puerto Rico and Florida, with certification to work in critical need areas. He is available on site for clinical services four days per week. Staffing numbers were found to be sufficient for the provision of detainee healthcare, in accordance with the NDS, and all professional licenses were present, current and primary source verified.

The GCDC medical clinic houses a multi-workspace nursing station with a pass-through window connecting to an 18-chair waiting room. A custody officer's desk is located inside the waiting room providing direct supervision. The clinic houses four examination/treatment rooms, a

⁵² A CCHP is a medical person who has demonstrated, through NCCHC testing, the possession, application, and interpretation of knowledge necessary for professional practice in correctional health care.

pharmacy, a one-chair dental suite, a specimen collection room, two administrative offices, and four medical observation rooms, three of which have negative air pressure capability for respiratory isolation. GCDC's electronic medical record (EMR) CorrecTek has been in place since May 2014, and language assistance for detainees with limited English proficiency is provided by Interpretalk Interpretive Services.

Detention Summary

EARM records document detainee ALMAZAN arrived at GCDC in Moore Haven, FL at 8:29 p.m. on **August 11, 2017**. At 9:28 p.m., detainee ALMAZAN was booked into the GCDC per the facility records. Upon arrival, detainee ALMAZAN was searched and photographed by Officer (b)(6); (b)(7)(C) and booked in by Officer (b)(6); (b)(7)(C) per the GCDC booking information form.

When interviewed, Officer (b)(6); (b)(7)(C) did not recall the detainee but stated his typical process is to pat search the incoming detainee, issue them facility clothing and take their photograph. (Note: (b)(6); (b)(7)(C) the Facility Administrator sat in on the interviews with officer staff.) Officer (b)(6); (b)(7)(C) stated on interview that he did recall the detainee because he was quiet and respectful to staff. (b)(6); (b)(7)(C) speaks Spanish and stated he uses the 216 Record of Persons and Property Transferred form to confirm the classification level as determined by ERO. In this case, the 216 form designated detainee ALMAZAN as medium high. The detainee's housing level was then marked as, "Close Observation" and he was approved for placement in general population with visits allowed.


On Saturday, **August 12, 2017**, at 2:28 a.m. his property was inventoried and he was allowed to retain possession of miscellaneous legal papers, a Bible, four pairs of underwear and a grey shirt and pants. The other items were placed in property bag 396. A property receipt was generated and signed by both the detainee and two officers at 2:45 a.m. on August 12, 2017. The \$9.00 in personal funds he brought from KNSPC were placed into a commissary account he could access through a kiosk to buy phone time, snacks and personal care items. The detainee also signed an acknowledgement that he had received both the NDS and facility handbooks, PREA information and that he participated in the facility orientation program.

At 8:10 p.m. on **August 13, 2017**, detainee ALMAZAN made his free three-minute phone call per the Audio File List from GCDC. On **August 17, 2017**, an immigration judge ordered ALMAZAN removed to Mexico.

On **August 23, 2017**, detainee ALMAZAN purchased \$5.00 in phone time per his account summary. At 3:23 p.m. on August 25, 2017, he completed a seven minute and 58 second phone call per the call record. This was the last phone call the detainee made while at GCDC.

On **August 30, 2017**, detainee ALMAZAN submitted a request asking for a job at the facility in the dorm or kitchen. He received medical clearance the following day to become a trustee and work at the facility. On the same date, he was moved to pod D. On **September 6, 2017**, he moved

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



to pod A. It is unclear when he began work in the food service area but both security and medical staff reported he served as a trustee and delivered meal trays into the medical unit. The account records confirm he was later paid for five days of work.

According to an email dated September 17, 2017 from Deputy Field Office Director (b)(6); (b)(7)(C) in anticipation of approaching Hurricane Irma, ERO transferred detainee ALMAZAN by bus to Folkston Processing Center (FPC) in Folkston, GA, on **September 7, 2017**, at 3:43 a.m. (Note: EARM records document the time of departure from GCDC as 2:56 p.m. with arrival at FPC at 9:00 p.m.) The balance of \$4.00 in his account was issued to him by check.

Following detainee ALMAZAN's transfer from GCDC, he received payroll for the five days he worked and \$5.00 was deposited into his account at GCDC on September 13, 2017. These funds remained at GCDC and were still in his account during the review team's site visit. The issue was brought to the attention of Deportation Officer (b)(6); (b)(7)(C) who stated he would ensure the funds were transferred to ERO staff at IAH/PCDC for inclusion with the property stored there to be sent to the detainee's next of kin.


Detainee ALMAZAN remained at FPC for less than 24 hours and departed that facility for IAH/PCADC at 5:59 p.m. on **September 8, 2017**, per EARM records.

Summary of Events

At 3:15 a.m., on **August 12, 2017** (b)(6); (b)(7)(C) LPN documented the medical intake screening, noting there were no barriers to communication, and responding "Yes" to ALMAZAN's ability to "Understand English". During interview she denied her personal ability to speak Spanish and when questioned about the level of ALMAZAN's English proficiency, she replied, "If I did the intake, he spoke English. We would use Interpretalk (*Language Service*) otherwise." When questioned about the frequency of Interpretalk use over a week period, she estimated, "maybe once or twice." Regarding Creative Correction's observation that all consent and agreement forms were in English, LPN (b)(6); (b)(7)(C) stated she was unaware of Spanish version forms. During interview (b)(6); (b)(7)(C) HSA stated Spanish forms are available for sick call requests and medical consents and agreed the Spanish versions should have been used for ALMAZAN. The intake screening documentation did not mention review of the medical summary sent by the Krome North Service Processing Center (KNSPC), with resulting failure to list current diagnoses and treatment. Vitals signs were recorded within normal limits (*See Appendix I for vital signs table*). The health questionnaire included a subjective history of liver cirrhosis⁵³, vision problems, and depression. He admitted to having tried or seriously considered killing or hurting himself, "Six times, about three years ago", but he denied current suicidal thinking. A chest x-ray was scheduled for tuberculosis⁵⁴ clearance, although there is no report evidencing this was done. He was noted,

⁵³ Liver cirrhosis is a chronic liver disease in which liver cells become inflamed and begin dying, causing scar tissue to form. Alcohol abuse is a common cause of cirrhosis.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



however, to have had a normal chest x-ray on July 12, 2017, while at KNSPC, having remained in continual ICE custody. He was assigned to chronic care clinic, referred to a provider on an urgent basis, and cleared for general population. The intake screen was electronically approved by (b)(6); (b)(7)(C) RN, DON on August 15, 2017.

Two days later on Monday, **August 14, 2017**, at 10:26 a.m. (b)(6); (b)(7)(C) conducted the intake mental health screening, noting ALMAZAN's diagnoses of liver cirrhosis, depression, and anxiety. He reported a history of alcohol dependence, having last used three months ago when he was arrested. He stated he had been prescribed trazadone⁵⁵ for the past three months while incarcerated in Metro West, Dade County. He was described as cooperative, with a calm demeanor, while presenting sadness and mild anxiety. He denied audiovisual hallucinations⁵⁶, delusions⁵⁷, and suicidal and homicidal ideations but reported bouts of depression and crying over the past three months. He attributed his sadness and anxiety to stress of his current situation, and having been divorced five years ago due to his alcohol problem. He reported his drinking worsened until he was incarcerated, having since suffered guilt, sadness and loss, using prayer and faith to manage his feelings. He admitted having, "tried to commit suicide many times by drinking excessively," but denied current intention, ideation, or plan. His mental health status was described as alert, appropriate in behavior, cooperative, fully oriented, neat, well-groomed, and appearing older than his stated age. His affect was good, and judgment was fair. He reported both sleep and appetite were within normal limits. The past medical history section of the assessment noted the only hospitalization was related to liver cirrhosis. His medications accurately reflected the pill line medications listed on the Krome medical summary, as listed:

Medication	Purpose
Clotrimazole 1%	Antifungal cream for athlete's foot
Ducosate Sodium 100 mg	Stool softener used to treat constipation
Folic Acid 1 mg	B vitamin used to enhance red blood cell production
Hydrocortisone 1%	Steroid used to treat skin conditions
Lactulose 10 GM/15 ml solution	Type of sugar solution used to treat chronic constipation and to reduce the amount of ammonia in the blood of patients with liver disease.
Maalox 30 cc	Antacid which neutralizes stomach acidity
Multivitamin	Nutritional supplement
Omeprazole 20 mg	Treatment of heartburn and esophageal reflux disease (GERD) ⁵⁸

⁵⁴ Tuberculosis is a serious bacterial infection which mostly affects the lungs.

⁵⁵ Trazadone is a sedative medication which can treat depression.

⁵⁶ Hallucinations are perceptions of having seen, heard, touched, tasted or smelled something that was not actually there, commonly a symptom of mental illness.

⁵⁷ Delusions are beliefs or altered reality persistently held despite evidence or agreement to the contrary, commonly a symptom of mental illness.

Proctosol 2.5%	Treatment of itching or swelling caused by hemorrhoids
Sertraline Hcl 100 mg	Treatment for depression and anxiety
Spirolactone 25 mg	Treatment for high blood pressure and fluid retention.
Trazodone 50 mg	Treatment for depression and sleep difficulty
Triamcinolone Acetonide 0.1%	Treatment for psoriasis
Rifaximin 550 mg	Treatment for irritable bowel syndrome with diarrhea

The mental health assessment findings were listed as depression, generalized anxiety disorder, and alcohol dependence, in remission. The plan was, "Appointment electronically created for patient to see psychiatrist as soon as possible." He was deemed eligible for program participation and job placement and was assigned to general population without segregation.

On the same day, at 10:27 a.m., (b)(6); (b)(7)(C), MD conducted the initial chronic care clinic for cirrhosis, stating during interview he communicated with ALMAZAN in Spanish and was unaware of the detainee's English proficiency. He documented, "51 year old male with history of liver cirrhosis, GERD, possible portal hypertension⁵⁹, constipation here today for initial clinical evaluation, the patient diagnosed seven years ago and he's been on treatment since then." ALMAZAN's personal risk factors were identified as smoking, "two per day", and "a lot" of alcohol. He denied past surgeries or hospitalizations. He was described as appearing well, in no acute distress, obese, well developed, and well nourished. He complained of external hemorrhoids⁶⁰, dry itchy skin and eyes, and headaches. He denied chest pain, abdominal pain, and nausea and vomiting. The review of systems revealed no abnormal findings, and the vital signs were all within normal limits. The abdominal assessment was described as, "Positive bowel sounds, non-tender, no hepatosplenomegaly⁶¹, no masses⁶²." The assessment listing included 1) liver cirrhosis/fatty liver; 2) GERD; 3) possible portal hypertension; 4) IBS⁶³, and 5) eczema⁶⁴. There was no reference to pancytopenia⁶⁵, as was noted in the last chronic care clinic at the Krome North SPC (KCSPC). When questioned about his suspicion of portal hypertension in the absence of KNSPC's previous diagnoses, he explained that once he was aware of the cirrhosis diagnosis he considered all possible outcomes and conducted laboratory testing to rule it out. He further

⁵⁸ GERD is short for gastroesophageal reflux disease, also known as acid reflux, is a digestive disease in which stomach acid or bile irritates the food pipe lining (esophagus).

⁵⁹ Portal hypertension refers to high blood pressure in the system of veins coming from the stomach, intestine, spleen, and pancreas which merge into the portal area before traveling through the liver.

⁶⁰ Hemorrhoids are swollen and inflamed veins in the rectum and anus which can cause discomfort and bleeding.

⁶¹ Hepatosplenomegaly refers to abnormal enlargement of the liver and spleen.

⁶² Masses are any localized enlargement or swelling in the human body.

⁶³ IBS, short for irritable bowel syndrome is an intestinal disorder causing pain in the belly, gas, diarrhea, and constipation.

⁶⁴ Eczema is a condition in which the skin becomes inflamed and itchy.

⁶⁵ Pancytopenia is a medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets.

stated there were no varices⁶⁶ or spider webbing⁶⁷ noted during the abdominal assessment. The plan included 1) Triamcinolone Acetonide 0.1% cream twice daily for 60 days; 2) PT⁶⁸, PTT⁶⁹, INR⁷⁰, psa⁷¹, cmp⁷², cbc⁷³, lipid panel⁷⁴, h pylori test⁷⁵, ammonia level⁷⁶ tomorrow; 3) follow-up Thursday with lab results; 4) increase fluid intake; 5) continue with all other meds for 30 days; 6) please renew when finishing; 7) follow-up in 90 days; 8) Proctosol 2.5% topical cream twice daily for 30 days. During interview, (b)(6); (b)(7)(C) explained that a nurse works directly with him to ensure his orders are carried out.

According to the laboratory report, the blood collection took place on August 17, 2017, with receipt in the lab and complete report forwarded on the following day, August 18, 2017. (b)(6); (b)(7)(C) reviewed the laboratory results, electronically noted as "Observation Report Date", on the same day as receipt. Questioned during interview, he stated that although the results were concerning, he knew ALMAZAN was scheduled for his follow-up clinic in two weeks, and because the PT and PTT were only slightly elevated, he felt comfortable waiting until the next appointment to address the seriously low platelet count⁷⁷ of 41. He further offered his opinion that he places urgency on levels lower than 30, at which time he transfers the patient to the hospital for treatment. On questioning whether he was aware of the pancytopenia condition previously diagnosed at KNSPC, he, along with (b)(6); (b)(7)(C) Regional Vice President of ACHS, expressed surprise and disbelief, voicing they had not been aware of the diagnosis, nor the significantly low platelet count of 37. Regarding his treatment plan (b)(6); (b)(7)(C) stated he believed he did the right thing in trying to excrete the excess ammonia in ALMAZAN's system. He further offered if he had been the physician at KNSPC and had known ICE was going to move him with his current medical condition, he would not have approved the transfer. When asked if a two to three hour flight

⁶⁶ Varices are abnormal veins in the lower part of the tube running from the throat to the stomach.

⁶⁷ Spider webbing, otherwise known as Spider angiomas, refers to surfaced veins, which have a local spot and radiating vessels to appear web-like, commonly caused by advanced liver disease.

⁶⁸ PT is short for prothrombin test, a blood test to determine how quickly the blood clots.

⁶⁹ PTT is short for partial thromboplastin time, a blood test which measures the time it takes for blood to clot.

⁷⁰ INR is short for international normalized ration, a blood test which evaluates blood clotting.

⁷¹ PSA is short for prostate specific antigen, a substance produced by the prostate gland, which is measure to determine prostate disease.

⁷² CMP is short for comprehensive metabolic panel which tests blood glucose level, electrolytes levels, kidney function, liver function, and nutritional problems.

⁷³ CBC is short for complete blood count, which tests levels of all types of blood cells to determine presence of disease.

⁷⁴ Lipid panel is a series of lab tests, which determine levels of fats and cholesterol in the blood.

⁷⁵ H-pylori test is short for helicobacter pylori, bacteria that causes infection in the stomach, such as ulcers.

⁷⁶ An ammonia level test determines the amount of ammonia produced by bacteria in the intestines. Ammonia is normally converted by the liver, producing urea which is eliminated in the urine. With liver disease, ammonia levels can rise due to the inability for the liver to convert it.

⁷⁷ A platelet count is the number of clot-producing cells in the blood.


transfer would have been appropriate considering the current medical condition, he stated, “I might say no”, basing his statement on the fact that because it is not known why the platelets are so low, the detainee might have an embolism.

Detainee ALMAZAN submitted an initial sick call request for vision problems, dated **August 16, 2017**, writing, “I Need See The Doctor be Cause He Tool mi I have 2 Apoimenes, Monday and Tuesday I ron’t Recib Notin in My Dormitory Please Because I ron’t See Noting and He Told my y Need Test for My Ayees PLEASE The Doctor is Emmanuel Please Help My I conT Read Noting Please Help My” (See Appendix II for sick call table (b)(6); (b)(7)(C)). LPN documented receipt of the sick call request at 9:00 p.m. on August 17, 2017, referring him to nurse sick ca (b)(6); (b)(7)(C). LPN document (b)(6); (b)(7)(C) l encounter, using “Nursing Protocol – Eyes, Ears, Nose, Teeth, and Throat.” The date of August 18, 2017, was stamped at the top of the first page; however the note was not signed off until October 15, 2017, suggesting the note could have been written or altered at any time during that time. There was no reference to barriers of communication, language preference, or use of interpretation assistance. V (b)(6); (b)(7)(C) rded within normal limits, and his vision test showed 20/20 in the right eye and 20/(b)(6); left eye. Of note, the eye examination conducted by KNSPC on July 19, 2017, showed 20/100 in the left eye and 20/200 in the right eye, and the vision testing done during this physical assessment on August 24, 2017, showed 20/200 in both eyes, suggesting the 20/20 recording was erroneous. The nursing assessment diagnosis was disturbed sensory perception: rule out visual disturbance, and the plan, based on “not acute” vision disturbance was to allow ALMAZAN to obtain his glasses from home and to use proper lighting. Documentation failed to show inquiry into the current location of his glasses or what his home situation was. As was documented in the August 22, 2017, provider assessment, he had his glasses while at Krome and believed they were in his property. Consequently, (b)(6); (b)(7)(C) failed to adequately address his complaint, which remained unresolved. Creative Correction notes that the provided medical record did not include a copy of this sick call encounter; but rather, it was provided just prior to the review close-out. Consequently, (b)(6); (b)(7)(C) was not interviewed.

A second Inmate/Detainee Request was dated **August 20, 2017**, in which ALMAZAN wrote, “DR – I need You Help Because My Medicates AHORA NO SEE MEDICIN I TAKE EVRY DA DR- (b)(6); (b)(7)(C) I fillin My EYES DRY. PLEASE I need My GLASES Please When I go To Court They Give to mi but I canT SEE NOTHING My EYES I filling Burning and MY HEAD I HAVE PAIN So I need My GLASES Please I (b)(6); (b)(7)(C) The sick call response was left blank, but the request was signed as received by (b)(6); on **August 21, 2017**. During interview LPN (b)(6); (b)(7)(C) ewed the medical record and verified a sick call encounter was not present, stating that he was not seen in nursing sick call because he had a pending appointment with the provider for this evaluation.

(b)(6); (b)(7)(C) Advanced Registered Nurse Practitioner (ARNP) conducted a provider assessment on **August 22, 2017**, at 3:17 p.m. to address ALMAZAN’s complaints of, “I am having a lot of pain in my joints. I cannot see, either. I had glasses at Krome but they say they are not in my

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



property here. My vision is very bad. The medication is helping some, but I still can only sleep two to three hours.” There is no documentation of barriers to communication, language preference, or use of interpretation assistance (b)(6); (b)(7)(C) documented his extensive history of alcohol dependence, and noted he was currently taking Zoloft and trazodone with some benefit. He was described as cooperative with a congruent affect⁷⁸, logical thought process, anxious mood, and a restless and fidgety manner. There is no objective assessment, including vital signs. The treatment plan was to continue Zoloft 100 mg daily and increase trazodone to 75 mg nightly to improve his insomnia. A Specific Authorization for Psychotropic Medications form was signed by ALMAZAN, but the specific medication was not indicated with a check mark. The treatment plan did not address the complaint of vision difficulty. He was electronically scheduled for follow-up in 60 days. As (b)(6); (b)(7)(C) no longer works for GCDC, an interview could not be conducted to clarify if the encounter was intended to serve only as a mental health follow-up, as opposed to a sick call assessment.

The initial health assessment was conducted by (b)(6); (b)(7)(C) RN on **August 24, 2017**, at 2:33 p.m., with review and approved electronic signature of (b)(6); (b)(7)(C) September 5, 2017. A review of the training and credentials file showed (b)(6); (b)(7)(C) was trained for conducting initial medical and dental assessments on January 12, 2016 and on August 22, 2017. Detainee ALMAZAN identified current complaints as right knee pain and vision difficulty. He denied blood in his sputum, blood in his stools, or black tarry stools⁷⁹. His vital signs and physical assessment were all within normal limits, including the abdomen, which was described as having normal bowel sounds and no masses or tenderness. Tremors were not observed, and his gait and coordination were normal. Examination of his skin showed no rashes, lesions⁸⁰ or infestations⁸¹. ALMAZAN’s visual acuity using the Snellen Eye Chart measured 20/200 in the right eye, 20/200 in the left eye, and 20/200 in both eyes, without correction, for which he was referred to the doctor for visual disturbance. The dental screening found no missing teeth and “four upper implants per patient.”

A third sick call request was submitted on **August 27, 2017**, in which ALMAZAN wrote, “I NEED SEE THE DOCTOR BECAUSE I have To Much Pain in My Bond’s I Want Somthin XXXike Bengay is Hard THE PA A and I want A see The doctor THE LAST Went I see HE PuT in THE Sistem For Examen in My Eyes I Need glasses PLE! I can’T Read NoThing I need Realy The Glases”. The Triage Decision By Nursing Staff noted referral to nurse sick call and was signed two days later on **August 29, 2017**, at 9:00 p.m. b (b)(6); (b)(7)(C), LPN

⁷⁸ Congruent affect means a person’s emotions are appropriate for the situation.

⁷⁹ Black tarry stools can indicate bleeding in the upper portion of the digestive tract.

⁸⁰ Lesions are regions of an organ or tissue which have suffered damage through injury or disease, such as a wound, ulcer or tumor.

⁸¹ Infestations refer to a state of being invaded or overrun with pests or parasites.

(b)(6); (b)(7)(C) LPN, CCHP conducted a sick call assessment on **August 30, 2017**, at 2:24 p.m. to address ALMAZAN's complaint of pain in both shoulders and both knees. The pain was described as moderate, constant and worsening. A pain scale was not used to determine pain level. Vital signs were all recorded within normal limits. The general examination noted an uncomfortable appearance with tenderness on palpation. There was no swelling or gait abnormality. The nursing assessment was Alteration in Comfort in joints. The plan was to provide ibuprofen 400 mg twice daily for five days as needed in accordance with the Nursing Protocol on Muscular Skeletal problems. (b)(6); (b)(7)(C) noted, "NO history of bleeding ulcers." He was provided patient education and instructed to return to sick call if symptoms worsen or persist more than seven days. Documentation fails to show ALMAZAN's complaint of vision difficulty was addressed. During interview, (b)(6); (b)(7)(C) who triaged this sick call request, offered that nurses allow only one complaint per sick call request and that the detainees are expected to submit an individual request for each complaint they have, with the sick call nurse prioritizing the issues. HSA (b)(6); (b)(7)(C) and (b)(6); (b)(7)(C) both agreed during interview that the two issues absolutely should have been addressed in a single visit. (b)(6); (b)(7)(C) electronically approved the sick call assessment on August 31, 2017.

On September 1, 2017, ALMAZAN completed a fourth sick call request, stating, "I Need See The Doctor The Name of Hem is Emmanuel. I wan'T To Se because I ned Glases THE Nurse OnLY No GIME Apoimen For Optical I have Pain in Myy Head and My EYES in My EYES I fell likefire and The People I see Strange Aron'T Read Nothing Please I need See THE DOCTOR For My ApoinmenT an Medicinefo EYES LiKe Vicine SO<Thin DROPS for My Eyes THANK YOU". (b)(6); (b)(7)(C) LPN documented receipt of the request the same day at 9:00 p.m. and referred him to nurse sick call. On **September 2, 2017**, at 4:56 p.m., (b)(6); (b)(7)(C) LPN conducted a sick call assessment to address ALMAZAN's complaint of having difficulty seeing, as things look blurry. He stated he had an appointment scheduled with an optometrist prior to entering the facility. Vital signs were all recorded within normal limits and his vision remained at 20/200 in both eyes. The assessment was disturbed sensory perception: Rule out visual disturbance. The plan included a "Routine referral to (b)(6); (b)(7)(C) within five days secondary to patient having difficulty seeing, may need glasses. Made same complaint during initial health assessment." The note was electronically approved by (b)(6); (b)(7)(C) on September 5, 2017.

Four days later on Wednesday, **September 6, 2017**, at 9:48 a.m. (b)(6); (b)(7)(C) initiated a sick call visit for complaints of visual disturbance, along with a thirty-day chronic care evaluation. Forty-six laboratory results, completed on August 18, 2017, were addressed, along with additional results provided the following day. Only the abnormal levels are included below, with comparisons of those that had also been done at Krome:

Test	Krome Result	Glades Result	Normal Limits
Bilirubin ⁸²	1.6	1.7	0.0-1.2

⁸² Bilirubin is an orange, yellow pigment produced by the liver.

Alkaline Phosphatase ⁸³	157	162	20-130
Hemoglobin ⁸⁴	10.5	11.3	13-18
Red Blood Cells ⁸⁵	3.28	3.65	4.5-5.9
Hematocrit ⁸⁶	29.3	34	40-52
White Blood Cells ⁸⁷	2.0	3.0	3.6-11
Platelets	37	41	150-400
Lymphocytes ⁸⁸	0.4	0.7	1.1-4.7
Ammonia		108	11-35
Activated PTT		41.6	50-89

ALMAZAN's general appearance and physical assessment findings were all within normal limits, with exception of the abdominal assessment, which described pain in the mid-epigastric area radiating to the chest. Bowel sounds were normal, and there was no tenderness, masses, or hepatosplenomegaly on palpation. The plan was written as follows:

1—I will increase lactulose doses and will continue with the current meds. CBC weekly the follow-up ++see below prednisone 100 mg X3 days then 0 mg x 3 days then 60 mg po x 3 days then 50 mg x 3 days the 40 mg x 3 days then 30 mg x 3 days then 20 mg x 3 days the 10 mg x 2 days then 5 mg x 2 days the 2.5 mg x 2 days then d/c.

2—FERROUS SULFATE, 325 mg #90, Sig: 1 time per day for 90 days

3—+++++cbc weekly x 4 weeks+++++

4—d/c dulcolax

5—lactulose 40 ml po daily x 90 days

6—FOLIC ACID, 1 MG #90, Sig: Take 1 Tablet by mouth 1 time per day for 90 days

7—MULTIVITAMIN, #90, Sig: Take 1 Tablet by mouth 1 time per day for 90 days

8—SPIRONOLACTONE, 25 MG #180, Sig: Take 1 Tablet by mouth 2 times per day for 90 days.

9—Xifaxan 550 mg po bid x 90 days

10—Patient c/o visual disturbance

11—OS 20/200 OD 20/200

12—ammonia level Q2 WEEK X 8 WEEKS

13—Renal diet x 180 days

14—cbc cmp lipid panel in 82 days

⁸³ Alkaline phosphatase is an enzyme found throughout the body, which can be elevated in liver disease.

⁸⁴ Hemoglobin is the protein molecule in the red blood cells that carries oxygen from the lungs to the body's tissues and returns carbon dioxide from the body back to the lungs.

⁸⁵ Red blood cells are the blood cells that contain hemoglobin and carry oxygen.

⁸⁶ Hematocrit is a volume percentage of red blood cells in the blood, usually at 47% in men.


⁸⁷ White blood cells are the cells involved in protecting the body against infection.

⁸⁸ Lymphocytes are a form of white blood cells that produce antibodies to fight infection.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz

Medical and Security Compliance Review

December 4-5, 2017



14==follow==up in 90 days

15==OMEPRAZOLE 40 MG #90, Sig: Take 1 Capsule by mouth 1 time per day for 90 days.”

(b)(6);
(b)(7)(C)


signed off his note at 10:23 a.m. on the same day. Creative Corrections notes there was no referral to the optometrist for ALMAZAN’s serious vision impairment. Without eyeglasses his ability to read written instructions, consents, or patient education was seriously declined. His frustration was clearly expressed in his sick call requests. Following is documentation of sick call requests and complaints during clinical encounters.

Date and Mode of Request	Date of Encounter Who Conducted	Treatment Plan	Completed
August 16, 2017 Sick Call Request	August 18, 2017 LPN	Approved to have glasses from home sent in.	No, as his glasses were not at his home
August 20, 2017 Sick Call Request	No sick call scheduled	None, as triage nurse believed detainee was scheduled for MD	No, as a provider failed to address the complaint.
August 22, 2017 Complained during encounter.	August 22, 2017 ARNP	None. Complaint was not addressed.	NA
August 24, 2017 during initial physical assessment.	August 24, 2017 RN	Referred to MD	No
August 27, 2017 Sick call	August 30, 2017 LPN	None, as only one of two complaints were addressed.	N/A
September 1, 2017 Chronic Care	September 1, 2017 MD	None, as not addressed in plan	N/A

The ACHS Medical policy J-E-07 Non-emergency Health Care Requests and Services, mirroring the NCCHC Standard of the same number and title, instructs that any patient who has been seen in sick call more than twice in 30 days for the same complaint, but who has not yet been seen by a practitioner will be scheduled for the clinician’s clinic. Although the sick call nurses’ dispositions were followed by provider assessments, the focus was limited to chronic care and mental health issues, leaving the vision problem unaddressed. A review of the commissary showed reading glasses were available for purchase, but with a maximum of \$10.00 in his account at any given time, he would not have been able to pay the cost of \$11.55. There is no indication that any attempts were made to obtain reading glasses for him, although according to HSA (b)(6); (b)(7)(C) an optometry appointment was pending but not completed because of his transfer.

The Transfer Summary, documented by RN (b)(6); (b)(7)(C) the same day as his departure, medically cleared him for travel. The listed diagnoses included only cirrhosis of the liver without alcohol, generalized anxiety disorder, and depression. The additional serious chronic care diagnoses of portal hypertension, pancytopenia, and irritable bowel syndrome were not listed, and with no accompanying medical records, to include laboratory results, most recent chronic care assessment,

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



and pending specialty services, these diagnoses were unknown on his arrival to PC. It remains unexplained why the cirrhosis diagnosis was erroneously changed to “cirrhosis without alcohol”, but the diagnosis followed him to Polk on **September 8, 2017**, and to the hospital where he died nine days later.


APPENDIX I Vital Signs

DATE	TEMPERATURE	PULSE	RESPIRATIONS	BLOOD PRESSURE	WEIGHT
August 12, 2017	98.1	66	18	106/70	168
August 14, 2017	98.3	62	18	101/66	165
August 16, 2017	97.0	59	18	104/70	164
August 24, 2017	98.4	65	16	112/78	163
August 30, 2017	98.6	74	18	106/68	165
September 2, 2017	98.3	83	18	113/77	166
September 6, 2017	97.6	80	18	122/76	170

APPENDIX II Sick Call Requests

DATE SUBMITTED	COMPLAINT	DATE TRIAGED	DATE OF ASSESSMENT	TREATMENT PROVIDED
August 16, 2017	Vision difficulty	August 17, 2017	August 17, 2017	Instructed to get glasses sent in from home. Vision difficulty unresolved.
August 20, 2017	Vision difficulty with headache	August 21, 2017	August 24, 2017	Referred to the doctor. Not evaluated by MD for vision difficulty until September 6, 2017.
August 27, 2017	General body pain Vision difficulty	August 29, 2017	August 30, 2017	Ibuprofen provided for pain. Vision difficulty remained unresolved.
September 1, 2017	Vision difficulty with headache	September 1, 2017	September 2, 2017	Routine referral to (b)(6); (b)(7)(C) within five days. Was seen for vision difficulty during chronic care clinic on September 6, but no MD order written for optometry. Transferred same day due to hurricane.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



CONCLUSION

Medical Compliance Findings

There were no NDS deficiencies found. Identified areas of concern are as follows:

- Sick call requests, consents for medical care and psychiatric medication use, and keep-on-person agreements were not provided in Spanish version. As evidenced during interviews, not all nurses were aware of the availability of Spanish version forms.
- There was no reference to barriers of communication, language preference, or use of interpretation assistance during most nursing and provider encounters. Throughout interviews with staff from all three facilities in which detainee ALMAZAN was detained, there is strong evidence he was not English proficient.
- A nursing note by a sick call LPN was not signed at the time of her August 16, 2017, encounter, but rather it was signed two months later on October 15, 2017. From a legal standpoint it cannot be determined the note was not initiated and/or altered immediately prior to the sign-off on the latter date.
- During the August 16, 2017, encounter the LPN failed to inquire about the location of the detainee's eyeglasses, which were not at his home, resulting in an unresolved issue. Creative Corrections considered this misinformation might have been a result of a preventable communication barrier related to the detainee's inability to proficiently speak and understand English.
- Multiple complaints on the same request form are not always addressed and nurses reported a practice of one complaint per request form, with prioritization of the complaint at the time of the sick call encounter.
- In spite of the detainee's early and repeated complaint of serious vision impairment, a request for optometry to get eyeglasses was never processed.
- Possibly related to the hurried nature of the hurricane evacuation, the transfer summary failed to ensure adequate continuity of care to by failing to include all relevant health information.


Security Compliance Findings

Creative Corrections cites the following deficiencies in relevant components of facility policies and post orders.

The GCDC Detainee Handbook, page 12 states, "Prior to departing the facility, any funds you have remaining will be returned to you."

Funds earned by the detainee were paid on September 13, 2017 following his transfer out of GCDC. However, no effort was made to forward the funds to the detainee at his next facility and the funds remained at GCDC during the site visit on December 7, 2017.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



IAH/PCADC

Facility Description

IAH/PCADC is located in Livingston, TX, approximately 74 miles northeast of Houston, TX. The facility is operated by the Management and Training Corporation (MTC) of Centerville, Utah. According to their website, MTC entered the field of corrections in 1987 and now oversees more than 25,000 offenders and detainees at 21 facilities. The IAH/PCADC was established in January 2006. The original design was for 524 adult detainees. In July 2007, IAH/PCADC added an additional 528 beds to bring it to the current capacity of 1052. On September 17 2017, the date of detainee ALMAZAN's death, the population was 26 USMS male detainees and 337 male ICE detainees for a total population of 363. The IAH/PCADC received American Correctional Association accreditation on January 23, 2017.

A double fence with two rolls of razor wire along the top and five rolls between the fences encircles the facility. Visitors must enter through a secure external sallyport with both gates operated by central control. Once inside the gates, visitors must display identification before passing through a metal detector and being permitted to pass through a secure door into the facility. Video surveillance cameras are used throughout the facility, including in the housing units to monitor and record events.


Per the officers interviewed, upon hire they receive 40 hours of classroom training and 40 hours of on the job training with a veteran officer before they are approved to work on their own. Additional training is provided for specific job duties when the officer is assigned to a post.

On September 7, 2017, IAH/PCADC had 261 ICE detainees. On September 8, 2017, IAH/PCADC received 127 detainees due to Hurricane Irma approaching the Florida area and the population surged to 388 ICE detainees. On September 9, 2017, an additional 124 detainees were received and the population rose to 512 ICE detainees. Over 48 hours, the detainee population almost doubled.

Healthcare Services

MTC Medical, with headquarters in Houston, Texas provides 24-hour nursing coverage seven days per week. The facility earned reaccreditation by the American Correctional Association on January 23, 2017. Although the facility is contracted under the NDS, MTC policies and procedures address the elevated standards of PBNDS 2011. The HSA, a registered nurse (RN) who has worked with MTC since April 2016, assumed her administrative role in September 2017. The Clinical Director is a contract MD who has worked at PCADC for about ten years. He delivers on-site medical services one six-hour day per week. For medical reasons, (b)(6); (b)(7)(C)

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



MD was not available during the three days detainee ALMAZAN was at the facility, and therefore he was unfamiliar with the case. He was not interviewed during this review. A part time certified physician assistant is on site from 6:00 p.m. to 7:00 p.m. on Mondays, Tuesdays, and Thursdays. On call coverage is shared between the two providers. A licensed professional counselor provides full time services, and an MTC psychiatrist is available via telemedicine four to six hours a week.

Nursing staff includes a full time director of nurses (DON), three fulltime RNs and six licensed vocational nurses (LVN), all assigned twelve-hour shifts from six to six. Two medical assistants and one pharmacy technician provide clinical and administrative support. There were no vacancies at the time of the review. ODO finds staffing adequate to provide basic medical services for all detainees. A credential review found all professional licenses current and primary source verified.

CHI St. Lukes in Livingston, approximately six minutes from PCADC and Conroe Hospital, approximately 50 miles are used for emergency and specialty care beyond the scope of services


The PCADC medical department consists of two examination rooms, a medical records room, x-ray room, medication room with a pill pass window, and a health services administrator (HSA) office. There are four medical observation cells, one suicide watch cell, and an infection control room with negative airflow. The detention officer's desk is located in the hallway, affording correctional supervision in the clinic. The clinic was found to be clean and adequately sized and equipped.

PCADC uses hard copy medical records, with the exception of chronic care appointment scheduling and electronic medication administration records. Detainees access sick call by filling out paper requests and depositing them into a locked box. Sick call request forms and deposit boxes were inconveniently located outside the locked cells in C Unit, where detainee ALMAZAN was housed. According to detainees who were residing in the same cell with detainee ALMAZAN, they request sick call forms from an officer and when completed put it up to the window so the officer who is making rounds can retrieve the requests. This practice does not ensure the confidentiality of detainees who request appointments for sensitive medical problems. According to the detainee handbook, "Detainees desiring routine medical care will fill out a sick call request which will be picked up daily by the nursing staff." Officer rounds are conducted through window observation only; however, intercoms are available in those units for contacting officers on duty.

Detention Summary

Detainee ALMAZAN arrived at IAH/PCADC on **Friday, September 8, 2017**. An I-203 Order to Detain form was present in the detention file but incorrectly listed the detainee's name as "Alaman" and his date of birth as June 6, 1966, rather than the correct date of June 26, 1966. Intake Officer Tristan Adams stated on interview that his main concern is ensuring the A numbers match and in this case they did. The IAH/PCADC records document the detainee arrived at 4:00 p.m. However, Officer Adams stated the document would have indicated the time the information was entered into the system, rather than the actual time of arrival. He was on duty the night the detainee arrived and recalled the bus arrived later in the evening. Video surveillance footage from

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



the vehicle sallyport shows the first of four buses arrived at 10:19 p.m. Detainees and their property were removed from the buses between the hours of 10:19 p.m. and 11:10 p.m.


The intake processing area contains a long bench with a curtain that can be drawn across the middle of the room. On the opposite side of the curtain are two folding tables and chairs. Acoustic boards for sound baffling have been added to the ceiling. Video surveillance footage from the intake area was reviewed. At 1:04 a.m. detainee ALMAZAN can be seen seated on the bench partially obscured by a curtain. At 1:21 a.m. a nurse arrives, sits next to him and appears to take his blood pressure. At 1:23 a.m. a blood pressure machine is wheeled to the detainee and his blood pressure is again taken. At 1:25 a.m. the detainee leaves the intake area.

The detention file contained intake screening forms for suicide and medical or mental impairments as well as screening for risk of victimization and abusiveness. Detainee ALMAZAN's classification review was completed on this date by Officer (b)(6); (b)(7)(C). It was documented that the detainee's primary language was Spanish. Officer (b)(6); (b)(7)(C) acknowledged he does not speak Spanish and he recalled that a fellow intake officer who does sat with him and went over the intake process in Spanish with detainee ALMAZAN. The officer appropriately rated detainee ALMAZAN high custody based on the severity of his charge, his serious offense history and his prior convictions. This rating was approved by Reception and Discharge Supervisor (b)(6); (b)(7)(C) (b)(6); (b)(7)(C) the same day.

On September 8, 2017, the clothing the detainee was wearing was inventoried. He had one pair of shoes, socks, underwear, sweatpants and one sweatshirt. Detainee ALMAZAN was issued facility clothing, linens and hygiene supplies. Neither the incoming property inventory form nor the facility property issued form were signed by the detainee. (b)(6); (b)(7)(C) stated that because there was such a large influx of detainees on this date, medical staff took half of the group and the officers took the other half. When the property was inventoried, the detainee was with the medical staff and was not available to sign the forms. Detainee ALMAZAN did sign a form acknowledging he received a copy of the facility handbook and PREA information form and that he viewed the ICE orientation video. Documentation confirms he was also fingerprinted. The detainee financial transaction history report shows he had no funds on arrival. It is unknown what happened to the \$4.00 check sent with the detainee from GCDC.

Officer (b)(6); (b)(7)(C) stated that additional property arrived in red mesh bags clearly marked with each detainee's name and A#. However, no property inventory had been completed by the sending facility. Per (b)(6); (b)(7)(C) ERO instructed staff not to inventory and distribute property from the mesh bags until the facility knew if the detainees would be retained at IAH/PCADC (b)(6); (b)(7)(C) stated that 28 detainees stayed at IAH/PCADC and their mesh bags were inventoried and allowable property distributed to those detainees. All other mesh bags were stored and then transferred with the detainees when they left IAH/PCADC after their temporary stay.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017




Detainee ALMAZAN was assigned to Dorm C, Bed 20-04. The log maintained by the officers assigned to this unit documented the detainee's placement in cell C-20 at 2:40 a.m. on **September 9, 2017**. Cell C-20 is a four person handicap accessible unit. The unit is accessed through a sallyport with two steel doors. The doors are opened remotely from central control when an intercom is pressed and staff are identified. Inside the unit, four single metal bunks are welded to the floor with one on the left wall, two on the back wall and one on the right wall. In the middle of the unit is a picnic style metal table with a bench on each side. A TV is mounted on the wall on the left side. Detainee ALMAZAN's bunk was directly under the TV on the left wall. Two phones are on the wall by the entry door as is a camera which is mounted near the ceiling. A single handicap shower is located behind a curtain and a stainless steel toilet and sink with grab bars are located behind a partial partition on the right hand wall which blocks the camera view of the bathroom facilities. An intercom on the inside of the unit by the door alerts in central control. A large window in the hallway provides a direct view into the unit.

IAH/PCADC utilizes indirect supervision with an officer assigned to the hallway outside the dorm. Dorm officer post orders require that a security round be conducted twice per hour at irregular intervals with no more than 40 minutes elapsing between rounds. The officers are not required to enter each dorm during these rounds. Officers do enter the dorms during the seven official counts conducted daily and to distribute and retrieve trays for all meals. Indoor recreation is offered in an area directly across from the dorm. There is also a large recreation field outside. Detainees are permitted one hour of recreation daily.

Video surveillance footage from inside Dorm C for detainee ALMAZAN's detention period was viewed. At 2:44 a.m. on September 9, 2017, detainee ALMAZAN entered the dorm carrying a bag of property. Detainee ALMAZAN took a seat at the table and spoke to another detainee. At 2:50 a.m. an officer entered the unit and handed detainee ALMAZAN a mattress and pillow. Detainee ALMAZAN, with the assistance of the detainee he was speaking with, made up his bed. Detainee ALMAZAN then placed his property in his assigned property storage box and laid down at 2:57 a.m. Between 3:00 a.m. and 6:30 a.m. detainee ALMAZAN went to the bathroom four times. Other than that, he laid on his bunk. At 6:36 a.m. he showered. At 6:43 a.m. breakfast trays were delivered by an officer. Detainee ALMAZAN did not eat but rather gave his tray to the other detainees. Throughout the morning, detainee ALMAZAN slept, only rising to use the bathroom or watch TV for a few minutes. When the lunch tray was delivered at 11:45 a.m., detainee ALMAZAN sat on his bunk eating a portion of the meal and then handed his tray to the other three detainees for them to share the remaining food.

Detainee ALMAZAN slept, laid on his bunk and went to the bathroom throughout the afternoon. At 6:07 p.m. he walked to the unit door. As the door is obscured by a wall, it is not known if the detainee left the unit but it is surmised he did, perhaps for pill call. At 6:17 p.m. an officer delivered meal trays to the unit. Detainee ALMAZAN returned to his bunk at 6:27 p.m., appeared to take an item off of his food tray and then handed the tray with the remaining food items on it to the

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



other detainees who were seated at the table eating. Those detainees took and shared the food from the tray.

Throughout the evening, the other detainees played checkers, watched TV and read. Detainee ALMAZAN did not participate in any of these activities and simply laid on his bunk or went to the bathroom.

On **September 10, 2017**, detainee ALMAZAN went to the unit door at 5:53 a.m. and returned to his bunk at 6:03 a.m. Again, he ate some food from his meal tray while seated on his bunk but brought the tray to the other detainees to share the remaining food. Again, he slept and went to the bathroom numerous times. At 10:13 a.m. he sat up on his bunk and ate what appeared to be a piece of fruit. At 11:34 a.m. the lunch trays were delivered and he ate some food while sitting on his bunk and then placed some items from the tray into a brown paper sack which he retained by his bunk. He then took the tray to the other detainees who shared the remaining items. Between 8:00 a.m. and 4:30 p.m. he went to the bathroom area nine times.


Dinner trays were delivered at 6:40 p.m. and again, detainee ALMAZAN ate some items from the tray at his bunk and gave the remaining items away to the other detainees. At 8:01 p.m. he went to the door of the unit and returned to his bunk at 8:16 p.m. Throughout the evening, he slept or went to the bathroom.

On **September 11, 2017**, at 5:31 a.m. detainee ALMAZAN went to the unit door. He returned to his bunk at 5:42 a.m. carrying his breakfast tray. Again, he sat on his bunk eating and then brought the tray to the three detainees seated at the table eating. They could be seen taking food items off the tray. Between 5:00 a.m. and 11:00 a.m., he went to the bathroom four times. At 11:54 a.m. lunch trays were delivered and the detainee ate on his bunk. He placed some items from his tray in a separate container and then offered the remaining food items to the other detainees. At 12:12 p.m. another detainee walked to detainee ALMAZAN's bunk and appeared to offer him some food. Detainee ALMAZAN did not take the food item and the other detainee walked away.

At 1:43 p.m. detainee ALMAZAN went to the unit door and returned to the unit at 1:48 p.m. He stood up speaking with another detainee until he returned to his bunk at 2:05 p.m. For the next several hours he sat or laid on his bunk, went through his property bin or went to the bathroom. At 6:11 p.m. he went to the unit door and returned to his bunk at 6:36 p.m. carrying some paperwork which he placed under his mattress.

At 7:04 p.m. the dinner trays arrived and another detainee offered detainee ALMAZAN a tray but he did not take it. At 7:28 p.m. Officer (b)(6); (b)(7)(C) entered the unit and a detainee spoke with the officer. The officer and the detainee then went to detainee ALMAZAN's bunk and appeared to speak with him while he remained laying down. Detainee ALMAZAN handed the officer his identification card and the officer walked away. A minute later, the officer returned to the

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



detainee's bunk and spoke with him again. The officer then walked toward the unit door while speaking on his handheld radio.

At 7:32 p.m. Officer N [REDACTED] returned to the unit with Office [REDACTED] Sergeant [REDACTED] and Lieutenant [REDACTED]. At 7:33 p.m. LVN [REDACTED] arrived in the unit pushing a wheelchair. The six staff surrounded detainee ALMAZAN's bunk so the view of the detainee from the camera was blocked. At 7:34 p.m. it appeared the detainee was helped into a sitting position on his bunk and at 7:35 p.m. he was assisted into the wheelchair. At 7:35 p.m. the detainee was wheeled off the unit by the nurses. The video surveillance footage from other cameras throughout the facility showed the detainee was wheeled into the medical unit at 7:38 p.m. and was taken to the vehicle sallyport at 8:38 p.m. for transport to the hospital.


Two of the three detainees who were housed with detainee ALMAZAN during his detention at IAH/PCADC were still housed at the facility during this review and were interviewed. Detainee [REDACTED] recalled detainee ALMAZAN and stated he was a "little sick" when he arrived. He stated detainee ALMAZAN did not eat or drink [REDACTED] slept most of the time and that he declined soup or other foods when offered. Detainee [REDACTED] stated detainee ALMAZAN didn't want to do anything and he thought he was sad or depressed. Detainee Garcia recalled that on September 11, 2017, detainee ALMAZAN vomited three or four times. When he observed drops of blood on the floor and some dried blood around the mouth of detainee ALMAZAN he stated he alerted the dorm officer.

Detainee [REDACTED] recalled detainee ALMAZAN was always sleeping and that he would only eat a few bites of his meal tray. He and the other detainees in the dorm would try to get detainee ALMAZAN to attend recreation or to play cards or chess in the dorm but he refused. Detainee [REDACTED] noted that if another detainee is not open to mingling with other detainees, they cannot force it. While he did not observe detainee ALMAZAN vomit up blood on September 11, 2017, he did observe dried blood around the detainee's mouth.

Both detainees noted that once the officer arrived and assessed the situation, he called an emergency on his radio. They estimated that security and medical staff arrived within two or three minutes and detainee ALMAZAN was removed from the dorm in a wheelchair.

Office [REDACTED] was assigned to Dorm C hallway for the 2:00 p.m. to 10:00 p.m. shift on September 11, 2017. Office [REDACTED] recalled that he had pulled detainee ALMAZAN from the dorm to the medication pill window at 5:15 p.m. and the detainee was walking slow and appeared dizzy. He asked the detainee if he was okay and detainee ALMAZAN responded that his stomach hurt. Officer [REDACTED] served dinner trays at 6:00 p.m. When he later picked up the dinner trays he was told by the other detainees in Dorm C that detainee ALMAZAN had been vomiting up blood. Officer [REDACTED] who speaks Spanish, noted that detainee ALMAZAN did not speak English. He went to detainee ALMAZAN's bunk and asked him if he had been vomiting up blood. The detainee responded that he did not know because he just flushed the toilet after he vomited

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



without looking. Office (b)(6); (b)(7)(C) observed blood on the detainee's lip and called a medical emergency on his radio.

The C Dorm logbook documents that the detainee was pulled for pill call at 6:14 p.m. At 7:00 p.m. dinner trays were served and at 7:30 p.m. one detainee was sent to medical. The C Dorm logbook had no entries related to this emergency, including the response of medical and security personnel. When asked, Office (b)(6); (b)(7)(C) acknowledged his error in not documenting the medical emergency. He stated that since this event he has been recording any unusual incidents in the logbook. As for an incident report, Office (b)(6); (b)(7)(C) stated he was told by an unknown supervisor that medical would document the incident and he did not need to do so.

Upon hearing the emergency call, Sergeant (b)(6); (b)(7)(C) responded first along with Lieutenant (b)(6); (b)(7)(C) followed by the two nurses with a wheelchair and emergency medical bag. Sergeant (b)(6); (b)(7)(C) stated that no staff observed the detainee vomiting blood so he was sent to medical to be evaluated.


(b)(6); (b)(7)(C) responded to the emergency medical call to Dorm C. (b)(6); (b)(7)(C) stated on interview that she observed dried blood on the detainee's lips. She recalled the detainee stated his chest hurt. (b)(6); (b)(7)(C) translated for the medical staff and they had him ask detainee ALMAZAN how long he had been vomiting blood. LVN (b)(6); (b)(7)(C) recalled the detainee responded that it had been five days. The detainee was then assisted into the wheelchair and wheeled to medical.

Physician's Assistant (b)(6); (b)(7)(C) was on duty and both LVN's stated they wheeled detainee ALMAZAN right in to the provider for examination. (b)(6); (b)(7)(C) ordered a blood draw. LVN (b)(6); (b)(7)(C) stated the detainee was able to transfer himself from the wheelchair to the chair for the blood draw. She took his blood pressure and recalled it was elevated but was lower the second time she took it. (b)(6); (b)(7)(C) then found out detainee ALMAZAN had cirrhosis so he cancelled the blood draw and said the detainee needed to go to the emergency room. (b)(6); (b)(7)(C) determined an ambulance wasn't necessary and he could go by facility van. (b)(6); (b)(7)(C) recalled the detainee was able to transfer himself from the chair back to the wheelchair for transport to the facility vehicle.

(b)(6); (b)(7)(C) recalled on interview that the detainee was reluctant to tell him anything. (b)(6); (b)(7)(C) surmised the detainee didn't want staff to know he was sick and believed if he went to the hospital he wouldn't get to go home. (b)(6); (b)(7)(C) stated he observed blood around the detainee's mouth and the detainee reported he had been vomiting blood for five days. (b)(6); (b)(7)(C) stated it was "obvious" to him that the detainee had varicies.

(b)(6); (b)(7)(C) was no longer employed at IAH/PCADC at the time of this review and was therefore not available to be interviewed. According to the critical incident report completed by (b)(6); (b)(7)(C) the medical emergency was called at 7:52 p.m. and the Warden was notified at 7:53 p.m. Lt. (b)(6); (b)(7)(C) documented that upon arrival at C-20, detainee ALMAZAN was "lying in bed moaning".

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



After he was brought to medical and examined by (b)(6); (b)(7)(C) the doctor determined the detainee needed to be transported to CHI St. Luke's Health Memorial Hospital.

The Stationary Guard Roster report documented that on September 11, 2017, at 8:45 p.m. Officers (b)(6); (b)(7)(C) and (b)(6); (b)(7)(C) transported detainee ALMAZAN to CHI St. Luke's Health Memorial Hospital in Livingston, TX, a distance of 7 miles. They arrived at 9:00 p.m. On interview (b)(6); (b)(7)(C) stated that she assisted detainee ALMAZAN into the van because he was wearing leg irons, handcuffs and a waist belt. As with all detainees who are transported in restraints, she stated a crate was used for the detainee to step up on to safely enter the van. She recalled the detainee was quiet and cooperative during the transport. Officer (b)(6); (b)(7)(C) carried the weapon and drove the van. Upon arrival at the hospital, she dropped the detainee and Officer (b)(6); (b)(7)(C) at the door where they were met by hospital staff with a wheelchair. The detainee was wheeled into the ER for treatment and (b)(6); (b)(7)(C) parked the van. (b)(6); (b)(7)(C) recalled the hospital staff had trouble getting an IV into detainee ALMAZAN's arm. The Hospital Activity Log the officers completed noted permission was received from the shift supervisor to remove one handcuff and the belly chain and to restrain the detainee with one cuff attached to the bed. These officers were relieved at 11:00 p.m. and returned to the facility at 11:15 p.m.


Officers (b)(6); (b)(7)(C) assumed vigil duty at 11:00 p.m. and documented that the detainee received an IV and the doctor informed them at 1:10 a.m. that the detainee needed to be transferred to another hospital. These officers stayed with the detainee until 6:15 a.m. on **September 12, 2017**. At 6:00 a.m. (b)(6); (b)(7)(C) reported for vigil duty and relieved (b)(6); (b)(7)(C)

A Texan EMS LLC report documents a paramedic and EMT responded to CHI St. Luke's Health Memorial Hospital at 6:45 a.m. to transport detainee ALMAZAN to Conroe Regional Medical Center (CRMC) in Conroe, TX for treatment of "upper GI bleed noticed when pt began vomiting blood @ 12 hours ago". The report noted detainee ALMAZAN was ambulatory and was able to walk to the stretcher. He was assessed and no abnormalities were found. It was documented he was being transported by ambulance due to the need to administer IV medications and oxygen en route. Upon arrival at CRMC at 8:13 a.m., EMS staff documented the detainee was able to ambulate to a chair and his care was turned over to staff at CRMC.

According to (b)(6); (b)(7)(C), he is weapons certified so he followed the ambulance in the facility van while (b)(6); (b)(7)(C) rode in the ambulance. (b)(6); (b)(7)(C) stated the trip usually takes an hour but it took 90 minutes due to heavy traffic. They logged an arrival time of 8:13 a.m. at CRMC and noted the detainee was admitted to the ICU. (b)(6); (b)(7)(C) recalled that the detainee was alert when not sleeping, ate his meals and was able to sit up to urinate. The officers logged that they were relieved at 4:40 p.m.

(b)(6); (b)(7)(C) has since been promoted to sergeant at PCADC. She will be referred to as officer throughout this report.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



Relieving Sergeant (b)(6); (b)(7)(C) and Officer (b)(6); (b)(7)(C) were Officers (b)(6); (b)(7)(C) and (b)(6); (b)(7)(C) who arrived at 4:32 p.m. They documented in the Hospital Activity Log that technicians were in the room performing an EKG and an X-Ray at 5:10 p.m. As medical staff were having trouble with the IV in the detainee's neck, the officers requested and received permission from the facility to remove the handcuffs from the detainee so an IV could be placed in his arm.

Officer (b)(6); (b)(7)(C) were relieved by (b)(6); (b)(7)(C) at 10:30 p.m. They documented that during their shift nursing staff checked the detainee's IV, changed his bedding, drew blood and assisted him to the restroom throughout the night.


On **September 13, 2017** Officers (b)(6); (b)(7)(C) reported for vigil duty at 6:26 a.m. Throughout their shift, they logged the detainee went for a procedure at 7:37 a.m. and returned to his room at 7:43 a.m. Staff logged that nursing staff **changed his linens, brought him food and delivered pain medication throughout the shift.** Officer (b)(6); (b)(7)(C) were relieved at 8:14 p.m. by Officers (b)(6); (b)(7)(C). Throughout their shift, they logged that nursing staff gave the detainee medication, walked him to the restroom, and checked his vital signs.

An email from Commande (b)(6); (b)(7)(C) sent this date to ERO officials inquired as to the plan for detainee ALMAZAN upon discharge from the hospital. She noted, "His condition is chronic and will only get worse with time. GI bleeds can happen suddenly and can vary in severity depending on where the bleed occurs".

In written statements dated September 25, 2017 and submitted to SDDO (b)(6); (b)(7)(C) and AFOD (b)(6); (b)(7)(C) documented a visit they made to the CRMC on September 13, 2017. They documented that upon their arrival, detainee ALMAZAN was asleep but he woke up while they were talking with MTC vigil officers. The deportation officers spoke with detainee ALMAZAN about the status of his immigration case and the detainee informed them he intended to appeal his case and had a petition pending. They then discussed with him whether he had family in the United States and he stated he had family in Florida and possibly New York. They then concluded their interview of detainee ALMAZAN. The deportation officers' statements do not document the time of their visit. The MTC hospital log does not document any visit to detainee ALMAZAN by ERO officers.

On **September 14, 2017** at 6:20 a.m. (b)(6); (b)(7)(C) reported for vigil duty. They logged that nursing staff checked the detainee's vital signs and at 8:10 a.m. Doctor (b)(6); (b)(7)(C) informed the nurse the detainee should be moved from the ICU to a "regular room". At 1:15 p.m. officers logged the detainee was "complaining of chest pain". At 2:20 p.m. the detainee stated he "had gas". At 2:40 p.m. the detainee was moved from the ICU to room 141. At 3:15 p.m. the detainee reported he **had pain. He was given Mylanta** and other unknown medications per the log. At 6:56 p.m. Officers (b)(6); (b)(7)(C) reported for vigil duty. They logged nursing staff checked vitals, gave pain medication and took a blood sample during their shift. Also on

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



this date, (b)(6); (b)(7)(C) noted in an email to Commander (b)(6); (b)(7)(C) that the detainee, when discharged, would be moved to HCDF until he could be moved back to Florida.

On **September 15, 2017** at 6:20 a.m. Officers (b)(6); (b)(7)(C) reported for vigil duty. Throughout their shift they logged that nursing staff checked the detainee's blood pressure and gave him medication. They also noted the detainee took a shower at 2:00 p.m. These officers were relieved at 6:37 p.m. by Officers (b)(6); (b)(7)(C)

Commander (b)(6); (b)(7)(C) in an email this date to various EPO officials provided a medical update on detainee ALMAZAN. In the email, Commander (b)(6); (b)(7)(C) noted that a cardiac stress test was being scheduled and it was possible the detainee would be discharged in time to make a flight back to KNSPC scheduled for **September 17, 2017**. If the detainee was not released in time for the Sunday flight, Commander (b)(6); (b)(7)(C) recommended that he be moved, when discharged, to "Houston CDF due to his combined chronic medical issues".

Officers (b)(6); (b)(7)(C) who had assumed vigil duty logged that nursing staff met with the detainee at 7:04 p.m. to review paperwork with the detainee authorizing a stress test scheduled for the following day. At 5:38 a.m. on **September 16, 2017** the detainee signed the paperwork. At 6:40 a.m. Officers (b)(6); (b)(7)(C) arrived for vigil duty. At 9:18 a.m. they logged that the detainee went for his heart stress test and returned at 10:49 a.m.


Officers (b)(6); (b)(7)(C) reported for vigil duty at 6:10 p.m. They logged that three nurses and a doctor entered the room at 00:34 a.m. on **September 17, 2017**. At 00:55 officers contacted the warden to receive permission to remove handcuffs for "blood gas testing" and noted it was an "emergency". At 1:04 a.m. the detainee was moved to the ICU and a chest X-Ray and blood samples were taken. At 2:01 a.m. officers called the facility to report the detainee was on life support. At 2:11 a.m. chest X-rays were again taken. At 2:31 a.m. the cuffs and belly chain were noted as removed after permission was received by a shift sergeant. At 3:23 a.m. Doctors (b)(6); (b)(7)(C) and Slaughter entered to check on the detainee and searched for veins for IV picks. At 4:41 a.m. nursing staff asked if the facility could notify detainee ALMAZAN's next of kin to "prepare for the worst". At 4:57 a.m. the detainee went into cardiac arrest and nurses started CPR. At 5:15 a.m. the detainee was pronounced dead. At 5:18 a.m. Warden David Stacks was notified by the vigil officers of the detainee's death.

Per an email from Assistant Officer in Charge (b)(6); (b)(7)(C) at KNSPC, at 8:04 a.m. EST he notified the detainee's sister (b)(6); (b)(7)(C) that her brother had passed away.

Vigil duties were performed as follows:

Date	Officers	Arrival	Departure
September 12, 2017	(b)(6); (b)(7)(C)	4:32 p.m. 10:30 p.m.	10:47 p.m. 7:15a.m.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017




September 13, 2017	(b)(6); (b)(7)(C)	6:26 a.m.	8:34 p.m.
September 14, 2017		8:14 p.m.	6:35 a.m.
September 15, 2017		6:20 a.m.	7:25 p.m.
September 16, 2017		6:56 p.m.	6:28 a.m.
September 17, 2017		6:20 a.m.	6:55 p.m.
September 17, 2017		6:37 p.m.	7:23 a.m.
		6:40 a.m.	6:22 p.m.
		6:10 p.m.	7:20 a.m.
		6:01 a.m.	7:02 a.m.

Warden Stacks completed a Critical Incident Report on September 17, 2017. In the report he noted that detainee ALMAZAN had been transported to IAH/PCADC at approximately 11:00 p.m. on September 8, 2017, “due to expected imminent damage and dangers from Hurricane Irma to the state of Florida”. Warden Stack also documented that the detainee arrived at the facility, “with noticeable jaundice skin”. Warden Stacks’ report lists the initial apparent cause of death as a heart attack. An autopsy was ordered by Precinct Judge Wayne Mack through Texas Range (b)(6); (b)(7)(C) (b)(6); (b)(7)(C) per the Warden’s report.

On **September 18, 2017**, Detainee ALMAZAN’s personal property was inventoried and photographed by Officer (b)(6); (b)(7)(C). The property consisted of one pair of pants, four shirts, 11 pairs of socks, one sweatpants, two t-shirts, eight pairs of underwear, three pairs of shoes, one wash rag, one ID card, one wristband, books, legal paperwork, a Bible, a watch, necklace, wallet, sunglasses, a homemade ring, one clear cup and \$2.10 in coins. Multiple hygiene items and multiple medications were also marked. (b)(6); (b)(7)(C) (b)(6); (b)(7)(C) noted on interview that the shirt with elephants on it which the detainee was wearing upon admission to Krome and for his intake photo as well as a pair of his shorts had small spots on them with a “moldy, reddish tint” that may have been blood. (b)(6); (b)(7)(C) (b)(6); (b)(7)(C) stated the property was turned over to Supervisory Detention and Deportation Officer (SDDO) (b)(6); (b)(7)(C).

Per SDDO (b)(6); (b)(7)(C) upon receipt of the property, it was taped shut in a cardboard box and secured in his office with the inventory sheet taped on top. The box was opened by the SDDO for the reviewers on October 18, 2017 and the contents were inspected. The various clothing items were reviewed and the elephant shirt and one pair of shorts did appear to have small spots of blood on them. The clothes he had worn on the trip from Folkston to IAH/PCADC were inspected and no blood was observed on the orange pants or cream colored t-shirt he wore during that trip.

Assistant Field Office Director (b)(6); (b)(7)(C) documented in an email dated September 18, 2017 that he was contacted that date by the brother of detainee ALMAZAN requesting that ERO assist with the payment to ship the body back to Florida.



On September 18, 2017, Texas Ranger (b)(6); (b)(7)(C) from Livingston, TX sent an email to AFOD (b)(6); (b)(7)(C) stating he had been contacted by Montgomery County Justice of the Peace (b)(6); (b)(7)(C). Judge Mack advised (b)(6); (b)(7)(C) that he had ordered an inquest into the death of detainee ALMAZAN (incorrectly identified as (b)(6); (b)(7)(C) in the email) and requested that Ranger (b)(6); (b)(7)(C) conduct the investigation. Upon speaking with AFOD (b)(6); (b)(7)(C) and being informed that an investigation into the death of the detainee was being conducted (b)(6); (b)(7)(C) sent the email to confirm with AFOD (b)(6); (b)(7)(C) that he was not conducting an investigation into the death.

The transportation of the body was funded by ERO and coordinated through All Faith's Mortuary per an invoice and purchase card transaction worksheet. The body was shipped via commercial air to Miami, FL on September 20, 2017. On the same date, the Field Office Director from the Houston Field Office notified the detainee's sister in writing of the death.


On September 20, 2017 the State of Texas issued a Certificate of Death which listed the cause of death as "pending".

Summary of Events

(b)(6); (b)(7)(C) RN, DON conducted the medical intake screening at 11:30 p.m., noting that 51 year old detainee ALMAZAN spoke English, and therefore an interpreter was not used. During interview, however (b)(6); (b)(7)(C) stated he spoke very little English but there was a medical person (b)(6); (b)(7)(C) interpreted for her. She was unable to ascertain who provided this assistance. Detention Officer who worked intake during the arrival of the Florida-evacuated detainees, recalled detainee ALMAZAN only spoke Spanish, requiring another intake officer to provide language assistance. (b)(6); (b)(7)(C) Detention Officer who was working in the detainee's unit, also stated detainee ALMAZAN spoke no English and that because he himself was fluent in Spanish, he provided interpretation assistance. Throughout interviews, other custody staff having had direct contact with detainee ALMAZAN also described his minimal ability to speak and understand English.

At five feet, one inch tall, detainee ALMAZAN weighed 170 pounds. A pain level of four on a scale of zero to ten was reported at the time of arrival, as he complained of general joint pain and discomfort in the upper right quadrant of his abdomen. The reviewer notes that pain in this location is common in liver cirrhosis. Vital signs were recorded within normal limits with the exception of a significantly elevated blood pressure of 180/109 (See Appendix I). Rechecks at unrecorded times noted a decrease in blood pressure to (b)(6); (b)(7)(C) 164/100 and finally to 152/86, levels that remained abnormally high (See Appendix II). RN (b)(6); (b)(7)(C) stated during interview she did not contact the provider regarding these blood pressures, as detainee ALMAZAN told her he had not received his medication for an undetermined period of time. According to the MTC nursing protocol a blood pressure read of 160/100 requires provider contact, which RN (b)(6); (b)(7)(C) stated she was aware of. When questioned if he would have wanted to be notified of the abnormal read, (b)(6); (b)(7)(C) A-

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



C stated that considering the diagnoses of cirrhosis and probable portal hypertension, it would have been important for him to know. (b)(6); (b)(7)(C) stated during interview that she was not aware what the interval period was between rechecks of the blood pressure, but she explained that she had administered his medication prior to the second and third check. However (b)(6); (b)(7)(C) VN, who said she was present at the time of detainee ALMAZAN's intake screen, stated during interview that she personally pulled him out of the screening area to help him relax and conducted the second and third blood pressure rechecks. When asked if she administered his medication prior to the rechecks, she stated she did not believe the meds had been given. A review of the medication administration record (MAR) does not indicate any of his medications were given until the 5:30 a.m. pill line the following morning. The MAR does indicated prescribed medications were regularly administered from that time until his hospital transfer. Of note, the next blood pressure check was not recorded until three days later prior to hospital transport.

Detainee ALMAZAN signed and dated a Spanish version of consent for medical treatment. He was noted to have had a chest x-ray on July 12, 2017, negative for tuberculosis, and he denied a history or current symptoms of infectious disease. Chronic medical issues, as supported by those listed on the medical summary from Glades County Detention Center (GCDC), included cirrhosis of the liver, depression, and generalized anxiety disorder (GAD). Other diagnoses established at both previous facilities, Krome Service Processing Center (KSPC) and GCDC but not listed on the medical summary, included portal hypertension⁹⁰, varices⁹¹, pancytopenia⁹², irritable bowel syndrome⁹³, and gastro-esophageal reflux disease⁹⁴. The medical summary from GCDC also failed to include pending referrals initiated while he was detained at KSPC, including an abdominal ultrasound and specialty consults for hematology and ophthalmology. According to medical records received from KSPC and GCDC, the referrals were never completed; nor were there references to the pending state of these referrals on the transfer summary forwarded from KSPC and received by GCDC.

Detainee ALMAZAN reported not being a smoker, but admitted to a significant history of alcohol abuse, stating he used "mucho" beer and tequila, last using about three months ago. He had been hospitalized and went through "the program". He was noted to have tremors, which was listed as a withdrawal symptom, and he admitted to having gone through a period of withdrawal at the time of his hospitalization. His mental health assessment was all shown to be normal (b)(6); (b)(7)(C) though following a "no" response to the question if he ever tried to harm himself, RN (b)(6); (b)(7)(C) stated,

⁹⁰ Portal hypertension is an increase in the blood pressure within a system of veins called the portal venous system. Veins coming from the stomach, intestine, spleen, and pancreas merge into the portal vein, which branches into small vessels and travels through the liver. When a sick liver is unable to accommodate the blood, it pools back, causing vessel enlargement and weakness (varices).


⁹¹ Varices are abnormal veins in the lower part of the esophagus and stomach.

⁹² Pancytopenia is a deficiency of all three cellular components of the blood (red cells, white cells, and platelets)

⁹³ Irritable bowel syndrome is an intestinal disorder causing stomach pain, gas, diarrhea, and constipation.

⁹⁴ Gastro-esophageal reflux disease is a digestive disease in which stomach acid or bile irritated the lining of the esophagus and stomach.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



“passive suicidal intent”. When asked to clarify what this meant, she stated in the past he had thoughts of wanting to die. His mood and behavior were found to be appropriate. RN (b)(6); (b)(7)(C) completed MTC’s “Treatment Plan: Special Needs and Restrictions” form, excusing him from a work program assignment for medical reasons. He was placed on no restrictions for the disciplinary process, and “chronically ill” was checked for special needs. Routine referrals were checked for mental health, medical doctor, and special diet (renal). He was assigned to a low bunk in handicap housing unit C-20.

(b)(6); (b)(7)(C) RN, HSA documented a verbal order from (b)(6); (b)(7)(C) PA to continue all medications as ordered by the previous facility. The transfer summary from GCDC listed his medication as follows:

Medication	Dosage	Indications
Sertraline	100 mg daily	Depression and anxiety
Trazadone	75 mg daily at bedtime	Depression and anxiety
Folic Acid	1 mg daily	Vitamin B folic acid deficiency related to liver disease.
Omeprazole	40 mg daily	Gastro-esophageal reflux disease (GERD)
Prednisone	100 mg daily for three days. Tapered doses: (100mg, 80mg, 60mg, 50 mg, 40 mg, 30 mg, 20 mg, each for three days; then 10 mg, 5 mg, 2.5 mg each for two days, then discontinue.	Steroid to treat inflammation
Spironolactone	25 mg twice daily	High blood pressure and fluid retention

The medications submitted on the MAR included a taper⁹⁵ on the prednisone, the addition of lactulose 30 mg twice daily, and the addition of Xifaxan 550 mg twice daily. Of note, Dr. (b)(6); (b)(7)(C) MD from GCDC added and/or adjusted medications on September 6, 2017. Neither the medication bottles nor the order information was forwarded to or received by PCADC. Specifically, he had increased lactulose to 40 ml started ferrous sulfate (iron) 325 mg one time daily, and added a multivitamin, one daily. (b)(6); (b)(7)(C) Advanced Registered Nurse Practitioner from GCDC ordered an increase of trazodone to 75 mg nightly on August 22, 2017. The dosage on the medical summary was 50 mg, but during interview, (b)(6); (b)(7)(C) explained she reconciled the medication labels and noted the current dosage. The reviewer observed that detainee ALMAZAN had never been prescribed a beta-blocker⁹⁶ as an important adjunct in his cirrhosis treatment. PA

⁹⁵ Drug tapering is the gradual discontinuation or reduction of a therapeutic dose of a particular drug required by a patient over a prolonged period of time, as a means of reducing potentially severe side effects.

young reported during interview he had questioned if he was receiving a beta-blocker and was surprised he was not. According to an article published by the gastroenterology department of the National Institutes of Health, related to the use of non-selective beta-blockers (NSBB)⁹⁷, they remain the cornerstone of therapy in cirrhotic patients with portal hypertension. In primary prophylaxis, patients with high-risk small varices or large/medium varices should receive primary prophylaxis with NSBB, except when contraindication to these drugs exist, in which case endoscopic band ligation should be performed.

IAH/PCADC utilizes indirect supervision with an officer assigned to the hallway outside the dorm. Dorm officer post orders require that a security round be conducted twice per hour at irregular intervals with no more than 40 minutes elapsing between rounds. The officers are not required to enter each dorm during these rounds. Officers do enter the dorms during the seven official counts conducted daily and to distribute and retrieve trays for all meals. Indoor recreation is offered in an area directly across from the dorm. There is also a large recreation field outside. Detainees are permitted one hour of recreation daily.

(b)(6); (b)(7)(C)

Licensed Professional Counselor, documented a mental health assessment following the referral for depression. Detainee ALMAZAN was described as clean, cooperative, fully oriented, and having normal speech. His mood was described as depressed, his affect was congruent, his thought process was logical, and he had no hallucinations or suicidal intent. His judgment and insight were fair. The narrative note stated, "Processed thoughts and feelings regarding being incarcerated. Discussed the importance of positive coping skills. Established skills he could use while incarcerated. Informed how to access mental health services. Will refer to psychiatrist for med management." He was not found to be a danger to himself or others. During interview, (b)(6); (b)(7)(C) did not recall detainee ALMAZAN ever discussing his medical condition, including any possibility that he had been vomiting or coughing up blood since his arrival.


According to MTC's policy addressing intake health screening, "When a referral for medical follow-up is initiated, the resident shall receive a health evaluation no later than two working days from the date of assessment." HSA (b)(6); (b)(7)(C) produced an electronic chronic care roster document, indicating that detainee ALMAZAN's chronic care clinic was pending at an unspecified date. He was transported to the hospital on Monday, September 11, the first working day since his arrival.

At 7:45 p.m. (b)(6); (b)(7)(C) LVN completed an emergency assessment form, noting, "Nurse called to tank C-20 because detainee was reportedly vomiting blood." Detainee ALMAZAN's vital signs were recorded as normal, with the exception of an abnormally elevated blood pressure of 151/95 and an abnormally rapid heart rate of 106. He was fully oriented to person, place, and time. He complained of pain in his mid chest. ERAU's review of the housing unit video clearly showed a

⁹⁶ Beta-blockers are a class of drug commonly used to treat high blood pressure. Nonselective beta-blockers are a subclass of beta-blockers, commonly used to treat portal hypertension.

⁹⁷ Gianelli V, Lattanzi B, Merli, M, Beta-blockers in liver cirrhosis, *Annals of Gastroenterology*. 2014;27(1):20-26.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



second nurse responded to the unit when the call came through. This nurse was identified as (b)(6); (b)(7)(C). When questioned during interview as to why she did not document a note, she explained that (b)(6); (b)(7)(C) was taking charge of the situation. She did report assisting with the detainee's transfer from the bed to the wheelchair, however. According to the "Provider Progress Notes/Orders", P (b)(6); (b)(7)(C) completed his evaluation of detainee ALMAZAN at 9:57 p.m. During interview (b)(6); (b)(7)(C) reported he incorrectly recorded the military time, intending to have signed off at 7:57 p.m. According to the note, he was brought to medical with complaints of vomiting blood, similar to an incident he reported having occurred seven years ago. He was believed to have cirrhosis with varices, information that was extracted from the chart, as (b)(6); (b)(7)(C) determined, "Pt [patient] poor historian". When questioned as to how he arrived at this description, (b)(6); (b)(7)(C) stated that detainee ALMAZAN offered no medical history, as if he did not want medical to know how sick he was. When directly questioned about his cirrhosis, however, he then admitted it. (b)(6); (b)(7)(C) voiced his opinion that the detainee did not speak English and that (b)(6); (b)(7)(C) Medical Assistant, provided interpretation. He was described as alert and oriented and appeared to be in no acute distress. (b)(6); (b)(7)(C) stated there were no symptoms or patient behaviors at the time of assessment to suggest this was an emergency situation. Bright red blood was observed on both the inside and outside his mouth, but there was no blood on his shirt or pants. He was diagnosed with gastrointestinal bleed of five days duration and was sent to the emergency room for evaluation on a stat basis, but not via 911.

A "Timeline/Checklist – Depart from the Facility" form was completed by an unidentified medical staff member at 8:42 p.m. According to this document (b)(6); (b)(7)(C) was notified of the need to transport detainee ALMAZAM to CHI St. Luke's via van with security escort. Hospital updates were recorded daily, as follows:


Reporting Nurse, Date, and Time	Report Summary
(b)(6); (b)(7)(C) September 12, 2017	Stable at this time. Most recent vitals: Blood pressure 99/58, pulse 75, and respirations 17. Pulse oxygen 97. Temperature remains normal. Two units of platelets given due to critical platelet level of 27. Post transfusion level is up to 55. All other labs remain within normal limits. Scheduled to have EGD ⁹⁸ in the morning. Previously receiving cardene drip ⁹⁹ via external jugular line. Has been stopped and is now receiving oral lisinopril ¹⁰⁰ .
(b)(6); (b)(7)(C) LVN September 13, 2017 5:35 p.m.	Alert and oriented. Blood pressure 117/58, pulse 88, R 19, Temperature 98.3, pulse oxygen 100. Received two units of platelets. Hemoglobin is 11.2, and platelets are 27.
(b)(6); (b)(7)(C)	Alert and oriented. Blood pressure 101/51, pulse 69, respirations 14,

⁹⁸ An EGD, short for esophagogastroduodenoscopy is a scope used to examine the lining of the esophagus, stomach, and duodenum (upper part of the small intestine)

⁹⁹ A cardene drip is an intravenous therapy infused with medication to treat high blood pressure.

¹⁰⁰ Lisinopril is a medication to treat hypertension.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
 Medical and Security Compliance Review
 December 4-5, 2017



September 14, 2017 6:41 a.m.		temperature 98.3, pulse oxygen 99. Continues lisinopril orally. Denied pain throughout the night.
(b)(6); (b)(7)(C)	RN	
September 14, 2017 6:31 p.m.		Alert and oriented. Blood pressure 125/73, pulse 79, respirations 18, temperature 98.7, and pulse oxygen 99. Continues oral lisinopril. Pain is eight of ten, reporting severe GERD. Moved to medical-surgical unit.
(b)(6); (b)(7)(C)		
September 15, 2017 5:40 a.m.		Remains stable. Removed from ICU room 18 to medical surgical floor, room 141. Blood pressure 93/54, temperature 98.1, pulse 72, respirations 18, pulse oxygen 97.
(b)(6); (b)(7)(C)	, RN	
September 16, 2017 7:24 p.m.		Remains stable. Blood pressure 1006/65, temperature 98.2, pulse 72, respirations 16, pulse oxygen 98. Had a normal cardiac stress test earlier in the day. Medications remain Zoloft, folic acid, metoprolol ¹⁰¹ , Protonix ¹⁰² , lactulose, and aldactone. Possible discharge Sunday after seen by doctor.
(b)(6); (b)(7)(C)		
September 17, 2017 2:32 a.m.		At about 1:00 a.m. patient coded and is now critical and has been moved to ICU, room 36. He is on life support and is intubated with agonal ¹⁰³ breathing. When able to get a blood pressure, it is in the 50s by palpation ¹⁰⁴ . Hemoglobin is 5. Blood being given. Warden Stacks has notified ICE personnel Simpson.

On September 20, 2017 the State of Texas issued a Certificate of Death which listed the cause of death as “pending”.

APPENDIX I

Vital Signs

DATE	TEMPERATURE	PULSE	RESPIRATIONS	BLOOD PRESSURE	Oxygen
September 8, 2017	97.0	98	14	180/109	98
				164/100	
				152/86	
September 11, 2017	97.5	106	18	151/95	100

APPENDIX II


¹⁰¹ Metoprolol is a beta-blocker to treat high blood pressure.

¹⁰² Protonix is a treatment for GERD.

¹⁰³ Agonal breathing is abnormal respirations characterized by gasping, and labored breathing.

¹⁰⁴ Palpation is a method of examining the body using the hands.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



American Heart Association Blood Pressure Parameter

Blood Pressure Category	Systolic (Upper number)		Diastolic (Lower number)
Normal Blood Pressure	Less than 120	and	Less than 80
Prehypertension	120-139	or	80-89
Stage One Hypertension	140-159	or	90-99
Stage Two Hypertension	160 or higher	or	100 or higher
Hypertension Crisis	Higher than 180	or	Higher than 110

CONCLUSIONS


Medical Compliance Findings

Medical Care, Section (III)(D), which states, “Non-English speaking detainees and detainees who are deaf or hard of hearing will be provided interpretation or translation services or other assistance as needed for medical care activities. Language assistance may be provided by another staff member competent in the language or by a professional service, such as a telephone translation service.”

- During the intake screening (b)(6); (b)(7)(C) stated ALMAZAN spoke English and therefore did not require language assistance. During interview, however (b)(6); (b)(7)(C) stated he “spoke very little English” but that an unidentified medical person provided interpretation. There was no documentation to substantiate this. (b)(6); (b)(7)(C) Intake Detention Officer recalled detainee ALMAZAN only spoke Spanish, requiring another intake officer to provide language assistance. (b)(6); (b)(7)(C) Detention Officer who was working in the detainee’s unit, also stated detainee ALMAZAN spoke no English and required interpretation assistance. There is no telephone access in the medical intake area.

Medical Care, Section (III)(D), which states, “Medical and mental health interviews and examinations shall be conducted in settings that respect detainees’ privacy.”

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
 Medical and Security Compliance Review
 December 4-5, 2017



- Curtain dividers and ceiling-mounted acoustic boards do not fully protect a detainee's privacy to fully and comfortably discuss sensitive medical information.

Medical Care, Section (III)(D), which states, "The clinical medical authority shall be responsible for review of all health screening forms within 24 hours or next business day to assess the priority for treatment (for example Urgent, Today, or Routine).

- The intake screen does not include a signature of review by the clinical medical authority. Of note, the evening detainee ALMAZAN was transferred to the hospital was the first business day for that review.

Medical Care, Section (III)(B), which states, "Health care personnel perform duties for which they are credentialed by training, licensure, certification, job descriptions, and/or written standing or direct orders by personnel authorized by law to give such orders."

- A seriously elevated blood pressure of 180/102 was not reported to a provider in accordance with MTC's Nursing Protocols. Additionally, regular blood pressure monitoring was not done during the three days detainee ALMAZAN was detained at PCADC.

Areas of Concern

- Sick call forms and deposit boxes are inconveniently placed in the hallway outside the locked unit. Detainees reported they access them when they go to recreation and after completion, hold them to the window when the officer passes by doing rounds. The officer then takes the request and deposits it in the locked box. This practice does not protect the privacy and confidentiality of the detainees. Detainee ALMAZAN did not request a sick call appointment during his detention.


Safety and Security Compliance Findings

Creative Corrections cites the following deficiencies in relevant components of facility policies and post orders.

Dorm Officer Post Orders, section III 8. Post Activity Log Entries requires unusual incidents to be recorded in the log.

- The medical emergency called to the detainee's dorm and the response of both security and medical staff was not logged.


DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



Stationary Guard Medical Officer Post Orders, section II, 9.B requires the assigned officer to maintain a daily log of activities to include visits by physicians, nurses, room attendants, and any other relevant information.

- Assigned vigil officers did not log the visit by two deportation officers to detainee ALMAZAN while he was hospitalized.

DETAINEE DEATH REVIEW: Filipe ALMAZAN-Ruiz
Medical and Security Compliance Review
December 4-5, 2017



From: (b)(6); (b)(7)(C)
Sent: 27 Dec 2017 09:22:42 -0500
To: (b)(6); (b)(7)(C)
Subject: FW: Almazan - Prelim findings

From: (b)(6); (b)(7)(C)
Sent: Friday, December 22, 2017 12:21 PM
To: (b)(6); (b)(7)(C)
Subject: Almazan - Prelim findings

- Almazan's serious medical conditions were omitted from his transfer summary for his transfer from KNSPC to GCDC, and copies of his abnormal laboratory reports and chronic care clinics did not accompany the transfer summary.
- KNSPC did not place a medical hold on Almazan pending his evaluation and treatment by a hematology specialist.
- KNSPC medical staff conducted at least two sick call encounters in English without the use of an interpreter or interpretation line.
- KNSPC medical staff did not completed a medical alert form for Almazan's diagnoses of two chronic diseases.

From: (b)(6); (b)(7)(C)
Sent: 29 Aug 2018 11:47:29 +0000
To: (b)(6); (b)(7)(C)
Cc:
Subject: ALMAZAN

(b)(6);
(b)(7)(C)

I'm hoping we don't have too many more questions, but I have a few below:

- Was it your understanding that (b)(6); (b)(7)(C) gave him BP medication between the first and second check, or once before the second and once before the third?
 - And do we know for sure she gave him his missed dose of Spironolactone as the medication? I didn't see that anywhere, but I may have missed that.
- Did we get the nursing protocol for BP for Polk, I don't have it in my documents? We wrote up, "Creative Corrections notes MTC nursing protocol requires provider contact after a blood pressure reading of 160/100 or higher". Would you say this is correct?
- PA Young states that (b)(6); (b)(7)(C) should have contacted him about the high BP considering ALMAZAN had been diagnosed with cirrhosis and possible portal hypertension, but the transfer summary does not list portal hypertension at all. Should (b)(6); (b)(7)(C) have known there was a likelihood of portal hypertension? This will help me reword this.

Thank you and I hope you are enjoying the California weather! 😊

(b)(6); (b)(7)(C)

Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW (b)(6); (b)(7)(C)
Washington, DC 20536
202-732-(b)(6); (desk)
202-253-(b)(7)(C) (cell)

From: (b)(6); (b)(7)(C)
Sent: 15 Nov 2017 19:37:55 +0000
To: (b)(6); (b)(7)(C)
(b)(6); (b)(7)(C)
Cc: (b)(6); (b)(7)(C)
Subject: ALMAZAN

Passwor (b)(6); (b)(7)(C)

(b)(6); (b)(7)(C)

Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW (b)(6); (b)(7)(C)
Washington, DC 20536
202-732-(b)(6); (b)(7)(C) desk)
202-253-(b)(7)(C) cell)

From: (b)(6); (b)(7)(C)
Sent: 17 Oct 2017 15:54:06 +0000
To: (b)(6); (b)(7)(C)
Subject: ALMAZAN

Here are the A numbers for the cell mates –


(b)(6); (b)(7)(C)

(b)(6); (b)(7)(C)

Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW (b)(6); (b)(7)(C)
Washington, DC 20536
202-737-(b)(6); (b)(7)(C) (desk)
202-253-(b)(6); (b)(7)(C) (cell)

Glades County Detention Center

(b)(6), (b)(7)(C)



Not ACA cert

NCCHC ✓


Pay trustee \$1 a day

NDS

Sherriff's office - Sworn Deputies

housing
2 main areas
housing 318 beds
4 ext. rec fields
excl. ICE

try not to
co-mingle A



Personnel in kitchen?

Using a tablet system

- Commissary
- Video visitation
- Educational programs
- movies
- texts, correspondences
email

- Grievances } Paper
- medical } Paper

- satellite Feed

Initial consult to Intake
Formal full in med.

- Admin office for med.
- US. Marshal / Attorney Room / Med.

Interpret talk in intake - not in room but available.

Med pass done in the housing unit
4 observations - 2 reg. pressure (can do suicide in obs)
Cert. Suicide cell in working area

Dentist ^{sum} 1 to 2 weeks

Name

(b)(6); (b)(7)(C)

Title: LPN

Length: 2 years (Per diem)

Company: Armor

- Give availability from full time off
- Received training/orientation
- Aching bones
- Sick calls picked up evening, done very next day
 - take back to medical (sick call sheet)
 - If emergency seen right away
 - This one was referred to just RN sick call
- Pops up on a task list
- 8/29 she triaged, sick call done 8/30
- eye glass issue addressed? not until 9/2
- 1 complaint per sick call
- Lock box in each dorm

(b)(6), (b)(7)(C)

Name

Title: HSA, CCHP

Length: 11 years - (HSA 4 years)

Company: Amnor

- CCHP = 6

- Britney Jones did intake no CCHP

- Vacancies - 1 LPN night shift

- Never a challenge w/ staffing

- Cat. 4 built facility, boxed up everything & printed summaries.

- Found out a day prior that they needed to get out

- Pharmacy packaged up here, got other meds from the local pharmacy.

- Did they do not do just 1 issue per sick call, all issues can be addressed at 1 time

- Document use of interpatalk w/ detainee name

- Spanish & English consent form

- When intake screen done - asks yes to understood english

- Lab process, use IR2. (Draw labs, package in cooler, fedex picks up & goes to laboratory for results) Quick turn around.

- 19 day delay from when labs were reviewed and when they were signed off on. → Clarification: collection date was 9/17

* Need to see documentation of when doctor reviewed!

- Did not know him

- Optometry - some one comes on site. Sub contractor

• If urgent can send off site

- Referral put in, next day left.

- FMC

(b)(6), (b)(7)(C)

Name: (b)(6); (b)(7)(C)

Title: Doctor - MD

Length: 9 years

Company: Armor

- Fluent in Spanish

- 8/14: suspicious of Portal Hypertension after he said cirrhosis
wasn't suspicious of varices.

Did not know about the pancytopenia

- Would have kept him here if he was only transferring ~~to~~ do it wouldn't have sent

- Palm West 35 min, Hendry 15 min - Hospitals

- Not a good idea to fly

- Not sure if the problem list shows up, but it should have been on transfer form

- Think it was alcohol related cirrhosis, not Hep virus

- Ammonia level can take a while to get

- If see platelet level below 30s get to hospital

Name: [redacted] (b)(6), (b)(7)(C)

Title: RN, DON

Length: Per diem OCT, Apr. DON

Company: Armor

- Sign off on Sick Call to ensure they are doing it correct, (LPN)
- Nursing protocols are signed off on by MD
- LPNs supervised by DON
- Transfer summary - pull chart, fill in summary appropriately
Diagnoses should come up automatically on transfer form.
Meds. too

Name: [redacted] (b)(6), (b)(7)(C)

Title: LPN, CCHP

Length: 10 years

Company: Armor

- 8:30, 2:30pm: pain in both knees & shoulders
- says he spoke english
- Have done sick call since she started
- Received training at orientation, DON checks in
- Nursing protocol - pain: mild, mod., severe
tells you what to do next
- Doesn't recall wanting eye glasses
- Remembers him b/c he was a kitchen trustee.

Name: (b)(6); (b)(7)(C)

Title: Clinical MHA Counselor

Length: Apr. 2017 - PT

Company: Armor

- 12-16 hrs a week
- 8112 encounter - believes it was conducted in English even though she is a Spanish speaker
- Remembers he spoke about chlamydia
- Do not recall if transfer forms came w/ him
- Initial MHA Consent form would have been given in English translated to Spanish then signed

(b)(6); (b)(7)(C)

Name:

Title: Sgt

Length: 10.5 year

Company: Glades County Sheriff

- Booking clerk started when went through academy
- Ft. Meyer training academy
- End of April promoted to Sgt.
- Remembers he was quite respectful
- If someone doesn't speak Spanish, ex. Russian, try to find another detainee who speaks it
- Dress them, go through property
- Classification based on 216
- Inventory property - even if a transfer
- Comes in a reel bag, put in a box and kept in a room
- Check comes in, get a receipt, drop the check in the box.

Name: (b)(6), (b)(7)(C)

Title: Correction Dep-Jh.

Length: July 2017 - worked in prison 2005, did Security for a bit, then
Came here

- Sponsored to go through academy
- Work lead
- Assigned to housing 1, then 2, now ~~intake~~ booking
- Took his picture
- Doesn't remember him
- Dressed him out
- Determine ~~classification~~ classification by 216.

Name: (b)(6), (b)(7)(C)

Title: LPN

Length: 8 months

Company: Armor

- said if she did the intake then she did intake
- If he verbalize that they understand then that's all they need to do
- Doesn't use interpretive much - only 1 or 2 x a week
- Didn't recognize that his vision being bad was an issue of communicate

would
not
use
interpretive

Name: (b)(6); (b)(7)(C)

Title: LPN

Length: March 2017

Company: Armor

- Aug 16: seen 8118
 - Electronically submitted to be scheduled
 - Should see the request w/in 48 hrs of request, seen by 24hrs
- Aug 20: sick call
possible nurse who saw sick call request knew he was having an exam

Name: (b)(6); (b)(7)(C)

Title: LPN

Length: 5 months

Company: Armor

- Recalls him but just his face.
- Gave meds
- Sick call 9/1
- Would not consider him fluent in english
- Believes he could understand what was being said to him in English.
- Will look at computer to see if he had

Name

(b)(6), (b)(7)(C)

Title RN

Length 4 years

Company Armor

- Remembers him, friendly.
- Initial health assessment 8/24. did eye exam
- Referred to physician, not sure how long it should take
- Says he spoke English very well, didn't use language line
- Spoke w/ him a lot (?)
- Ask detainee about dental & does a view of the mouth, and initial dental assessment.

A

Name:

(b)(6), (b)(7)(C)

Title: LPN

Length: 6 months

Company: Armor

- since call 9/2
- recalls him from the visit
- all referred to MD then does the referral for optometrist
- Used nursing protocol
- Not sure, but believes there are reading glasses in the commissary.
- Do not know if they contacted Krome about new glasses

(b)(6); (b)(7)(C)

- VP Armor

- Is there a way to get glasses/readers? Not sure. Could get from family but didn't apply in this case.

- Transfer sheet? Lactulose was not on bc ordered day he transferred Xifaxin - had been on while, not sure why it wouldn't have been on the transfer form.

Multi-Vitamin wasn't in either

Diagnoses - Thrombocytopenia wasn't in bc when it was entered in the system.

- Does facility just stop med notes after someone leaves facility? Yes

Asking about cirrhosis of liver w/o ascites then cirrhosis of liver w/o alcohol? Not sure how that happened if ~~was~~ is a manual entry. Wouldn't have pulled from them checking no alcohol use.

Glades medication

8/12 Clotrimazole
Xifaxan

8/13 Xifaxan
Clomtrimazole

8/14 Xi faxan

8/15 Lactulose
Folic acid
Hydrocortisone
Xifaxan
trimcinolone

IAH - Visit 10/17 - , 2017

Arrived @ Polk 9/8/17 from Folkston

- Med. Intake (immediate health service referral for Dep., Anx., Cirrhosis) 2330
- Consent for medication in Spanish - signed
- Chest Xray
- Continue meds from previous facility - ordered by TSA & PAC

9/11/17

- mental health assessment done - R. Jefferson

9/11/17

- Brought to med from dorm for vomiting blood.
- Transferred to hospital by van - per R. Jefferson Young (1757 9/11)
- NWSU note @ 1945 (as time reported)
- Detainee admitted to hospital and van returns
- Admission date 9/12

9/12/17

- Moved from CHI St. Lukes to Conroe Regional for treatment via ambulance @ 6:45, arrive to Conroe @ 8:13

Daily hospital updates given.

9/15/17

- moved from ICU to Med Surg.

9/16/17

- noted doing better, possible discharge following day

9/18/17

- 1:00 coded, critical moved to ICU. On life support.
- Time of death 5:15 am


- ICE Blue Inge Red
- Marshals White or Striped

Dorms (24 or 8) → Windows in
↓
outside inside

Mexico - Cent. Amer → few from South America

5 days of vomiting → officer & roommate
Reas activity morning, outside afternoon

C-20



10/17/17

HSA, RN

April 16 - Sept 16 (HOA)

MTC

- Policies from PB NDS 2011 → facility in NDS
- Pablo Splenser ~~member~~ Clinical Director → been here 10 years
- Psych - Dr. Erika Spice good used by telephone (Telemed) through MTC
- If need telepsych just call her.
- Very good, quick
- PAC → has a CMTC → comes M T Th 6-7 pm
- seeing chronic care, sick call
- He reviews labs, exams (also Dr. Splenser)
- Nurse coverage 12 hrs shift. Always a nurse here. There a times when there is an LPN w/ an RN.
- 1 med. record staff
- No vacancies (layoffs in July)
- Used Kingwood hospital (toward Houston)
- EMS good
- Livingston hospital nearby.
- Speak little spanish
- 1 speaks spanish RN - Does intake screening
- Use a language line
- 1 neg pressure cell (for TB) - Chicken Pox / Shingles
- 4 med. observation
- 1 suicide call
- No one knew he was vomiting blood
- Detainers come to pill window
- Instructed on strike call 2020-10-17-00006.2661

(b)(6); (b)(7)(C)

continue

- Funds done by supervisor
- Finger print detainees
- Get phone cards - \$10 a card (Horton)
- Can order commissary over phone (Morris)

Name


(b)(6); (b)(7)(C)

Title - RN, DON
Length - 14 months
Company - MTC

- ACA accredited, was here for last accreditation 1/23/17
- Not NCCHC certified
- 12 hr shifts, 2 PRN positions
- No vacancies
- Nurses fairly easy to recruit
- Nurses feel comfortable calling provider after hours
- PA & Dr both involved (PA = minor, Dr = more serious)
- Transfer Summary, Medications, Property
 - * Have medications at time of intake
 - * Match up med. bottles & transfer summary
 - * 2 med. ordered & 1 increased at other facility and did not know
- Will call other facilities to clarify
- If received lab work, would have gone into chart
- Medical personnel was translating - Rosa Martinez & Villarreal - in clinic can do language line, in clinic have access.
- He said he had not had medicine. Rechecked BP
Had not had BP med, received it at intake
- Told her he had been in (alcohol) rehab 3 mon. prior

(b)(6); (b)(7)(C)

Name:



TITLE: RAID Sup

length: 9 1/2 years

Company: MTC

- started as Det. Officer
- 40 hrs Pre service and ~~OST~~ started at intake moved up
- Vaguely remembers detainees
- Turned property over on 9/18/17 & given to Bennett
- Was told to not touch the property until they knew what they were doing - roughly 28 detainees stayed there
- property from there inventoried & stored there
- Some detainees did have accounts open
- Did not sign property form (on him) b/c he went straight to medical
- Pull off bus, take money, over see everything
- Had extra staff for this surge.
- Buses came from Airport
- C-20 & C-1 one for medical units
- No other contact w/ Amazon

(b)(6); (b)(7)(C)

Name:

TRW: Sgt.

Length: 1.5 year

Company: MTC

- Started as officer, made Sgt 4-5 months.
- Worked at TX Death Row 8 yrs, some lapse in time btw
- Lt is supervisor
- Lt. Walker → quit
- Working 2-10 then now permanent graveyard
- No contact other than emergency
- Officer called emergency - said blood
- Got him to hospital
- Went the next day to hospital, no more vigils after that from him
- He said it was blood he vomited
- Followed down to medical, once he saw Dr. Hanks and said he needed to go to hospital got officers to take him. Only select few are weapons certified
- Went to Livingston first, then transported him to Conroe by ambulance. Officer rode w/ in ambulance, he drove van.
- Did not get up off bed for the bathroom ~~with~~
- ~~the~~ Nurse did have to help him.
- Had 2 IVs
- Very cooperative.
- Surprised he died
- EPA offered to officers that were there when he died

(b)(6); (b)(7)(C)

Name:

Title: LVN

length: 1 year

Company: MTC

- Part time, 24 a week

- Came in that day to finish paper work. (b)(6); (b)(7)(C) was the nurse
one, that is why ~~she~~ only she filled out anything.

- Wheeled him to medical

- Wanted blood drawn, but when he decided to send to
hospital canceled the blood draw

- PUMAZAN was able to get up and down from chair & wheel
chair.

- Nothing seemed like he needed emergency transport

- Translator used - possibly Martiney (possibly got the record as well)

- Took vitals, very calm

- Remembers him from Intake - may have ~~been~~ ^{taken} BP again

* Sick logs from
Glades → reach to
POC on those (push back)

10/18/17

* IHSC - Chief [redacted] took him off
original move to Glade 9/13
no stray

Name: [redacted]

Title: FMC → started 9/5/17

Company: IHSC

- If needed will talk to Cmsr. [redacted]
- Wasn't aware of him until he went to the ER
- Only receive a 216 (name) before hand
- Get the transfer form
- Trying to figure out how DON had varicies
- ICE has top priority on movement. Doesn't believe he was on a medical hold.
- Chemical stress test
- Doesn't know why he went from Krome to Glades
- Need to get more better on transfer of medical doc.
- Less than a day at Folkston
- Medicine for BP given a 5am, not at intake
- Facility is NDS → going to PBNDS 2011 (possibly)

[redacted]

6000

- Took us to the property
- Told to keep until this was done

Disposition of property

10/18/17

A# (b)(6); (b)(7)(C)
Name (b)(6); (b)(7)(C)

- Didn't talk much
- Never eat much, tried to encourage him to eat
- Walked very slow
- Witnessed him vomiting blood
- Seemed sick when arrived
- Seemed like he wanted to die, very sad, sleep all day
- Didn't verbally say he was depressed
- Didn't drink much.
- Walked to pill window, slow, then straight back to bed
- Would not talk to nurse at pill window
- 3-4 x of vomiting, last one was blood
- ~~Area~~ Didn't talk to anyone
- Knows can get forms and put on window for sick call
- Response was really fast from security & medical

10/18/17

A#: (b)(6); (b)(7)(C)

Name: (b)(6); (b)(7)(C)

- Tried to talk to him about health
- Tried to help him eat more
- Tried to get him out to yard but wouldn't go
- Noticed ^{vomit} blood (other roommate saw)
- Wouldn't eat much, a few bites that's it. Would drink some water
- Tried to talk to him about family, take a little then wanted to go to sleep
- Knows how to get form and let them know, ^{get it going to yard or call guard to get.}
-

Name: (b)(6); (b)(7)(C)

Title: Detention Officer now Sgt

Length: 7.5 years

Company: MTC

- No Detention experience before
- No Contact prior
- Didn't respond to the alarm
- Just happened to be the one on for transportation.
- Weapon Certified
- Health had weapon at Livingston Hospital
- Helped him in van
- Didn't speak on drive
- Cooperative
- Hospital had trouble getting an IV in.
- Hospital brought a wheel chair to get him out of van
- Worked next day at hospital in Conroe
- In ICU on that day
- Says he spoke English
- Didn't get up to use restroom
- Would ~~let~~ some

Name:

(b)(6); (b)(7)(C)

Title: Detention Officer

Length: 9 years +

Company: MTC

* Did not speak English

- No contact before hospital
- 2-10 Shift, rotate posts
- Only went to the hospital on 9/16, arrived at 6:10pm
- Relieved GARTH WARE & BARNES
- Howell had weapon
- Didn't speak w/ him b/c he doesn't speak Spanish
- Wanted water, he didn't do it had nurse do it.
- He started yelling, wanted urinal, got gloves gave it to him
- Needed to go to the bathroom, asked to take off hand cuffs, tried to get out of bed. Pressed nurse button
- Nurse came in, he asked for medicine, said lower abdomen hurt.
- Nurse gave him medicine by IV. He got drowsy, started to fall asleep. He goes out to where Officer Howell was.
- 30-45 min pass, he is yelling that he was hurting
- Started trying to get hand cuffs off
- Switched w/ Howell w/ the weapon
- Heard nurse call code Blue
- Howell was in room w/ KUMAZAN when everything happened
- Detainee no longer awake or responsive
- Moved to CCU, a lot of staff going in and out
- Was told by nurse to contact next of kin
- Was told he went into cardiac arrest 3x
- Last time they worked on him for around 20 minutes
- After detainee died contacted Warden Stokes, told to stay until relieved

- Glades med. contractor Armor Correctional Health Care


Pod A (30 bunks)
60 beds

Building 8 - 1, 2, 3 bottom
4, 5, 6 upper

5

1 officer
each pod

TV on wall
TV from ceiling
2 Camera above door
2 others in pod
Cameras



Talk to AOC about sitting w/ us to go over his
wear abouts Start to Glades (Why to Glades?)

Pod 4,
Pod 5,
Pod 6, Bunk 34

(b)(6); (b)(7)(C)

Name: [Redacted]

Title: RN

Length: May 2017

Company: IHSC -

- Sick call July 16 3:34 pm
- Unspecified skin issue
- Omitted the physical exam of skin (per witness)
- Would have examined skin if given treatment

(b)(6); (b)(7)(C)

Name: [Redacted] (LT)

Title: RN

Length: 2013 ^{contractor}, 2015 PHS

Company: PHS

- Pre-screen speak to the detainees one-on-one - Ask a lot of questions regarding potential health & security threats
- If you notice struggling language use interpreter
- Done where interpretation line service available
- Transfer summaries come w/ them
- If he came from a jail need have a transfer summary
- Priority 2 status - needs a medical provider w/in 24 hours ~ scheduled at intake
- Intake sometimes the detainees will say they are not on medications.

Name: (b)(6); (b)(7)(C) (LT, CMD)

Title: NP

Length: 8 years

Company: PHS

- Looks familiar
- Used interpretation service, ask if they speak english if they say no or a little use language line.
- It has happened that she does not receive transfer summaries
- Doesn't remember if he came straight from metro west
- Seen transfer summaries on post from metro west
- Don't remember if he said he drinks a lot to try to kill self
- Would have to be sent out to see ophthalmologist, can take a couple weeks to get an appointment
- Administrator ~~schedules~~ ^{schedules} appointments - (b)(6); (b)(7)(C)
- Mental Health referral is in house
- Abdominal exam - does not remember exam on this particular detainee
- 8/9 - follow up for abnormal lab results. Did not use language line
- PA Mederos - Perez - if he was off would see patient
- Was skin issues due to chiroisis - not sure?
- Put in for an U/S (takes a couple weeks)
- Ordered a hematology consult
- ~~Janet~~ Janell would be monitoring the time frame of patients seeing specialists
- Cannot recall if a Medical hold on PUMAZIAN
- Medical transfers done by RNs - can pull up ECW to see all diagnosis to put on medical transfer summary

(b)(6); (b)(7)(C)

Name:

Title: tSA, CPT


Length: 2007

Company: PHS

- 5 vacancies - down to nurses & also radiology techs
- Other unit shut down - now ~~absorbed~~ & they have them
- Hematology referrals are hard to get
- Not sure why U/S was hard to get
- Ophthalmology 30 days - not excessive
- Depends on who is approving referrals is how fast
- Referrals do not transfer w/ them - next facility would have to start from scratch
- Do not know if he was on a medical hold
- Nurses trained on how to do a transfer summary
 - Templates are in computer - populates it
- eCW sign off time is not accurate
- Review signature - not sure why it says that
- Action - for detainee ex. Nurse to do EKG
- If doctor wants a follow up it will just be scheduled not as an action
- Have a lot of issues w/ eCW
- Nurse puts in referral, the provider will see and schedule
- Go to unit and announce sick call
- Keep a log, a section for what compliant
- Expected that staff went to school, should know disease processes
- Mid level providers are the ones who really should know disease processes

(b)(6); (b)(7)(C)

Name:



Title: LCDR RN

Length: 2010

Company: PHS (2013)

- July 24 2017 - sick call refusal

- Sick call done 8-3p

- Someone does sick call 8 - Pod 1-3, 4-6

- Outside buildings done by someone else

- In dorms. call each ^{Pod} individually

- Day shift nurse makes note of left overs go to Pod and call out individually

- Desk officer in Medical

- Spill over isn't often

- Complaint is not on the spill over list

- Refusal decision made when calling for it multiple times and doesn't show up

- 7/26 encounter was not a reschedule of the missed sick call

- Will continue to monitor if that she keeps calling to see if they want to come.

(b)(6), (b)(7)(C)

Name:

Title: Security Officer

Length: 5 y 9mo

Company: AKA1

- Normal post processing 4
- ~~PA~~ Did the interview w/ Detainee Almazan
- Interview one at a time
- Gets another officer that speaks Spanish to help.
- He gives uniform based on Classification. Search them.
Sign for uniforms & property.
- Ask for a forwarding address for any property that is left behind - He did not provide one.
- Came at 1700 - have him for a couple hours then Medical would get them
- Do not always get a list ahead of time.
- Processing 1 or 2 would do photo
- Property intake is done by Property Officer - values & cash too.
- Don't assign bunkos
- Med intake done in Intake
- ~~Processing 3 would do~~ JPAT would have out processed
- Shouldn't have sat for 2 hours

(b)(6); (b)(7)(C)

Name

Title: LT

Length: 2.5 y

Company: Akal

- Came w/ AGS, got promoted to Akal
- Work transportation
- Receiving LT that detainee
- Recognize him
- Come and ask information of detainees.
- Had just come in to duty port
- Not possible that he was sitting from Pre-screen to intake for 2 hours.
- His part is "Processing" not intake
- Supervisor reviews checklist and signs off on it

(b)(6); (b)(7)(C)

From

- Transfer Summary Metro West?
- Picked up at probation office by FUG OPs
- = Move out due to room and if not ready to be sent home. Krome is a staging facility to send out.
- Folkston would have had the information on how he got to Polk

(b)(6), (b)(7)(C)

Name

Title: RA

length: 1 year +

Company: ~~Green~~

- Does not remember him
- Speaks english is pre-populated
- Described itchiness over entire body
- When you go into eCW can look at problem list
- Would you know the connection btw chinross & itchiness? No
- Should have documented that there was an issue w/
his eyes if prescribed an eye drop.

(b)(6); (b)(7)(C)

Name -

Title - Psychologist

Length - 3 year

Company - STC, Int.

- Speaks Spanish, did not evaluate if he spoke Spanish
- Mentioned Chirosts
- Alcohol abuse uncomplicated - b/c no withdrawal issues b/c had not been drinking for 3 months
- Saw An Binder
- Typical that it took 2 weeks, if needed sooner would have made note
- Can diagnosis, did for depression - would go on to the next facility

Name:

(b)(6); (b)(7)(C)

TRF: Family Dr

Length: 4.5 year

Company: STG

- Lab review 814
- Explain ~ has cirrhosis, had Hep B (?), platelets can be low, ALT, AST go up.
- Platelet was 37, very low, risk of uncontrolled bleeding
- Complaints of nose bleeds, don't know if it is controlled
- If everything controlled it's ok that it took time to get specialist
- Should all of this information have gone to the other facility. Should have been on the transfer form
- Transfer form was lacking important info
- Diagnoses should have been active and that's why those didn't show on transfer summary
- Medical hold could have been placed.
- Asepsis can just come up.

(b)(6); (b)(7)(C)

Name:

Title: MD FS ^{→ P10} ^{surge} Clinical Director

Length: 7/5/11

Company: PHS

- Patient low RBC, WBC, Platelet
- Del at risk for bleeding
- Probably been going for years
- Had referral to hematology, never went due to being transferred.
- Urgent tests would have been sent to ER
- Would have still cleared him to fly
- His conditions should have been on the ~~form~~ Transfer summary
- He would have put the Panecitapina
- Although ~ problem list should list chronic issues
- Labs are not included in transfer summary
- 100% compliance rate
- With consult pending maybe a med. hold but hard to say. Should have stayed to get consults.
- Gladys will not take a patient if they can't handle one.
- Med Provider can put a patient on a hold
- He schedules his own staff.
- Actions are to notify other staff members of what to do.
- ~~Telephone encounter~~ Amendments to a note will show.
- Time stamps ~ should be what the time zone they are in. MST must have been a glitch.
- Nurses know they should stay w/in their scope.

Name:

(b)(6), (b)(7)(C)

Title: RN

Length: 1 Year

Company: Engenisis

- 10 engineer contractors left
- Intake
- If he came from another facility he would have had a med. summary.
- e CW would have it, should have been scanned in
- Used interruption
- Does not recall him having glasses w/ him
- Did not mention that he drank to die.
- Trained to see alcohol/drawl
- Abnormal intake based on cirrhosis
- Only came in w/ Zoloft

(b)(6); (b)(7)(C)

Name

Title: NP

Length: 6-year

Company: STG

- 8/4 - (b)(6); (b)(7)(C) asked her to see (b)(6); (b)(7)(C), NP

- Speaks Spanish

- Told he was exposed to Hep B

- Said he was on meds that he didn't tell the NP. He knows the meds well.

- Said he had been taken Ritonavir 6-7 years

- Hep B - had a history

- Discontinued Aspirin

- Had no active bleeding

- Did not check on referrals

- Didn't ~~feel~~ feel he was critical

- Hemoglobin of 9 would be sent to hospital

- Platelet was critical (change in thought?)

- Med hold should have been placed.

(b)(6); (b)(7)(C)

Name:

Title: RN

Length: 10.5 year

Company: STG, Int.

- 7/27: Late entry noted (Due to having too much sick call date)
 - ~~Not filling in to sick at the same time~~
 - Documentation done after sick call
 - If a complaint to something not able to address send to provider. Can go back into record to see if provider has seen it.
- Doesn't speak ~~English~~ Spanish, did not use interpretation line.
- Would use RN protocol for sore throat.
 - If checked throat, would have documented findings
- Only encounter said no findings on throat but told him to gargle w/ salt water
- Doesn't remember if he seemed sick

From: (b)(6); (b)(7)(C)
Sent: 4 Oct 2018 17:34:00 +0000
To: (b)(6); (b)(7)(C)
Subject: ALMAZAN - Polk Questions

(b)(6); (b)(7)(C)

I am really hoping this is it for ALMAZAN 😊. Just two questions below:

- During intake to Polk he reported significant alcohol abuse and for the first time exhibited tremors. Is that unusual that he had tremors and this was the first time it's reported?
- How did Polk know to do the taper on the steroid if they didn't that on the transfer summary? Did they have the medication labels or was it because it is common practice? I believe they did not have his medicines, since we found them in his property.

(b)(6); (b)(7)(C)

Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW, 1 Floor
Washington, DC 20536
202-732-(b)(6); (b)(7)(C) (desk)
202-253-(b)(6); (b)(7)(C) (cell)

From: (b)(6); (b)(7)(C)
Sent: 7 Aug 2018 13:41:37 +0000
To: (b)(6); (b)(7)(C)
Subject: ALMAZAN Glades Medical Intake

Hi Joyce,

I am searching everywhere for the medical intake screening at Glades for ALMAZAN. I know we have it but for some reason in my file it's missing. Could you send me a copy of yours? Thank you!!

(b)(6); (b)(7)(C)

Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW; 1 (b)(6); (b)(7)(C)
Washington, DC 20536
202-732-(b)(6); (b)(7)(C) desk)
202-253-(b)(7)(C) cell)

From: (b)(6); (b)(7)(C)
Sent: 18 Sep 2018 20:34:04 +0000
To: (b)(6); (b)(7)(C)
Subject: RE: logged on

Signing off.

Worked on (b)(6); (b)(7)(C) and ALMAZAN. Also administrative COR work.

(b)(6); (b)(7)(C)

Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW (b)(6); (b)(7)(C)
Washington, DC 20536
202-732-(b)(6); (b)(7)(C) desk
202-253-(b)(6); (b)(7)(C) cell

From: (b)(6); (b)(7)(C)
Sent: Tuesday, September 18, 2018 3:48 PM
To: (b)(6); (b)(7)(C)
Subject: RE: logged on

Back on.

(b)(6); (b)(7)(C)

Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW (b)(6); (b)(7)(C)
Washington, DC 20536
202-732-(b)(6); (b)(7)(C) desk
202-253-(b)(6); (b)(7)(C) cell

From: (b)(6); (b)(7)(C)
Sent: Tuesday, September 18, 2018 2:08 PM
To: (b)(6); (b)(7)(C)
Subject: RE: logged on

Going to my doctors appointment

(b)(6); (b)(7)(C)

Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW; (b)(6); (b)(7)(C)
Washington, DC 20536
202-732-(b)(6); (b)(7)(C) desk
202-253-(b)(6); (b)(7)(C) cell

From (b)(6); (b)(7)(C)

Sent: Tuesday, September 18, 2018 6:58 AM

To (b)(6); (b)(7)(C)

Subject: logged on

From: (b)(6); (b)(7)(C)
Sent: 13 Oct 2017 11:21:07 -0400
To: (b)(6); (b)(7)(C)
Cc:
Subject: RE: OPR Interviews -IAH

Thank you!

Sent with BlackBerry Work
(www.blackberry.com)

From: (b)(6); (b)(7)(C)
Date: Friday, Oct 13, 2017, 11:18 AM
To: (b)(6); (b)(7)(C)
Cc:
Subject: FW: OPR Interviews -IAH

FYSA-Change in interview times as requested.

(b)(6); (b)(7)(C)
Supervisory Detention and Deportation Officer
COR/Exotic/ERA
500 Hilbig Road
Conroe, Texas 77301
863-87(b)(6);

From: (b)(6); (b)(7)(C)
Sent: Friday, October 13, 2017 10:17 AM
To: (b)(6); (b)(7)(C)
Cc:
Subject: FW: OPR Interviews -IAH

FYI. In regard to the OPR interviews.

Sent with BlackBerry Work
(www.blackberry.com)

From: IAH MDM <iah.mdm@icloud.com>
Date: Friday, Oct 13, 2017, 10:15 AM
To: (b)(6); (b)(7)(C)
Cc: (b)(6); (b)(7)(C)
Subject: OPR interviews -IAH

(b)(6); (b)(7)(C)

Be advised I have changed and set up, at OPR's request, a new interview time and date for Officer (b)(6); (b)(7)(C)
(b)(6); (b)(7)(C)

The two officers will be at the front lobby conference room on the date of 10-18-17. Office (b)(6); (b)(7)(C) will interview at 3:00 p.m. and Officer (b)(6); (b)(7)(C) will interview at 4:00 p.m.

(b)(6);
(b)(7)(C)

Sent from my iPhone

From: (b)(6); (b)(7)(C)
Sent: 5 Oct 2017 13:12:50 -0400
To: (b)(6); (b)(7)(C)
Cc:
Subject: RE: Polk County Jail

Thank you for the update! Looks like we are rescheduling for the second week of November.

R/

(b)(6); (b)(7)(C)

CDR, USPHS
IHSC Investigations Unit Chief, RN
DHS/ICE/ERO/IHSC
610 W. Ash St., Ste (b)(6); (b)(7)(C)
San Diego, CA 92101
(619) 338- (b)(6); (b)(7)(C) Office
(202) 321- (b)(6); (b)(7)(C) B
(866) 833-7133 Fax (secure)

~~Warning: This document is UNCLASSIFIED//FOR OFFICIAL USE ONLY (U//FOUO). It contains information that may be exempt from public release under the Freedom of Information Act (5 U.S.C. 552). It is to be controlled, stored, handled, transmitted, distributed, and disposed of in accordance with DHS policy relating to FOUO information and is not to be released to the public or other personnel who do not have a valid "need-to-know" without prior approval of an authorized DHS official. No portion of this report should be furnished to the media, either in written or verbal form.~~

From: (b)(6); (b)(7)(C)
Sent: Thursday, October 05, 2017 8:00 AM
To: (b)(6); (b)(7)(C)
Cc:
Subject: RE: Polk County Jail

I confirmed with (b)(6); (b)(7)(C) (copied above), one of the ODO Section Chiefs, and yes their staff is conducting the national detention standards inspection the week of October 29, 2017.

(b)(6); (b)(7)(C)

ICE - OPR
202-423- (b)(6);

- sent with BB, so excuse typos -

From: (b)(6); (b)(7)(C)
Date: Thursday, Oct 05, 2017, 10:33 AM
To: (b)(6); (b)(7)(C)

Cc: (b)(6); (b)(7)(C) >
Subject: RE: Polk County Jail

Ma'am,

Do you know if there is annual inspection scheduled for the last week of October 31 thru November 2nd? We're trying to lessen the impact on the facility.

R/

(b)(6); (b)(7)(C)

(b)(6); (b)(7)(C)

CDR, USPHS
IHSC Investigations Unit Chief, RN
DHS/ICE/ERO/IHSC
610 W. Ash St., Ste. (b)(6); (b)(7)(C)
San Diego, CA 92101
(619) 338 (b)(6); (b)(7)(C) Office
(202) 321 (b)(6); (b)(7)(C) 8B
(866) 833-7133 Fax (secure)

~~Warning: This document is UNCLASSIFIED//FOR OFFICIAL USE ONLY (U//FOUO). It contains information that may be exempt from public release under the Freedom of Information Act (5 U.S.C. 552). It is to be controlled, stored, handled, transmitted, distributed, and disposed of in accordance with DHS policy relating to FOUO information and is not to be released to the public or other personnel who do not have a valid "need-to-know" without prior approval of an authorized DHS official. No portion of this report should be furnished to the media, either in written or verbal form.~~

From: (b)(6); (b)(7)(C)
Sent: Thursday, October 05, 2017 7:31 AM
To: (b)(6); (b)(7)(C)
Cc: (b)(6); (b)(7)(C)
Subject: RE: Polk County Jail

Yes, I overheard the discussion during the DMC Meeting yesterday, so I was expecting an email from you. Thank (b)(6); (b)(7)(C)

(b)(6); (b)(7)(C)

Section Chief
ERAU – OPR – ICE
202-423 (b)(6); (b)(7)(C)

From: (b)(6); (b)(7)(C)
Sent: Thursday, October 05, 2017 10:28 AM
To: (b)(6); (b)(7)(C)

Cc: (b)(6); (b)(7)(C)

Subject: RE: Polk County Jail

Great, thank you! We are trying to reschedule our visit due to funding. We were originally scheduled for next week; however, will possible be on-site the last week of Oct. or early Nov.

R/
(b)(6); (b)(7)(C)

(b)(6); (b)(7)(C)

CDR, USPHS
IHSC Investigations Unit Chief, RN
DHS/ICE/ERO/IHSC
610 W. Ash St., Ste (b)(6);
San Diego, CA 92101
(619) 338 (b)(6);
(202) 321 (b)(7)(C) Office
(866) 833-7133 BB
(866) 833-7133 Fax (secure)

~~Warning: This document is UNCLASSIFIED//FOR OFFICIAL USE ONLY (U//FOUO). It contains information that may be exempt from public release under the Freedom of Information Act (5 U.S.C. 552). It is to be controlled, stored, handled, transmitted, distributed, and disposed of in accordance with DHS policy relating to FOUO information and is not to be released to the public or other personnel who do not have a valid "need-to-know" without prior approval of an authorized DHS official. No portion of this report should be furnished to the media, either in written or verbal form.~~

From: (b)(6); (b)(7)(C)

Sent: Thursday, October 05, 2017 7:16 AM

To: (b)(6); (b)(7)(C)

Cc: (b)(6); (b)(7)(C)

Subject: RE: Polk County Jail

(b)(6);
(b)(7)(C)

Our team is slated to be on-site at Polk County Detention Center for the ALMAZAN DDR the week of October 16, 2017.

(b)(6); (b)(7)(C)

Section Chief
ERAU – OPR – ICE
202-423 (b)(6);

From: (b)(6); (b)(7)(C)

Sent: Thursday, October 05, 2017 10:13 AM

To: (b)(6); (b)(7)(C)

Subject: Polk County Jail

Good morning,

Can you please confirm your dates for the Polk County Jail detainee death review? We'd liked to schedule our on-site review so it doesn't conflict with your dates.

R/

(b)(6); (b)(7)(C)

CDR, USPHS

IHSC Investigations Unit Chief, RN

DHS/ICE/ERO/IHSC

610 W. Ash St.,

San Diego, CA 92101

(619) 338- Office

(202) 321- BB

(866) 833-7133 Fax (secure)

~~Warning: This document is UNCLASSIFIED//FOR OFFICIAL USE ONLY (U//FOUO). It contains information that may be exempt from public release under the Freedom of Information Act (5 U.S.C. 552). It is to be controlled, stored, handled, transmitted, distributed, and disposed of in accordance with DHS policy relating to FOUO information and is not to be released to the public or other personnel who do not have a valid "need-to-know" without prior approval of an authorized DHS official. No portion of this report should be furnished to the media, either in written or verbal form.~~

From: (b)(6); (b)(7)(C)
Sent: 24 Sep 2018 20:29:30 +0000
To: (b)(6); (b)(7)(C)
Subject: RE: signed on

Signing off. I worked on ALMAZAN and (b)(6); (b)(7)(C) as well as COR issuance letter for PREA contract. There is some more information I'll need on that I will get Wednesday. Then you'll sign it 😊

See you tomorrow.

(b)(6); (b)(7)(C)

Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW (b)(6); (b)(7)(C)
Washington, DC 20536
202-732-(b)(6); (b)(7)(C) desk)
202-253-(b)(7)(C) cell)

From: (b)(6); (b)(7)(C)
Sent: Monday, September 24, 2018 7:01 AM
To: (b)(6); (b)(7)(C)
Subject: signed on

From: Walder, Alison L
Sent: 12 Feb 2018 16:20:32 -0500
To: Dennis, Chelsea Y
Subject: Status of DDRs

(b)(5)

Status of FY17 DDRs (re the highlighted deaths, the TLs have all been advised to prioritize writing of these reports when not on travel for PREA or a DDR):

(b)(6); (b)(7)(C) in the final iteration of edits/comments, and will Chelsea will take them upstairs as soon as you sign off.

(b)(6); (b)(7)(C) in the final iteration of edits/comments, and will Chelsea will take them upstairs as soon as you sign off.

(b)(6); currently being drafted by the TL, and should be ready for my review when I return next week.

(b)(6); (b)(7)(C) un-merged SME reports received week of Feb 5 (I've asked Creative to come back to this one once Samimi is finished, time permitting)

(b)(6); (b)(7)(C) un-merged SME reports received week of Feb 5
un-merged SME reports received week of Feb 12
un-merged SME reports received week of Feb 5
un-merged SME reports received week of Feb 5

Status of FY18 DDRs:

(b)(6); (b)(7)(C) Creative report expected March 2, 2017
onsite review scheduled for March 6-8, 2017

From: (b)(6); (b)(7)(C)
To:
Subject: RE: DDR Files
Date: Wednesday, April 11, 2018 9:45:55 PM

Only (b)(6); (b)(7)(C) has been published. Everything else is still pending.

Sent with BlackBerry Work
(www.blackberry.com)

From: (b)(6); (b)(7)(C)
Date: Wednesday, Apr 11, 2018, 5:56 PM
To: (b)(6); (b)(7)(C)
Subject: RE: DDR Files

(b)(6); (b)(7)(C)

I will be preparing the last batch of old DDR files this week for submission. I understand that I should submit anything that has been published. Can you tell me which DDR's have yet to be published? Obviously (b)(6); (b)(7)(C) But have (b)(6); (b)(7)(C) Almazan or (b)(6); (b)(7)(C) been published? Thank you!

From: (b)(6); (b)(7)(C)
Sent: Tuesday, March 27, 2018 2:42 PM
To: (b)(6); (b)(7)(C)
Cc:
Subject: RE: DDR Files

(b)(6); (b)(7)(C)

I hope you had a great trip. Miami was much nicer than the snow they got here in DC ☺

Thank you for the update. This is perfect. If anything changes I will let you know.

(b)(6); (b)(7)(C)

Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW (b)(6); (b)(7)(C)
Washington, DC 20536
202-732- (b)(6); (b)(7)(C) desk
202-253- (b)(6); (b)(7)(C) cell)


From: (b)(6); (b)(7)(C)
Sent: Tuesday, March 27, 2018 2:37 PM
To: (b)(6); (b)(7)(C)
Cc:
Subject: DDR Files

Hell (b)(6); (b)(7)(C)

I hope you are doing well and had an uneventful week in Miami.

I am gathering old DDR files and putting them in folders for mailing to you, similar to how I handled the FOIA request files. These folders will include all materials received prior to the review and while on site, all videos and my working notes. The following files will be sent in the next day or so:

(b)(6); (b)(7)(C)



Please let me know if there are any changes you wish to make to this process. I will email you each time I prepare a shipment. I estimate that I have another 10- 15 files to submit.

Thank you!

From: (b)(6); (b)(7)(C)
To:
Subject: RE: DDR Files
Date: Thursday, April 12, 2018 8:56:29 AM

Thank you!

From: (b)(6); (b)(7)(C)
Sent: Wednesday, April 11, 2018 9:45 PM
To: (b)(6); (b)(7)(C)
Subject: RE: DDR Files

Only (b)(6); (b)(7)(C) has been published. Everything else is still pending.

Sent with BlackBerry Work
(www.blackberry.com)

From: (b)(6); (b)(7)(C)
Date: Wednesday, Apr 11, 2018, 5:56 PM
To: (b)(6); (b)(7)(C)
Subject: RE: DDR Files

(b)(6);
(b)(7)(C)

I will be preparing the last batch of old DDR files this week for submission. I understand that I should submit ~~anything that~~ has been published. Can you tell me which DDR's have yet to be published? Obviously (b)(6); (b)(7)(C). But have (b)(6); (b)(7)(C), Almazan or (b)(6); (b)(7)(C) been published? Thank you!

From: (b)(6); (b)(7)(C)
Sent: Tuesday, March 27, 2018 2:42 PM
To: (b)(6); (b)(7)(C)
Cc:
Subject: RE: DDR Files

(b)(6); (b)(7)(C)

I hope you had a great trip. Miami was much nicer than the snow they got here in DC ☺

Thank you for the update. This is perfect. If anything changes I will let you know.

(b)(6); (b)(7)(C)

Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW (b)(6); (b)(7)(C)
Washington, DC 20536
202-732-(b)(6); (desk)
202-253-(b)(7)(C) (cell)

From: (b)(6); (b)(7)(C)

Sent: Tuesday, March 27, 2018 2:37 PM

To: (b)(6); (b)(7)(C)

Cc:

Subject: DDR Files

Hello (b)(6);
(b)(7)(C)

I hope you are doing well and had an uneventful week in Miami.

I am gathering old DDR files and putting them in folders for mailing to you, similar to how I handled the FOIA request files. These folders will include all materials received prior to the review and while on site, all videos and my working notes. The following files will be sent in the next day or so:

(b)(6); (b)(7)(C)

Please let me know if there are any changes you wish to make to this process. I will email you each time I prepare a shipment. I estimate that I have another 10- 15 files to submit.

Thank you!

From: (b)(6); (b)(7)(C)
To:
Subject: RE: DDR Files
Date: Wednesday, April 11, 2018 5:56:55 PM

(b)(6);
(b)(7)(C)

I will be preparing the last batch of old DDR files this week for submission. I understand that I should submit anything that has been published. Can you tell me which DDR's have yet to be published? Obviously (b)(6); (b)(7)(C). But have (b)(6); (b)(7)(C), Almazan or (b)(6); (b)(7)(C) been published? Thank you!

(b)(6); (b)(7)(C)
From: (b)(6); (b)(7)(C)
Sent: Tuesday, March 27, 2018 2:42 PM
To: (b)(6); (b)(7)(C)
Cc:
Subject: RE: DDR Files

Hi (b)(6); (b)(7)(C)

I hope you had a great trip. Miami was much nicer than the snow they got here in DC ☺

Thank you for the update. This is perfect. If anything changes I will let you know.

(b)(6); (b)(7)(C)
Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW; (b)(6); (b)(7)(C)
Washington, DC 20536
202-732-(b)(6); (b)(7)(C)esk
202-253-(b)(6); (b)(7)(C)ell

(b)(6); (b)(7)(C)
From: (b)(6); (b)(7)(C)
Sent: Tuesday, March 27, 2018 2:37 PM
To: (b)(6); (b)(7)(C)
Cc:
Subject: DDR Files

Hello (b)(6); (b)(7)(C)

I hope you are doing well and had an uneventful week in Miami.

I am gathering old DDR files and putting them in folders for mailing to you, similar to how I handled the FOIA request files. These folders will include all materials received prior to the review and while on site, all videos and my working notes. The following files will be sent in the next day or so:

(b)(6); (b)(7)(C)

(b)(6); (b)(7)(C)

Please let me know if there are any changes you wish to make to this process. I will email you each time I prepare a shipment. I estimate that I have another 10- 15 files to submit.
Thank you!

Subjective: as stated, _____

Date/Time of Onset: _____ New Onset Chronic

History: None Cardiovascular x's ___ years Renal disease x's ____ years Family history

Recent changes or discontinuation of meds? No Yes: _____

Special Diet? No Yes: Type _____ Compliance with medications, diet etc. No Yes

Pain Scale 0-10 _____ Aggravating Factors: _____

Quality: _____ Alleviating Factors: _____

Location: _____ Does the pain radiate? Y / N If Yes _____ Duration: _____

Objective: Vital Signs: Temp _____ Pulse _____ Resp _____ B/P _____ Pulse Ox: _____ Weight _____

Orthostatic B/P: Time _____ Sitting _____ Standing _____ Lying _____

General Appearance: No Acute Distress Acute Distress: _____

Skin: Warm Hot Cool Dry Pale Ashen Moist / Clammy

Mental Status: Alert & Oriented X's 4 Confused Delusional Combative

Pulse: Normal Strong Tachy Thready Weak Bounding

Pupils: PERLA **OR** Pupils Unequal Constricted Dilated

Right Size _____ mm Left Size _____ mm

Gait: Steady Unsteady Unable to stand

Lung Sounds: **Right** **Left** Heart Sounds: _____

Clear Normal Dull / Toned

Wheezing

Rhonchi

Diminished

Crackles

Assessment Decision: Does the patient have any of the objective findings below present? → **If YES: Contact Provider**

- | | |
|---|--|
| <input type="checkbox"/> Blood pressure - systolic \geq 160, diastolic \geq 100 | Date/Time: _____ |
| <input type="checkbox"/> Change in mental status / Level of consciousness | Person Contacted: _____ |
| <input type="checkbox"/> Noncompliance with diet/medications, etc. | <input type="checkbox"/> See T.O. <input type="checkbox"/> See Progress Note |
| <input type="checkbox"/> Visual disturbances <input type="checkbox"/> Severe headache | <input type="checkbox"/> No further orders received |
| <input type="checkbox"/> Decreased Urine Output <input type="checkbox"/> Chest pain | <input type="checkbox"/> Follow up scheduled with _____ |

Plan as ordered by provider:

- Bedrest x's 48 hours
- If chronic or ongoing/continuing problem, bedrest until seen by Provider
- BP checks everyday x's 3 days
- other: _____

→ **If NO:** No treatment is required:

- No action indicated at this time - instructed to RTC is symptoms persist or worsen
- Other: _____

Education:

- Instructions to return if condition worsens or if no improvement
- Instructed on medication(s), dosage, administration times, and expected outcome of each medication given/recommended
 - Patient verbalizes understanding of the plan, risks, benefits, and alternatives and agrees to plan.

• Note above medication orders have been approved by the physician. No changes in dosage, duration, or medication may be made unless prior approval by a provider has been obtained, i.e. Telephone Order **Documented** in the chart.

Medical Staff Signature: _____ Date/Time: _____

Interpreter? Y / N Name: _____ Language: _____

Provider Speaks: English / Spanish / Other: _____ Patient Speaks: English / Spanish / Other: _____

Patient Name:	Allergies: _____
Patient ID#	Medications: _____
DOB	

From: (b)(6); (b)(7)(C)
Sent: 10 Oct 2018 12:33:02 +0000
To: (b)(6); (b)(7)(C)
Subject: Re: ALMAZAN Questions
Attachments: 2018_10_10_08_29_03.pdf

Good morning, Kara. Here is MTC's blood pressure protocol (aka nursing guideline) as requested. ☑ Let me know if there is anything else you need.

From: (b)(6); (b)(7)(C)
Sent: Tuesday, October 9, 2018 8:09:53 AM
To: (b)(6); (b)(7)(C)
Subject: RE: ALMAZAN Questions

Thank you! Very helpful.

Do you have a copy of the MTC Hypertension Nursing Guidelines? Thank you!!

(b)(6); (b)(7)(C)

Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza S (b)(6); (b)(7)(C)
Washington, DC 20536
202-732-(b)(6); (b)(7)(C) desk
202-253-(b)(6); (b)(7)(C) cell

From: (b)(6); (b)(7)(C)
Sent: Monday, October 8, 2018 9:49 AM
To: (b)(6); (b)(7)(C)
Subject: Re: ALMAZAN Questions

Thank you for the clarifications, (b)(6); (b)(7)(C) Hope all is well in ERAU Land! 😊

From: (b)(6); (b)(7)(C)
Sent: Friday, October 5, 2018 12:40 PM
To: (b)(6); (b)(7)(C)
Subject: FW: ALMAZAN Questions

I'm not going to say last question any more when it comes to this one. There were two comments you replied you weren't sure what we were asking. I've updated them to hopefully make it clearer. If you still have a question let me know! They are on page 4 and 5.

Thank you!

(b)(6); (b)(7)(C)

Management & Program Analyst

ICE/OPR/ERAU

950 L'Enfant Plaza SW

Washington, DC 20536

202-732- (b)(6); (b)(7)(C) (desk)

202-253- (b)(7)(C) (cell)

From: (b)(6); (b)(7)(C)

Sent: Monday, September 24, 2018 9:01 AM

(b)(6); (b)(7)(C)

Subject: Re: ALMAZAN Questions

Happy Monday (b)(6); (b)(7)(C) 😊

My responses for KNSPC are attached. I have one document to scan to you later today. I have a lengthy dental appointment in Mnpls today but will get the scan and GCDC responses to you either later today or early tomorrow.

From: (b)(6); (b)(7)(C)

Sent: Wednesday, September 19, 2018 2:23:02 PM

To: (b)(6); (b)(7)(C)

Subject: ALMAZAN Questions

(b)(6); (b)(7)(C)

Attached are comments and questions from Alison on ALMAZAN. I went through what she had sent and tried to answer as much as I could but a few things I need confirmation on or just didn't know. Let me know if you have any questions. Thank you!

(b)(6); (b)(7)(C)

Management & Program Analyst

ICE/OPR/ERAU

950 L'Enfant Plaza SW

Washington, DC 20536

202-732- (b)(6); (b)(7)(C) (desk)

202-253- (b)(7)(C) (cell)

Subjective: as stated, _____

Date/Time of Onset: _____ New Onset Chronic

History: None Cardiovascular x's ___ years Renal disease x's ____ years Family history

Recent changes or discontinuation of meds? No Yes: _____

Special Diet? No Yes: Type _____ Compliance with medications, diet etc. No Yes

Pain Scale 0-10 _____ Aggravating Factors: _____

Quality: _____ Alleviating Factors: _____

Location: _____ Does the pain radiate? Y / N If Yes _____ Duration: _____

Objective: Vital Signs: Temp _____ Pulse _____ Resp _____ B/P _____ Pulse Ox: _____ Weight _____

Orthostatic B/P: Time _____ Sitting _____ Standing _____ Lying _____

General Appearance: No Acute Distress Acute Distress: _____

Skin: Warm Hot Cool Dry Pale Ashen Moist / Clammy

Mental Status: Alert & Oriented X's 4 Confused Delusional Combative

Pulse: Normal Strong Tachy Thready Weak Bounding

Pupils: PERLA **OR** Pupils Unequal Constricted Dilated

Right Size _____ mm Left Size _____ mm

Gait: Steady Unsteady Unable to stand

Lung Sounds: **Right** **Left** Heart Sounds: _____

Clear Normal Dull / Toned

Wheezing

Rhonchi

Diminished

Crackles

Assessment Decision: Does the patient have any of the objective findings below present? → **If YES: Contact Provider**

- | | |
|---|--|
| <input type="checkbox"/> Blood pressure - systolic \geq 160, diastolic \geq 100 | Date/Time: _____ |
| <input type="checkbox"/> Change in mental status / Level of consciousness | Person Contacted: _____ |
| <input type="checkbox"/> Noncompliance with diet/medications, etc. | <input type="checkbox"/> See T.O. <input type="checkbox"/> See Progress Note |
| <input type="checkbox"/> Visual disturbances <input type="checkbox"/> Severe headache | <input type="checkbox"/> No further orders received |
| <input type="checkbox"/> Decreased Urine Output <input type="checkbox"/> Chest pain | <input type="checkbox"/> Follow up scheduled with _____ |

Plan as ordered by provider:

- Bedrest x's 48 hours
- If chronic or ongoing/continuing problem, bedrest until seen by Provider
- BP checks everyday x's 3 days
- other: _____

→ **If NO:** No treatment is required:

- No action indicated at this time - instructed to RTC is symptoms persist or worsen
- Other: _____

Education:

- Instructions to return if condition worsens or if no improvement
- Instructed on medication(s), dosage, administration times, and expected outcome of each medication given/recommended
 - Patient verbalizes understanding of the plan, risks, benefits, and alternatives and agrees to plan.

• Note above medication orders have been approved by the physician. No changes in dosage, duration, or medication may be made unless prior approval by a provider has been obtained, i.e. Telephone Order **Documented** in the chart.

Medical Staff Signature: _____ Date/Time: _____

Interpreter? Y / N Name: _____ Language: _____

Provider Speaks: English / Spanish / Other: _____ Patient Speaks: English / Spanish / Other: _____

Patient Name:	Allergies: _____
Patient ID#	Medications: _____
DOB	

From: (b)(6); (b)(7)(C)
Sent: 23 Oct 2018 12:36:22 +0000
To: (b)(6); (b)(7)(C)
Subject: Re: ALMAZAN - Question about Blood Draw at KNSPC

Another Outlook problem, as this was sent yesterday.

From: (b)(6); (b)(7)(C)
Sent: Monday, October 22, 2018 6:45:05 AM
To: (b)(6); (b)(7)(C)
Subject: Re: ALMAZAN - Question about Blood Draw at KNSPC

Good mornin (b)(6); (b)(7)(C)

For some strange reason my last week's reply to this question disappeared into a dark hole somewhere, but I am happy to answer it again in case you didn't get it. These specific dates could be the result of various reasons:

- The provider wanted to wait a certain period of time to see if treatment was effective.
- For current accuracy, the provider wanted the result to be obtained just prior to the next assessment.
- The labs might have been deemed non-urgent, in order to allow the tech better availability to do urgent testing.

Have a great week!!!

From: (b)(6); (b)(7)(C)
Sent: Thursday, October 18, 2018 3:24:55 PM
To: (b)(6); (b)(7)(C)
Subject: ALMAZAN - Question about Blood Draw at KNSPC

Hi (b)(6); (b)(7)(C)

We noticed that for the initial health assessment and for the pancytopenia (and I spelled that right the first time 😊) follow up, that blood draws were ordered for days after. So from the 7/19 appointment the provider ordered for the draw to take place on 7/28 and the 8/4 appointment the provider ordered for the draw to take place on 8/11. Do you have any insight as to why that would be, such as techs only come to the facility certain days? Thanks!

(b)(6); (b)(7)(C)
Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW (b)(6); (b)(7)(C)
Washington, DC 20536
202-732-(b)(6); (b)(7)(C) desk)
202-253-(b)(6); (b)(7)(C) cell)

From: (b)(6); (b)(7)(C)
Sent: 25 Sep 2018 12:58:55 +0000
To: (b)(6); (b)(7)(C)
Subject: RE: ALMAZAN - GCDC Comments/Questions

Thank you (b)(6); (b)(7)(C)

Sent with BlackBerry Work
(www.blackberry.com)

From: (b)(6); (b)(7)(C)
Date: Tuesday, Sep 25, 2018, 8:52 AM
(b)(6); (b)(7)(C)
Subject: Re: ALMAZAN - GCDC Comments/Questions

Good morning, (b)(6); (b)(7)(C) I attached my responses to the Glades questions and scanned intake screen you requested. As far as the Krome question addressing the KOP agreement, I can't find one either and wonder if it was mistakenly the Glades one being referred to. I will let you know if I find anything else to better clarify.

++

From: (b)(6); (b)(7)(C)
Sent: Friday, September 21, 2018 9:28:16 AM
To: (b)(6); (b)(7)(C)
Subject: ALMAZAN - GCDC Comments/Questions

H (b)(6); (b)(7)(C)

Here is GCDC's comments and questions from Alison. The very first section is on the intake which I wrote (b)(6); (b)(7)(C) on the ones I know I can answer but I can't find the intake screening anywhere in my files even though I know I have it! Could you send me the intake screening? Let me know if you have any questions or concerns! Thanks, I hope you had a nice vacation 😊!

(b)(6); (b)(7)(C)

Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW; (b)(6); (b)(7)(C)
Washington, DC 20536
202-732-(b)(6); (b)(7)(C) desk)
202-253-(b)(6); (b)(7)(C) cell)

From: (b)(6); (b)(7)(C)
Sent: 8 Aug 2018 21:12:07 +0000
To: (b)(6); (b)(7)(C)
Cc:
Subject: RE: ALMAZAN DDR Medical Narrative Polk County Adult Detention Center

Can you cc (b)(6); (b)(7)(C) on all the Almazan documents that you return back.
Thank you!

Sent with BlackBerry Work
(www.blackberry.com)

From: (b)(6); (b)(7)(C) >
Date: Wednesday, Aug 08, 2018, 1:20 PM
To: (b)(6); (b)(7)(C)
Cc:
Subject: ALMAZAN DDR Medical Narrative Polk County Adult Detention Center

Good afternoon (b)(6); (b)(7)(C)

Here is the Polk DDR comments. Please let me know if you have any concerns or need anything clarified. Thanks!

(b)(6); (b)(7)(C)
Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW (b)(6); (b)(7)(C)
Washington, DC 20536
202-732-(b)(6) (desk)
202-253-(b)(7) (cell)

From: (b)(6); (b)(7)(C)
Sent: 24 Sep 2018 15:03:33 +0000
To: (b)(6); (b)(7)(C)
Subject: RE: ALMAZAN Questions

Thank you (b)(6); (b)(7)(C)

I hope everything goes well at the dentist 😊

(b)(6); (b)(7)(C)

Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW; (b)(6); (b)(7)(C)
Washington, DC 20536
202-733-(b)(6); (b)(7)(C) desk)
202-251-(b)(6); (b)(7)(C) cell)

From: (b)(6); (b)(7)(C)
Sent: Monday, September 24, 2018 9:01 AM
(b)(6); (b)(7)(C)
Subject: Re: ALMAZAN Questions

Happy Monday, (b)(6); (b)(7)(C) 😊

My responses for KNSPC are attached. I have one document to scan to you later today. I have a lengthy dental appointment in Mnpls today but will get the scan and GCDC responses to you either later today or early tomorrow.

From: (b)(6); (b)(7)(C)
Sent: Wednesday, September 19, 2018 2:23:02 PM
To: (b)(6); (b)(7)(C)
Subject: ALMAZAN Questions

(b)(6); (b)(7)(C)

Attached are comments and questions from Alison on ALMAZAN. I went through what she had sent and tried to answer as much as I could but a few things I need confirmation on or just didn't know. Let me know if you have any questions. Thank you!

(b)(6); (b)(7)(C)

Management & Program Analyst

ICE/OPR/ERAU

950 L'Enfant Plaza SW (b)(6); (b)(7)(C)

Washington, DC 20536

202-73 (b)(6); (b)(7)(C) desk)

202-29 (b)(6); (b)(7)(C) cell)

From: (b)(6); (b)(7)(C)
Sent: 18 Oct 2018 16:57:55 +0000
To: (b)(6); (b)(7)(C)
Cc:
Subject: RE: ALMAZAN Questions

Thank you (b)(6); (b)(7)(C)

(b)(6); (b)(7)(C)

Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW (b)(6); (b)(7)(C)
Washington, DC 20536
202-732-(b)(6); (b)(7)(C) desk)
202-253-(b)(6); (b)(7)(C) cell)

From: (b)(6); (b)(7)(C)
Sent: Thursday, October 18, 2018 11:20 AM
To: (b)(6); (b)(7)(C)
Cc:
Subject: Re: ALMAZAN Questions

(b)(6); (b)(7)(C)

IHSC's EMR automatically schedules any "abnormal intake" for a 24 -hour H&P by a provider; so it can only be assumed the appointment had been made by the intake nurse who noted it as abnormal. IF that was the case, the nurse would not be responsible for ensuring the detainee was seen within that 24-hour period, as the responsibility would have been electronically handed off to the provider. We have no evidence of an appointment having been scheduled within that time period; nor do we know at what point the process broke down, only that it was seriously delayed.

I hope this answers your question...please let me know if further clarification is needed.

From: (b)(6); (b)(7)(C)
Sent: Wednesday, October 17, 2018 9:23 AM
To: (b)(6); (b)(7)(C)
Subject: FW: ALMAZAN Questions

(b)(6); (b)(7)(C)

I need to clarify one thing at KNSPC. At intake he was priority 2 status, and should have been seen in 24 hours. We know his appointment didn't happen for 7 days. Did we ever have an appointment that was made for him that was within 24 hours? I don't believe we did, but just double checking. Also, would it have been the responsibility of the RN that conducted his intake to make sure the appointment had been scheduled in 24 hours?

Thanks!

(b)(6); (b)(7)(C)

Management & Program Analyst

ICE/OPR/ERAU

950 L'Enfant Plaza SW (b)(6); (b)(7)(C)

Washington, DC 20536

202-732 (b)(6); (desk)

202-253 (b)(7)(C) (cell)

From: (b)(6); (b)(7)(C)

Sent: Tuesday, October 9, 2018 9:10 AM

To: (b)(6); (b)(7)(C)

Subject: RE: ALMAZAN Questions

Thank you! Very helpful.

Do you have a copy of the MTC Hypertension Nursing Guidelines? Thank you!!

(b)(6); (b)(7)(C)

Management & Program Analyst

ICE/OPR/ERAU

950 L'Enfant Plaza SW; (b)(6); (b)(7)(C)

Washington, DC 20536

202-732 (b)(6); (desk)

202-253 (b)(7)(C) (cell)

From: (b)(6); (b)(7)(C)

Sent: Monday, October 8, 2018 9:49 AM

To: (b)(6); (b)(7)(C)

Subject: Re: ALMAZAN Questions

Thank you for the clarifications. (b)(6); (b)(7)(C) Hope all is well in ERAU Land! 😊

From: (b)(6); (b)(7)(C)
Sent: Friday, October 5, 2018 12:40 PM
To: (b)(6); (b)(7)(C)
Subject: FW: ALMAZAN Questions

I'm not going to say last question any more when it comes to this one. There were two comments you replied you weren't sure what we were asking. I've updated them to hopefully make it clearer. If you still have a question let me know! They are on page 4 and 5.

Thank you!

(b)(6); (b)(7)(C)

Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW; (b)(6); (b)(7)(C)
Washington, DC 20536
202-732-(b)(6); (b)(7)(C) desk)
202-253-(b)(7)(C) cell)

From: (b)(6); (b)(7)(C)
Sent: Monday, September 24, 2018 9:01 AM

(b)(6); (b)(7)(C)

Subject: Re: ALMAZAN Questions

Happy Monday, (b)(6); (b)(7)(C) 😊

My responses for KNSPC are attached. I have one document to scan to you later today. I have a lengthy dental appointment in Mnpls today but will get the scan and GCDC responses to you either later today or early tomorrow.

From: (b)(6); (b)(7)(C)
Sent: Wednesday, September 19, 2018 2:23:02 PM
To: (b)(6); (b)(7)(C)
Subject: ALMAZAN Questions

(b)(6); (b)(7)(C)

Attached are comments and questions from (b)(6); (b)(7)(C) on ALMAZAN. I went through what she had sent and tried to answer as much as I could but a few things I need confirmation on or just didn't know. Let me know if you have any questions. Thank you!

(b)(6); (b)(7)(C)

Management & Program Analyst

ICE/OPR/ERAU

950 L'Enfant Plaza SW (b)(6); (b)(7)(C)

Washington, DC 20536

202-7 (b)(6); (b)(7)(C) desk)

202-2 (b)(6); (b)(7)(C) cell)

From: (b)(6); (b)(7)(C)
Sent: 9 Aug 2018 14:12:26 +0000
To: (b)(6); (b)(7)(C)
Cc:
Subject: RE: Detainee Death Review Healthcare and Security Compliance Analysis
(b)(6); (b)(7)(C) FINAL 8-3-18

Great. Thank you.

(b)(6); (b)(7)(C)
Management and Program Analyst
External Reviews and Analysis Unit
Office of Professional Responsibility
Immigration and Customs Enforcement
950 L'Enfant Plaza, SW
Washington, DC 20536
Office: (202) 73 (b)(6);
Cell: (202) 425 (b)(6);

From: (b)(6); (b)(7)(C)
Sent: Wednesday, August 8, 2018 4:12 PM
To: (b)(6); (b)(7)(C)
Cc:
Subject: RE: Detainee Death Review Healthcare and Security Compliance Analysis (b)(6); (b)(7)(C) FINAL 8-3-18

Hey there (b)(6); (b)(7)(C)

(b)(6); (b)(7)(C) has been away, and has questions from (b)(6); (b)(7)(C) awaiting her on the ALMAZAN DDR. Since you have only one more, I will ask her to give (b)(6); (b)(7)(C) priority so you put this report behind you ☺.

(b)(6); (b)(7)(C)

From: (b)(6); (b)(7)(C)
Sent: Wednesday, August 8, 2018 3:23 PM
To: (b)(6); (b)(7)(C)
Cc:
Subject: Detainee Death Review Healthcare and Security Compliance Analysis (b)(6); (b)(7)(C) FINAL 8-3-18

(b)(6); (b)(7)(C)

There's just one more items I need to get addressed. It's not in your report and it's fine, I just wanted bit of guidance/input from (b)(6); (b)(7)(C)

Thank you!

(b)(6); (b)(7)(C)
Management and Program Analyst

External Reviews and Analysis Unit
Office of Professional Responsibility
Immigration and Customs Enforcement
950 L'Enfant Plaza, SW
Washington, DC 20536
Office: (202) 73[REDACTED]
Cell: (202) 425-[REDACTED]

From: (b)(6); (b)(7)(C)
Sent: 3 Oct 2017 16:52:58 +0000
To: (b)(6); (b)(7)(C)
(b)(6); (b)(7)(C)
Cc: (b)(6); (b)(7)(C)
Subject: Hotel Change - ALMAZAN DDR

Good afternoon,

After talking with (b)(6); (b)(7)(C) about going all the way to Lufkin, we decided the better choice would be the Woodlands area. I found a SpringHill Suites at the government rate for the entire week. It will be much closer to civilization and also the airport. From this hotel it will be just over an hour to the facility, Lufkin if roughly the same amount of time.

Here is the link: <https://www.marriott.com/hotels/travel/houln-springhill-suites-houston-the-woodlands/>

Let me know if you have any issues getting into this hotel or canceling the other ones.

(b)(6); (b)(7)(C)

Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW (b)(6); (b)(7)(C)
Washington, DC 20536
202-732-(b)(6) (desk)
202-253-(b)(7) (cell)

From: (b)(6); (b)(7)(C)
Sent: 5 Dec 2017 09:39:59 -0500
To: (b)(6); (b)(7)(C)
Cc:
Subject: Interviews today - Almazan

Good morning (b)(6); (b)(7)(C)

We're having some issues getting our medical interviewees today. I understand you're out of the office – can you please let me know who can assist?

Thanks,

(b)(6); (b)(7)(C)

MEDICAL SUMMARY OF FEDERAL PRISONER / ALIEN IN TRANSIT
U.S. Department of Justice

TB Clearance

1) PPD Completed: _____ Date _____
 Results: _____

2) CXR Completed: 07-12-2017 Date _____
 Results: Negative

(b)(6); (b)(7)(C) _____
 Signature: RN
9-10-17
 Date

Note: Dates listed above must be within one year of this transfer

I. PRISONER / ALIEN

Name:	Prisoner / Alien Reg #	D.O.B.
FELIPE ALMAZAN RUIZ	A028866428	06-26-1966
Departed From:	Date Departed:	
GCDC	09-07-2017	
Destination:	Reason for Transfer:	
FOLKSTON	ATW	
District Name:	District #	Date in Custody:

II. CURRENT MEDICAL PROBLEMS

300.02 GENERALIZED ANXIETY DISORDER, 311 DEPRESSION, 571.5 CIRRHOSIS OF LIVER WITHOUT ALCOHOL

Date	Medication	Dosage	Directions	Number
2017-08-22	SERTRALINE HCL	100 MG TAB	100	Take 1 Tablet by mouth 1 time per day for 60 days 60
2017-08-22	TRAZODONE	50 MG TABLET	50	1 po q HRS 60
2017-08-22	TRAZODONE HCL	50 MG	1/2 tab PO at bedtime x 60 days	60
2017-09-06	FOLIC ACID	1 MG TABLET	1	Take 1 Tablet by mouth 1 time per day for 90 days 90
2017-09-06	OMEPRAZOLE	40 MG		Take 1 Capsule by mouth 1 time per day for 90 days 90
2017-09-06	PREDNISONE	50 MG		Take 2 Tablets by mouth 1 time per day for 3 days 6
2017-09-06	SPIRONOLACTONE	25 MG TABLET	25	Take 1 Tablet by mouth 2 times per day for 90 days 180

Additional Comments:
 NKDA

III. SPECIAL NEEDS AFFECTING TRANSPORTATION

Is prisoner medically able to travel by BUS, VAN or CAR? Y If no, Why not? _____

Is prisoner able to travel by airplane? Y If no, Why not? _____

Is prisoner medically able to stay overnight at another facility en route to destination? Y If not, Why not? _____

Is there any medical reason for restricting the length of time prisoner can be in travel status? N If yes, state reason: _____

Does prisoner require any medical equipment while in transport status? N If yes, What equipment? _____

Sign & Print Name – Certifying Health Authority:

(b)(6); (b)(7)(C) _____
 Signature: RN

Phone Number:

863-946-

Date Signed:

(b)(6); (b)(7)(C)

TREATMENT PLAN

SPECIAL NEEDS & RESTRICTICONS

BUNK ASSIGNMENT:

No Restriction

Lower Only

Other housing needs _____

Duration: _____

Expiration: _____

WORK/PROGRAM ASSIGNMENT:

Unassigned per medical/psychiatry

No reaching over shoulder

Sedentary Work Only

Four hour work restriction

Excuse from school thru _____

Limited standing > _____ hrs

No walking > _____ yds

No lifting > _____ lbs

No bending at the waist

No squatting

No climbing

Limited sitting

NO RESTRICTIONS

OR

No food service

No repetitive use of hands

No walking on wet or uneven surfaces

No work in direct sunlight

No temperature extremes

No humidity extremes

No exposure to environmental pollutants

No work with chemicals or irritants

No work requiring safety boots

No work around machines or moving parts

No work exposure to loud noises

No work requiring complex instructions

DISCIPLINARY PROCESS:

NO RESTRICTIONS

OR

Consult representative of medical department before taking disciplinary action

SPECIAL NEEDS:

Chronically ill

On Dialysis

Adolescent in Adult facility

Infected with serious communicable disease -

Physically Disabled

Frail or elderly

Pregnant

Terminally ill

Mentally ill or suicidal

Developmentally disabled

Suspected victim of physical or sexual abuse

Precautions required: _____

(b)(6); (b)(7)(C)

Date: _____

18/08/07
Date

2330
Time

028 866 428

ALMAZAN-RUIZ, FELIPE

ADM 09/08/17 DOB 06/26/66

INTAKE SCREEN

(Page 1 of 3)

Translator available Yes NA Name Speaks english

Date/Time of Arrival at the facility: 9/8/2017

In the last 21 days what countries have you visited outside of the U.S.? None

Have you been in contact with anyone who traveled from these countries in the last 21-days and who is sick? Yes No

In the last 21-days have you been in close contact with anyone who has been diagnosed with an infectious disease? Yes No

If yes please explain:

Do you have any current medical, mental health or dental problems that need attention now?


NONE YES - explain: include any special health or dietary needs:

*** Note Detainee should be instructed on sick call process for any non-urgent healthcare needs.

Do you have a family history of any Medical conditions? Yes No If yes list conditions:

Recheck 164/100 → Recheck 152/80 r/c

Are you experiencing any pain? NO YES - Rate 3 / 10



Vitals: T 97.0 P 98 R 14 B/P 180/109 SaO2 98% HT 61 WT 170 lbs

Location joint pain (all) Duration

Do you have any physical injuries, open wounds, cuts or bruises or signs of trauma/violence?

NONE NOTED/DENIES YES (describe)

Do you have a past history of serious infectious or communicable illness (to include TB)? NO YES

(include any treatment or previous symptoms)

Do you have any recent communicable illness symptoms: NO YES If yes, indicate:

- Chronic Fatigue Weight Loss / Loss of Appetite Frequent Productive Cough
 Night Sweats Bloody Sputum - *** Fever Weakness

*** If yes, contact the medical provider to determine if the patient requires placement in Respiratory Isolation (Negative Air Flow Room) until testing is completed and the patient is cleared to be placed in the general population.

Do you have any Chronic Diagnosis? NO YES If yes, Note Diagnosis below and refer to Chronic Clinic

Cirrhosis

If Diabetic - Blood Sugar HTN DM SZR RESP HIV other

MENTAL HEALTH DX: Depression Anxiety

Do you have a history of Physical Illness, Surgeries or Dental Problems? NO YES

(include past hospitalizations, surgeries and treatments)

Do you identify yourself as a Transgender? NO YES

(If so, document history of transition-related care and notify security supervisor)

Are you currently taking any medications, including over the counter and/or herbal? Yes No

Comments: 40R quad abd pain

If yes Current Medication listed on transfer paperwork - See Orders

Patient states he/she is on the current medications, however they are not

(b)(6); (b)(7)(C) received.

DON

9/8/2017
Date

2330
Time

028 866 428
ALMAZAN-RUIZ, FELIPE
ADM 09/08/17 DOB 06/26/66

Allergies: NKDA

Do you have a current or past history of Mental Illness or disabilities? NO YES If yes, continue below:

Treatment: INPT OUTPT During Previous Incarcerations

Hallucinations: Auditory Visual

Diagnosis: Depression Anxiety

Do you have current, recent or past history of Physical, Emotional or Sexual Assault? NO YES

If yes - Perpetrator or Victim

When _____

Have you been sexually assaulted prior to arrival at this facility? NO YES If yes:

**Security Supervisor notified immediately _____ Name _____ Date/Time _____

Do you have a history of domestic abuse or violence? NO Yes

** If yes refer to Mental Health within 72 hours or sooner if appropriate

Do you use Tobacco? NO YES If yes:

Type: Cigarettes Pipe Oral

How Much? _____ How Often? _____

Do you have a history of Alcohol or Substance Abuse? NO YES If yes: Legal or Illegal Beer Tequila

Type: Alcohol Marijuana Cocaine Meth Heroin Inhalants LSD Opiate Other

How Much? "mucho" How Often? _____

Method: IV Smoke Ingest Snorting Other _____

Last drug(s) used? _____ When? _____

(if a female patient reports current Opiate use, make sure she was offered the pregnancy test. If positive she must be referred to the provider to avoid opiate withdrawal risk to the fetus)

Current or past illnesses & health problems r/t substance abuse:

Hepatitis Seizures Trauma Liver Disease Infections

Do you get sick when you quit using those drugs? NO YES (i.e.: convulsions)

If yes, what happens? _____

Any history of substance abuse hospitalization NO YES

If yes, when and for? _____

Any history of detoxification and outpatient treatment? NO YES

If yes, when and for? _____

Do you have any withdrawal symptoms? NO YES Symptoms: Shaking

Have you ever thought about killing yourself? NO YES

If yes, when and why? _____

Have you ever tried to harm yourself? NO YES If yes, when, how and why? passive SI

Do you want to harm yourself now? NO YES If yes, do you have a plan? _____

Do you want to harm someone else? NO YES If yes to what degree - explain? _____

you NO YES (If yes, notify Security Supervisory **immediately** !)

9/8/2017
Date

2030
Time

028 866 428

ALMAZAN-RUIZ, FELIPE

ADM 09/08/17 DOB 06/26/66

INTAKE SCREEN

(Page 3 of 3)

OBSERVATIONS

Is this person unconscious, semiconscious, bleeding, mentally unstable, severely intoxicated, in alcohol or drug withdrawal or disoriented to person/place/time or otherwise urgently in need of medical attention? NO YES

If yes, immediately refer to medical personnel for further evaluation & care.

IS THE PATIENT DISPLAYING ANY SYMPTOMS or UNUSUAL BEHAVIOR?

- | | | | |
|--|---|---|---|
| <input checked="" type="checkbox"/> NO | <input type="checkbox"/> YES | | |
| <input checked="" type="checkbox"/> Appearance - appropriate | <input type="checkbox"/> Weakness | <input type="checkbox"/> Seeing visions | <input type="checkbox"/> Yellowing of skin or eyes/jaundice |
| <input checked="" type="checkbox"/> Appropriate behavior | <input type="checkbox"/> Slurred Speech | <input type="checkbox"/> Unusual suspiciousness | <input type="checkbox"/> Rashes |
| <input checked="" type="checkbox"/> Normal gait | <input type="checkbox"/> Hyperventilation | <input type="checkbox"/> Disheveled | <input type="checkbox"/> Infestations (lice/crabs) |
| <input checked="" type="checkbox"/> Alert responsive | <input type="checkbox"/> Persistent cough | <input type="checkbox"/> Hearing voices | <input type="checkbox"/> Evidence of self mutilation |
| | <input type="checkbox"/> Body deformities | <input type="checkbox"/> Bizarre / insensible | <input type="checkbox"/> Alcohol or drug withdrawal |
| | <input type="checkbox"/> Abnormal gait | <input type="checkbox"/> Loud / obnoxious | <input type="checkbox"/> Communication difficulties |
| | <input type="checkbox"/> Tremors | <input type="checkbox"/> Disorderly | <input type="checkbox"/> Other physical abnormalities |
| | <input type="checkbox"/> Lethargy | <input type="checkbox"/> Sweating | <input type="checkbox"/> Assaultive or violent behavior |
| | <input type="checkbox"/> Needle Marks | <input type="checkbox"/> Other: _____ | |

Is his/her mood?

- | | | | |
|---|---|--------------------------------------|--|
| <input checked="" type="checkbox"/> WNL / Cooperative | <input type="checkbox"/> Crying/Tearful | <input type="checkbox"/> Confused | <input type="checkbox"/> Embarrassed |
| | <input type="checkbox"/> Incoherent | <input type="checkbox"/> Passive | <input type="checkbox"/> Uncooperative |
| | <input type="checkbox"/> Depressed | <input type="checkbox"/> Intoxicated | <input type="checkbox"/> Scared <input type="checkbox"/> Anxious |

Recent Tattoo(s) NO YES Any body piercings NO YES

DISPOSITION

- General Population with NO Immediate Health Services Referral
- General Population with Immediate Health Services Referral to Depression Anxiety Cirrhosis
- Transfer to Hospital for Emergency Treatment
- Constant Suicide Watch - provider contacted for order
- Medical Observation / Isolation Single Cell Housing
- If a female patient and pregnancy test is positive, refer to provider to avoid opiate withdrawal risks to fetus
- If answered yes to Domestic abuse or violence, Mental Health referral made within 72 hours.

ROUTINE REFER

- | | | |
|---|--|-------------------|
| <input type="checkbox"/> None | <input checked="" type="checkbox"/> Mental Health Services <u>9/11/20</u> | (b)(6); (b)(7)(C) |
| <input checked="" type="checkbox"/> MD/NP/PA | <input checked="" type="checkbox"/> Special Dietary Need <u>Renal</u> | |
| <input checked="" type="checkbox"/> Pharmacy / Order Meds | <input type="checkbox"/> Instructed detainee to submit sick call request for non-urgent health care need | |
| <input type="checkbox"/> Request Records / Call MD | <input type="checkbox"/> Dental Clinic | |

Provider Speaks: English / Spanish / Other: _____ Patient Speaks: English / Spanish / Other: _____

Language: _____

9/8/20
Date

2330
Time

028 866 428
ALMAZAN-RUIZ, FELIPE
ADM 09/08/17 DOB 06/26/66

FORMA DE CONSENTIMIENTO MEDICO

PROGRAMA DE CUIDADO DE SALUD

FORMA DE CONSENTIMIENTO MEDICO

El propósito de la clínica es proveer a usted atención médica. Los informes médicos que te obtengan serán mantenidos en su expediente médico, confidencial. Se espera usted que se someta a un examen médico para determinar su estado de salud al presente.

Yo, por la presente consiento o autorizo a una evaluación o examen médico para determinar mi estado salud presente. También consiento a cualquier otra evaluación o procedimiento médico, cuidado rutinario, y tratamiento médico o dental o salud mental que el personal médico de la clínica considere necesario, aconsejable o apropiado.

Yo autorizo la divulgación de mi historial médico a cualquier hospital en case de que hospitalización sea necesaria or recomendada. Yo autorizo la divulgación de mi información médica para el reporte a entidades federales y/o estatales para la vigilancia y control de enfermedades.

Esta forma se me ha explicado completamente y yo entiendo su contenido. También entiendo que no se me han hecho garantía con respecto al resultado de tratamientos o exámenes administrados en la clínica.

He recibido instrucciones sobre cómo acceder a:

- cuidado medico en esta unidad , dental y mental
- el programa de tarifa-por-servicio NA
- el proceso de queja para las quejas relacionadas con la salud

Pacientes se sexo femenino:

- Servicios de embarazo incluyendo pruebas, rutina o atención prenatal especializada, atención en el posparto, Posparto seguimiento, servicios de lactancia y los servicios de aborto como se indica
- Asesoramiento y asistencia para las mujeres embarazadas de acuerdo con su expreso deseos en la planificación de su embarazo, si desean aborto, servicios adoptivos o para mantener al niño
- Rutina, apropiados para la edad, ginecológica servicios de atención médica, incluyendo ofreciendo cuidados preventivos específicos de las mujeres

Solamente medicamentos basicos seran proveídos de acuerdo a los protocolos medicos. El Paciente podra obtener medicamento y sera responsable para tomarse las pastillas de acuerdo a las instrucciones para tomarse como en la vida libre.

Este privilegio sera dado solamente a los Paciente que sean capaces y responsables.

El Detenido tiene que:

1. Tomar el medicamento como es señalado y no deben abandonar dosis ni tampoco tomar dosis dobles.
2. Cuidar el medicamento, no se debe vender, no se debe cambiar, no descuidar el medicamento para que sea extraviado o robado.
3. No acumular medicamento en el dormitorio.
4. Ser cumplido todo el tiempo.

Felipe Almazan
 Detenido Signature
 (b)(6); (b)(7)(C)

<i>9/8/2017</i> Date	<i>2336</i> Time
<i>9/8/2017</i> Date	<i>2330</i> Time

028 866 428
ALMAZAN-RUIZ, FELIPE
ADM 09/08/17 DOB 06/26/66

Intake Screening and Testing

Provider Speaks: English / Spanish / Other: _____ Patient Speaks: English / Spanish / Other: _____

Interpreter? Y / N - Name: _____ Language: _____

TB - CLEARED AT PREVIOUS FACILITY - via

CXR - date completed 07/12/2017 Negative
(Documentation of negative Chest X-ray on file)

Negative PPD - date completed _____ (must have documentation of Negative PPD on file)

OR

TB - CLEARANCE REQUIRED AT THIS FACILITY

CXR required and scheduled

(b)(6); (b)(7)(C)

Date 9/8/2017 Time 2230

Date/Time PPD Planted _____		Dose 0.1cc Tuberculin Aplisol
Site: _____		
Vaccine Manufacturer	Lot Number	Expiration Date of Vaccine
Administered by (signature) _____		
Date PPD Read _____	Results _____	mm Induration
Results Read by (signature) _____		

Female Patients:

Have you recently been Pregnant _____ Yes _____ NO (if yes, when): _____

Is there a possibility that you are currently pregnant? _____ Yes _____ No

*** If pregnant PPD planted and read ***

Urine Pregnancy Test _____ Negative _____ Positive _____ Initials

Date _____ Time _____

Medical Staff Signature _____ Date _____ Time _____

028 866 428 ALMAZAN-RUIZ, FELIPE ADM 09/08/17 DOB 06/26/66	Allergies: <u>NKDA</u>
--	------------------------



INSTITUTION: INSTITUTION: IAH Secure Adult Detention Center - Polk County
Person(s) present: Reginald Jefferson NCC, LPC-S, LMFT, PhD Candidate

DATE: September 11, 2017

TIME: 1000

ALLERGIES: NKA

Housing: ICE / General Population

S: 48yo male from Mexico referred for depression

O: Appearance: clean, well-groomed disheveled unkempt Eye Contact: good fair poor
Attitude: cooperative uncooperative guarded suspicious hostile
Speech: normal abnormal low vol. high vol. rapid pressured English 2nd language
Orientation: person place time situation alert drowsy
Mood: euthymic dysthymic neutral depressed irritable euphoric angry anxious apathetic
Affect: congruent normal non-congruent blunt flat exaggerated
Thought Process: logical goal directed tangential circumstantial perseveration disorganized
Thought Content: no AH no VH no paranoia no suicidal ideations no homicidal ideations
 auditory hallucinations visual hallucinations delusions
Insight: poor fair good Judgment: poor fair good


A: Reports depression due to being incarcerated. Reports sleep problems. States likes to watch television. Requesting medication to deal with triggers for depressive symptoms. Reports med txt hx/Cerosis of the liver. No psyche txt hx, No SI/SA/AVH/delusions, No Hx SUDs.

Compliant with treatment yes no Side Effects:

DIAGNOSIS: F43.21 Adjustment Disorder with Depressive Mood

P: Patient not a danger to self or other at this time.
Follow up with Psychiatrist: Next Available Follow up with Psychologist: Prn per Protocol

Processed thoughts and feelings regarding being incarcerated. Discussed the importance of positive coping skills. Established skills he could use while incarcerated. Informed how to access mental health services. Will refer to psychiatrist for med management.



C. LPC-S, LMFT
NCC, LPC-S, LMFT, PhD Candidate

ARF 028 866 428

Detainee Name ALMAZAN-RUIZ, FELIPE

ID# ADM 09/08/17 DOB 06/26/66

DOB 2020-ICLI-00006 2730

SUBJECTIVE DATA: (what is the patient being seen for): Dt- brought to medical c/c/o
Vomity blood. Has Hx of same 7 yrs ago.
Med Hx ⊕ for Cirrhosis & Varices

Pain Scale 0-10 _____ Aggravating Factors: _____ Pt poor historian,
Quality: _____ Alleviating Factors: _____ got Hx from chart,
Location: _____ Does the pain radiate? Y/N If Yes _____ Duration: _____

Past Medical/Surgical History, Significant Family History, Social History: _____

OBJECTIVE DATA: Vital Signs: Temp 97.5 Pulse 100 Resp 18 BP 151/95 Wt 170lbs SaO₂ 100%

Heart _____ Ears Pt in NAD ACO
Lungs _____ Nose blood noted to mouth and
Neck _____ Throat oral cavity only
Abdomen _____ Skin _____

Extremities _____ Blood noted to Lips (chapped, bright
Additional Findings red, No blood to shirt or pants

REVIEW OF CURRENT MEDICATIONS _____ Initials _____

ASSESSMENT (DIAGNOSIS): Varices - GI bleed x 5 days

PLAN: _____

FOLLOW-UP: PRN 30 day 60 Days 90 days Referral _____ Other _____

Medication (s) Order: Send to ER for eval STAT
(Not 911)

Lab/Radiology Order: _____

Other orders: _____

Time Frame for any requested consults within 2 weeks within 30 days other: _____

EDUCATION: Diet (b)(6); (b)(7)(C) _____ Risk Factors and Reducers _____
 Signs and Sy _____
 Patient verb _____ Benefits, and alternatives and agrees to the plan _____

Provider Signature/ Title: _____ Date/Time: 9/11/17 1757

Interpreter? / N Name: _____ Language: Spanish

Provider Speaks: English / Spanish / Other: _____ Patient Speaks: English / Spanish / Other: _____

028 866 428
ALMAZAN-RUIZ, FELIPE
ADM 09/08/17 DOB 06/26/66
Allergies: NKA

Date/Time injury: 9/11/17 injury Activity at onset: lying in bed on arrival.
 Date/Time reported: 9/11/17 1945 Interpreter Y N Name: (b)(6); (b)(7)(C)

Subjective: (State what occurred, who / what / where / how)
nurse called to tank C-20 because detainee was reportedly vomiting blood.

Objective: Pain Scale: (0-10) 9

Date	Time	Temp	Pulse	Resp	BP	SaO2	BG	Narrative
9/11/17	1950	97.5	106	18	151/95	100%		Detainee A#0x3 - clo pain to mid chest. PA ordered to send out P/H (+) Hx of cirrhosis & varices.

Assessment Decision:
 No Further Care Needed Further Care Required Other _____

Plan:
 Cleared to Return to Current Housing in Facility per Provider: _____ Date/Time _____
 Transfer to ER per Provider Order - see Emergency Treatment Order
 Place in Medical Housing for _____ until _____
 Other: _____

Education:
 _____ on further medical interventions required
 _____ understands understanding of the plan, risks, benefits, and alternatives and agrees to plan.
 Date/Time: 9/11/17 2200

028 866 428
ALMAZAN-RUIZ, FELIPE
ADM 09/08/17 DOB 06/26/66

Allergies: NKA
 Medications: see mar

Departing Facility Via:

Transport via VAN:

Date	Time	Initials	Comments
9/16/17	1042	(b)(6); (b)(7)(C)	(b)(6); (b)(7)(C) Security Supervisor _____ notified of need to transport via VAN to CHI ST. LUKAS <input checked="" type="checkbox"/> MAR <input type="checkbox"/> Progress notes <input checked="" type="checkbox"/> Patient left via van with security escort

Transport via EMS:

Date	Time	Initials	Comments
			911 / EMS Activated Security Supervisor _____ notified of need to transport via EMS to _____ <input type="checkbox"/> MAR <input type="checkbox"/> Progress notes Date/Time EMS arrived at facility _____

Returning to Facility:

Returned from ER Admitted to Hospital and returned

Vital Signs: Temp _____ Pulse _____ Resp _____ B/P _____ SaO2 (room air) _____

Pain Scale: (0-10) _____

Date	Time	Initials	Comments
			Patient returned to the facility
			Hospital Records and Orders Received forwarded to medical provider for review
<input type="checkbox"/> Continue previous orders <input type="checkbox"/> New orders from provider noted <input type="checkbox"/> New medication(s) entered into pharmacy system			

Assessment / Notes: _____

Telephone Order: _____

(b)(6); (b)(7)(C) _____
The Order per Provider

Date/Time

Medical Staff Signature

Date / Time

<p>028 866 428 ALMAZAN-RUIZ, FELIPE ADM 09/08/17 DOB 06/26/66</p>	<p>Allergies: NKOA Medications: see mar</p>
--	---

Date	Time	Initials	Transport Patient to
9/11/17	1957	(b)(6); (b)(7)(C)	CHI St. Luke's
ER for further evaluation and treatment related to:			vomiting blood & Hx of cirrhosis & varices
Per Provider Transport - Verbal order	Provider	<input type="checkbox"/> Via EMS <input checked="" type="checkbox"/> Via Facility Van	Date/Time
(b)(6); (b)(7)(C)			9/11/17 1957
Receiving staff member - Sign	Name Printed		Date/Time
(b)(6); (b)(7)(C)			9/11/17 2000
		Title:	LVN

When the Patient is Released from the ER/Hospital, please do the following:

ADD FACILITY SPECIFIC INFORMATION HERE

If you should have any questions regarding this Patient, please contact:

HSA Name

Phone # & Extension

936-9167

(b)(6); (b)(7)(C)

028 866 428
ALMAZAN-RUIZ, FELIPE
ADM 09/08/17 DOB 06/26/66

11
2017
-1066
31

Patient Name: _____

Patient ID#: 028 Plate 428

Age: 51 Race: 51

Estimated Date of Release: UNKNOWN

Date / Time Out: 9/11/17

Date / Time Return: N/A

Type of ER Trip - Van Ambulance Air

Admit: Yes / No Allergies: NKDIA

Presented with Complaint (s) of: hematemesis ER H/H 12.5 / 33.2

Facility Diagnosis: ALT 68 AST 102 WBC 14.28 platelets 18

Chronic Care: Yes / No Last Visit _____ Compliant: Yes / No CC Diagnosis (s) _____

Risk factors: Hep ABC; Non-Reactive

Current Medications: _____

Tests prior to leaving (i.e. EKG - labs) Yes / No If yes results _____

Facility: Vitals → Time ↓	Temp	Pulse	Resp	BP	SaO2	Recent CC results - i.e. A1c - PT/INR

Tests in the ER and results: _____

Medications received in the ER/Hosp _____

Vitals at Hosp	Temp	Pulse	Resp	BP	SaO2	Medication changes at Hosp:
Today	98.3	69	14	101/51	100% RA	

Diagnosis from the hospital: Cirrhosis liver NPO → advanced liquid
EGD Hypertensive portal gastropathy fundus, body of the stomach
and antrum

Recommendations from the hospital: CXR No active CHF No findings of high concern for pneumonia

Return Vitals	Temp	Pulse	Resp	BP	SaO2	Seen upon return - Date Time By:

Notes: PO lisinopril
Denies Abd. discomfort

(b)(6); (b)(7)(C)

Subject: HOSPITAL DAILY REPORT

DETAINEE NAME: XXXXXXXXXXXXXXXX

ALIEN NUMBER: XXXXXXXXXXXXXXXX

DATE OF BIRTH: 06/26/1966

COUNTRY OF CITIZENSHIP: MEXICO

DATE OF ARRIVAL: 09/08/17

RELEVANT MEDICAL HISTORY: Detainee with history of heavy alcohol use, last drank 3 months ago. Presented to medical reporting he was vomiting blood x5 days, assessed by RN who noted blood in mouth. Reports history of this happening 7 years ago as well. Has history of cirrhosis of the liver with varices.

DATE OF ADMISSION: 9/11/17

CURRENT DIAGNOSIS: GI BLEED

ATTENDING PHYSICIAN: (b)(6); (b)(7)(C)

CURRENT STATUS: PT STABLE AT THIS TIME. MOST RECENT VITALS B/P-99/58, P-75, R-17, O2-97% REMAINS AFEBILE. 2UNITS OF PLATELETS GIVEN DUE TO CRITICAL PLATELET LEVEL OF 27. POST TRANSFUSION LEVEL IS 55. ALL OTHER LABS REMAIN WITHIN NORMAL LIMITS. DETAINEE SCHEDULED TO HAVE EGD IN THE MORNING. DETAINEE WAS PREVIOUSLY RECEIVING CARDENE DRIP VIA EXTERNAL JUGULAR LINE, HAS BEEN STOPPED NOW RECEIVING LISINOPRIL PO.

DISCHARGE PLAN: NONE AT THIS TIME

REPORT GIVEN BY (b)(6); (b)(7)(C)

CONROE REGIONAL HOSPITAL (936) 539-(b)(6); (b)(7)(C)

(b)(6); (b)(7)(C)

LVN

TAH-SADF-POLK

Livingston, Tx 77351

936-967-(b)(6); (b)(7)(C)

936-967-8846-Fax

MTC Medical

5. Location of Social Impact

(b)(6); (b)(7)(C)

From: (b)(6); (b)(7)(C)
Sent: Wednesday, September 13, 2017 5:35 PM
To: (b)(6); (b)(7)(C)
Cc:
Subject: RE: HOSPITAL DAILY REPORT

Hospital Daily Report

Hospital day # 2

Detainee Name: Felipe Almazan Ruiz

Alien #: A028866428

Date of Birth: 06-26-1966

Country of Citizenship: Mexico

Date of Arrival: 09-08-2017

Relevant Medical History: Cirrhosis of the Liver

Date of Admission: 09-12-2017 (correct date of admission)

Current Diagnosis: Upper GI Bleed

Attending physician: (b)(6); (b)(7)(C)

Current Status: (NOTE: include Vitals, Meds, Labs, etc.) report received from Dee, RN at 1200 A+O x 4 BP 117/58, P88, R19, T98.3, 100% on RA Afebrile, received 2 units of platelets hemoglobin is 11.2, platelets 27*L

Discharge Plan: NO DISCHARGE PLAN AT THIS TIME.

PLEASE CONTACT MEDICAL FOR ANY FURTHER INQUIRIES.

DWOODS-LVN

From: (b)(6); (b)(7)(C)
Sent: Wednesday, September 13, 2017 7:44 AM
(b)(6); (b)(7)(C)
Subject: RE: HOSPITAL DAILY REPORT

I should also mention that you do need to have the detainee full name and A#. I always have to remove it when I am communicating out of the ICE network (to your emails) or encrypt the emails to protect PII per policy. You all however when you send me this information are sending it to an ICE email (in network).

Very Respectfully,

(b)(6); (b)(7)(C) RN, BSN, CCNM
Houston Field Medical Coordinator
ICE Health Service Corps / USPHS
16038 Vickery Dr, Suite (b)(6); (b)(7)(C)
Houston, TX 77032

(b)(6); (b)(7)(C)

From: (b)(6); (b)(7)(C)
Sent: Thursday, September 14, 2017 6:31 PM
To: (b)(6); (b)(7)(C)
Cc:
Subject: Detainee Felipe Almazan Ruiz

Hospital Daily Report

Hospital day # 3

Detainee Name: Felipe Almazan Ruiz

Alien #: A028866428

Date of Birth: 06-26-1966

Country of Citizenship: Mexico

Date of Arrival: 09-08-2017

Relevant Medical History: Cirrhosis of the Liver

Date of Admission: 09-12-2017 (correct date of admission)

Current Diagnosis: Upper GI Bleed

Attending physician: (b)(6); (b)(7)(C)

Current Status: (NOTE: include Vitals, Meds, Labs, etc.) report received from Desiree RN A+O x 4 BP 125/73, P 79, R 18, T 98.7, 99% on RA Afebrile, Continues to be on Lisinopril PO. Pain 8/10, reporting severe GERD.

Discharge Plan: NO DISCHARGE PLAN AT THIS TIME.

Thank You,

(b)(6); (b)(7)(C)

MTC Medical

(b)(6); (b)(7)(C)

From: (b)(6); (b)(7)(C)
Sent: Thursday, September 14, 2017 6:31 PM
To: (b)(6); (b)(7)(C)
Cc:
Subject: Detainee Felipe Almazan Ruiz

Hospital Daily Report

Hospital day # 3

Detainee Name: Felipe Almazan Ruiz

Alien #: A028866428

Date of Birth: 06-26-1966

Country of Citizenship: Mexico

Date of Arrival: 09-08-2017

Relevant Medical History: Cirrhosis of the Liver

Date of Admission: 09-12-2017 (correct date of admission)

Current Diagnosis: Upper GI Bleed

Attending physician: (b)(6); (b)(7)(C)

Current Status: (NOTE: include Vitals, Meds, Labs, etc.) report received from Desiree RN A+O x 4 BP 125/73, P 79, R 18, T 98.7, 99% on RA Afebrile, Continues to be on Lisinopril PO. Pain 8/10, reporting severe GERD.

Discharge Plan: NO DISCHARGE PLAN AT THIS TIME.

Thank You,

(b)(6); (b)(7)(C)

MTC Medical

Moved to Med-Surg floor

(b)(6); (b)(7)(C)

(b)(6); (b)(7)(C)

Direct number to floor 936-53

(b)(6); (b)(7)(C)

From:
Sent:
To:

(b)(6); (b)(7)(C)

Thursday, September 14, 2017 6:41 AM

(b)(6); (b)(7)(C)

Subject:

Hospital Daily Report

Hospital Daily Report

Hospital day # 24

Detainee Name: Felipe Almazan Ruiz

Alien #: A028866428

Date of Birth: 06-26-1966

Country of Citizenship: Mexico

Date of Arrival: 09-08-2017

Relevant Medical History: Cirrhosis of the Liver

Date of Admission: 09-12-2017 (correct date of admission)

Current Diagnosis: Upper GI Bleed

Attending physician: (b)(6); (b)(7)(C)

Current Status: (NOTE: include Vitals, Meds, Labs, etc.) report received from Arlene, RN at 0500 A+O x 4 BP 101/51, P 69, R 14, T 98.3, 99% on RA Afebrile, Continues to be on Lisinopril PO. Denied pain throughout the night.

Discharge Plan: NO DISCHARGE PLAN AT THIS TIME.

(b)(6); (b)(7)(C)

LVN

MTC Medical

IAH Secure Adult Detention Center

Livingston, TX 77351

FULL TIME: DAYS/ NIGHTS

936-967-(b)(6); (b)(7)(C)

936-967-8846 Fax

(b)(6); (b)(7)(C)

From:

(b)(6); (b)(7)(C)

Sent:

Friday, September 15, 2017 5:40 AM

To:

(b)(6); (b)(7)(C)

Cc:

Subject:

HOSPITAL DAILY REPORT

Hospital Day # **4**

DETAINEE NAME: Almazan-Ruiz, Felipe

ALIEN NUMBER: A 028 866 428

DATE OF BIRTH: 06/26/1966

COUNTRY OF CITIZENSHIP: MEXICO

DATE OF ARRIVAL: 09/08/17

RELEVANT MEDICAL HISTORY: Detainee with history of heavy alcohol use, last drank 3 months ago. Presented to medical reporting hematemesis x5 days, assessed by RN who noted blood in mouth. Reports history of this happening 7 years ago as well. Has history of cirrhosis of the liver with varices.

DATE OF ADMISSION: 9/12/17

CURRENT DIAGNOSIS: GI BLEED

ATTENDING PHYSICIAN: (b)(6); (b)(7)(C)

CURRENT STATUS: Pt remains stable at this time. Removed from ICU Rm 18 to Med Surg floor RM 141. Most recent vital signs T-98.1, B/P- 93/54, P-72, R-18, O2 @ 97% on RA. Labs scheduled to be drawn this morning (CBC,BMP). No changes to medication at this time. Pt c/o abd pain x1 during shift, morphine given. EGD performed. Summary: hypertensive portal gastropathy was found in fundus, body of the stomach and antrum. Patchy erythema in bulb and 2nd portion. Recommendations: avoid all NSAIDs, resume low salt diet as tolerated, PPI 20mg daily.

DISCHARGE PLAN: NONE AT THIS TIME

REPORT GIVEN BY: (b)(6); (b)(7)(C)

CONROE REGIONAL HOSPITAL

(936) 539-1111

Any further questions please contact medical dept.

(b)(6); (b)(7)(C)

LVN

IAH-SADF-POLK

Livingston, Tx 77351

936-967-(b)(6); (b)(7)(C)

936-967-8846-Fax

MTC Medical

A. L. ...

(b)(6); (b)(7)(C)

From: (b)(6); (b)(7)(C)
Sent: Saturday, September 16, 2017 7:24 PM
To: (b)(6); (b)(7)(C)
Cc:
Subject: Almazan-Ruiz, Felipe

Hospital Day #5

DETAINEE NAME: Almazan-Ruiz, Felipe

ALIEN NUMBER: A 028 866 428

DATE OF BIRTH: 06/26/1966

COUNTRY OF CITIZENSHIP: MEXICO

DATE OF ARRIVAL: 09/08/17

RELEVANT MEDICAL HISTORY: Detainee with history of heavy alcohol use, last drank 3 months ago. Presented to medical reporting hematemesis x5 days, assessed by RN who noted blood in mouth. Reports history of this happening 7 years ago as well. Has history of cirrhosis of the liver with varices.

DATE OF ADMISSION: 9/12/17

CURRENT DIAGNOSIS: GI BLEED

ATTENDING PHYSICIAN: (b)(6); (b)(7)(C)

CURRENT STATUS: Pt remains stable at this time. Med Surg floor RM 141. Most recent vital signs T-98.2, B/P- 106/65, P- 72, R-16, O2 @ 98% on RA. Pt had a cardiac stress test this morning and the test was normal. No changes to medication at this time. Meds remain Zoloft, Folic acid, metoprolol, protonix, lactulose, and aldactone.

DISCHARGE PLAN: possible discharge Sunday after seen by MD

REPORT GIVEN BY: (b)(6); (b)(7)(C)

CONROE REGIONAL HOSPITAL

(936) 539-(b)(6)

Any further questions please contact medical dept.

Thank you,

(b)(6); (b)(7)(C)

Weekends/nightshift

MTC Medical/IAH Detention Center

Livingston, Texas

Tel: 936-96-(b)(6); (b)(7)(C)

Fax: 936-967-8846

(b)(6); (b)(7)(C)

From: (b)(6); (b)(7)(C)
Sent: Sunday, September 17, 2017 2:32 AM
To: (b)(6); (b)(7)(C)
Cc:
Subject: RE: Almazan-Ruiz, Felipe

Hospital Day #6

DETAINEE NAME: Almazan-Ruiz, Felipe

ALIEN NUMBER: A 028 866 428

DATE OF BIRTH: 06/26/1966

COUNTRY OF CITIZENSHIP: MEXICO

DATE OF ARRIVAL: 09/08/17

RELEVANT MEDICAL HISTORY: Detainee with history of heavy alcohol use, last drank 3 months ago. Presented to medical reporting hematemesis x5 days, assessed by RN who noted blood in mouth. Reports history of this happening 7 years ago as well. Has history of cirrhosis of the liver with varices.

DATE OF ADMISSION: 9/12/17

CURRENT DIAGNOSIS: GI BLEED

ATTENDING PHYSICIAN: (b)(6); (b)(7)(C)

CURRENT STATUS: At about 0100 Pt coded & is now critical & pt has been moved to ICU RM #36. Pt is on life support/intubated with agonal breathing. When they are able to get B/P it is in the 50's by palpation. Hemoglobin is 5. They are giving him blood at this time. Warden Stacks has notified ICE personal Simpson.

DISCHARGE PLAN: none

REPORT GIVEN BY: (b)(6); (b)(7)(C)

CONROE REGIONAL HOSPITAL

(936) 539 (b)(6); (b)(7)(C)

Any further questions please contact medical dept.

Thank you,

(b)(6); (b)(7)(C)

Weekends/nightshift

MTC Medical/IAH Detention Center

Livingston, Texas

Tel: 936-967-(b)(6); (b)(7)(C)

Fax: 936-967-8846

CONROE REGIONAL MEDICAL CENTER

504 Medical Center Blvd.
Conroe, TX 77304

FAX

DATE:

9/15/17

FROM:

One North

TO:

(b)(6); (b)(7)(C)

DEPARTMENT:

1 NORTH - MEDICAL/SURGICAL

PHONE NUMBER:

936 967

(b)(6); (b)(7)(C)

TOTAL NO. OF PAGES, INCLUDING COVER:

FAX NUMBER:

PHONE NUMBER:

(936) 539

(b)(6); (b)(7)(C)

RE:

FAX NUMBER:

Ruiz, Felipe labs

(936) 788-8037

- URGENT
- FOR REVIEW
- PLEASE COMMENT
- PLEASE REPLY
- PLEASE RECYCLE

NOTES/COMMENTS:

~~PATIENT INFORMATION *PLEASE KEEP CONFIDENTIAL*~~

~~This fax and any files transmitted with it may contain PRIVILEGED or CONFIDENTIAL information and may be read or used only by the intended recipient. If you are not the intended recipient of this fax please be advised you have received this in error and that any use, dissemination, distribution, forwarding, printing or copying of this fax is strictly prohibited. If you have received this fax in error, please immediately destroy it and all attachments and notify sender at the telephone number listed.~~



0914:CR:000128R R117.FCLTIC 019023078363

Specimen Inquiry Report

Conroe Regional Medical Center, Conroe TX

~~*** CONFIDENTIAL ***~~

Med. Director: (b)(6); (b)(7)(C)

CAP#21190-01

PATIENT: RUIZ FELIPE

ACCT#: (b)(6); (b)(7)(C)

LOC: B.MEDU

U#: 0H00861890

FD: (b)(6); (b)(7)(C)

AGE/SX: 51/M

ROOM: B.141

REG: 09/12/17

RESOR:

STATUS: ADM IN

BED: W

DIS:

0914:CR:000128R COMP, Coll: 09/14/17-0450 Recd: 09/14/17-0503 (RN#07674936) ****

Test	Result	Flag	Reference	Site Verified
COMP METABOLIC				
> NA	137.0		133-144 mmol/L	09/14/17-0541
> K	4.2		3.5-5.1 mmol/L	09/14/17-0541
> CL	105		95-105 mmol/L	09/14/17-0541
> CO2	25		21-32 mmol/L	09/14/17-0541
> ANION GAP	7.0		4.0-15.0 GAP calc	09/14/17-0541

0914:CR:00071R RUIZ, FELIPE BH002307333

Specimen Inquiry Report

Conroe Regional Medical Center, Conroe TX

*** CONFIDENTIAL ***

Med. Director (b)(6); (b)(7)(C)

CAP#21190-01

PATIENT: RUIZ, FELIPE

ACCT#: (b)(6); (b)(7)(C)

LOC: B.MEDU

UH: BH00861890

FD: DO: ABBAL

AGE/SX: 51/M

ROOM: B.141

REG: 09/12/17

RESDR: (b)(6); (b)(7)(C)

STATUS: ADM IN

BEO: W

DIS:

0914:CR:00071R COMP, Coll: 09/14/17-0450 Recd: 09/14/17-0503 (R#07674936) ****

Test	Result	Flag	Reference	Site Verified
CBC				
> WBC	3.5	L	4.1-12.1 k/mm3	09/14/17-0542
> RBC	2.71	L	3.8-5.5 M/mm3	09/14/17-0542
> HGB	8.7	L	10.6-15.8 G/DL	09/14/17-0542
> HCT	25.5	L	36.0-47.4 %	09/14/17-0542
> MCV	93.1		88.1-101.1 fL	09/14/17-0542

0914:CR:CG00013R RUIZ,FELIPE BH0023078383

Specimen Inquiry Report

Conroe Regional Medical Center, Conroe TX

*** CONFIDENTIAL ***

Med. Director: (b)(6); (b)(7)(C)

MD CAP#21198-01

PATIENT: RUIZ, FELIPE

ACCT#: (b)(6); (b)(7)(C)

LOC: B.MEDU

U#: BH00861890

FD: (b)(6); (b)(7)(C) MD: ABBAI

AGE/SX: 51/M

ROOM: B.141

REG: 09/12/17

RESID: (b)(6); (b)(7)(C)

STATUS: ADM IN

BED: W

DIS:

0914:CR:CG00013R COMP, Coll: 09/14/17-0450 Recd: 09/14/17-0503 (R#07674936) ****

Test	Result	Flag	Reference	Site Verified
PT				
> PT PATIENT	17.3	H	9.4-12.5 SECONDS	09/14/17-0538
> INR	1.52	H	0.85-1.11 INR Unit	09/14/17-0538

Therapeutic range for INR is dependent upon the situation.
 2.0-3.0 Prophylaxis / venous thromboembolism, Treatment of
 DVT, Acute myocardial infarction stroke prevention,
 Systemic embolism prevention in fibrillation
 3.0-4.5 AMI recurrence prevention, Systemic embolism

Patient Information Form

Hospital Name: Conroe Regional Medical Center Phone: (936) 539- (b)(6)

Hospital Address: 504 MEDICAL CENTER BLVD CONROE, TX 77304

Patient Demographics		Admit and Length of Stay Information	
Patient Name: <u>RUIZ, FELIPE</u>	Medical Rec #: <u>U-29245316</u>	SSN: (b)(6); (b)(7)(C)	Admit Type: <u>ELECTIVE</u>
Marital Status: <u>Single</u>	Gender: <u>M</u>	Date of Birth: <u>06-26-1966</u>	Age: <u>51</u>
Religion: <u>NONE</u>	Episode ID: <u>BH9023078383</u>	Height: _____	Weight: _____
Unit: <u>CR</u>		Room: <u>B ICU4</u>	Bed: <u>B ICU18</u>
Prior to Admission: <u>Bed Only</u>		Est. Discharge Date: <u>09-12-2017</u>	ALC Date: _____
PC: (b)(6); (b)(7)(C)		Attending Physician: (b)(6); (b)(7)(C)	Phone Number: _____

Diagnosis Information:
 Rugs: _____ Primary: UPPER GI BLEED Secondary: _____

Discharge Notes:
 Notes: _____

Mode of Transportation: _____ Payer Source: _____
 Will patient receive radiation or dialysis off-site? _____
 Yes No Schedule of Treatments: _____

Patient Address	Next of Kin	Emergency Contact:
Living Arrangement: _____ Select One	First Name/MI: <u>FELIPE</u>	First Name/MI: _____
Facility Name: _____	Last Name: <u>RUIZ</u>	Last Name: _____
Street: <u>3400 FM 350 SOUTH</u>	Street: <u>3400 FM 350 SOUTH</u>	Street: _____
City: <u>LIVINGSTON</u>	City: <u>LIVINGSTON</u>	City: _____
State/Zip: <u>TX 77351</u>	State/Zip: <u>TX 77351</u>	State/Zip: _____
Home Phone: <u>936-96 (b)(6); (b)(7)(C)</u>	Home Phone: <u>936-96 (b)(6); (b)(7)(C)</u>	Home Phone: _____
Work Phone: <u>999-999 (b)(7)(C)</u>	Work Phone: _____	Work Phone: _____
Relation: <u>01</u>	Relation: _____	Relation: _____
<input type="checkbox"/> Emerg. Contact <input type="checkbox"/> POA	<input type="checkbox"/> Emerg. Contact <input type="checkbox"/> POA	<input type="checkbox"/> Emerg. Contact <input type="checkbox"/> POA

Payer Information: Ins. Group ID#: _____
 Primary Payer: OVERRIDE WITH PAYOR NAME Member ID#: (b)(6); (b)(7)(C)
 Contact person at Ins. Co. (First/MI/Last): _____ Phone: _____
 Patient has met 3 consecutive, acute level of care days during this admission & may be eligible for the Medicare Extended Care Benefit. Yes No N/A Unknown
 Secondary Payer: OVERRIDE WITH PAYOR NAME Member ID: (b)(6); (b)(7)(C) Phone #: _____
 Other Payer: _____ Member ID#: _____ Phone #: _____

Income If known: Private Funds SSA SSI
 Pension VA Other
 Patient Medicaid Eligible? Yes No If Yes, submitted by our financial office? Yes No

Contact person in financial office (First/MI/Last): _____
No Fault: Must have claim number, name of insurance company, name of insured, telephone number, and policy number. This information is needed even if no fault is exhausted. No faults must have secondary insurance information.

Case Contact: First/MI/Last: (b)(6); (b)(7)(C) Phone: (936) 539- (b)(6); (b)(7)(C) Date: 09-12-2017

9/12/2017
03:33 PM

HCA Corporate
Insurance Certification Report - IQ
CONFIDENTIAL PATIENT INFORMATION

For Facility: Conroe Regional Medical Center

===== ENCOUNTER / HCM DATA =====

Acct No.: BH9023078383 Patient Name: RUIZ, FELIPE Age: 51Y DOB: 6/26/1966

Start Date: 9/12/2017 8:20AM Adm Phys: (b)(6); (b)(7)(C) MD MRN: BH0086189C
Location: CR-3 INTENSIVE C Att Phys: (b)(6); (b)(7)(C) MD Fac: Conroe Regio
Room: B. ICU18-W Disch Date: Enc Type: INPATIENT (Inpatient)
Accommodation: Home Addr: 3400 FM 350 SCUTH Sex: M
LIVINGSTON, TX Marital Stat: Single
County: Country: United States of Ame
Zip Code: 77351
Home Phone: 936-967 (b)(6); (b)(7)(C)
Work Phone: 999-999-9999 SSN: <Blocked>

Emer Contacts:
Name: RUIZ, FELIPE Home Tel: 936-967 (b)(6); (b)(7)(C) Work Tel:
Relationship: Self

HCM DRG: Ver: Current Stay: 1 ALOS: GLOS: Outlier:

Admit Complaint: UPPER GI BLEED
HCM Diagnosis:
HCM Procedure:
Dx Category:
Admit Review:

===== PAYER(S) =====

OVERRIDE WITH PAYOR NAME Status: P Cert?
Auth No: NR/ Insur No: 028866428
OVERRIDE WITH PAYOR NAME Status: S Cert?
Auth No: NR/ Insur No: 028866428

===== LAST COMPLETED REVIEW ONLY =====

Review Date Care Date Review Category Reviewer ID
9/12/2017 9/12/2017 (b)(6); (b)(7)(C)
Severity Intensity

Reviewer Comments:
---9/12/2017 1531 by (b)(6); (b)(7)(C)
Point of entry: per cpoe admit Inpt payer override with payor Name
transfer from Livingston
Presenting symptoms: Gi bleed,
Failed OP treatment:
Vital signs: p 93, p84, 77, bp 181/107, 184/95, 203/95, 211/104
Medications/route:
Labs/Cultures: h/h 11.2/30.1
Imaging:
Diet/Activity:
Oxygen:
PI/OT/ST:

Referral From: Conroe Regional Medical Center

From: (b)(6); (b)(7)(C) To: IAH Immigration
 Phone: (936) 539 (b)(6); (b)(7)(C) Attention: (b)(6); (b)(7)(C)
 Fax: (936) 788-8076

Comment: 028866428 ins # our fax 936 788 8076 tax id 621 801 361 npi 1962455816

Regarding Patient: RUI, F
 SSN: XXX-XX-5555
 Member ID: 028866428

The following documents are included in this fax:

Name	Pages
Patient Information Form (rev.7/2012) 09-12-17 03:37 pm	1
Insurance Certification Report - IQ	2

Patient Health Information Legal Disclosure: This facsimile transmission contains confidential information, some or all of which may be protected health information as defined by HIPAA (the federal Health Insurance Portability & Accountability ACT) or personal information protected by state data privacy or security laws. This transmission is intended for the exclusive use of the individual or entity to whom it is addressed and may contain information that is proprietary, privileged, confidential and/or exempt from disclosure under applicable law. If you are not the intended recipient (or an employee or agent responsible for delivering this facsimile transmission to the intended recipient), you are hereby notified that any disclosure, dissemination, distribution or copying of this information is strictly prohibited and may be subject to legal restriction or sanction. If you received this in error, please notify (b)(6); (b)(7)(C) or e-mail at (b)(6); (b)(7)(C) to arrange the return or destruction of the information and all copies

9/12/2017 2:30 PM
 VS-68 17 96910
 106/56
 DLE
 EGD
 admitting
 2 units placed 55/h
 9.

9/12/2017
03:33 PM

HCA Corporate
Insurance Certification Report - IQ
CONFIDENTIAL PATIENT INFORMATION

PAGE 2

For Facility: Conroe Regional Medical Center

Acct No.: BH9C23078363

Patient Name: RUIZ, FELIPE

Age: 51Y DOB: 6/26/1966

Facility: Conroe Regional Medical Center

===== LAST COMPLETED REVIEW ONLY (continued) =====

Treatments:

Level of care eval/referrals: 9/12 to ICU dx GI bleed, left ^{ES} with ns at 100 ml hr, bp 218/ cardene gtt, , h/h stable platellets 27, plan is for EGD today or tomorrow, bp controlled , cardene gtt turned off lisinopril po stated at 1300

MD Treatment Plans:

Comments/Other:

===== LAST INTERQUAL REVIEW ONLY =====

Review Date Reviewer ID

9/12/2017 (b)(6); (b)(7)(C)

InterQual Version: InterQual® 2017.1

Review date: 09-12-2017

Review Status: In Primary

Product: LOC:Acute Adult

Criteria subset: General Medical

Criteria status: Critical Met

(Symptom or finding within 24h)

(Excludes PC medications unless noted)

Select Day, One:

Episode Day 1, One:

CRITICAL, >= One:

General, >= One:

IV medication administration, Both:

Medication, >= One:

Antihypertensive

Administration, >= One:

Titration q1-2h and monitoring

InterQual® and CareEnhance® Review Manager © 2017 McKesson

Corporation and/or one of its subsidiaries. All Rights Reserved.

CPT only © 2016 American Medical Association. All Rights Reserved.

===== CONFIDENTIALITY STATEMENT =====

~~CONFIDENTIAL - Contains proprietary information. Not intended for external distribution.~~

Referral From: Conroe Regional Medical Center

From: (b)(6); (b)(7)(C) To: IAH DENTENTION CENTER
Phone: (936) 539 (b)(6); (b)(7)(C) Attention: (b)(6); (b)(7)(C)
Fax: (936) 788-8076
Comment: NOTES AS REQUESTED

Regarding Patient: RUI.F
SSN: XXX-XX-5555
Member ID: 028866428

The following documents are included in this fax:

Name	Pages
Insurance Certification Report - IQ	4
0913_12:23:13	1
0913_12:23:04	4

Patient Health Information Legal Disclosure: This facsimile transmission contains confidential information, some or all of which may be protected health information as defined by HIPAA (the federal Health Insurance Portability & Accountability ACT) or personal information protected by state data privacy or security laws. This transmission is intended for the exclusive use of the individual or entity to whom it is addressed and may contain information that is proprietary, privileged, confidential and/or exempt from disclosure under applicable law. If you are not the intended recipient (or an employee or agent responsible for delivering this facsimile transmission to the intended recipient), you are hereby notified that any disclosure, dissemination, distribution or copying of this information is strictly prohibited and may be subject to legal restriction or sanction. If you received this in error, please notify (b)(6); (b)(7)(C) or e-mail (b)(6); (b)(7)(C) arrange the return or destruction of the information and all copies

9/13/2017
11:41 AM

HCA Corporate
Insurance Certification Report - Selected Review - IQ
CONFIDENTIAL PATIENT INFORMATION

For Facility: Conroe Regional Medical Center

===== ENCOUNTER / HCM DATA =====

Acct No.: BH9023078383 Patient Name: RUIZ, FELIPE Age: 51Y DOB: 6/26/1966
Start Date: 9/12/2017 8:20AM Adm Phys: (b)(6); (b)(7)(C) MD MRN: BHC0861890
Location: CR-3 INTENSIVE C Att Phys: (b)(6); (b)(7)(C) MD Fac: Conroe Regio
Room: B.1CU16-W Disch Date: Accommodation: Enc Type: INPATIENT(Inpatient)
Home Addr: 3400 FM 350 SOUTH Sex: M
LIVINGSTON, TX Marital Stat: Single
County: Country: United States of Ame
Zip Code: 77351
Home Phone: 936-967-(b)(6); (b)(7)(C)
Work Phone: 999-999-9999 SSN: <Blocked>

Emer Contacts:
Name: RUIZ, FELIPE Home Tel: 936-967-8000 Work Tel:
Relationship: Self

HCM DRG: 872 Ver: 34 Current Stay: 1 ALOS: 4.5 GLOS: 3.8 Outlier:

Admit Complaint: UPPER GI BLEED
HCM Diagnosis:
HCM Procedure:
Dx Category:
Admit Review:

===== PAYER(S) =====

OVERWRITE WITH PAYOR NAME Status: P Cert?
Auth No: NR/I Insur No: 028866428
From Thru #Days Type Status Auth No Ref No Service
Cert - P

Company:
Submit by: Date: Time:
Submit to:
Phone: Fax:

OVERWRITE WITH PAYOR NAME Status: S Cert?
Auth No: NR/I Insur No: 028866428

===== CURRENT REVIEW =====

Review Date Care Date Review Category (b)(6); (b)(7)(C)
9/13/2017 9/13/2017

Severity Intensity

Reviewer Comments: (b)(6); (b)(7)(C)
---9/13/2017 1133
Vital signs:
36.6, 57, 109/66 TC 89/54, 94 %

9/13/2017
11:41 AM

HCA Corporate
Insurance Certification Report - Selected Review - IQ
CONFIDENTIAL PATIENT INFORMATION

PAGE 2

For Facility: Conroe Regional Medical Center

Acct No.: BH9C23078383 Patient Name: RUIZ, FELIPE
Facility: Conroe Regional Medical Center

Age: 51Y DOB: 6/26/1966

===== CURRENT REVIEW =====

Medications/Route:

PO MEDS, PROTONIX IV, LEVAQUIN IV, IV TRANDATE PRN, IV ZOFRAN PRN, IV MORPHINE PRN,

IV's:

IVE @ 75 CC/HR, IV CARDENE GTT TITRATED

Labs/Cultures:

H&H 8.4/23.8, PLT 35, RBC 2.60, PT/ INR 16.6/1.46

Imaging/Other tests:

Diet/Activity:

CL DIET

Oxygen: AS NEEDED

PT/OT/ST:

Other treatments:

BLOOD PRODUCT TRANSFUSION- PLATELETS

Level of care eval/referrals:

CARDIO, GI, CRIT CARE

Barriers to Discharge:

IV MEDS, PLAN STRESS WHEN HGB 10

Comments/Other:

===== INTERQUAL REVIEW HISTORY =====

Review Date Reviewer ID

9/13/2017 (b)(6);(b)(7)(C)

InterQual Version: InterQual® 2017.1

Review date: 09-13-2017

Review Status: In Primary

Product: LOC:Acute Adult

Criteria subset: General Medical

Criteria status: Critical Met

(Symptom or finding within 24h)

(Excludes PC medications unless noted)

Select Day, One:

Episode Day 1, One:

CRITICAL, >= One:

General, >= One:

IV medication administration, Both:

Medication, >= One:

Calcium channel blocker

Administration, >= One:

Titration q1-2h and monitoring

InterQual® and CareEnhance® Review Manager © 2017 McKesson
Corporation and/or one of its subsidiaries. All Rights Reserved.
CPT only © 2016 American Medical Association. All Rights Reserved.

9/13/2017
11:41 AM

HCA Corporate
Insurance Certification Report - Selected Review - IQ
CONFIDENTIAL PATIENT INFORMATION

PAGE 3

For Facility: Conroe Regional Medical Center

Acct No.: BH9023078363

Patient Name: RUIZ, FELIPE

Age: 51Y DOB: 6/26/1966

Facility: Conroe Regional Medical Center

===== PAYER(S) (continued) =====

===== CONFIDENTIALITY STATEMENT =====

~~CONFIDENTIAL - Contains proprietary information. Not intended for external distribution.~~

CONROE MEDICAL CENTER (COCCR)

Clinical Note

REPORT#: 0912-0490 REPORT STATUS: Signed

DATE: 09/12/17 TIME: 1522

PATIENT: RUIZ, FELIPE

ACCOUNT#: (b)(6); (b)(7)(C)

DOB: 06/26/56 AGE: 51

SEX: M

ADM DT: 09/12/17

UNIT #: BH00861890

ROOM/BED: B.ICU18-W

ATTEND: (b)(6); (b)(7)(C)

AUTHOR:

* ALL edits or amendments must be made on the electronic/computer document *

**** See Addendum ****

Clinical Note

Note:

2035335

Electronically Signed by (b)(6); (b)(7)(C) MD on 09/12/17 at 1522

Addendum 1: 09/12/17 1524 b

(b)(6); (b)(7)(C)

2035363

Electronically Signed by (b)(6); (b)(7)(C) MD on 09/12/17 at 1525

RPT #: 0912-0490

END OF REPORT

CONROE MEDICAL CENTER (COCCR)
Pulmonology Progress Note
REPORT#: 0912-0575 REPORT STATUS: Draft
DATE: 09/12/17 TIME: 1714

PATIENT: RUIZ, FELIPE
ACCOUNT#: (b)(6); (b)(7)(C)
DOB: 06/26/66 AGE: 51 SEX: M
ADM DT: 09/12/17
UNIT #: BH00861890
ROOM/BED: B.ICU18-W
ATTEND: (b)(6); (b)(7)(C)
AUTHOR: (b)(6); (b)(7)(C)

* ALL edits or amendments must be made on the electronic/computer document *

Subjective

Chief Complaint:
RFC: GI bleed/ICu management.

Objective

Physical Exam

VS/I&O:
Last Documented:

	Result	Date Time
Temp	98.3	09/12 1600
Pulse Ox	100	09/12 1447
O2 Flow Rate	2	09/12 1447
B/P	117/58	09/12 1400
Pulse	88	09/12 1400
Resp	19	09/12 1400

Medications:

Active Meds + DC'd Last 24 Hrs
Folic Acid 1 MG DAILY PO
Lactulose 30 ML BID PO (CKD)
Pantoprazole 40 MG Q12HR IV
Trazodone HCl 50 MG BEDTIME PO
Metoprolol Succinate 12.5 MG DAILY PO
Sertraline HCl 100 MG DAILY PO
Sodium Chloride 250 ML ASDIR IV
Labetalol HCl 10 MG Q4H PRN PRN IV
Levofloxacin 100 ML Q24H IV
Morphine Sulfate 1 MG Q4H PRN PRN IV
Ondansetron HCl 4 MG Q4H PRN PRN IV
Sodium Chloride 250 ML ASDIR PRN IV
Sodium Chloride 10 ML ASDIR IV
Sodium Chloride 1,000 ML Q13H20M IV
Lisinopril 20 MG DAILY PO (DC)
Nicardipine/Sodium Chloride 250 ML ASDIR IV

Patient: RUIZ, FELIPE
 Unit#: BH00861890
 Date: 09/12/17
 BH9023078383

Acct#:


Nicardipine/Sodium Chloride 250 ML .STK-MED ONE IV (DC)

General appearance: alert, awake
Head/eyes: normocephalic, PERRL, EOMI, clear cornea
Neck: full range of motion, non-tender, normal thyroid, supple/no meningismus, no bruit/NL carotids, no JVD, no lymphadenopathy
Cardiovascular: regular rate & rhythm
Respiratory/chest: decreased breath sounds
Abdomen: soft, non-tender, no distention, no guarding, no mass/organomegaly, no rebound
Extremities: moves all, normal capillary refill, no edema
Musculoskeletal: full range of motion, normal inspection



Results

Findings/Data:
 Laboratory Tests

09/12/17 1200:



09/12/17 1155:



Laboratory Tests

	09/12 1530	09/12 1530	09/12 1530
Chemistry			
Ammonia (11.0 - 32.0 mcMOL/L)			90.0 *H
CK-MB (CK-2) (1.0 - 3.6 NG/ML)	4.9 H		
Troponin I (0.000 - 0.045 NG/ML)	0.270 *H		
B-Natriuretic Peptide (0.00 - 100.00 PG/ML)		226.59 H	

	09/12 1155
Chemistry	
Sodium (133 - 144 mmol/L)	133.0

Patient: RUIZ, FELIPE
 Unit#: BH00861890
 Date: 09/12/17
 BH9023078383

Acct#:

Potassium (3.5 - 5.1 mmol/L)	4.2
Chloride (95 - 105 mmol/L)	102
Carbon Dioxide (21 - 32 mmol/L)	24
Anion Gap (4.0 - 15.0 GAP calc)	7.0
BUN (7 - 18 MG/DL)	67 H
Creatinine (0.55 - 1.30 MG/DL)	1.36 H
Glomerular Filtr Rate (> 60 estGFR)	55 L
Glucose (70 - 110 MG/DL)	132 H
Calcium (8.5 - 10.1 MG/DL)	7.8 L
Total Bilirubin (0.00 - 1.00 MG/DL)	6.56 H
Direct Bilirubin (0.00 - 0.30 MG/DL)	3.35 H
Indirect Bilirubin (0.2 - 1.3 MG/DL)	3.21 H
AST (15 - 37 Unit/L)	81 H
ALT (12 - 78 Unit/L)	49
Total Alk Phosphatase (45 - 117 Unit/L)	107
Total Protein (6.4 - 8.2 G/DL)	5.4 L
Albumin (3.4 - 5.0 G/DL)	2.9 L
Albumin/Globulin Ratio (1.2 - 2.2 RATIO)	1.2
Specimen Appearance (1 NORMAL Index/DL)	3 SMALL 5-10 MG
Specimen Hemolysis (1 NORMAL Index/DL)	2 TRACE 10-25 MG

Laboratory Tests

	09/12 1200
Coagulation	
PT (9.4 - 12.5 SECONDS)	17.3 H
INR (0.85 - 1.11 INR Unit)	1.52 H
PTT (Dade) (24 - 37.7 SECONDS)	29.4

Laboratory Tests

	09/12 1200
Hematology	
WBC (4.1 - 12.1 k/mm ³)	15.1 H
RBC (3.8 - 5.5 M/mm ³)	3.50 L
Hgb (10.6 - 15.8 G/DL)	11.2
Hct (36.0 - 47.4 %)	30.1 L
MCV (80.1 - 101.1 fL)	86.0
MCH (25.3 - 35.3 pg)	32.0
MCHC (32.7 - 35.1 G/DL)	37.2 H
RDW (12.2 - 16.4 %)	17.2 H
Plt Count (155 - 337 K/mm ³)	27 *L
MPV (7.6 - 10.4 fL)	10.3

Patient: RUIZ, FELIPE
 Unit#: BH00861890
 Date: 09/12/17
 BH9023078383

Acct#:

Gran % (37.8 - 82.6 %)		65.8
Lymph % (Auto) (14.1 - 45.4 %)		12.1 L
Mono % (Auto) (2.5 - 11.7 %)		12.7 H
Eos % (Auto) (0.0 - 6.2 %)		1.7
Baso % (Auto) (0.0 - 2.6 %)	0.5	
Gran # (2.0 - 13.7 K/mm3)		9.95 H
Lymph # (Auto) (0.6 - 3.8 K/mm3)		1.82
Mono # (Auto) (0.11 - 0.59 K/mm3)		1.91 H
Eos # (Auto) (0.0 - 0.4 K/mm3)		0.25
Baso # (Auto) (0.0 - 0.1 K/mm3)		0.08
Add Manual Diff (CRITERIA DIFF/SCN)	MAN DIFF INDICATED	
Total Counted (100 #CELLS)		100
Immature Gran % (0.0 - 2.0 %)		7.2 H
Seg Neutrophils % (40 - 75 %)		73
Lymphocytes % (Manual) (12.6 - 43.5 %)		12 L
Monocytes % (Manual) (4.2 - 12.7 %)		14 H
Eosinophils % (Manual) (0.0 - 5.2 %)		1
Nucleated RBC % (0.0 - 1.0 /100WBC%)		1.7 H
Nucleated RBCs # (0.00 - 0.05 K/mm3)		0.25 H
Toxic Granulation (NONE ON SCAN)	SLIGHT	
Platelet Estimate (ADEQUATE ON SCAN)	MRK DECR L	
Plt Morphology Comment (NORMAL PLTS ON SCAN)	LARGE RARE	
Polychromasia (NONE ON SCAN)	SLIGHT	
Hypochromasia (NONE ON SCAN)	SLIGHT	
Poikilocytosis (NONE ON SCAN)	SLIGHT	
Anisocytosis (NONE ON SCAN)	SLIGHT	
Ovalocytes (NONE ON SCAN)	FEW	
Acanthocytes (Spur) (NONE ON SCAN)	RARE	
Schistocytes (NONE ON SCAN)	RARE	

Diagnosis, Assessment & Plan

Free Text A&P:

GI Bleed: management per GI
 hypotension : better.

RPT #: 0912-0575
 END OF REPORT

Referral From: Conroe Regional Medical Center

From: (b)(6); (b)(7)(C) To: IAH IMMIGRATION DETENTION
Phone: (936) 539-(b)(6); Attention: (b)(6); (b)(7)(C)
Fax: (936) 788-8076
Comment: TAX ID: (b)(6); (b)(7)(C) AX : 936-788-8076

Regarding Patient: RUI, F
SSN: XXX-XX-5555
Member ID: 028866428

The following documents are included in this fax:

Name	Pages
Insurance Certification Report - IQ	4
0913_12:23:13	1
0913_12:23:04	4
RAD/XR CHEST 1 V	1
Specimen Inquiry	1
US/US ABDOMEN LTD	2
HISTORY AND PHYSICAL	3
0913_12:22:40	8
Specimen Inquiry	2
Specimen Inquiry	1
Specimen Inquiry	1
Specimen Inquiry	2
Specimen Inquiry	2
Specimen Inquiry	1
ELECTROCARDIOGRAM	1
ENDOWORKS REPORT	2
HISTORY AND PHYSICAL	1
Specimen Inquiry	1
0913_12:21:25	1
HISTORY AND PHYSICAL_FAKAL_09122017_B.HIM201709130071.rtf	1
Clinical Rounds Report_20170913.rtf	7
HISTORY AND PHYSICAL_FAKAL_09122017_B.HIM201709120324.rtf	3
US ABDOMEN LTD_US_09122017_020697791.rtf	1
XR CHEST 1 V_RAD_09122017_020697794.rtf	1

Patient Health Information Legal Disclosure: This facsimile transmission contains confidential information, some or all of which may be protected health information as defined by HIPAA (the federal Health Insurance Portability & Accountability ACT) or personal information protected by state data privacy or security laws. This transmission is intended for the exclusive use of the individual or entity to whom it is addressed and may contain information that is proprietary, privileged, confidential and/or exempt from disclosure under applicable law. If you are not the intended recipient (or an employee or agent responsible for delivering this facsimile transmission to the intended recipient), you are hereby notified that any disclosure, dissemination, distribution or copying of this information is strictly prohibited and may be subject to legal restriction or sanction. If you received this in error, please notify (b)(6); (b)(7)(C)

arrange the return or destruction of the information and all copies

9/13/2017
11:41 AM

HCA Corporate
Insurance Certification Report - Selected Review - IQ
CONFIDENTIAL PATIENT INFORMATION

PAGE 1

For Facility: Conroe Regional Medical Center

===== ENCOUNTER / HCM DATA =====

Acct No.: (b)(6); (b)(7)(C) Patient Name: RUIZ, FELIPE Age: 51Y DOB: 6/26/1966
Start Date: 9/12/2017 8:20AM Adm Phys (b)(6); (b)(7)(C) MD MRN: BHC0861890
Location: CR-3 INTENSIVE C Att Phys (b)(6); (b)(7)(C) MD Fac: Conroe Regio
Room: B. ICU16-W Disch Date:
Accommodation: Enc Type: INPATIENT (Inpatient)
Home Addr: 3400 FM 350 SOUTH Sex: M
Marital Stat: Single
LIVINGSTON, TX
County:
Country: United States of Ame
Zip Code: 77351
Home Phone: 936-967-8000
Work Phone: 999-999-9999 SSN: <Blocked>

Emer Contacts:
Name: RUIZ, FELIPE Home Tel: 936-967-8000 Work Tel:
Relationship: Self

ECM DRG: 872 Ver: 34 Current Stay: 1 ALOS: 4.5 GLOS: 3.8 Outlier:

Admit Complaint: UPPER GI BLEED
HCM Diagnosis:
HCM Procedure:
Dx Category:
Admit Review:

===== PAYER(S) =====

OVERWRITE WITH PAYOR NAME Status: P Cert?
Auth No: NR/I Insur No: 028866428
From Thru #Days Type Status Auth No Ref No Service
Cert - P

Company:
Submit by: Date: Time:
Submit to:
Phone: Fax:

OVERWRITE WITH PAYOR NAME Status: S Cert?
Auth No: NR/I Insur No: 028866428

===== CURRENT REVIEW =====

Review Date Care Date Review Category (b)(6); (b)(7)(C)
9/13/2017 9/13/2017

Severity Intensity

Reviewer Comments: (b)(6); (b)(7)(C)
---9/13/2017 1133 by (b)(6); (b)(7)(C)
Vital signs:
36.6, 57, 109/68 TO 89/54, 94 %

9/13/2017
11:41 AM

HCA Corporate
Insurance Certification Report - Selected Review - IQ
CONFIDENTIAL PATIENT INFORMATION

PAGE 2

For Facility: Conroe Regional Medical Center

Acct No.: (b)(6);(b)(7)(C) Patient Name: RUIZ, FELIPE
Facility: Conroe Regional Medical Center

Age: 51Y DOB: 6/26/1966

===== CURRENT REVIEW =====

Medications/Route:

PO MEDS, PROTONIX IV, LEVAQUIN IV, IV TRANDATE PRN, IV ZOFRAN PRN, IV MORPHINE PRN,

IV's:

IVF @ 75 CC/HR, IV CARDENE GTT TITRATED

Labs/Cultures:

H&H 8.4/23.8, PLT 35, RBC 2.60, PT/ INR 16.6/1.46

Imaging/Other tests:

Diet/Activity:

CL DIET

Oxygen: AS NEEDED

PT/OT/ST:

Other treatments:

BLOOD PRODUCT TRANSFUSION- PLATELETS

Level of care eval/referrals:

CARDIO, GI, CRIT CARE

Barriers to Discharge:

IV MEDS, PLAN STRESS WHEN HGB 10

Comments/Other:

===== INTERQUAL REVIEW HISTORY =====

Review Date Reviewer ID
9/13/2017 (b)(6);(b)(7)(C)

InterQual Version: InterQual® 2017.1

Review date: 09 13 2017

Review Status: In Primary

Product: LOC:Acute Adult

Criteria subset: General Medical

Criteria status: Critical Met

(Symptom or finding within 24h)

(Excludes PO medications unless noted)

Select Day, One:

Episode Day 1, One:

CRITICAL, >= One:

General, >= One:

IV medication administration, Both:

Medication, >= One:

Calcium channel blocker

Administration, >= One:

Titration q1-2h and monitoring

InterQual® and CareEnhance® Review Manager © 2017 McKesson
Corporation and/or one of its subsidiaries. All Rights Reserved.
CPI only © 2016 American Medical Association. All Rights Reserved.

9/13/2017
11:41 AM

HCA Corporate
Insurance Certification Report - Selected Review - IQ
CONFIDENTIAL PATIENT INFORMATION

PAGE 3

For Facility: Conroe Regional Medical Center

Acct No.: BH9023078383
Facility: Conroe Regional Medical Center

Patient Name: RUIZ, FELIPE

Age: 51Y DOB: 6/26/1966

===== PAYER(S) (continued) =====

===== CONFIDENTIALITY STATEMENT =====

~~CONFIDENTIAL - Contains proprietary information. Not intended for external distribution.~~

FAX: (b)(6); (b)(7)(C) 936-585-4 (b)(6); (b)(7)(C) Campus: C St: ADM
FAX: (b)(6); (b)(7)(C) 936-585-4 (b)(6); (b)(7)(C)

Patient Name: RUIZ, FELIPE

Unit No: BH00861890

EXAMS:

020697794 RAD/XR CHEST 1 V

To be performed PORTABLE?

Travel Mode:

Isolation Type:

Reason for Exam: leucocytosis

Comments:

*?

Location: T 18

Chest x-ray exam, AP frontal projection, 9/12/2017

CLINICAL HISTORY: Leukocytosis, ICU patient.

Comparison exams: None of the chest

Elevation the right hemidiaphragm difficult to assess in terms of age given lack of prior exams. Probable scarring versus atelectatic changes mainly at the right lung base. No active CHF. Overlying lines obscure detail. No findings of high concern for pneumonia

** Electronically Signed by (b)(6); (b)(7)(C) *
** on 09/12/2017 at 1726 **
Reported and signed by (b)(6); (b)(7)(C)

CC: (b)(6); (b)(7)(C)

Dictated Date/Time: 09/12/2017 (1726)

Technologist: (b)(6); (b)(7)(C)

Transcribed Date/Time: 09/12/2017 (1726) By: (b)(6); (b)(7)(C)

Orig Print D/T: S: 09/12/2017 (1729)

CONROE MED CTR IN/OBS
MEDICAL IMAGING
504 MEDICAL CENTER BLVD
CONROE, TEXAS 77304
PHONE #: 936-539-7026
FAX #: 936-539-7681

NAME: RUIZ, FELIPE
PHYS: (b)(6); (b)(7)(C)
DOB: 06/26/1966 AGE: 51 SEX: M
ACCT NO: (b)(6); (b)(7)(C) LOC: B.ICU18 W
EXAM DATE: 09/12/2017 STATUS: ADM IN
RAD NO: DC Dt:

PAGE 1 Signed Report Printed From PCI

Patient Name: RUIZ, FELIPE

Unit No: BH00861890

EXAMS:

020697791 US/US ABDOMEN LTD

Travel Mode:

Isolation Type:

Reason for Exam: RUQ abd pain.H/O non alcoholic liver cirrhosis

Comments:

*?

Site:R16

Limited Abdominal Ultrasound

History: Right upper quadrant abdominal pain, history of nonalcoholic liver cirrhosis.

Comparison: No prior similar studies are available for comparison.

Technique: Gray scale and color Doppler imaging were utilized.

Findings:

This examination is markedly limited due to poor beam penetration.

The liver is measures 15.2 cm in length. Evaluation of the liver is markedly limited. The main portal vein is not well visualized.

The gallbladder is not well-visualized. Sonographic Murphy sign is negative.

The common bile duct is not identified on this examination.

The right kidney measures 10.9 x 5.8 x 4.2 cm, with a cortical thickness measuring 1.9 cm. It demonstrates no hydronephrosis, nephrolithiasis or cortical thinning.

The pancreas is not visualized.

The visualized portions of the abdominal aorta and IVC are unremarkable.

There is no evidence of ascites.

Impression:

1. *Markedly limited examination due to poor beam penetration. The liver, gallbladder, common bile duct and pancreas are inadequately visualized on this examination.*
2. *Unremarkable right kidney and visualized portions of the abdominal*

CONROE MED CTR IN/OBS
 MEDICAL IMAGING
 504 MEDICAL CENTER BLVD
 CONROE, TEXAS 77304
 PHONE #: 936-539-7026
 FAX #: 936-539-7681

NAME: RUIZ, FELIPE
 PHYS: (b)(6); (b)(7)(C)
 DOB: (b)(6); (b)(7)(C) AGE: 51 SEX: M
 ACCT NO: (b)(6); (b)(7)(C) LOC: B.ICU18 W
 EXAM DATE: 09/12/2017 STATUS: ADM IN
 RAD NO:

Patient Name: RUIZ, FELIPE

Unit No: BH00861890

EXAMS:

020697791 US/US ABDOMEN LTD

Travel Mode:

Isolation Type:

Reason for Exam: RUQ abd pain.H/O non alcoholic liver cirrhosis

Comments:

*?

<Continued>

aorta and IVC.

** Electronically Signed by (b)(6); (b)(7)(C) on 09/12/2017 at 1909 **
Reported and signed by: (b)(6); (b)(7)(C)

CC: (b)(6); (b)(7)(C)

Technologist: Tammy Snow - Agency
Trnscribd D/T: 09/12/2017 (1909) t.SDR.RH16
Orig Print D/T: S: 09/12/2017 (1913) Probe:

CONROE MED CTR IN/OBS
MEDICAL IMAGING
504 MEDICAL CENTER BLVD
CONROE, TEXAS 77304
PHONE #: 936-539-7026
FAX #: 936-539-7681

NAME: RUIZ, FELIPE
PHYS: (b)(6); (b)(7)(C)
DOB: 06/26/1966 AGE: 51 SEX: M
ACCT NO: BH9023078383 LOC: B.ICU18 W
EXAM DATE: 09/12/2017 STATUS: ADM IN
RAD NO:

0912-0324

CONROE REGIONAL MEDICAL CENTER
504 Medical Center Blvd.
Conroe, Texas 77304

PATIENT NAME: RUIZ, FELIPE
ACCOUNT NO: BH9023078383
MEDICAL RECORD NO: BH00861890
REPORT TYPE: HISTORY AND PHYSICAL

ADMIT DATE: 09/12/17
ROOM NO: B.ICU18
AGE: 51
SEX: M

ADMITTING PHYSICIAN: (b)(6); (b)(7)(C)
ATTENDING PHYSICIAN: (b)(6); (b)(7)(C)

ADMISSION DATE: 09/12/2017

PRIMARY CARE PHYSICIAN: None. The patient is from immigration jail center.

CHIEF COMPLAINT: Hematemesis.

HISTORY OF PRESENT ILLNESS: The patient is a 51-year-old Hispanic incarcerated male, who was taken to Livingston Memorial Emergency Room with complaints of abdominal pain, right flank pain, _____, and hematemesis. He has a past medical history significant for nonalcoholic liver cirrhosis, generalized anxiety disorder, and depression. He was in his usual state of health until early morning, he complained of abdominal pain, right flank pain and started throwing up blood. His hemoglobin level at the Livingston ER was fairly stable at 12.5 and hematocrit was 33.2. He was started on Sandostatin drip and then transferred to Conroe Regional Medical Center ICU for further care. Of note, his platelet level significantly decreased to 18,000.

PAST MEDICAL HISTORY: As mentioned above, which includes,
1. Nonalcoholic liver cirrhosis.
2. Depression.
3. Generalized anxiety disorder.

PAST SURGICAL HISTORY: None.

ALLERGIES: NO KNOWN DRUG ALLERGIES.

MEDICATIONS FROM JAIL: Reviewed. These include folic acid 1 mg daily, Zoloft 100 mg daily, trazodone 50 mg at bedtime, Aldactone 25 mg b.i.d., and omeprazole 40 mg daily.

SOCIAL HISTORY: The patient is incarcerated. He is originally from Florida; however, because of the flooding, he was transferred to Texas Jail.

FAMILY HISTORY: The patient is unaware of any medical problems running in the family.

REVIEW OF SYSTEMS:

GENERAL: Positive for malaise and fatigue.

HEENT: No headaches.

CARDIOVASCULAR: No active chest pain.

RESPIRATORY: No shortness of breath.

GASTROINTESTINAL: He presents with right upper quadrant abdominal pain and

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: (b)(6); (b)(7)(C)

hematemesis.

GENITOURINARY: Denies dysuria or hematuria.

MUSCULOSKELETAL: No active joint pain.

NEUROLOGICAL: He is moving all 4 extremities. Speech appears to be clear.

PSYCHIATRIC: He has history of depression.

LABORATORY AND DIAGNOSTIC DATA: From Livingston ER, sodium 127, potassium 4.3, BUN 85, and creatinine 1.5. Albumin decreased to 3.3. AST 102, ALT 68, ALKP 123, and total bilirubin 10.8. CPK elevated at 322. Lipase mildly elevated at 367. BNP elevated at 4850. PTT 22.1. Troponin I 0.076. WBC 14.28, hemoglobin 12.5, hematocrit 33.2, and platelets decreased to 18.

ASSESSMENT AND PLAN: A 51-year-old incarcerated Hispanic male with history of nonalcoholic liver cirrhosis, now presents with:

1. Gastrointestinal bleed. Differential diagnosis could be variceal, esophageal, or gastric bleeding versus peptic ulcer disease versus gastritis. The patient has been started on octreotide drip. We will also initiate IV PPI and monitor hemoglobin/hematocrit levels, so far are stable. GI consultation has been requested for evaluation of possible EGD.
2. Right upper quadrant abdominal pain. We will check hepatitis panel and right upper quadrant ultrasound.
3. Renal failure, unknown acute or chronic. We will hold Aldactone and other nephrotoxic medications. Could be in the setting of gastrointestinal bleed.
4. Mild troponinemia at the Livingston ER with a troponin level of 0.076. Could be in the setting of stress, gastrointestinal bleed. We will monitor troponin levels over here and also monitor EKG. We will hold antiplatelets secondary to active gastrointestinal bleed.
5. Jaundice with elevated total bilirubin of 6.56 in the setting of liver cirrhosis. Once again, check hepatitis panel. GI has been consulted.
6. Severe thrombocytopenia secondary to liver cirrhosis. The patient will need platelet transfusion prior to EGD.
7. Depression. Continue home regimen of sertraline and trazodone.
8. Uncontrolled hypertension. The patient is on Cardene drip. Lisinopril was initiated. We will titrate medications as needed. We will discontinue lisinopril in view of renal failure and initiate beta blocker in view of history of liver cirrhosis.
9. GI and deep vein thrombosis prophylaxis to be achieved with Protonix/SCDs. Unable to give any blood thinners due to active gastrointestinal bleed.

Case discussed with the patient, the guards, and the RN in detail.

It has been a pleasure participating in the medical care of the patient. If you have any questions, please do not hesitate to call.

Dictated By: (b)(6); (b)(7)(C)

WT: HP:B.HIM/FAKAL/NTS
DD: 09/12/2017 15:22:12

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: BH9023078383

DT: 09/12/2017 19:48:10
Conf#: 2035335/DID#: 3991040

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: BH9023078383

Patient Care Inquiry (PCI: OE Database COCCR)

DRAFT COPY

Run: 09/13/17-11:22 by (b)(6); (b)(7)(C) 2020-ICLI-00006 2771

Page 3 of 3

CONROE MEDICAL CENTER (COCCR)
 GE Consultation Note
 REPORT#: 0912-0667 REPORT STATUS: Signed
 DATE: 09/12/17 TIME: 2044

PATIENT: RUIZ, FELIPE
 ACCOUNT#: (b)(6); (b)(7)(C)
 DOB: 06/26/66 AGE: 51 SEX: M
 ADM DT: 09/12/17
 UNIT #: BH00861890
 ROOM/BED: R ICU18-W
 ATTEND: (b)(6); (b)(7)(C)
 AUTHOR: (b)(6); (b)(7)(C)

* ALL edits or amendments must be made on the electronic/computer document *

History

Medications:

Home Medications:

Medication	Dose/Rte/Freq Max Daily Dose	Days	Qty	Entered	Last Reviewed
SERTRALINE (ZOLOFT) Strength: 100 MG TAB	100 MG PO DAILY			09/12/17 1103	09/12/17 1104
traZODone (DESYREL) Strength: 50 MG TAB	50 MG PO BEDTIME			09/12/17 1103	09/12/17 1104
FOLIC ACID Strength: 1 MG TAB	1 MG PO DAILY			09/12/17 1103	09/12/17 1104
OMEPRAZOLE ER (PRILOSEC) Strength: 40 MG CAP, DR	40 MG PO DAILY			09/12/17 1104	09/12/17 1104
SPIRONOLACTONE (ALDACTONE) Strength: 25 MG TAB	25 MG PO BID			09/12/17 1104	09/12/17 1104

Current Hospital Medications:

Anti-Infective Agents

Medication	Dose	Sig/Sch Route	Start time Stop Time	Status	Last Admin
Levofloxacin (LEVAQUIN 500MG/ 100ML)	100 ML	Q24H IV	09/12 1530 09/19 1531	AC	09/12 1624

Cardiovascular Drugs

Medication	Dose	Sig/Sch Route	Start time Stop Time	Status	Last Admin
Metoprolol Succinate (TOPROL XL)	12.5 MG	DAILY PO	09/12 1700 10/12 1701	AC	09/12 1626
Labetalol HCl (TRANDATE)	10 MG	Q4H PRN PRN IV	09/12 1530 10/12 1531	AC	
Lisinopril (PRINIVIL)	20 MG	DAILY PO	09/12 1100 10/12 1101	DC	09/12 1133
Nicardipine/Sodium Chloride	250 ML	ASDIR IV	09/12 1000 10/12 1001	AC	

Patient: RUIZ, FELIPE
 Unit#: BH00861890
 Date: 09/12/17
 BH9023078383

Acct#:

(CARDENE-NAACL 50 MG/ 250 ML IV)					
Nicardipine/Sodium Chloride (CARDENE-NAACL 50 MG/ 250 ML IV)	250 ML	STK-MED ONE IV	09/12 0953	DC	09/12 0959

Central Nervous System Agents

Medication	Dose	Sig/Sch Route	Start time Stop Time	Status	Last Admin
Trazodone HCl (DESYREL)	50 MG	BEDTIME PO	09/12 2100 10/12 2101	AC	09/12 2015
Sertraline HCl (ZOLOFT)	100 MG	DAILY PO	09/12 1700 10/12 1701	AC	09/12 1626
Morphine Sulfate (MORPHINE SULFATE)	1 MG	Q4H PRN PRN IV	09/12 1515 10/12 1516	AC	

Electrolytic, Caloric, And Wat

Medication	Dose	Sig/Sch Route	Start time Stop Time	Status	Last Admin
Lactulose (CHRONULAC 20 GM/30 ML)	30 ML	BID PO	09/12 2100 10/12 2101	CKD	09/12 2015
Sodium Chloride (NORMAL SALINE 250 ML)	250 ML	ASDIR IV	09/12 1600 09/13 1555	AC	
Sodium Chloride (NORMAL SALINE 250 ML)	250 ML	ASDIR PRN IV	09/12 1515 10/12 1516	AC	
Sodium Chloride (SODIUM CHLORIDE 0.9% 20ML)	10 ML	ASDIR IV	09/12 1515 10/12 1516	AC	
Sodium Chloride (SODIUM CHLORIDE 0.9% 1000 ML)	1,000 ML	Q13H20M IV	09/12 1515 10/12 1516	AC	09/12 1624

Gastrointestinal Drugs

Medication	Dose	Sig/Sch Route	Start time Stop Time	Status	Last Admin
Pantoprazole (PROTONIX)	40 MG	Q12HR IV	09/12 2100 10/12 2101	AC	09/12 2015
Ondansetron HCl (ZOFTRAN)	4 MG	Q4H PRN PRN IV	09/12 1515 10/12 1516	AC	09/12 1625

Patient: RUIZ, FELIPE
Unit#: BH00861890
Date: 09/12/17
BH9023078383

Acct#:

Vitamins

Medication	Dose	Sig/Sch Route	Start time Stop Time	Last Status Admin
Folic Acid (FOLVITE)	1 MG	DAILY PO	09/13 0900 10/13 0901	AC

Allergies:

Coded Allergies:

No Known Allergies (09/12/17)

Objective

Physical Exam

VS/I&O:

Last Documented:

	Result	Date Time
Pulse O ₂	96	09/12 2000
B/P	106/56	09/12 2000
Pulse	68	09/12 2000
Resp	17	09/12 2000
Temp	36.8	09/12 1838
O ₂ Flow Rate	2	09/12 1447

Medications:

Active Meds + DC'd Last 24 Hrs

Folic Acid 1 MG DAILY PO
Lactulose 30 ML BID PO (CKD)
Pantoprazole 40 MG Q12HR IV
Trazodone HCl 50 MG BEDTIME PO
Metoprolol Succinate 12.5 MG DAILY PO
Sertraline HCl 100 MG DAILY PO
Sodium Chloride 250 ML ASDIR IV
Labetalol HCl 10 MG Q4H PRN PRN IV
Levofloxacin 100 ML Q24H IV
Morphine Sulfate 1 MG Q4H PRN PRN IV
Ondansetron HCl 4 MG Q4H PRN PRN IV
Sodium Chloride 250 ML ASDIR PRN IV
Sodium Chloride 10 ML ASDIR IV

Patient: RUIZ, FELIPE
 Unit#: BH00861890
 Date: 09/12/17
 BH9023078383

Acct#:


Sodium Chloride 1,000 ML .Q13H20M IV
 Lisinopril 20 MG DAILY PO (DC)
 Nicardipine/Sodium Chloride 250 ML ASDIR IV
 Nicardipine/Sodium Chloride 250 ML .STK-MED ONE IV (DC)

General appearance: alert, awake



Results

Findings/Data:
 Laboratory Tests

09/12/17 1200:



09/12/17 1155:



Laboratory Tests

	09/12 1530	09/12 1530	09/12 1530
Chemistry			
Ammonia (11.0 - 32.0 mcMOL/L)			90.0 *H
CK-MB (CK-2) (1.0 - 3.6 NG/ML)	4.9 H		
Troponin I (0.000 - 0.045 NG/ML)	0.270 *H		
B-Natriuretic Peptide (0.00 - 100.00 PG/ML)		226.59 H	

	09/12 1155
Chemistry	
Sodium (133 - 144 mmol/L)	133.0
Potassium (3.5 - 5.1 mmol/L)	4.2
Chloride (95 - 105 mmol/L)	102
Carbon Dioxide (21 - 32 mmol/L)	24
Anion Gap (4.0 - 15.0 GAP calc)	7.0
BUN (7 - 18 MG/DL)	67 H

Patient: RUIZ, FELIPE
 Unit#: BH00861890
 Date: 09/12/17
 BH9023078383

Acct#:

Creatinine (0.55 - 1.30 MG/DL)	1.36 H
Glomerular Filtr Rate (>60 estGFR)	55 L
Glucose (70 - 110 MG/DL)	132 H
Calcium (8.5 - 10.1 MG/DL)	7.8 L
Total Bilirubin (0.00 - 1.00 MG/DL)	6.56 H
Direct Bilirubin (0.00 - 0.30 MG/DL)	3.35 H
Indirect Bilirubin (0.2 - 1.3 MG/DL)	3.21 H
AST (15 - 37 Unit/L)	81 H
ALT (12 - 78 Unit/L)	49
Total Alk Phosphatase (45 - 117 Unit/L)	107
Total Protein (6.4 - 8.2 G/DL)	5.4 L
Albumin (3.4 - 5.0 G/DL)	2.9 L
Albumin/Globulin Ratio (1.2 - 2.2 RATIO)	1.2
Specimen Appearance (1 NORMAL Index/DL)	3 SMALL 5-10 MG
Specimen Hemolysis (1 NORMAL Index/DL)	2 TRACE 10-25 MG

Laboratory Tests

	09/12 1200
Coagulation	
PT (9.4 - 12.5 SECONDS)	17.3 H
INR (0.85 - 1.11 INR Unit)	1.52 H
PTT (Dade) (24 - 37.7 SECONDS)	29.4

Laboratory Tests

	09/12 1200
Hematology	
WBC (4.1 - 12.1 k/mm ³)	15.1 H
RBC (3.8 - 5.5 M/mm ³)	3.50 L
Hgb (10.6 - 15.8 G/DL)	11.2
Hct (36.0 - 47.4 %)	30.1 L
MCV (80.1 - 101.1 fL)	86.0
MCH (25.3 - 35.3 pg)	32.0
MCHC (32.7 - 35.1 G/DL)	37.2 H
RDW (12.2 - 16.4 %)	17.2 H
Plt Count (155 - 337 K/mm ³)	27 *L
MPV (7.6 - 10.4 fL)	10.3
Gran % (37.8 - 82.6 %)	65.8
Lymph % (Auto) (14.1 - 45.4 %)	12.1 L
Mono % (Auto) (2.5 - 11.7 %)	12.7 H
Eos % (Auto) (0.0 - 6.2 %)	1.7
Baso % (Auto) (0.0 - 2.6 %)	0.5

Patient: RUIZ, FELIPE
 Unit#: BH00861890
 Date: 09/12/17
 BH9023078383

Acct#:

Gran # (2.0 - 13.7 K/mm3)	9.95 H
Lymph # (Auto) (0.6 - 3.8 K/mm3)	1.82
Mono # (Auto) (0.11 - 0.59 K/mm3)	1.91 H
Eos # (Auto) (0.0 - 0.4 K/mm3)	0.25
Baso # (Auto) (0.0 - 0.1 K/mm3)	0.08
Add Manual Diff (CRITERIA DIFF/SCN)	MAN DIFF INDICATED
Total Counted (100 #CELLS)	100
Immature Gran % (0.0 - 2.0 %)	7.2 H
Seg Neutrophils % (40 - 75 %)	73
Lymphocytes % (Manual) (12.6 - 43.5 %)	12 L
Monocytes % (Manual) (4.2 - 12.7 %)	14 H
Eosinophils % (Manual) (0.0 - 5.2 %)	1
Nucleated RBC % (0.0 - 1.0 /100WBC%)	1.7 H
Nucleated RBCs # (0.00 - 0.05 K/mm3)	0.25 H
Toxic Granulation (NONE ON SCAN)	SLIGHT
Platelet Estimate (ADEQUATE ON SCAN)	MRK DECR L
Plt Morphology Comment (NORMAL PLTS ON SCAN)	LARGE RARE
Polychromasia (NONE ON SCAN)	SLIGHT
Hypochromasia (NONE ON SCAN)	SLIGHT
Poikilocytosis (NONE ON SCAN)	SLIGHT
Anisocytosis (NONE ON SCAN)	SLIGHT
Ovalocytes (NONE ON SCAN)	FEW
Acanthocytes (Spur) (NONE ON SCAN)	RARE
Schistocytes (NONE ON SCAN)	RARE

Laboratory Tests

	09/12 1530
Serology	
Hepatitis A IgM Ab (Nonreactive SCREEN)	NonReactive
Hep Bs Antigen (Nonreactive SCREEN)	NEG-NONREAC
Hep B Core IgM Ab (Nonreactive SCREEN)	NonReactive
Hepatitis C Antibody (Nonreactive SCREEN)	NR

Radiology data:

Recent Impressions:

ULTRASOUND - US ABDOMEN LTD 09/12 1637

*** Report Impression - Status: SIGNED Entered: 09/12/2017 1913

Impression:

1. Markedly limited examination due to poor beam penetration. The liver, gallbladder, common bile duct and pancreas are inadequately

Patient: RUIZ, FELIPE
Unit#: BH00861890
Date: 09/12/17
BH9023078383

Acct#:

visualized on this examination.

2. Unremarkable right kidney and visualized portions of the abdominal aorta and IVC.

Impression By: t.SDR.RH16 (b)(6); (b)(7)(C) MD

Diagnosis, Assessment & Plan

Free Text A&P:

Consult: Hematemesis

HISTORY OF PRESENT ILLNESS: The patient is a 51-year-old Hispanic incarcerated male, who was taken to Livingston Memorial Emergency Room with complaints of abdominal pain, and hematemesis. He has a past medical history significant for nonalcoholic liver cirrhosis, generalized anxiety disorder, and depression. He has been diagnosed with cirrhosis 7 years ago. He is currently in the Department of Corrections.

PAST MEDICAL HISTORY: As mentioned above, which includes,

1. Nonalcoholic liver cirrhosis.
2. Depression.
3. Generalized anxiety disorder.

SURGICAL HISTORY: None.

ALLERGIES: NO KNOWN DRUG ALLERGIES.

MEDICATIONS FROM JAIL: Reviewed.

SOCIAL HISTORY: The patient is incarcerated. He is originally from Florida; however, because of the flooding, he was transferred to Texas Jail.

FAMILY HISTORY: The patient is unaware of any medical problems running in the family.

REVIEW OF SYSTEMS:

Otherwise negative.

GASTROINTESTINAL: He presents with right upper quadrant abdominal pain and

Patient: RUIZ, FELIPE
Unit#: BH00861890
Date: 09/12/17
BH9023078383

Acct#:

hematemesis.
PSYCH: depression.

Vitals as above:

General appearance: alert, awake, oriented
Head/Eyes: atraumatic, EOMI, icteric
ENT: moist mucosal membranes
Cardiovascular: regular rate & rhythm, normal heart sounds
Respiratory: clear to auscultation, no distress, no tenderness, aerating well
Abdomen/GI: active bowel sounds, soft, non tenderness
Extremities: moves all, no edema-all extremities
Musculoskeletal: full range of motion
Neuro/CNS: alert, oriented X 3
Psychiatry: unable to evaluate

LABORATORY AND DIAGNOSTIC DATA: Reviewed

ASSESSMENT AND PLAN: A 51-year-old incarcerated Hispanic male with history of nonalcoholic liver cirrhosis, now presents with hematemesis
Possible varices though PLTs are low will transfuse then have EGD possible banding
Agree with octreotide and PPI drip with abx
EGD planned tomorrow
NPO for now
Follow up CBC in the AM

Electronically Signed by (b)(6); (b)(7)(C) on 09/12/17 at 2054

RPT #: 0912-0667
END OF REPORT

Specimen Inquiry Report

Conroe Regional Medical Center, Conroe TX

*** CONFIDENTIAL ***

Med. Director: (b)(6), (b)(7)(C)

CAP#21190-01

PATIENT: RUIZ, FELIPE

ACCT#: (b)(6), (b)(7)(C)

LOC: B ICU4

U#: BH00861890

FD:

OD: ABBAL

AGE/SX: 51/M

ROOM: B ICU18

REG: 09/12/17

RESDR: (b)(6), (b)(7)(C)

MD

ANENA

STATUS: ADM IN

BED: W

DIS:

0912:CR:H00272R COMP, Coll: 09/12/17-2020 Recd: 09/12/17-2059 (R#07673889)

Test	Result	Flag	Reference	Site Verified
<u>CBC</u>				
> WBC	8.9		4.1-12.1 k/mm3	09/12/17-2105
> RBC	2.78	L	3.8-5.5 M/mm3	09/12/17-2105
> HGB	9.0	L	10.6-15.8 G/DL	09/12/17-2105
> HCT	24.6	L	36.0-47.4 %	09/12/17-2105
> MCV	88.5		80.1-101.1 fL	09/12/17-2105
> MCH	32.4		25.3-35.3 pg	09/12/17-2105
> MCHC	36.6	H	32.7-35.1 G/DL	09/12/17-2105
> RDW	17.2	H	12.2-16.4 %	09/12/17-2105
> RDW-SD	50.8	H	35.1-43.9 fL	09/12/17-2105
> PLT	55	L	155-337 K/mm3	09/12/17-2105
> MPV	11.1	H	7.6-10.4 fL	09/12/17-2105
> NEUT %	69.9		37.8-82.6 %	09/12/17-2105
> IMM GRAN %	4.9	H	0.0-2.0 %	09/12/17-2105
> LYMPH %	11.4	L	14.1-45.4 %	09/12/17-2105
> MONO %	11.9	H	2.5-11.7 %	09/12/17-2105
> EOS %	1.8		0.0-6.2 %	09/12/17-2105
> BASO %	0.1		0.0-2.6 %	09/12/17-2105
> NRBC% per100WBC	0.8		0.0-1.0 /100WBC%	09/12/17-2105
> NEUT #	6.21		2.0-13.7 K/mm3	09/12/17-2105
> IMM GRAN #	0.44	H	0.00-0.03 K/mm3	09/12/17-2105
> LYMPH #	1.02		0.6-3.8 K/mm3	09/12/17-2105
> MONO #	1.06	H	0.11-0.59 K/mm3	09/12/17-2105

Name: RUIZ, FELIPE

Age/Sex: 51/M

Acct# (b)(6), (b)(7)(C)

Unit#BH00861890

SPEC #: 0912:CR.H00272R

PATIENT: RUIZ, FELIPE

#BH9023078383 (Continued)

Test	Result	Flag	Reference	Site
> EOS #	0.16		0.0-0.4 K/mm3	09/12/17-2105
> BASO #	0.01		0.0-0.1 K/mm3	09/12/17-2105
> NRBC#	0.07	H	0.00-0.05 K/mm3	09/12/17-2105

Name: RUIZ, FELIPE

Age/Sex: 51/M

Acct#BH9023078383 Unit#BH00861890

Specimen Inquiry Report

Conroe Regional Medical Center, Conroe TX

*** CONFIDENTIAL ***

Med. Director: (b)(6); (b)(7)(C)

CAP#21190-01

PATIENT: RUIZ, FELIPE

ACCT#: (b)(6); (b)(7)(C)

LOC: B. ICU4

U#: BH00861890

FD: (b)(6); (b)(7)(C) OD: ABBAL

AGE/SX: 51/M

ROOM: B. ICU18

REG: 09/12/17

RESID: (b)(6); (b)(7)(C)

ANSNA

STATUS: ADM IN

BED: W

DIS:

17:CR:BC0011419S RES, Coll: 09/12/17-1530 Recd: 09/12/17-1619 (R#07673570
Source: BLOOD Desc: PERIPHERAL

(b)(6); (b)(7)(C)

Procedure

Result

Verified

Site

> BLOOD CULTURE Preliminary
NO GROWTH AFTER 12 HOURS

09/13/17-0419

Name: RUIZ, FELIPE

Age/Sex: 51/M

Acct#BH9023078383 Unit#BH00861890

Specimen Inquiry Report

Conroe Regional Medical Center, Conroe TX

*** CONFIDENTIAL ***

Med. Director: (b)(6) (b)(7)(C)

CAP#21190-01

PATIENT: RUIZ, FELIPE ACCT#: (b)(6) (b)(7)(C) LOC: B ICU4 U#: BH00861890
FD: OD: ABBAL AGE/SX: 51/M ROOM: B ICU18 REG: 09/12/17
RESDR: Ansari, Nazia MD ANSNA STATUS: ADM IN BED: W DIS:

17: CR: BC0011420S RES, Coll: 09/12/17-1530 Recd: 09/12/17-1619 (R#07673570) (b)(6); (b)(7)(C)
Source: BLOOD Desc: PERIPHERAL

Procedure	Result	Verified	Site
> BLOOD CULTURE Preliminary NO GROWTH AFTER 12 HOURS		09/13/17-0419	

Name: RUIZ, FELIPE Age/Sex: 51/M Acct#BH9023078383 Unit#BH00861890

Specimen Inquiry Report

Conroe Regional Medical Center, Conroe TX

*** CONFIDENTIAL ***

Med. Director: (b)(6), (b)(7)(C)

CAP#21190-01

PATIENT: RUIZ, FELIPE

ACCT#: (b)(6), (b)(7)(C)

LOC: B-ICU4

U#: BH00861890

FD: OD: ABBAL

AGE/SX: 51/M

ROOM: B-ICU18

REG: 09/12/17

RESDR: (b)(6), (b)(7)(C)

ANSNA

STATUS: ADM IN

BED: W

DIS:

0913:CR:H00074R COMP, Coll: 09/13/17-0420 Recd: 09/13/17-0614 (R#07673571)

Test	Result	Flag	Reference	Site Verified
CBC				
> WBC	5.9		4.1-12.1 k/mm3	09/13/17-0649
> RBC	(b)(6), (b)(7)(C)	L	3.8-5.5 M/mm3	09/13/17-0649
> HGB	8.4	L	10.6-15.8 G/DL	09/13/17-0649
> HCT	23.8	L	36.0-47.4 %	09/13/17-0649
> MCV	91.5		80.1-101.1 fL	09/13/17-0649
> MCH	32.3		25.3-35.3 pg	09/13/17-0649
> MCHC	35.3	H	32.7-35.1 G/DL	09/13/17-0649
> RDW	18.3	H	12.2-16.4 %	09/13/17-0649
> RDW-SD	54.3	H	35.1-43.9 fL	09/13/17-0649
> PLT	35	*L	155-337 K/mm3	09/13/17-0649
ON 09/13/17 AT 0647, B.LAB.BRD CALLED TO ELAINA HULL. The report was confirmed by read back protocols Y/N: Y.				
> MPV	11.9	H	7.6-10.4 fL	09/13/17-0649
> NEUT %	67.6		37.8-82.6 %	09/13/17-0649
> IMM GRAN %	4.3	H	0.0-2.0 %	09/13/17-0649
> LYMPH %	13.6	L	14.1-45.4 %	09/13/17-0649
> MONO %	11.6		2.5-11.7 %	09/13/17-0649
> EOS %	2.7		0.0-6.2 %	09/13/17-0649
> BASO %	0.2		0.0-2.6 %	09/13/17-0649
> NRBC% per100WBC	0.3		0.0-1.0 /100WBC%	09/13/17-0649
> NEUT #	3.98		2.0-13.7 K/mm3	09/13/17-0649
> IMM GRAN #	0.25	H	0.00-0.03 K/mm3	09/13/17-0649
> LYMPH #	0.80		0.6-3.8 K/mm3	09/13/17-0649

Name: RUIZ, FELIPE

Age/Sex: 51/M

Acct#: (b)(6), (b)(7)(C)

Unit#BH00861890

SPEC #: 0913-CR-H00074R

PATIENT: RUIZ, FELIPE

#BH9023078383 (Continued)

Test	Result	Flag	Reference	Site Verified
MONO #	0.68	H	0.11-0.59 K/mm ³	09/13/17-0649
EOS #	0.16		0.0-0.4 K/mm ³	09/13/17-0649
BASO #	0.01		0.0-0.1 K/mm ³	09/13/17-0649
NRBC#	0.02		0.00-0.05 K/mm ³	09/13/17-0649

Name: RUIZ, FELIPE

Age/Sex: 51/M

Acct#BH9023078383 Unit#BH00861890

Specimen Inquiry Report

Conroe ~~Regional~~ Medical Center, Conroe TX

*** CONFIDENTIAL ***

Med Director: (b)(6); (b)(7)(C)

CAP#21190-01

PATIENT: RUIZ, FELIPE

ACCT#: (b)(6); (b)(7)(C)

LOC: B ICU4

U#: BH00861890

FD: OD: ABBAL

AGE/SX: 51/M

ROOM: B ICU18

REG: 09/12/17

RESDR: (b)(6); (b)(7)(C)

ANSNA

STATUS: ADM IN

BED: W

DIS:

0913:CR:C00117R COMP, Coll: 09/13/17-0420 Recd: 09/13/17-0614 (R#07673571)

Test	Result	Flag	Reference	Site
<u>COMP METABOLIC</u>				
> NA	138.0		133-144 mmol/L	09/13/17-0653
> K	3.8		3.5-5.1 mmol/L	09/13/17-0653
> CL	107	H	95-105 mmol/L	09/13/17-0653
> CO2	23		21-32 mmol/L	09/13/17-0653
> ANION GAP	8.0		4.0-15.0 GAP calc	09/13/17-0653
> GLU	57	L	70-110 MG/DL	09/13/17-0653
> BUN	40	D H	7-18 MG/DL	09/13/17-0653
> GFR	100		>60 estGFR	09/13/17-0653
<p>The estimated glomerular filtration rate is computed using patient race, age, sex, and serum creatinine. If any of the needed data elements are missing the Laboratory can not compute an estimation of the glomerular filtration rate. The GFR value units = ml/min/1.73 meter squared. Estimated GFR values above 60 should be interpreted as >60, not an exact number.</p> <p>--- DRUG DOSAGE ALERT ---</p> <p>Drug dosage adjustments utilize different calculation parameters</p>				
> CREAT	0.81		0.55-1.30 MG/DL	09/13/17-0653
<p>Results may be depressed if patient is taking N-Acetylcysteine (NAC) and Metamizole (Dipyrone)</p>				
> T. PROT	4.8	L	6.4-8.2 G/DL	09/13/17-0653
> ALB	2.4	L	3.4-5.0 G/DL	09/13/17-0653
> A/G RATIO	1.0	L	1.2-2.2 RATIO	09/13/17-0653
> CA	7.5	L	8.5-10.1 MG/DL	09/13/17-0653
> BILT	3.15	H	0.00-1.00 MG/DL	09/13/17-0653
> BILD	1.78	H	0.00-0.30 MG/DL	09/13/17-0653
> BILI INDIRECT	1.37	H	0.2-1.3 MG/DL	09/13/17-0653

Name: RUIZ, FELIPE

Age/Sex: 51/M

Acct#BH9023078383 Unit#BHC0861890

SPEC #: 0913.CR.C00117R

PATIENT: RUIZ, FELIPE

#BH9023078383 (Continued)

Test	Result	Flag	Reference	Site Verified
> AST	61	H	15-37 Unit/L	09/13/17-0653
> ALT	44		12-78 Unit/L	09/13/17-0653
> ALKP TOTAL	85		45-117 Unit/L	09/13/17-0653
> INDEX HEMOLYSIS	1 NORMAL <10 MG		1 NORMAL Index/DL	09/13/17-0653
> INDEX ICTERIC	2 TRACE 2-5 MG		1 NORMAL Index/DL	09/13/17-0653
> INDEX LIPEMIA	1 NORMAL <50 MG		1 NORMAL Index/DL	09/13/17-0653

Name: RUIZ, FELIPE

Age/Sex: 51/M

Acct#BH9023078383 Unit#BH00861890

Specimen Inquiry Report

Conroe Regional Medical Center, Conroe TX

*** CONFIDENTIAL ***

Med. Director: (b)(6), (b)(7)(C)

CAP#21190-01

PATIENT: RUIZ, FELIPE

ACCT#: (b)(6), (b)(7)(C)

LOC: B ICU4

U#: BH00861890

FD: (b)(6), (b)(7)(C) OD: ARBAL

AGE/SX: 51/M

ROOM: B ICU18

REG: 09/12/17

RESDR: (b)(6), (b)(7)(C)

ND

ANSNA

STATUS: ADM IN

BED: W

DIS:

0913:CR:CG00015R COMP, Coll: 09/13/17-0420 Recd: 09/13/17-0614 (R#07673576)

Test	Result	Flag	Reference	Site Verified
PT				
> PT PATIENT	16.6	H	9.4-12.5 SECONDS	09/13/17-0702
> INR	1.46	H	0.85-1.11 INR Unit	09/13/17-0702
<p>-----</p> <p>Therapeutic range for INR is dependent upon the situation.</p> <p>2.0-3.0 Prophylaxis / venous thromboembolism, Treatment of DVT, Acute myocardial infarction stroke prevention, Systemic embolism prevention in fibrillation</p> <p>3.0-4.5 AMI recurrence prevention, Systemic embolism prevention in prosthetic heart</p> <p>3.0-5.4 AMI mortality reduction</p>				

Name: RUIZ, FELIPE Age/Sex: 51/M Acct#BH902307838 Unit#BH00861890

0913-0004

CONROE REGIONAL MEDICAL CENTER
504 Medical Center Blvd.
Conroe, Texas 77304

PATIENT NAME: RUIZ, FELIPE
ACCOUNT NO: BH9023078383
MEDICAL RECORD NO: BH00861890
REPORT TYPE: ELECTROCARDIOGRAM

ADMIT DATE: 09/12/17
ROOM NO: B.ICU18
AGE: 51
SEX: M

ADMITTING PHYSICIAN (b)(6); (b)(7)(C)
ATTENDING PHYSICIAN (b)(6); (b)(7)(C)

Order:

20170912-0085

Test Reason : tropinemia at outside eR

Test Date/Time Stamp:

Tue Sep 12 2017 17:17:29

Blood Pressure : ***/*** mmHG

Vent. Rate : 070 BPM Atrial Rate : 070 BPM

P-R Int : 182 ms QRS Dur : 078 ms

QT Int : 416 ms P-R-T Axes : -14 009 032 degrees

QTc Int : 449 ms

Normal sinus rhythm n

Nonspecific ST and T wave abnormality

Abnormal ECG

No previous ECGs available

Confirmed by (b)(6); (b)(7)(C) on 9/13/2017 7:14:36 AM

Referred By (b)(6); (b)(7)(C) Confirmed by (b)(6); (b)(7)(C)

Electronically Signed by (b)(6); (b)(7)(C) MD on 09/13/17 at 0714

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: BH9023078383

Patient Care Inquiry (FCI: OE Database COCCR)

Run: 09/13/17-11:21 by (b)(6); (b)(7)(C)

0913-0071

CONROE REGIONAL MEDICAL CENTER
504 Medical Center Blvd.
Conroe, Texas 77304

PATIENT NAME: RUIZ, FELIPE
ACCOUNT NO: BH9023078383
MEDICAL RECORD NO: BH00861890
REPORT TYPE: HISTORY AND PHYSICAL

ADMIT DATE: 09/12/17
ROOM NO: B.ICU18
AGE: 51
SEX: M

ADMITTING PHYSICIAN: (b)(6); (b)(7)(C)
ATTENDING PHYSICIAN: [Redacted]

ADMISSION DATE: 09/12/2017

ADDENDUM TO THE HISTORY AND PHYSICAL REPORT:

Confirmation #2035335

Please to assessment and plan after DVT prophylaxis.

Sepsis. The patient has significant leukocytosis with a WBC count of 15.1, renal failure, and the patient was tachycardic upon arrival with a heart rate of 108. We will initiate antibiotics. We will not give fluid liberally as the BNP level was more than 4000 at the outside ER. We will obtain x-ray and BNP level to reassess the fluid status. The patient does have symptoms of volume overload at present.

It has been a pleasure participating in the medical care of the patient. If you have any questions, please do not hesitate to call.

Dictated By: (b)(6); (b)(7)(C)

WT: HP:B.HIM/FAKAL/NTS
DD: 09/12/2017 15:25:01
DT: 09/12/2017 19:14:36
Conf#: 2035363/DID#: 3991068

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: BH9023078383

Specimen Inquiry Report

Conroe Regional Medical Center, Conroe TX

*** CONFIDENTIAL ***

Med Director: (b)(6), (b)(7)(C)

CAP#21190-01

PATIENT: RUIZ, FELIPE

ACCT#: (b)(6), (b)(7)(C)

LOC: B. ICU4

U#: BH00861890

FD: (b)(6), (b)(7)(C) OD: ABBAL

AGE/SX: 51/M

ROOM: B. ICU18

REG: 09/12/17

RESDE: (b)(6), (b)(7)(C)

ANSNA

STATUS: ADM IN

BED: W

DIS:

17:CR:B0015805R RES, Coll: 09/12/17-1530 Recd: 09/12/17-1619 (R#07673572) Fakhri, Alifiya
Source: URINE Desc: CLEAN CATCH

Procedure	Result	Verified	Site
> URINE CULTURE Preliminary ROUTINE WORKUP	<10,000 CFU/ML GRAM POSITIVE FLORA	09/13/17-0910	

Name: RUIZ, FELIPE Age/Sex: 51/M Acct#BR9023078383 Unit#BH00861890

CONROE MEDICAL CENTER (COCCR)
Clinical Note
REPORT#: 0913-0215 REPORT STATUS: Draft
DATE: 09/13/17 TIME: 1024

PATIENT: RUIZ, FELIPE
ACCOUNT#: (b)(6); (b)(7)(C)
DOB: 06/26/66 AGE: 51 SEX: M
ADM DT: 09/12/17
MD

UNIT #: BH00861890
ROOM/BED: B.ICU18-W
ATTEND: (b)(6); (b)(7)(C)
AUTHOR: (b)(6); (b)(7)(C)

* ALL edits or amendments must be made on the electronic/computer document *

Clinical Note

Note:

Seen 9/13
See consult
Admitted with GI bleed hypotension
Denies chest pain
Trop mildly elevated
EKG normal
No H/O CAD
stress test when Hb close to 10

RPT #: 0913-0215
END OF REPORT

0913-0071

CONROE REGIONAL MEDICAL CENTER
504 Medical Center Blvd.
Conroe, Texas 77304

PATIENT NAME: RUIZ, FELIPE
ACCOUNT NO: (b)(6); (b)(7)(C)
MEDICAL RECORD NO: BH00861899
REPORT TYPE: HISTORY AND PHYSICAL

ADMIT DATE: 09/12/17
ROOM NO: B.ICU18
AGE: 51
SEX: M

ADMITTING PHYSICIAN: (b)(6); (b)(7)(C)
ATTENDING PHYSICIAN: (b)(6); (b)(7)(C)

ADMISSION DATE: 09/12/2017

ADDENDUM TO THE HISTORY AND PHYSICAL REPORT:

Confirmation #2035335

Please to assessment and plan after DVT prophylaxis.

Sepsis. The patient has significant leukocytosis with a WBC count of 15.1, renal failure, and the patient was tachycardic upon arrival with a heart rate of 108. We will initiate antibiotics. We will not give fluid liberally as the BNP level was more than 4000 at the outside ER. We will obtain x-ray and BNP level to reassess the fluid status. The patient does have symptoms of volume overload at present.

It has been a pleasure participating in the medical care of the patient. If you have any questions, please do not hesitate to call.

Dictated By: (b)(6); (b)(7)(C)

WPI: HP:B.HIM/FAKAI/NTS
DD: 09/12/2017 15:25:01
DT: 09/12/2017 19:14:36
Conf#: 2035363/DID#: 3991068

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: BH9023078293

RUIZ, FELIPE

NURS: B. ICU4

MR: BHC0861890

ACCT: (b)(6); (b)(7)(C)

BED: B. ICU18-W

SEX: M DOB: 06/26/66 AGE: 51

ADMIT: 09/12/17

ATTN DR: (b)(6); (b)(7)(C)

This report is NOT part of the permanent medical record process per Company Policy.

NOTE: Truncated results are preceded by '-->'. Please Consult chart for entire result.

ALLERGIES

Coded Allergies Reaction

No Known Allergies

MED	CURRENT MEDICATIONS			(*D = Deactivated Order)		
	DOSE	SIG/SCH	ROUTE	START	STOP	ST
CARDENE-NACL 50 MG/250 ML IV	250 ML	ASDIR	IV	09/12	10/12	
CHRONULAC 20 GM/30 ML	30 ML	BID	PO	09/12	10/12	
DESYREL	50 MG	BEDTIME	PO	09/12	10/12	
POLVITE	1 MG	DAILY	PO	09/13	10/13	
LEVAQUIN 500MG/100ML	100 ML	Q24H	IV	09/12	09/19	
MORPHINE SULFATE	1 MG	-->Q4H PRN	IV	09/12	10/12	
NORMAL SALINE 250 ML	250 ML	ASDIR/PRN	IV	09/12	10/12	
NORMAL SALINE 250 ML	250 ML	ASDIR	IV	09/12	09/13	
PROTONIX	40 MG	Q12HR	IV	09/12	10/12	
SODIUM CHLORIDE 0.9% 1000 ML	1000 ML	Q13H20M	IV	09/12	10/12	
SODIUM CHLORIDE 0.9% 20ML	10 ML	ASDIR	IV	09/12	10/12	
TOPROL XL	12.5 MG	DAILY	PO	09/12	10/12	
TRANDATE	10 MG	-->Q4H PRN	IV	09/12	10/12	
ZOPRAN	4 MG	-->Q4H PRN	IV	09/12	10/12	
ZOLOFT	100 MG	DAILY	PO	09/12	10/12	

RADIOLOGY IMPRESSIONS - FROM: 09/12/17 TO: 09/13/17

09/12/17 - ULTRASOUND - US ABDOMEN LTD REPORT STATUS: Signed

Dictated by Physician (b)(6); (b)(7)(C) MD: 281-241-(b)(6)

Impression:

1. Markedly limited examination due to poor beam penetration. The liver, gallbladder, common bile duct and pancreas are inadequately visualized on this examination.
2. Unremarkable right kidney and visualized portions of the abdominal aorta and IVC.

LABORATORY INFORMATION - FROM: 09/12/17 0000 TO: 09/13/17 0236

09/12/17	09/12/17	09/12/17	09/12/17
20:20	15:30	12:00	11:55

HEMATOLOGY

WBC	8.9	H	15.1
RBC	L 2.79	L	3.50
HGB	L 9.0		11.2

HCT	L 24.6	L 30.1
MCV	88.5	86.0
MCH	32.4	32.0
MCHC	H 36.6	H 37.2
RDW	H 17.2	H 17.2
RDW-SD	H 50.6	H 49.1
PLT	L 55	*L 27
MPV	H 11.1	10.3
GRAN %	69.9	65.8
IMM GRAN %	H 4.9	H 7.2

LABORATORY INFORMATION - FROM: 09/12/17 8008 TO: 09/13/17 0236

09/12/17	09/12/17	09/12/17	09/12/17
20:20	15:30	12:00	11:55

LYMPH %	L 11.4	L 12.1
MONO %	H 11.9	H 12.7
EOS %	1.8	1.7
BASO %	0.1	0.5
NRBC%	0.8	H 1.7
GRAN #	6.21	H 9.95
IMM GRAN #	H 0.44	H 1.06
LYMPH #	1.01	1.82
MONO #	H 1.06	H 1.91
EOS #	0.16	0.25
BASO #	0.01	0.08
NRBC#	H 0.07	H 0.25
MAN DIFF NEEDED		-->MAN DIFF
TOTAL CELLS		100
SEC		73
LYMPH		L 12
MONOCYTE		H 14
EOS		1
NRBC		H 7
POLYCHROM		SLIGHT
HYPG		SLIGHT
POIK		SLIGHT
ANISO		SLIGHT
OVALOCYTES		FEW
SCHISTO		RARE
TOXIC GRANULAT		SLIGHT
ACANTHOCYTES		RARE
PLT EST		L MRK DECR
PLT MORPH		LARGE RARE
COAGULATION		
PT PATIENT		H 17.3
INR		H 1.52
PTT		29.4
CHEMISTRY		
NA		133.0
K		4.2
CL		102
CO2		24

ANION GAP		7.0
GLU		H 132
BUN		H 67
GFR		L 55
CREAT		H 1.36
T.PROT		L 5.4
ALB		L 2.9
A/G RATIO		1.2
CA		L 7.8
BILT		H 6.56
BILE		H 3.35
BILI INDIRECT		H 3.21
AST		H 81
ALT		49
ALKP TOTAL		107
AMM	*H 90.0	
BNF	H 226.59	
CKMB	H 4.9	
TROPI	*H 0.270	
INDEX HEMOLYSIS		-->2 TRACE 1
INDEX ICTERIC		-->3 SMALL

This report is NOT part of the permanent medical record -process per Company Policy.

NOTE: Truncated results are preceded by '-->'. Please Consult chart for entire result.

LABORATORY INFORMATION - FROM: 09/12/17 0000 TO: 09/13/17 0236

09/12/17	09/12/17	09/12/17	09/12/17
20:20	15:30	12:00	11:55
-----	-----	-----	-----

INDEX LIPEMIA				-->1 NORMAL
SEROLOGY				
HAVMAB	-->NonReacti			
HBSAG	>NEG NONRE			
HB CORE IGM	-->NonReacti			
HCVAB	NR			

Vital Signs - FROM: 09/12/17 0000 TO: 09/13/17 0236

09/13/17	09/13/17	09/13/17	09/12/17
02:00	01:00	00:00	23:00
-----	-----	-----	-----

Temp F				
Temp C				
Pulse	59	58	64	75
Resp	13	12	17	30
B/P:	87/51	86/50	96/53	99/58
SPO2%	94	94	97	97

09/12/17	09/12/17	09/12/17	09/12/17
22:10	22:00	21:45	21:30
-----	-----	-----	-----

Temp F				
Temp C				
Pulse	62	63	66	64
Resp	15	16	16	16
B/P:		90/53		
SPO2%	97	98	98	97

09/12/17	09/12/17	09/12/17	09/12/17
21:15	21:01	21:00	20:45

Temp F				
Temp C				
Pulse	67	83	77	66
Resp	17	30	29	13
B/P:		92/66		
SPO2%	96	93	95	95

09/12/17	09/12/17	09/12/17	09/12/17
20:30	20:15	20:00	19:45

Temp F				
Temp C				
Pulse	68	68	68	69
Resp	16	15	17	44
B/P:			106/56	
SPO2%	95	96	96	95

Vital Signs - FROM: 09/12/17 0000 TO: 09/13/17 0236

09/12/17	09/12/17	09/12/17	09/12/17
19:36	19:30	19:15	19:00

Temp F				
Temp C				
Pulse	67	68	69	69
Resp	30	27	17	17
B/P:				111/59
SPO2%	96	97	98	98

09/12/17	09/12/17	09/12/17	09/12/17
18:45	18:38	18:30	18:16

Temp F		98.2		98.6
Temp C		36.8		37.0
Pulse	68	76	72	74
Resp	17	17	26	18
B/P:		101/55		101/55
SPO2%	98	100	98	100

09/12/17	09/12/17	09/12/17	09/12/17
18:15	18:00	17:35	17:00

Temp F	98.5
--------	------

Temp C			36.9	
Pulse	76	73	73	74
Resp	20	25	18	21
B/P:		101/55	111/59	111/59
SPO2%	98	99	98	99

09/12/17	09/12/17	09/12/17	09/12/17
16:00	15:00	14:47	14:30

Temp F	98.3			
Temp C				
Pulse	78	80		84
Resp	29	18		18
B/P:	117/59	116/56		118/55
SPO2%	97	96	100	96

09/12/17	09/12/17	09/12/17	09/12/17
14:15	14:00	13:45	13:30

Temp F				
Temp C				
Pulse	86	88	84	87
Resp	18	19	14	15
B/P:	113/59	117/58	114/55	113/58
SPO2%	96	97	96	97

09/12/17	09/12/17	09/12/17	09/12/17
13:15	13:00	12:45	12:30

Temp F				
Temp C				
Pulse	95	90	92	91
Resp	20	16	15	16
B/P:	108/57	100/55	113/57	118/55
SPO2%	97	96	96	96

This report is NOT part of the permanent medical record -process per Company Policy.

NOTE: Truncated results are preceded by '-->'. Please Consult chart for entire result.

Vital Signs - FROM: 09/12/17 0900 TO: 09/13/17 0236

09/12/17	09/12/17	09/12/17	09/12/17
12:15	12:01	11:45	11:30

Temp F				
Temp C				
Pulse	96	108	97	100
Resp	19	29	18	21
B/P:	123/58	134/62	114/58	122/59
SPO2%	96	97	99	99

09/12/17 09/12/17 09/12/17 09/12/17
11:15 11:00 10:45 10:30

Temp F
Temp C
Pulse 104 100 99 105
Resp 51 24 25 31
B/P: 120/58 134/55 135/65 142/71
SPO2% 99 100 100 100

09/12/17 09/12/17 09/12/17 09/12/17
10:15 10:01 10:00 09:52

Temp F
Temp C
Pulse 93 90 87 82
Resp 25 25 19 22
B/P: 137/60 186/78 201/91 218/135
SPO2% 100 100 100 100

09/12/17 09/12/17 09/12/17 09/12/17
09:51 09:47 09:45 09:31

Temp F
Temp C
Pulse 93 80 82 75
Resp 47 16 26 18
B/P: 211/104 194/94 203/95 170/90
SPO2% 100 100 100 100

09/12/17 09/12/17 09/12/17 09/12/17
09:30 09:15 09:13 09:02

Temp F
Temp C
Pulse 77 76 77 84
Resp 16 18 18 23
B/P: 182/92 173/92 184/87 184/95
SPO2% 100 100 100 100

Vital Signs - FROM: 09/12/17 0000 TO: 09/13/17 0236
09/12/17
09:01

Temp F
Temp C
Pulse 93
Resp 48
B/P: 181/107
SPO2% 100

	I/O - FROM: 09/12/17 0700		TO: 09/13/17 0700		
INTAKE	0700 - 1500	1500 - 2300	2300 - 0700		24 HR TOTAL
IV #1:		825			825
IVPBs :		100			100
IV #2:		45			45
IV #3:		75			75
Eld Produc		520			520
TOTAL		1565			1565
OUTPUT	0700 - 1500	1500 - 2300	2300 - 0700		24 HR TOTAL
Urine		900			900
TOTAL		900			900
	-----		-----		-----
FLUID BALANCE		665			665

0912 0324

CONROE REGIONAL MEDICAL CENTER
504 Medical Center Blvd.
Conroe, Texas 77304

PATIENT NAME: RUIZ, FELIPE ADMIT DATE: 09/12/17
ACCOUNT NO: (b)(6); (b)(7)(C) ROOM NO: B. ICU18
MEDICAL RECORD NO: BH00861890 AGE: 51
REPORT TYPE: HISTORY AND PHYSICAL SEX: M

ADMITTING PHYSICIAN
ATTENDING PHYSICIAN

(b)(6); (b)(7)(C)

ADMISSION DATE: 09/12/2017

PRIMARY CARE PHYSICIAN: None. The patient is from immigration jail center.

CHIEF COMPLAINT: Hematemesis.

HISTORY OF PRESENT ILLNESS: The patient is a 51-year-old Hispanic incarcerated male, who was taken to Livingston Memorial Emergency Room with complaints of abdominal pain, right flank pain, and hematemesis. He has a past medical history significant for nonalcoholic liver cirrhosis, generalized anxiety disorder, and depression. He was in his usual state of health until early morning, he complained of abdominal pain, right flank pain and started throwing up blood. His hemoglobin level at the Livingston ER was fairly stable at 12.5 and hematocrit was 33.2. He was started on Sandostatin drip and then transferred to Conroe Regional Medical Center ICU for further care. Of note, his platelet level significantly decreased to 18,000.

FAST MEDICAL HISTORY: As mentioned above, which includes,

1. Nonalcoholic liver cirrhosis.
2. Depression.
3. Generalized anxiety disorder.

FAST SURGICAL HISTORY: None.

ALLERGIES: NO KNOWN DRUG ALLERGIES.

MEDICATIONS FROM JAIL: Reviewed. These include folic acid 1 mg daily, Zoloft 100 mg daily, trazodone 50 mg at bedtime, Aldactone 25 mg b.i.d., and omeprazole 40 mg daily.

SOCIAL HISTORY: The patient is incarcerated. He is originally from Florida; however, because of the flooding, he was transferred to Texas Jail.

FAMILY HISTORY: The patient is unaware of any medical problems running in the family.

REVIEW OF SYSTEMS:

GENERAL: Positive for malaise and fatigue.

HEENT: No headaches.

CARDIOVASCULAR: No active chest pain.

RESPIRATORY: No shortness of breath.

GASTROINTESTINAL: He presents with right upper quadrant abdominal pain and

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: (b)(6); (b)(7)(C)

hematemesis.

GENITOURINARY: Denies dysuria or hematuria.

MUSCULOSKELETAL: No active joint pain.

NEUROLOGICAL: He is moving all 4 extremities. Speech appears to be clear.

PSYCHIATRIC: He has history of depression.

LABORATORY AND DIAGNOSTIC DATA: From Livingston ER, sodium 127, potassium 4.3, EUN 85, and creatinine 1.5. Albumin decreased to 3.3. AST 132, ALT 69, ALKP 123, and total bilirubin 10.8. CPK elevated at 322. Lipase mildly elevated at 367. BNP elevated at 4850. PTT 22.1. Troponin I 0.076. WBC 14.2B, hemoglobin 12.5, hematocrit 33.2, and platelets decreased to 18.

ASSESSMENT AND PLAN: A 51-year old incarcerated Hispanic male with history of nonalcoholic liver cirrhosis, now presents with:

1. Gastrointestinal bleed. Differential diagnosis could be variceal, esophageal, or gastric bleeding versus peptic ulcer disease versus gastritis. The patient has been started on octreotide drip. We will also initiate IV PPI and monitor hemoglobin/hematocrit levels, so far are stable. GI consultation has been requested for evaluation of possible EGD.
2. Right upper quadrant abdominal pain. We will check hepatitis panel and right upper quadrant ultrasound.
3. Renal failure, unknown acute or chronic. We will hold Aldactone and other nephrotoxic medications. Could be in the setting of gastrointestinal bleed.
4. Mild troponinemia at the Livingston ER with a troponin level of 0.076. Could be in the setting of stress, gastrointestinal bleed. We will monitor troponin levels over here and also monitor EKG. We will hold antiplatelets secondary to active gastrointestinal bleed.
5. Jaundice with elevated total bilirubin of 6.56 in the setting of liver cirrhosis. Once again, check hepatitis panel. GI has been consulted.
6. Severe thrombocytopenia secondary to liver cirrhosis. The patient will need platelet transfusion prior to EGD.
7. Depression. Continue home regimen of sertraline and trazodone.
8. Uncontrolled hypertension. The patient is on Cardene drip. Lisinopril was initiated. We will titrate medications as needed. We will discontinue lisinopril in view of renal failure and initiate beta blocker in view of history of liver cirrhosis.
9. GI and deep vein thrombosis prophylaxis to be achieved with Protonix/SCDs. Unable to give any blood thinners due to active gastrointestinal bleed.

Case discussed with the patient, the guards, and the RN in detail.

It has been a pleasure participating in the medical care of the patient. If you have any questions, please do not hesitate to call.

Dictated By: (b)(6); (b)(7)(C) MD

WT: EP:B.HIM/FAKAT/NTS
DD: 09/12/2017 15:22:12

PATIENT NAME: RUIZ, FRIEPE

ACCOUNT #: (b)(6); (b)(7)(C)

DT: 09/12/2017 19:48:10

Conf#: 2035335/CID#: 3991040

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: BH9023078393

Patient Name: RUIZ, FELIPE

Unit No: RH09861890

EXAMS:
020697791 US ABDOMEN LTD

CPT CODE:
76705

Site:R16

Limited Abdominal Ultrasound

History: Right upper quadrant abdominal pain, history of nonalcoholic liver cirrhosis.

Comparison: No prior similar studies are available for comparison.

Technique: Gray scale and color Doppler imaging were utilized.

Findings:

This examination is markedly limited due to poor beam penetration.

The liver measures 15.2 cm in length. Evaluation of the liver is markedly limited. The main portal vein is not well visualized.

The gallbladder is not well-visualized. Sonographic Murphy sign is negative.

The common bile duct is not identified on this examination.

The right kidney measures 13.9 x 5.8 x 4.2 cm, with a cortical thickness measuring 1.9 cm. It demonstrates no hydronephrosis, nephrolithiasis or cortical thinning.

The pancreas is not visualized.

The visualized portions of the abdominal aorta and IVC are unremarkable.

There is no evidence of ascites.

Impression:

1. Markedly limited examination due to poor beam penetration. The liver, gallbladder, common bile duct and pancreas are inadequately visualized on this examination.
2. Unremarkable right kidney and visualized portions of the abdominal aorta and IVC.

** Electronically Signed by (b)(6); (b)(7)(C) on 09/12/2017 at 1909 **
Reported and signed by (b)(6); (b)(7)(C)

(b)(6); (b)(7)(C) MD

Technologist: (b)(6); (b)(7)(C) - Agency
Transcrd D/T: 09/12/2017 (1909) t.SDR.RH16
Orig Print D/T: S: 09/12/2017 (1913) Probe:

CONROE MED CTR IN/OBS
MEDICAL IMAGING
504 MEDICAL CENTER BLVD
CONROE, TEXAS 77304
PHONE #: 936-539-7026
FAX #: 936-539-7681

NAME: RUIZ, FELIPE
PHYS (b)(6); (b)(7)(C)
DOB: 06/26/1966 AGR: 51 SEX: M
ACCT NO: (b)(6); (b)(7)(C) LOC: B.ICU19 W
EXAM DATE: 09/12/2017 STATUS: ADM IN
RAD NO:

Specimen Inquiry Report

*** CONFIDENTIAL ***

Conroe

Med. Director: (b)(6), (b)(7)(C)

Center, Conroe TX

MD CAS#21190-01

PATIENT: RUIZ, FELIPE

ACCT#: (b)(6), (b)(7)(C)

LOC: H ICU4

UP: BR00861090

RD: (b)(6), (b)(7)(C) OR: ABBAL

AGE/SEX: 51/M

ROOM: H ICU18

REG: 09/12/17

RESDR: (b)(6), (b)(7)(C)

ANSNA

STATUS: ADM IN

BED: W

DIS:

0914:CR:H00071R COMP, Coll: 09/14/17-0450 Recd: 09/14/17-0503 (R#07674936)

Test	Result	Flag	Reference	Site	Verified
CBC					
> WBC	3.5	L	4.1-12.1 k/mm3		09/14/17-0542
> RBC	2.74	L	3.8-5.5 M/mm3		09/14/17-0542
> HGB	8.7	L	10.6-15.8 G/DL		09/14/17-0542
> HCT	25.5	L	36.0-47.4 %		09/14/17-0542
> MCV	93.1		80.1-101.1 fL		09/14/17-0542
> MCH	31.8		25.3-35.3 pg		09/14/17-0542
> MCHC	34.1		32.7-35.1 G/DL		09/14/17-0542
> RDW	18.7	H	12.2-16.4 %		09/14/17-0542
> RDW-SD	53.2	H	35.1-43.9 fL		09/14/17-0542
> PLT	33	*L	155-337 K/mm3		09/14/17-0542
Critical values after the first occurrence are excluded from call documentation requirements for this analyte due to the patient diagnosis or therapy protocols.					
> MPV	11.3	H	7.6-10.4 fL		09/14/17-0542
> NEUT %	56.4		37.8-82.6 %		09/14/17-0542
> IMM GRAN %	2.8	H	0.0-2.0 %		09/14/17-0542
> LYMPH %	27.1		14.1-45.4 %		09/14/17-0542
> MONO %	9.1		2.5-11.7 %		09/14/17-0542
> EOS %	4.6		0.0-6.2 %		09/14/17-0542
> BASO %	0.6		0.0-2.6 %		09/14/17-0542
> NRBC% per100WBC	0.0		0.0-1.0 /100WBC		09/14/17-0542
> NEUT #	1.98	L	2.0-13.7 K/mm3		09/14/17-0542
> IMM GRAN #	0.10	H	0.00-0.03 K/mm3		09/14/17-0542
> LYMPH #	0.95		0.6-3.0 K/mm3		09/14/17-0542
Name: RUIZ, FELIPE Age/Sex: 51/M Acct#BH902307838 Unit#BR00861090					

SPEC #: 0914 CR H00071R PATIENT: RUIZ, FELIPE #BH9021076383 (Continued)

Test	Result	Flag	Reference	Site
MONO #	0.32		0.11-0.59 K/mm ³	09/14/17-0542
EOS #	0.16		0.0-0.4 K/mm ³	09/14/17-0542
BASO #	0.00		0.0-0.1 K/mm ³	09/14/17-0542
NRECH	0.00		0.00-0.05 K/mm ³	09/14/17-0542

Name: RUIZ, FELIPE Age/Sex: 51/M Acct#: (b)(6) (b)(7)(C) Unit#: BH00861890

0913-0070

CONROE REGIONAL MEDICAL CENTER
504 Medical Center Blvd.
Conroe, Texas 77304

EGD

PATIENT NAME: RUIZ, FELIPE
ACCOUNT NO: (b)(6); (b)(7)(C)
MEDICAL RECORD NO: BH00861890
REPORT TYPE: ENDOWORKS REPORT

ADMIT DATE: 09/12/17
ROOM NO: B.ICU18
AGE: 51
SEX: M

ADMITTING PHYSICIAN (b)(6); (b)(7)(C) MD
ATTENDING PHYSICIAN MD

Indications: Hematemesis (578.0).

Consent: The benefits, risks, and alternatives to the procedure were discussed and informed consent was obtained from the patient.

Pre-Sedation Assessment: H and P completed, I have examined the patient on this date and have reviewed the medical history, drug history, and previous anesthesia experience. Results of the relevant diagnostic studies have been reviewed. Planned choice of anesthesia, risk, complications, benefits and alternatives have been discussed.

Preparation: EKG, pulse, pulse oximetry, and blood pressure were monitored throughout the procedure. An intravenous line was inserted. The patient was kept NPO.

Medications: See anesthesia report.

Procedure: The gastroscope was passed through the mouth under direct visualization and was advanced with ease to the 2nd portion of the duodenum. The scope was withdrawn and the mucosa was carefully examined. The views were good.

Findings: Esophagus: The proximal third of the esophagus, middle third of the esophagus, and distal third of the esophagus appeared to be normal. Stomach: Hypertensive portal gastropathy was found in the fundus, body of the stomach, and antrum. Duodenum: Patchy erythema in bulb and 2nd portion.

Specimens Sent: None, unless otherwise noted.

Estimated Blood Loss: Insignificant.

Unplanned Events: There were no unplanned events.

Summary: Normal proximal third of the esophagus, middle third of the esophagus, and distal third of the esophagus. Hypertensive portal gastropathy was found in the fundus, body of the stomach, and antrum (572.8). Patchy erythema in bulb and 2nd portion.

Recommendations: Avoid all non-steroidal anti-inflammatory drugs (NSAID's) including but not limited to Aspirin, Ibuprofen, Advil, Motrin, and Nuprin. Return to floor. Resume low salt diet as tolerated. Continue current medications. PPI 20 mg daily.

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: (b)(6); (b)(7)(C)

Patient Care Inquiry (PCI: OE Database COCCR)

Run: 09/13/17-11:21 by (b)(6); (b)(7)(C)

Assisted By: The procedure was assisted by N/A.

Procedure Codes: [43235]EGD
Version 1, electronically signed by [(b)(6); (b)(7)(C)] I.D. on 09/13/2017 at 07:42 AM.

Electronically Signed by [(b)(6); (b)(7)(C)] on 09/13/17 at 0742

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: [(b)(6); (b)(7)(C)]

Patient Care Inquiry (PCI: OE Database COCCR)

Run: 09/13/17-11:21 by [(b)(6); (b)(7)(C)] 2020-GLI-00006 2808

Patient: RUIZ, FELIPE
 Unit#: BH00861890
 Date: 09/12/17
 BH9023078383

Acct#:

Potassium (3.5 - 5.1 mmol/L)	4.2
Chloride (95 - 105 mmol/L)	102
Carbon Dioxide (21 - 32 mmol/L)	24
Anion Gap (4.0 - 15.0 CAP calc)	7.0
BUN (7 - 18 MG/DL)	67 H
Creatinine (0.55 - 1.30 MG/DL)	1.36 H
Glomerular Filtr Rate (> 60 estGFR)	55 L
Glucose (70 - 110 MG/DL)	132 H
Calcium (8.5 - 10.1 MG/DL)	7.8 L
Total Bilirubin (0.00 - 1.00 MG/DL)	6.56 H
Direct Bilirubin (0.00 - 0.30 MG/DL)	3.35 H
Indirect Bilirubin (0.2 - 1.3 MG/DL)	3.21 H
AST (15 - 37 Unit/L)	81 H
ALT (12 - 78 Unit/L)	49
Total Alk Phosphatase (45 - 117 Unit/L)	107
Total Protein (6.4 - 8.2 G/DL)	5.4 L
Albumin (3.4 - 5.0 G/DL)	2.9 L
Albumin/Globulin Ratio (1.2 - 2.2 RATIO)	1.2
Specimen Appearance (1 NORMAL Index/DL)	3 SMALL 5-10 MG
Specimen Hemolysis (1 NORMAL Index/DL)	2 TRACE 10-25 MG

Laboratory Tests

	09/12 1200
Coagulation	
PT (9.4 - 12.5 SECONDS)	17.3 H
INR (0.85 - 1.11 INR Unit)	1.52 H
PTT (Dade) (24 - 37.7 SECONDS)	29.4

Laboratory Tests

	09/12 1200
Hematology	
WBC (4.1 - 12.1 k/mm3)	15.1 H
RBC (3.8 - 5.5 M/mm3)	3.50 L
Hgb (10.6 - 15.8 G/DL)	11.2
Hct (36.0 - 47.4 %)	30.1 L
MCV (80.1 - 101.1 fL)	86.0
MCH (25.3 - 35.3 pg)	32.0
MCHC (32.7 - 35.1 G/DL)	37.2 H
RDW (12.2 - 16.4 %)	17.2 H
Plt Count (155 - 337 K/mm3)	27 *L
MPV (7.6 - 10.4 fL)	10.3

Patient: RUIZ, FELIPE
 Unit#: BH00861890
 Date: 09/12/17
 BH9023078383

Acct#:

Gran % (37.8 - 82.6 %)	65.8
Lymph % (Auto) (14.1 - 45.4 %)	12.1 L
Mono % (Auto) (2.5 - 11.7 %)	12.7 H
Eos % (Auto) (0.0 - 6.2 %)	1.7
Baso % (Auto) (0.0 - 2.6 %)	0.5
Gran # (2.0 - 13.7 K/mm3)	9.95 H
Lymph # (Auto) (0.6 - 3.8 K/mm3)	1.82
Mono # (Auto) (0.11 - 0.59 K/mm3)	1.91 H
Eos # (Auto) (0.0 - 0.4 K/mm3)	0.25
Baso # (Auto) (0.0 - 0.1 K/mm3)	0.08
Add Manual Diff (CRITERIA DIFF/SCN)	MAN DIFF INDICATED
Total Counted (100 #CELLS)	100
Immature Gran % (0.0 - 2.0 %)	7.2 H
Seg Neutrophils % (40 - 75 %)	73
Lymphocytes % (Manual) (12.6 - 43.5 %)	12 L
Monocytes % (Manual) (4.2 - 12.7 %)	14 H
Eosinophils % (Manual) (0.0 - 5.2 %)	1
Nucleated RBC % (0.0 - 1.0 /100WBC%)	1.7 H
Nucleated RBCs # (0.00 - 0.05 K/mm3)	0.25 H
Toxic Granulation (NONE ON SCAN)	SLIGHT
Platelet Estimate (ADEQUATE ON SCAN)	MRK DECR L
Plt Morphology Comment (NORMAL PLTS ON SCAN)	LARGE RARE
Polychromasia (NONE ON SCAN)	SLIGHT
Hypochromasia (NONE ON SCAN)	SLIGHT
Poikilocytosis (NONE ON SCAN)	SLIGHT
Anisocytosis (NONE ON SCAN)	SLIGHT
Ovalocytes (NONE ON SCAN)	FEW
Acanthocytes (Spur) (NONE ON SCAN)	RARE
Schistocytes (NONE ON SCAN)	RARE

Diagnosis, Assessment & Plan

Free Text A&P:

GI Bleed: management per GI
 hypotension : better.

RPT #: 0912-0575
 END OF REPORT

Patient: RUIZ, FELIPE

Unit#: BH00861890

Date: 09/12/17

Acct#:

(b)(6); (b)(7)(C)

Nicardipine/Sodium Chloride 250 ML .STK-MED ONE IV (DC)

General appearance: alert, awake

Head/eyes: normocephalic, PERRL, EOML, clear cornea

Neck: full range of motion, non-tender, normal thyroid, supple/no meningismus, no bruit/NL carotids, no JVD, no lymphadenopathy

Cardiovascular: regular rate & rhythm

Respiratory/chest: decreased breath sounds

Abdomen: soft, non-tender, no distention, no guarding, no mass/organomegaly, no rebound

Extremities: moves all, normal capillary refill, no edema


Musculoskeletal: full range of motion, normal inspection

Results


Findings/Data:

Laboratory Tests

09/12/17 1200:



09/12/17 1155:



Laboratory Tests

	09/12 1530	09/12 1530	09/12 1530
Chemistry			
Ammonia (11.0 - 32.0 mcMOL/L)			90.0 *H
CK-MB (CK-2) (1.0 - 3.6 NG/ML)	4.9 H		
Troponin I (0.000 - 0.045 NG/ML)	0.270 *H		
B-Natriuretic Peptide (0.00 - 100.00 PG/ML)		226.59 H	

	09/12 1155
Chemistry	
Sodium (133 - 144 mmol/L)	133.0

CONROE MEDICAL CENTER (COCCR)
Pulmonology Progress Note
REPORT#: 0912-0575 REPORT STATUS: Draft
DATE: 09/12/17 TIME: 1714

PATIENT: RUIZ, FELIPE
ACCOUNT#: (b)(6); (b)(7)(C)
DOB: 06/26/66 AGE: 51 SEX: M
ADM DT: 09/12/17
UNIT #: BH00861890
ROOM/BED: B. ICU18-W
ATTEND: (b)(6); (b)(7)(C)
AUTHOR: (b)(6); (b)(7)(C)

* ALL edits or amendments must be made on the electronic/computer document *

Subjective

Chief Complaint:
RFC: GI bleed/ICu management.

Objective

Physical Exam

VS/I&O:
Last Documented:

	Result	Date Time
Temp	98.3	09/12 1600
Pulse Ox	100	09/12 1447
O2 Flow Rate	2	09/12 1447
B/P	117/58	09/12 1400
Pulse	88	09/12 1400
Resp	19	09/12 1400

Medications:

Active Meds + DC'd Last 24 Hrs
Folic Acid 1 MG DAILY PO
Lactulose 30 ML BID PO (CKD)
Pantoprazole 40 MG Q12HR IV
Trazodone HCl 50 MG BEDTIME PO
Metoprolol Succinate 12.5 MG DAILY PO
Sertraline HCl 100 MG DAILY PO
Sodium Chloride 250 ML ASDIR IV
Labetalol HCl 10 MG Q4H PRN PRN IV
Levofloxacin 100 ML Q24H IV
Morphine Sulfate 1 MG Q4H PRN PRN IV
Ondansetron HCl 4 MG Q4H PRN PRN IV
Sodium Chloride 250 ML ASDIR PRN IV
Sodium Chloride 10 ML ASDIR IV
Sodium Chloride 1,000 ML Q13H20M IV
Lisinopril 20 MG DAILY PO (DC)
Nicardipine/Sodium Chloride 250 ML ASDIR IV

Specimen Inquiry Report

Conroe Regional Medical Center, Conroe TX

*** CONFIDENTIAL ***

Med. Director: (b)(6), (b)(7)(C)

CAP#21190-01

PATIENT: RUIZ, FELIPE

ACCT#: (b)(6), (b)(7)(C)

LOC: B ICU4

U#: BH00861890

FD: OD: ASSAL

AGE/SX: 51/M

ROOM: B.ICU18

REG: 09/12/17

RESID: (b)(6), (b)(7)(C)

ANSNA

STATUS: ADM IN

BED: W

DIS:

0912:CR:S00025R COMP, Coll: 09/12/17-1530 Recd: 09/12/17-1619 (R#07673575)

Test	Result	Flag	Reference	Site Verified
<u>HEPACUTE</u>				
> HAVMAb	NonReactive		Nonreactive SCREEN	09/12/17-1750
> HBSAG	NEG-NONREAC		Nonreactive SCREEN	09/12/17-1750
> HB CORE IGM	NonReactive		Nonreactive SCREEN	09/12/17-1750
> HCVAb	NR		Nonreactive SCREEN	09/12/17-1750

Name: RUIZ, FELIPE

Age/Sex: 51/M

Acct: (b)(6), (b)(7)(C)

Unit#BH00861890

CONROE MEDICAL CENTER (COCCR)

Clinical Note

REPORT#:0912-0490 REPORT STATUS: Signed

DATE:09/12/17 TIME: 1522

PATIENT: RUIZ, FELIPE

ACCOUNT#: (b)(6); (b)(7)(C)

DOB: 06/26/66 AGE: 51

SEX: M

ADM DT: 09/12/17

UNIT #: BH00861890

ROOM/BED: B.ICU18-W

ATTEND: (b)(6); (b)(7)(C)

AUTHOR:

* ALL edits or amendments must be made on the electronic/computer document *

****See Addendum****

Clinical Note

Note:

2035335

Electronically Signed by (b)(6); (b)(7)(C) on 09/12/17 at 1522

Addendum 1: 09/12/17 1524 by (b)(6); (b)(7)(C)

2035363

Electronically Signed by (b)(6); (b)(7)(C) on 09/12/17 at 1525

RPT #:0912-0490

END OF REPORT

FAX: (b)(6); (b)(7)(C)
FAX: [redacted]

936-585 (b)(6); (b)(7)(C)
936-58 [redacted]

Campus: C St: ADM

Patient Name: RUIZ, FELIPE

Unit No: BHC0861890

EXAMS:
C20697794 XR CHEST 1 V

CPT CODE:
71010

CXR

Location: T 18

Chest x-ray exam, AP frontal projection, 9/12/2017

CLINICAL HISTORY: Leukocytosis, ICU patient.

Comparison exams: None of the chest.

Elevation the right hemidiaphragm difficult to assess in terms of age given lack of prior exams. Probable scarring versus atelectatic changes mainly at the right lung base. No active CHF. Overlying lines obscure detail. No findings of high concern for pneumonia

** Electronically Signed by (b)(6); (b)(7)(C)
** on 09/12/2017 at 1726 **

Reported and signed by: (b)(6); (b)(7)(C)

CC: (b)(6); (b)(7)(C)

Dictated Date/Time: 09/12/2017 (1726)

Technologist: (b)(6); (b)(7)(C)

Transcribed Date/Time: 09/12/2017 (1726) By: (b)(6); (b)(7)(C)

Orig Print D/T: S: 09/12/2017 (1729)

CONROE MED CTR IN/OBS
MEDICAL IMAGING
504 MEDICAL CENTER BLVD
CONROE, TEXAS 77304
PHONE #: 936-539-7026
FAX #: 936-539-7681

NAME: RUIZ, FELIPE
PHYS: (b)(6); (b)(7)(C)
DOB: 06/26/1966 AGE: 51 SEX: M
ACCT NO: (b)(6); (b)(7)(C) LOC: B.ICU18 W
EXAM DATE: 09/12/2017 STATUS: ADM IN
RAD NO: DC Dt:

PAGE 1

Signed Report



To: 1st A-nobody


Fax: 919369678846

From: CHKR

Phone

Pages: 45 (including banner)

IMNET/EPRS fax request.



MEMORANDUM OF TRANSFER

0300267948 GOVT
 ALMAZON RUIZ, FELIPE
 9519 ZAHEER, SYED
 ED 09/11/2017
 DOB: 06/26/1966 51Y M S
 0010282353

- Lufkin
- Livingston
- San Augustine

SECTION A (To Be Filled Out At Transferring Hospital)

1. Name of Hospital: HI St. Luke's Health Memorial Livingston
 Address: 1717 Highway 59 Loop N Livingston, Texas 77351
 Phone Number: ()

2. Patient Information (if known)
 Patient's Full name: Felipe Almazon Ruiz
 Address: 3400 FM 350 South Livingston, TX 77351
 Phone Number: ()
 Sex: M F Age: 51
 National origin: Mexico Race: Hispanic
 Religion: ()
 Physical Handicaps: ()

3. Next of Kin information (if known)
 Next of Kin: ()
 Address: ()
 Phone Number: ()

4. Date of Arrival: 9/11/17 Time: 2:02

5. Initial contact with receiving hospital:
 Date: 9/12/17 Time: 0:39
 Name: (b)(6); (b)(7)(C) ng hospital:

6. Accepting physician secured by transferring physician:
 Date: 9/12/17 Time: 09:40
 Name of accepting physician: (b)(6); (b)(7)(C)
 Address: 509 Medical Center Blvd Conroe, TX 77309
 Phone Number: (936) 539 1111

7. Transferring physician's signature (b)(6); (b)(7)(C) nder ngsto
 physician's orders:
 Address: (b)(6); (b)(7)(C)
 Phone Number: ()

8. I further have determined that the patient would benefit from transfer to another health care facility due to the following reasoning:
 Specialty Care for patient's condition not available at this institution
 Hospital bed accommodations at this facility not available
 Patient and/or family request
 Patient would benefit from higher level of clinical care

I further have determined the risks and benefits of transfer and have explained these to the patient. These are as follows:
 Risks: MVC, death, physical disability
 Benefits: Higher level of care gastroenterology

9. Accepting hospital secured by transferring hospital:
 Date: 9/12/17 Time: 09:40
 Name: (b)(6); (b)(7)(C)

10. (b)(6); (b)(7)(C)

11. Type of vehicle, company used, equipment and personnel in attendance:
Texan EMS ground octreotide amp / IV accos cardiac 10²

12. Name of Receiving Hospital: Conroe Regional
 Address: 509 Medical Center Blvd Conroe TX 77309
 Phone Number: (936) 539 1111

13. Diagnosis: Upper GI bleed

14. Attachments:
 X-Ray X MD Progress Notes X
 Lab Reports X Nurses Progress Notes X
 H & P X Medication Record X
 Other: ()

PHYSICIAN CERTIFICATION: Based upon the information available at the time of the (b)(6); (b)(7)(C) able expected from the provision of appropriate medical treatment at another medical facility outweigh the increased risks of the tra (b)(6); (b)(7)(C) of labor, the unborn child. The patient has been examined and is determined to be:
 Stable Unstable Physician Signature: (b)(6); (b)(7)(C)

PATIENT CERTIFICATION: I, the undersigned, hereinafter referred to as the patient, acknowledge that the physician named above has explained to me the risks and benefits of a transfer to another medical facility. I further acknowledge that I have an emergency medical condition which has/has not been stabilized and that the medical benefits of the transfer outweigh the risks. I herewith request that I be transferred to another health care facility, and hereby consent to the release of all appropriate medical records available at the time of transfer, to the recei (b)(6); (b)(7)(C)
 Patient of (b)(6); (b)(7)(C) Date/Time 9/12/17 09:40
 Witness: (b)(6); (b)(7)(C) Date/Time ()

SECTION B (TO BE FILLED OUT AT RECEIVING HOSPITAL)


1. Name of Hospital: _____
 Address: _____
 Phone Number: ()

2. Date of Arrival: _____
 Time: _____

3. Hospital Administration signature: _____
 Title: _____

4. Receiving physician assuming patient responsibility:
 Date: _____ Time: _____
 Receiving physician's signature: _____
 Address: _____
 Phone Number: ()

5. If response to transfer request was delayed beyond thirty (30) minutes, document the reason(s) for the delay, including any time extensions agreed to by transferring hospital. Use additional sheets, if necessary.



FINAL (SIGNED)



MMC LIVINGSTON

Abdominal Pain Flank Pain ICD10, Transfer of Care Note add on

Patient: ALMAZON RUIZ, FELIPE	Sex: Male	DOS: 09/11/2017 23:20	MR#: 0010282353
Age: 51Y	DOB: 06/26/1966	Room: RM4	Bed: A
Attending Physician: (b)(6); (b)(7)(C)		Created By: (b)(6); (b)(7)(C)	Creation Date: 09/11/2017 23:20

Physician date / time: 09/11/2017 10:06 PM On arrival EMS arrival
 Informant: patient ~~spouse~~ ~~paramedics~~ witness:
 Exam limited by: ~~unconsciousness~~ ~~mental impairment~~ ~~uncooperativeness~~ ~~intoxication~~
~~communication barrier~~
 History limited by: ~~unconsciousness~~ ~~mental impairment~~ ~~uncooperativeness~~ ~~intoxication~~
~~communication barrier~~

Transfer from: See transfer record

HPI Reviewed Updated

Complaint: ~~abdominal pain~~ vomiting ~~diarrhea~~ ~~flank pain~~ R L
 Onset: 1 min hrs days ago Duration: 1 min hrs days
 gradual onset sudden onset waxing waning
persistent worse since:
 Timing: still present gone now better
constant intermittent episodes lasting:
 Context: ~~travel out of country~~ ~~bad food~~ ~~recent trauma~~

Comments: 51 Year old male, with a PMHx of Hep C, presents to the ED with a complaint of vomiting blood. The patient reports that he has vomited blood about 3 times. He states that he has abdominal pain at a 7/10. The patient notes that he also has blood in his stool. The patient denies all other complaints.

Severity: pain max: 0 1 2 3 4 5 6 7 8 9 10 Scale: Numeric Wong Baker ©
 pain currently: 0 1 2 3 4 5 6 7 8 9 10 Scale: Numeric Wong Baker ©

Documentation Cont. Next Page

Circle positives strikethrough ~~negatives~~ unmarked = not applicable

FINAL (SIGNED)




MMC LIVINGSTON

Abdominal Pain Flank Pain ICD10, Transfer of Care Note add on

Patient:	Sex:	DOS:	MR#:
ALMAZON RUIZ, FELIPE	Male	09/11/2017 23:20	0010282353

Quality: pain ~~aching~~ ~~dull~~
~~burning~~ ~~cramping~~ ~~sharp~~
~~stabbing~~ ~~fullness~~

Location:



Migration (show migration: m)

Associated Symptoms:

~~fever~~ ~~chills~~ ~~nausea~~
vomiting x 3
bloody ~~blood streaks~~ ~~coffee grounds~~
~~diarrhea~~ x
blood streaks ~~grossly bloody~~ ~~mucous~~
~~sweating~~ ~~loss of appetite~~ ~~chest pain~~ ~~testicular pain~~ ~~back pain~~ ~~neck pain~~

Exacerbated by: ~~supine~~ ~~upright position~~ ~~movements~~ ~~walking~~ ~~cough~~ ~~deep breaths~~
~~food~~ nothing

Relieved by: ~~supine~~ ~~upright position~~ ~~remaining still~~ ~~antacids~~ ~~food~~ nothing

Similar symptoms previously:

Recently: ~~seen~~ ~~treated by doctor~~ ~~hospitalized~~

ROS

Reviewed Updated

CONST recent: ~~illness~~ ~~injury~~

GI ~~constipation~~ stools: ~~black~~ bloody

Comments: bloody stools per patient.

CVS ~~palpitations~~

RESP ~~shortness of breath~~ ~~cough~~ ~~hurts to breathe~~

GU urine: ~~bloody~~ ~~dark~~ ~~problems urinating~~ LMP date: ~~pregnant~~ ~~post-menopausal~~

MUSC ~~joint pain~~

SKIN ~~rash~~

LYMPH ~~swollen glands~~ ~~ankle swelling~~ ~~R~~ ~~L~~

EYES ~~problems with vision~~

Circle positives strikethrough ~~negatives~~ unmarked = not applicable

FINAL (SIGNED)



MMC LIVINGSTON

Abdominal Pain Flank Pain ICD10, Transfer of Care Note add on

Patient:	Sex:	DOS:	MR#:
ALMAZON RUIZ, FELIPE	Male	09/11/2017 23:20	0010282353

ENT ~~sore throat~~

NEURO ~~headache~~ ~~dizziness~~ ~~light-headedness~~

PSYCH ~~anxiety~~ ~~depression~~

except as marked positive, all systems above reviewed and found negative

HISTORY

Reviewed Updated

~~No chronic diseases~~

Cardiac disease: Afib CAD CHF MI

Diabetes: Type 1 Type 2 diet oral insulin

Hypertension

Peptic ulcer

Gall stones

Kidney stones

Bladder infection

Kidney infection

Ischemic bowel risk factors: valvular disease elderly low BP recent MI

Pancreatitis

GERD

Diverticulitis

Abdominal aneurysm

CVA TIA: deficit: R L

Ectopic pregnancy

Fecal impaction

Hepatitis c

Hyperlipidemia

Intestinal obstruction

Circle positives ~~strikethrough negatives~~ unmarked = not applicable

FINAL (SIGNED)



MMC LIVINGSTON

Abdominal Pain Flank Pain ICD10, Transfer of Care Note add on

Patient: ALMAZON RUIZ, FELIPE	Sex: Male	DOS: 09/11/2017 23:20	MR#: 0010282353
---	---------------------	---------------------------------	---------------------------

Ovarian: cyst(s) fibroids

Pelvic infection: STD

Old records reviewed / summary

Surgeries / Procedures: none appendectomy cholecystectomy endoscopy upper lower
 hernia repair R L

cardiac bypass	cardiac stent	hysterectomy	BTL	C-section	tonsillectomy
----------------	---------------	--------------	-----	-----------	---------------

Full Problem List Reviewed Updated

Upper GI bleed (2017)

Allergies Reviewed Updated

No Known Allergies

Home Medications Reviewed Updated

Immunizations Reviewed Updated

SOCIAL HISTORY Reviewed Updated

Tobacco Use

Never smoker
 None Reported : TOBACCO HISTORY Last Documented By (b)(6); (b)(7)(C) on 09/12/2017 01:58

Alcohol Use

Recreational Drug Use

FAMILY HISTORY Reviewed Updated

gall stones ovarian cysts CAD ulcer kidney stones aortic aneurysm

Circle positives strikethrough ~~negatives~~ unmarked = not applicable

FINAL (SIGNED)



CHI St. Luke's Health

MMC LIVINGSTON

Abdominal Pain Flank Pain ICD10, Transfer of Care Note add on

Patient:	Sex:	DOS:	MR#:
ALMAZON RUIZ, FELIPE	Male	09/11/2017 23:20	0010282353

VITAL SIGNS

 Reviewed Updated

Last Set of Vitals: Interpretation: normal hypoxic

BP: 160/103 09/12/2017 02:31
 Pulse: 94 09/12/2017 01:10
 Temp: 98.1 F 09/11/2017 21:36
 Resp: 18 09/11/2017 21:36
 O2 Sat: 99.0% 09/11/2017 21:36
 Additional Vitals:

PHYSICAL EXAM

 Nursing assessment reviewed

CONST

no acute distress distress: mild moderate severe
alert anxious lethargic

Comments: Patient is alert and in no acute distress on exam.

EYES

inspection normal scleral icterus pale conjunctivae
 EOM palsy R L anisocoria R L

Comments: Normal on exam.

ENT

normal inspection pharyngeal erythema
pharynx normal abnormal TM R L hearing deficit R L

Comments: Normal on exam.

NECK

normal inspection thyromegaly lymphadenopathy

Comments: Normal on exam.

RESP

no respiratory distress wheezes R L rales R L rhonchi R L

Circle positives strikethrough ~~negatives~~ unmarked = not applicable

FINAL (SIGNED)



CHI St. Luke's Health

MMC LIVINGSTON

Abdominal Pain Flank Pain ICD10, Transfer of Care Note add on

Patient: ALMAZON RUIZ, FELIPE	Sex: Male	DOS: 09/11/2017 23:20	MR#: 0010282353
---	---------------------	---------------------------------	---------------------------

breath sounds normal

Comments: Normal breath sounds on exam.

CVS

regular rate and rhythm

irregularly irregular rhythm tachycardia bradycardia

heart sounds normal

JVD present gallop: S3 S4


equal pulses / full

murmur: grade /6 systolic diastolic
decreased pulse(s): radial R L femoral R L
dorsalis pedis R L

Comments: Normal heart sounds on exam.

LEGEND

T	= Tenderness
G	= Guarding
R	= Rebound
m	= Mild
mod	= Moderate
sv	= Severe



ABD

soft, non-tender

rigid distended
tenderness guarding rebound generalized RUQ LUQ RLQ LLQ

no organomegaly

hepatomegaly splenomegaly

normal bowel sounds

abnormal bowel sounds: increased decreased absent tympanic

no abdominal bruit

prominent aortic pulsation

no pulsatile mass

McBurney's point tenderness psoas Rovsing's sign obturator sign
mass:

Comments: No abdominal tenderness on exam.

GU

external inspection normal catheter present

PELVIC EXAM

normal external exam vaginal bleeding vaginal discharge
normal speculum exam cervical motion tenderness

Circle positives strikethrough ~~negatives~~ unmarked = not applicable

FINAL (SIGNED)



MMC LIVINGSTON

Abdominal Pain Flank Pain ICD10, Transfer of Care Note add on

Patient:	Sex:	DOS:	MR#:
ALMAZON RUIZ, FELIPE	Male	09/11/2017 23:20	0010282353

normal bimanual exam	adnexal tenderness	adnexal mass	R	L
	enlarged uterus	tender uterus		
MALE GENITAL				
normal inspection	testicular tenderness	R	L	testicular swelling
	inguinal tenderness	R	L	inguinal swelling
				R
				L
RECTAL				
non-tender	tenderness	fecal impaction		
heme negative stool	stool: heme positive	trace	black	bloody

BACK

normal inspection CVA tenderness R L

Comments: Normal on exam.

SKIN

color normal cyanosis diaphoresis pallor
no rash skin rash zoster-like
warm dry intact embolic lesions signs of IVDA
 pressure ulcer location:
 depth / stage: 1 2 3 4

Comments: Normal on exam.

EXTREMITIES

non tender calf tenderness R L
normal ROM Homan's sign R L
no pedal edema pedal edema R L

Comments: Normal on exam.

NEURO

oriented x4 disoriented to: person place time situation
CN's normal (2-12) weakness R L facial droop R L
motor normal speech abnormalities cognition abnormalities
sensation normal sensory loss R L

Comments: Patient is alert and oriented x 4 on exam.

Circle positives strikethrough ~~negatives~~ unmarked = not applicable

FINAL (SIGNED)



MMC LIVINGSTON

Abdominal Pain Flank Pain ICD10, Transfer of Care Note add on

Patient: ALMAZON RUIZ, FELIPE	Sex: Male	DOS: 09/11/2017 23:20	MR#: 0010282353
---	---------------------	---------------------------------	---------------------------

PSYCH

mood normal depressed mood
affect normal depressed affect

Comments: Normal on exam.

RESULTS Reviewed Updated

Laboratory

ED Laboratory Results						
Order	Test	Value	Reference Range	Comments	Status	Collection
AMYLASE SERUM	Amylase	112 H	(12-103 U/L)		Final Result	09/11/2017 23:29:00
CBC PLATELET AUTO DIFF	WBC	14.28 H	(4.80-10.80 10 ³ /ul)		Final Result	09/11/2017 23:29:00
CBC PLATELET AUTO DIFF	RBC	3.94 L	(4.70-6.10 10 ⁶ /ul)		Final Result	09/11/2017 23:29:00
CBC PLATELET AUTO DIFF	Hemoglobin	12.5 L	(14.0-18.0 gm/dl)		Final Result	09/11/2017 23:29:00
CBC PLATELET AUTO DIFF	Hematocrit	33.2 L	(42.0-50.0)		Final Result	09/11/2017 23:29:00
CBC PLATELET AUTO DIFF	MCV	84.3	(80.0-94.0 fL)		Final Result	09/11/2017 23:29:00
CBC PLATELET AUTO DIFF	MCH	31.7 H	(27.0-31.0 pg)		Final Result	09/11/2017 23:29:00
CBC PLATELET AUTO DIFF	MCHC	37.7 H	(33.0-37.0 gm/dl)		Final Result	09/11/2017 23:29:00
CBC PLATELET AUTO DIFF	RDW	16.0 H	(11.5-14.5)		Final Result	09/11/2017 23:29:00
CBC PLATELET AUTO DIFF	Platelet	18 LL	(130-400 10 ³ /ul)		Final Result	09/11/2017 23:29:00
CBC PLATELET AUTO DIFF	NE	72.4	(42.0-75.0)		Final Result	09/11/2017 23:29:00
CBC PLATELET AUTO DIFF	LY	7.8 L	(13.0-42.0)		Final Result	09/11/2017 23:29:00
CBC PLATELET AUTO DIFF	MO	11.9	(4.0-14.0)		Final Result	09/11/2017 23:29:00
CBC PLATELET AUTO DIFF	EO	0.9 L	(1.0-3.0)		Final Result	09/11/2017 23:29:00
CBC PLATELET AUTO DIFF	BA	0.6 L	(1.0-3.0)		Final Result	09/11/2017 23:29:00
CBC PLATELET AUTO DIFF	IG	6.4 H	(0.0-0.4)		Final Result	09/11/2017 23:29:00
CBC PLATELET AUTO DIFF	NRBC, Auto	1	(0-2 /100WBC)		Final Result	09/11/2017 23:29:00

Circle positives strikethrough ~~negatives~~ unmarked = not applicable

FINAL (SIGNED)



CHI St. Luke's Health

MMC LIVINGSTON

Abdominal Pain Flank Pain ICD10, Transfer of Care Note add on

Patient:	Sex:	DOS:	MR#:		
ALMAZON RUIZ, FELIPE	Male	09/11/2017 23:20	0010282353		
CBC PLATELET AUTO DIFF	Nucleated RBC	0	(0-2 /100WBC)		Final Result 09/11/2017 23:29:00
CBC PLATELET AUTO DIFF	Neutrophils	10 L	(42-75)	Decreased platelets, NO Platelet clumping , few large platelets seen on peripheral blood smear.	Final Result 09/11/2017 23:29:00
CKMB	CKMB	7.49 HH	(0.00-2.36 ng/ml)	RESULT CALLED TO CHELSEA BULLORD RN (ER) AT 0003 THEN READ BACK //HH/	Final Result 09/11/2017 23:29:00
CMP COMPREHENSIVE METABOLIC PANEL	Glucose	127 H	(75-110 mg/dl)		Final Result 09/11/2017 23:29:00
CMP COMPREHENSIVE METABOLIC PANEL	BUN	85.0 H	(6.0-17.0 mg/dl)		Final Result 09/11/2017 23:29:00
CMP COMPREHENSIVE METABOLIC PANEL	Creatinine	1.5 H	(0.4-1.2 mg/dl)		Final Result 09/11/2017 23:29:00
CMP COMPREHENSIVE METABOLIC PANEL	Sodium	127 L	(137-145 mmol/l)		Final Result 09/11/2017 23:29:00
CMP COMPREHENSIVE METABOLIC PANEL	Potassium	4.3	(3.5-5.0 mmol/l)		Final Result 09/11/2017 23:29:00
CMP COMPREHENSIVE METABOLIC PANEL	Chloride	95 L	(98-107 mmol/l)		Final Result 09/11/2017 23:29:00
CMP COMPREHENSIVE METABOLIC PANEL	CO2	22	(22-30 mmol/l)		Final Result 09/11/2017 23:29:00
CMP COMPREHENSIVE METABOLIC PANEL	Calcium	8.6	(8.4-10.2 mg/dl)		Final Result 09/11/2017 23:29:00
CMP COMPREHENSIVE METABOLIC PANEL	T Protein	6.5	(5.1-8.7 gm/dl)		Final Result 09/11/2017 23:29:00
CMP COMPREHENSIVE METABOLIC PANEL	Albumin	3.3 L	(3.5-4.6 gm/dl)		Final Result 09/11/2017 23:29:00
CMP COMPREHENSIVE METABOLIC PANEL	A/G Ratio	1.0 L	(1.1-2.2)		Final Result 09/11/2017 23:29:00

Circle positives strikethrough ~~negatives~~ unmarked = not applicable

FINAL (SIGNED)



MMC LIVINGSTON

Abdominal Pain Flank Pain ICD10, Transfer of Care Note add on

Patient:	Sex:	DOS:	MR#:		
ALMAZON RUIZ, FELIPE	Male	09/11/2017 23:20	0010282353		
CMP COMPREHENSIVE METABOLIC PANEL	AST (SGOT)	102 H	(11-36 U/L)	Final Result	09/11/2017 23:29:00
CMP COMPREHENSIVE METABOLIC PANEL	ALT (SGPT)	68 H	(11-40 U/L)	Final Result	09/11/2017 23:29:00
CMP COMPREHENSIVE METABOLIC PANEL	Alkaline Phos	123 H	(47-114 U/L)	Final Result	09/11/2017 23:29:00
CMP COMPREHENSIVE METABOLIC PANEL	Total Bilirubin	10.8 H	(0.2-1.2 mg/dl)	Final Result	09/11/2017 23:29:00
CMP COMPREHENSIVE METABOLIC PANEL	Globulin	3.2	(2.3-3.5 gm/dl)	Final Result	09/11/2017 23:29:00
CMP COMPREHENSIVE METABOLIC PANEL	Anion Gap	11		Final Result	09/11/2017 23:29:00
CMP COMPREHENSIVE METABOLIC PANEL	Calcium, Corrected	9.2	(8.4-10.2 mg/dl)	Final Result	09/11/2017 23:29:00
				Various formulas exist for corrected serum calcium results, each yielding different values. This corrected result was based on the formula: Corrected Calcium = SerumCalcium + [0.8 * (4 - SerumAlbumin)]	
CPK	CPK	322 H	(30-135 U/L)	Final Result	09/11/2017 23:29:00
LIPASE SERUM	Lipase	367 H	(8-223 U/L)	Final Result	09/11/2017 23:29:00
PRO BNP B - NATRIURETIC PEPTIDE	Pro BNP(B-Peptide)	4850 HH	(0-125 pg/ml)	Final Result	09/11/2017 23:29:00
				RESULT CALLED TO CHELSEA BULLORD RN (ER) AT 0003 THEN READ BACK //HH/	
PROTIME PT INR	Protime	15.1 H	(9.0-11.8 seconds)	Final Result	09/11/2017 23:29:00

Circle positives strikethrough ~~negatives~~ unmarked = not applicable

FINAL (SIGNED)



MMC LIVINGSTON

Abdominal Pain Flank Pain ICD10, Transfer of Care Note add on

Patient: ALMAZON RUIZ, FELIPE	Sex: Male	DOS: 09/11/2017 23:20	MR#: 0010282353
---	---------------------	---------------------------------	---------------------------

PROTIME PT INR	INR	1.4 H	(0.9-1.1)	INR results are intended ONLY to monitor Oral Anticoagulant therapy in stabilized patients. The INR Therapeutic Range is 2.0 - 3.0 Patients with a mechanical heart, the INR Range is 2.5 - 3.5	Final Result	09/11/2017 23:29:00
PTT PARTIAL THROMBOPLASTIN TM	aPTT	22.1 L	(25.3-35.7 seconds)		Final Result	09/11/2017 23:29:00

Documentation Cont. Next Page

Circle positives strikethrough ~~negatives~~ unmarked = not applicable

FINAL (SIGNED)



MMC LIVINGSTON

Abdominal Pain Flank Pain ICD10. Transfer of Care Note add on

Patient:	Sex:	DOS:	MR#:
ALMAZON RUIZ, FELIPE	Male	09/11/2017 23:20	0010282353

TROPONIN I QUANTITATIVE	Troponin-I	0.076 H	(0.000-0.034 ng/ml)	The 99th Percentile URL is 0.034 ng/mL. The Joint European Society of Cardiology/American College of Cardiology (ESC/ACC) and the National Academy of Clinical Biochemistry Standards of Laboratory Practices (NACB) recommends that the diagnosis of AMI includes the presence of clinical history suggestive of Acute Coronary Syndrome (ACS) and a maximum concentration of cardiac troponin exceeding the 99th percentile of a normal reference population [upper reference limit (URL)] on at least one occasion during the first 24 hours after the clinical event.	Final Result	09/11/2017 23:29:00
----------------------------	------------	---------	------------------------	---	--------------	------------------------

Rhythm Strip

Rate: Rhythm: NSR

EKG

Circle positives strikethrough ~~negatives~~ unmarked = not applicable

FINAL (SIGNED)



MMC LIVINGSTON

Abdominal Pain Flank Pain ICD10, Transfer of Care Note add on

Patient:	Sex:	DOS:	MR#:
ALMAZON RUIZ, FELIPE	Male	09/11/2017 23:20	0010282353

Viewed by me Interpreted by me Discussed with cardiologist

Normal NAD normal intervals normal axis normal QRS normal ST/T

Rate rhythm: NSR sinus tach A-fib

EKG changed unchanged from:

Repeat EKG changed unchanged from:

X-Rays Done

KUB Upright abdomen 3-view CXR: PA/Lat AP

Viewed by me Interpreted by me Discussed with radiologist

Normal NAD normal bowel gas no free air no mass

No infiltrates normal heart size normal mediastinum

CT Scan Done

Abdomen Pelvis

Viewed by me Interpreted by me Discussed with radiologist

Normal NAD normal bowel gas no free air no mass

Ultrasound / FAST Exam

Abdomen Pelvis Heart / Pericardium

Viewed by me Interpreted by me Discussed with radiologist

Normal NAD

Pulse Ox

99 % Room Air O₂ L/min FiO₂ %

NC RB mask NRB mask other:

interpretation: normal hypoxic time:

PROCEDURES

Circle positives strikethrough ~~negatives~~ unmarked = not applicable

FINAL (SIGNED)



CHI St. Luke's Health

MMC LIVINGSTON

Abdominal Pain Flank Pain ICD10, Transfer of Care Note add on

Patient:	Sex:	DOS:	MR#:
ALMAZON RUIZ, FELIPE	Male	09/11/2017 23:20	0010282353

Feeding Tube Insertion – Procedure Note

Time: "Time out" at:

Indication: dislodged malfunctioning
G-tube J-tube nasal feeding tube

Preparation: risks, benefits, alternatives explained:

to patient parent guardian

topical anesthesia used: lidocaine gel benzocaine spray

tube size:

Procedure: successful unsuccessful

performed by: me ED physician PA nurse

tube inserted into: abdominal stoma oropharynx nostril R L

no significant resistance met

confirmed placement: by aspiration by auscultation X-ray

Secured with: tape suture dressing

Complications: none bleeding vomiting

PROGRESS

Time 02:30 AM unchanged improved re-examined non-surgical

Comments: 09/12/2017 Patient placed on Octreotide drip due to Esophageal and GI bleed

Spoke with DR. Abas of Conroe regional concerning care and transfer of patient, patient was accepted.

PROGRESS

Time: unchanged improved re-examined

PLAN

Interventions:

EGDT for sepsis considered

Circle positives strikethrough ~~negatives~~ unmarked = not applicable

FINAL (SIGNED)



MMC LIVINGSTON

Abdominal Pain Flank Pain ICD10, Transfer of Care Note add on

Patient:	Sex:	DOS:	MR#:
ALMAZON RUIZ, FELIPE	Male	09/11/2017 23:20	0010282353

CP: EKG ASA
AMI: EKG ASA Thrombolytics PCI transfer
CAP: VS antibiotic(s) pathogen BC CXR CT transfer
Pregnancy: HCG US
Rh Negative Pregnancy: Rhogam

Treatment exclusions: refused not indicated contraindicated not available

Discussed with Dr:
 will see patient in: ED hospital office
 Additional history from: family caretaker paramedics other:
 Counseled patient family regarding: laboratory radiology results diagnosis
 need for follow-up:
 Rx given:
 Critical care time: (excluding separately billable procedures) 120 min
 Comments: 09/12/2017 Patient placed on Octreotide drip due to Esophageal and GI bleed

PLAN

Discussed with Dr:
 will see patient in: ED hospital office

Orders:

Order Date	Description	Frequency	Ordered By	Status
9/11/2017	Nurse Reminder to Enter Lab Orders for Protocol	PRN	(b)(6), (b)(7)(C)	Active
9/11/2017	AMYLASE SERUM	STAT		Dates Met
9/11/2017	CKMB	STAT		Dates Met
9/11/2017	CPK	STAT		Dates Met
9/11/2017	LIPASE SERUM	STAT		Dates Met
9/11/2017	CMP COMPREHENSIVE METABOLIC PANEL	STAT		Dates Met
9/11/2017	TROPONIN I QUANTITATIVE	Once		Dates Met
9/11/2017	PTT PARTIAL THROMBOPLASTIN TM	STAT		Dates Met
9/11/2017	PROTIME PT INR	STAT		Dates Met
9/11/2017	CBC PLATELET AUTO DIFF	STAT		Dates Met

Circle positives strikethrough ~~negatives~~ unmarked = not applicable

FINAL (SIGNED)



CHI St. Luke's Health

MMC LIVINGSTON

Abdominal Pain Flank Pain ICD10, Transfer of Care Note add on

Patient:	Sex:	DOS:	MR#:	
ALMAZON RUIZ, FELIPE	Male	09/11/2017 23:20	0010282353	
9/11/2017	PRO BNP B - NATRIURETIC PEPTIDE	Once	(b)(6), (b)(7)(C)	Dates Met
9/11/2017	Insert Saline Lock	STAT		Dates Met
9/11/2017	Obtain Consent for Procedure / Place in Chart	STAT		Dates Met
9/11/2017	Transfusion Vital Signs per Protocol	STAT		Dates Met
9/11/2017	TYPE AND SCREEN	STAT		Dates Met
9/11/2017	CROSSMATCH X 2	STAT		Dates Met
9/11/2017	Transfuse 2 units PRBCs	STAT		Dates Met
9/11/2017	UA URINALYSIS WITH MICROSCOPY	Once		Dates Met

CLINICAL IMPRESSION Initial visit unless marked: subsequent sequelae

CV

Acute MI: STEMI NSTEMI anterior inferior lateral posterior

Angina: stable unstable

Aorta dissection: abdomen thoracic

Aortic aneurysm: abdomen thoracic with rupture

Ischemic chest pain

Ischemic colitis

Mesenteric ischemia: acute chronic

GI

Appendicitis: acute chronic with peritonitis: general local

Bowel obstruction

Clostridium difficile enterocolitis

Constipation

Crohn's disease: small bowel large bowel with: abscess bleeding fistula obstruction

Diverticulitis: small bowel large bowel with: abscess bleeding perforation

Fecal impaction

Gastritis: acute chronic alcoholic with bleeding

Gastroenteritis: infectious viral

GERD: with esophagitis

Circle positives strikethrough ~~negatives~~ unmarked = not applicable

FINAL (SIGNED)



MMC LIVINGSTON

Abdominal Pain Flank Pain ICD10, Transfer of Care Note add on

Patient:	Sex:	DOS:	MR#:
ALMAZON RUIZ, FELIPE	Male	09/11/2017 23:20	0010282353

Irritable bowel: with diarrhea

Peptic ulcer disease: acute chronic with: hemorrhage perforation

Perforated intestine

Ulcerative colitis: involving: rectum sigmoid colon
with: abscess bleeding fistula obstruction

Volvulus

GU

Ovarian cyst: follicular simple

PID: acute chronic GC chlamydia

Pregnancy: 1st 2nd 3rd trimester + pregnancy test ectopic-tubal
labor: preterm term false < 37 wk > 37 wk

Pyelonephritis: acute chronic

Torsion: testicular R L ovarian R L

Ureterolithiasis: with gout

UTI: cystitis: acute chronic with hematuria

LIVER / GB / PANCREAS

Biliary colic: with gallstones

Cholecystitis: acute chronic with: gallstones obstruction

Hepatitis: acute chronic viral: A B C alcoholic drug induced:

Pancreatitis: acute chronic alcoholic biliary idiopathic

OTHER

Dehydration

Peritonitis, acute

Pneumonia: aspiration atypical bronchopneumonia interstitial lobar
viral: RSV influenza: A B bacterial:

Sepsis, severe: with shock

SIRS

Circle positives strikethrough ~~negatives~~ unmarked = not applicable

FINAL (SIGNED)



CHI St. Luke's Health

MMC LIVINGSTON

Abdominal Pain Flank Pain ICD10, Transfer of Care Note add on

Patient:	Sex:	DOS:	MR#:
ALMAZON RUIZ, FELIPE	Male	09/11/2017 23:20	0010282353

SIGN / SYMPTOMS

Abdominal pain: RUQ LUQ RLQ LLQ
 acute abdomen generalized with: rebound tenderness

Fever

Flank pain

Nausea

Vomiting

Diarrhea

Comments: Upper GI bleed

Current Problems Reviewed Updated

Upper GI bleed (2017)

DISPOSITION

Decision made at: 02:35 AM Left department at:

To: Home Transfer Admit Morgue
 Nursing Home Police Funeral Home Medical Examiner

Present on arrival: pressure ulcer UTI

patient condition: unchanged improved stable serious critical deceased
 ambulatory active drinking fluid eating pain controlled

Care transferred to Dr. Abas time: 05:15 AM

Basis For Discharge Decision:

patient exam: stable improved unchanged
 tenderness migratory no rebound no rigidity

test results: no abnormal no serious abnormal min abnormal mod abnormal

social support: adequate good excellent

follow up: available arranged discussed with physician

Circle positives strikethrough ~~negatives~~ unmarked = not applicable

FINAL (SIGNED)



CHI St. Luke's Health

MMC LIVINGSTON

Abdominal Pain Flank Pain ICD10, Transfer of Care Note add on

Patient:	Sex:	DOS:	MR#:
ALMAZON RUIZ, FELIPE	Male	09/11/2017 23:20	0010282353

Basis For Admit Decision:

- need for: further evaluation additional testing monitoring telemetry
- pain control IV hydration IV medication IV antibiotics
- culture results surgery / intensive care

TRANSFER OF CARE

Relinquishing Scribe: Cheyenne Cooke	Report given to	Assuming Scribe: (b)(6); (b)(7)(C)
Relinquishing Mid-Level:	Report given to	Assuming Mid-Level:
Relinquishing Mid-Level:	Report given to	Assuming Physician:
Relinquishing Physician:	Report given to	Assuming Physician:

Brief history:

Items pending that need to be checked and documented:

- Labs:
- X-Ray results:
- Pain control:
- CT results:
- MRI results:
- US results:
- Procedure(s):
- Other:

Physician / consult arrival:

Tentative impression of patient:

- admit discharge transfer

Pending results:

Circle positives strikethrough ~~negatives~~ unmarked = not applicable

FINAL (SIGNED)



CHI St. Luke's Health

MMC LIVINGSTON

Abdominal Pain Flank Pain ICD10, Transfer of Care Note add on

Patient: ALMAZON RUIZ, FELIPE	Sex: Male	DOS: 09/11/2017 23:20	MR#: 0010282353
---	---------------------	---------------------------------	---------------------------

TRANSFERRING SIGNATURE

Transferring Mid-Level signing out:

Signature

Date/Time

Transferring Physician signing out

Signature

Date/Time

SIGNATURE

By signing my name below, (b)(6); (b)(7)(C) I attest that this documentation has been prepared under the direction and in the presence of

(b)(6); (b)(7)(C) Electronically signed (b)(6); (b)(7)(C) Date 09/12/2017 Time: 02:35 AM

09/12/2017 05:17

Mid-level Signature OR Scribe Signature

Date/Time

Emergency Physician Attestation


This scribe's documentation has been prepared under my direction and personally reviewed by me in its entirety. I confirm that the note accurately reflects all work, treatment, procedures, and medical decision making performed by me.

(b)(6); (b)(7)(C) ges have been reviewed and completed

09/12/2017 05:18

Authorized Signature

Date/Time



Circle positives strikethrough ~~negatives~~ unmarked = not applicable

Printed: 09/11/2017 21:36:16

**MMC LIVINGSTON
LIV ED Triage Report**



Page 1 of 1

Patient: ALMAZON RUIZ, FELIPE

Visit ID: 0300267948

Age: 51Y DOB:08/28/1966 Sex: M Acuity: 3


Med Rec: 0010282353

Chief Complaint: Hemoptysis		Onset: 2 days	Head Circum.:
Triage D/T: 09/11/2017 21:25 Room/Bed: Arrival D/T: 09/11/2017 21:02 Arrived from: Forensic Facility Mode of Arrival: Law Enforcement Accompanied by: Other		EMS: EMS Unit: Pre Hospital Care: [None entered]	Infection Control: Screening: *Domestic Violence, *TB, Out US Last 30 Days NC Suicide Risk: Screened - No Suicide Risk Pregnant?: LMP:
Informant: Self	Consent to Treat?:	Radio Call: N	

Patient Narrative:
by x-rays and ct scans of liver; no vomiting or blood and abd pain; pt came here from mtc detention center; came here from center in florida.
(b)(6); (b)(7)(C)

Stroke Assessment Last Known Well:							
NPO since:	Last Intake Solid:	D/T	Last Intake Liquid:	D/T			
BP	Temperature	Pulse	Respirations	SpO ₂	FSBS	GCS	Height
149/97 mmHg	98.1 F	99 bpm	18	98% O ₂ L/m		15	61 in
Site: Arm, Upper Lt	Site: Forehead	Site:	Qly:	Co/Del:	M - 6	Weight	
Poe:		Qly:			V - 5	77.13 kg	
Type:		Type:			E - 4		

Pain Assessment	Score: 7/10	Scale: 7, Numeric Scale	Location: abd
Character: stabbing	Non Verbal Signs:		
Distribution:	Intensified By:		
Radiation:	Relieved By:		
Duration:	Goal:		



Dr: (Unassigned) Electronically Signed By: WRIGHT, BRENDA Dt Signed: 09/11/2017 21:36:10
PCP: NONE, NONE

CHI ST. LUKE'S HEALTH - LIVINGSTON
 LABORATORY - CLIA # 45D0697930
 1717 HIGHWAY 59 BYPASS
 LIVINGSTON, TEXAS 77351
 PH: (936) 329-8589

=====

PATIENT: ALMAZON RUIZ, FELIPE	MR #: V0010282353
DOB: 06/26/1966	
SEX: M	LOC: ER LIVINGSTON
ENCOUNTER #: V0300267948	
ATTD. PHYSICIAN: (b)(6); (b)(7)(C)	ADMITTED: 09/11/2017

=====

HEMATOLOGY

Collected	09/11/2017		Reference	Units
Ord Physician	23:29 ¹			
	ZAHEER, SYED J, MD			
WBC	14.28	H	4.80-10.80	10 ³ /ul
RBC	3.94	L	4.70-6.10	10 ⁶ /ul
Hemoglobin	12.5	L	14.0-18.0	gm/dl
Hematocrit	33.2	L	42.0-50.0	%
MCV	84.3		80.0-94.0	fL
MCH	31.7	H	27.0-31.0	pg
MCHC	37.7	H	33.0-37.0	gm/dl
RDW	16.0	H	11.5-14.5	%
Platelet	18	LP	130-400	10 ³ /ul
MPV	Not Measured ²		7.4-10.4	fL
NE%	72.4		42.0-75.0	%
LY%	7.8	L	13.0-42.0	%
MO%	11.9		4.0-14.0	%
EO%	0.9	L	1.0-3.0	%
BA%	0.6	L	1.0-3.0	%
IG%	6.4	H	0.0-0.4	%
NRBC, Auto	1		0-2	1 ⁰⁰ WBC
Nucleated RBC	0		0-2	1 ⁰⁰ WBC

Manual
Differentials

¹AUTO DIFF
 Critical values were called to (b)(6); (b)(7)(C) 0045 by FS30723 on 09/12/2017 00:46 AM. Results were read back by (b)(6); (b)(7)(C)

²MPV NOT MEASURED WHEN INSTRUMENT HAS SUPPRESSED OR UNREPORTABLE RESULT. THIS WILL MOST OFTEN HAPPEN WITH THE MPV WHEN THERE IS AN ABNORMAL PLATELET DISTRIBUTION DUE TO A CRITICAL LOW VALUE OR PLATELET CLUMPING.

=====

ALMAZON RUIZ, FELIPE	REPORT: Final Chart Livingston	PRINTED: 09/12/2017 18:43
ER LIVINGSTON		
(b)(6); (b)(7)(C)	PAGE: 1 OF 8	

CHI ST. LUKE'S HEALTH - LIVINGSTON
LABORATORY - CLIA # 45D0697930
1717 HIGHWAY 59 BYPASS
LIVINGSTON, TEXAS 77351
PH: (936) 329-8589

PATIENT: ALMAZON RUIZ, FELIPE

MR #: V0010282353

DOB: 06/26/1966

SEX: M

LOC: ER LIVINGSTON

ENCOUNTER #: V0300267948

ATTENDING PHYSICIAN: (b)(6); (b)(7)(C)

ADMITTED: 09/11/2017

Collected	09/11/2017 23:29 ³	Reference	Units
Ord Physician	(b)(6); (b)(7)(C)		
Neutrophils	10 L	42-75	%
Nucleated RBC	0	0-2	/100WBC
Platelet Morphology	Decreased platelets, NO Platelet clumping, few large platelets seen on peripheral blood smear.		

³AUTO DIFF

Critical values were called to (b)(6); (b)(7)(C) by FS30723 on 09/12/2017 00:46 AM. Results were read back by (b)(6); (b)(7)(C)

(b)(6); (b)(7)(C)

ALMAZON RUIZ, FELIPE

ER LIVINGSTON

(b)(6); (b)(7)(C)

REPORT: Final Chart Livingston

PRINTED: 09/12/2017 18:43

PAGE: 2 OF 8

CHI ST. LUKE'S HEALTH - LIVINGSTON
LABORATORY - CLIA # 45D0697930
1717 HIGHWAY 59 BYPASS
LIVINGSTON, TEXAS 77351
PH: (936) 329-8589

PATIENT: ALMAZON RUIZ, FELIPE

MR #: V0010282353

DOB: 06/26/1966

SEX: M

LOC: ER LIVINGSTON

ENCOUNTER #: V0300267948

ATTD. PHYSICIAN: (b)(6); (b)(7)(C)

ADMITTED: 09/11/2017

COAGULATION

	Test		Units	Reference	Ord Physician
09/11/2017 23:29	Prottime	15.1	H seconds	9.0-11.8	(b)(6); (b)(7)(C)
	INR	1.4*	H	0.9-1.1	
	aPTT	22.1	L seconds	25.3-35.7	

*INR results are intended ONLY to monitor Oral Anticoagulant therapy in stabilized patients. The INR Therapeutic Range is 2.0 - 3.0 Patients with a mechanical heart, the INR Range is 2.5 - 3.5

ALMAZON RUIZ, FELIPE

PRINTED: 09/12/2017 18:43

ER LIVINGSTON

REPORT: Final Chart Livingston

(b)(6); (b)(7)(C)

PAGE: 3 OF 8

CHI ST. LUKE'S HEALTH - LIVINGSTON
 LABORATORY - CLIA # 45D0697930
 1717 HIGHWAY 59 BYPASS
 LIVINGSTON, TEXAS 77351
 PH: (936) 329-8589

PATIENT: ALMAZON RUIZ, FELIPE

MR #: V0010282353

DOB: 06/26/1966

SEX: M

LOC: ER LIVINGSTON

ENCOUNTER #: V0300267948

ATTD. PHYSICIAN: (b)(6); (b)(7)(C)

ADMITTED: 09/11/2017

CHEMISTRY

Collected	09/11/2017	Reference	Units
	23:29		
Ord Physician	ZAHEER, SYED J, MD		
Sodium	127 L	137-145	mmol/l
Potassium	4.3	3.5-5.0	mmol/l
Chloride	95 L	98-107	mmol/l
CO2	22	22-30	mmol/l
Glucose	127 H	75-110	mg/dl
BUN	85.0 H	6.0-17.0	mg/dl
Creatinine	1.5 H	0.4-1.2	mg/dl
T Protein	6.5	5.1-6.7	gm/dl
Albumin	3.3 L	3.5-4.6	gm/dl
Globulin	3.2	2.3-3.5	gm/dl
A/G Ratio	1.0 L	1.1-2.2	%
Calcium	8.6	8.4-10.2	mg/dl
Calcium, Corrected	9.2*	8.4-10.2	mg/dl
Total Bilirubin	10.8 H	0.2-1.2	mg/dl
AST (SGOT)	102 H	11-36	U/L
ALT (SGPT)	68 H	11-40	U/L
Alkaline Phos	123 H	47-114	U/L

*Various formulas exist for corrected serum calcium results, each yielding different values. This corrected result was based on the formula: Corrected Calcium = SerumCalcium + [0.8 * (4 - SerumAlbumin)]

ALMAZON RUIZ, FELIPE
 ER LIVINGSTON

PRINTED: 09/12/2017 18:43

(b)(6); (b)(7)(C)

REPORT: Final Chart Livingston

PAGE: 4 OF 8

CHI ST. LUKE'S HEALTH - LIVINGSTON
LABORATORY - CLIA # 45D0697930
1717 HIGHWAY 59 BYPASS
LIVINGSTON, TEXAS 77351
PH: (936) 329-8589

PATIENT: ALMAZON RUIZ, FELIPE

MR #: V0010282353

DOB: 06/26/1966

SEX: M

LOC: ER LIVINGSTON

ENCOUNTER #: V0300267948

ATTD. PHYSICIAN

(b)(6); (b)(7)(C)

ADMITTED: 09/11/2017

Collected	09/11/2017 23:29	Reference	Units
Ord Physician	ZAHEER, SYED J. MD		
Amylase	112 H	12-103	U/L
Lipase	367 H	8-223	U/L
EGFR if African American	>60		mL/min/1.73m ² 2
EGFR if Non-African American	52 ^o		mL/min/1.73m ² 2

CARDIAC SECTION

*Estimated Glomerular Filtration Rate (eGFR) Reference Intervals
Decision Points for 18 years and older and average body mass:

- >= 60 Does not exclude kidney disease.
- 30 - 59 Suggests moderate chronic kidney disease and indicates the need for further investigation including assessment of proteinuria and cardiovascular factors.
- < 30 Usually indicates a need for referral for assessment and management of chronic kidney failure.

ALMAZON RUIZ, FELIPE
ER LIVINGSTON

PRINTED: 09/12/2017 18:43

(b)(6); (b)(7)(C)

REPORT: Final Chart Livingston

PAGE: 5 OF 8

CHI ST. LUKE'S HEALTH - LIVINGSTON
 LABORATORY - CLIA # 45D0697930
 1717 HIGHWAY 59 BYPASS
 LIVINGSTON, TEXAS 77351
 PH: (936) 329-8589

PATIENT: ALMAZON RUIZ, FELIPE

MR #: V0010282353

DOB: 06/26/1966

SEX: M

LDC: ER LIVINGSTON

ENCOUNTER #: V0300267948

ATTD. PHYSICIAN: ZAHEER, SYED J, MD

ADMITTED: 09/11/2017

Collected	09/11/2017 23:29 ⁷	Reference	Units
Ord Physician	ZAHEER, SYED J, MD		
CKMB	7.49⁸ HP	0.00-2.36	ng/ml
Troponin-I	0.076 ⁹ H	0.000-0.034	ng/ml
CPK	322 H	30-135	U/L

**SPECIAL
CHEMISTRY**

⁷Critical values were called (b)(6); (b)(7)(C) RN by HF 132001 on 09/12/2017 00:03 AM. Results were read back by (b)(6); (b)(7)(C).
⁸RESULT CALLED TO (b)(6); (b)(7)(C) RN (ER) AT 0003 THEN READ BACK //HH//
⁹The 99th Percentile URL is 0.034 ng/mL.

The Joint European Society of Cardiology/American College of Cardiology (ESC/ACC) and the National Academy of Clinical Biochemistry Standards of Laboratory Practices (NACB) recommends that the diagnosis of AMI includes the presence of clinical history suggestive of Acute Coronary Syndrome (ACS) and a maximum concentration of cardiac troponin exceeding the 99th percentile of a normal reference population [upper reference limit (URL)] on at least one occasion during the first 24 hours after the clinical event.

ALMAZON RUIZ, FELIPE
 ER LIVINGSTON

PRINTED: 09/12/2017 18:43

REPORT: Final Chart Livingston

(b)(6); (b)(7)(C)

PAGE: 6 OF 8

CHI ST. LUKE'S HEALTH - LIVINGSTON
 LABORATORY - CLIA # 45D0697930
 1717 HIGHWAY 59 BYPASS
 LIVINGSTON, TEXAS 77351
 PH: (936) 329-8589

=====

PATIENT: **ALMAZON RUIZ, FELIPE** MR #: V0010282353
 DOB: 06/26/1966
 SEX: M LOC: ER LIVINGSTON
 ENCOUNTER #: V0300267948
 ATTD. PHYSICIAN: (b)(6); (b)(7)(C) ADMITTED: 09/11/2017

=====

Collected	09/11/2017 23:29 ⁰⁰	Reference	Units
Ord Physician	ZAHEER, SYED J, MD		
Pro-BNP(B-Peptide)	4850 HP	0-125	pg/ml

¹⁰Critical values were called (b)(6); (b)(7)(C) by I:1132001 on 09/12/2017 00:03 AM. Results were read back (b)(6); (b)(7)(C) RN.
¹¹RESULT CALLED TO (b)(6); (b)(7)(C) (ER) AT 0003 THEN READ BACK //HH/

=====

ALMAZON RUIZ, FELIPE REPORT: Final Chart Livingston PRINTED: 09/12/2017 18:43
 ER LIVINGSTON (b)(6); (b)(7)(C) PAGE: 7 OF 8

CHI ST. LUKE'S HEALTH - LIVINGSTON
LABORATORY - CLIA # 45D0697930
1717 HIGHWAY 59 BYPASS
LIVINGSTON, TEXAS 77351
PH: (936) 329-8589

PATIENT: ALMAZON RUIZ, FELIPE

MR #: V0010282353

DOB: 06/26/1966

SEX: M

LDC: ER LIVINGSTON

ENCOUNTER #: V0300267948

ATTD. PHYSICIAN: (b)(6); (b)(7)(C)

ADMITTED: 09/11/2017

BLOOD BANK TESTS

	Test	Analyte	Result	Ord Physician
09/11/2017 23:29	TYPE & SCREEN	ABO Blood Type	O	ZAH-EER, SYED J, MD
		Rh	Positive	
		Antibody Screen	Negative	
09/11/2017 22:13	CROSSMATCH x 2	Crossmatch	Completed: Compatible	ZAH-EER, SYED J, MD

ALMAZON RUIZ, FELIPE
ER LIVINGSTON
(b)(6); (b)(7)(C)

REPORT: Final Chart Livingston

PRINTED: 09/12/2017 18:43

PAGE: 8 OF 8



CHI St. Luke's Health

Lufkin • Livingston • San Augustine
Memorial Specialty

BLOOD BANK TRANSFUSION RECORD

ATT

0300267948 SPAI
ALMAZON RUIZ, FELIPE

ED 09/11/2017 0010282353
DOB: 06/26/1966 51Y M

Patient ABO/Rh: O POSITIVE


Donor ABO/Rh: O POSITIVE

Product: LR - PPHC

Donor Unit W0446 17 361217

Crossmatch Interpretation: COMPATIBLE

Tech ID (b)(6), (b)(7)(C)

Blood Band #: 

Antibody Screen: NEGATIVE

Segment #: E5204141A

Expiry Date: 10-21-17

Unit #: 192

Date/Time: 9/17/17 0730

TRANSFUSERS MUST SIGN

certify that prior to transfusion we have verified the identity of this unit and its intended recipient have checked each item in the presence of the recipient

Date _____ Time _____

Date _____ Time _____





CHI St. Luke's Health

Lufkin • Livingston • San Augustine
Memorial Specialty

BLOOD BANK TRANSFUSION RECORD

0300267948 SPAI
ALMAZON RUIZ, FELIPE
EO 09/11/2017 0010282353
DOB: 06/26/1966 51Y M

RE

Patient ABO/Rh: O POSITIVE
 Donor ABO/Rh: O POSITIVE
 Product: UR-PLATE
 Donor Unit: W0446 17 361220
 Crossmatch Interpretation: COMPATIBLE

Blood Band #:



Antibody Screen: NEGATIVE
 Segment #: E5204109A
 Expiry Date: 10-21-17
 Unit #: 2082

Tech ID: (b)(6)
(b)(7)(C)

Date/Time: 9/12/17 0120

TRANSFUSERS MUST SIGN

We certify that prior to transfusion we have verified the identity of this unit and its intended recipient and have checked each item in the presence of the recipient.

Date Time

Date Time



REV. (01/2015) KWIK COPY PRINTING



BLOOD BANK TRANSFUSION RECORD

Lufkin • Livingston • San Augustine
Memorial Specialty

ATTN

0300267948 SPAI
ALMAZON RUIZ, FELIPE

ED 09/11/2017 0010282353
DOB: 06/26/1966 51Y M

Patient ABO/Rh: O POSITIVE

Donor ABO/Rh: O POSITIVE

Product: UR-PPHC

Donor Unit W0446 17 361217

Crossmatch Interpretation: COMPATIBLE

Tech ID: (b)(6); (b)(7)(C)

RELEASED

also 1/18

(b)(6);
(b)(7)(C)

Blood Band #:

Antibody Screen: NEGATIVE

Segment #: E5204141A

Expiry Date: 10-21-17

Unit #: 1022

Date/Time: 9/12/17 0130

TRANSFUSERS MUST SIGN

I certify that prior to transfusion we have verified the identity of this unit and its intended recipient and have checked each item in the presence of the recipient.

X _____ Date _____ Time _____

X _____ Date _____ Time _____



REV. (01/30/15) KWIK COPY PRINTING



BLOOD BANK TRANSFUSION RECORD

Lufkin • Livingston • San Augustine
Memorial Specialty

RE

0300267948 SPAI
ALMAZON RUIZ, FELIPE

ED 09/11/2017 0010282353
DOB: 06/26/1966 51Y M

Patient ABO/Rh: O POSITIVE

Donor ABO/Rh: O POSITIVE

Product: UR-PPHC

Donor Unit W0446 17 361220

Crossmatch Interpretation: COMPATIBLE

Tech ID: (b)(6); (b)(7)(C)

RELEASED

9/13/17

Blood Band #:

Antibody Screen: NEGATIVE

Segment #: E5204109A

Expiry Date: 10-21-17

Unit #: 2082

Date/Time: 9/12/17 0130

TRANSFUSERS MUST SIGN

I certify that prior to transfusion we have verified the identity of this unit and its intended recipient and have checked each item in the presence of the recipient.

X _____ Date _____ Time _____

X _____ Date _____ Time _____



MMC LIVINGSTON
Ambulatory Assessment/History Report
09/11/2017 21:02 Through 09/14/2017 04:01

Patient Name: **ALMAZON RUIZ, FELIPE**
 Visit ID: **0300267948** MR Number: **0010282353** DOB: **06/26/1966**
 Admitted: **09/11/2017 21:02** Attending: (b)(6); (b)(7)(C)

Assessment Date		Entry Date
Vitals	Entered By: (b)(6); (b)(7)(C) Pt. Location: UNKNOWN_LOCATION UNKNOWN_BED Temp Pulse Resp BP O2 % Ht Wt	
09/11/2017 21:36	98.1 F 99 18 149/97 99.0% 61.00 in 77.13 kgs Forehead Arm, Upper Lt	09/11/2017 21:36

Vitals	Entered By: (b)(6); (b)(7)(C) Pt. Location: LIV EMERGENCY DEPARTMENT RM-04-A Temp Pulse Resp BP O2 % Ht Wt	
09/12/2017 00:46		09/12/2017 00:50

Assessment Date		Entry Date
	IV Medications Entered By: (b)(6); (b)(7)(C) Pt. Location: LIV EMERGENCY DEPARTMENT RM-04-A	

09/12/2017 00:49	Site: Jugular, Left Started by: (b)(6); (b)(7)(C)	09/12/2017 00:49
09/12/2017 03:04	Fluid: octreotide 25mcg 120 25 Started by: (b)(6); (b)(7)(C)	09/12/2017 03:04
	Fluid: NSS 1000 150 Started by: (b)(6); (b)(7)(C)	09/12/2017 03:04

MMC LIVINGSTON
Daily Focus Assessment Report
 09/11/2017 21:02 Through 09/14/2017 04:01

Patient Name: **ALMAZON RUIZ, FELIPE**
 Visit ID: **0300267948** MR Number: **0010282353** DOB: **06/26/1968**
 Admitted: **09/11/2017 21:02** Attending: **(b)(6); (b)(7)(C)**

Assessment Date	Entry Date
Actions Entered By: (b)(6); (b)(7)(C) Pt. Location: LIV EMERGENCY DEPARTMENT RM-04-A	

09/12/2017 00:47	Critical Value - Name: Platelets	09/12/2017 00:47
	Critical Value - Result: 18000	09/12/2017 00:47
	Critical Value - Date/Time Received: 09/12/2017 00:48	09/12/2017 00:47
	Critical Value - Name of MD: Zaheer	09/12/2017 00:47
	Notified:	
	Critical Value - Date/Time MD: 09/12/2017 00:48	09/12/2017 00:47
	Notified:	
	Critical Value - Comments/Orders: No new orders	09/12/2017 00:47
	Received:	
	Rounding Action: Pt Visually Checked	09/12/2017 00:47
	No change from previous assessment by this clinician	

Assessment Date	Entry Date
ED Med Time(s) Entered By: (b)(6); (b)(7)(C) Pt. Location: LIV EMERGENCY DEPARTMENT RM-04-A	

09/12/2017 02:15	Pain Assessment	Pain Location: abd	09/12/2017 03:02
		Pain Scale: Numeric	
		Pain Score: 5/10	
		Pain Goal: acceptable pain reduction	
09/12/2017 02:15	Name Of IV Push Med Given: octreotide		09/12/2017 03:02
	Dose: 25mcg		09/12/2017 03:02
	Time IV Push Med Given: 09/12/2017 02:15		09/12/2017 03:02
	Response: No ADR		09/12/2017 03:02

Assessment Date	Entry Date
Rounding Entered By: (b)(6); (b)(7)(C) Pt. Location: LIV EMERGENCY DEPARTMENT RM-04-A	

09/12/2017 02:33	Rounding Action	Will continue to monitor patient for complaints or changes in status. Personal needs met Other	09/12/2017 02:33
------------------	-----------------	--	------------------

MMC LIVINGSTON
Daily Focus Assessment Report
 09/11/2017 21:02 Through 09/14/2017 04:01

Patient Name: **ALMAZON RUIZ, FELIPE**
 Visit ID: **0300267948** MR Number: **0010282353** DOB: **06/26/1966**
 Admitted: **09/11/2017 21:02** Attending: **(b)(6); (b)(7)(C)**

Assessment Date	Entry Date
Rounding Entered By: (b)(6); (b)(7)(C) Pt. Location: LIV EMERGENCY DEPARTMENT RM-04-A	

09/12/2017 02:33 **Group Note: Assisted to BR by guards with wheelchair. Dizzy when standing. NSR on monitor** 09/12/2017 02:35

Rounding Status No change from previous assessment by this clinician 09/12/2017 02:33
 Pt resting, no complaints voiced at this time
 Pt. denies any complaints at this time.

Assessment Date	Entry Date
Rounding Entered By: (b)(6); (b)(7)(C) Pt. Location: LIV EMERGENCY DEPARTMENT RM-04-A	

09/12/2017 02:35 **Rounding Action** Other 09/12/2017 02:35
Group Note: IV attempted x3. EJ by (b)(6); 09/12/2017 02:36
Rounding Status Pt resting, no complaints voiced at this time 09/12/2017 02:35
 Pt. denies any complaints at this time.

Assessment Date	Entry Date
Rounding Entered By: (b)(6); (b)(7)(C) Pt. Location: LIV EMERGENCY DEPARTMENT RM-04-A	

09/12/2017 03:30 **Rounding Action** Will continue to monitor patient for complaints or changes in status. 09/12/2017 06:18
Rounding Status No change from previous assessment by this clinician 09/12/2017 06:18
 Pt resting, no complaints voiced at this time
 Pt. denies any complaints at this time.

MMC LIVINGSTON
Daily Focus Assessment Report
09/11/2017 21:02 Through 09/14/2017 04:01

Patient Name: **ALMAZON RUIZ, FELIPE**
 Visit ID: **0300267948** MR Number: **0010282353** DOB: **08/26/1988**
 Admitted: **09/11/2017 21:02** Attending: (b)(6); (b)(7)(C)

Assessment Date	Entry Date
<p>Rounding Entered By: (b)(6); (b)(7)(C)</p> <p>Pt. Location: LIV EMERGENCY DEPARTMENT RM-04-A</p>	

09/12/2017 05:57	Rounding Action	Will continue to monitor patient for complaints or changes in status. Personal needs met	09/12/2017 05:57
	Rounding Status	No change from previous assessment by this clinician Pt resting, no complaints voiced at this time Pt. denies any complaints at this time.	09/12/2017 05:57

MMC LIVINGSTON

Discharge Assessment/Summary Report

09/11/2017 21:02 through 09/14/2017 04:01

Patient Name: **ALMAZON RUIZ, FELIPE**

Visit ID: **0300267946**

MR Number: **0010282353**

DOB: **06/26/1966**

Discharged: **09/12/2017 07:00**

Attending: (b)(6); (b)(7)(C)

Allergies

Allergy Date

No Known Allergies

(b)(6); (b)(7)(C)

09/11/2017

Last Documented by on 09/11/2017 21:35

Vitals

Entered By: (b)(6); (b)(7)(C)

Entry Date

Pt. Location: UNKNOWN_LOCATION UNKNOWN_BED

Temp Pulse Resp BP O2 % Ht Wt

09/11/2017 21:36 98.1 F 16 99.0% 61.00 In 77.13 kgs 09/11/2017 21:36
Forehead

Vitals

Entered By: (b)(6); (b)(7)(C)

Entry Date

Pt. Location: LIV EMERGENCY DEPARTMENT RM-04-A

Temp Pulse Resp BP O2 % Ht Wt

09/12/2017 00:49 91 09/12/2017 02:37

09/12/2017 04:10 142/109 09/12/2017 05:58
Arm, Upper Lt

Assessment Date

Transfer

Entry Date

Entered By: (b)(6); (b)(7)(C)

Pt. Location: LIV EMERGENCY DEPARTMENT RM-04-A

09/12/2017 06:45 Admit to: ICU 09/12/2017 06:55
Other

09/12/2017 06:45 **Group Note: 17** 09/12/2017 08:56

09/12/2017 06:45 Transported With: Oxygen 09/12/2017 06:55
Cardiac / Apnea Monitor
TR/DC with IV line intact
Other

09/12/2017 06:45 **Group Note: Octreotide infusion** 09/12/2017 06:56

09/12/2017 06:45 Report Given To Loretta 09/12/2017 06:55

Report Given On Current
IV Therapy
Vital Signs
Fall Precautions
Transfer to Another Facility Yes
Notified of Discharge/Transfer Other

09/12/2017 06:45 **Group Note: MTC guards** 09/12/2017 06:57

09/12/2017 06:45 MOT Completed Yes 09/12/2017 06:55

Receiving Physician Abbass
Receiving Facility Conroe Regional

MMC LIVINGSTON

IV Site and Fluid Report

09/11/2017 21:02 Through 09/14/2017 04:01

Patient Name: ALMAZON RUIZ, FELIPE

Visit ID: 0300267948

MR Number: 0040282253

DOB: 06/26/1966

Admitted: 09/11/2017 21:02

Attending: (b)(6); (b)(7)(C)

IV Site: Jugular, Left
Started 09/12/2017 00:49 By gelb

Pt Location: LIV EMERGENCY DEPARTMENT RM-04-A
Type: Venous **Entered Date:** 09/12/2017 00:49
Catheter Sz: 18 ga **Position Modifier:**
Catheter Length: **Unsuccessful Attempts:**
Lumens No.:
Note:

Added By: (b)(6); (b)(7)(C) **On** 09/12/2017 00:49
Pt Location: LIV EMERGENCY DEPARTMENT RM-04-A
IV Site Started By: (b)(6); (b)(7)(C) **in** 09/12/2017 00:49
IV Site: Jugular, Left
IV Type: Venous
Catheter Sz: 18 ga

Fluid: NSS
Entry For Date 09/12/2017 03:04 By gelb

Pt Location: LIV EMERGENCY DEPARTMENT RM-04-A
Fluid Started By: (b)(6); (b)(7)(C) **Fluid Started Date:** 09/12/2017 03:04
Lumen Used: **Entered Date:** 09/12/2017 03:04
Rate: 150 ml/hr **IV Pump:** y
Starting Volume: 1000 ml **Volume Infused:**
Bag No.: **Bag Complete Date:**

Added By: (b)(6); (b)(7)(C) **On** 09/12/2017 03:04
Entry For Date: 09/12/2017 03:04
Fluid: NSS
Pt Location: LIV EMERGENCY DEPARTMENT RM-04-A
IV Site: Jugular, Left
Fluid Started By: (b)(6); (b)(7)(C) **On** 09/12/2017 03:04
Starting Volume: 1000
Rate: 150 ml/hr
IV Pump: y

Fluid: octreotide 25mcg
Entry For Date 09/12/2017 03:04 By gelb

Pt Location: LIV EMERGENCY DEPARTMENT RM-04-A
Fluid Started By: (b)(6); (b)(7)(C) **Fluid Started Date:** 09/12/2017 03:04
Lumen Used: **Entered Date:** 09/12/2017 03:04
Rate: 25 mcg/hr **IV Pump:** y
Starting Volume: 120 ml **Volume Infused:**
Bag No.: **Bag Complete Date:**

MMC LIVINGSTON

IV Site and Fluid Report

09/11/2017 21:02 Through 09/14/2017 04:01

Patient Name: ALMAZON RUIZ, FELIPE

Visit ID: 0300267948

MR Number: 0010282353

DOB: 06/26/1966

Admitted: 09/11/2017 21:02

Attending: (b)(6); (b)(7)(C)

Fluid: octreotide 25mcg
Entry For Date 09/12/2017 03:04 By gelb

Pt Location: LIV EMERGENCY DEPARTMENT RM-04-A

Fluid Started By: (b)(6); (b)(7)(C)

Fluid Started Date: 09/12/2017 03:04

Lumen Used:

Entered Date: 09/12/2017 03:04

Rate: 25 mcg/hr

IV Pump: y

Starting Volume: 120 ml

Volume Infused:

Bag No.:

Bag Complete Date:

Added By: (b)(6); (b)(7)(C) n 09/12/2017 03:04

Entry For Date: 09/12/2017 03:04

Fluid: octreotide 25mcg

Pt Location: LIV EMERGENCY DEPARTMENT RM-04-A

IV Site: Jugular, Left

Fluid Started By: (b)(6); (b)(7)(C) n 09/12/2017 03:04

Starting Volume: 120

Rate: 25 mcg/hr

IV Pump: y

MMC LIVINGSTON

IV Assessment Report

09/11/2017 21:02 Through 09/14/2017 04:01

Patient Name: ALMAZON RUIZ, FELIPE

Visit ID: 0300267948

MR Number: 0010282353

DOB: 06/26/1966

Admitted: 09/11/2017 21:02

Attending: (b)(6); (b)(7)(C)

Assessment Date

IV Site: Jugular, Left

Entered By: (b)(6); (b)(7)(C)

Catheter Sz: 18 ga

IV Site Started By: (b)(6); (b)(7)(C)

Type: Venous

No. of Lumens:

Note:

Pt. Location: LIV EMERGENCY DEPARTMENT RM-04-A

Entered Date: 09/12/2017 00:49

Site Started Date: 09/12/2017 00:49

Site Discontinued Date:

No. Unsuccessful Attempts:

09/14/2017 04:02

NOTE: All strikeouts were executed by person making original entry.

Page 1 of 1

MMC LIVINGSTON			
Vital Sign Report			
09/11/2017 21:02 Through 09/14/2017 04:01			
Patient Name: ALMAZON RUIZ, FELIPE		Med Rec No: 0010282353	
Visit Id: 0300267948		Admitted: 09/11/2017 21:02	
Birth Date: 08/26/1966		Discharged: 09/12/2017 07:00	
Attend Phys: (b)(6); (b)(7)(C)			

	Assess Date/Time:	Assess Date/Time:	Assess Date/Time:	Assess Date/Time:	Assess Date/Time:	Assess Date/Time:
Vital Type	09/11/2017 21:36	09/12/2017 00:29	09/12/2017 00:31	09/12/2017 00:34	09/12/2017 00:37	09/12/2017 00:40
	Bed: UNKNOWN_BE	Bed: RM-04-A	Bed: RM-04-A	Bed: RM-04-A	Bed: RM-04-A	Bed: RM-04-A

The cells below display the Vital Signs, Notes, Documenter, Co-signer (if applicable), and Date/Time entered.

Temp	98.1 F Forehead 09/11/2017 21:36 By: brwr					
Pulse	99 09/11/2017 21:36 By: brwr	H 103 09/12/2017 00:50 By: gelb	91 09/12/2017 00:50 By: gelb	89 09/12/2017 00:50 By: gelb	92 09/12/2017 00:50 By: gelb	
BP	149/97 Arm, Upper Lt 09/11/2017 21:36 By: brwr	142/104 Arm, Upper Lt 09/12/2017 00:50 By: gelb	161/109 Arm, Upper Lt 09/12/2017 00:50 By: gelb	162/98 Arm, Upper Lt 09/12/2017 00:50 By: gelb	162/94 Arm, Upper Lt 09/12/2017 00:50 By: gelb	158/95 Arm, Upper Lt 09/12/2017 00:50 By: gelb
Resp	16 09/11/2017 21:36 By: brwr					
Wt	77.13 kgs 09/11/2017 21:36 By: brwr					
Ht	61.00 in 09/11/2017 21:36 By: brwr					
BMI*	32.5					
BP, Mean		117 Arm Upper Lt 09/12/2017 00:50 By: gelb	124 Arm, Upper Lt 09/12/2017 00:50 By: gelb	124 Arm, Upper Lt 09/12/2017 00:50 By: gelb	120 Arm, Upper Lt 09/12/2017 00:50 By: gelb	116 Arm, Upper Lt 09/12/2017 00:50 By: gelb
BSA*	1.76					
O2 Sat%, PulseOx	99.0% 09/11/2017 21:36 By: brwr					
* = calculation						

Continued On Next Page...

MMC LIVINGSTON

Vital Sign Report

09/11/2017 21:02 Through 09/14/2017 04:01

Patient Name:	ALMAZON RUIZ, FELIPE				
Visit Id:	0300267948	Med Rec No:	0010282353		
Birth Date:	06/26/1986	Admitted:	09/11/2017 21:02		
Attend Phys:	(b)(6); (b)(7)(C)	Discharged:	09/12/2017 07:00		

	Assess Date/Time:	Assess Date/Time:	Assess Date/Time:	Assess Date/Time:	Assess Date/Time:	Assess Date/Time:
	09/12/2017 00:43	09/12/2017 00:46	09/12/2017 00:49	09/12/2017 00:52	09/12/2017 00:55	09/12/2017 00:58
Vital Type	Bed: RM-04-A	Bed: RM-04-A	Bed: RM-04-A	Bed: RM-04-A	Bed: RM-04-A	Bed: RM-04-A

The cells below display the Vital Signs, Notes, Documenter, Co-signer (if applicable), and Date/Time entered.

Pulse	94 09/12/2017 00:50 By: gelb	97 09/12/2017 00:50 By: gelb	91 09/12/2017 02:37 By: gelb	88 09/12/2017 02:37 By: gelb	91 09/12/2017 02:37 By: gelb	95 09/12/2017 02:37 By: gelb
BP	158/102 Arm, Upper Lt 09/12/2017 00:50 By: gelb	156/105 Arm, Upper Lt 09/12/2017 00:50 By: gelb	157/96 Arm, Upper Lt 09/12/2017 02:37 By: gelb	155/94 Arm, Upper Lt 09/12/2017 02:37 By: gelb	149/101 Arm, Upper Lt 09/12/2017 02:37 By: gelb	167/105 Arm, Upper Lt 09/12/2017 02:37 By: gelb
BP, Mean	119 Arm, Upper Lt 09/12/2017 00:50 By: gelb	130 Arm, Upper Lt 09/12/2017 00:50 By: gelb	110 Arm, Upper Lt 09/12/2017 02:37 By: gelb	118 Arm, Upper Lt 09/12/2017 02:37 By: gelb	120 Arm, Upper Lt 09/12/2017 02:37 By: gelb	131 Arm, Upper Lt 09/12/2017 02:37 By: gelb
* = calculation						

	Assess Date/Time:	Assess Date/Time:	Assess Date/Time:	Assess Date/Time:	Assess Date/Time:	Assess Date/Time:
	09/12/2017 01:01	09/12/2017 01:04	09/12/2017 01:07	09/12/2017 01:10	09/12/2017 02:16	09/12/2017 02:31
Vital Type	Bed: RM-04-A	Bed: RM-04-A	Bed: RM-04-A	Bed: RM-04-A	Bed: RM-04-A	Bed: RM-04-A

The cells below display the Vital Signs, Notes, Documenter, Co-signer (if applicable), and Date/Time entered.

Pulse	91 09/12/2017 02:37 By: gelb	80 09/12/2017 02:37 By: gelb	90 09/12/2017 02:37 By: gelb	94 09/12/2017 02:37 By: gelb		
BP	162/97 Arm, Upper Lt 09/12/2017 02:37 By: gelb	156/100 Arm, Upper Lt 09/12/2017 02:37 By: gelb	146/97 Arm, Upper Lt 09/12/2017 02:37 By: gelb	160/107 Arm, Upper Lt 09/12/2017 02:37 By: gelb	153/99 Arm, Upper Lt 09/12/2017 02:36 By: gelb	160/103 Arm, Upper Lt 09/12/2017 02:36 By: gelb
BP, Mean	117 Arm, Upper Lt 09/12/2017 02:37 By: gelb	112 Arm, Upper Lt 09/12/2017 02:37 By: gelb	113 Arm, Upper Lt 09/12/2017 02:37 By: gelb	125 Arm, Upper Lt 09/12/2017 02:37 By: gelb	117 Arm, Upper Lt 09/12/2017 02:36 By: gelb	126 Arm, Upper Lt 09/12/2017 02:36 By: gelb
* = calculation						

Continued On Next Page...

MMC LIVINGSTON

Vital Sign Report

09/11/2017 21:02 Through 09/14/2017 04:01

Patient Name: ALMAZON RUIZ, FELIPE

Visit Id: 0300267948

Med Rec No: 0010282353

Birth Date: 06/26/1966

Admitted: 09/11/2017 21:02

Attend Phys: (b)(6); (b)(7)(C)

Discharged: 09/12/2017 07:00

	Assess Date/Time: 09/12/2017 04:10	Assess Date/Time: 09/12/2017 04:40	Assess Date/Time: 09/12/2017 05:10	Assess Date/Time: 09/12/2017 05:40
Vital Type	Bed: RM-04-A	Bed: RM-04-A	Bed: RM-04-A	Bed: RM-04-A

The cells below display the Vital Signs, Notes, Documenter, Co-signer (if applicable), and Date/Time entered.

BP	142/109 Arm, Upper Lt 09/12/2017 05:58 By: gelb	145/104 Arm, Upper Lt 09/12/2017 05:58 By: gelb	145/96 Arm, Upper Lt 09/12/2017 05:58 By: gelb	152/101 Arm, Upper Lt 09/12/2017 05:58 By: gelb
BP, Mean	122 Arm, Upper Lt 09/12/2017 05:58 By: gelb	121 Arm, Upper Lt 09/12/2017 05:58 By: gelb	114 Arm, Upper Lt 09/12/2017 05:58 By: gelb	116 Arm, Upper Lt 09/12/2017 05:58 By: gelb

* = calculation

Staff IDs:

brw (b)(6); (b)(7)(C)

gelb



(b)(6), (b)(7)(C)

ATTN :

From : TEXAN EMS

Subject: EMS Patient Care Report

Fax/Print Date: 09/18/2017

To: Conroe Regional (Fax:)

From: TEXAN EMS LLC (Phone: 0)

Fax Confidentiality Notice: The information contained in this faxed patient report is private and confidential. It may contain Protected Health Information (PHI) deemed confidential by HIPAA regulations. It is intended only for the use of Conroe Regional, and the privileges are not waived by virtue of this information having been directly printed or sent by fax. Any use, dissemination, distribution or copying of the information contained in this communication is strictly prohibited by anyone except Conroe Regional. If you have received this fax in error, please notify TEXAN EMS LLC by calling 0 and immediately destroy this fax/print-out.

Run#: TE22002

Medical Record#:

Call Date: 09/12/2017

Call received:	05:45:52	Dispatched:	06:45:53	En Route:	06:45:54
Arrival at scene:	05:45:56	Patient Contact:	06:45:57	Departure from Scene:	06:45:58
Arrival at destination:	08:13:43	Return to service:	08:13:47		

Dispatch As/Chief Complaint: **Other means of transport contradicted**

Medical History

Current Medication: no list presented

Allergies: NKDA

Pertinent Past History: HTN

Patient Information

Last Name: Alamazon Ruiz	Address: 3400 FM 350 S.
First Name: Felipe Middle Initial:	City: LIVINGSTON State: TX Zip: 77351
DOB: 05/26/1966 Weight (lb): Height (ft):	County: POLK Phone: 9369678000
Physician Name: none	

Next of Kin

Name:	Phone:
-------	--------

Origin

Facility: CHI St. Lukes of East Texas	City: LIVINGSTON Zip: 77351
Street Address: 1717 Hwy 59 Bypass	County: POLK Phone #: 936-327-8500

Patient Assessment

Suspected Illnesses: Abdominal pain/problems	Amputations:
Skin: Normal	Extremities:
Abdominal: Normal	Decubitus To:
Breathing: Clear L+R	Site of Pain: Pain Scales:
EKG Revealed: NSR (07:04:55)	Patient Has In Place: IV octreotide drip 25mcg/hr, O2 4lpm via NC, EKG

Neurological

Level: A-OX4
 Glasgow Coma Scale: 15 (Motor Resp.: 6 Verbal Resp.: 5 Eye Opening: 4)

Vital Signs & Interventions

Interventions: Assessment, Cardiac monitoring, IV fluids, IV medication, Oxygen

Vitals

BP	Pulse	Resp	SpO2	+O2	EtcO2	Time
151/87	87	20	100	Y		06:49:28
150/90	92	20	99	Y		08:13:35

Meds Administration

Meds	Dose	Unit	Route	Time
octreotide	25/n	mcg	IV	06:50:26

IV/IO

Fluid	Cath.	Adm.	Flow	Site	Time
NS	20	10 D	TKO	L. EJ	06:50:45

CPAP Pressure: Oxygen (LPM): 4 **Oxygen Via:** Nasal Cannula **Airway:** Size: **Tube Depth:**

Narrative

Narrative: Med 2 manneq by EM (b)(6); (b)(7)(C) and myself Paramedic (b)(6); (b)(7)(C) responded to CHI St. Lukes of East Texas on 1717 Hwy 59 Bypass (b)(6); (b)(7)(C) for a 51 year old Male requiring transport to Conroe Regional on 504 Medical Center Blvd, CONROE for bx of upper GI bleed noticed when pt began vomiting blood @ 12 hrs ago. At the Hospital - ER, patient was found ambulatory. Patient ambulated to EMS stretcher and secured with 3 straps, rails raised for safety and placed in semi-fowlers position for comfort. V/S: ((06:49:28) BP: 151/87, Pulse: 87, Resp: 20, SpO2: 100, EtcO2:). Skin: Normal. Blood Glucose: N/A. Pupils: Assessed with No Abnormalities. EKG: (07:04:55) NSR. Primary Assessment: [Pt has no complaints. Pt receiving O2 2lpm via NC. EKG reveals NSR.C]. Secondary Assessment: HEENT: Head: Assessed with No Abnormalities. Ears: Assessed with No Abnormalities. Throat: Assessed with No Abnormalities. Chest: Assessed with No Abnormalities. BBS: Clear L+R. ABD (b)(6); (b)(7)(C) Assessed with No Abnormalities. Back: Assessed with No Abnormalities. PMS: no abnormalities noted Patient requires EMS transport due to: IV meds en route. O2 en route. EKG en route. Patient Allergies: NKDA - Current Medication: no list presented - Medical Doctor: none Patient has in place: IV octreotide drip 25mcg/hr, O2 4lpm via NC, EKG Upon arrival to Hospital - ER, patient ambulated to chair. Patient care released to [RNe]. Med 2 returned to service without incident. END REPORT.

Unit ID: Med 2

Medic Name: (b)(6); (b)(7)(C)

Driver Name: (b)(6); (b)(7)(C)

Report Ends.



HOUSTON SSC FAX

TO: (b)(6); (b)(7)(C)

FROM: (b)(6); (b)(7)(C) - Houston

FAX: 919369678646

FAX:

PHONE:

PHONE:

PAGE NUM: 49

DATE: 9/19/2017 10:42:16 AM

COMMENTS:

~~**CONFIDENTIAL**~~

NOTICE OF DEATH - Must be completed in full for ALL deaths.

DATE OF DEATH: 9/17/17 TIME OF DEATH: 0515 DEATH PRONOUNCED BY: M.D. RN JUSTICE OF THE PEACE

NEXT OF KIN NOTIFICATION: Name of notified next of kin:

PHYSICIAN NOTIFICATION: (b)(6); (b)(7)(C) JUSTICE OF THE PEACE (JP) NOTIFICATION: NA
Attending physician notified: JP notified: Judge Mack
Preliminary cause of death: GI Bleed Reason: Prisoner
Death certificate to be completed by: Attending physician Other: JP:
JP requested autopsy
Note: Consent from next of kin is not required if an autopsy is ordered by a Justice of the Peace or Medical Examiner as part of a death inquest.

(b)(6); (b)(7)(C) DATE: 9/17/17 TIME: 0551

DISPOSITION REQUESTS

Conroe Regional Medical Center, its physicians, and representatives are authorized to do the following:
1. AUTOPSY No Yes
2. STILLBORN INFANTS/NEONATAL DEATHS
3. BELONGINGS

AUTHORIZATION FOR RELEASE OF REMAINS:

Conroe Regional Medical Center is authorized to release remains to the following funeral home:
Name of funeral home: EICKENHORST FUNERAL SERVICES % MONT. COUNTY FORENSICS CENTER
Address: 350 HILKX RD. CONROE TX 77301 Telephone number: 936 536-3791

Authorization for Release of Body
Signature: Judge Wayne L. Mack Relationship: JP Mont. Co Date: 9-17-2017 Time: 0930

RECEIPT OF REMAINS

Indicate presence of communicable disease on tag per policy.
Funeral Home Signature: (b)(6); (b)(7)(C) Date: 9-17-2017 Time: 9:30 AM
Witness: (b)(6); (b)(7)(C) Date: 9-17-17 Time: 0930

EDEMFO322 CRMCHCCP02 09/17/2017 05:37 OWZB489



Conroe Regional Medical Center Page 1 of 2 EDEMFO322 / Rev. Date 3/20/2017

RUIZ, FELIPE Acct # BH9023078383 MR# BH00861890 Loc: B.GCU36-D DOB: 06/26/66 51 M 08/12/17 Ansari, Nazia MD

DEATH DEATH REPORT

(b)(6); (b)(7)(C)
936-539 (b)(6); (b)(7)(C)

TOP
OSIS

Conroe Regional
MEDICAL CENTER
A 100% Physician Hospital

D.O.O
9-17-17

MRI URN Number: BH547883 ADMISSION FORM Printed: 09/17/17 09:31

Patient c RUIZ FELIPE	Unit # BH00861890	Service/Location CORONARY CARE	Status ADM IN	F/C CONIM	Date 09/12/17	Account# BH9023078383
PATIENT Soc Sec No: xxx-xx-5555 DOB: 06/26/66 Age: 51 Sex: M MS: S Race: Othe Religion: NON Address: 3400 FM 350 SOUTH LIVINGSTON, TX 77351 Home Ph: 936-967-8000 County:			PATIENT EMPLOYER UNEMPLOYED UNEMPLOYED N/A, TX 99999 Work Phone: 999-999-9999 Occupation: UNEM			
G.U.A.R.A.N.T.O.R RUIZ FELIPE SS#: xxx-xx-5555 Address: 3400 FM 350 SOUTH LIVINGSTON, TX 77351 Home Ph: 936-967-8000 County: Relationship to Patient: SELF DOB: 01/01/01			G.U.A.R.A.N.T.O.R EMPLOYER UNEMPLOYED UNEMPLOYED N/A, TX 99999 Work Phone: 999-999-9999 Occupation: UNEM			
OTHER GUARANTOR IAH DETENTION, SERVICE Address: SS#: 777 77 7777 Home Ph: Relationship to Patient: OTHER County: DOB: 01/01/01			OTHER GUARANTOR EMPLOYER Work Phone: Occupation:			
PERSON TO NOTIFY RUIZ FELIPE 3400 FM 350 SOUTH LIVINGSTON, TX 77351 Home: 936-967-8000 Work: Rel to Patient SELF		NEXT OF KIN RUIZ FELIPE 3400 FM 350 SOUTH LIVINGSTON, TX 77351 Home: 936-967-8000 Work: Rel to Patient SELF		TEMPORARY ADDRESS Comment: Exp:		
INSURANCE # 1 IMMIGRATION HEALTH SERVICE PO BOX 149345 AUSTIN, TX 78714 Phone: 800-479-0523		Ins # 1: MISC01.CR Policy #: 028866428 Subscriber: RUIZ FELIPE Rel to Pt: SELF Eff: 09/12/17 To: 09/12/17 Rel: Y Assign: Y Group: 9999 - UNEMPLOYED		AUTHORIZATION Treat/Pre Cert: NR/1 Ins Verif: 09/12/17 Verif Phone: SEE CARD Pre Cert Phone: Contact:		
INSURANCE # 2 HURRICANE 1201 FRANK LUFKIN, TX 75904 Phone: 999-999-9999		Ins # 2: MISC02.CR Policy #: 028866428 Subscriber: RUIZ FELIPE Rel to Pt: SELF Eff: 09/12/17 To: 09/12/17 Rel: Y Assign: Y Group: 9999 - UNEMPLOYED		AUTHORIZATION Treat/Pre Cert: NR/1 Ins Verif: 09/12/17 Verif Phone: SEE CARD Pre Cert Phone: Contact:		
INSURANCE # 3 Phone:		Ins # 3: Policy #: Subscriber: Rel to Pt: Eff: Group: To: Rel: Assign:		AUTHORIZATION Treat/Pre Cert: Ins Verif: Verif Phone: Pre Cert Phone: Contact:		
DOCCURRENCES Code Type 11 ONSET OF SYMPTOMS/ILLNESS Adm Priority EL Acmision Comment		CONDITIONS Date 09/12/17 Time Code Type Fin. Class COMM Special Prgm. Preferred Lang ENG		ACCIDENT INFO Accident: Type: Location of Accident: Date: Time: Other persons involved		
PHYSICIANS Attending Physician: Ansari, Nazia MD Prime Care Physician: Abbas, Ali MD Admitting Physician: Ansari, Nazia MD Family Physician: Other Physician: Abbas, Ali MD Emergency Room Physician:						
ADMISSION/REGISTRATION Date: 09/12/17 Time: 08:20 Source: Trns From a Hospital Rm/Bed: GCU36/D Arrival: Principal Admitting Diagnosis/Reason for Visit: UPPER GI BLEED Admitted by: R.BAD.SR1						

UH 9023078383

FELIPE

Printed By: Device/ Printer: B.NURADA / CRMICH8NUW35.2 / CRMCHCCP02



FACE FACESHEET

Conroe Regional Medical Center

Page 1 of 1
EADM0001 / Rev. Date

c RUIZ FELIPE
Acct # BH9023078383 MR# BH00861890
DOB: 06/26/66 51 M 09/12/17
Ansari, Nazia MD

NOTICE OF DEATH - Must be completed in full for ALL deaths.

DATE OF DEATH: 9/17/17 TIME OF DEATH: 0515 DEATH PRONOUNCED BY: [X] M.D. [] RN [] JUSTICE OF THE PEACE

NEXT OF KIN NOTIFICATION: [] Name of notified next of kin:

PHYSICIAN NOTIFICATION (b)(6); (b)(7)(C) JUSTICE OF THE PEACE (JP) NOTIFICATION: [] NA
[X] Attending physician notified: Preliminary cause of death: GI Bleed
Reason: Prisoner
[X] JP notified: Judge Mack
[X] JP requested autopsy
*Note: Consent from next of kin is not required if an autopsy is ordered by a Justice of the Peace or Medical Examiner as part of a death inquest.

(b)(6); (b)(7)(C) DATE: 9/17/17 TIME: 0551

DISPOSITION REQUESTS

Conroe Regional Medical Center, its physicians, and representatives are authorized to do the following:
1. AUTOPSY [] No [X] Yes
2. STILLBORN INFANTS/NEONATAL DEATHS
3. BELONGINGS

AUTHORIZATION FOR RELEASE OF REMAINS:

Conroe Regional Medical Center is authorized to release remains to the following funeral home:
Name of funeral home: EICKENHOLST FUNERAL SERVICES / MONT. COUNTY FORENSICS CTR.
Address: 350 HILAK RD. CONROE TX 77301 Telephone number: 936 536-3791

Authorization for Release of Body

Signature: Judge Wayne L. Mack Relationship: JP Mont. Co. Date: 9-17-2017 Time: 0930

RECEIPT OF REMAINS

Indicate presence of known or suspected communicable disease on tag per policy.
Funeral Home: 113959
Signature: (b)(6); (b)(7)(C) Date: 9-17-2017 Time: 9:30 AM
Witness: Date: 9-17-17 Time: 0930

EDEMFC0322 CRMCHCCP02 09/17/2017 05:37 OWZ9489



DEATH DEATH REPORT

Conroe Regional Medical Center EDEMFC0322 of 2 Date 3/20/2017

RUIZ, FELIPE Acct # BH902307838 BHD0861890 Loc: B, CCU3B-D DOB: 1/55 51 M 08/12/17 Ansari, Nazia MD

LIFE GIFT DONATION REFERRAL

ORGAN DONATION REFERRAL FOR IMMINENT DEATH (Ventilator-dependent patients only)

Referral criteria:

- 1) At first indication that the patient begins to lose neuro reflexes; GCS of < 5
- OR
- 2) Plan to discuss withdrawal of life sustaining therapies with the family (this patient has the potential to donate liver and/ or kidneys immediately after cardiac death).

- 1. Contact LifeGift Org: (b)(6); (b)(7)(C) 6562 to determine eligibility for organ donation.
- 2. LifeGift Coordinator: 2017-09-1502
- 3. LifeGift Response:

- The patient is NOT a candidate for organ donation due to: incarceration
Do not approach the family.
- The patient is a candidate for organ donation.
Provide next of kin contact information to LifeGift Coordinator. LifeGift Coordinator will contact next of kin.

Signature: (b)(6); (b)(7)(C) Date: 9/17/17 Time: 0543

TISSUE DONATION REFERRAL FOLLOWING CARDIAC DEATH

Referral criteria:

Call LifeGift within one hour of cardiac asystole to determine suitability for tissue donation.

- 1. Date of death: 9/17/17 Time of death: 0515
- 2. Contact LifeGift Organ Donation Coordinator at (714) 727-9444 or (800) 633-6562 to determine eligibility for eye/tissue donation.
- 3. Name of LifeGift Coordinator: (b)(6); (b)(7)(C) Case: 2017-09-1502
- 4. LifeGift Response:

- The patient is NOT a candidate for tissue and eye donation due to: incarceration
Do not approach the family.
- The patient is a candidate for donation of the following:
 Eye
 Tissue
 Provide next of kin contact information to Life Gift Coordinator. LifeGift Coordinator will contact next of kin.

Signature: (b)(6); (b)(7)(C) Date: 9/17/17 Time: 0543

OUTCOME FOR POTENTIAL DONORS

- Patient is a registered donor.
- Next of kin consented to donation.
- Next of kin does NOT consent to donation

Signature: _____ Date: _____ Time: _____

EDEMFO322 CRMCHCCP32_09/17/2017 05:37 QWZ9489

DEATH DEATH REPORT

Conroe Regional Medical Center
EDEMFO322 Date 3/20/2017

RUIZ, FELIPE
 Acct # BH9023076383 BH00861890
 Loc: B,CCU36-D DOB: 7/66 51 M 09/12/17
 Ansan, Nazia MD

LIFE GIFT DONATION REFERRAL

ORGAN DONATION REFERRAL FOR IMMINENT DEATH (Ventilator-dependent patients on y)

Referral criteria:

- 1) At first indication that the patient begins to lose neuro reflexes; GCS of < 5
- OR
- 2) Plan to discuss withdrawal of life sustaining therapies with the family (this patient has the potential to donate liver and/or kidneys immediately after cardiac death).

1. Contact LifeGift Organ Donation Center at (713) 737-8111 or (800) 633-6562 to determine eligibility for organ donation.

2. LifeGift Coordinator: (b)(6); (b)(7)(C) 2017-09-1502

3. LifeGift Response:

The patient is NOT a candidate for organ donation due to: incarceration

Do not approach the family.

The patient is a candidate for organ donation.

Provide next of kin contact information to LifeGift Coordinator. LifeGift Coordinator will contact next of kin.

(b)(6); (b)(7)(C)
Signature: _____

Date: 9/17/17 Time: 0543

TISSUE DONATION REFERRAL FOLLOWING CARDIAC DEATH

Referral criteria:

Call LifeGift within one hour of cardiac asystole to determine suitability for tissue donation.

1. Date of death: 9/17/17 Time of death: 0515

2. Contact LifeGift Organ Donation Center at (713) 737-8111 or (800) 633-6562 to determine eligibility for eye/tissue donation.

3. Name of LifeGift Coordinator: (b)(6); (b)(7)(C) Case: 2017-09-1502

4. LifeGift Response:

The patient is NOT a candidate for tissue and eye donation due to: incarceration

Do not approach the family.

The patient is a candidate for donation of the following:

- Eye
- Tissue

Provide next of kin contact information to Life Gift Coordinator. LifeGift Coordinator will contact next of kin.

(b)(6); (b)(7)(C)
Signature: _____

Date: 9/17/17 Time: 0543

OUTCOME FOR POTENTIAL DONORS

- Patient is a registered donor.
- Next of kin consented to donation.
- Next of kin does NOT consent to donation.

Signature: _____ Date: _____ Time: _____

EDEMFO322 CRMCHCCP02.09/17/2017 05:37 QWZ9489



DEATH
DEATH REPORT

Conroe Regional Medical Center
Page 2 of 2
EDEMFO322 / Rev. Date 3/20/2017

RUIZ, FELIPE
Acct # BH9023078383 MR# BH00861890
Loc: B.CCU36-D DOB: 06/26/66 51 M 09/12/17
Ansal, Nazia MD



MRI URN Number: BH547863 ADMISSION FORM Printed: 09/17/17 21:40

Patient c RUIZ FELIPE	Unit # BH00861890	Service/Location CORONARY CARE	Status DIS IN	F/C COMM	Date 09/12/17	Account# BH9023078383
P.A.T.I.E.N.T. Soc Sec No: DOB: Age: Sex: MS: Race: Religion: xxx-xx-5555 06/26/68 51 M S Othc NON Address: 3400 FM 350 SOUTH LIVINGSTON, TX 77351 Home Ph: 936-967-8000 County:			P.A.T.I.E.N.T. EMPLOYER UNEMPLOYED UNEMPLOYED N/A, TX 99999 Work Phone: 999-999-9999 Occupation: UNEM			
G.U.A.R.A.N.T.O.R. RUIZ, FELIPE SS# kxx-xx-5555 Address: 3400 FM 350 SOUTH LIVINGSTON, TX 77351 Home Ph: 936-967-8000 County: Relationship to Patient: SELF DOB: 01/01/01			G.U.A.R.A.N.T.O.R. EMPLOYER UNEMPLOYED UNEMPLOYED N/A, TX 99999 Work Phone: 999-999-9999 Occupation: UNEM			
O.T.H.E.R. G.U.A.R.A.N.T.O.R. IAH DENTENTION, SERVICE SS#: 777 77 7777 Address: Home Ph: Relationship to Patient: OTHER DOB: 01/01/01			O.T.H.E.R. G.U.A.R.A.N.T.O.R. EMPLOYER UNEMPLOYED UNEMPLOYED N/A, TX 99999 Work Phone: 999-999-9999 Occupation: UNEM			
P.E.R.S.O.N. T.O. N.O.T.I.F.Y. RUIZ, FELIPE 3400 FM 350 SOUTH LIVINGSTON, TX 77351 Home: 936-967-8000 Work: Rel to Patient SELF		N.E.X.T. O.F. K.I.N. RUIZ, FELIPE 3400 FM 350 SOUTH LIVINGSTON, TX 77351 Home: 936-967-8000 Work: Rel to Patient SELF		T.E.M.P.O.R.A.R.Y. A.D.D.R.E.S.S. Exp: Comment:		
I.N.S.U.R.A.N.C.E. # 1 IMMIGRATION HEALTH SERVICE PO BOX 149345 AUSTIN, TX 78714 Phone: 800-479-0523		Ins # 1: MISC01.CR Policy #: 028866428 Subscriber: RUIZ, FELIPE Rel to Pt: SELF Eff: 09/12/17 To: 09/12/17 Rel: Y Assign: Y Group: 9999 - UNEMPLOYED		A.U.T.H.O.R.I.Z.A.T.I.O.N. Treat/Precert: NR/1 Ins Verif: 09/12/17 Verif Phone: SEE CARD Pre Cert Phone: Contact:		
I.N.S.U.R.A.N.C.E. # 2 HURRICANE 12C1 FRANK LUFKIN, TX 75904 Phone: 999-999-9999		Ins # 2: MISC02.CR Policy #: 028866428 Subscriber: RUIZ, FELIPE Rel to Pt: SELF Eff: 09/12/17 To: 09/12/17 Rel: Y Assign: Y Group: 9999 - UNEMPLOYED		A.U.T.H.O.R.I.Z.A.T.I.O.N. Treat/Precert: NR/1 Ins Verif: 09/12/17 Verif Phone: SEE CARD Pre Cert Phone: Contact:		
I.N.S.U.R.A.N.C.E. # 3		Ins # 3: Policy #: Subscriber: Rel to Pt: Eff: To: Rel: Assign: Group:		A.U.T.H.O.R.I.Z.A.T.I.O.N. Treat/Precert: Ins Verif: Verif Phone: Pre Cert Phone: Contact:		
O.C.C.U.R.R.E.N.C.E.S. Code Type 11 ONSET OF SYMPTOMS/ILLNESS		C.O.N.D.I.T.I.O.N.S. Date Time Code Type 09/12/17		A.C.C.I.D.E.N.T. I.N.F.O. Accident: Type: Location of Accident: Date: Time: Other persons involved:		
Adm Priority EL	Admission Comment	Fin. Class COMM	Special Prgm.	Preferred Lang ENG		
A.T.T.E.N.D.I.N.G. P.H.Y.S.I.C.I.A.N. (b)(6); (b)(7)(C)		A.D.M.I.T.T.I.N.G. P.H.Y.S.I.C.I.A.N. (b)(6); (b)(7)(C)		E.M.E.R.G.E.N.C.Y. R.O.O.M. P.H.Y.S.I.C.I.A.N. (b)(6); (b)(7)(C)		
P.R.I.M.E. C.A.R.E. P.H.Y.S.I.C.I.A.N. (b)(6); (b)(7)(C)		F.A.M.I.L.Y. P.H.Y.S.I.C.I.A.N. (b)(6); (b)(7)(C)		O.T.H.E.R. P.H.Y.S.I.C.I.A.N. (b)(6); (b)(7)(C)		
A.D.M.I.S.S.I.O.N. R.E.G.I.S.T.R.A.T.I.O.N. Date: 09/12/17 Time: 08:20 Source: Tms From a Hospital Rm/Bed: CCU36/D Arrval: Principal Admitting Diagnosis/Reason for Visit: UPPER GI BLEED Admitted by: R.BAD.SR1						

U H 9 0 2 3 0 7 8 3 8 3

F E L I P E

Printed By/ Device: Printer: R.HIM.JLD / CRMCH1CHIC29.2 / CRHIMP07



Conroe Regional Medical Center



FACE
FACESHEET

Page 1 of 1
EADMP030: / Rev. Date

c RUIZ, FELIPE
Acct # BH9023078383 MR# BH00861890
DOB: 06/26/66 51 V 09/12/17
Ansari, Nazia MD

0913-0071

CONROF REGIONAL MEDICAL CENTER
504 Medical Center Blvd.
Conroe, Texas 77304

PATIENT NAME: RUIZ, FELIPE
ACCOUNT NO: BH9023078383
MEDICAL RECORD NO: BH00861890
REPORT TYPE: HISTORY AND PHYSICAL

ADMIT DATE: 09/12/17
ROOM NO: B.141
AGE: 51
SEX: M

ADMITTING PHYSICIAN [redacted]
ATTENDING PHYSICIAN [redacted]

ADMISSION DATE: 09/12/2017

ADDENDUM TO THE HISTORY AND PHYSICAL REPORT:

Confirmation #2035335

Please to assessment and plan after DVT prophylaxis.

Sepsis. The patient has significant leukocytosis with a WBC count of 15.1, renal failure, and the patient was tachycardic upon arrival with a heart rate of 108. We will initiate antibiotics. We will not give fluid liberally as the BNP level was more than 4000 at the outside ER. We will obtain x-ray and BNP level to reassess the fluid status. The patient does have symptoms of volume overload at present.

It has been a pleasure participating in the medical care of the patient. If you have any questions, please do not hesitate to call.

Dictated by [redacted]

WT: HP:B.HIM/FAKAL/NTS
DD: 09/12/2017 15:25:01
DT: 09/12/2017 19:14:36
Conf#: 2035363/DT# 2001068

Authenticated by [redacted] MD on 09/14/2017 09:05:15 PM

Electronically signed by [redacted] MD on 09/14/17 at 2105

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: BH9023078383

0912-0324

CONROE REGIONAL MEDICAL CENTER
504 Medical Center Blvd.
Conroe, Texas 77304

PATIENT NAME: RUIZ, FELIPE
ACCOUNT NO: BH9023078383
MEDICAL RECORD NO: BH00861890
REPORT TYPE: HISTORY AND PHYSICAL

ADMIT DATE: 09/12/17
ROOM NO: B.141
AGE: 51
SEX: M

ADMITTING PHYSICIAN (b)(6); (b)(7)(C) MD
ATTENDING PHYSICIAN MD

ADMISSION DATE: 09/12/2017

PRIMARY CARE PHYSICIAN: None. The patient is from immigration jail center.

CHIEF COMPLAINT: Hematemesis.

HISTORY OF PRESENT ILLNESS: The patient is a 51-year-old Hispanic incarcerated male, who was taken to Livingston Memorial Emergency Room with complaints of abdominal pain, right flank pain, _____, and hematemesis. He has a past medical history significant for nonalcoholic liver cirrhosis, generalized anxiety disorder, and depression. He was in his usual state of health until early morning, he complained of abdominal pain, right flank pain and started throwing up blood. His hemoglobin level at the Livingston ER was fairly stable at 12.5 and hematocrit was 33.2. He was started on Sandostatin drip and then transferred to Conroe Regional Medical Center ICU for further care. Of note, his platelet level significantly decreased to 18,000.

PAST MEDICAL HISTORY: As mentioned above, which includes,
1. Nonalcoholic liver cirrhosis.
2. Depression.
3. Generalized anxiety disorder.

PAST SURGICAL HISTORY: None.

ALLERGIES: NO KNOWN DRUG ALLERGIES.

MEDICATIONS FROM JAIL: Reviewed. These include folic acid 1 mg daily, Zoloft 100 mg daily, trazodone 50 mg at bedtime, Aldactone 25 mg b.i.d., and omeprazole 40 mg daily.

SOCIAL HISTORY: The patient is incarcerated. He is originally from Florida; however, because of the flooding, he was transferred to Texas Jail.

FAMILY HISTORY: The patient is unaware of any medical problems running in the family.

REVIEW OF SYSTEMS:

GENERAL: Positive for malaise and fatigue.

HEENT: No headaches.

CARDIOVASCULAR: No active chest pain.

RESPIRATORY: No shortness of breath.

GASTROINTESTINAL: He presents with right upper quadrant abdominal pain and

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: BH9023078383

hematemesis.

GENITOURINARY: Denies dysuria or hematuria.

MUSCULOSKELETAL: No active joint pain.

NEUROLOGICAL: He is moving all 4 extremities. Speech appears to be clear.

PSYCHIATRIC: He has history of depression.

LABORATORY AND DIAGNOSTIC DATA: From Livingston ER, sodium 127, potassium 4.3, BUN 85, and creatinine 1.5. Albumin decreased to 3.3. AST 102, ALT 68, ALKP 123, and total bilirubin 10.8. CPK elevated at 322. Lipase mildly elevated at 367. BNP elevated at 4850. PTT 22.1. Troponin I 0.076. WBC 14.28, hemoglobin 12.5, hematocrit 33.2, and platelets decreased to 18.

ASSESSMENT AND PLAN: A 51-year-old incarcerated Hispanic male with history of nonalcoholic liver cirrhosis, now presents with:

1. Gastrointestinal bleed. Differential diagnosis could be variceal, esophageal, or gastric bleeding versus peptic ulcer disease versus gastritis. The patient has been started on octreotide drip. We will also initiate IV PPI and monitor hemoglobin/hematocrit levels, so far are stable. GI consultation has been requested for evaluation of possible EGD.
2. Right upper quadrant abdominal pain. We will check hepatitis panel and right upper quadrant ultrasound.
3. Renal failure, unknown acute or chronic. We will hold Aldactone and other nephrotoxic medications. Could be in the setting of gastrointestinal bleed.
4. Mild troponinemia at the Livingston ER with a troponin level of 0.076. Could be in the setting of stress, gastrointestinal bleed. We will monitor troponin levels over here and also monitor EKG. We will hold antiplatelets secondary to active gastrointestinal bleed.
5. Jaundice with elevated total bilirubin of 6.56 in the setting of liver cirrhosis. Once again, check hepatitis panel. GI has been consulted.
6. Severe thrombocytopenia secondary to liver cirrhosis. The patient will need platelet transfusion prior to EGD.
7. Depression. Continue home regimen of sertraline and trazodone.
8. Uncontrolled hypertension. The patient is on Cardene drip. Lisinopril was initiated. We will titrate medications as needed. We will discontinue lisinopril in view of renal failure and initiate beta blocker in view of history of liver cirrhosis.
9. GI and deep vein thrombosis prophylaxis to be achieved with Protonix/SCDs. Unable to give any blood thinners due to active gastrointestinal bleed.

Case discussed with the patient, the guards, and the RN in detail.

It has been a pleasure participating in the medical care of the patient. If you have any questions, please do not hesitate to call.

Dictated By: (b)(6); (b)(7)(C) MD

WT: HP: B.HIM/FAKAL/NTS
DD: 09/12/2017 15:22:12
DT: 09/12/2017 19:48:10

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: BH9023078383

Conf#: 2035335/DIR#: 3991040

Authenticated by (b)(6); (b)(7)(C) MD on 09/14/2017 09:05:15 PM

Electronically signed by (b)(6); (b)(7)(C) MD on 09/14/17 at 2105

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: BH9023078383

0917-0047

CONROE REGIONAL MEDICAL CENTER
504 Medical Center Blvd.
Conroe, Texas 77304

PATIENT NAME: RUIZ, FELIPE
ACCOUNT NO: BH9023078383
MEDICAL RECORD NO: BH00861890
REPORT TYPE: DISCHARGE SUMMARY

ADMIT DATE: 09/12/17
ROOM NO: B.CCU36
AGE: 51
SEX: M

ADMITTING PHYSICIAN (b)(6); (b)(7)(C) MD
ATTENDING PHYSICIAN MD

ADMISSION DATE: 09/12/2017
DISCHARGE DATE: 09/17/2017

PRIMARY CARE PHYSICIAN: None. The patient is from immigration facility in Florida jail.

ADMITTING DIAGNOSIS: Hematemesis.

HOSPITAL COURSE: The patient was a 51-year-old Hispanic incarcerated male who was taken to Livingston Memorial Emergency Room with complaints of abdominal pain, right flank pain and hematemesis. He has a past medical history significant for nonalcoholic liver cirrhosis, generalized anxiety disorder and depression. Hemoglobin level at Livingston ER was stable at 12.5 and hematocrit was stable at 33.3. He was transferred to Conroe ICU. In the hospital, he was started on octreotide drip and was followed by Dr. Varia from GI and underwent EGD that was consistent with hypertensive portal gastropathy in the fundus, body of the stomach and antrum; patchy erythema in the bulb and second portion of the duodenum was seen. He was recommended to avoid any use of NSAIDs, recommended low-salt diet and continue medications, PPI 20 mg daily. He had mild treponema with a troponin level of 0.076 and 0.027. He was followed by Dr. Adnan Siddiqui. He underwent stress test on 09/16/2017 that was read as normal. No reversible ischemia was seen. He had normal left ventricular systolic function, calculated at 72% on stress imaging. He was fairly stable for discharge; however, a call was received early in the morning saying that the patient was hypotensive and code save had to be run. Stat labs revealed a drop of hemoglobin to 5.9 from 9.4 yesterday on 09/16/2017. The patient immediately went into respiratory failure. He was intubated. Code blue was called and he was unable to be resuscitated, and then he was pronounced dead early in the morning.

DIAGNOSES LEADING TO EXPIRATION OF THE PATIENT:

1. Possible gastrointestinal bleed with a massive drop in hemoglobin/hematocrit from 9.4/26.3 on 09/16/2017 to 5.9/18.4 on 09/17/2017 in setting of severe thrombocytopenia due to nonalcoholic liver cirrhosis.
2. Nonalcoholic liver cirrhosis, status post esophagogastroduodenoscopy consistent with hypertensive portal gastropathy.
3. Severe thrombocytopenia secondary to nonalcoholic liver cirrhosis.
4. Abnormal liver function tests secondary to nonalcoholic liver cirrhosis. Of note, at the time of admission, his total bilirubin was elevated at 6.56, this morning it had normalized to 0.99.
5. Sudden respiratory failure requiring ventilator support.
6. Cardiac arrest, the patient was then pronounced dead.

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: BH9023078383

CONSULTANTS:

- 1. (b)(6); (b)(7)(C) from GI.
- (b)(6); (b)(7)(C) from critical care, (b)(6); (b)(7)(C) from critical care.
- 3. (b)(6); (b)(7)(C) from cardiology.

PRINCIPAL PROCEDURES: EGD, stress test, intubation, and central line placement.

Dictated by (b)(6); (b)(7)(C)

WT: DS:B.HIM/FAKAL/NTS
 DD: 09/17/2017 10:14:56
 DT: 09/17/2017 10:40:26
 Conf#: 2043774/DID#: 3999515

Authenticated by (b)(6); (b)(7)(C) MD on 09/17/2017 01:04:50 PM

Electronically Signed by (b)(6); (b)(7)(C) MD on 09/17/17 at 1305

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: BH9023078383

0916-0091

CONROE REGIONAL MEDICAL CENTER
504 Medical Center Blvd.
Conroe, Texas 77304

PATIENT NAME: RUIZ, FELIPE
ACCOUNT NO: BH9023078383
MEDICAL RECORD NO: BH00861890
REPORT TYPE: DISCHARGE SUMMARY

ADMIT DATE: 09/12/17
ROOM NO: B.141
AGE: 51
SEX: M

ADMITTING PHYSICIAN: (b)(6); (b)(7)(C) MD
ATTENDING PHYSICIAN: MD

ADMISSION DATE: 09/12/2017
DISCHARGE DATE:

PRIMARY CARE PHYSICIAN: None. The patient is from immigration facility jail from Florida.

ADMITTING DIAGNOSIS: Hematemesis.

HOSPITAL COURSE: The patient is a 51-year-old Hispanic incarcerated male who was taken to Livingston Memorial Emergency Room with complaints of abdominal pain, right flank pain, and hematemesis. He has a past medical history significant for nonalcoholic liver cirrhosis, generalized anxiety disorder, and depression. Hemoglobin level at the Livingston ER was stable at 12.5 and hematocrit was 33.2. He was transferred to (b)(6); (b)(7)(C) in the hospital, he was started on octreotide drip and was followed by (b)(6); (b)(7)(C) from GI and underwent EGD that was consistent with hypertensive portal gastropathy in the fundus, body of the stomach and antrum, patchy erythema in the bulb and second portion of the duodenum was seen. He was recommended to avoid any use of NSAIDs. Recommended low-salt diet and continue medications, PPI 20 mg daily. He also had mild troponinemia with a troponin level of 0.076 and 0.27. He was followed by (b)(6); (b)(7)(C) Currently, he is undergoing stress test. If the stress test is negative, cardiology _____ for discharge. He will be a poor candidate for any antiplatelet secondary to history of liver cirrhosis causing severe thrombocytopenia.

LFTs were elevated including total bilirubin and this was attributed to history of known alcoholic liver cirrhosis. Acute hepatitis panel was negative.

CONDITION ON DISCHARGE: Stable.

DISPOSITION: Jail if stress test is negative.

DISCHARGE INSTRUCTIONS: Follow up with PCP in 2 to 7 days.

DISCHARGE DIAGNOSES:

1. Hematemesis in a patient with history of liver cirrhosis, status post EGD consistent with changes of hypertensive portal gastropathy. Mild gastritis and duodenitis was seen and recommended PPI 20 mg daily. Avoid use of NSAIDs.
2. Mild troponinemia. If stress test negative, the patient will be discharged back to jail.
3. Troponinemia was in the setting of gastrointestinal bleed.
4. Chronic kidney disease, stable.

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: BH9023078383

5. Jaundice secondary to liver cirrhosis.
6. Thrombocytopenia secondary to liver cirrhosis.
7. Hypertension.

CONSULTANTS: [REDACTED] from GI and [REDACTED] from critical care.

PRINCIPAL PROCEDURES: EGD.

It has been a pleasure participating in the medical care of the patient. If you have any questions, please do not hesitate to call.

Dictated By: [REDACTED]

WT: DS:B.HIM/FAKAL/NTS
DD: 09/16/2017 12:39:31
DT: 09/16/2017 13:41:13
Conf#: 2042757/DID#: 3998491

Authenticated by [REDACTED] MD on 09/16/2017 03:38:38 PM

Electronically Signed by [REDACTED] MD on 09/16/17 at 1538

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: BH9023078383

CONROE MEDICAL CENTER (COCCR)
Critical Care Consult Note
REPORT#:0917-0019 REPORT STATUS: Signed
DATE:09/17/17 TIME: 0441

PATIENT: RUIZ, FELIPE UNIT #: BH00861890
ACCOUNT#: BH9023078383 ROOM/BED: B.CCU36-D
DOB: 06/26/56 AGE: 51 SEX: M ATTEND: (b)(6); (b)(7)(C)
ADM DT: 09/12/17 AUTHOR: [Redacted]
Medellin MD

* ALL edits or amendments must be made on the electronic/computer document *

History of Present Illness

HPI

Requesting clinician: HOSPITALIST

Reason for consult:

CRITICAL CARE

Chief complaint:

CODE BLUE

HPI:

MR RUIZ IS A 51 YO HM WHO PRESENTED TO MEDICAL ATTENTION VIA A LOCAL JAIL POST TX FROM FLORIDA DETENTION. THE PT APRESENTED TO WITH A HX OF ABDOMINAL PAIN ABND HEMATEMESIS. TH EPT WAS ADMITTED TO THE MEDICAL WARD SERVICE AND SUBSEQUENTLY A CODE SAVE WAS CALLED FOR NEAR SYNCOPHE AND HYPOTENSION AND NOTED RESP DISTRESS POST TRENDELENBERG. THE PT DEVELOPING MARKED HYPOTENSION POST INTUBATION FOR AGONAL BREATHING. THUS THE CURRENT CONSULTATION. THE FAMILY IS CURRENTLY UNAVAIL.

History

Past History

Past medical history: GI bleed, CIRRHOSIS

Allergies:

Coded Allergies:

No Known Allergies (09/12/17)

Objective

Physical Exam:

VS/I&O:

Last Documented:

	Result	Date Time
Pulse Ox	100	09/17 0115
FiO2	100	09/17 0115
O2 Flow Rate	12.00	09/17 0115

Patient: RUIZ, FELIPE
 Unit#: BHC0861890
 Date: 09/17/17
 BH9023078383

Acct#:

Pulse	101	09/17 0115
Resp	20	09/17 0115
B/P	87/59	09/16 2348
O2 Delivery	Room air	09/16 2348
Temp	37.2	09/16 2348


General appearance: altered mental state, respiratory support
Head/Eyes: abnl conjunctiva/sclera (ICTERUS), atraumatic, normocephalic
ENT: normal ear left, normal ear right, normal nose
Neck: full range of motion, non-tender, normal thyroid
Cardiovascular: normal heart sounds, normal S1 S2, regular rate and rhythm
Respiratory/Chest: decreased breath sounds, aerating well, clear to auscultation, symmetric expansion
Abdomen: abnormal bowel sounds, distended, soft
Extremities: no clubbing, no cyanosis, no edema

Results:



Findings/Data:

Laboratory Tests



09/17/17 0330:



09/17/17 0127:



09/16/17 0535:



Laboratory Tests

09/17 09/17

Patient: RUIZ, FELIPE
 Unit#: BH00861890
 Date: 09/17/17
 BH9023078383

Acct#:

	0440	0129
Blood Gas		
Puncture Site (DESCRIPTION ARTKIT)	ART LINE	RT RADIAL
ABG pH (7.35 - 7.45 pH units)	7.28 L	7.11 *L
ABG pCO2 (35 - 45 mmHg)	39	44
ABG pO2 (80 - 100 mmHg)	97	200 H
ABG HCO3 (22.0 - 26.0 mmol/L)	18.5 L	14.0 L
ABG Base Excess (-3.0 - 3.0 mmol/L)	-8.2 I	-15.6 L
ABG Hematocrit (36 - 54 %)		24 L
Aller Test (POSITIVE Circ.CHK)	POSITIVE	POSITIVE
Cord O2 Saturation (95 - 100 % (calc))	99	100
Sodium (135 - 148 mmol/L)	145	132 I
Potassium (3.5 - 5.3 mmol/L)	4.4	4.5
Chloride (98 - 106 mmol/L)	104	104
Glucose (70 - 119 mg/dL)	98	87
Ionized Calcium (1.13 - 1.32 mmol/L)	1.10 I	0.80 I
Respiration Rate (PT RespRate /MIN)	18	12
O2 Delivery Method (DESCRIPTION COMMENT)	CMV	AC
Filter Flow (0 L/MIN)	0	
FiO2 (21 - 100 % (calc))	> 100 H	100
Tidal Volume (ML)	500	500
PEEP (0.0 - 99.9 cm H2O)	5	5
Pressure Support (0 cm H2O)	0.0	

Laboratory Tests

	09/17 0330	09/17 0200
Chemistry		
Sodium (133 - 144 mmol/L)	148.0 H	
Potassium (3.5 - 5.1 mmol/L)	5.4 H	
Chloride (95 - 105 mmol/L)	105	
Carbon Dioxide (21 - 32 mmol/L)	25	
Anion Gap (4.0 - 15.0 GAP calc)	18.0 H	
BUN (7 - 18 MG/DL)	15	
Creatinine (0.55 - 1.30 MG/DL)	1.49 H	
Glomerular Filtr Rate (> 60 estGFR)	50 L	
Glucose (70 - 110 MG/DL)	87	
Lactic Acid (0.4 - 2.0 mmol/L)		12.8 *H
Calcium (8.5 - 10.1 MG/DL)	8.0 L	
Total Bilirubin (0.00 - 1.00 MG/DL)	0.99	
Direct Bilirubin (0.00 - 0.30 MG/DL)	0.47 H	
Indirect Bilirubin (0.2 - 1.3 MG/DL)	0.52	
AST (15 - 37 Unit/L)	114 H	

Patient: RUIZ, FELIPE
 Unit#: BH00861890
 Date: 09/17/17
 BH9023078383

Acct#:

ALT (12 - 78 Unit/L)	54
Total Alk Phosphatase (45 - 117 Unit/L)	84
Total Protein (6.4 - 8.2 G/DL)	2.6 L
Albumin (3.4 - 5.0 G/DL)	1.2 L
Albumin/Globulin Ratio (1.2 - 2.2 RATIO)	0.9 L
Specimen Appearance (1 NORMAL Index/DL)	1 NORMAL < 2 MG
Specimen Hemolysis (1 NORMAL Index/DL)	1 NORMAL < 10 MG

	09/17 0127	09/17 0027
Chemistry		
Sodium (133 - 144 mmol/L)	143.0	
Potassium (3.5 - 5.1 mmol/L)	3.4 L	
Chloride (95 - 105 mmol/L)	114 H	
Carbon Dioxide (21 - 32 mmol/L)	13 *L	
Anion Gap (4.0 - 15.0 GAP calc)	16.0 H	
BUN (7 - 18 MG/DL)	13	
Creatinine (0.55 - 1.30 MG/DL)	1.01	
Glucose (70 - 110 MG/DL)	92	
POC Glucose (70 - 119 MG/DL)		110
Calcium (8.5 - 10.1 MG/DL)	6.1 *L	
Phosphorus (2.5 - 4.9 MG/DL)	3.8	
Magnesium (1.6 - 2.6 MG/DL)	2.1	
Specimen Appearance (1 NORMAL Index/DL)	1 NORMAL < 2 MG	
Specimen Hemolysis (1 NORMAL Index/DL)	1 NORMAL < 10 MG	

	09/16 0535
Chemistry	
Sodium (133 - 144 mmol/L)	136.0
Potassium (3.5 - 5.1 mmol/L)	4.0
Chloride (95 - 105 mmol/L)	101
Carbon Dioxide (21 - 32 mmol/L)	27
Anion Gap (4.0 - 15.0 GAP calc)	8.0
BUN (7 - 18 MG/DL)	17
Creatinine (0.55 - 1.30 MG/DL)	0.62
Glucose (70 - 110 MG/DL)	100
Calcium (8.5 - 10.1 MG/DL)	8.3 L
Specimen Appearance (1 NORMAL Index/DL)	1 NORMAL < 2 MG
Specimen Hemolysis (1 NORMAL Index/DL)	1 NORMAL < 10 MG

Laboratory Tests

09/17

Patient: RUIZ, FELIPE
 Unit#: BH00861890
 Date: 09/17/17
 BH9023078383

Acct#:

0127

Coagulation	
PT (9.4 - 12.5 SECONDS)	22.6 H
INR (0.85 - 1.11 INR Unit)	1.96 H
PTT (Dade) (24 - 37.7 SECONDS)	60.4 H

Laboratory Tests

09/17
0330

Hematology

WBC (4.1 - 12.1 k/mm3)	12.4 H
RBC (3.8 - 5.5 M/mm3)	1.70 *L
Hgb (10.6 - 15.8 G/DL)	5.4 *L
Hct (36.0 - 47.4 %)	16.5 *L
MCV (80.1 - 101.1 fL)	97.1
MCH (25.3 - 35.3 pg)	31.8
MCHC (32.7 - 35.1 G/DL)	32.7
RDW (12.2 - 16.4 %)	16.2
Plt Count (155 - 337 K/mm3)	24 *L
MPV (7.6 - 10.4 fL)	11.2 H
Gran % (37.8 - 82.6 %)	59.3
Lymph % (Auto) (14.1 - 45.4 %)	20.5
Mono % (Auto) (2.5 - 11.7 %)	6.2
Eos % (Auto) (0.0 - 6.2 %)	1.4
Baso % (Auto) (0.0 - 2.6 %)	0.1
Gran # (2.0 - 13.7 K/mm3)	7.34 H
Lymph # (Auto) (0.6 - 3.8 K/mm3)	2.54
Mono # (Auto) (0.11 - 0.59 K/mm3)	0.77 H
Eos # (Auto) (0.0 - 0.4 K/mm3)	0.17
Baso # (Auto) (0.0 - 0.1 K/mm3)	0.01
Add Manual Diff (CRITERIA DIFF/SCN)	MAN DIFF INDICATED
Total Counted (100 #CELLS)	100
Immature Gran % (0.0 - 2.0 %)	12.5 H
Seg Neutrophils % (40 - 75 %)	82 H
Lymphocytes % (Manual) (12.6 - 43.5 %)	12 L
Monocytes % (Manual) (4.2 - 12.7 %)	4 L
Eosinophils % (Manual) (0.0 - 5.2 %)	2
Nucleated RBC % (0.0 - 1.0 /100WBC%)	1.1 H
Nucleated RBCs # (0.00 - 0.05 K/mm3)	0.13 H
Toxic Granulation (NONE ON SCAN)	SLIGHT
Platelet Estimate (ADEQUATE ON SCAN)	MRK DECR L

09/17 | 09/16

Patient: RUIZ, FELIPE
 Unit#: BH00861890
 Date: 09/17/17
 BH9023078383

Acct#:

	0127	0535
Hematology		
WBC (4.1 - 12.1 k/mm ³)	9.8	2.9 L
RBC (3.8 - 5.5 M/mm ³)	1.81 *L	2.89 L
Hgb (10.6 - 15.8 G/DL)	5.9 *L	9.4 L
Hct (36.0 - 47.4 %)	18.4 *L	26.3 L
MCV (80.1 - 101.1 fL)	101.7 H	91.0
MCH (25.3 - 35.3 pg)	32.6	32.5
MCHC (32.7 - 35.1 G/DL)	32.1 L	35.7 H
RDW (12.2 - 16.4 %)	18.0 H	17.6 H
Plt Count (155 - 337 K/mm ³)	35 *L	26 *L
MPV (7.6 - 10.4 fL)	11.5 H	10.0
Gran % (37.8 - 82.6 %)	49.8	63.2
Lymph % (Auto) (14.1 - 45.4 %)	33.7	23.3
Mono % (Auto) (2.5 - 11.7 %)	6.0	9.0
Fos % (Auto) (0.0 - 6.2 %)	2.4	3.5
Baso % (Auto) (0.0 - 2.6 %)	0.1	0.0
Gran # (2.0 - 13.7 K/mm ³)	4.87	1.82 L
Lymph # (Auto) (0.6 - 3.8 K/mm ³)	3.29	0.67
Mono # (Auto) (0.11 - 0.59 K/mm ³)	0.59	0.26
Eos # (Auto) (0.0 - 0.4 K/mm ³)	0.23	0.10
Baso # (Auto) (0.0 - 0.1 K/mm ³)	0.01	0.00
Add Manual Diff (CRITERIA DIFF/SCN)	MAN DIFF INDICATED	
Total Counted (100 #CFIIS)	100	
Immature Gran % (0.0 - 2.0 %)	8.0 H	1.0
Seg Neutrophils % (40 - 75 %)	72	
Lymphocytes % (Manual) (12.6 - 43.5 %)	23	
Monocytes % (Manual) (4.2 - 12.7 %)	4 L	
Eosinophils % (Manual) (0.0 - 5.2 %)	1	
Nucleated RBC % (0.0 - 1.0 /100WBC%)	0.4	0.0
Nucleated RBCs # (0.00 - 0.05 K/mm ³)	0.04	0.00
Platelet Estimate (ADEQUATE ON SCAN)	MRK DECR L	
Macrocytosis (NONE ON SCAN)	SLIGHT	

Radiology data:

Recent Impressions:

NUCLEAR MEDICINE - NM MYOCRD SPECT R/S MULT 09/16 0730

*** Report Impression - Status: SIGNED Entered: 09/16/2017 1256

IMPRESSION:

1. Normal myocardial perfusion imaging stress test
2. No reversible ischemia

Patient: RUIZ, FELIPE
Unit#: BH00861890
Date: 09/17/17
BH9023078383

Acct#:

3. Normal left ventricular systolic function, calculated EF 72% on stress imaging

Impression By: t.SDR.RM20 - (b)(6); (b)(7)(C)

RADIOLOGY - XR CHEST 1 V 09/17 0127

*** Report Impression - Status: SIGNED Entered: 09/17/2017 0147

IMPRESSION:

ETT in the right mainstem bronchus. It should be pulled back 7 cm.

*****FOR INTERNAL CODING PURPOSES ONLY*****

RESULT CODE: CVR

Impression By: (b)(6); (b)(7)(C) M.D.

RADIOLOGY - XR CHEST 1 V 09/17 0222

*** Report Impression - Status: SIGNED Entered: 09/17/2017 0248

IMPRESSION:

Readjusted endotracheal tube now with tip terminating approximately 3 cm above the carina in appropriate appearing position

Impression By: t.SDR.SR31 - (b)(6); (b)(7)(C) M.D.

RADIOLOGY - XR CHEST 1 V 09/17 0222

*** Report Impression - Status: SIGNED Entered: 09/17/2017 0248

IMPRESSION:

Readjusted endotracheal tube now with tip terminating approximately 3 cm above the carina in appropriate appearing position

Impression By: (b)(6); (b)(7)(C) M.D.

Results: labs reviewed, vital signs stable, x-ray personally reviewed, current med profile rev'd

Treatment & Prophylaxis

Treatment & Prophylaxis

VTE Prophylaxis

VTE prophylaxis initiated: Yes

Oxygen: ventilator

Patient: RUIZ, FELIPE
Unit#: BH00861890
Date: 09/17/17
BH9023078383

Acct#:

Ventilator: assist control
Lines: CVC, PA
Tube feeding: No
Anti-infectives: aztreonam, ceftriaxone
IV fluids: NS
Pressors and inotropes: norepinephrine
Ulcer prophylaxis: pantoprazole

Diagnosis, Assessment & Plan

Diagnosis, Assessment & Plan

Problem List/A&P:

1. Respiratory failure
2. Lactic acidosis
3. Cirrhosis
4. GIB (gastrointestinal bleeding)
5. Hemorrhagic shock

Free Text A&P:

9/17

AT THIS POINT HE DOES NOT SEEM TO BE DOING POORLY DESPITE AGGRESSIVE MEDICAL MANAGEMENT. I AM CONCERNED ABOUT HIS SEPTIC SHOCK AND HEMORRHAGIC SHOCK ASSOCIATED WITH CIRRHOSIS AND GIB. CERTAINLY THE PROGNOSIS IS QUITE POOR. WILL PLAN

DW RN/FP

VIEWED CXR

C LINE

A LINE

NGT TO SUCTION

PRBC

FFP

PLATELETS

PRESSOR SUPPORT/IV FLUIDS

ALBUMIN

COAGULANT HEME/GI

ATX

NEBS

THIAMINE

Patient: RUIZ, FELIPE
Unit#: BH00861890
Date: 09/17/17
BH9023078383

Acct#:

NUTRITION CONSULT
PHARM CONSULT
PAN CULTURES

Electronically Signed by (b)(6); (b)(7)(C) MD on 09/17/17 at 0502

RPT #: 0917-0019
END OF REPORT

CONROE MEDICAL CENTER (COCCR)
 GE Consultation Note
 REPORT#:0912-0667 REPORT STATUS: Signed
 DATE:09/12/17 TIME: 2044

PATIENT: RUIZ, FELIPE UNIT #: BH00861890
 ACCOUNT#: BH9023078383 ROOM/BED: B.ICU18-W
 DOB: 06/26/66 AGE: 51 SEX: M ATTEND: (b)(6), (b)(7)(C)
 ADM DT: 09/12/17 AUTHOR: [Redacted]

* ALL edits or amendments must be made on the electronic/computer document *

History

Medications:

Home Medications:

Medication	Dose/Rte/Freq Max Daily Dose	Days	Qty	Entered	Last Reviewed
SERTRALINE (ZOLOFT) Strength: 100 MG TAB	100 MG PO DAILY			09/12/17 1103	09/12/17 1104
traZODone (DESYREL) Strength: 50 MG TAB	50 MG PO BFDTIME			09/12/17 1103	09/12/17 1104
FOLIC ACID Strength: 1 MG TAB	1 MG PO DAILY			09/12/17 1103	09/12/17 1104
OMEPRAZOLE ER (PRILOSEC) Strength: 40 MG CAP.DR	40 MG PO DAILY			09/12/17 1104	09/12/17 1104
SPIRONOLACTONE (ALDACTONE) Strength: 25 MG TAB	25 MG PO BID			09/12/17 1104	09/12/17 1104

Current Hospital Medications:

Anti-Infective Agents

Medication	Dose	Sig/Sch Route	Start time Stop time	Status	Last Admin
Levofloxacin (LEVAQUIN 500MG/ 100ML)	100 ML	Q24H IV	09/12 1530 09/19 1531	AC	09/12 1624

Cardiovascular Drugs

Medication	Dose	Sig/Sch Route	Start time Stop Time	Status	Last Admin
Metoprolol Succinate (TOPROL XL)	12.5 MG	DAILY PO	09/12 1700 10/12 1701	AC	09/12 1626
Labetalol HCl (TRANDATE)	10 MG	Q4H PRN PRN IV	09/12 1530 10/12 1531	AC	
Lisinopril (PRINIVIL)	20 MG	DAILY PO	09/12 1100 10/12 1101	DC	09/12 1133
Nicardipine/Sodium Chloride	250 ML	AS DIR IV	09/12 1000 10/12 1001	AC	

Patient: RUIZ, FELIPE
 Unit#: BH00861890
 Date: 09/12/17
 BH9023078383

Acct#:

(CARDENE-NACL 50 MG/ 250 ML IV)					
Nicardipine/Sodium Chloride (CARDENE-NACL 50 MG/ 250 ML IV)	250 ML	.STK-MED ONE IV	09/12 0953	DC	09/12 0959

Central Nervous System Agents

Medication	Dose	Sig/Sch Route	Start time Stop Time	Status	Last Admin
Trazodone HCl (DFSYRFI)	50 MG	BFDTIME PO	09/12 2100 10/12 2101	AC	09/12 2015
Sertraline HCl (ZOLOFT)	100 MG	DAILY PO	09/12 1700 10/12 1701	AC	09/12 1626
Morphine Sulfate (MORPHINE SULFATE)	1 MG	Q4H PRN PRN IV	09/12 1515 10/12 1516	AC	

Electrolytic, Caloric, And Wat

Medication	Dose	Sig/Sch Route	Start time Stop Time	Status	Last Admin
Lactulose (CHRONULAC 20 GM/30 ML)	30 ML	BID PO	09/12 2100 10/12 2101	CKD	09/12 2015
Sodium Chloride (NORMAL SALINE 250 ML)	250 ML	ASDIR IV	09/12 1600 09/13 1555	AC	
Sodium Chloride (NORMAL SALINE 250 ML)	250 ML	ASDIR PRN IV	09/12 1515 10/12 1516	AC	
Sodium Chloride (SODIUM CHLORIDE 0.9% 20ML)	10 ML	ASDIR IV	09/12 1515 10/12 1516	AC	
Sodium Chloride (SODIUM CHLORIDE 0.9% 1000 ML)	1,000 ML	.Q13H20M IV	09/12 1515 10/12 1516	AC	09/12 1624

Gastrointestinal Drugs

Medication	Dose	Sig/Sch Route	Start time Stop Time	Status	Last Admin
Pantoprazole (PROTONIX)	40 MG	Q12HR IV	09/12 2100 10/12 2101	AC	09/12 2015
Ondansetron HCl (ZOFAN)	4 MG	Q4H PRN PRN IV	09/12 1515 10/12 1516	AC	09/12 1625

Patient: RUIZ, FELIPE
 Unit#: BH00861890
 Date: 09/12/17
 BH9023078383

Acct#:

Vitamins

Medication	Dose	Sig/Sch Route	Start time Stop Time	Status	Last Admin
Folic Acid (FOLVITE)	1 MG	DAILY PO	09/13 0900 10/13 0901	AC	

Allergies:**Coded Allergies:**

No Known Allergies (09/12/17)

Objective**Physical Exam****VS/I&O:**

Last Documented:

	Result	Date Time
Pulse Ox	96	09/12 2000
B/P	106/56	09/12 2000
Pulse	68	09/12 2000
Resp	17	09/12 2000
Temp	36.8	09/12 1838
O2 Flow Rate	2	09/12 1447

Medications:Active Meds + DC'd Last 24 Hrs

Folic Acid 1 MG DAILY PO
 Lactulose 30 ML BID PO (CKD)
 Pantoprazole 40 MG Q12HR IV
 Trazodone HCl 50 MG BEDTIME PO
 Metoprolol Succinate 12.5 MG DAILY PO
 Sertraline HCl 100 MG DAILY PO
 Sodium Chloride 250 ML ASDIR IV
 Labetalol HCl 10 MG Q4H PRN PRN IV
 Levofloxacin 100 ML Q24H IV
 Morphine Sulfate 1 MG Q4H PRN PRN IV
 Ondansetron HCl 4 MG Q4H PRN PRN IV
 Sodium Chloride 250 ML ASDIR PRN IV
 Sodium Chloride 10 ML ASDIR IV

Patient: RUIZ, FELIPE
 Unit#: BH00861890
 Date: 09/12/17
 BH9023078383

Acct#:

Sodium Chloride 1,000 ML .Q13H20M IV
 Lisinopril 20 MG DAILY PO (DC)
 Nicardipine/Sodium Chloride 250 ML ASDIR IV
 Nicardipine/Sodium Chloride 250 ML .STK-MED ONE IV (DC)


General appearance: alert, awake

Results



Findings/Data:

Laboratory Tests

09/12/17 1200:



09/12/17 1155:



Laboratory Tests

	09/12 1530	09/12 1530	09/12 1530
Chemistry			
Ammonia (11.0 - 32.0 mcMOL/L)			90.0 *H
CK-MB (CK-2) (1.0 - 3.6 NG/ML)	4.9 H		
Troponin I (0.000 - 0.045 NG/ML)	0.270 *H		
B-Natriuretic Peptide (0.00 - 100.00 PG/ML)		226.59 H	

	09/12 1155
Chemistry	
Sodium (133 - 144 mmol/L)	133.0
Potassium (3.5 - 5.1 mmol/L)	4.2
Chloride (95 - 105 mmol/L)	102
Carbon Dioxide (21 - 32 mmol/l)	24
Anion Gap (4.0 - 15.0 GAP calc)	7.0
BUN (7 - 18 MG/DL)	67 H

Patient: RUIZ, FELIPE
 Unit#: BH00861890
 Date: 09/12/17
 BH9023078383

Acct#:

Creatinine (0.55 - 1.30 MG/DL)	1.36 H
Glomerular Filtr Rate (>60 estGFR)	55 L
Glucose (70 - 110 MG/DL)	132 H
Calcium (8.5 - 10.1 MG/DL)	7.8 L
Total Bilirubin (0.00 - 1.00 MG/DL)	6.56 H
Direct Bilirubin (0.00 - 0.30 MG/DL)	3.35 H
Indirect Bilirubin (0.2 - 1.3 MG/DL)	3.21 H
AST (15 - 37 Unit/L)	81 H
ALT (12 - 78 Unit/L)	49
Total Alk Phosphatase (45 - 117 Unit/l)	107
Total Protein (6.4 - 8.2 G/DL)	5.4 L
Albumin (3.4 - 5.0 G/DL)	2.9 L
Albumin/Globulin Ratio (1.2 - 2.2 RATIO)	1.2
Specimen Appearance (1 NORMAL Index/DL)	3 SMALL 5-10 MG
Specimen Hemolysis (1 NORMAL Index/DL)	2 TRACE 10-25 MG

Laboratory Tests

09/12
 1200

Coagulation	
PT (9.4 - 12.5 SECONDS)	17.3 H
INR (0.85 - 1.1 INR Unit)	1.52 H
PTT (Dade) (24 - 37.7 SECONDS)	29.4

Laboratory Tests

	09/12 1200
Hematology	
WBC (4.1 - 12.1 k/mm3)	15.1 H
RBC (3.8 - 5.5 M/mm3)	3.50 L
Hgb (10.6 - 15.8 G/DL)	11.2
Hct (36.0 - 47.4 %)	30.1 L
MCV (80.1 - 101.1 fL)	86.0
MCH (25.3 - 35.3 pg)	32.0
MCHC (32.7 - 35.1 G/DL)	37.2 H
RDW (12.2 - 16.4 %)	17.2 H
Pit Count (155 - 337 K/mm3)	27 *L
MPV (7.6 - 10.4 fL)	10.3
Gran % (37.8 - 82.6 %)	65.8
Lymph % (Auto) (14.1 - 45.4 %)	12.1 L
Mono % (Auto) (2.5 - 11.7 %)	12.7 H
Eos % (Auto) (0.0 - 6.2 %)	1.7
Baso % (Auto) (0.0 - 2.6 %)	0.5

Patient: RUIZ, FELIPE
 Unit#: BH00861890
 Date: 09/12/17
 BH9023078383

Acct#:

Gran # (2.0 - 13.7 K/mm3)	9.95 H
Lymph # (Auto) (0.6 - 3.8 K/mm3)	1.82
Mono # (Auto) (0.11 - 0.59 K/mm3)	1.91 H
Eos # (Auto) (0.0 - 0.4 K/mm3)	0.25
Baso # (Auto) (0.0 - 0.1 K/mm3)	0.08
Add Manual Diff (CRITERIA DIFF/SCN)	MAN DIFF INDICATED
Total Counted (100 #CELLS)	100
Immature Gran % (0.0 - 2.0 %)	7.2 H
Seg Neutrophils % (40 - 75 %)	73
Lymphocytes % (Manual) (12.6 - 43.5 %)	12 L
Monocytes % (Manual) (4.2 - 12.7 %)	14 H
Eosinophils % (Manual) (0.0 - 5.2 %)	1
Nucleated RBC % (0.0 - 1.0 /100WBC%)	1.7 H
Nucleated RBCs # (0.00 - 0.05 K/mm3)	0.25 H
Toxic Granulation (NONE ON SCAN)	SLIGHT
Platelet Estimate (ADFQUATE ON SCAN)	MRK DFCR I
Plt Morphology Comment (NORMAL PLTS ON SCAN)	LARGE RARE
Polychromasia (NONE ON SCAN)	SLIGHT
Hypochromasia (NONE ON SCAN)	SLIGHT
Poikilocytosis (NONE ON SCAN)	SLIGHT
Anisocytosis (NONE ON SCAN)	SLIGHT
Ovalocytes (NONE ON SCAN)	FEW
Acanthocytes (Spur) (NONE ON SCAN)	RARE
Schistocytes (NONE ON SCAN)	RARE

Laboratory Tests

	09/12 1530
Serology	
Hepatitis A IgM Ab (Nonreactive SCREEN)	NonReactive
Hep Bs Antigen (Nonreactive SCREEN)	NEG-NONREAC
Hep B Core IgM Ab (Nonreactive SCREEN)	NonReactive
Hepatitis C Antibody (Nonreactive SCREEN)	NR

Radiology data:

Recent Impressions:

ULTRASOUND - US ABDOMEN LTD 09/12 1637

*** Report Impression - Status: SIGNED Entered: 09/12/2017 1913

Impression:

1. Markedly limited examination due to poor beam penetration. The liver, gallbladder, common bile duct and pancreas are inadequately

Patient: RUIZ, FELIPE
Unit#: BH00861890
Date: 09/12/17
BH9023078383

Acct#:

visualized on this examination.

2. Unremarkable right kidney and visualized portions of the abdominal aorta and IVC.

Impression By: t.SDR.RH16 -

(b)(6); (b)(7)(C)

Diagnosis, Assessment & Plan

Free Text A&P:

Consult: Hematemesis

HISTORY OF PRESENT ILLNESS: The patient is a 51-year-old Hispanic incarcerated male, who was taken to Livingston Memorial Emergency Room with complaints of abdominal pain, and hematemesis. He has a past medical history significant for nonalcoholic liver cirrhosis, generalized anxiety disorder, and depression. He has been diagnosed with cirrhosis 7 years ago. He is currently in the Department of Corrections.

PAST MEDICAL HISTORY: As mentioned above, which includes,

1. Nonalcoholic liver cirrhosis.
2. Depression.
3. Generalized anxiety disorder.

SURGICAL HISTORY: None.

ALLERGIES: NO KNOWN DRUG ALLERGIES.

MEDICATIONS FROM JAIL: Reviewed.

SOCIAL HISTORY: The patient is incarcerated. He is originally from Florida; however, because of the flooding, he was transferred to Texas Jail.

FAMILY HISTORY: The patient is unaware of any medical problems running in the family.

REVIEW OF SYSTEMS:

Otherwise negative.

GASTROINTESTINAL: He presents with right upper quadrant abdominal pain and

Patient: RUIZ, FELIPE
Unit#: BH00861890
Date: 09/12/17
BH9023078383

Acct#:

hematemesis.
PSYCH: depression.

Vitals as above:

General appearance: alert, awake, oriented
Head/Eyes: atraumatic, EOMI, icteric
ENT: moist mucosal membranes
Cardiovascular: regular rate & rhythm, normal heart sounds
Respiratory: clear to auscultation, no distress, no tenderness, aerating well
Abdomen/GI: active bowel sounds, soft, non tenderness
Extremities: moves all, no edema-all extremities
Musculoskeletal: full range of motion
Neuro/CNS: alert, oriented X 3
Psychiatry: unable to evaluate

LABORATORY AND DIAGNOSTIC DATA: Reviewed

ASSESSMENT AND PLAN: A 51-year-old incarcerated Hispanic male with history of nonalcoholic liver cirrhosis, now presents with hematemesis
Possible varices though PLTs are low will transfuse then have EGD possible banding
Agree with octreotide and PPI drip with abx
EGD planned tomorrow
NPO for now
Follow up CBC in the AM

Electronically Signed by (b)(6); (b)(7)(C) on 09/12/17 at 2054

RPT #: 0912-0667
END OF REPORT

Page 8 of 8

0918-0005

CONROE REGIONAL MEDICAL CENTER
504 Medical Center Blvd.
Conroe, Texas 77304

PATIENT NAME: RUIZ, FELIPE
ACCOUNT NO: BH9023078383
MEDICAL RECORD NO: BH00861890
REPORT TYPE: ELECTROCARDIOGRAM

ADMIT DATE: 09/12/17
ROOM NO: B.CCU36
AGE: 51
SEX: M

ADMITTING PHYSICIAN (b)(6); (b)(7)(C)
ATTENDING PHYSICIAN

Order:

20170917-0006

Test Reason : CHEST PAIN

Test Date/Time Stamp:

Sun Sep 17 2017 04:56:16

Blood Pressure : ***/*** mmHG

Vent. Rate : 055 BPM Atrial Rate : 081 BPM

P-R Int : 000 ms QRS Dur : 140 ms

QT Int : 408 ms P-R-T Axes : -18 151 147 degrees

QTc Int : 390 ms

Sinus rhythm with 2nd degree AV block (Mobitz I)
Right bundle branch block
ST elevation, consider inferior injury or acute infarct
** ** ACUTE MI ** **

Abnormal ECG

When compared with ECG of 17 SEP 2017 00:33, (Unconfirmed)

Sinus rhythm is now with 2nd degree AV block (Mobitz I)

Vent. rate has decreased BY 67 BPM

Right bundle branch block is now present

Confirmed by (b)(6); (b)(7)(C) on 9/18/2017 7:42:16 AM

Referred by: (b)(6); (b)(7)(C) Confirmed by (b)(6); (b)(7)(C)

Electronically signed by (b)(6); (b)(7)(C) on 09/18/17 at 0742

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: BH9023078383

0918-0002

CONROE REGIONAL MEDICAL CENTER
504 Medical Center Blvd.
Conroe, Texas 77304

PATIENT NAME: RUIZ, FELIPE
ACCOUNT NO: BH9023078383
MEDICAL RECORD NO: BH00861890
REPORT TYPE: ELECTROCARDIOGRAM

ADMIT DATE: 09/12/17
ROOM NO: B.CCU36
AGE: 51
SEX: M

ADMITTING PHYSICIAN (b)(6); (b)(7)(C) MD
ATTENDING PHYSICIAN (b)(6); (b)(7)(C) MD

Order:
20170917-0050
Test Reason : UNKNOWN
Test Date/Time Stamp:
Sun Sep 17 2017 00:33:17
Blood Pressure : ***/*** mmHG
Vent. Rate : 122 BPM Atrial Rate : 122 BPM
P-R Int : 158 ms QRS Dur : 072 ms
QT Int : 298 ms P-R-T Axes : 022 114 026 degrees
QTc Int : 424 ms

Sinus tachycardia
Left posterior fascicular block
Abnormal ECG
When compared with ECG of 12-SEP-2017 17:17,
vent. rate has increased BY 52 BPM
Left posterior fascicular block is now present
T wave inversion no longer evident in anterior leads

Confirmed by (b)(6); (b)(7)(C) on 9/18/2017 7:41:06 AM
Referred By: (b)(6); (b)(7)(C) Confirmed by (b)(6); (b)(7)(C)

Electronically Signed by (b)(6); (b)(7)(C) on 09/18/17 at 0741

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: BH9023078383

0913-0004

CONROE REGIONAL MEDICAL CENTER
504 Medical Center Blvd.
Conroe, Texas 77304

PATIENT NAME: RUIZ, FELIPE
ACCOUNT NO: BH9023078383
MEDICAL RECORD NO: BH00861890
REPORT TYPE: ELECTROCARDIOGRAM

ADMIT DATE: 09/12/17
ROOM NO: B.ICU18
AGE: 51
SEX: M

ADMITTING PHYSICIAN (b)(6); (b)(7)(C)
ATTENDING PHYSICIAN (b)(6); (b)(7)(C)

Order:

20170912-0085

Test Reason : tropinemia at outside eR

Test Date/Time Stamp:

Tue Sep 12 2017 17:17:29

Blood Pressure : ***/*** mmHG

Vent. Rate : 070 BPM Atrial Rate : 070 BPM

P-R Int : 182 ms QRS Dur : 078 ms

QT Int : 416 ms P-R-T Axes : -14 009 032 degrees

QTc Int : 449 ms

Normal sinus rhythm n
Nonspecific ST and T wave abnormality
Abnormal ECG

No previous ECGs available

Confirmed by (b)(6); (b)(7)(C) on 9/13/2017 7:14:36 AM

Referred By: (b)(6); (b)(7)(C) Confirmed by (b)(6); (b)(7)(C)

Electronically signed by (b)(6); (b)(7)(C) on 09/13/17 at 0714

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: BH9023078383

0917-0008

CONROE REGIONAL MEDICAL CENTER
504 Medical Center Blvd.
Conroe, Texas 77304

PATIENT NAME: RUIZ, FELIPE
ACCOUNT NO: BH9023078383
MEDICAL RECORD NO: BH00861890
REPORT TYPE: eECHOCARDIOGRAM REPORT

ADMIT DATE: 09/12/17
ROOM NO: B.CCU36
AGE: 51
SEX: M

ADMITTING PHYSICIAN
ATTENDING PHYSICIAN

(b)(6); (b)(7)(C)

BH9023078383
BH00861890
ECHO2DDOP

Echocardiogram Report

Name: RUIZ, FELIPE
Patient Location: B.ICU4 B.ICU18 W
MRN: BH00861890
URN: BH547883
Account #: BH9023078383
Gender: Male
DOB: 06/26/1966
Age: 51 yrs
Ethnicity: Other
Reason For Study: CHEST PAIN

Study Date: 09/13/2017 01:38 PM

BP: 89/50 mmHg
Height: 66 in
Weight: 171 lb
Gender: Male

BSA: 1.9 m2

Cardiac Measurements with Normal Values:

Ao root diam: 3.1 cm 20-37 mm ACS: 2.4 cm 15-26 mm
LA dimension: 4.1 cm 19-40 mm
LVIDd: 4.6 cm 37-56 mm
LVIDs: 2.8 cm - IVSd: 0.94 cm 6-11 mm
RVDD: 3.0 cm 7-23 mm

MMode/2D Measurements Calculations

LVPwd: 0.87 cm FS: 39.2 %
EDV(Teich): 98.9 ml
ESV(Teich): 29.9 ml
EF(Teich): 69.7 %
Ao root area: 7.7 cm2 LVOT diam: 2.1 cm
LVOT area: 3.5 cm2

Doppler Measurements Calculations

MV E max vel: 86.3 cm/sec MV dec slope: 461.6 cm/sec2
MV A max vel: 81.6 cm/sec MV dec time: 0.19 sec
MV E/A: 1.1 LV V1 max PG: 7.6 mmHg
Ao V2 max: 161.9 cm/sec LV V1 max: 137.9 cm/sec
Ao max PG: 10.5 mmHg
AVA(V,D): 3.0 cm2 TR max vel: 240.2 cm/sec
PA V2 max: 111.5 cm/sec TR max PG: 23.1 mmHg
PA max PG: 5.0 mmHg

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: BH9023078383

RVSP(TR): 33.1 mmHg

RAP systole: 10.0 mmHg

Conclusions

A complete two-dimensional transthoracic echocardiogram was performed (2D, M-mode, Doppler and color flow Doppler). The study was technically adequate. The left ventricle is normal in size. There is normal left ventricular wall thickness. Ejection Fraction = >65%. Left ventricular systolic function is normal. The transmitral spectral Doppler flow pattern is normal for age. The left ventricular wall motion is normal.

Left Ventricle

The left ventricle is normal in size. There is normal left ventricular wall thickness. Left ventricular systolic function is normal. Ejection Fraction = >65%. The transmitral spectral Doppler flow pattern is normal for age. The left ventricular wall motion is normal.

Right Ventricle

The right ventricle is normal in size and function.

Atria

The left atrium is mildly dilated. Right atrial size is normal. IAS not well visualized.

Mitral Valve

The mitral valve is normal in structure and function.

Tricuspid Valve

The tricuspid valve is normal in structure and function. Doppler findings do not suggest pulmonary hypertension.

Aortic Valve

The aortic valve opens well. The aortic valve is mildly sclerotic. The aortic valve is not well visualized.

Pulmonic Valve

The pulmonic valve is not well visualized. Trace pulmonic valvular regurgitation.

Great Vessels

The aortic root is normal size.

Pericardium/Pleural

There is no pericardial effusion.

Electronically signed by (b)(6); (b)(7)(C) 09/17/2017 12:35 PM
Ordering Physician: (b)(6); (b)(7)(C)

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: BH9023078383

Referring Physician: (b)(6); (b)(7)(C)
Performed By: (b)(6); (b)(7)(C)

Electronically signed by (b)(6); (b)(7)(C) MD on 09/17/17 at 1236

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: BH9023078383

Patient Name: RUIZ, FELIPE

Unit No: BH00861890

EXAMS:
020699234 NM MYOCRD SPECT R/S MULT

CPT CODE:
78452

Pharmacologic Myocardial Perfusion Imaging Rest/Stress test; 1-day Protocol

INDICATION:

Diagnosis of coronary artery disease in patient with atypical chest pain

Clinical history:

Patient is a 51-year-old male with cardiac risk factors and atypical chest pain

PROCEDURE:

Pharmacological stress testing was performed with Lexiscan 0.4 mg/5 mL from a prefilled syringe that was discarded after single use. The heart rate increased appropriately during Lexiscan infusion. Following Lexiscan injection and saline flush, the patient was injected with 32.0 mCi of sestamibi and stress gated tomographic imaging was performed. Prior, resting imaging was also performed following the injection of 14.7 mCi of Sestamibi.

FINDINGS:

The EKG portion of the stress test shows no acute ST changes. Overall quality of the study is fair. The left ventricle is normal in size. On the raw images, there is no motion artifact. There is significant amount of gut uptake noted on both stress and rest images.

Stress:

The stress SPECT images demonstrate homogenous tracer distribution throughout the myocardium. The gated stress SPECT imaging reveals normal myocardial thickening and wall motion. The calculated left ventricle ejection fraction of 72%.

Rest:

The rest SPECT images again demonstrate homogenous tracer distribution throughout the myocardium.

In comparing the stress and rest images, there is no reversible ischemia. There is no transient ischemic dilatation, calculated TID is 1.00.

IMPRESSION:

1. Normal myocardial perfusion imaging stress test
2. No reversible ischemia
3. Normal left ventricular systolic function, calculated EF 72% on stress imaging

Patient Name: RUIZ, FELIPE

Unit No: BE00861890

EXAMS:
020699234 NM MYOCRD SPECT R/S MULT
<Continued>

CPT CODE:
78452

** Electronically Signed by (b)(6); (b)(7)(C) on 09/16/2017 at 1253 **
Reported and signed by: (b)(6); (b)(7)(C)

Nuclear Medicine Cardiology exams performed on dual head cameras with appropriate software for processing and reporting.
CC: (b)(6); (b)(7)(C) MD

(b)(6); (b)(7)(C)

FAX: 936-585 (b)(6); Campus: C St: ADM
 FAX: 936-585 (b)(7)(C)
 FAX: M 936-756

Patient Name: RUIZ, FELIPE

Unit No: BHC0861890

EXAMS:
020699688 XR CHEST 1 V

CPT CODE:
71010

AFTER HOURS SERVICE ON: 9/17/2017 5:06 AM

AP Portable Chest

Location Code M12

HISTORY: POST LINE PLACEMENT

FINDINGS:

Inspiration is shallow. NGT remains in the distal stomach. The ETT is midway between the clavicles and the carina, approximately 3 cm above the carina. There are no infiltrates. There are no pleural effusions. There is no pneumothorax. Cardiac silhouette and mediastinum appear within normal limits.

IMPRESSION:

- 1. No active intrathoracic findings.
- 2. ETT and NGT in place.

** Electronically Signed by (b)(6); (b)(7)(C) **
 ** on 09/17/2017 at 0507 **
 Reported and signed by: (b)(6); (b)(7)(C)

CC: (b)(6); (b)(7)(C)

Dictated Date/Time: 09/17/2017 (0507)
 Technologist: (b)(6); Bickerstaff - Agency
 Transcribed Date/Time: 09/17/2017 (0507) By: (b)(6); (b)(7)(C)
 Orig Print D/T: S: 09/17/2017 (0510)

FAX: (b)(6); (b)(7)(C) 936-585 (b)(6); (b)(7)(C) Campus: C St: ADM
FAX: 936-585 (b)(6); (b)(7)(C)

Patient Name: RUIZ, FELIPE Unit No: BH00861890

** Report Has Been Amended **

EXAMS: 020699673 XR CHEST 1 V CPT CODE: 71010

Addendum - 09/17/2017 SIGNED 09/17/2017

ADDENDUM: 020699673 RAD/CXR1

Addendum:

Results were verbally communicated by telephone to nurse (b)(6); (b)(7)(C) (b)(6); (b)(7)(C) at 1:53 AM by WHRA on-call.

** Electronically Signed by (b)(6); (b)(7)(C) **
** on 09/17/2017 at 0154 **
Reported and signed by: (b)(6); (b)(7)(C)
Dictated Date/Time: 09/17/2017 (0154)

Report

AFTER HOURS SERVICE ON: 9/17/2017 1:41 AM

AP Portable Chest

Location Code M12

HISTORY: ETT PLACEMENT

FINDINGS:

Inspiration is shallow. NG tube is noted in the stomach. The ETT is located in the right mainstem bronchus. There are no pleural effusions. There is no pneumothorax. Cardiac silhouette and mediastinum appear within normal limits.

IMPRESSION:

ETT in the right mainstem bronchus. It should be pulled back 7 cm.
*****FOR INTERNAL CODING PURPOSES ONLY*****
RESULT CODE: CVR

** Electronically Signed by (b)(6); (b)(7)(C) **
** on 09/17/2017 at 0143 **
Reported and signed by (b)(6); (b)(7)(C)

FAX: (b)(6); (b)(7)(C)
FAX: [Redacted]

936-585 (b)(6); (b)(7)(C)
936-585 [Redacted]

Campus: C St: ADM

Patient Name: RUIZ, FELIPE

Unit No: BH00861890

** Report Has Been Amended **

EXAMS:
020699673 XR CHEST 1 V
<Continued>

CPT CODE:
71010

CC: (b)(6); (b)(7)(C)

Dictated Date/Time: 09/17/2017 (0143)

Technologist: (b)(6); (b)(7)(C)

Transcribed Date/Time: 09/17/2017 (0143)

By: (b)(6); (b)(7)(C)

Orig Print D/T: S: 09/17/2017 (0147)

FAX:
FAX:

(b)(6); (b)(7)(C)

936-585
936-585

(b)(6);
(b)(7)(C)

Campus: C St: ADM

Patient Name: RUIZ, FELIPE

Unit No: BH00861890

EXAMS:
020699673 XR CHEST 1 V

CPT CODE:
71010

AFTER HOURS SERVICE ON: 9/17/2017 1:41 AM

AP Portable Chest

Location Code M12

HISTORY: ETT PLACEMENT

FINDINGS:

Inspiration is shallow. NG tube is noted in the stomach. The ETT is located in the right mainstem bronchus. There are no pleural effusions. There is no pneumothorax. Cardiac silhouette and mediastinum appear within normal limits.

IMPRESSION:

ETT in the right mainstem bronchus. It should be pulled back 7 cm.
*****FOR INTERNAL CODING PURPOSES ONLY*****
RESULT CODE: CVR

** Electronically Signed by (b)(6); (b)(7)(C) **
** on 09/17/2017 at 0143 **
Reported and signed by (b)(6); (b)(7)(C) M.D.

CC: (b)(6); (b)(7)(C)

Dictated Date/Time: 09/17/2017 (0143)
Technologist: (b)(6); (b)(7)(C)
Transcribed Date/Time: 09/17/2017 (0143) By: (b)(6); (b)(7)(C)
Orig Print D/T: S: 09/17/2017 (0147)

FAX: (b)(6); (b)(7)(C) 936-585- (b)(6); (b)(7)(C) Campus: C St: ADM
 FAX: 936-585- (b)(6); (b)(7)(C)
 FAX: M 936-756- (b)(6); (b)(7)(C)

Patient Name: RUIZ, FELIPE

Unit No: BH00861890

EXAMS:
020699678 XR CHEST 1 V

CPT CODE:
71010

- XR CHEST 1 V, - XR CHEST 1 V, 9/17/2017 2:17 AM

Reason For Examination: POST CODE/INTUBATION

Comparison: Exam of one hour prior

Location: R16

Findings

On examination of 2:13 AM endotracheal tube appears to be at the level of the carina. The enteric tube crosses the midline, possibly within the antrum/1st portion duodenum

Examination of 2:20 AM the endotracheal tube has been retracted to more satisfactory position approximately 3 cm above the carina. Enteric tube position is unchanged. Remainder of the exam findings are also similar to prior

IMPRESSION:

Readjusted endotracheal tube now with tip terminating approximately 3 cm above the carina in appropriate appearing position

** Electronically Signed by (b)(6); (b)(7)(C) M.D. **

** on 09/17/2017 at 08:45
Reported and signed by (b)(6); (b)(7)(C) M.D.

CC: (b)(6); (b)(7)(C)

Dictated Date/Time: 09/17/2017 (0245)
Technologist: Alonzo Bickerstaff - Agency (b)(6); (b)(7)(C)
Transcribed Date/Time: 09/17/2017 (0245) By:
Orig Print D/T: S: 09/17/2017 (0248)

FAX: (b)(6); (b)(7)(C)
FAX: (b)(6); (b)(7)(C)

936-585 (b)(6); (b)(7)(C)
936-585 (b)(6); (b)(7)(C)

Campus: C St: ADM

Patient Name: RUIZ, FELIPE

Unit No: BH00861890

EXAMS:
020697794 XR CHEST 1 V

CPT CODE:
71010

Location: T 18

Chest x-ray exam, AP frontal projection, 9/12/2017

CLINICAL HISTORY: Leukocytosis, ICU patient.

Comparison exams: None of the chest

Elevation the right hemidiaphragm difficult to assess in terms of age given lack of prior exams. Probable scarring versus atelectatic changes mainly at the right lung base. No active CHF. Overlying lines obscure detail. No findings of high concern for pneumonia

** Electronically Signed by (b)(6); (b)(7)(C) I.D. **
** on 09/12/2017 at 1726 **
Reported and signed by: (b)(6); (b)(7)(C)

CC: (b)(6); (b)(7)(C)

Dictated Date/Time: 09/12/2017 (1726)
Technologist: (b)(6); (b)(7)(C)
Transcribed Date/Time: 09/12/2017 (1726) By: (b)(6); (b)(7)(C)
Orig Print D/T: S: 09/12/2017 (1729)

Patient Name: RUIZ, FELIPE

Unit No: BH00861890

EXAMS:
020697791 US ABDOMEN LTD

CPT CODE:
76705

Site:R16

Limited Abdominal Ultrasound

History: Right upper quadrant abdominal pain, history of nonalcoholic liver cirrhosis.

Comparison: No prior similar studies are available for comparison.

Technique: Gray scale and color Doppler imaging were utilized.

Findings:

This examination is markedly limited due to poor beam penetration.

The liver is measures 15.2 cm in length. Evaluation of the liver is markedly limited. The main portal vein is not well visualized.

The gallbladder is not well-visualized. Sonographic Murphy sign is negative.

The common bile duct is not identified on this examination.

The right kidney measures 10.9 x 5.8 x 4.2 cm, with a cortical thickness measuring 1.9 cm. It demonstrates no hydronephrosis, nephrolithiasis or cortical thinning.

The pancreas is not visualized.

The visualized portions of the abdominal aorta and IVC are unremarkable.

There is no evidence of ascites.

Impression:

1. Markedly limited examination due to poor beam penetration. The liver, gallbladder, common bile duct and pancreas are inadequately visualized on this examination.
2. Unremarkable right kidney and visualized portions of the abdominal aorta and IVC.

** Electronically Signed by (b)(6); (b)(7)(C) on 09/12/2017 at 1909 **
Reported and signed by: (b)(6); (b)(7)(C)

CC: (b)(6); (b)(7)(C)

Technologist: (b)(6); (b)(7)(C) - Agency
Transcribed D/T: 09/12/2017 (1909) (b)(6); (b)(7)(C)
Orig Print D/T: S: 09/12/2017 (1913) Probe:

0913-0070

CONROE REGIONAL MEDICAL CENTER
504 Medical Center Blvd.
Conroe, Texas 77304PATIENT NAME: RUIZ, FELIPE
ACCOUNT NO: (b)(6); (b)(7)(C)
MEDICAL RECORD NO: BH00861890
REPORT TYPE: ENDOWORKS REPORTADMIT DATE: 09/12/17
ROOM NO: B.ICU18
AGE: 51
SEX: MADMITTING PHYSICIAN (b)(6); (b)(7)(C)
ATTENDING PHYSICIAN (b)(6); (b)(7)(C)

Indications: Hematemesis (578.0).

Consent: The benefits, risks, and alternatives to the procedure were discussed and informed consent was obtained from the patient.

Pre-Sedation Assessment: H and P completed, I have examined the patient on this date and have reviewed the medical history, drug history, and previous anesthesia experience. Results of the relevant diagnostic studies have been reviewed. Planned choice of anesthesia, risk, complications, benefits and alternatives have been discussed.

Preparation: EKG, pulse, pulse oximetry, and blood pressure were monitored throughout the procedure. An intravenous line was inserted. The patient was kept NPO.

Medications: See anesthesia report.

Procedure: The gastroscope was passed through the mouth under direct visualization and was advanced with ease to the 2nd portion of the duodenum. The scope was withdrawn and the mucosa was carefully examined. The views were good.

Findings: Esophagus: The proximal third of the esophagus, middle third of the esophagus, and distal third of the esophagus appeared to be normal. Stomach: Hypertensive portal gastropathy was found in the fundus, body of the stomach, and antrum. Duodenum: Patchy erythema in bulb and 2nd portion.

Specimens Sent: None, unless otherwise noted.

Estimated Blood Loss: Insignificant.

Unplanned Events: There were no unplanned events.

Summary: Normal proximal third of the esophagus, middle third of the esophagus, and distal third of the esophagus. Hypertensive portal gastropathy was found in the fundus, body of the stomach, and antrum (572.8). Patchy erythema in bulb and 2nd portion.

Recommendations: Avoid all non-steroidal anti-inflammatory drugs (NSAID's) including but not limited to Aspirin, Ibuprofen, Advil, Motrin, and Nuprin. Return to floor. Resume low salt diet as tolerated. Continue current medications. PPI 20 mg daily.

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: (b)(6); (b)(7)(C)

Assisted By: The procedure was assisted by N/A.

Procedure Codes: [43235]EGD
Version 1, electronically signed by (b)(6); (b)(7)(C) on 09/13/2017 at 07:42 AM.

Electronically signed by (b)(6); (b)(7)(C) on 09/13/17 at 0742

PATIENT NAME: RUIZ, FELIPE

ACCOUNT #: (b)(6); (b)(7)(C)

(b)(6); (b)(7)(C)

8/18/2017

ALMAZAN RUIZ, FELIPE

AlienNumber,
A028866428

GCSO17MNI005042

8/18/2017

Final Treatment

c/o of difficulty seeing

(b)(6); (b)(7)(C)

(b)(6);
(b)(7)(C)

(b)(6);
(b)(7)(C)

(b)(6);
(b)(7)(C)

(b)(6);
(b)(7)(C)

(b)(6);
(b)(7)(C)



8/22/2017	ALMAZAN RUIZ, FELIPE	AlienNumber, A028866428	GCSO17MNI005042	Manual	(b)(6); (b)(7)(C)	8/23/2017	PT HAS ALREADY BEEN REFERRED TO MD	c/o eyes burning/vision difficulty request glasses/review meds
-----------	----------------------	----------------------------	-----------------	--------	----------------------	-----------	---------------------------------------	---

(b)(6); (b)(7)(C)

(b)(6); (b)(7)(C)

8/30/2017	ALMAZAN RUIZ, FELIPE	AlienNumber, A028866428	GCSO17MNI005042	8/30/2017	Final Treatment				inmate c/o painful joints and requests eye exam.
-----------	----------------------	----------------------------	-----------------	-----------	-----------------	--	--	--	--

(b)(6); (b)(7)(C)

(b)(6); (b)(7)(C)

9/2/2017	ALMAZAN RUIZ, FELIPE	AlienNumber, A028866428	GCSO17MNI005042	9/2/2017	Final Treatment					PATIENT C/O HEADACHE AND EYE PAIN. PATIENT REQUEST GLASSES TO SEE.
----------	----------------------	----------------------------	-----------------	----------	-----------------	--	--	--	--	---

(b)(6); (b)(7)(C)

From: (b)(6); (b)(7)(C)
Sent: 6 Dec 2017 16:33:03 +0000
To: (b)(6); (b)(7)(C)
Subject: FW: Krome and Glades interview list - ADDING ON
Attachments: Almazan-Ruiz Sick Call Logs.pdf

Can you print out one copy of this? Thank you!

(b)(6); (b)(7)(C)
Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW (b)(6); (b)(7)(C)
Washington, DC 20536
202-732-(b)(6); (b)(7)(C) (desk)
202-253-(b)(6); (b)(7)(C) (cell)

From: (b)(6); (b)(7)(C)
Sent: Thursday, November 30, 2017 5:10 PM
To: (b)(6); (b)(7)(C)
Cc:
Subject: RE: Krome and Glades interview list - ADDING ON

The following requested items are attached ..

Glades Medical Staff Interview Schedule
Almazan-Ruiz Sick Call activity log
Glades Medical Staff Listing and Monthly Schedule

From: (b)(6); (b)(7)(C)
Sent: Thursday, November 30, 2017 12:56 PM
To: (b)(6); (b)(7)(C)
Cc:
(b)(6); (b)(7)(C)
Subject: RE: Krome and Glades interview list - ADDING ON

Major (b)(6); (b)(7)(C)

Please see below regarding the death inquiry. Three more individuals for interview. Also, the staffing roster and plan, as well as the sick call logs, are requested.

Thanks.

Sent with BlackBerry Work (www.blackberry.com)

From: (b)(6); (b)(7)(C)
Date: Thursday, Nov 30, 2017, 12:42 PM
To: (b)(6); (b)(7)(C)
Cc:
Subject: RE: Krome and Glades interview list - ADDING ON

Good afternoon,

I apologize to have to add more employees to the list, however we need to speak to 3 LPNs at Glades that triaged sick calls. Unfortunately, their signatures are hard to read and we have not yet received the staffing roster. What we could decipher was:

(b)(6); (b)(7)(C)

If possible, would we be able to get the medical staffing roster and staffing plan prior to arriving? Also, we are still missing the sick call log. Was there any luck getting that from the contractor. Thank you!

(b)(6); (b)(7)(C)
Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW (b)(6); (b)(7)(C)
Washington, DC 20536
202-732-(b)(6); (b)(7)(C) desk)
202-253-(b)(6); (b)(7)(C) cell)

From: (b)(6); (b)(7)(C)
Sent: Thursday, November 30, 2017 12:16 PM
To: (b)(6); (b)(7)(C)
Cc:
Subject: RE: Krome and Glades interview list

Good afternoon,

I wanted to check back on the interview schedule for Krome and Glades. Will it be possible to get it by tomorrow? Thank you and please let me know if there are any issues.

(b)(6); (b)(7)(C)
Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW (b)(6); (b)(7)(C)
Washington, DC 20536
202-732-(b)(6); (b)(7)(C) desk)
202-253-(b)(6); (b)(7)(C) cell)

From: (b)(6); (b)(7)(C)
Sent: Monday, November 27, 2017 9:42 AM
To: (b)(6); (b)(7)(C)

Cc: (b)(6); (b)(7)(C)
Subject: RE: Krome and Glades interview list

Good morning,

I have attached the interview schedule template we use. I'm also re-attaching the list of people we would like to interview. There is one additional name for Krome, highlighted. There is no change to the Glades list.

Here is a list of documents we will need at Krome for review, if any are available now to be sent we would be glad to review them ahead of time:

- Original copy of the eCW available on site
- Credential files on site: (b)(6); (b)(7)(C)
the others were reviewed at the last DDR.
- All scanned medical documents not previously filed in the record
- All complete telephone encounters
- Nursing Guidelines for sore throat, foot fungus, and general body itching (pruritus)
- MARS for the month of August
- MedPARS and schedule of outside appointments for hematology, ophthalmology, and radiology (ultrasound)
- Non-formulary approval of the drug Rifaximin
- Sick call logs for the period of July 11 to August 12, 2017

Here is a list of documents we will need at Glades for review, if any are available now to be sent we would be glad to review them ahead of time:

- Original medical record on site
- Credential files of all interviewees on site
- Staff Roster
- Staff Schedule
- 2017 Staffing Guidelines
- Copies of psychiatry and optometry consultations if done
- Physical examination/dental training record for (b)(6); (b)(7)(C)
- Nursing Protocols for muscular skeletal problems, general pain, and vision disturbance
- Copy of problem list
- Medication administration records for August and September 2017

(b)(6); (b)(7)(C)

Management & Program Analyst
ICE/OPR/ERAU
950 L'Enfant Plaza SW; 1st Floor
Washington, DC 20536
202-732-(b)(6);
202-253-4782 (cell)

From: (b)(6); (b)(7)(C)
Sent: Friday, November 24, 2017 6:22 PM
To: (b)(6); (b)(7)(C)
Subject: Krone and Glades interview list

Good evening,

I wanted to go ahead and send our interview list for Krome and Glades. On Monday, December 4, we can start at 8:00 with an in-brief and tour at Krome. Interviews can start around 9:15. We will be at Krome Monday and Tuesday - start time Tuesday for interviews can be at 8:30. We will start at Glades on Wednesday, December 6. We plan to leave from Doral and drive up to Moore Haven that morning. The in-brief and tour can start at Glades mid morning. Interviews will start right after. We plan to be there Wednesday and Thursday - start for interviews on Thursday can be at 8:30.

Since we don't know the employees schedules we ask if the facility can fill in the schedule. Each interview will be about 30 minutes with a 15 minute buffer between each one.

The tours are a requirement, however the inbrief and outbriefs are optional. Just let me know if you do want to have those at both locations and I'll factor them in.

Thank you and please let me know if you have any questions.

Sent with BlackBerry Work
(www.blackberry.com)

Private and Confidential:

~~The sender intends to communicate the contents of this transmission only to the person to whom it is addressed. This transmission may contain information that is privileged, confidential or otherwise exempt from disclosure under applicable law. If you have received this transmission in error, please notify us immediately and promptly destroy the original transmission. Please notify the sender of this error by replying to e-mail. Under Florida law, e-mail addresses are public records. If you do not want your e-mail address released in response to a public records request, do not send electronic mail to this entity. Instead, contact this office by phone or in writing.~~

(b)(6); (b)(7)(C)



8/18/2017	ALMAZAN RUIZ, FELIPE	AlienNumber, A028866428	GCSO17MNI005042	8/18/2017	Final Treatment					c/o of difficulty seeing
-----------	----------------------	----------------------------	-----------------	-----------	-----------------	--	--	--	--	--------------------------

(b)(6); (b)(7)(C)



8/22/2017	ALMAZAN RUIZ, FELIPE	AlienNumber, A028866428	GCSO17MNI005042	Manual	(b)(6); (b)(7)(C)	8/23/2017	PT HAS ALREADY BEEN REFERRED TO MD	c/o eyes burning/vision difficulty request glasses/review meds
-----------	----------------------	----------------------------	-----------------	--------	----------------------	-----------	---------------------------------------	---

(b)(6); (b)(7)(C)



(b)(6); (b)(7)(C)

9/2/2017	ALMAZAN RUIZ, FELIPE	AlienNumber, A028866428	GCSO17MNI005042	9/2/2017	Final Treatment					PATIENT C/O HEADACHE AND EYE PAIN. PATIENT REQUEST GLASSES TO SEE.
----------	----------------------	----------------------------	-----------------	----------	-----------------	--	--	--	--	---

(b)(6); (b)(7)(C)

From: (b)(6); (b)(7)(C)
Sent: 10 Oct 2017 14:44:13 -0400
To: (b)(6); (b)(7)(C)
Cc:
Subject: FW: List of Employees to Interview
Attachments: Interview Schedule_ALMAZAN-Ruiz.docx

(b)(6); (b)(7)(C)

Good afternoon. Please see attached list for interviews. Also email below for the IAH contract physician request.

Please advise if the list and the request is acceptable.

Thank you,

(b)(6); (b)(7)(C)

SDDO
Montgomery County Detention Center
Conroe, Texas

From: (b)(6); (b)(7)(C)
Date: Tuesday, Oct 10, 2017, 1:38 PM
To: (b)(6); (b)(7)(C)
Cc:
Subject: RE: List of Employees to Interview

Attached is the completed Interview Schedule. The only two individuals that are not listed are (b)(6); (b)(7)(C) who has since resigned and no longer employed by MTC, and (b)(6); (b)(7)(C) who is the contracted doctor for IAH. They are requesting if it would be possible to interview Mr. (b)(6); (b)(7)(C) on Tuesday at 17:00 hours.

If you have any questions please let me know.

(b)(6); (b)(7)(C)

Deportation Officer
Conroe, TX
Office – 936-524-(b)(6);
Cell – 832-4354-(b)(7)(C)

From: (b)(6); (b)(7)(C)
Sent: Tuesday, October 10, 2017 7:35 AM
To: (b)(6); (b)(7)(C)
Subject: FW: List of Employees to Interview
Importance: High

Gents,

Good morning. Please coordinate this request and provide a response by Wednesday morning for schedules/availability for interview(s).

Thank you,

(b)(6); (b)(7)(C)

Supervisory Detention and Deportation Officer
COR/Exotic/ERA
500 Hilbig Road
Conroe, Texas 77301
863-873 (b)(6);
(b)(7)(C)

From: (b)(6); (b)(7)(C)
Sent: Tuesday, October 10, 2017 7:21 AM
To: (b)(6); (b)(7)(C)
Subject: List of Employees to Interview

Good mornin (b)(6); (b)(7)(C)

Below is a the list of officers and medical personnel that we would like to interview. I have attached our Interview Schedule. Since we don't know everyone's schedule while we are there could someone fill in the times for those from the list below and get it back to us by Thursday? We do like to alternate between Security and Medical, but we know that is not always possible. Some of the documents got to our SMEs late last week which means we may need to add to the list. I will let you know.

Security:

(b)(6); (b)(7)(C) - Performed the Intake
(b)(6); (b)(7)(C) signed off on classification
(b)(6); (b)(7)(C) (first name unknown) - Appears he was the Dorm C officer when detainee was taken to hospital. Nothing logged so I am going off the shift report.
(b)(6); (b)(7)(C) Transported detainee to Hospital on 9/11/17
(b)(6); (b)(7)(C) Transported detainee to Hospital on 9/11/17
(b)(6); (b)(7)(C) Shift sergeant when detainee went out to hospital
(b)(6); (b)(7)(C) - Shift Supervisor; when detainee went out to hospital
(b)(6); (b)(7)(C) - With detainee at hospital when he died.
(b)(6); (b)(7)(C) - With detainee at hospital when he died.

* May only need to speak to one of them.

Medical:

(b)(6); (b)(7)(C) RN, HAS **Need to speak with her first, or at least the first part of the first day**
(b)(6); (b)(7)(C) RN, DON - conducted the intake screen
(b)(6); (b)(7)(C) Psych Counselor - conducted the initial mental health assessment
(b)(6); (b)(7)(C) - conducted the emergency assessment prior to ER transport

(b)(6); (b)(7)(C)

LVN - responded to the housing unit prior to ER transport

Please let me know if I should work with someone else on this. Also, will you be our contact for onsite? If not, would you know who that would be we have need to request one item to be physically present and also just talk about logistics. Thank you!

(b)(6); (b)(7)(C)

Management & Program Analyst

ICE/OPR/ERAU

950 L'Enfant Plaza SW, (b)(6); (b)(7)(C)

Washington, DC 20536

202-73 (b)(6); (b)(7)(C) (desk)

202-25 (b)(6); (b)(7)(C) (cell)

TUESDAY

INTERVIEW TIME	WITNESS NAME
8:30-8:45AM	In-Brief (Optional)
8:45 -9:15AM	Tour
9:30 -10:00AM	(b)(6); (b)(7)(C)
10:15-10:45AM	
11:00-11:30AM	
11:45-1:00PM	
1:00-1:30PM	
1:45-2:15PM	
2:30-3:00PM	
3:15-3:45PM	
4:00-4:30PM	

WEDNESDAY

INTERVIEW TIME	WITNESS NAME
8:30-9:00AM	
9:15-9:45AM	
10:00 -10:30AM	
10:45-11:15AM	
11:30-12:00PM	
12:00-1:00PM	LUNCH
1:00-1:30PM	
1:45-2:15PM	(b)(6); (b)(7)(C)
2:30-3:00PM	
3:15-3:45PM	
4:00-4:30PM	

THURSDAY

INTERVIEW TIME	WITNESS NAME
8:30-9:00AM	
9:15-9:45AM	
10:00 -10:30AM	
10:45-11:15AM	
11:30-12:00PM	
12:00-1:00PM	LUNCH
1:00-1:30PM	
1:45-2:15PM	(b)(6); (b)(7)(C)
2:30-3:00PM	
3:15-3:45PM	
4:00-4:30PM	

No Photo Available

ALMAZAN RUIZ, FELIPE, #GCSO17MNI005042 @ RELEASE

Male, 51 years old, DOB 6/26/1966

Allergies: NKDA

Diagnoses: CIRRHOSIS OF LIVER WITHOUT ALCOHOL, DEPRESSION, GENERALIZED ANXIETY DISORDER

2017-08	01 Tue	02 Wed	03 Thu	04 Fri	05 Sat	06 Sun	07 Mon	08 Tue	09 Wed	10 Thu	11 Fri	12 Sat	13 Sun	14 Mon	15 Tue	16 Wed	17 Thu	18 Fri	
01 - 0430 BS Labs - Send Out																		YES (DSMITH)	
01 - 0430 BS Labs - Send Out																			
02 - 0900 CLOTRIMAZOLE 1 % CRM by mouth 2 times per day for 7 days Req Start: 8/12/2017 Req End: 8/18/2017 Fully Administered: 8/18/2017												(b)(6); Med not available/ will re-fax order	KOP (b)(6)	KOP (b)(6)	KOP (b)(6)	KOP (b)(6)	KOP (b)(6)	KOP (b)(6); (b)(7)(C)	
02 - 0900 DOBUSATE SODIUM 100 MG Take 1 Capsule by mouth 2 times per day for 30 days as needed Req Start: 8/12/2017 Req End: 9/10/2017 Discontinued: 9/7/2017												YES (b)(6); (b)(7)(C)	YES (b)(6)	YES (b)(6)	YES (b)(6)	YES (b)(6)	YES (b)(6); (b)(7)(C)	YES	YES
02 - 0900 FOLIC ACID 1 MG Take 1 Tablet by mouth 1 time per day for 30 days Req Start: 8/12/2017 Req End: 9/10/2017 Discontinued: 9/6/2017												YES (b)(6); (b)(7)(C)	YES (b)(6)	YES (b)(6)	NO (b)(6) Med not available/Pharmacy notified via fax	YES (b)(6); (b)(7)(C)	YES (b)(6); (b)(7)(C)	YES	YES
02 - 0900 HYDROCORTISONE 1 % CRM topical 2 times per day for 7 days Req Start: 8/12/2017 Req End: 8/18/2017 Fully Administered: 8/18/2017												YES	YES (b)(6); (b)(7)(C)	YES (b)(6)	NO (b)(6) Med not available/Pharmacy notified via fax	NO (b)(6); (b)(7)(C)	NO (b)(6); (b)(7)(C)	NO (b)(6); (b)(7)(C)	NO
02 - 0900 IBUPROFEN 200 MG Take 2 Tablets by mouth 2 times per day for 5 days as needed Req Start: 8/24/2017 Req End: 8/29/2017 Fully Administered: 8/29/2017																			
02 - 0900 LACTULOSE 10 GM/15 ML SOLN 10 SOLN by mouth 2 times per day for 30 days as needed Req Start: 8/12/2017 Req End: 9/10/2017 Discontinued: 9/6/2017												YES (b)(6); (b)(7)(C)	YES (b)(6)	YES (b)(6)	NO (b)(6) Med not available/Pharmacy notified via fax	YES (b)(6); (b)(7)(C)	YES (b)(6); (b)(7)(C)	YES	YES
02 - 0900 Maalox 30 cc Take 1 Liquid by mouth 2 times per day for 5 days as needed Req Start: 8/12/2017 Req End: 8/16/2017 Fully Administered: 8/16/2017												YES (b)(6); (b)(7)(C)	YES (b)(6); (b)(7)(C)	YES (b)(6)	YES (b)(6)	YES (b)(6)	YES (b)(6)		
02 - 0900 MULTIVITAMIN Take 1 Tablet by mouth 1 time per day for 30 days Req Start: 8/12/2017 Req End: 9/10/2017 Discontinued: 9/6/2017												YES (b)(6); (b)(7)(C)	YES (b)(6); (b)(7)(C)	YES (b)(6)	YES (b)(6); (b)(7)(C)	YES (b)(6); (b)(7)(C)	YES (b)(6); (b)(7)(C)	YES	YES
02 - 0900 OMEPRAZOLE DR 20 MG CAPSULE 20 Take 1 Capsule by																			

month 1 time per day for 30 days Req Start: 8/12/2017 Req End: 9/10/2017 Discontinued: 9/6/2017					YES (b)(6); (b)(7)(C)	YES (b)(6)	YES (b)(6)	YES (b)(6); (b)(7)(C)	YES	YES	
02 - 0900 PROCTOSOL 2.5% Apply 1 Cream topical 2 times per day for 30 days Req Start: 8/14/2017 Req End: 9/13/2017 Discontinued: 9/7/2017							KOP (b)(6);	KOP (b)(6); (b)(7)(C)		KOP (b)(6);	
02 - 0900 SERTRALINE HCL 100 MG TAB 100 Take 1 Tablet by mouth 1 time per day for 60 days Req Start: 8/23/2017 Req End: 10/21/2017 Discontinued: 9/7/2017											
02 - 0900 SPIRONOLACTONE 25 MG TABLET 25 Take 1 Tablet by mouth 2 times per day for 30 days Req Start: 8/12/2017 Req End: 9/10/2017 Discontinued: 9/6/2017					YES (b)(6); (b)(7)(C)	YES (b)(6)	YES (b)(6);	YES (b)(6); (b)(7)(C)	YES	YES	
02 - 0900 TRIAMCINOLONE 0.1% CREAM 0.1 CRM 2 times per day for 60 days Req Start: 8/14/2017 Req End: 10/13/2017 Discontinued: 9/7/2017							KOP (b)(6);	KOP (b)(6); (b)(7)(C)	KOP	KOP (b)(6);	
02 - 0900 XIFAXAN 550 MG TAB 550 Take 1 Tablet by mouth 2 times per day for 30 days Req Start: 8/12/2017 Req End: 9/10/2017 Discontinued: 9/6/2017					NO (b)(6); Med not available/Pharmacy notified via telephone	NO (b)(6); Med not available/Pharmacy notified via fax	NO (b)(6); Med not available/ will re-fax order	NO (b)(6); Med not available/Pharmacy notified via fax	YES (b)(6);	NO (b)(6); (b)(7)(C); Med not available/ will re-fax order	NO (b)(6); Med not available/Phar notified via fax
05 - 2100 CIOTRIMAZOLE 1 % CRM by mouth 2 times per day for 7 days Req Start: 8/12/2017 Req End: 8/18/2017 Fully Administered: 8/18/2017					NO (b)(6); Med not available/ will re-fax order	NO (b)(6); Med not available/ will re-fax order	KOP (b)(6); (b)(7)(C)	KOP (b)(6); (b)(7)(C)	KOP	KOP	KOP
05 - 2100 DOCUSATE SODIUM 100 MG Take 1 Capsule by mouth 2 times per day for 30 days as needed Req Start: 8/12/2017 Req End: 9/10/2017 Discontinued: 9/7/2017					YES (b)(6); (b)(7)(C)	YES (b)(6); (b)(7)(C)	YES (b)(6); (b)(7)(C)	YES (b)(6); (b)(7)(C)	YES (b)(6); (b)(7)(C)	YES (b)(6); (b)(7)(C)	
05 - 2100 HYDROCORTISONE 1 % CRM topical 2 times per day for 7 days Req Start: 8/12/2017 Req End: 8/18/2017 Fully Administered: 8/18/2017					YES (b)(6); (b)(7)(C)	YES (b)(6); (b)(7)(C)	YES (b)(6); (b)(7)(C)	YES (b)(6); (b)(7)(C)	YES (b)(6); (b)(7)(C)	YES (b)(6); (b)(7)(C)	
05 - 2100 IBIUPROFEN 200 MG Take 2 Tablets by mouth 2 times per day for 5 days as needed Req Start: 8/24/2017 Req End: 8/29/2017 Fully Administered: 8/29/2017											
05 - 2100 LACTULOSE 10 GM/15 ML SOLN 10 SOLN by mouth 2 times per day for 30 days as needed Req Start: 8/12/2017 Req End: 9/10/2017					YES (b)(6);	YES (b)(6); (b)(7)(C)	YES (b)(6); (b)(7)(C)	YES (b)(6); (b)(7)(C)	YES (b)(6); (b)(7)(C)	YES (b)(6);	

Purple	Treat ONCE during this time	Silver	Dose/Treatment is NOT to be administered	Orange	PRN - Dispense/Treat as needed	Pink	Dose previously dispensed (KOP)
--------	-----------------------------	--------	--	--------	--------------------------------	------	---------------------------------

Details							
Date	Yes-No-KOP	Shift	Medication/Order	User	Reason	Comments	
8/12/2017	YES	02 - 0900	FOLIC ACID 1 MG	(b)(6)	NA	NA	
8/12/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG	(b)(7)(C)	NA	NA	
8/12/2017	YES	02 - 0900	MULTIVITAMIN		NA	NA	
8/12/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20		NA	NA	
8/12/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA	
8/12/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25		NA	NA	
8/12/2017	NO	02 - 0900	CLOTRIMAZOLE 1 %		Med not available/ will re-fax order	NA	
8/12/2017	YES	02 - 0900	HYDROCORTISONE 1 %		NA	NA	
8/12/2017	NO	02 - 0900	XIFAXAN 550 MG TAB 550		Med not available/Pharmacy notified via telephone	NA	
8/12/2017	YES	02 - 0900	Maalox 30 cc		NA	NA	
8/12/2017	YES	05 - 2100	SERTRALINE HCL 100 MG TAB 100		NA	NA	
8/12/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG		NA	NA	
8/12/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA	
8/12/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA	NA	
8/12/2017	NO	05 - 2100	CLOTRIMAZOLE 1 %		Med not available/ will re-fax order	NA	
8/12/2017	YES	05 - 2100	HYDROCORTISONE 1 %		NA	NA	
8/12/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA	NA	
8/12/2017	NO	05 - 2100	XIFAXAN 550 MG TAB 550		Med not available/ will re-fax order	NA	
8/12/2017	YES	05 - 2100	Maalox 30 cc		NA	NA	
8/13/2017	YES	02 - 0900	FOLIC ACID 1 MG		NA	NA	
8/13/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG		NA	NA	
8/13/2017	YES	02 - 0900	MULTIVITAMIN		NA	NA	
8/13/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20		NA	NA	
8/13/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA	
8/13/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25		NA	NA	
8/13/2017	KOP	02 - 0900	CLOTRIMAZOLE 1 %		NA	NA	
8/13/2017	YES	02 - 0900	HYDROCORTISONE 1 %		NA	NA	
8/13/2017	NO	02 - 0900	XIFAXAN 550 MG TAB 550		Med not available/Pharmacy notified via fax	NA	
8/13/2017	YES	02 - 0900	Maalox 30 cc		NA	NA	
8/13/2017	YES	05 - 2100	SERTRALINE HCL 100 MG TAB 100		NA	NA	
8/13/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG		NA	NA	
8/13/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA	
8/13/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA	NA	
8/13/2017	NO	05 - 2100	CLOTRIMAZOLE 1 %		Med not available/ will re-fax order	NA	
8/13/2017	YES	05 - 2100	HYDROCORTISONE 1 %		NA	NA	
8/13/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA	NA	
8/13/2017	NO	05 - 2100	XIFAXAN 550 MG TAB 550		Med not available/ will re-fax order	NA	
8/13/2017	NO	05 - 2100	Maalox 30 cc		NOT NEEDED	NA	
8/14/2017	YES	02 - 0900	FOLIC ACID 1 MG		NA	NA	
8/14/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG		NA	NA	
8/14/2017	YES	02 - 0900	MULTIVITAMIN		NA	NA	
8/14/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20		NA	NA	
8/14/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA	
8/14/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25		NA	NA	
8/14/2017	KOP	02 - 0900	CLOTRIMAZOLE 1 %		NA	NA	
8/14/2017	YES	02 - 0900	HYDROCORTISONE 1 %		NA	NA	
8/14/2017	NO	02 - 0900	XIFAXAN 550 MG TAB 550		Med not available/ will re-fax order	NA	
8/14/2017	YES	02 - 0900	Maalox 30 cc		NA	NA	
8/14/2017	YES	05 - 2100	SERTRALINE HCL 100 MG TAB 100		NA	NA	
8/14/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG		NA	NA	
8/14/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA	
8/14/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA	NA	
8/14/2017	KOP	05 - 2100	CLOTRIMAZOLE 1 %		NA	NA	
8/14/2017	YES	05 - 2100	HYDROCORTISONE 1 %		NA	NA	
8/14/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA	NA	
8/14/2017	YES	05 - 2100	XIFAXAN 550 MG TAB 550		NA	NA	
8/14/2017	NO	05 - 2100	Maalox 30 cc		NOT NEEDED	NA	
8/14/2017	YES	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA	
8/14/2017	YES	05 - 2100	PROCTOSOL 2.5%		NA	NA	
8/15/2017	NO	02 - 0900	FOLIC ACID 1 MG		Med not available/Pharmacy notified via fax	NA	
8/15/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG		NA	NA	
8/15/2017	YES	02 - 0900	MULTIVITAMIN		NA	NA	
8/15/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20		NA	NA	
8/15/2017	NO	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		Med not available/Pharmacy notified via fax	NA	
8/15/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25		NA	NA	
8/15/2017	KOP	02 - 0900	CLOTRIMAZOLE 1 %		NA	NA	
8/15/2017	NO	02 - 0900	HYDROCORTISONE 1 %		Med not available/Pharmacy notified via fax	NA	

8/15/2017	NO	02 - 0900	XIFAXAN 550 MG TAB 550	(b)(6); (b)(7)(C)	Med not available/Pharmacy notified via fax	NA
8/15/2017	YES	02 - 0900	Maalox 30 cc		NA	NA
8/15/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/15/2017	KOP	02 - 0900	PROCTOSOL 2.5%		NA	NA
8/15/2017	YES	05 - 2100	SERTRALINE HCL 100 MG TAB 100		NA	NA
8/15/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG		NA	NA
8/15/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/15/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/15/2017	KOP	05 - 2100	CLOTRIMAZOLE 1 %		NA	NA
8/15/2017	YES	05 - 2100	HYDROCORTISONE 1 %		NA	NA
8/15/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA	NA
8/15/2017	YES	05 - 2100	XIFAXAN 550 MG TAB 550		NA	NA
8/15/2017	YES	05 - 2100	Maalox 30 cc		NA	NA
8/15/2017	NO	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		Med not available/Pharmacy notified via fax	NA
8/15/2017	NO	05 - 2100	PROCTOSOL 2.5%		Med not available/Pharmacy notified via fax	NA
8/16/2017	YES	02 - 0900	FOLIC ACID 1 MG		NA	NA
8/16/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG		NA	NA
8/16/2017	YES	02 - 0900	MULTIVITAMIN		NA	NA
8/16/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20		NA	NA
8/16/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/16/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/16/2017	KOP	02 - 0900	CLOTRIMAZOLE 1 %		NA	NA
8/16/2017	NO	02 - 0900	HYDROCORTISONE 1 %		Med not available/ will re-fax order	NA
8/16/2017	YES	02 - 0900	XIFAXAN 550 MG TAB 550		NA	NA
8/16/2017	YES	02 - 0900	Maalox 30 cc		NA	NA
8/16/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/16/2017	KOP	02 - 0900	PROCTOSOL 2.5%		NA	NA
8/16/2017	YES	05 - 2100	SERTRALINE HCL 100 MG TAB 100		NA	NA
8/16/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG		NA	NA
8/16/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/16/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/16/2017	KOP	05 - 2100	CLOTRIMAZOLE 1 %		NA	NA
8/16/2017	YES	05 - 2100	HYDROCORTISONE 1 %		NA	NA
8/16/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA	NA
8/16/2017	NO	05 - 2100	XIFAXAN 550 MG TAB 550		Med not available/ will re-fax order	NA
8/16/2017	YES	05 - 2100	Maalox 30 cc		NA	NA
8/16/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/16/2017	KOP	05 - 2100	PROCTOSOL 2.5%		NA	NA
8/17/2017	YES	01 - 0430 BS	Labs - Send Out		NA	NA
8/17/2017	YES	02 - 0900	FOLIC ACID 1 MG		NA	NA
8/17/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG		NA	NA
8/17/2017	YES	02 - 0900	MULTIVITAMIN		NA	NA
8/17/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20		NA	NA
8/17/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/17/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/17/2017	KOP	02 - 0900	CLOTRIMAZOLE 1 %		NA	NA
8/17/2017	NO	02 - 0900	HYDROCORTISONE 1 %		Med not available/ will re-fax order	NA
8/17/2017	NO	02 - 0900	XIFAXAN 550 MG TAB 550		Med not available/ will re-fax order	NA
8/17/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/17/2017	KOP	02 - 0900	PROCTOSOL 2.5%		NA	NA
8/17/2017	YES	05 - 2100	SERTRALINE HCL 100 MG TAB 100		NA	NA
8/17/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG		NA	NA
8/17/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/17/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/17/2017	KOP	05 - 2100	CLOTRIMAZOLE 1 %		NA	NA
8/17/2017	YES	05 - 2100	HYDROCORTISONE 1 %		NA	NA
8/17/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA	NA
8/17/2017	NO	05 - 2100	XIFAXAN 550 MG TAB 550		Med not available/ will re-fax order	NA
8/17/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/17/2017	KOP	05 - 2100	PROCTOSOL 2.5%		NA	NA
8/18/2017	YES	02 - 0900	FOLIC ACID 1 MG		NA	NA
8/18/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG		NA	NA
8/18/2017	YES	02 - 0900	MULTIVITAMIN		NA	NA
8/18/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20		NA	NA
8/18/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/18/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/18/2017	KOP	02 - 0900	CLOTRIMAZOLE 1 %		NA	NA
8/18/2017	NO	02 - 0900	HYDROCORTISONE 1 %		Med not available/Pharmacy notified via fax	NA
8/18/2017	NO	02 - 0900	XIFAXAN 550 MG TAB 550		Med not available/Pharmacy notified via fax	NA
8/18/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/18/2017	KOP	02 - 0900	PROCTOSOL 2.5%		NA	NA
8/18/2017	YES	05 - 2100	SERTRALINE HCL 100 MG TAB 100		NA	NA
8/18/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG		NA	NA

8/18/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10	(b)(6); (b)(7)(C)	NA	NA
8/18/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/18/2017	KOP	05 - 2100	CLOTRIMAZOLE 1 %		NA	NA
8/18/2017	KOP	05 - 2100	HYDROCORTISONE 1 %		NA	NA
8/18/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA	NA
8/18/2017	NO	05 - 2100	XIFAXAN 550 MG TAB 550		Med not available/Pharmacy notified via fax	NA
8/18/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/18/2017	KOP	05 - 2100	PROCTOSOL 2.5%		NA	NA
8/19/2017	YES	02 - 0900	FOLIC ACID 1 MG		NA	NA
8/19/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG		NA	NA
8/19/2017	YES	02 - 0900	MULTIVITAMIN		NA	NA
8/19/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20		NA	NA
8/19/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/19/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/19/2017	NO	02 - 0900	XIFAXAN 550 MG TAB 550		Med not available/Pharmacy notified via fax	NA
8/19/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/19/2017	KOP	02 - 0900	PROCTOSOL 2.5%		NA	NA
8/19/2017	YES	05 - 2100	SERTRALINE HCL 100 MG TAB 100		NA	NA
8/19/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG		NA	NA
8/19/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/19/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/19/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA	NA
8/19/2017	NO	05 - 2100	XIFAXAN 550 MG TAB 550		Med not available/Pharmacy notified via fax	NA
8/19/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/19/2017	KOP	05 - 2100	PROCTOSOL 2.5%		NA	NA
8/20/2017	YES	02 - 0900	FOLIC ACID 1 MG		NA	NA
8/20/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG		NA	NA
8/20/2017	YES	02 - 0900	MULTIVITAMIN		NA	NA
8/20/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20		NA	NA
8/20/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/20/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/20/2017	YES	02 - 0900	XIFAXAN 550 MG TAB 550		NA	NA
8/20/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/20/2017	KOP	02 - 0900	PROCTOSOL 2.5%		NA	NA
8/20/2017	YES	05 - 2100	SERTRALINE HCL 100 MG TAB 100		NA	NA
8/20/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG		NA	NA
8/20/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/20/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/20/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA	NA
8/20/2017	YES	05 - 2100	XIFAXAN 550 MG TAB 550		NA	NA
8/20/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/20/2017	KOP	05 - 2100	PROCTOSOL 2.5%		NA	NA
8/21/2017	NO	02 - 0900	FOLIC ACID 1 MG		Med not available/Pharmacy notified via fax	NA
8/21/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG		NA	NA
8/21/2017	YES	02 - 0900	MULTIVITAMIN		NA	NA
8/21/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20		NA	NA
8/21/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/21/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/21/2017	NO	02 - 0900	XIFAXAN 550 MG TAB 550		Med not available/Pharmacy notified via fax	NA
8/21/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/21/2017	KOP	02 - 0900	PROCTOSOL 2.5%		NA	NA
8/21/2017	YES	05 - 2100	SERTRALINE HCL 100 MG TAB 100		NA	NA
8/21/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG		NA	NA
8/21/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/21/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/21/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA	NA
8/21/2017	YES	05 - 2100	XIFAXAN 550 MG TAB 550		NA	NA
8/21/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/21/2017	KOP	05 - 2100	PROCTOSOL 2.5%		NA	NA
8/22/2017	NO	01 - 0430 BS	Labs - Send Out		Unable	NA
8/22/2017	YES	02 - 0900	FOLIC ACID 1 MG		NA	NA
8/22/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG		NA	NA
8/22/2017	YES	02 - 0900	MULTIVITAMIN		NA	NA
8/22/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20		NA	NA
8/22/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/22/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/22/2017	YES	02 - 0900	XIFAXAN 550 MG TAB 550		NA	NA
8/22/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/22/2017	KOP	02 - 0900	PROCTOSOL 2.5%		NA	NA
8/22/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG		NA	NA
8/22/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/22/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/22/2017	YES	05 - 2100	XIFAXAN 550 MG TAB 550		NA	NA

8/22/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1	(b)(6); (b)(7)(C)	NA	NA
8/22/2017	KOP	05 - 2100	PROCTOSOL 2.5%		NA	NA
8/22/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA	NA
8/22/2017	YES	05 - 2100	TRAZODONE HCL 50 MG		NA	NA
8/23/2017	YES	02 - 0900	FOLIC ACID 1 MG		NA	NA
8/23/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG		NA	NA
8/23/2017	YES	02 - 0900	MULTIVITAMIN		NA	NA
8/23/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20		NA	NA
8/23/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/23/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/23/2017	YES	02 - 0900	XIFAXAN 550 MG TAB 550		NA	NA
8/23/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/23/2017	KOP	02 - 0900	PROCTOSOL 2.5%		NA	NA
8/23/2017	YES	02 - 0900	SERTRALINE HCL 100 MG TAB 100		NA	NA
8/23/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG		NA	NA
8/23/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/23/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/23/2017	YES	05 - 2100	XIFAXAN 550 MG TAB 550		NA	NA
8/23/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/23/2017	KOP	05 - 2100	PROCTOSOL 2.5%		NA	NA
8/23/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA	NA
8/23/2017	YES	05 - 2100	TRAZODONE HCL 50 MG		NA	NA
8/24/2017	YES	01 - 0430 BS	Labs - Send Out		NA	NA
8/24/2017	YES	02 - 0900	FOLIC ACID 1 MG		NA	NA
8/24/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG		NA	NA
8/24/2017	YES	02 - 0900	MULTIVITAMIN		NA	NA
8/24/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20		NA	NA
8/24/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/24/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/24/2017	YES	02 - 0900	XIFAXAN 550 MG TAB 550		NA	NA
8/24/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/24/2017	KOP	02 - 0900	PROCTOSOL 2.5%		NA	NA
8/24/2017	YES	02 - 0900	SERTRALINE HCL 100 MG TAB 100		NA	NA
8/24/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG		NA	NA
8/24/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/24/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/24/2017	YES	05 - 2100	XIFAXAN 550 MG TAB 550		NA	NA
8/24/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/24/2017	KOP	05 - 2100	PROCTOSOL 2.5%		NA	NA
8/24/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA	NA
8/24/2017	YES	05 - 2100	TRAZODONE HCL 50 MG		NA	NA
8/24/2017	YES	05 - 2100	IBUPROFEN 200 MG		NA	NA
8/25/2017	YES	02 - 0900	FOLIC ACID 1 MG		NA	NA
8/25/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG		NA	NA
8/25/2017	YES	02 - 0900	MULTIVITAMIN		NA	NA
8/25/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20		NA	NA
8/25/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/25/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/25/2017	YES	02 - 0900	XIFAXAN 550 MG TAB 550		NA	NA
8/25/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/25/2017	KOP	02 - 0900	PROCTOSOL 2.5%		NA	NA
8/25/2017	YES	02 - 0900	SERTRALINE HCL 100 MG TAB 100		NA	NA
8/25/2017	YES	02 - 0900	IBUPROFEN 200 MG		NA	NA
8/25/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG		NA	NA
8/25/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/25/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/25/2017	YES	05 - 2100	XIFAXAN 550 MG TAB 550		NA	NA
8/25/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/25/2017	KOP	05 - 2100	PROCTOSOL 2.5%		NA	NA
8/25/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA	NA
8/25/2017	YES	05 - 2100	TRAZODONE HCL 50 MG		NA	NA
8/25/2017	YES	05 - 2100	IBUPROFEN 200 MG		NA	NA
8/26/2017	YES	02 - 0900	FOLIC ACID 1 MG		NA	NA
8/26/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG		NA	NA
8/26/2017	YES	02 - 0900	MULTIVITAMIN		NA	NA
8/26/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20		NA	NA
8/26/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/26/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/26/2017	YES	02 - 0900	XIFAXAN 550 MG TAB 550		NA	NA
8/26/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/26/2017	KOP	02 - 0900	PROCTOSOL 2.5%		NA	NA
8/26/2017	YES	02 - 0900	SERTRALINE HCL 100 MG TAB 100		NA	NA
8/26/2017	YES	02 - 0900	IBUPROFEN 200 MG		NA	NA

8/26/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG	(b)(6); (b)(7)(C)	NA
8/26/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10		NA
8/26/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA
8/26/2017	YES	05 - 2100	XIFAXAN 550 MG TAB 550		NA
8/26/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		NA
8/26/2017	KOP	05 - 2100	PROCTOSOL 2.5%		NA
8/26/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA
8/26/2017	YES	05 - 2100	TRAZODONE HCL 50 MG		NA
8/26/2017	YES	05 - 2100	IBUPROFEN 200 MG		NA
8/27/2017	YES	02 - 0900	FOLIC ACID 1 MG		NA
8/27/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG		NA
8/27/2017	YES	02 - 0900	MULTIVITAMIN		NA
8/27/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20		NA
8/27/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		NA
8/27/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25		NA
8/27/2017	YES	02 - 0900	XIFAXAN 550 MG TAB 550		NA
8/27/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		NA
8/27/2017	KOP	02 - 0900	PROCTOSOL 2.5%		NA
8/27/2017	YES	02 - 0900	SERTRALINE HCL 100 MG TAB 100		NA
8/27/2017	YES	02 - 0900	IBUPROFEN 200 MG		NA
8/27/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG		NA
8/27/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10		NA
8/27/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA
8/27/2017	YES	05 - 2100	XIFAXAN 550 MG TAB 550		NA
8/27/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		NA
8/27/2017	KOP	05 - 2100	PROCTOSOL 2.5%		NA
8/27/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA
8/27/2017	YES	05 - 2100	TRAZODONE HCL 50 MG		NA
8/27/2017	YES	05 - 2100	IBUPROFEN 200 MG		NA
8/28/2017	YES	02 - 0900	FOLIC ACID 1 MG		NA
8/28/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG		NA
8/28/2017	YES	02 - 0900	MULTIVITAMIN		NA
8/28/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20		NA
8/28/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		NA
8/28/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25		NA
8/28/2017	YES	02 - 0900	XIFAXAN 550 MG TAB 550		NA
8/28/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		NA
8/28/2017	KOP	02 - 0900	PROCTOSOL 2.5%		NA
8/28/2017	YES	02 - 0900	SERTRALINE HCL 100 MG TAB 100		NA
8/28/2017	YES	02 - 0900	IBUPROFEN 200 MG		NA
8/28/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG		NA
8/28/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10		NA
8/28/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA
8/28/2017	YES	05 - 2100	XIFAXAN 550 MG TAB 550		NA
8/28/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		NA
8/28/2017	KOP	05 - 2100	PROCTOSOL 2.5%		NA
8/28/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA
8/28/2017	YES	05 - 2100	TRAZODONE HCL 50 MG		NA
8/28/2017	YES	05 - 2100	IBUPROFEN 200 MG		NA
8/29/2017	YES	02 - 0900	FOLIC ACID 1 MG		NA
8/29/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG		NA
8/29/2017	YES	02 - 0900	MULTIVITAMIN		NA
8/29/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20		NA
8/29/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		NA
8/29/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25		NA
8/29/2017	YES	02 - 0900	XIFAXAN 550 MG TAB 550		NA
8/29/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		NA
8/29/2017	KOP	02 - 0900	PROCTOSOL 2.5%		NA
8/29/2017	YES	02 - 0900	SERTRALINE HCL 100 MG TAB 100		NA
8/29/2017	YES	02 - 0900	IBUPROFEN 200 MG		NA
8/29/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG		NA
8/29/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10		NA
8/29/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA
8/29/2017	YES	05 - 2100	XIFAXAN 550 MG TAB 550		NA
8/29/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		NA
8/29/2017	KOP	05 - 2100	PROCTOSOL 2.5%		NA
8/29/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA
8/29/2017	YES	05 - 2100	TRAZODONE HCL 50 MG		NA
8/30/2017	YES	02 - 0900	FOLIC ACID 1 MG		NA
8/30/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG		NA
8/30/2017	YES	02 - 0900	MULTIVITAMIN		NA
8/30/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20		NA
8/30/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		NA

8/30/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25	(b)(6); (b)(7)(C)	NA	NA
8/30/2017	YES	02 - 0900	XIFAXAN 550 MG TAB 550		NA	NA
8/30/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/30/2017	KOP	02 - 0900	PROCTOSOL 2.5%		NA	NA
8/30/2017	YES	02 - 0900	SERTRALINE HCL 100 MG TAB 100		NA	NA
8/30/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG		NA	NA
8/30/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/30/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/30/2017	YES	05 - 2100	XIFAXAN 550 MG TAB 550		NA	NA
8/30/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/30/2017	KOP	05 - 2100	PROCTOSOL 2.5%		NA	NA
8/30/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA	NA
8/30/2017	YES	05 - 2100	TRAZODONE HCL 50 MG		NA	NA
8/31/2017	YES	02 - 0900	FOLIC ACID 1 MG		NA	NA
8/31/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG		NA	NA
8/31/2017	YES	02 - 0900	MULTIVITAMIN		NA	NA
8/31/2017	YES	02 - 0900	OMEPRazole DR 20 MG CAPSULE 20		NA	NA
8/31/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/31/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/31/2017	YES	02 - 0900	XIFAXAN 550 MG TAB 550		NA	NA
8/31/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/31/2017	KOP	02 - 0900	PROCTOSOL 2.5%		NA	NA
8/31/2017	YES	02 - 0900	SERTRALINE HCL 100 MG TAB 100		NA	NA
8/31/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG		NA	NA
8/31/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA
8/31/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA	NA
8/31/2017	YES	05 - 2100	XIFAXAN 550 MG TAB 550		NA	NA
8/31/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA
8/31/2017	KOP	05 - 2100	PROCTOSOL 2.5%		NA	NA
8/31/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA	NA
8/31/2017	YES	05 - 2100	TRAZODONE HCL 50 MG		NA	NA

No Photo Available

ALMAZAN RUIZ, FELIPE, #GCSO17MNI005042 @ RELEASE

Male, 51 years old, DOB 6/26/1966

Allergies: NKDA

Diagnoses: CIRRHOSIS OF LIVER WITHOUT ALCOHOL, DEPRESSION, GENERALIZED ANXIETY DISORDER

2017-09	01 Fri	02 Sat	03 Sun	04 Mon	05 Tue	06 Wed	07 Thu	08 Fri	09 Sat	10 Sun	11 Mon	12 Tu
01 - 0430 BS CBC												
01 - 0430 BS Labs - Send Out			(b)(6); (b)(7)(C)									
01 - 0430 BS Labs - Send Out												
01 - 0430 BS Labs - Send Out												
02 - 0900 DOCUSATE SODIUM 100 MG Take 1 Capsule by mouth 2 times per day for 30 days as needed Req Start: 8/12/2017 Req End: 9/10/2017 Discontinued: 9/7/2017	YES	YES	YES	YES	YES	YES	MISSED					
	(b)(6); (b)(7)(C)											
02 - 0900 FERROUS SULFATE 325MG; 1 time per day for 90 days Req Start: 9/7/2017 Req End: 12/5/2017 Discontinued: 9/7/2017												
02 - 0900 FOLIC ACID 1 MG TABLET 1 Take 1 Tablet by mouth 1 time per day for 90 days Req Start: 9/7/2017 Req End: 12/5/2017 Discontinued: 9/7/2017												
02 - 0900 FOLIC ACID 1 MG Take 1 Tablet by mouth 1 time per day for 30 days Req Start: 8/12/2017 Req End: 9/10/2017 Discontinued: 9/6/2017	YES	YES	YES	YES	YES	YES						
	(b)(6); (b)(7)(C)											
02 - 0900 LACTULOSE 10 GM/15 ML SOLN 10 40ml p o daily x 90 days Req Start: 9/7/2017 Req End: 10/7/2017 Discontinued: 9/7/2017												
02 - 0900 LACTULOSE 10 GM/15 ML SOLN 10 SOLN by mouth 2 times per day for 30 days as needed Req Start: 8/12/2017 Req End: 9/10/2017 Discontinued: 9/6/2017	YES	YES	YES	YES	YES	YES						
	(b)(6); (b)(7)(C)											
02 - 0900 MULTIVITAMIN Take 1 Tablet by mouth 1 time per day for 30 days Req Start: 8/12/2017 Req End: 9/10/2017 Discontinued: 9/6/2017	YES	YES	YES	YES	YES	YES						
	(b)(6); (b)(7)(C)											
02 - 0900 MULTIVITAMIN Take 1 Tablet by mouth 1 time per day for 90 days Req Start: 9/7/2017 Req End: 12/5/2017 Discontinued: 9/7/2017												
02 - 0900 OMEPRAZOLE 40 MG CPDR 40 Take 1 Capsule by mouth 1 time per day for 90 days Req Start:												

day for 3 days Req Start: 9/7/2017 Req End: 9/9/2017 Discontinued: 9/7/2017														
02 - 0900 PROCTOSOL 2.5% Apply 1 Cream topical 2 times per day for 30 days Req Start: 8/14/2017 Req End: 9/13/2017 Discontinued: 9/7/2017	KOP (b)(6); (b)(7)(C)	KOP	KOP	KOP	KOP	KOP	KOP	REVOKED (AUTO LABS) Released	REVOKED (AUTO LABS) Released	REVOKED (AUTO LABS) Released	REVOKED (AUTO LABS) Released	REVOKED (AUTO LABS) Released	REVOKED (AUTO LABS) Released	REVOKED (AUTO LABS) Released
02 - 0900 SERTRALINE HCL 100 MG TAB 100 Take 1 Tablet by mouth 1 times per day for 60 days Req Start: 8/23/2017 Req End: 10/21/2017 Discontinued: 9/7/2017	YES (b)(6); (b)(7)(C)	YES	YES	YES	YES	YES	YES							
02 - 0900 SPIRONOLACTONE 25 MG TABLET 25 Take 1 Tablet by mouth 2 times per day for 30 days Req Start: 8/12/2017 Req End: 9/10/2017 Discontinued: 9/6/2017	YES (b)(6); (b)(7)(C)	YES	YES	YES	YES	YES	YES							
02 - 0900 SPIRONOLACTONE 25 MG TABLET 25 Take 1 Tablet by mouth 2 times per day for 90 days Req Start: 9/6/2017 Req End: 12/5/2017 Discontinued: 9/7/2017														
02 - 0900 TRIAMCINOLONE 0.1% CREAM 0.1 CRM 2 times per day for 60 days Req Start: 8/14/2017 Req End: 10/13/2017 Discontinued: 9/7/2017	KOP (b)(6); (b)(7)(C)	KOP (b)(6); (b)(7)(C)	KOP (b)(6); (b)(7)(C)	KOP (b)(6); (b)(7)(C)	KOP	KOP	KOP	REVOKED (AUTO LABS) Released	REVOKED (AUTO LABS) Released	REVOKED (AUTO LABS) Released	REVOKED (AUTO LABS) Released	REVOKED (AUTO LABS) Released	REVOKED (AUTO LABS) Released	REVOKED (AUTO LABS) Released
02 - 0900 XIFAXAN 550 MG TAB 550 Take 1 Tablet by mouth 2 times per day for 30 days Req Start: 8/12/2017 Req End: 9/10/2017 Discontinued: 9/6/2017	YES (b)(6); (b)(7)(C)	YES	YES	YES	YES	YES	YES							
02 - 0900 XIFAXAN 550 MG TAB 550 Take 1 Tablet by mouth 2 times per day for 30 days Req Start: 9/6/2017 Req End: 10/6/2017 Discontinued: 9/7/2017														
05 - 2100 DOXUSATE SODIUM 100 MG Take 1 Capsule by mouth 2 times per day for 30 days as needed Req Start 8/12/2017 Req End: 9/10/2017 Discontinued: 9/7/2017	YES (b)(6); (b)(7)(C)	YES	YES	YES	YES	YES	YES							
05 - 2100 LACTULOSE 10 GM/15 ML SOLN 10 40ml p o daily x 90 days Req Start: 9/7/2017 Req End: 10/7/2017 Discontinued: 9/7/2017														
05 - 2100 LACTULOSE 10 GM/15 ML SOLN 10 SOLN by mouth 2 times per day for 30 days as needed Req Start: 8/12/2017 Req End: 9/10/2017	NO (b)(6); (b)(7)(C)	NO	NO	NO	NO	NO	NO							

9/1/2017	KOP	02 - 0900	PROCTOSOL 2.5%	TFALHE	NA	NA
9/1/2017	YES	02 - 0900	SERTRALINE HCL 100 MG TAB 100	KHUGHES	NA	NA
9/1/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG	I.MONTOYA	NA	NA
9/1/2017	NO	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10	LMONTOYA	NOT NEEDED	NA
9/1/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25	I.MONTOYA	NA	NA
9/1/2017	YES	05 - 2100	XIFAXAN 550 MG TAB 550	I.MONTOYA	NA	NA
9/1/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1	FSAPP	NA	NA
9/1/2017	KOP	05 - 2100	PROCTOSOL 2.5%	TFALHE	NA	NA
9/1/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50	LMONTOYA	NA	NA
9/1/2017	YES	05 - 2100	TRAZODONE HCL 50 MG	LMONTOYA	NA	NA
9/10/2017	REVOKED	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1	AUTO LABS	Released	NA
9/10/2017	REVOKED	02 - 0900	PROCTOSOL 2.5%	AUTO LABS	Released	NA
9/10/2017	REVOKED	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1	AUTO LABS	Released	NA
9/10/2017	REVOKED	05 - 2100	PROCTOSOL 2.5%	AUTO LABS	Released	NA
9/11/2017	REVOKED	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1	AUTO LABS	Released	NA
9/11/2017	REVOKED	02 - 0900	PROCTOSOL 2.5%	AUTO LABS	Released	NA
9/11/2017	REVOKED	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1	AUTO LABS	Released	NA
9/11/2017	REVOKED	05 - 2100	PROCTOSOL 2.5%	AUTO LABS	Released	NA
9/12/2017	REVOKED	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1	AUTO LABS	Released	NA
9/12/2017	REVOKED	02 - 0900	PROCTOSOL 2.5%	AUTO LABS	Released	NA
9/12/2017	REVOKED	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1	AUTO LABS	Released	NA
9/12/2017	REVOKED	05 - 2100	PROCTOSOL 2.5%	AUTO LABS	Released	NA
9/13/2017	REVOKED	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1	AUTO LABS	Released	NA
9/13/2017	REVOKED	02 - 0900	PROCTOSOL 2.5%	AUTO LABS	Released	NA
9/13/2017	REVOKED	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1	AUTO LABS	Released	NA
9/14/2017	REVOKED	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1	AUTO LABS	Released	NA
9/2/2017	YES	02 - 0900	FOLIC ACID 1 MG	(b)(6); (b)(7)(C)	NA	NA
9/2/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG	(b)(6); (b)(7)(C)	NA	NA
9/2/2017	YES	02 - 0900	MULTIVITAMIN	(b)(6); (b)(7)(C)	NA	NA
9/2/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20	(b)(6); (b)(7)(C)	NA	NA
9/2/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10	(b)(6); (b)(7)(C)	NA	NA
9/2/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25	(b)(6); (b)(7)(C)	NA	NA
9/2/2017	YES	02 - 0900	XIFAXAN 550 MG TAB 550	(b)(6); (b)(7)(C)	NA	NA
9/2/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1	(b)(6); (b)(7)(C)	NA	NA
9/2/2017	KOP	02 - 0900	PROCTOSOL 2.5%	(b)(6); (b)(7)(C)	NA	NA
9/2/2017	YES	02 - 0900	SERTRALINE HCL 100 MG TAB 100	(b)(6); (b)(7)(C)	NA	NA
9/2/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG	(b)(6); (b)(7)(C)	NA	NA
9/2/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10	(b)(6); (b)(7)(C)	NA	NA
9/2/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25	(b)(6); (b)(7)(C)	NA	NA
9/2/2017	YES	05 - 2100	XIFAXAN 550 MG TAB 550	(b)(6); (b)(7)(C)	NA	NA
9/2/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1	(b)(6); (b)(7)(C)	NA	NA
9/2/2017	KOP	05 - 2100	PROCTOSOL 2.5%	(b)(6); (b)(7)(C)	NA	NA
9/2/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50	(b)(6); (b)(7)(C)	NA	NA
9/2/2017	YES	05 - 2100	TRAZODONE HCL 50 MG	(b)(6); (b)(7)(C)	NA	NA
9/3/2017	YES	01 - 0450 BS	Labs - Send Out	(b)(6); (b)(7)(C)	NA	NA
9/3/2017	YES	02 - 0900	FOLIC ACID 1 MG	(b)(6); (b)(7)(C)	NA	NA
9/3/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG	(b)(6); (b)(7)(C)	NA	NA
9/3/2017	YES	02 - 0900	MULTIVITAMIN	(b)(6); (b)(7)(C)	NA	NA
9/3/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20	(b)(6); (b)(7)(C)	NA	NA
9/3/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10	(b)(6); (b)(7)(C)	NA	NA
9/3/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25	(b)(6); (b)(7)(C)	NA	NA
9/3/2017	YES	02 - 0900	XIFAXAN 550 MG TAB 550	(b)(6); (b)(7)(C)	NA	NA
9/3/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1	(b)(6); (b)(7)(C)	NA	NA
9/3/2017	KOP	02 - 0900	PROCTOSOL 2.5%	(b)(6); (b)(7)(C)	NA	NA
9/3/2017	YES	02 - 0900	SERTRALINE HCL 100 MG TAB 100	(b)(6); (b)(7)(C)	NA	NA
9/3/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG	(b)(6); (b)(7)(C)	NA	NA
9/3/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10	(b)(6); (b)(7)(C)	NA	NA
9/3/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25	(b)(6); (b)(7)(C)	NA	NA
9/3/2017	YES	05 - 2100	XIFAXAN 550 MG TAB 550	(b)(6); (b)(7)(C)	NA	NA
9/3/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1	(b)(6); (b)(7)(C)	NA	NA
9/3/2017	KOP	05 - 2100	PROCTOSOL 2.5%	(b)(6); (b)(7)(C)	NA	NA
9/3/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50	(b)(6); (b)(7)(C)	NA	NA
9/3/2017	YES	05 - 2100	TRAZODONE HCL 50 MG	(b)(6); (b)(7)(C)	NA	NA
9/4/2017	YES	02 - 0900	FOLIC ACID 1 MG	(b)(6); (b)(7)(C)	NA	NA
9/4/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG	(b)(6); (b)(7)(C)	NA	NA
9/4/2017	YES	02 - 0900	MULTIVITAMIN	(b)(6); (b)(7)(C)	NA	NA
9/4/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20	(b)(6); (b)(7)(C)	NA	NA
9/4/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10	(b)(6); (b)(7)(C)	NA	NA
9/4/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25	(b)(6); (b)(7)(C)	NA	NA
9/4/2017	YES	02 - 0900	XIFAXAN 550 MG TAB 550	(b)(6); (b)(7)(C)	NA	NA
9/4/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1	(b)(6); (b)(7)(C)	NA	NA
9/4/2017	KOP	02 - 0900	PROCTOSOL 2.5%	(b)(6); (b)(7)(C)	NA	NA
9/4/2017	YES	02 - 0900	SERTRALINE HCL 100 MG TAB 100	(b)(6); (b)(7)(C)	NA	NA

9/4/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG	(b)(6); (b)(7)(C)	NA	NA	
9/4/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA	
9/4/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA	NA	
9/4/2017	YES	05 - 2100	XIFAXAN 550 MG TAB 550		NA	NA	
9/4/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA	
9/4/2017	KOP	05 - 2100	PROCTOSOL 2.5%		NA	NA	
9/4/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA	NA	
9/4/2017	YES	05 - 2100	TRAZODONE HCL 50 MG		NA	NA	
9/5/2017	YES	02 - 0900	FOLIC ACID 1 MG		NA	NA	
9/5/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG		NA	NA	
9/5/2017	YES	02 - 0900	MULTIVITAMIN		NA	NA	
9/5/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20		NA	NA	
9/5/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA	
9/5/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25		NA	NA	
9/5/2017	YES	02 - 0900	XIFAXAN 550 MG TAB 550		NA	NA	
9/5/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA	
9/5/2017	KOP	02 - 0900	PROCTOSOL 2.5%		NA	NA	
9/5/2017	YES	02 - 0900	SERTRALINE HCL 100 MG TAB 100		NA	NA	
9/5/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG		NA	NA	
9/5/2017	YES	05 - 2100	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA	
9/5/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA	NA	
9/5/2017	YES	05 - 2100	XIFAXAN 550 MG TAB 550		NA	NA	
9/5/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA	
9/5/2017	KOP	05 - 2100	PROCTOSOL 2.5%		NA	NA	
9/5/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA	NA	
9/5/2017	YES	05 - 2100	TRAZODONE HCL 50 MG		NA	NA	
9/6/2017	YES	02 - 0900	FOLIC ACID 1 MG		NA	NA	
9/6/2017	YES	02 - 0900	DOCUSATE SODIUM 100 MG		NA	NA	
9/6/2017	YES	02 - 0900	MULTIVITAMIN		NA	NA	
9/6/2017	YES	02 - 0900	OMEPRAZOLE DR 20 MG CAPSULE 20		NA	NA	
9/6/2017	YES	02 - 0900	LACTULOSE 10 GM/15 ML SOLN 10		NA	NA	
9/6/2017	YES	02 - 0900	SPIRONOLACTONE 25 MG TABLET 25		NA	NA	
9/6/2017	YES	02 - 0900	XIFAXAN 550 MG TAB 550		NA	NA	
9/6/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA	
9/6/2017	KOP	02 - 0900	PROCTOSOL 2.5%		NA	NA	
9/6/2017	YES	02 - 0900	SERTRALINE HCL 100 MG TAB 100		NA	NA	
9/6/2017	YES	05 - 2100	DOCUSATE SODIUM 100 MG		NA	NA	
9/6/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA	
9/6/2017	KOP	05 - 2100	PROCTOSOL 2.5%		NA	NA	
9/6/2017	YES	05 - 2100	TRAZODONE 50 MG TABLET 50		NA	NA	
9/6/2017	YES	05 - 2100	TRAZODONE HCL 50 MG		NA	NA	
9/6/2017	YES	05 - 2100	SPIRONOLACTONE 25 MG TABLET 25		NA	NA	
9/6/2017	YES	05 - 2100	XIFAXAN 550 MG TAB 550		NA	NA	
9/7/2017	MISSFD	02 - 0900	DOCUSATE SODIUM 100 MG		NA	NA	
9/7/2017	KOP	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA	
9/7/2017	KOP	02 - 0900	PROCTOSOL 2.5%		NA	NA	
9/7/2017	KOP	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		NA	NA	
9/7/2017	KOP	05 - 2100	PROCTOSOL 2.5%		NA	NA	
9/8/2017	REVOKED	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		AUTO LABS	Released	NA
9/8/2017	REVOKED	02 - 0900	PROCTOSOL 2.5%		AUTO LABS	Released	NA
9/8/2017	REVOKED	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		AUTO LABS	Released	NA
9/8/2017	REVOKED	05 - 2100	PROCTOSOL 2.5%		AUTO LABS	Released	NA
9/9/2017	REVOKED	02 - 0900	TRIAMCINOLONE 0.1% CREAM 0.1		AUTO LABS	Released	NA
9/9/2017	REVOKED	02 - 0900	PROCTOSOL 2.5%		AUTO LABS	Released	NA
9/9/2017	REVOKED	05 - 2100	TRIAMCINOLONE 0.1% CREAM 0.1		AUTO LABS	Released	NA
9/9/2017	REVOKED	05 - 2100	PROCTOSOL 2.5%		AUTO LABS	Released	NA

9/20/2017 4:42:57 PM

ALMAZAN RUIZ, FELIPE

Current Problems as of 9/20/2017 4:42:53 PM:

Problem	Code	Start
---------	------	-------

CIRRHOSIS OF LIVER WITHOUT ALCOHOL	571.5	08-14-2017
DEPRESSION 311	08-14-2017	
GENERALIZED ANXIETY DISORDER	300.02	08-14-2017

9/20/2017 4:43:00 PM

ALMAZAN RUIZ, FELIPE

Current Medications as of 9/20/2017 4:42:58 PM:

Drug	Strength	Start
FOLIC ACID	1 MG	9/11/2017 12:00:00 AM
OMEPRAZOLE	40 MG	9/11/2017 12:00:00 AM
SPIRONOLACTONE	25 MG	9/11/2017 12:00:00 AM



U.S. Immigration and Customs Enforcement

ALMAZAN RUIZ, FELIPE DIONISIO

A: 028866428 (b)(6); (b)(7)(C); (b)(7)(E)
Facility Code: KRO Housing Area: P6-34
51 Y old Male, DOB: 06/26/1966
Account Number: 1000613977
18201 S.W. 12TH ST., MIAMI, FL-33194
Appointment Facility: Krome North Service Processing Center

08/11/2017

Appointment Provider: (b)(6); (b)(7)(C)

Reason for Appointment

1. Transfer Summary

History of Present Illness

Transfer Summary:

Alien

Cleared for travel? Yes

Date of departure 08/11/2017

Reason for transfer Custody

Final Destination, if known Glades

TB Clearance

TB Screening Modality: CXR

CXR Date 07/12/2017

CXR Results TB Screening: Negative; not consistent with TB

Is the detainee/resident being treated for active TB Disease? No

Special Needs Affecting Transportation

Is there any medical / dental / or mental health reasons for restricting the length of time alien can be on travel status?

No

Are there any restriction or special equipment required for travel? No

Is a medical escort required? No

Are any transmission-based precautions required during transport? No

Additional Comments

Additional Comments None

Current Medications

Taking

- Sertraline HCl 100 MG Tablet 1 tablet QHS, stop date 10/17/2017, KOP: No, Drug Source: In House Pharmacy
Rifaximin 550 MG Tablet 1 tablet BID, stop date 12/02/2017, KOP: No, Drug Source: In House Pharmacy, Notes: Required for travel
Folic Acid 1 MG Tablet 1 tablet Daily AM, stop date 12/02/2017, KOP: No, Drug Source: In House Pharmacy, Notes: Required for travel
Docusate Sodium 100 MG Capsule 1 capsule with a full glasses as needed BID, stop date 11/02/2017, KOP: No, Drug Source: In House Pharmacy, Notes: Required for travel
Multivitamin - Tablet 1 tablet Daily AM, stop date 12/02/2017, KOP: No, Drug Source: In House Pharmacy, Notes: Required for travel
Omeprazole 20mg Capsule 1 tablet Daily AM, stop date 12/02/2017, KOP: No, Drug Source: In House Pharmacy, Notes: Required for travel
Lactulose 10GM/15ML Solution 15 ml prn BID, stop date 11/07/2017, KOP: No, Drug Source: In House Pharmacy
Spironolactone 25 MG Tablet 1 tablet BID, stop date 11/07/2017, KOP: No, Drug Source: In House Pharmacy
Aluminum-Magnesium-Simethicone 400mg/400mg/40mg/5ml Suspension 10 ml prn QID, stop date 08/16/2017, KOP: Yes, Drug Source: Stock, Notes: Not required for travel
Clotrimazole 1 % Cream 1 application to affected area BID, stop date 08/16/2017, KOP: Yes, Drug Source: Stock, Notes: Not required for travel

Patient: ALMAZAN RUIZ, FELIPE DIONISIO DOB: 06/26/1966 Progress Note RN 08/11/2017

(b)(6); (b)(7)(C)

Note generated by eClinicalWorks EMR/PM Software (www.eClinicalWorks.com)

(b)(7)(E)

8/11/2017

(b)(6);
(b)(7)(C)

Hydrocortisone 1 % Cream 1 application to affected area BID, stop date 08/16/2017, KOP: Yes, Drug Source: Stock,
tes: Not required for travel
Trazodone HCl 50 MG Tablet 1 tablet QHS, stop date 11/09/2017, KOP: No, Drug Source: In House Pharmacy

Past Medical History

Cirrhosis x 8 years

Allergies

N.K.D.A.

Disposition: Medically cleared for custody

Appointment Provider: (b)(6); (b)(7)(C) RN



Electronically signed by (b)(6); (b)(7)(C) RN, RN on 08/11/2017 16:23:26 (Eastern Daylight Time)
Sign off status: Completed

Krome North Service Processing Center
18201 S.W. 12TH ST.
MIAMI, FL 33194
Tel: 305-207-2170
Fax:

Patient: ALMAZAN RUIZ, FELIPE DIONISIO DOB: 06/26/1966 Progress Note (b)(6); (b)(7)(C)
RN 08/11/2017

Note generated by eClinicalWorks EMR/PM Software (www.eClinicalWorks.com)

(b)(7)(E)

8/11/2017

ALMAZAN RUIZ, FELIPE, 06-26-1966, #GCSO17MNI005042
09-06-2017 Encounter as of 09-20-2017 Wed 05:06:16 PM

Patient c/o visual disturbance
OS 20/200 OD 20/200 30 DAY CLINIC CIRRHOSIS
knee pain and joint pain CHRONIC CARE CLINIC:

Date/Time: 09-06-2017 Wed / 09:48

Patient Name: FELIPE ALMAZAN RUIZ
No: GCSO17MNI005042
DOB: 06-26-1966
Sex: Male
Location: 1*DORM 1*D*048 1*DORM 1*D*048

Clinic Membership:
571.5 CIRRHOSIS OF LIVER WITHOUT ALCOHOL
311 DEPRESSION
300.02 GENERALIZED ANXIETY DISORDER

PAST MEDICAL HISTORY:

51 years old male with history of liver cirrhosis, Gerd, possible portal hypertension, constipation here today for 30 days clinical evaluation , the patient disgnose 7 years ago and he's been on treatment since then

Duration of condition(s): 5-10 years

Prior hospitalization(s): No change since last visit
Complications: none

CURRENT MEDICATIONS:

DOCUSATE SODIUM 100 MG
FOLIC ACID 1 MG
LACTULOSE 10 GM/15 ML SOLN 10
MULTIVITAMIN
OMEPRAZOLE DR 20 MG CAPSULE 20
PROCTOSOL 2.5%
SERTRALINE HCL 100 MG TAB 100
SPIRONOLACTONE 25 MG TABLET 25
TRAZODONE 50 MG TABLET 50
TRIAMCINOLONE 0.1% CREAM 0.1
XIFAXAN 550 MG TAB 550

DATA REVIEW:

CMP

Sodium 141 Normal mmol/L 135-145 Final CL
Potassium 4.3 Normal mmol/L 3.5-5.5 Final CL
Chloride 104 Normal mmol/L 95-110 Final CL
Carbon Dioxide 26 Normal mmol/L 19-34 Final CL
Anion Gap 15.3 Normal mmol/L 10-20 Final CL
Glucose 86 Normal mg/dL 70-110 Final CL
Calcium 8.8 Normal mg/dL 8.4-10.2 Final CL
Protein, Total 6.9 Normal g/dL 5.5-8.7 Final CL
Albumin 3.6 Normal g/dL 3.2-5.0 Final CL
Bilirubin Total 1.7 Above Normal mg/dL 0.1-1.2 Final CL
Alkaline Phos 162 Above Normal U/L 20-130 Final CL
AST (SGOT) 35 Normal U/L 10-40 Final CL
ALT (SGPT) 25 Normal U/L 10-60 Final CL
Urea Nitrogen 17 Normal mg/dl 6-22 Final CL
Creatinine.. 0.70 Normal mg/dL 0.43-1.13 Final CL
eGFR NonAfrican Am > 60 Final CL
eGFR African Amer > 60 Final CL
eGFR less than 60 (ml/min/1.73) square meters

Lipids Profile

Triglycerides 45 Normal mg/dL 0-150 Final CL

Cholesterol 92 Normal mg/dL 0-200 Final CL

HDL 54 Normal mg/dL 0-60 Final CL

NON-HDL 38 mg/dl Final CL

Goals for Patients with CHD or CHD risk equivalents:

LDL: < 70 mg/dl

NON-HDL: < 100 mg/dl

Goals for Patients with 2+ risk factors:

LDL: < 130 mg/dl

NON-HDL: < 160 mg/dl

Goals for Patients with 0-1 risk

ALMAZAN RUIZ, FELIPE, 06-26-1966, #GCSO17MNI005042
09-06-2017 Encounter as of 09-20-2017 Wed 05:06:16 PM

factors:

LDL: <160 mg/dl
NON-HDL: <190 mg/dl
LDL Cholesterol 29 Normal mg/dL 0-130 Final CL
Chol/HDL Ratio 1.7 Normal 1.5-5.6 Final CL

H Pylori Ab IgG (THIS IS THE ONE DR. NOEL ORDERS)

H Pylori Ab IgG 0.70 Normal U/mL 0.00-0.90 Final CL
< or = 0.90 Negative
0.91-1.09 Equivocal
> or = 1.10 Positive

PSA Diagnostic

PSA Diagnostic 0.1 Normal ng/mL 0-4.0 Final CL

Prothrombin Time

PT Seconds 9.4-12.5 In Lab CL
Pro Time INR In Lab CL
Status Observation Date Performing Lab Performing MD
PTT
Activated PTT 41.6 Above Normal Seconds 25.1-36.5 Final CL
Therapeutic PTT range of 50-89 seconds

CBC

WBC 3.0 Below Normal 10³/uL 3.6-11.0 Final CL
RBC 3.65 Below Normal 10⁶/uL 4.50-5.90 Final CL
Hemoglobin 11.3 Below Normal g/dL 13.0-18.0 Final CL
Hematocrit 34.8 Below Normal % 40.0-52.0 Final CL
MCV 95.6 Normal fl 81.0-97.0 Final CL
MCH 31.0 Normal pg 26.0-34.0 Final CL
MCHC 32.4 Normal g/dL 31.0 - 37.0 Final CL
RDW 17.4 Above Normal % 11.5-15.0 Final CL
Platelet Count 41 Below Normal 10³/uL 150-400 Final CL
Mean Platelet Vol 9.6 Normal fl 7.4-10.4 Final CL
Neutrophil % 65.7 Normal % 36.0-66.0 Final CL
Lymphocyte % 25.2 Normal % 23.0-43.0 Final CL
Monocyte % 4.8 Normal % 0.0-10.0 Final CL
Eosinophil % 3.9 Normal % 0.0-5.0 Final CL
Basophil % 0.4 Normal % 0.0-1.0 Final CL
Neutrophil Abs# 2.0 Normal 10³/uL 1.6-8.2 Final CL
Lymphocyte Abs # 0.7 Below Normal 10³/uL 1.1-4.7 Final CL
Monocyte Abs # 0.1 Normal 10³/uL 0.0-1.1 Final CL
Eosinophil Abs # 0.1 Normal 10³/uL 0.0-0.5 Final CL
Basophil Abs # 0.0 Normal 10³/uL 0.0-0.4 Final CL

Ammonia

Ammonia 108 Above Normal umol/L 11-35 Final CL
Test Performed by: IRL - Florida
5361 NW 33 Avenue
Adherence
Ft Lauderdale, FL 33309

SUBJECTIVE:

the patient is complaining of abdominal pain radiating to the chest otherwise he's denies all others symptoms
Stability of condition(s): Stable
Issues with medication(s): None.
Other: none

OBJECTIVE:

T: 97.6 P: 80 R: 18 BP: 122 / 76 Weight: 170 lbs

GENERAL APPEARANCE:

Well-developed, well-nourished 51 year old w male in no acute distress.

HEAD:

Normocephalic. Atraumatic.

EYES:

PERRLA. EOMI. Sclera non-icteric.

ENT:

EAC's clear. TM's white and shiny. Nares patent. Oral mucosa pink and moist. Oropharynx clear.

NECK:

Supple with full range of motion. No tenderness or lymphadenopathy. No JVD or carotid bruits.

LUNGS:

Clear to auscultation. Respiratory effort

ALMAZAN RUIZ, FELIPE, 06-26-1966, #GCSO17MNI005042
09-06-2017 Encounter as of 09-20-2017 Wed 05:06:16 PM

non-labored.

HEART:

RRR. S1 S2 WNL.. No murmurs or rubs.

EXTREMITIES:

Pedal pulses are palpable and equal. No extremity edema.

ABDOMEN:

Positive bowel sounds. Non-tender. No hepatosplenomegaly. No masses. pain mid epigastric radiating to the chest

GU:

Deferred.

RECTAL:

Deferred.

MUSCULOSKELETAL:

Moves all extremities well. No deformities, cyanosis or clubbing. Gait steady.

SKIN:

Warm, dry, normal color. Turgor elastic.

NEUROLOGICAL:

No sensory or motor deficits. Deep tendon reflexes 2+ bilaterally.

PSYCHIATRIC:

Awake and alert. No depression, agitation or anxiety noted.

ASSESSMENT:

- 1===THROMBOCYTOPENIA
- 2===571.5 CIRRHOSIS OF LIVER WITHOUT ALCOHOL
- 3===311 DEPRESSION
- 4===300.02 GENERALIZED ANXIETY DISORDER
- 5===mild increase total bili and alpk
- 6===Normochromic anemia
- 7===Degree of Control - poor Status - Improved
- 8===Patient's adherence to treatment plan: poor
- 9===Patient's understanding of condition: GOOD

PLAN:

- 1===I will increase lactulose doses and will continue with the current meds cbc weekly the follow-up ,++ see below
prednisone 100 mg x3 days then 80 mg x 3 days then 60 mg po x 3 days then 50 mg x 3 days ' the 40 mg x 3 days then 30 mg x 3 days then
20 mg x 3 days the 10 mg x 2 days then 5 mg x 2 days the 2.5 mg x 2 days then d/c
- FERROUS SULFATE, 325MG #90, Sig: 1 time per day for 90 days
- 2====++++cbc weekly x 4 weeks++++
- 3====d/c dulcolax
- 4=====lactulose 40 ml po daily x 90 days =====
- 5===FOLIC ACID, 1 MG #90, Sig: Take 1 Tablet by mouth 1 time per day for 90 days
- 6===MULTIVITAMIN, #90, Sig: Take 1 Tablet by mouth 1 time per day for 90 days
- 7===SPIRONOLACTONE, 25 MG #180, Sig: Take 1 Tablet by mouth 2 times per day for 90 days
- 8===xifaxan 550 mg po bid x 90 days
- 9===Patient c/o visual disturbance
- 10===OS 20/200 OD 20/200
- 11===ammonia level Q2 WEEK X 8 WEEKS
- 12===Renal diet x 180 days
- 13===cbc cmp lipid panel in 82 days
- 14===follow-up in 90 days
- 15===OMEPRAZOLE, 40 MG #90, Sig: Take 1 Capsule by mouth 1 time per day for 90 days

EDUCATION

- Adherence
- Weight Loss
- Medications
- Disease Process
- Smoking Cessation
- Transmission prevention
- Exercise daily
- Care after release
- Diet renal diet
- Lab Results explained
- Adjustment to Incarceration
- Other Med compliances

Electronically Approved by (b)(6); (b)(7)(C) MD on 09-06-2017 10:23:31 AM.

ALMAZAN RUIZ, FELIPE, 06-26-1966, #GCSO17MNI005042
08-14-2017 Encounter as of 09-20-2017 Wed 05:07:24 PM

CIRRHOSIS CHRONIC CARE CLINIC - INITIAL:

Name: FELIPE ALMAZAN RUIZ DOB: 06-26-1966
ID: Location: 1*DORM 1*C*013 1*DORM 1*C*013
Race: W Sex: Male

Date: 08-14-2017 Mon

ALLERGIES:
NKDA

CLINICS:
51 years old male with history of liver cirrhosis, Gerd, possible portal hypertension, constipation here today for initial clinical evaluation, the patient diagnosed 7 years ago and he's been on treatment since then

PERSONAL RISK FACTORS:

Smoking: yes 2 per day
High Blood Pressure: NO
High Cholesterol: NO
Obesity: NO
Diabetes: NO
Alcohol: yes a lot
Substance Abuse: NO
Injection Drug Use: NO
Sedentary Lifestyle: NO
Multiple Sexual Partners: NO
Tattooing/Body Piercing: NO

FAMILY HISTORY:

Anemia: NO
Asthma: NO
Cancer: mother neck cancer
Diabetes: NO
Heart Disease: NO
High Blood Pressure: NO
Mental Illness: NO
Tuberculosis: NO
Kidney Disease: father die

SURGERIES/HOSPITALIZATIONS:

Inmate denies surgeries and/or hospitalizations.

GENERAL DESCRIPTION/CHIEF COMPLAINT:

FELIPE ALMAZAN RUIZ is a appears well, in no acute distress, obese, well-developed, well-groomed, and well-nourished 51 year old male presenting for initial chronic disease clinic visit. current complaints external hemorrhoid, dry itchy skin dry eyes itching, headaches, otherwise the patient denies chest pain headaches abd pain nausea no vomiting

REVIEW OF SYSTEM

EYES =normal: no papilledema or stye
EARS: no tinnitus, vertigo or hearing loss
Mouth/throat no throat pain, gum diseases or hoarseness
RESP no shortness of breath or cough
CARDIO: no chest pain, dyspnea, claudication or edema
GASTRO: no dyspepsia nausea, vomiting, diarrhea or constipation
GENITOURINARY: deferred
RECTUM: deferred
MUCULOSKELETAL: no joint pain or arthritis
NEUROPSYCHIATRY: no weakness, seizure, memory changes, or depression
REVIEW OF SYSTEMS:
SKIN: no discoloration, dry scaly rashes
HEAD: no head ache masses or dizziness
EYES: Sclera non-icteric. Conjunctivae and lids are clear bilaterally. No redness. No hyphema. PERRLA. Full EOMs intact. No nystagmus. No photophobia. Fundoscopic exam is grossly

Current Medications:

CLOTRIMAZOLE 1 %
DOCUSATE SODIUM 100 MG
FOLIC ACID 1 MG
HYDROCORTISONE 1 %
LACTULOSE 10 GM/15 ML SOLN 10
Maalox 30 cc
MULTIVITAMIN
OMEPRAZOLE DR 20 MG CAPSULE 20
SERTRALINE HCL 100 MG TAB

ALMAZAN RUIZ, FELIPE, 06-26-1966, #GCSO17MNI005042
08-14-2017 Encounter as of 09-20-2017 Wed 05:07:24 PM

100

SPIRONOLACTONE 25 MG TABLET 25
TRAZODONE 50 MG TABLET 50
XIFAXAN 550 MG TAB 550

PHYSICAL EXAM:

Vital Signs:
Temp: 98.3
Blood Pressure: 101 / 66
Pulse: 62
Resp: 18
Height: 5 ft 3 in
Weight: 165 lbs
Peak Flow: %
Pain Scale:
Functional Assessment:

GENERAL APPEARANCE:

Well-developed, well-nourished male in no acute distress.

HEAD:

Normocephalic. Atraumatic.

EYES:

Sclera non-icteric. Conjunctivae and lids are clear bilaterally. No redness. No hyphema. PERRLA. Full EOMs intact. No nystagmus. No photophobia. Fundoscopic exam is grossly normal: no papilledema or stye

ENT:

EAC's clear. TM's white and shiny. Nares patent. Oral mucosa pink and moist. Oropharynx clear.

NECK:

Supple with full range of motion. No tenderness or lymphadenopathy. No JVD or carotid bruits.

LUNGS:

Clear to auscultation. Respiratory effort non-labored.

HEART:

RRR. S1 S2 WNL.. No murmurs or rubs.

EXTREMITIES:

Pedal pulses are palpable and equal. No extremity edema. Color and temperature are uniform. Skin is warm and dry. Sensation and circulation are fully intact distally. Full ROM. Non-tender to palpation. dry scaly skin rashes

ABDOMEN:

Positive bowel sounds. Non-tender. No hepatosplenomegaly. No masses.

GU:

Deferred.

RECTAL:

external hemorrhoid

No sensory or motor deficits. Deep tendon reflexes 2+ bilaterally.

PSYCHIATRIC Awake and alert. No depression, noted. agitation or anxiety

MUSCULOSKELETAL:

Moves all extremities well. No deformities, cyanosis or clubbing. Gait steady,

SKIN:

Warm, dry, normal color. Turgor elastic.

NEUROLOGICAL: no weakness, seizure, memory changes, or depression

ASSESSMENT:

- 1===liver cirrhosis/ fatty liver
- 2===Gerd
- 3===possible portal hypertension
- 4===IBS
- 5===eczema

PLAN:

- 1===TRIAMCINOLONE ACETONIDE, 0.1 % #120, Sig: CRM 2 times per day for 60 days
- 2===PT PTT INR ,psa, crmp cbc lipid panel , h pylori test ammonia level tomorrow
- 3===follow=up thursday with labs results
- 4===increase fluid intake
- 5===continue with all others meds for 30 days
- 6===please renew when there are finishing
- 7===follow=up in 90 days
- 8===PROCTOSOL 2.5%, #60, Sig: Apply 1 Cream topical 2 times per day for 30 days

EDUCATION PROVIDED:

Disease Process/Treatment:

Abnormal Labs:

Medication Management (purposes, side effects):

Lifestyle Changes:

Nutrition: renal diet

Smoking/Tobacco

ALMAZAN RUIZ, FELIPE, 06-26-1966, #GCSO17MN!005042
08-14-2017 Encounter as of 09-20-2017 Wed 05:07:24 PM

Use:

Exercise: daily
Alcohol/Substance Abuse:
Other: meds compliances

Electronically Approved by (b)(6); (b)(7)(C) MD on 08-14-2017 10:27:32 AM.

ALMAZAN RUIZ, FELIPE, 06-26-1966, #GCSO17MNI005042
08-14-2017 Encounter as of 09-20-2017 Wed 04:43:42 PM

INITIAL MENTAL HEALTH EVALUATION:

Patient Name: FELIPE ALMAZAN RUIZ
No: GCSO17MNI005042
DOB: 06-26-1966
Sex: Male
Location: 1*DORM 1*C*013 1*DORM 1*C*013

Date / Time: 08-14-2017 Mon / 10:26
Reason for Referral: Intake Screening
Charges:

CHIEF COMPLAINT:
ASSESSMENT OF THE PRESENT ILLNESS:

Pt reports he has a history of cirrohsis, depression, and anxiety. Pt reports a hx of alcohol dependence and reports he has not had a drink in 3 months. Pt reports he has been prescribed trazadone for the past 3 months when he was incarcerated in metro west in dade county. Pt has current immigration hold. Pt presents with calm demeanor and is cooperative. Pts mood is sad with mild symptoms of anxiety. Pt denies SI/HI. Pt denies hx of AV hallucinations. Pt attributes his feelings of sadness and anxiety to stress of his current situation. Pt reports bouts of depression and crying for the past 3 months. Pt reports he lost his marriage 5 years ago due to his alcohol problem and reports he has continued to worsen with regards to alcohol use until he was incarcerated. Pt reports he feels guilt, sadness, and loss now. Pt reports he uses prayer and his faith to manage his feelings.

Pre-Incarceration Medications: has liver cirrohsis
Past Psychotropics: Desyrel / trazodone
Alcohol: YES
Amount: As much as I could get
Last Drink: Day of arrest
Hx of DT's: YES
Drugs: No

Past Psychotropics:
Current Psychotropics:
Current Psychotropics: Desyrel / trazodone

PAST MEDICAL HX:

Illnesses: cirrohsis
Hospitalization: related to liver cirrohsis
Surgeries: none
Head Injuries: Hit in head i n a fight years ago.
Allergies
NKDA

Current Non-Psychotropic Medications:
CLOTRIMAZOLE 1 %
DOCUSATE SODIUM 100 MG
FOLIC ACID 1 MG
HYDROCORTISONE 1 %
LACTULOSE 10 GM/15 ML SOLN 10
Maalox 30 cc
MULTIVITAMIN
OMEPRAZOLE DR 20 MG CAPSULE 20
PROCTOSOL 2.5%
SERTRALINE HCL 100 MG TAB 100
SPIRONOLACTONE 25 MG TABLET 25
TRAZODONE 50 MG TABLET 50
TRIAMCINOLONE ACETONIDE 0.1 %
XIFAXAN 550 MG TAB 550 PAST PSYCHIATRIC HX:

Hospitalizations: No
Outpatient Treatment: No
Suicide Attempts: reports he has tried to commit suicide many times by drinking excessively.
Hx of Arrests - Juvenile/Adult: YES - alcohol related , lewdness for urinating in public
Hx of Sexual Abuse: No
Hx of Predatory Behavior: No
Hx of Physical Abuse: No
Hx of Violent Behavior: No

SOCIAL HISTORY:

Education: 10th grade
Hx of Developmental/Education Disabilities: No
Marital Status: Divorced
Armed Forces:

ALMAZAN RUIZ, FELIPE, 06-26-1966, #GCSO17MNI005042
08-14-2017 Encounter as of 09-20-2017 Wed 04:43:42 PM

No

Occupation:
plumbing FAMILY HISTORY:

Family Psych Hx: denies
Family Hx of Suicide: No
Family Alcohol/Drug Abuse: No

MENTAL STATUS EXAMINATION:

General: Alert
Behavior: Appropriate
Attitude: Cooperative
Orientation: Person, Place, Time, and Situation
Eye Contact: Fair
Appearance: Neat, Well-Groomed, and Appears older than age
Psychomotor Activity: Normal
Memory
Immediate: Fair
Recent: Fair
Remote: Fair

Concentration: Good
Ability to Think Abstractly: With similarities and differences Good - With proverbs Good -
Hallucinations: Denies
Delusions: Absent
Speech: Coherent
Mood: Depressed, and Anxious
Affect: Appropriate
Sleep: WNL
Appetite: WNL
Hopelessness: No
Suicide: Intention - No Plan - No Ideation - No, reports past ideation and overdrinking in attempts to die
Homicide: Ideation - No Intention - No Plan - No
Insight: Fair
Judgment: Fair

DIAGNOSIS:

Axis I
311 DEPRESSION
300.02 GENERALIZED ANXIETY DISORDER
303.90 ALCOHOL DEPENDENCE, in remission PLAN:

APPT: Appointment electronically created for patient to see psychiatrist as soon as possible.
DISPOSITION:

Housing: General Population Segregated: No

Eligibility: Program Participation, Job Placement, and Job Placement

Electronic Signature:
Electronically Approved by MARCI VANDHUYNSLAGER, LMHC on 08-14-2017 10:41:35 AM.

ALMAZAN RUIZ, FELIPE, 06-26-1966, #GCSO17MNI005042
08-14-2017 Encounter as of 09-20-2017 Wed 04:43:52 PM

INITIAL MENTAL HEALTH EVALUATION:

Patient Name: FELIPE ALMAZAN RUIZ
No: GCSO17MNI005042
DOB: 06-26-1966
Sex: Male
Location: 1*DORM 1*C*013 1*DORM 1*C*013

Date / Time: 08-14-2017 Mon / 10:26
Reason for Referral: Intake Screening
Charges:

CHIEF COMPLAINT:
ASSESSMENT OF THE PRESENT ILLNESS:

Pt reports he has a history of cirrohsis, depression, and anxiety. Pt reports a hx of alcohol dependence and reports he has not had a drink in 3 months. Pt reports he has been prescribed trazadone for the past 3 months when he was incarcerated in metro west in dade county. Pt has current immigration hold. Pt presents with calm demeanor and is cooperative. Pts mood is sad with mild symptoms of anxiety. Pt denies SI/HI. Pt denies hx of AV hallucinations. Pt attributes his feelings of sadness and anxiety to stress of his current situation. Pt reports bouts of depression and crying for the past 3 months. Pt reports he lost his marriage 5 years ago due to his alcohol problem and reports he has continued to worsen with regards to alcohol use until he was incarcerated. Pt reports he feels guilt, sadness, and loss now. Pt reports he uses prayer and his faith to manage his feelings.

Pre-Incarceration Medications: has liver cirrohsis
Past Psychotropics: Desyrel / trazodone
Alcohol: YES
Amount: As much as I could get
Last Drink: Day of arrest
Hx of DT's: YES
Drugs: No

Past Psychotropics:
Current Psychotropics:
Current Psychotropics: Desyrel / trazodone

PAST MEDICAL HX:

Illnesses: cirrohsis
Hospitalization: related to liver cirrohsis
Surgeries: none
Head Injuries: Hit in head i n a fight years ago.
Allergies
NKDA

Current Non-Psychotropic Medications:
CLOTRIMAZOLE 1 %
DOCUSATE SODIUM 100 MG
FOLIC ACID 1 MG
HYDROCORTISONE 1 %
LACTULOSE 10 GM/15 ML SOLN 10
Maalox 30 cc
MULTIVITAMIN
OMEPRAZOLE DR 20 MG CAPSULE 20
PROCTOSOL 2.5%
SERTRALINE HCL 100 MG TAB 100
SPIRONOLACTONE 25 MG TABLET 25
TRAZODONE 50 MG TABLET 50
TRIAMCINOLONE ACETONIDE 0.1 %
XIFAXAN 550 MG TAB 550 PAST PSYCHIATRIC HX:

Hospitalizations: No
Outpatient Treatment: No
Suicide Attempts: reports he has tried to commit suicide many times by drinking excessively.
Hx of Arrests - Juvenile/Adult: YES - alcohol related , lewdness for urinating in public
Hx of Sexual Abuse: No
Hx of Predatory Behavior: No
Hx of Physical Abuse: No
Hx of Violent Behavior: No

SOCIAL HISTORY:

Education: 10th grade
Hx of Developmental/Education Disabilities: No
Marital Status: Divorced
Armed Forces:

ALMAZAN RUIZ, FELIPE, 06-26-1966, #GCSO17MNI005042
08-14-2017 Encounter as of 09-20-2017 Wed 04:43:52 PM

No

Occupation:
plumbing FAMILY HISTORY:

Family Psych Hx: denies
Family Hx of Suicide: No
Family Alcohol/Drug Abuse: No

MENTAL STATUS EXAMINATION:

General: Alert.
Behavior: Appropriate
Attitude: Cooperative
Orientation: Person, Place, Time, and Situation
Eye Contact: Fair
Appearance: Neat, Well-Groomed, and Appears older than age
Psychomotor Activity: Normal

Memory

Immediate: Fair
Recent: Fair
Remote: Fair

Concentration: Good
Ability to Think Abstractly: With similarities and differences Good - With proverbs Good -
Hallucinations: Denies
Delusions: Absent
Speech: Coherent
Mood: Depressed, and Anxious
Affect: Appropriate
Sleep: WNL
Appetite: WNL
Hopelessness: No
Suicide: Intention - No Plan - No Ideation - No, reports past ideation and overdrinking in attempts to die
Homicide: Ideation - No Intention - No Plan - No
Insight: Fair
Judgment: Fair

DIAGNOSIS:

Axis I
311 DEPRESSION
300.02 GENERALIZED ANXIETY DISORDER
303.90 ALCOHOL DEPENDENCE, in remission PLAN:

APPT: Appointment electronically created for patient to see psychiatrist as soon as possible.

DISPOSITION:

Housing: General Population Segregated: No

Eligibility: Program Participation, Job Placement, and Job Placement

Electronic Signature:

Electronically Approved by (b)(6); (b)(7)(C) MHC on 08-14-2017 10:41:35 AM.

ALMAZAN RUIZ, FELIPE, 06-26-1966, #GCSO17MNI005042
08-22-2017 Encounter as of 09-20-2017 Wed 04:44:18 PM

"I am having a lot of pain in my joints. I cannot see either. I had glasses at Krome but they say they are not in my property here. My vision is very bad. The medication is helping some but I still can only sleep 2-3 hours."
51 y.o. male with extensive history of alcohol dependence. He is currently taking Zoloft and Trazodone with some benefit. He reports difficulty sleeping and has other medical complaints. Discussed increasing Trazodone to 75 mg nightly to improve insomnia.
PROGRESS NOTE OUTPATIENT MENTAL HEALTH :

Date / Time: 08-22-2017 Tue / 15:17

S: Reason for Encounter/Patient Statement: Suggested by LCSW

Appearance:
Groomed. Red-Eyed

Orientation: Person. Place. Situation.

Eye Contact: Appropriate
Behavior: Restless. Fidgety.
Attitude: Cooperative.
Mood: Anxious..
Affect: Congruent.
Speech: Goal-Directed. Coherent.
Thought Content: Unremarkable.
Suicidal: NO thoughts, intent or plan.

Homicidal: NO homicidal thoughts, intent or plan.

Perceptions:
No distortions.
Thought Processes: Logical.
Recent Memory: Intact
Remote Memory: Intact

Vegetative Functions
Sleep: Decreased

Appetite: Good

LAB RESULTS/ORDERS:n/a

RESPONSE TO TREATMENT:

Fair

SIDE EFFECTS:
None noticed/reported,
Last A.I.M.S. evaluation

/a,

A: DIAGNOSTIC IMPRESSION:

311 DEPRESSION
300.02 GENERALIZED ANXIETY DISORDER

TARGET SYMPTOMS:

Anxiety,
Anxiety,
Depression,
Insomnia,
Medical issues.,

PLAN:

RX: Continue Zoloft 100mg daily and increase Trazodone 75 mg nightly
Next appointment: Electronically placed for Follow-up in 60 days.

E: PATIENT EDUCATION:

Treatment Plan
Alternatives
Risks/Benefits
Therapeutic/Side Effects
Understood

ALMAZAN RUIZ, FELIPE, 06-26-1966, #GCSO17MNI005042
08-22-2017 Encounter as of 09-20-2017 Wed 04:44:18 PM

Agreed

Electronically Approved by (b)(6); (b)(7)(C) ARNP on 08-22-2017 03:19:09 PM.

ALMAZAN RUIZ, FELIPE, 06-26-1966, #GCSO17MNI005042
08-24-2017 Encounter as of 09-20-2017 Wed 04:44:44 PM

INITIAL HEALTH ASSESSMENT:

Patient Name: FELIPE ALMAZAN RUIZ
MNI #: GCSO17MNI005042
DOB: 06-26-1966
Sex: Male
Location: 1*DORM 1*C*013 1*DORM 1*C*013

Intake Date: 08/11/2017

Date / Time: 08-24-2017 Thu / 10:06

SIGNIFICANT PAST MEDICAL HISTORY:

YES - Hx of Cirrhosis of Liver effective 2009 as per patient.
Hospitalizations / Surgery:
Denies

ALLERGIES:

NKDA
No

Mother: Throat cancer (Expired)
Father: KF (Expired)
Brother: Cirrohosis (Expired)

HABITS/BEHAVIORS:

Alcohol Use: No
Tobacco Use: No
Drug Use: No

Have you ever injected drugs?

No

Fever, blood in sputum, prolonged cough or night sweats? No
Blood in stools or black / tarry stools? No
Skin lesions, "spider bites", or infections? No
Unintentional weight loss more than 10%? No
Experiencing penile discharge, burning or lesions? No
Lumps or lesions on testicles? No

Any current complaints: YES - "Right knee pain and I can't see."
Any current injuries? No

PHYSICAL EXAMINATION:

T: 98.4 P: 65 R: 16 BP: 112 / 78 Ht: 5 ft 3 in Wt: 163 lbs

Visual Acuity: OD 20/200 OU 20/200 OS 20/200 Without Correction
Patient c/o visual disturbance and is unable to purchase glasses from commissary or have family member send glasses in. Based on the results of patient snellen acuity. Nurse will refer to patinet to MD for visual disturbance.
General Condition:

51 year old w male free-moving, good hygiene, well developed.

Mental Status:

Alert and oriented x 3. Cooperative.

Motor:

Normal gait and coordination. No tremors noted.

Head/Neck:

Atraumatic. No lesions or infestations. Neck supple. Thyroid not enlarged.

Eyes, Ears, Nose:

PERRL. Sclera white. EACs pink and patent. TM's intact and clear. No septal deviation.

Oral:

Mucosa is pink and moist. Pharynx without lesions or exudate.

Dental:

See Dental Screening

Lymph Nodes:

No tenderness or enlargement at cervical or axillary nodes.

Breasts:

No lesions or masses.

Skin:

Pink, warm and dry. Good turgor. No rashes, lesions or infestations.

Heart:

RRR without adventitious sounds.

Lungs:

ALMAZAN RUIZ, FELIPE, 06-26-1966, #GCSO17MNI005042
08-24-2017 Encounter as of 09-20-2017 Wed 04:44:44 PM

CTA.

Abdomen:

Normal bowel sounds. No masses or tenderness noted.

Genitals:

Deferred.

Back:

Full ROM. No scoliosis.

Extremities:

Pedal pulses present and equal bilaterally. No edema or cyanosis noted.

CURRENT MEDICATIONS:

DOCUSATE SODIUM 100 MG

FOLIC ACID 1 MG

LACTULOSE 10 GM/15 ML SOLN 10

MULTIVITAMIN

OMEPRAZOLE DR 20 MG CAPSULE 20

PROCTOSOL 2.5%

SERTRALINE HCL 100 MG TAB 100

SPIRONOLACTONE 25 MG TABLET 25

TRAZODONE 50 MG TABLET 50

TRIAMCINOLONE 0.1% CREAM 0.1

XIFAXAN 550 MG TAB 550

DENTAL ASSESSMENT:

Describe any significant dental problems or history:

MENTAL HEALTH ASSESSMENT:

Have you been hospitalized in a psychiatric unit? No

Have you received outpatient counseling/treatment for emotional/nervous problems? No

Past Psychiatric Medications? No

Do you have current emotional problems? YES - Depression, "but I have already seen MH and have started medication." Patient will follow up with MH as needed.

Have you ever attempted suicide? No

Are you thinking about suicide now? No

Do you ever think of hurting yourself or others? No

Have you ever been a victim of sexual assault or physical abuse? No

Have you ever perpetrated sexual assault or physical abuse? No

PREVENTIVE HEALTH AND EDUCATION:

Immunizations: Received routine childhood vaccinations? No

Communicable Disease Screening (PT-022) Completed? Yes

Tuberculosis Screening (PT-024) Completed? Yes

Health education and prevention provided? YES Nurse educated patient on how to access healthcare services such as sick call, dental and MH if needed at a later time. Patient verbalized education.

ANNUAL HEALTH MAINTENANCE:

Date of Incarceration: ALMAZAN RUIZ, FELIPE, 08-12-2017 Sat 03:15:00 AM Intake Understand English?: Y

Date of Incarceration: 08/11/2017

Intake Weight: 168.8 lbs

Current Weight: 163 lbs

Occult blood cards given times three with instructions on stool collection. Patient verbalized understanding.

ASSESSMENT:

No significant health conditions identified at present.

TREATMENT/PLAN:

Reviewed Mental Health Intake (MH-014)

Reviewed Intake Screening

Provided instructions on accessing health care in the institution.

Instructed in oral hygiene and provided preventive oral education.

Follow-up in Sick Call as needed; Routine Health Maintenance

REFERRAL: Routine referral to Provider Sick Call electronically created.

Armor PT-028 (Revised May 2017)

Automated

ALMAZAN RUIZ, FELIPE, 06-26-1966, #GCSO17MNI005042
08-24-2017 Encounter as of 09-20-2017 Wed 04:44:44 PM

Entries:

The following items were created by (b)(6); (b)(7)(C) RN on 08-24-2017 02:30:04 PM:

ORDER: Provider - ROUTINE

Electronically Approved (b)(6); (b)(7)(C) RN on 08-24-2017 02:29:24 PM. NURSING PROTOCOL - MUSCULAR SKELETAL:

Patient Name: FELIPE ALMAZAN RUIZ
NO: GCSO17MNI005042
DOB: 06-26-1966
Sex: Male
Date: 08-24-2017 Thu
Time: 14:30
Location: 1*DORM 1*C*013 1*DORM 1*C*013

SUBJECTIVE:

Complaint: "I have right knee pain."
Acute problem, began: 2 day(s) ago
Chronic problem, duration: 1 week(s)
How condition began: Unknown
Pain: Mild
Pattern of Pain: Up and Down.
Level of activity related to pain: Able to function okay
Radiation of pain: Remains at affected area
Other characteristics of pain: Dull
Condition made better by: Advil/Ibuprofen, Rest, Elevation of affected area,
Condition made worse by: Stooping/Bending, standing long periods of time
Associated Symptoms
Fever? No
Nausea/vomiting? No
Other Symptoms:

Allergies: NKDA
Hx of Bleeding Ulcer or complications of pain medication? No

CURRENT MEDICAL PROBLEMS:

300.02, GENERALIZED ANXIETY DISORDER
311, DEPRESSION
571.5, CIRRHOSIS OF LIVER WITHOUT ALCOHOL

OBJECTIVE:

Vital Signs: VITAL SIGNS: (6) Weight: 163 lbs, Height: 5 ft 3 in, BMI: 28.9, BSA (Mosteller): 1.81, BSA (DuBois): 1.77, Blood Pressure: 112 / 78, Temperature: 98.4 °F, Pulse: 65, Respiration: 16
General Appearance: No acute distress,
Describe are of concern:
Describe gait and mobility: Freely moves about
Describe range of motion of area concerned
Swelling: No
Tenderness: No
Pupils: Equal and reactive,
Neck: Supple,

ASSESSMENT:

Alteration in Comfort Location - Right knee Related to Occasional pain.

PLAN/EDUCATION: Nurse educated patient to provide periods of rest when ever right knee pain is aggravated, exercise as tolerated to strengthen muscles, increase fluids and avoid straineous activities. Nurse instructed patient on treatment plan for today. Patient verbalized all understanding.

For Chronic Pain related to back problems or joint problems

Tx given: Ibuprofen 200 mg; two (2) tabs BID x 5 days PRN
(NO history of bleeding ulcers)

Instructions given: Warm pads and head can provide relief

Education given: Exercises as tolerated to improve muscle tone and strength.

Return to sick call if symptoms worsent or persist more than 7 days.

DENTAL SCREENING:

Inmate/Detainee Name: FELIPE ALMAZAN RUIZ
MNI#: GCSO17MNI005042
Date of Birth:

Missing Teeth: 0
Fillings:

ALMAZAN RUIZ, FELIPE, 06-26-1966, #GCSO17MNI005042
08-24-2017 Encounter as of 09-20-2017 Wed 04:44:44 PM

0
Suspected: 0

Dentures: N/A
Partials: N/A
Other: 4 upper implants as per patient

Electronically Approved by (b)(6); (b)(7)(C) RN on 08-24-2017 02:33:41 PM.

Electronically Approved by (b)(6); (b)(7)(C) MD on 09-05-2017 04:02:46 PM.

ALMAZAN RUIZ, FELIPE, 06-26-1966, #GCSO17MNI005042
08-30-2017 Encounter as of 09-20-2017 Wed 04:44:58 PM

NURSING PROTOCOL - MUSCULAR SKELETAL:

Patient Name: FELIPE ALMAZAN RUIZ
NO: GCSO17MNI005042
DOB: 06-26-1966
Sex: Male
Date: 08-30-2017 Wed
Time: 14:20
Location: 1*DORM 1*C*013 1*DORM 1*C*013

SUBJECTIVE:

Complaint: Joint Pain - Bilateral Shoulder Bilateral Knee Bilateral Elbow
Acute problem, began: N/A
Chronic problem, duration: 6 month(s)
How condition began: Unknown
Pain: Moderate
Pattern of Pain: Constant. Worsening.
Level of activity related to pain: Able to function okay
Radiation of pain: Remains at affected area
Other characteristics of pain: None
Condition made better by: Advil/Ibuprofen,
Condition made worse by: Any movement
Associated Symptoms
Fever? No
Nausea/vomiting? No
Other Symptoms:

Allergies: NKDA
Hx of Bleeding Ulcer or complications of pain medication? No

CURRENT MEDICAL PROBLEMS:

300.02, GENERALIZED ANXIETY DISORDER
311, DEPRESSION
571.5, CIRRHOSIS OF LIVER WITHOUT ALCOHOL

OBJECTIVE:

Vital Signs: VITAL SIGNS: (6) Weight: 165.2 lbs, Height: 5 ft 3 in, BMI: 29.3, BSA (Mosteller): 1.83, BSA (DuBois): 1.78, Blood Pressure: 106 / 68, Temperature: 98.6 °F, Pulse: 74, Respiration: 18
General Appearance: Uncomfortable,
Describe are of concern:
Describe gait and mobility: Freely moves about
Describe range of motion of area concerned
Swelling: No
Tenderness: YES

ASSESSMENT:

Alteration in Comfort Location - IN JOINTS AREA Related to UNKNOWN.

PLAN/EDUCATION:

For Chronic Pain related to back problems or joint problems
Tx given: Ibuprofen 200 mg; two (2) tabs BID x 5 days PRN
(NO history of bleeding ulcers)
Instructions given: Warm pads and heat can provide relief
Education given: Exercises as tolerated to improve muscle tone and strength.

Return to sick call if symptoms worsen or persist more than 7 days.

Electronically Approved by (b)(6); (b)(7)(C) LPN, CCHP on 08-30-2017 02:24:30 PM.

Electronically Approved by (b)(6); (b)(7)(C) RN on 08-31-2017 01:27:37 PM.

ALMAZAN RUIZ, FELIPE, 06-26-1966, #GCSO17MNI005042
09-02-2017 Encounter as of 09-20-2017 Wed 04:45:11 PM

NURSING PROTOCOL - EYES, EARS, NOSE, TEETH AND THROAT:

Patient Name: FELIPE ALMAZAN RUIZ
NO: GCSO17MNI005042
DOB: 06-26-1966
Sex: Male
Date: 09-02-2017 Sat
Time: 16:50
Location: 1*DORM 1*D*048 1*DORM 1*D*048

SUBJECTIVE:

Complaint: Vision problem / eye glasses- patient states he's having difficulty seeing, things look blurry.
Acute problem, began: A few week(s) ago
Chronic problem, duration: N/A
Pain: None
Description of problem: Patient is having difficulty seeing.
Condition made better by: Nothing is helping, patient had an appointment scheduled with an optometrist prior to entering the facility. ,
Condition made worse by: unsure
Associated Symptoms
Fever: No
Drainage: No
Cough: No
Shortness of Breath: No
Sneezing: No
Other: none
Allergies: NKDA
Other Comments: None at this time.

CURRENT MEDICAL PROBLEMS:

300.02, GENERALIZED ANXIETY DISORDER
311, DEPRESSION
571.5, CIRRHOSIS OF LIVER WITHOUT ALCOHOL

OBJECTIVE:

Vital Signs: VITAL SIGNS: (6) Weight: 166 lbs 4 oz, Height: 5 ft 3 in, BMI: 29.4, BSA (Mosteller): 1.83, BSA (DuBois): 1.79, Blood Pressure: 113 / 77, Temperature: 98.3 °F, Pulse: 83, Respiration: 18

General Appearance: No acute distress
Describe area of concern: unremarkable
Eye: Vision R: 20/200 Vision L: 20/200 Sclera: Clear, white.
Signs of Infection: None

ASSESSMENT:

Disturbed Sensory Perception: R/O Visual disturbance.

PLAN/EDUCATION:

Routine referral to Dr. Noel within 5 days secondary to Patient having difficulty seeing, may need glasses. Made same complaint during Initial Health Assessment.

Electronically Approved by (b)(6); (b)(7)(C) on 09-02-2017 04:56:23 PM.

Electronically Approved by (b)(6); (b)(7)(C) MD on 09-05-2017 04:03:19 PM.

ALMAZAN RUIZ, FELIPE, 06-26-1966, #GCSO17MNI005042
09-06-2017 Encounter as of 09-20-2017 Wed 04:45:26 PM

Patient c/o visual disturbance
OS 20/200 OD 20/200 30 DAY CLINIC CIRRHOSIS
knee pain and joint pain CHRONIC CARE CLINIC:

Date/Time: 09-06-2017 Wed / 09:48

Patient Name: FELIPE ALMAZAN RUIZ
No: GCSO17MNI005042
DOB: 06-26-1966
Sex: Male
Location: 1*DORM 1*D*048 1*DORM 1*D*048

Clinic Membership:
571.5 CIRRHOSIS OF LIVER WITHOUT ALCOHOL
311 DEPRESSION
300.02 GENERALIZED ANXIETY DISORDER

PAST MEDICAL HISTORY:

51 years old male with history of liver cirrhosis, Gerd, possible portal hypertension, constipation here today for 30 days clinical evaluation, the patient diagnose 7 years ago and he's been on treatment since then

Duration of condition(s): 5-10 years

Prior hospitalization(s): No change since last visit
Complications: none

CURRENT MEDICATIONS:

DOCUSATE SODIUM 100 MG
FOLIC ACID 1 MG
LACTULOSE 10 GM/15 ML SOLN 10
MULTIVITAMIN
OMEPRAZOLE DR 20 MG CAPSULE 20
PROCTOSOL 2.5%
SERTRALINE HCL 100 MG TAB 100
SPIRONOLACTONE 25 MG TABLET 25
TRAZODONE 50 MG TABLET 50
TRIAMCINOLONE 0.1% CREAM 0.1
XIFAXAN 550 MG TAB 550

DATA REVIEW:

CMP
Sodium 141 Normal mmol/L 135-145 Final CL
Potassium 4.3 Normal mmol/L 3.5-5.5 Final CL
Chloride 104 Normal mmol/L 95-110 Final CL
Carbon Dioxide 26 Normal mmol/L 19-34 Final CL
Anion Gap 15.3 Normal mmol/L 10-20 Final CL
Glucose 86 Normal mg/dL 70-110 Final CL
Calcium 8.8 Normal mg/dL 8.4-10.2 Final CL
Protein, Total 6.9 Normal g/dL 5.5-8.7 Final CL
Albumin 3.6 Normal g/dL 3.2-5.0 Final CL
Bilirubin Total 1.7 Above Normal mg/dL 0.1-1.2 Final CL
Alkaline Phos 162 Above Normal U/L 20-130 Final CL
AST (SGOT) 35 Normal U/L 10-40 Final CL
ALT (SGPT) 25 Normal U/L 10-60 Final CL
Urea Nitrogen 17 Normal mg/dl 6-22 Final CL
Creatinine.. 0.70 Normal mg/dL 0.43-1.13 Final CL
eGFR NonAfrican Am > 60 Final CL
eGFR African Amer > 60 Final CL
eGFR less than 60 (ml/min/1.73) square meters
Lipids Profile
Triglycerides 45 Normal mg/dL 0-150 Final CL
Cholesterol 92 Normal mg/dL 0-200 Final CL
HDL 54 Normal mg/dL 0-60 Final CL
NON-HDL 38 mg/dl Final CL
Goals for Patients with CHD or CHD risk equivalents:
LDL: < 70 mg/dl
NON-HDL: < 100 mg/dl

Goals for Patients with 2+ risk factors:
LDL: < 130 mg/dl
NON-HDL: < 160 mg/dl

Goals for Patients with 0-1 risk

ALMAZAN RUIZ, FELIPE, 06-26-1966, #GCSO17MNI005042
09-06-2017 Encounter as of 09-20-2017 Wed 04:45:26 PM

factors:

LDL: <160 mg/dl
NON-HDL: <190 mg/dl
LDL Cholesterol 29 Normal mg/dL 0-130 Final CL
Chol/HDL Ratio 1.7 Normal 1.5-5.6 Final CL

H Pylori Ab IgG (THIS IS THE ONE (b)(6); _____ ORDERS)
H Pylori Ab IgG 0.70 Normal U/mL 0.00-0.90 Final CL
< or = 0.90 Negative
0.91-1.09 Equivocal
> or = 1.10 Positive

PSA Diagnostic

PSA Diagnostic 0.1 Normal ng/mL 0-4.0 Final CL

Prothrombin Time

PT Seconds 9.4-12.5 In Lab CL
Pro Time INR In Lab CL
Status Observation Date Performing Lab Performing MD
PTT
Activated PTT 41.6 Above Normal Seconds 25.1-36.5 Final CL
Therapeutic PTT range of 50-89 seconds

CBC

WBC 3.0 Below Normal 10³/uL 3.6-11.0 Final CL
RBC 3.65 Below Normal 10⁶/uL 4.50-5.90 Final CL
Hemoglobin 11.3 Below Normal g/dL 13.0-18.0 Final CL
Hematocrit 34.8 Below Normal % 40.0-52.0 Final CL
MCV 95.6 Normal fl 81.0-97.0 Final CL
MCH 31.0 Normal pg 26.0-34.0 Final CL
MCHC 32.4 Normal g/dL 31.0 - 37.0 Final CL
RDW 17.4 Above Normal % 11.5-15.0 Final CL
Platelet Count 41 Below Normal 10³/uL 150-400 Final CL
Mean Platelet Vol 9.6 Normal fl 7.4-10.4 Final CL
Neutrophil % 65.7 Normal % 36.0-66.0 Final CL
Lymphocyte % 25.2 Normal % 23.0-43.0 Final CL
Monocyte % 4.8 Normal % 0.0-10.0 Final CL
Eosinophil % 3.9 Normal % 0.0-5.0 Final CL
Basophil % 0.4 Normal % 0.0-1.0 Final CL
Neutrophil Abs# 2.0 Normal 10³/uL 1.6-8.2 Final CL
Lymphocyte Abs # 0.7 Below Normal 10³/uL 1.1-4.7 Final CL
Monocyte Abs # 0.1 Normal 10³/uL 0.0-1.1 Final CL
Eosinophil Abs # 0.1 Normal 10³/uL 0.0-0.5 Final CL
Basophil Abs # 0.0 Normal 10³/uL 0.0-0.4 Final CL

Ammonia

Ammonia 108 Above Normal umol/L 11-35 Final CL
Test Performed by: IRL - Florida
5361 NW 33 Avenue
Adherence
Ft Lauderdale, FL 33309

SUBJECTIVE:

the patient is complaining of abdominal pain radiating to the chest otherwise he's denies all others symptoms
Stability of condition(s): Stable
Issues with medication(s): None.
Other: none

OBJECTIVE:

T: 97.6 P: 80 R: 18 BP: 122 / 76 Weight: 170 lbs

GENERAL APPEARANCE:

Well-developed, well-nourished 51 year old w male in no acute distress.

HEAD:

Normocephalic. Atraumatic.

EYES:

PERRLA. EOMI. Sclera non-icteric.

ENT:

EAC's clear. TM's white and shiny. Nares patent. Oral mucosa pink and moist. Oropharynx clear.

NECK:

Supple with full range of motion. No tenderness or lymphadenopathy. No JVD or carotid bruits.

LUNGS:

Clear to auscultation. Respiratory effort

ALMAZAN RUIZ, FELIPE, 06-26-1966, #GCSO17MNI005042
09-06-2017 Encounter as of 09-20-2017 Wed 04:45:26 PM

non-labored.

HEART:

RRR. S1 S2 WNL.. No murmurs or rubs.

EXTREMITIES:

Pedal pulses are palpable and equal. No extremity edema.

ABDOMEN:

Positive bowel sounds. Non-tender. No hepatosplenomegaly. No masses. pain mid epigastric radiating to the chest

GU:

Deferred.

RECTAL:

Deferred.

MUSCULOSKELETAL:

Moves all extremities well. No deformities, cyanosis or clubbing. Gait steady.

SKIN:

Warm, dry, normal color. Turgor elastic.

NEUROLOGICAL:

No sensory or motor deficits. Deep tendon reflexes 2+ bilaterally.

PSYCHIATRIC:

Awake and alert. No depression, agitation or anxiety noted.

ASSESSMENT:

1===THROMBOCYTOPENIA

2===571.5 CIRRHOSIS OF LIVER WITHOUT ALCOHOL

3===311 DEPRESSION

4===300.02 GENERALIZED ANXIETY DISORDER

5===mild increase total bili and alpk

6===Normochromic anemia

7===Degree of Control - poor Status - Improved

8===Patient's adherence to treatment plan: poor

9===Patient's understanding of condition: GOOD

PLAN: '

1===I will increase lactulose doses and will continue with the current meds cbc weekly the follow-up ,++ see below
prednisone 100 mg x3 days then 80 mg x 3 days then 60 mg po x 3 days then 50 mg x 3 days ' the 40 mg x 3 days then 30 mg x 3 days
then 20 mg x 3 days the 10 mg x 2 days then 5 mg x 2 days the 2.5 mg x 2 days then d/c

FERROUS SULFATE, 325MG #90, Sig: 1 time per day for 90 days

2====+++++cbc weekly x 4 weeks+++++

3===d/c dulcolax

4=====lactulose 40 ml po daily x 90 days =====

5===FOLIC ACID, 1 MG #90, Sig: Take 1 Tablet by mouth 1 time per day for 90 days

6===MULTIVITAMIN, #90, Sig: Take 1 Tablet by mouth 1 time per day for 90 days

7===SPIRONOLACTONE, 25 MG #180, Sig: Take 1 Tablet by mouth 2 times per day for 90 days

8===xifaxan 550 mg po bid x 90 days

9===Patient c/o visual disturbance

10===OS 20/200 OD 20/200

11===ammonia level Q2 WEEK X 8 WEEKS

12===Renal diet x 180 days

13===cbc cmp lipid panel in 82 days

14===follow=up in 90 days

15===OMEPRAZOLE, 40 MG #90, Sig: Take 1 Capsule by mouth 1 time per day for 90 days

EDUCATION

Adherence

Weight Loss

Medications

Disease Process

Smoking Cessation

Transmission prevention

Exercise daily

Care after release

Diet renal diet

Lab Results explained

Adjustment to Incarceration

Other Med compliances

(b)(6); (b)(7)(C)

Electronically Approved by [redacted] on 09-06-2017 10:23:31 AM.

Collection Date: 2017-08-17 Thu

Patient	ID	Birth Date	Sex	SSN
ALMAZAN RUIZ, FELIPE	GCS017MNI005042	06-26-1966	M	

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date
CMP							
Sodium	141		Normal	mmol/L	135-145	Final	
Potassium	4.3		Normal	mmol/L	3.5-5.5	Final	
Chloride	104		Normal	mmol/L	95-110	Final	
Carbon Dioxide	26		Normal	mmol/L	19-34	Final	
Anion Gap	15.3		Normal	mmol/L	10-20	Final	
Glucose	86		Normal	mg/dL	70-110	Final	
Calcium	8.8		Normal	mg/dL	8.4-10.2	Final	
Protein, Total	6.9		Normal	g/dL	5.5-8.7	Final	
Albumin	3.6		Normal	g/dL	3.2-5.0	Final	
Bilirubin Total		1.7	Above Normal	mg/dL	0.1-1.2	Final	
Alkaline Phos		162	Above Normal	U/L	20-130	Final	
AST (SGOT)	35		Normal	U/L	10-40	Final	
ALT (SGPT)	25		Normal	U/L	10-60	Final	
Urea Nitrogen	17		Normal	mg/dl	6-22	Final	
Creatinine	0.70		Normal	mg/dL	0.43-1.13	Final	
eGFR NonAfrican Am	> 60					Final	
eGFR African Amer	> 60					Final	
eGFR less than 60 (mL/min/1.73) square meters may indicate chronic kidney disease. This is an estimated GFR based on the Modification of Diet in Renal Disease (MDRD) equation (Ann Intern Med 1999;130:461-70.), results for which depend on race. This estimate should not be used for renal-dosing of medications or dosing adjustments of radiocontrast dye without patient-specific correction for height and weight. Limitations of the eGFR, guidelines on chronic kidney disease definitions, and clinical action plans can be found at www.kidney.org and NEJM 2006;354:2473-83.							
Test Performed by: IRL - Florida							
5361 NW 33 Avenue							
Ft Lauderdale, FL 33309							

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Per Lab
Lipids Profile								
Triglycerides	45		Normal	mg/dL	0-150	Final		CL
If patient is taking N-Acetylcysteine, Triglycerides may be falsely decreased.								
If patient is taking Metamizole, Triglycerides and HDL may be falsely decreased.								
Cholesterol	92		Normal	mg/dL	0-200	Final		CL
HDL	54		Normal	mg/dL	0-60	Final		CL
NON-HDL	38			mg/dl		Final		CL
Goals for Patients with CHD or CVD risk equivalents:								
LDL: < 70 mg/dl								
NON-HDL: <100 mg/dl								
Goals for Patients with 2+ risk factors:								
LDL: <130 mg/dl								
NON-HDL: <160 mg/dl								
Goals for Patients with 0-1 risk factors:								

LDL:	<160 mg/dl								
NON-HDL:	<190 mg/dl								
LDL Cholesterol		29		Normal	mg/dL	0-130	Final		CL
Chol/HDL Ratio		1.7		Normal		1.5-5.6	Final		CL
Test Performed by: IRL - Florida									
5361 NW 33 Avenue									
Ft Lauderdale, FL 33309									

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Performing Lab	Performing MD
H Pylori Ab IgG (THIS IS THE ONE DR. NOEL ORDERS)									
H Pylori Ab IgG				U/mL	0.00-0.90	In Lab		CL	
Test Performed by: IRL - Florida									
5361 NW 33 Avenue									
Ft Lauderdale, FL 33309									

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Perf Lab
PSA Diagnostic								
PSA Diagnostic	0.1		Normal	ng/mL	0-4.0	Final		CL
PSA is intended to be used as an aid in the detection and management of prostate cancer.								
See the 2013 American Urological Association (AUA) guidelines for result interpretation.								
Test Performed by: IRL - Florida								
5361 NW 33 Avenue								
Ft Lauderdale, FL 33309								

Performing ID	Name	Address	City	State	Zip	Country	County
CL^Core Lab^							

Message Type	Control Number	Filler Accession ID	Group Number
Results	LB174_0005626AA		

Order Status: P
 CMP ID# 010103
 ORDER Sequence#1 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA
 Collection Date: 08-17-2017 02:34
 Lab Receipt Date: 08-18-2017 13:08
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 08-18-2017 14:08
 Results Status: All Final Results Available, Order Complete.

Lipids Profile ID# 010009
 ORDER Sequence#2 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA
 Collection Date: 08-17-2017 02:34
 Lab Receipt Date: 08-18-2017 13:08
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 08-18-2017 14:08
 Results Status: All Final Results Available, Order Complete.

H Pylori Ab IgG (THIS IS THE ONE DR. NOEL ORDERS) ID# 060031
 ORDER Sequence#3 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA
 Collection Date: 08-17-2017 02:34
 Lab Receipt Date: 08-18-2017 13:08
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 08-18-2017 14:08
 Results Status: I

PSA Diagnostic ID# 026003
 ORDER Sequence#4 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA
 Collection Date: 08-17-2017 02:34
 Lab Receipt Date: 08-18-2017 13:08
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 08-18-2017 14:08
 Results Status: All Final Results Available, Order Complete.

Date/Time	Sending Application/Facility	Receiving Application/Facility
08-18-2017 14:11	2/NBSP/ARMCO	CorrecTeK/ARMCOGL

Process ID	Version	Accept Ack.	Appl. Ack.
P-Production	2.3		

Collection Date: 2017-08-17 Thu

Patient	ID	Birth Date	Sex	SSN
ALMAZAN RUIZ, FELIPE	GCSO17MNI005042	06-26-1966	M	

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date
CMP							
Sodium	141		Normal	mmol/L	135-145	Final	
Potassium	4.3		Normal	mmol/L	3.5-5.5	Final	
Chloride	104		Normal	mmol/L	95-110	Final	
Carbon Dioxide	26		Normal	mmol/L	19-34	Final	
Anion Gap	15.3		Normal	mmol/L	10-20	Final	
Glucose	86		Normal	mg/dL	70-110	Final	
Calcium	8.8		Normal	mg/dL	8.4-10.2	Final	
Protein, Total	6.9		Normal	g/dL	5.5-8.7	Final	
Albumin	3.6		Normal	g/dL	3.2-5.0	Final	
Bilirubin Total		1.7	Above Normal	mg/dL	0.1-1.2	Final	
Alkaline Phos		162	Above Normal	U/L	20-130	Final	
AST (SGOT)	35		Normal	U/L	10-40	Final	
ALT (SGPT)	25		Normal	U/L	10-60	Final	
Urea Nitrogen	17		Normal	mg/dl	6-22	Final	
Creatinine	0.70		Normal	mg/dL	0.43-1.13	Final	
eGFR NonAfrican Am	> 60					Final	
eGFR African Amer	> 60					Final	
eGFR less than 60 (ml/min/1.73) square meters may indicate chronic kidney disease. This is an estimated GFR based on the Modification of Diet in Renal Disease (MDRD) equation (Ann Intern Med 1999;130:461-70.), results for which depend on race. This estimate should not be used for renal-dosing of medications or dosing adjustments of radiocontrast dye without patient-specific correction for height and weight. Limitations of the eGFR, guidelines on chronic kidney disease definitions, and clinical action plans can be found at www.kidney.org and NEJM 2006;354:2473-83.							
Test Performed by: IRL - Florida							
5361 NW 33 Avenue							
Ft Lauderdale, FL 33309							

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Per Lab
Lipids Profile								
Triglycerides	45		Normal	mg/dL	0-150	Final		CL
If patient is taking N-Acetylcysteine, Triglycerides may be falsely decreased.								
If patient is taking Metamizole, Triglycerides and HDL may be falsely decreased.								
Cholesterol	92		Normal	mg/dL	0-200	Final		CL
HDL	54		Normal	mg/dL	0-60	Final		CL
NON-HDL	38			mg/dl		Final		CL
Goals for Patients with CHD or CHD risk equivalents:								
LDL: < 70 mg/dl								
NON-HDL: <100 mg/dl								
Goals for Patients with 2+ risk factors:								
LDL: <130 mg/dl								
NON-HDL: <160 mg/dl								
Goals for Patients with 0-1 risk factors:								

LDL:	<160 mg/dl								
NON-HDL:	<190 mg/dl								
L.DL Cholesterol	29	Normal	mg/dL	0-130	Final				CL
Chol/HDL Ratio	1.7	Normal		1.5-5.6	Final				CL
Test Performed by: IRL - Florida									
5361 NW 33 Avenue									
Ft Lauderdale, FL 33309									

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Performing Lab	Performing MD
H Pylori Ab IgG (THIS IS THE ONE DR. NOEL ORDERS)									
H Pylori Ab IgG				U/ml	0.00-0.90	In Lab		CL	
Test Performed by: IRL - Florida									
5361 NW 33 Avenue									
Ft Lauderdale, FL 33309									

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Perf Lab
PSA Diagnostic								
PSA Diagnostic	0.1		Normal	ng/mL	0-4.0	Final		CL
PSA is intended to be used as an aid in the detection and management of prostate cancer.								
See the 2013 American Urological Association (AUA) guidelines for result interpretation.								
Test Performed by: IRL - Florida								
5361 NW 33 Avenue								
Ft Lauderdale, FL 33309								

Performing ID	Name	Address	City	State	Zip	Country	County
CL^Core Lab^							

Message Type	Control Number	Filler Accession ID	Group Number
Results	LB174_0005626AA		

Order Status: P
 CMP ID# 010103
 ORDER Sequence#1 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA
 Collection Date: 08-17-2017 02:34
 Lab Receipt Date: 08-18-2017 13:08
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 08-18-2017 13:58
 Results Status: All Final Results Available, Order Complete.

Lipids Profile ID# 010009
 ORDER Sequence#2 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA
 Collection Date: 08-17-2017 02:34
 Lab Receipt Date: 08-18-2017 13:08
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 08-18-2017 13:58
 Results Status: All Final Results Available, Order Complete.

H Pylori Ab IgG (THIS IS THE ONE DR. NOEL ORDERS) ID# 060031
 ORDER Sequence#3 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA
 Collection Date: 08-17-2017 02:34
 Lab Receipt Date: 08-18-2017 13:08
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 08-18-2017 13:58
 Results Status: I

PSA Diagnostic ID# 026003
 ORDER Sequence#4 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA
 Collection Date: 08-17-2017 02:34
 Lab Receipt Date: 08-18-2017 13:08
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 08-18-2017 13:58
 Results Status: All Final Results Available, Order Complete.

Date/Time	Sending Application/Facility	Receiving Application/Facility
08-18-2017 14:02	&NBSP/ARMCO	CorrecTeK/ARMCOGL

Process ID	Version	Accept Ack.	Appl. Ack.
P-Production	2.3		

Collection Date: 2017-08-17 Thu

Patient	ID	Birth Date	Sex	SSN
ALMAZAN RUIZ, FELIPE	GCSO17MNI005042	06-26-1966	M	

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Performing Lab	Performing MD
CBC									
WBC		3.0	Below Normal	10 ³ /uL	3.6-11.0	Final		CL	
RBC		3.65	Below Normal	10 ⁶ /uL	4.50-5.90	Final		CL	
Hemoglobin		11.3	Below Normal	g/dL	13.0-18.0	Final		CL	
Hematocrit		34.8	Below Normal	%	40.0-52.0	Final		CL	
MCV	95.6		Normal	fL	81.0-97.0	Final		CL	
MCH	31.0		Normal	pg	26.0-34.0	Final		CL	
MCHC	32.4		Normal	g/dL	31.0 - 37.0	Final		CL	
RDW		17.4	Above Normal	%	11.5-15.0	Final		CL	
Platelet Count		41	Below Normal	10 ³ /uL	150-400	Final		CL	
Mean Platelet Vol	9.6		Normal	fL	7.4-10.4	Final		CL	
Neutrophil %	65.7		Normal	%	36.0-66.0	Final		CL	
Lymphocyte %	25.2		Normal	%	23.0-43.0	Final		CL	
Monocyte %	4.8		Normal	%	0.0-10.0	Final		CL	
Eosinophil %	3.9		Normal	%	0.0-5.0	Final		CL	
Basophil %	0.4		Normal	%	0.0-1.0	Final		CL	
Neutrophil Abs#	2.0		Normal	10 ³ /uL	1.6-8.2	Final		CL	
Lymphocyte Abs #		0.7	Below Normal	10 ³ /uL	1.1-4.7	Final		CL	
Monocyte Abs #	0.1		Normal	10 ³ /uL	0.0-1.1	Final		CL	
Eosinophil Abs #	0.1		Normal	10 ³ /uL	0.0-0.5	Final		CL	
Basophil Abs #	0.0		Normal	10 ³ /uL	0.0-0.4	Final		CL	
Test Performed by: IRL - Florida									
5361 NW 33 Avenue									
Ft Lauderdale, FL 33309									

Performing ID	Name	Address	City	State	Zip	Country	County
CL^Core Lab							

Message Type	Control Number	Filler Accession ID	Group Number
Results	LB174_0005626AA		

Order Status: P

CBC ID# 050004

ORDER Sequence#1 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA

Collection Date: 08-17-2017 02:34

Lab Receipt Date: 08-18-2017 13:08

Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 08-18-2017 13:49
 Results Status: All Final Results Available, Order Complete.

Date/Time	Sending Application/Facility	Receiving Application/Facility
08-18-2017 13:55	&NBSP/ARMCO	CorrecteK/ARMCOGI

Process ID	Version	Accept Ack.	Appl. Ack.
P=Production	2.3		

Collection Date: 2017-08-17 Thu

Patient	ID	Birth Date	Sex	SSN
ALMAZAN RUIZ, FJJIPE	GCS017MNI005042	06-26-1966	M	

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Performing Lab	Performing MD
CBC									
WBC		3.0	Below Normal	10 ³ /uL	3.6-11.0	Final		CL	
RBC		3.65	Below Normal	10 ⁶ /uL	4.50-5.90	Final		CL	
Hemoglobin		11.3	Below Normal	g/dL	13.0-18.0	Final		CL	
Hematocrit		34.8	Below Normal	%	40.0-52.0	Final		CL	
MCV	95.6		Normal	fL	81.0-97.0	Final		CL	
MCH	31.0		Normal	pg	26.0-34.0	Final		CL	
MCHC	32.4		Normal	g/dL	31.0 - 37.0	Final		CL	
RDW		17.4	Above Normal	%	11.5-15.0	Final		CL	
Platelet Count		41	Below Normal	10 ³ /uL	150-400	Final		CL	
Mean Platelet Vol	9.6		Normal	fL	7.4-10.4	Final		CL	
Neutrophil %	65.7		Normal	%	36.0-66.0	Final		CL	
Lymphocyte %	25.2		Normal	%	23.0-43.0	Final		CL	
Monocyte %	4.8		Normal	%	0.0-10.0	Final		CL	
Eosinophil %	3.9		Normal	%	0.0-5.0	Final		CL	
Basophil %	0.4		Normal	%	0.0-1.0	Final		CL	
Neutrophil Abs#	2.0		Normal	10 ³ /uL	1.6-8.2	Final		CL	
Lymphocyte Abs #		0.7	Below Normal	10 ³ /uL	1.1-4.7	Final		CL	
Monocyte Abs #	0.1		Normal	10 ³ /uL	0.0-1.1	Final		CL	
Eosinophil Abs #	0.1		Normal	10 ³ /uL	0.0-0.5	Final		CL	
Basophil Abs #	0.0		Normal	10 ³ /uL	0.0-0.4	Final		CL	
Test Performed by: IRL - Florida									
5361 NW 33 Avenue									
Ft Lauderdale, FL 33309									

Performing ID	Name	Address	City	State	Zip	Country	County
CL^Core Lab							

Message Type	Control Number	Filler Accession ID	Group Number
Results	LB174_0005626AA		

Order Status: P

CBC ID# 050004

ORDER Sequence#1 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA

Collection Date: 08-17-2017 02:34

Lab Receipt Date: 08-18-2017 13:08

Ordering Provider: (b)(6); (b)(7)(C)
Observation Rpt Date: 08-18-2017 13:49
Results Status: All Final Results Available, Order Complete.

Date/Time	Sending Application/Facility	Receiving Application/Facility
08-18-2017 13:55	&NBSP/ARMCO	CorrecTeK/ARMCOGI.

Process ID	Version	Accept Ack.	Appl. Ack.
P Production	2.3		

Collection Date: 2017-08-17 Thu

Patient	ID	Birth Date	Sex	SSN
ALMAZAN RUIZ, FELIPE	GCSO17MNI005042	06-26-1966	M	

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date
Prothromin Time							
PT		13.6	Above Normal	Seconds	9.4-12.5	Final	
Pro Time INR	1.2					Final	
PT reference range: 9.4-12.5							
Use INR for clinical decision making - Recommended Therapeutic Range:							
INDICATION TARGETED INR RANGE							
Prevention and treatment of VTE 2 - 3							
Atrial Fibrillation 2 - 3							
Acute myocardial infarction 2 - 3							
Valvular heart disease 2 - 3							
Prosthetic tissue heart valve 2 - 3							
Prosthetic mechanical heart valves 2.5 - 3.5							
Recurrent Thromboembolism 2.5 - 3.5							
Targeted INR range of 2-3 is appropriate for patients who have a mechanical bileaflet in the aortic position, normal cardiac chamber size, and no other risk factors for stroke.							
"Co-administration of argatroban and warfarin produces a combined effect on INR. Consult pharmacist or physician to determine if warfarin dose should be held when INR is elevated and patient is receiving argatroban."							
Test Performed by: IRL - Florida							
5361 NW 33 Avenue							
Ft Lauderdale, FL 33309							

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Performing Lab	Performing MD
PTT									
Activated PTT		41.6	Above Normal	Seconds	25.1-36.5	Final		CL	
Therapeutic PTT range of 50 to 89 seconds corresponds to 0.3-0.7 units anti-Xa activity.									
Test Performed by: IRL - Florida									
5361 NW 33 Avenue									
Ft Lauderdale, FL 33309									

Performing ID	Name	Address	City	State	Zip	Country	County
CL^Core Lab^AAA							

Message Type	Control Number	Filler Accession ID	Group Number
Results	LB174_0005626AA		

Order Status: P
 Prothromin Time ID# 050012
 ORDER Sequence#1 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA
 Collection Date: 08-17-2017 02:34
 Lab Receipt Date: 08-18-2017 13:08
 Ordering Provider: (b)(6); (b)(7)(C)

Observation Rpt Date: 08-18-2017 13:56
Results Status: All Final Results Available, Order Complete.

PTT ID# 050016
ORDER Sequence#2 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA
Collection Date: 08-17-2017 02:34
Lab Receipt Date: 08-18-2017 13:08
Ordering Provider: (b)(6); (b)(7)(C)
Observation Rpt Date: 08-18-2017 13:56
Results Status: All Final Results Available, Order Complete.

Date/Time	Sending Application/Facility	Receiving Application/Facility
08-18-2017 14:00	&NBSP/ARMCO	CorrecTeK/ARMCOGL

Process ID	Version	Accept Ack.	Appl. Ack.
P--Production	2.3		

Collection Date: 2017-08-17 Thu

Patient	ID	Birth Date	Sex	SSN
ALMAZAN RUIZ, FELIPE	GCSO17MNI005042	06-26-1966	M	

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Performing Lab	Performing MD
Prothromin Time									
PT				Seconds	9.4-12.5	In Lab		CL	
Pro Time INR						In Lab		CL	
Test Performed by: IRI. - Florida									
5361 NW 33 Avenue									
Ft Lauderdale, FL 33309									

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Performing Lab	Performing MD
PTT									
Activated PTT		41.6	Above Normal	Seconds	25.1-36.5	Final		CL	
Therapeutic PTT range of 50-89 seconds corresponds to									
0.3-0.7 units anti-Xa activity.									
Test Performed by: IRI. Florida									
5361 NW 33 Avenue									
Ft Lauderdale, FL 33309									

Performing ID	Name	Address	City	State	Zip	Country	County
CL^Core Lab^^^							

Message Type	Control Number	Filler Accession ID	Group Number
Results	LB174_0005626AA		

Order Status: P

Prothromin Time ID# 050012

ORDER Sequence#1 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA

Collection Date: 08-17-2017 02:34

Lab Receipt Date: 08-18-2017 13:08

Ordering Provider: (b)(6); (b)(7)(C)

Observation Rpt Date: 08-18-2017 13:56

Results Status: I

PTT ID# 050016

ORDER Sequence#2 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA

Collection Date: 08-17-2017 02:34

Lab Receipt Date: 08-18-2017 13:08

Ordering Provider: (b)(6); (b)(7)(C)

Observation Rpt Date: 08-18-2017 13:56

Results Status: All Final Results Available, Order Complete.

Date/Time	Sending Application/Facility	Receiving Application/Facility
08-18-2017 13:59	&NBSP/ARMCO	CorrecTeK/ARMCOGL

Process ID	Version	Accept Ack.	Appl. Ack.
P=Production	2.3		

Collection Date: 2017-08-17 Thu

Patient	ID	Birth Date	Sex	SSN
ALMAZAN RUIZ, FELIPE	GCSO17MNI005042	06-26-1966	M	

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Performing Lab	Performing MD
Prothromin Time									
PT				Seconds	9.4-12.5	In Lab		CL	
Pro Time INR						In Lab		CL	
Test Performed by: IRL - Florida									
5361 NW 33 Avenue									
Ft Lauderdale, FL 33309									

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Performing Lab	Performing MD
PTT									
Activated PTT		41.6	Above Normal	Seconds	25.1-36.5	Final		CL	
Therapeutic PTT range of 50-89 seconds corresponds to									
0.3-0.7 units anti-Xa activity.									
Test Performed by: IRL - Florida									
5361 NW 33 Avenue									
Ft Lauderdale, FL 33309									

Performing ID	Name	Address	City	State	Zip	Country	County
CL/Cor Lab							

Message Type	Control Number	Filler Accession ID	Group Number
Results	LB174_0005626AA		

Order Status: P
 Prothromin Time ID# 050012
 ORDER Sequence#1 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA
 Collection Date: 08-17-2017 02:34
 Lab Receipt Date: 08-18-2017 13:08
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 08-18-2017 13:56
 Results Status: I

PTT ID# 050016
 ORDER Sequence#2 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA
 Collection Date: 08-17-2017 02:34
 Lab Receipt Date: 08-18-2017 13:08
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 08-18-2017 13:56
 Results Status: All Final Results Available, Order Complete.

Date/Time	Sending Application/Facility	Receiving Application/Facility
08-18-2017 13:59	&NBSP/ARMCO	CorrecTeK/ARMCOGL

Process ID	Version	Accept Ack.	Appl. Ack.
P-Production	2.3		

Collection Date: 2017-08-17 Thu

Patient	ID	Birth Date	Sex	SSN
ALMAZAN RUIZ, FELIPE	GCSO17MNI005042	06-26-1966	M	

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date
CMP							
Sodium	141		Normal	mmol/L	135-145	Final	
Potassium	4.3		Normal	mmol/L	3.5-5.5	Final	
Chloride	104		Normal	mmol/L	95-110	Final	
Carbon Dioxide	26		Normal	mmol/L	19-34	Final	
Anion Gap	15.3		Normal	mmol/L	10-20	Final	
Glucose	86		Normal	mg/dL	70-110	Final	
Calcium	8.8		Normal	mg/dL	8.4-10.2	Final	
Protein, Total	6.9		Normal	g/dL	5.5-8.7	Final	
Albumin	3.6		Normal	g/dL	3.2-5.0	Final	
Bilirubin Total		1.7	Above Normal	mg/dL	0.1-1.2	Final	
Alkaline Phos		162	Above Normal	U/L	20-130	Final	
AST (SGOT)	35		Normal	U/L	10-40	Final	
ALT (SGPT)	25		Normal	U/L	10-60	Final	
Urea Nitrogen	17		Normal	mg/dL	6-22	Final	
Creatinine	0.70		Normal	mg/dL	0.43-1.13	Final	
eGFR NonAfrican Am	> 60					Final	
eGFR African Amer	> 60					Final	
eGFR less than 60 (ml/min/1.73) square meters may indicate chronic kidney disease. This is an estimated GFR based on the Modification of Diet in Renal Disease (MDRD) equation (Ann Intern Med 1999;130:461-70.), results for which depend on race. This estimate should not be used for renal-dosing of medications or dosing adjustments of radiocontrast dye without patient-specific correction for height and weight. Limitations of the eGFR, guidelines on chronic kidney disease definitions, and clinical action plans can be found at www.kidney.org and NEJM 2006;354:2473-83.							
Test Performed by: IRL - Florida							
5361 NW 33 Avenue							
Ft Lauderdale, FL 33309							

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Per Lab
Lipids Profile								
Triglycerides	45		Normal	mg/dL	0-150	Final		CL
If patient is taking N-Acetylcysteine, Triglycerides may be falsely decreased.								
If patient is taking Metamizole, Triglycerides and HDL may be falsely decreased.								
Cholesterol	92		Normal	mg/dL	0-200	Final		CL
HDL	54		Normal	mg/dL	0-60	Final		CL
NON-HDL	38			mg/dL		Final		CL
Goals for Patients with CHD or CHD risk equivalents:								
LDL: < 70 mg/dL								
NON-HDL: <100 mg/dL								
Goals for Patients with 2+ risk factors:								
LDL: <130 mg/dL								
NON-HDL: <160 mg/dL								
Goals for Patients with 0-1 risk factors:								

LDL:	<160 mg/dl								
NON-HDL:	<190 mg/dl								
LDL Cholesterol		29	Normal	mg/dL	0-130	Final			CL
Chol/HDL Ratio		1.7	Normal		1.5-5.6	Final			CL
Test Performed by: IRL - Florida									
5361 NW 33 Avenue									
Ft Lauderdale, FL 33309									

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Performing Lab	Performing MD
H Pylori Ab IgG (THIS IS THE ONE DR. NOEL ORDERS)									
H Pylori Ab IgG				U/mL	0.00-0.90	In Lab		CL	
Test Performed by: IRL - Florida									
5361 NW 33 Avenue									
Ft Lauderdale, FL 33309									

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Performing Lab	Performing MD
PSA Diagnostic									
PSA Diagnostic				ng/mL	0-4.0	In Lab		CL	
Test Performed by: IRL - Florida									
5361 NW 33 Avenue									
Ft Lauderdale, FL 33309									

Performing ID	Name	Address	City	State	Zip	Country	County
CL^Core Lab^							

Message Type	Control Number	Filler Accession ID	Group Number
Results	LB174_0005626AA		

Order Status: P
 CMP ID# 010103
 ORDER Sequence#1 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA
 Collection Date: 08-17-2017 02:34
 Lab Receipt Date: 08-18-2017 13:08
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 08-18-2017 13:48
 Results Status: All Final Results Available, Order Complete.

Lipids Profile ID# 010009
 ORDER Sequence#2 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA
 Collection Date: 08-17-2017 02:34
 Lab Receipt Date: 08-18-2017 13:08
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 08-18-2017 13:48
 Results Status: All Final Results Available, Order Complete.

H Pylori Ab IgG (THIS IS THE ONE DR. NOEL ORDERS) ID# 060031
 ORDER Sequence#3 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA
 Collection Date: 08-17-2017 02:34
 Lab Receipt Date: 08-18-2017 13:08
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 08-18-2017 13:48
 Results Status: I

PSA Diagnostic ID# 026003
 ORDER Sequence#4 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA
 Collection Date: 08-17-2017 02:34
 Lab Receipt Date: 08-18-2017 13:08
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 08-18-2017 13:48
 Results Status: I

Date/Time	Sending Application/Facility	Receiving Application/Facility
08-18-2017 13:54	&NBSP/ARMCO	CorrecTek/ARMCOGL

Process ID	Version	Accept Ack.	Appl. Ack.
P-Production	2.3		

Collection Date: 2017-08-17 Thu

Patient	ID	Birth Date	Sex	SSN
ALMAZAN RUIZ, FELIPE	GCS017MNI005042	06-26-1966	M	

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date
CMP							
Sodium	141		Normal	mmol/L	135-145	Final	
Potassium	4.3		Normal	mmol/L	3.5-5.5	Final	
Chloride	104		Normal	mmol/L	95-110	Final	
Carbon Dioxide	26		Normal	mmol/L	19-34	Final	
Anion Gap	15.3		Normal	mmol/L	10-20	Final	
Glucose	86		Normal	mg/dL	70-110	Final	
Calcium	8.8		Normal	mg/dL	8.4-10.2	Final	
Protein, Total	6.9		Normal	g/dL	5.5-8.7	Final	
Albumin	3.6		Normal	g/dL	3.2-5.0	Final	
Bilirubin Total		1.7	Above Normal	mg/dL	0.1-1.2	Final	
Alkaline Phos		162	Above Normal	U/L	20-130	Final	
AST (SGOT)	35		Normal	U/L	10-40	Final	
ALT (SGPT)	25		Normal	U/L	10-60	Final	
Urea Nitrogen	17		Normal	mg/dl	6-22	Final	
Creatinine	0.70		Normal	mg/dl	0.43-1.13	Final	
eGFR NonAfrican Am	> 60					Final	
eGFR African Amer	> 60					Final	
eGFR less than 60 (ml/min/1.73) square meters may indicate chronic kidney disease. This is an estimated GFR based on the Modification of Diet in Renal Disease (MDRD) equation (Ann Intern Med 1999;130:461-70.), results for which depend on race. This estimate should not be used for renal-dosing of medications or dosing adjustments of radiocontrast dye without patient-specific correction for height and weight. Limitations of the eGFR, guidelines on chronic kidney disease definitions, and clinical action plans can be found at www.kidney.org and NEJM 2006;354:2473-83.							
Test Performed by: 1RL - Florida							
5361 NW 33 Avenue							
Ft Lauderdale, FL 33309							

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Per Lab
Lipids Profile								
Triglycerides	45		Normal	mg/dL	0-150	Final		CL
If patient is taking N-Acetylcysteine, Triglycerides may be falsely decreased.								
If patient is taking Metamizole, Triglycerides and HDL may be falsely decreased.								
Cholesterol	92		Normal	mg/dL	0-200	Final		CL
HDL	54		Normal	mg/dL	0-60	Final		CL
NON-HDL	38			mg/dL		Final		CL
Goals for Patients with CHD or CVD risk equivalents:								
LDL: < 70 mg/dL								
NON-HDL: < 100 mg/dL								
Goals for Patients with 2+ risk factors:								
LDL: < 130 mg/dL								
NON-HDL: < 160 mg/dL								
Goals for Patients with 0-1 risk factors:								

LDL:	<160 mg/dl							
NON-HDL:	<190 mg/dl							
LDL Cholesterol	29	Normal	mg/dL	0-130	Final			CL
Cho/HDL Ratio	1.7	Normal		1.5-5.6	Final			CL
Test Performed by: IRL - Florida								
5361 NW 33 Avenue								
Ft Lauderdale, FL 33309								

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Perf Lab
H Pylori Ab IgG (THIS IS THE ONE DR. NOEL ORDERS)								
H Pylori Ab IgG	0.70		Normal	U/mL	0.00-0.90	Final		CL
< or = 0.90	Negative							
0.91-1.09	Equivocal							
> or = 1.10	Positive							
THE STOOL (FECAL) H. PYLORI ANTIGEN TEST IS THE PREFERRED TEST FOR DETECTING AND MONITORING GASTRIC H. PYLORI INFECTION.								
THE H. PYLORI IgG TEST THAT IS RESULTED ABOVE IS NOT RECOMMENDED FOR DIAGNOSIS OR ANTIBIOTIC MONITORING. PLEASE SEE THE INFORMATION BELOW.								
The serum H. pylori IgG test is not useful in determining acute or recurrent H. pylori infection or for monitoring the response to antibiotic therapy. If positive, it only indicates that the patient had H. pylori infection sometime in the past. It does not provide any clinically useful information about possible present infection in the patient. It cannot be used for monitoring antibiotic therapy.								
Test Performed by: IRL - Florida								
5361 NW 33 Avenue								
Ft. Lauderdale, FL 33309								

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Perf Lab
PSA Diagnostic								
PSA Diagnostic	0.1		Normal	ng/mL	0-4.0	Final		CL
PSA is intended to be used as an aid in the detection and management of prostate cancer.								
See the 2013 American Urological Association (AUA) guidelines for result interpretation.								
Test Performed by: IRL - Florida								
5361 NW 33 Avenue								
Ft. Lauderdale, FL 33309								

Performing ID	Name	Address	City	State	Zip	Country	County
CL^Core Lab^^^							

Message Type	Control Number	Filler Accession ID	Group Number
Results	LB174_0005626AA		

Order Status: F
 CMP ID# 010103
 ORDER Sequence#1 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA
 Collection Date: 08-17-2017 02:34
 Lab Receipt Date: (b)(6); (b)(7)(C)
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 08-18-2017 19:09
 Results Status: All Final Results Available, Order Complete.

Lipids Profile ID# 010009

ORDER Sequence#2 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA
 Collection Date: 08-17-2017 02:34
 Lab Receipt Date: 08-18-2017 13:08
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 08-18-2017 19:09
 Results Status: All Final Results Available, Order Complete.

H Pylori Ab IgG (THIS IS THE ONE DR. NOEL ORDERS) ID# 060031
 ORDER Sequence#3 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA
 Collection Date: 08-17-2017 02:34
 Lab Receipt Date: 08-18-2017 13:08
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 08-18-2017 19:09
 Results Status: All Final Results Available, Order Complete.

PSA Diagnostic ID# 026003
 ORDER Sequence#4 Control Number: LB174_0005626AA Filler Accession ID: LB174_0005626AA
 Collection Date: 08-17-2017 02:34
 Lab Receipt Date: 08-18-2017 13:08
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 08-18-2017 19:09
 Results Status: All Final Results Available, Order Complete.

Date/Time	Sending Application/Facility	Receiving Application/Facility
08-18-2017 19:17	&NBSP/ARMCO	CorrecTeK/ARMCOGL

Process ID	Version	Accept Ack.	Appl. Ack.
P=Production	2.3		

Collection Date: 2017-08-24 Thu

Patient	ID	Birth Date	Sex	SSN
ALMAZAN RUIZ, FELIPE	GCSO17MNI005042	06-26-1966	M	

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Performing Lab	Performing MD
Ammonia									
Ammonia		108	Above Normal	umol/L	11-35	Final		CL	
Test Performed by: IRL - Florida									
5361 NW 33 Avenue									
Ft Lauderdale, FL 33309									

Performing ID	Name	Address	City	State	Zip	Country	County
CL^Core Lab^^^							

Message Type	Control Number	Filler Accession ID	Group Number
Results	LB174_00057D650		

Order Status: F
 Ammonia ID# 020007
 ORDER Sequence#1 Control Number: LB174_00057D650 Filler Accession ID: LB174_00057D650
 Collection Date: 08-24-2017 00:16
 Lab Receipt Date: 08-25-2017 11:20
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 08-25-2017 11:39
 Results Status: All Final Results Available, Order Complete.

Date/Time	Sending Application/Facility	Receiving Application/Facility
08-25-2017 11:41	&NBSP/ARMCO	CorrecTeK/ARMCOGI.

Process ID	Version	Accept Ack.	Appl. Ack.
P=Production	2.3		

Collection Date: 2017-09-01 Fri

Patient	ID	Birth Date	Sex	SSN
ALMAZAN RUIZ, FELIPE	GCSO17MNI005042	06-26-1966	M	

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date
CMP							
Sodium	140		Normal	mmol/L	135-145	Final	
Potassium	4.0		Normal	mmol/L	3.5-5.5	Final	
Chloride	104		Normal	mmol/L	95-110	Final	
Carbon Dioxide	27		Normal	mmol/L	19-34	Final	
Anion Gap	13.0		Normal	mmol/L	10-20	Final	
Glucose	82		Normal	mg/dL	70-110	Final	
Calcium	8.9		Normal	mg/dL	8.4-10.2	Final	
Protein, Total	6.8		Normal	g/dL	5.5-8.7	Final	
Albumin	3.6		Normal	g/dL	3.2-5.0	Final	
Bilirubin Total		1.3	Above Normal	mg/dL	0.1-1.2	Final	
Alkaline Phos		151	Above Normal	U/L	20-130	Final	
AST (SGOT)	34		Normal	U/L	10-40	Final	
ALT (SGPT)	23		Normal	U/L	10-60	Final	
Venipuncture should occur prior to sulfasalazine or sulfapyridine administration due to the potential for falsely depressed results.							
Urea Nitrogen	11		Normal	mg/dL	6-22	Final	
Creatinine	0.80		Normal	mg/dL	0.43-1.13	Final	
eGFR NonAfrican Am	> 60					Final	
eGFR African Amcr	> 60					Final	
eGFR less than 60 (ml/min/1.73) square meters may indicate chronic kidney disease. This is an estimated GFR based on the Modification of Diet in Renal Disease (MDRD) equation (Ann Intern Med 1999;130:461-70.), results for which depend on race. This estimate should not be used for renal-dosing of medications or dosing adjustments of radiocontrast dye without patient-specific correction for height and weight. Limitations of the eGFR, guidelines on chronic kidney disease definitions, and clinical action plans can be found at www.kidney.org and NEJM 2006;354:2473-83.							
Test Performed by: IRL - Florida							
5361 NW 33 Avenue							
Et Lauderdale, FL 33309							

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Per Lab
Lipids Profile								
Triglycerides	43		Normal	mg/dL	0-150	Final		CL
If patient is taking N-Acetylcysteine, Triglycerides may be falsely decreased.								
If patient is taking Metamizole, Triglycerides and HDL may be falsely decreased.								
Cholesterol	95		Normal	mg/dL	0-200	Final		CL
HDL	56		Normal	mg/dL	0-60	Final		CL
NON-HDL	39			mg/dL		Final		CL
Goals for Patients with CHD or CHD risk equivalents:								
LDL:	< 70 mg/dL							
NON-HDL:	<100 mg/dL							
Goals for Patients with 2+ risk factors:								
LDL:	<130 mg/dL							

NON-HDL:	<160 mg/dl							
Goals for Patients with 0-1 risk factors:								
LDL:	<160 mg/dl							
NON-HDL:	<190 mg/dl							
L.DL Cholesterol	30		Normal	mg/dL	0-130	Final		CL
Chol/HDL Ratio	1.7		Normal		1.5-5.6	Final		CL
Test Performed by: IRL - Florida								
5361 NW 33 Avenue								
Ft Lauderdale, FL 33309								

Performing ID	Name	Address	City	State	Zip	Country	County
CL^Core Lab^							

Message Type	Control Number	Filler Accession ID	Group Number
Results	LB174_0005975BE		

Order Status: P
 CMP ID# 010103
 ORDER Sequence#1 Control Number: LB174_0005975BE Filler Accession ID: LB174_0005975BE
 Collection Date: 09-01-2017 00:54
 Lab Receipt Date: 09-02-2017 13:52
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 09-02-2017 14:23
 Results Status: All Final Results Available, Order Complete.

Lipids Profile ID# 010009
 ORDER Sequence#2 Control Number: LB174_0005975BE Filler Accession ID: LB174_0005975BE
 Collection Date: 09-01-2017 00:54
 Lab Receipt Date: 09-02-2017 13:52
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 09-02-2017 14:23
 Results Status: All Final Results Available, Order Complete.

Date/Time	Sending Application/Facility	Receiving Application/Facility
09-02-2017 14:24	&NBSP/ARMCO	CorrecTeK/ARMCOGI.

Process ID	Version	Accept Ack.	Appl. Ack.
P-Production	2.3		

Collection Date: 2017-09-01 Fri

Patient	ID	Birth Date	Sex	SSN
ALMAZAN RUIJZ, FELIPE	GCSO17MNI005042	06-26-1966	M	

Test Name	Normal Results	Abnormal Results	Abnormal Flags	Units	Reference Range	Status	Observation Date	Performing Lab	Performing MD
CBC									
WBC		2.8	Below Normal	10 ³ /uL	3.6-11.0	Final		CL	
RBC		3.63	Below Normal	10 ⁶ /uL	4.50-5.90	Final		CL	
Hemoglobin		11.3	Below Normal	g/dL	13.0-18.0	Final		CL	
Hematocrit		33.1	Below Normal	%	40.0-52.0	Final		CL	
MCV	91.1		Normal	fl	81.0-97.0	Final		CL	
MCH	31.2		Normal	pg	26.0-34.0	Final		CL	
MCHC	34.3		Normal	g/dL	31.0 - 37.0	Final		CL	
RDW		16.3	Above Normal	%	11.5-15.0	Final		CL	
Platelet Count		35	Below Normal	10 ³ /uL	150-400	Final		CL	
Mean Platelet Vol	9.6		Normal	fl	7.4-10.4	Final		CL	
Neutrophil %		67.4	Above Normal	%	36.0-66.0	Final		CL	
Lymphocyte %	25.8		Normal	%	23.0-43.0	Final		CL	
Monocyte %	4.6		Normal	%	0.0-10.0	Final		CL	
Eosinophil %	1.5		Normal	%	0.0-5.0	Final		CL	
Basophil %	0.7		Normal	%	0.0-1.0	Final		CL	
Neutrophil Abs#	1.9		Normal	10 ³ /uL	1.6-8.2	Final		CL	
Lymphocyte Abs #		0.7	Below Normal	10 ³ /uL	1.1-4.7	Final		CL	
Monocyte Abs #	0.1		Normal	10 ³ /uL	0.0-1.1	Final		CL	
Eosinophil Abs #	0.0		Normal	10 ³ /uL	0.0-0.5	Final		CL	
Basophil Abs #	0.0		Normal	10 ³ /uL	0.0-0.4	Final		CL	
Test Performed by: IRL - Florida									
5361 NW 33 Avenue									
Ft Lauderdale, FL 33309									

Performing ID	Name	Address	City	State	Zip	Country	County
CL^Core Lab^^^							

Message Type	Control Number	Filler Accession ID	Group Number
Results	LB174_0005975BE		

Order Status: F
 CBC ID# 050004
 ORDER Sequence#I Control Number: LB174_0005975BE Filler Accession ID: LB174_0005975BE
 Collection Date: 09-01-2017 00:54

Lab Receipt Date: 09-02-2017 13:52
 Ordering Provider: (b)(6); (b)(7)(C)
 Observation Rpt Date: 09-02-2017 15:45
 Results Status: All Final Results Available, Order Complete.

Date/Time	Sending Application/Facility	Receiving Application/Facility
09-02-2017 15:47	&NBSP/ARMCO	CorrecTeK/ARMCOGL

Process ID	Version	Accept Ack.	Appl. Ack.
P=Production	2.3		

FOR DOCTOR

Armor Correctional Health, Inc

(b)(6); (b)(7)(C)

SICK CALL REQUEST

FROM: (PLEASE PRINT)

Felipe Almonar Ruiz 1005042

(Inmate Name)
(Nombre) (Non)

(ID #)

06-26-66

D-1 B50-48

01-9-17

(Date of Birth)
(Fecha de Nacimiento)
(Dat Nesans Prizonye a)

(Localidad)
(Lojman)
(Housing Unit/Cell#)

(Fecha)
(Dat)
(Date / Time)

ONLY THE DOCTOR
GIVE THE DATE FOR
APPOINTMENT PLEASE
HELP MY

PROBLEM: (BE SPECIFIC)

PROBLEMA:

PWOBLE'M:

I Need See The Doctor The Name of Her

is (b)(6); (b)(7)(C), I want (b)(6); (b)(7)(C) because (b)(6); (b)(7)(C)

The Nurse ONLY NAME THE APPOINTMENT FOR OPTICAL

I have Pain in My Head and My EYES in My EYES

I FEEL LIKE FIRE and The People I see Strange

Aront Read Notning Please I need See THE DOCTOR

For My Apoinment on Medicine for EYES like VITINE

o SOMTHIN' DROPS for MY EYES THANK YOU

DATE/TIME RECEIVED: 9/1/17 2100 NURSE SIGNATURE: (b)(6); (b)(7)(C)

TRIAGE DECISION BY NURSING STAFF (Only check ONE box below)

Urgent: _____ Refer to Behavioral Health: _____

Referral to HCP: _____ Refer to Nurse Sick Call: _____

Refer to Dental: _____

Call Provider w/ Assessment: Temp _____ Pulse _____ Resp _____ BP _____ Wt _____

Other

TRIAGE DATE/TIME: 9/1/17 2100 NURSE SIGNATURE: (b)(6); (b)(7)(C)

Armor Correctional Health, Inc

SICK CALL REQUEST

FROM: (PLEASE PRINT)

Felipe Almazan R

1005042

(Inmate Name)
(Nombre) (Non)

(ID #)

6-26-1966

C-1-Bed13

27-8-17

(Date of Birth)
(Fecha de Nacimiento)
(Dat Nesans Prizonye a)

(Localidad)
(Lojman)
(Housing Unit/Cell#)

(Fecha)
(Dat)
(Date / Time)

PROBLEM: (BE SPECIFIC)

PROBLEMA:

PWOBLEM:

I NEED SEE THE DOCTOR BECAUSE I have To Much Pain in My Bond's I Want Somthin like Bengay is Hard THE PAI And I want A see The doctor THE LAST Went I see He Put in THE sistem FOR Examen in My Eyes I Need glasses PLEASE I Can'T Read Nothing I need Really The Glasses

8/29/17 DATE/TIME RECEIVED: 2:04S NURSE SIGNATURE (b)(6); (b)(7)(C)

TRIAGE DECISION BY NURSING STAFF (Only check ONE box)

- Urgent: Refer to Behavioral Health: Refer to Nurse Sick Call: Refer to HCP: Refer to Dental: Call Provider w/ Assessment: Temp Pulse Resp BP Wt Other

8/29/17 TRIAGE DATE/TIME: 2:00 NURSE SIGNATURE: (b)(6); (b)(7)(C)

Amaziah Rose, Felicia

Specific Authorization for Psychotropic Medications

I, the undersigned, hereby authorize the professional staff of this facility to administer treatment, limited to mental health medications, as follows:

ANXIOLYTICS/SEDATIVES/HYPNOTICS:

COMMON SIDE EFFECTS: The most common side effects are drowsiness, confusion, light-headedness, agitation, startedependent, difficulty walking, and problems with coordination.

APPROXIMATE LENGTH OF CARE: Generally, this medication will start to work in a few hours. Short-term use of this medication is recommended as dependency may develop. It is important that you take this medication as prescribed to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimum amount of medication needed to relieve your symptoms.

ATYPICAL ANTIPSYCHOTIC MEDS: Olanzapine Quetiapine

COMMON SIDE EFFECTS: You may feel drowsy when first taking these medications. Get up slowly from sitting or lying positions as these medications may cause low blood pressure. Short-term side effects may include insomnia, weight gain, agitation, headache, constipation, dry mouth, muscle rigidity, increased prolactin levels that may lead to an increase in breast tissue and milk production. Sensitivity to sun or sun lamps may develop, therefore excessive exposure must be avoided.

LESS COMMON SIDE EFFECTS: somnolence, dizziness, shaking, dizziness, constipation, nausea, and increased heart rate. In some people with heart problems or a slow heart beat, Geodon can cause serious and potentially fatal heart beat irregularities. Headache has been noted in dizziness. Long-term use may also potentially cause an irreversible muscular movement disorder called Tardive Dyskinesia.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of psychosis, bipolar mania, and antidepressants. It will help alleviate the symptoms quicker than other treatments available. Other treatments include activity therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within a few days. Long-term usage of this medication may be required to gain maximum benefit. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimal amount of medication to relieve your symptoms.

TYPICAL ANTIPSYCHOTIC MEDS: Chlorpromazine (Thorazine) Haloperidol (Haldol) Fluphenazine (Prolixin) Thioridazine (Miltaine) Perphenazine (Ferenbolin) Others

COMMON SIDE EFFECTS: You may feel drowsy when first taking these medications. Get up slowly from sitting or lying positions as these medications may cause low blood pressure. Short-term side effects may include dry mouth, blurred vision, tremors, nasal congestion, constipation, drowsiness, difficulty walking, muscle spasms, increases in appetite or weight gain, in relation or lack of menstrual periods in women, restlessness, stiffness and light-headedness. Sensitivity to sun or sun lamps may develop, therefore excessive exposure must be avoided.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of psychosis and schizophrenia. It will help alleviate the symptoms quicker than other treatments available. Other treatments include activity therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within a few days. Long-term usage of this medication may be required to gain maximum benefit. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimal amount of medication to relieve your symptoms.

SERENIN ANTIMANIPRISSANTS: Prozac (Fluoxetine) Zoloft (Sertraline) Effor Others

COMMON SIDE EFFECTS: Short-term side effects may include dry mouth, tremors, nausea, nervousness, anxiety, dizziness, headache, drowsiness, insomnia, constipation and sexual dysfunction.

LESS COMMON SIDE EFFECTS: other side effects you may experience are constipation, heartburn, blurred vision, rash, tooth changes, dizziness, and hot flashes.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of depression. Other treatments include activity therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within 10-14 days but may take up to 4-6 weeks for significant changes in mood to occur. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimal amount of medication to relieve your symptoms.

TRICYCLIC OR TETRACYCLIC ANTIDEPRESSANTS: Amitriptyline (Elavil) Doxepin (Sinequan) Nortriptyline (Pamelor) Imipramine (Tofranil) Others

COMMON SIDE EFFECTS: You may feel drowsy when first taking these medications. Get up slowly from sitting or lying positions as these medications may cause low blood pressure. Short-term side effects may include dry mouth, blurred vision, tremors, nasal congestion, constipation, drowsiness, difficulty walking, and light-headedness. Sensitivity to sun or sun lamps may develop, therefore excessive exposure must be avoided.

LESS COMMON SIDE EFFECTS: An uncommon side effect with Trazodone is priapism which is a spontaneous erection requiring medical intervention.

ALTERNATIVE THERAPIES: It has been determined, at this time, that this category of medication is effective for treatment of depression. Other treatments include activity therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within a few days but may take up to 4-6 weeks for significant changes in mood to occur. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimal amount of medication to relieve your symptoms.

ANTI-PAROXISMAN:

Captopril (Lisinopril)

Prochlorperazine (Compazine)

Arbutin (Furosemide)

COMMON SIDE EFFECTS: Short-term side effects may include dizziness, dry mouth, nausea, constipation, blurred vision, dizziness, weakness, drowsiness, fatigue, headache, difficulty swallowing, constipation, rapid or pounding heartbeat, eye pain, and tired.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of this condition. Other treatments include lowering or discontinuation of anti-psychotic medications. Other treatments include lowering or discontinuation of anti-psychotic medications.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within a few hours. It is generally used for short lengths of time. However, in certain, long-term usage is needed. Your health care practitioner will adjust the dosage from time to time based on your symptoms. Perhaps blood tests may be ordered to monitor that the medication is safe. The practitioner will review the medication and its effects every month.

DEBAMINE/TEREPTOL:

Valproic acid

Lithium Salts (Depakote, Depakol)

Trazodone

COMMON SIDE EFFECTS: The most common side effects are tremor, dizziness, sedation, malaise, drowsiness, dizziness, blurred vision, dry mouth, constipation, rapid or pounding heartbeat, eye pain, and headache.

VALPROIC ACID TOXICITY: The development of extreme drowsiness, fatigue, blurred vision, mental confusion or disorientation on your part requires immediate medical evaluation and intervention.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of bipolar disorder. It will help alleviate the symptoms quicker than other treatments available. Other treatments include cognitive therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within a few days. Long-term usage of this medication may be required to gain maximum benefit. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimum amount of medication to relieve your symptoms. You will need periodic blood testing levels for as long as you take the medication.

LITHIUM:

Lithium Oxide

Lithium Citrate

COMMON SIDE EFFECTS: Possible side effects may include tremor, fatigue, nausea, weight gain, increased thirst, hives, muscle weakness, increased blood, thyroid disorder, and increased risk of sodium.

SYMPTOMS OF TOXICITY: When there is too much lithium in your system you can experience difficulty walking, severe drowsiness, slurred speech, extreme drowsiness, severe vomiting, muscle weakness.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of bipolar disorder. It will help alleviate the symptoms quicker than other treatments available. Other treatments include cognitive therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within a few days. Long-term usage of this medication may be required to gain maximum benefit. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimum amount of medication to relieve your symptoms. You will need periodic blood testing levels for as long as you take the medication.

WELLBUTRIN:

Wellbutrin

COMMON SIDE EFFECTS: Possible side effects may include tremor, fatigue, nausea, weight gain, increased thirst, hives, muscle weakness, increased blood, thyroid disorder, and increased risk of sodium.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of depression. Alternative treatments include cognitive therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: Generally, this medication will start to work in 1-2 weeks with maximum benefit in 4-6 weeks. Long-term use of this medication may be required to gain maximum benefit. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimum amount of medication needed to relieve your symptoms.

RISKS AND HAZARDS: During use of any of these medications, avoid alcohol or other drug use. Avoid operation of a motor vehicle or other activities that require alertness until you know how this drug affects you. Sudden discontinuation of medications may cause medical problems please discuss discontinuation with the medical staff prior to stopping the medication.

I understand that I can decide to stop taking this medication at any time by telling the practitioner or my other health care staff member. If I decide to stop taking this medication, it will not affect my ability to receive other health care services. I understand that by signing this form I am agreeing to let ARMOR C LLC, a controlled agent, treat me with a psychotropic drug. I have been given and have had explained information about the treatment and alternative treatments, the risk and hazards associated with this treatment, the possible side effects that may experience from this treatment, and the appropriate levels of care. I have been given a chance to ask questions about my treatment and have had an opportunity to ask questions about my treatment. I have been given a chance to ask questions about my treatment and have had an opportunity to ask questions about my treatment. I might have about my treatment with the provider and that a copy of this form is available to (b)(6), (b)(7)(C)

Patient Signature

Staff Signature:

8/22/17 Time: 3:00 P
8/24/17 Time: 3:00 P

PRINT NAME

Almazan Ruiz, Felipe

DOB

6/26/66 M

MR

TITLE

CMACS

Amazon River, Felicit

Specific Authorization for Psychotropic Medications

I, the undersigned, hereby authorize the professional staff of this facility to administer treatment, limited to mental health medications, as follows:

ANXIOLYTIC/SEDATIVE/HYPNOTIC: Clonazepam Lorazepam Diazepam

COMMON SIDE EFFECTS: The most common side effects are drowsiness, confusion, light-headedness, agitation, slurred speech, difficulty walking, and problems with coordination.

APPROXIMATE LENGTH OF CARE: Generally, this medication will start to work in a few hours. Short-term use of this medication is recommended as dependency may develop. It is important that you take this medication as prescribed to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimal amount of medication needed to relieve your symptoms.

ATYPICAL ANTIPSYCHOTIC MEDS: Risperidone Olanzapine

COMMON SIDE EFFECTS: You may feel drowsy when first taking these medications. Get up slowly from sitting or lying positions as these medications may cause low blood pressure. Short-term side effects may include dizziness, weight gain, agitation, headache, constipation, blurred vision, increased prolactin levels that may lead to an increase in breast tissue and milk production. Sensitivity to sun or sun lamps may develop, therefore excessive exposure must be avoided.

LESS COMMON SIDE EFFECTS: somnolence, stiffness, shakiness, dizziness, constipation, nausea, and increased heart rate. In some people with heart problems or a slow heartbeat, Geodon can cause serious and potentially fatal heart rhythm irregularities. Risperidone has been linked to diabetes. Long-term use may also potentially cause an irreversible muscular movement disorder called Tardive Dyskinesia.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of psychosis, bipolar mania, and schizoaffective. It will help alleviate the symptoms quicker than other treatments available. Other treatments include actively therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within a few days. Long-term usage of this medication may be required to gain maximum benefit. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimal amount of medication to relieve your symptoms.

TYPICAL ANTIPSYCHOTIC MEDS: Chlorpromazine (Thorazine) Haloperidol (Haldol) Prochlorperazine (Compazine) Thioridazine (Miltown) Meprobamate (Meproban) Other

COMMON SIDE EFFECTS: You may feel drowsy when first taking these medications. Get up slowly from sitting or lying positions as these medications may cause low blood pressure. Short-term side effects may include dry mouth, blurred vision, tremors, nasal congestion, constipation, drowsiness, difficulty urinating, muscle spasms, increase in appetite or weight gain, bloating or lack of menstrual periods in women, restlessness, stiffness and light-headedness. Sensitivity to sun or sun lamps may develop, therefore excessive exposure must be avoided.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of psychosis and schizoaffective. It will help alleviate the symptoms quicker than other treatments available. Other treatments include actively therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within a few days. Long-term usage of this medication may be required to gain maximum benefit. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimal amount of medication to relieve your symptoms.

SEROTONIN ANTIDEPRESSANTS: Paroxetine (Paxil) Sertraline (Zoloft) Venlafaxine (Effexor) Other

COMMON SIDE EFFECTS: Short-term side effects may include dry mouth, tremors, nausea, nervousness, anxiety, diarrhea, headache, drowsiness, insomnia, sedation and sexual dysfunction.

LESS COMMON SIDE EFFECTS: other side effects you may experience are constipation, heartburn, blurred vision, rash, bottle changes, dizziness, and hot flashes.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of depression. Other treatments include actively therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within 10-14 days but may take as long as 4-6 weeks for significant changes in mood to occur. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimal amount of medication to relieve your symptoms.

TRICYCLIC OR TETRACYCLIC ANTIDEPRESSANTS: Amitriptyline (Elavil) Imipramine (Tofranil) Doxepin (Sinequan) Other

COMMON SIDE EFFECTS: You may feel drowsy when first taking these medications. Get up slowly from sitting or lying positions as these medications may cause low blood pressure. Short-term side effects may include dry mouth, blurred vision, tremors, nasal congestion, constipation, drowsiness, difficulty urinating, and light-headedness. Sensitivity to sun or sun lamps may develop, therefore excessive exposure must be avoided.

LESS COMMON SIDE EFFECTS: An uncommon side effect with Trazodone is priapism which is a painful erection requiring medical intervention.

ALTERNATIVE THERAPIES: It has been determined, at this time, that this category of medication is effective for treatment of depression. Other treatments include actively therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within a few days but may take as long as 4-6 weeks for significant changes in mood to occur. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimal amount of medication to relieve your symptoms.

ANTI-PARKINSONIAN:

Cogentin (Benztropine)

Benadryl (Diphenhydramine)

Aricept (Donepezil)

COMMON SIDE EFFECTS: Short-term side effects may include drowsiness, dry mouth, nausea, nervousness, blurred vision, dizziness, weakness, constipation, confusion, difficulty urinating, constipation, rapid or pounding heartbeat, eye pain, and rash.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of side effects of anti-psychotic medications. Other treatments include lowering or discontinuation of anti-psychotic medications.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within a few hours. It is generally used for short lengths of time. However, in some cases, long-term usage is needed. Your health care practitioner will adjust the dosage from time to time based on your symptoms. Particular blood tests may be ordered to monitor that the medication is safe. The practitioner will review the medication and its effects every month.

DEPRESSANTS/TRICICLICS:

Valproic acid

Depressants (Diazepam, Doxepin)

Triciclics

COMMON SIDE EFFECTS: The most common side effects are drowsiness, dizziness, headache, constipation, dry mouth, blurred vision, weight gain, and increased heart rate.

VALPROIC ACID TOXICITY: The development of extreme drowsiness, fatigue, slurred speech, mental confusion or disorientation on your part requires immediate medical evaluation and intervention.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of bipolar disorder. It will help alleviate the symptoms quicker than other treatments available. Other treatments include psychotherapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within a few days. Long-term usage of this medication may be required to gain maximum benefit. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the smallest amount of medication to relieve your symptoms. You will need periodic blood Trough/Pre-dose levels for as long as you take this medication.

LITHIUM:

Lithium Carbonate

Lithium Citrate

COMMON SIDE EFFECTS: Possible side effects may include, tremor, thirst, weight gain, increased urination, loose stools, constipation, increased heart rate, thyroid disorder, and increased risk of seizure.

SYMPTOMS OF TOXICITY: When there is too much lithium in your system you can experience difficulty walking, nervousness, slurred speech, severe drowsiness, severe vomiting, muscle twitching.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of bipolar disorder. It will help alleviate the symptoms quicker than other treatments available. Other treatments include psychotherapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within a few days. Long-term usage of this medication may be required to gain maximum benefit. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the smallest amount of medication to relieve your symptoms. You will need periodic blood lithium levels for as long as you take this medication.

WELLBUTRIN:

Wellbutrin

COMMON SIDE EFFECTS: Possible side effects may include, dry mouth, weight gain, increased urination, loose stools, constipation, increased heart rate, thyroid disorder, and increased risk of seizure.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of depression. Alternative treatments include psychotherapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: Generally, this medication will start to work in 1-2 weeks with maximum benefit in 4-6 weeks. Long-term use of this medication may be required to gain maximum benefit. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the smallest amount of medication needed to relieve your symptoms.

RISKS AND HAZARDS: During use of any of these medications, avoid alcohol or other drug use. Avoid operation of a motor vehicle or other activities that require alertness until you know how this drug affects you. Serious discontinuation of medications may cause medical problems please discuss discontinuation with the medical staff prior to stopping the medication.

I understand that I can decide to stop taking this medication at any time by telling the physician or my other health care staff member. If I decide to stop taking this medication, it will not affect my ability to receive other health care services. I understand that by signing this form I am agreeing to let ARMOR CHC, a contracted agent, treat me with a psychotropic drug. I have been given and have had explained information about this treatment and the risks and hazards associated with this treatment, the possible side effects that may experience from this treatment, and the consequences of not taking this medication. I have been given a chance to ask questions about my treatment and have had my questions answered. I have been given a copy of this form.

Patient Signature: X

Staff Signature: _____

PATIENT NAME

Almazan Ruiz, Felipe

6/26/66 M

6/26/66

8/22/17 Time: 3:00 P
8/22/17 Time: 3:00 P



Glades County Detention Center

Inmate/Detainee Request or Grievance Form

(Must Check One of the Above Boxes)

07 MN-1005043

Inmate/Detainee Name: FELIPE AIMAZAN

Alien #: _____

Inmate/Detainee Gender: _____

Date of Request: 8-20-17

MNI#: 100 5043

Housing Area: C-1 - PAD-13

To: ICE Property Medical Mail Sergeant Lieutenant Captain Other: _____

(b)(6); (b)(7)(C)

You Help Because My Medication

AHORA NO SE VE NADA MEDICIN I TAKE EVERY DAY

(b)(6); (b)(7)(C)

I fillin My EYES DRY PLEASE

I need My GLASSES Please When I go To Court

They Give to mi but I can't SEE NOTHING M

EYES I filling Burning and MY HEAD I HAVE

PAIN So I need MY GLASSES PLEASE

(b)(6); (b)(7)(C)

Inmate/Detainee Signature

Response

Received By: (b)(6); (b)(7)(C)

Title: LEN

Date: 8/21/17

Response By: _____

Title: _____

Date: _____

Grievance Officer Approval: _____

Title: _____

Date: _____

KEEP ON PERSON (KOP) CONTRACT


If I meet the requirements for the "Keep on Person" medication program, and agree to the requirements below, I will be allowed to keep my medication in my possession:

1. I understand that only medications that are approved and ordered by the facility clinician will qualify for this program.
2. I understand that medication may be given to me in a special package that will contain no more than a (30) day supply of medication. The package will contain a label that includes my name, identification number, the medication name, and directions for its use.
3. I understand I must follow instructions on the medication label. Health care staff can check my medicine at any time to make sure I am taking it correctly.
4. I understand, if I believe I am having a problem with the medication, it is my responsibility to notify the nurse or doctor as soon as possible.
5. I AM RESPONSIBLE FOR MY MEDICATION. If I lose, tamper with, share or trade the medication, I will be terminated from the program and may be subject to disciplinary action.
6. If I am transferred or released from this facility I may take the medication with me to complete the prescription. I understand that the medication is not in a child proof container, and accept responsibility.
7. I have received a pre-printed information sheet on all my initial Keep on Person Medications.
8. Once released, I will need to follow up with my health care provider as needed.
9. My Keep on Person (KOP) Medication(s) is/are:

HYDROCORTISONE 1% CREAM APPLY TO AFFECTED AREA TWICE A DAY FOR 5 DAYS

ALLERGIES: NKDA

I HAVE READ THE KEEP ON PERSON (KOP) CONTRACT. I ACCEPT THESE TERMS AND ACCEPT RESPONSIBILITY FOR MY MEDICATION. I KNOW HOW TO TAKE MY MEDICATIONS PROPERLY. ALL OF MY QUESTIONS HAVE BEEN ANSWERED.



PATIENT'S SIGNATURE

8/18/17 2100

DATE

(b)(6); (b)(7)(C)

WITNESS (MEDICAL STAFF)

08-18-2017 Fri 07:34 AM

DATE

PATIENT NAME: FELIPE ALMAZAN RUIZ	NO: GCSO17MNI005042	D.O.B. 06-26-1966	SEX: M	LOCATION: 1*DORM 1*C*013 1*DORM 1*C*013
---	-------------------------------	-----------------------------	------------------	--

Armor Correctional Health, Inc

SICK CALL REQUEST

FROM: (PLEASE PRINT)

Felipe Almazan 017 MN1005042

(Inmate Name)
(Nombre) (Non)

(ID #)

5-26-66

C-1

8-16-17

(Date of Birth)
(Fecha de Nacimiento)
(Dat Nesans Prizonye a)

(Localidad)
(Lojman)
(Housing Unit/Cell#)

(Fecha)
(Dat)
(Date / Time)

PROBLEM: (BE SPECIFIC)

PROBLEMA:

PWOBLE'M:

I Need See The Doctor be Cause He Told mi
I have 2 Apoinmentes, Monday and Tuesday
I ron't Recib Notin in My Dormitory
Please Because I ron't See Noting and HE
Told my y Need TEST FOR MY EYES PLEASE
The Doctor is (b)(6); (b)(7)(C) Please Help My
I Cant Read Noting PLEASE HELP MY

DATE/TIME RECEIVED: 2:00 8/17/17 NURSE SIGNATURE: (b)(6); (b)(7)(C)

TRIAGE DECISION BY NURSING STAFF (Only check ONE box below)

- Urgent: _____ Refer to Behavioral Health: _____
- Referral to HCP: _____ Refer to Nurse Sick Call: _____
- Refer to Dental: _____
- Call Provider w/ Assessment: Temp _____ Pulse _____ Resp _____ BP _____ Wt _____
- Other

TRIAGE DATE/TIME: 8/17/17 2:00 NURSE SIGNATURE: (b)(6); (b)(7)(C)

**Armor Correctional Health Services, Inc.
Informed Consent To Mental Health Treatment**

Felipe Almaraz Ruiz, agree to participate in mental health treatment at the GLDC Department (or designated volunteer service) (b)(6); (b)(7)(C). I hereby authorize staff members assigned to the Mental Health Department (or designated volunteer service) (b)(6); (b)(7)(C) to provide such treatment as agreed to and to perform the following services:

CONFIDENTIALITY:

Treatment staff members follow all ethical standards prescribed by state and federal law. Providers are required by law to practice guidelines and standards of care to keep records of the services you receive. These records are confidential with the exceptions noted below. Discussions between a mental health professional and a client are confidential. No information will be released without the client's written consent unless mandated by law. Possible exceptions to confidentiality include but are not limited to the following situations: child abuse; abuse of the elderly or disabled; abuse of patients in mental health facilities; sexual exploitation; AIDS/HIV infection and possible transmission; criminal prosecutions; child custody cases; suits in which the mental health of a party is in issue; situations where the treatment provider has a duty to disclose, or where, in the treatment provider's judgment, it is necessary to warn or disclose; a negligence suit brought by the client against the provider; or the filing of a complaint with the licensing or certifying board. If you have any questions regarding confidentiality, you should bring them to the attention of your treatment provider so that you and he/she can discuss this matter further.

CONSENT TO TREATMENT:

By signing this Client Information and Consent Form I acknowledge that I have read, understand, and agree to the terms and conditions contained in the Information and Client Consent form. I have been given appropriate opportunity to address any questions or request clarification for anything that is unclear to me. I am voluntarily agreeing to receive mental health assessment, treatment and services for myself and I understand that I may stop such treatment or services at any time. I also agree to respect the privacy of other clients and any information they may disclose in a group setting.

I understand that no warranty or promise has been made to me regarding the participation in or outcome of the proposed treatment. No information (b)(6); (b)(7)(C) will be provided as a result of attending the service(s) listed at (b)(6); (b)(7)(C). Terms of this agreement will expire upon discharge from this facility: (b)(6); (b)(7)(C) or upon my request.

NOTE: If you have a legal guardian mental health services will not be provided without the signature of your court appointed guardian. I understand that it is my duty to inform treatment staff of my legal status as it relates to guardianship.

Felipe Almaraz Ruiz 8/14/17
Signature - Client Date

(b)(6); (b)(7)(C) Date 8/14/17
(b)(6); (b)(7)(C) Date

<u>Felipe Almaraz Ruiz</u>	<u>A 028864928</u>	<u>02/24/88</u>	<u>M</u>	<u>GLDC</u>
NAME	NO.	D.O.B.	SEX	LOCATION

KEEP ON PERSON (KOP) CONTRACT


If I meet the requirements for the "Keep on Person" medication program, and agree to the requirements below, I will be allowed to keep my medication in my possession:

1. I understand that only medications that are approved and ordered by the facility clinician will qualify for this program.
2. I understand that medication may be given to me in a special package that will contain no more than a (30) day supply of medication. The package will contain a label that includes my name, identification number, the medication name, and directions for its use.
3. I understand I must follow instructions on the medication label. Health care staff can check my medicine at any time to make sure I am taking it correctly.
4. I understand, if I believe I am having a problem with the medication, it is my responsibility to notify the nurse or doctor as soon as possible.
5. I AM RESPONSIBLE FOR MY MEDICATION. If I lose, tamper with, share or trade the medication, I will be terminated from the program and may be subject to disciplinary action.
6. If I am transferred or released from this facility I may take the medication with me to complete the prescription. I understand that the medication is not in a child proof container, and accept responsibility.
7. I have received a pre-printed information sheet on all my initial Keep on Person Medications.
8. Once released, I will need to follow up with my health care provider as needed.
9. My Keep on Person (KOP) Medication(s) is/are:

clotrimazole 1%

ALLERGIES: **NKDA**

I HAVE READ THE KEEP ON PERSON (KOP) CONTRACT. I ACCEPT THESE TERMS AND ACCEPT RESPONSIBILITY FOR MY MEDICATION. I KNOW HOW TO TAKE MY MEDICATIONS PROPERLY. ALL OF MY QUESTIONS HAVE BEEN ANSWERED.


 PATIENT'S SIGNATURE

8/12/17
 DATE

(b)(6); (b)(7)(C)

WITNESS (MEDICAL STAFF)

08-12-2017 Sat 07:32 PM
 DATE

PATIENT NAME: FELIPE ALMAZAN RUIZ	NO: GCSO17MNI005042	D.O.B. 06-26-1966	SEX: M	LOCATION: 1*DORM 1*C*013 1*DORM 1*C*013
---	-------------------------------	-----------------------------	------------------	--

**Armor Correctional Health Services, Inc.
Informed Consent To Mental Health Treatment**

Felipe Almazan Ruiz, ^{OLD} agree to participate in mental health treatment at the Department (or designated volunteer services) to administer such treatment as agreed to and to perform the following services: (b)(6); (b)(7)(C)

CONFIDENTIALITY:

Treatment staff members follow all ethical standards prescribed by state and federal law. Providers are required by law to practice guidelines and standards of care to keep records of the services you receive. These records are confidential with the exceptions noted below. Discussions between a mental health professional and a client are confidential. No information will be released without the client's written consent unless mandated by law. Possible exceptions to confidentiality include but are not limited to the following situations: child abuse; abuse of the elderly or disabled; abuse of patients in mental health facilities; sexual exploitation; AIDS/HIV infection and possible transmission; criminal prosecutions; child custody cases; suits in which the mental health of a party is in issue; situations where the treatment provider has a duty to disclose, or where, in the treatment provider's judgment, it is necessary to warn or disclose; a negligence suit brought by the client against the provider; or the filing of a complaint with the licensing or certifying board. If you have any questions regarding confidentiality, you should bring them to the attention of your treatment provider so that you and he/she can discuss this matter further.

CONSENT TO TREATMENT:

By signing this Client Information and Consent Form I acknowledge that I have read, understand, and agree to the terms and conditions contained in the Information and Client Consent form. I have been given appropriate opportunity to address any questions or request clarification for anything that is unclear to me. I am voluntarily agreeing to receive mental health assessment, treatment and services for myself and I understand that I may stop such treatment or services at any time. I also agree to respect the privacy of other clients and any information they may disclose in a group setting.

I understand that no warranty or promise has been made to me regarding the participation in or outcome of the proposed treatment. No letters to the court or other documentation will be provided as a result of attending the service(s) listed at (b)(6); (b)(7)(C) at the terms of this agreement will expire upon discharge from this facility: (b)(6); (b)(7)(C), or upon my request.

NOTE: If you have a legal guardian mental health services will not be provided without the signature of your court appointed guardian. I understand that it is my duty to inform treatment staff of my legal status as it relates to guardianship.

Felipe Almazan Ruiz 8/14/17
Signature - Client Date

<div style="border: 1px solid black; padding: 5px;">(b)(6); (b)(7)(C)</div>	Date	8/14/17	Date	B.O.B.	SEX:	LOCATION:
<u>Felipe Almazan Ruiz</u> A 02886428 02/26/66 M <u>GCDC</u>						

Amazon Ruiz, Felipe

Specific Authorization for Psychotropic Medications

I, the undersigned, hereby authorize the professional staff of this facility to administer treatment limited to mental health medications, as follows:
ANTIDEPRESSANTS/SEDATIVES/HYPNOTICS: Amitriptyline Doxepin Imipramine Nortriptyline Trazodone

COMMON SIDE EFFECTS: The most common side effects are drowsiness, constipation, light-headedness, agitation, blurred vision, difficulty walking, and problems with coordination.

APPROXIMATE LENGTH OF CARE: Generally, this medication will start to work in a few hours. Short-term use of this medication is recommended as dependency may develop. It is important that you take this medication as prescribed to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimal amount of medication needed to relieve your symptoms.

ATYPICAL ANTIPSYCHOTIC MEDS: Risperidol Olanzapine

COMMON SIDE EFFECTS: You may feel drowsy when first taking these medications. Get up slowly from sitting or lying positions as these medications may cause low blood pressure. Short-term side effects may include insomnia, weight gain, agitation, headache, constipation, muscle rigidity, increased prolactin levels that may lead to an increase in breast tissue and milk production. Sensitivity to sun or sun lamps may develop, therefore excessive exposure must be avoided.

LESS COMMON SIDE EFFECTS: orthostatic hypotension, stiffness, nausea, dizziness, constipation, nausea, and increased heart rate. In some people with heart problems or a slow heart beat, Geodon can cause serious and potentially fatal heart beat irregularities. Risperidol has been linked to diabetes. Long-term use may also potentially cause an irreversible muscular movement disorder called Tardive Dyskinesia.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of psychosis, bipolar mania, and schizophrenia. It will help alleviate the symptoms quicker than other treatments available. Other treatments include actively therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to work within a few days. Long-term use of this medication may be required to gain maximum benefit. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimal amount of medication to relieve your symptoms.

TYPICAL ANTIPSYCHOTIC MEDS: Chlorpromazine (Thorazine) Haloperidol (Haldol) Fluphenazine (Prolixin)
 Thioridazine (Miltaine) Perphenazine (Trilafon) Others

COMMON SIDE EFFECTS: You may feel drowsy when first taking these medications. Get up slowly from sitting or lying positions as these medications may cause low blood pressure. Short-term side effects may include dry mouth, blurred vision, tremors, nasal congestion, constipation, drowsiness, difficulty walking, muscle spasms, increase in appetite or weight gain, reduction or lack of menstrual periods in women, restlessness, stiffness and light-headedness. Sensitivity to sun or sun lamps may develop, therefore excessive exposure must be avoided.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of psychosis and schizophrenia. It will help alleviate the symptoms quicker than other treatments available. Other treatments include actively therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to work within a few days. Long-term use of this medication may be required to gain maximum benefit. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimal amount of medication to relieve your symptoms.

SSRI/NDRI ANTIDEPRESSANTS: Prozac (Fluoxetine) Zoloft (Sertraline) Effexor (Venlafaxine)
 Others

COMMON SIDE EFFECTS: Short-term side effects may include dry mouth, tremors, nausea, nervousness, anxiety, diarrhea, headache, drowsiness, insomnia, and sexual dysfunction.

LESS COMMON SIDE EFFECTS: other side effects you may experience are constipation, heartburn, blurred vision, rash, taste changes, dizziness, and hot flashes.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of depression. Other treatments include actively therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to work within 10-14 days but may take as long as 4-6 weeks for significant changes in mood to occur. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimal amount of medication to relieve your symptoms.

TRICYCLIC OR TETRACYCLIC ANTIDEPRESSANTS: Amitriptyline (Elavil) Nortriptyline (Pampral)
 Imipramine (Desyrel) Doxepin

COMMON SIDE EFFECTS: You may feel drowsy when first taking these medications. Get up slowly from sitting or lying positions as these medications may cause low blood pressure. Short-term side effects may include dry mouth, blurred vision, tremors, nasal congestion, constipation, drowsiness, difficulty walking, and light-headedness. Sensitivity to sun or sun lamps may develop, therefore excessive exposure must be avoided.

LESS COMMON SIDE EFFECTS: An uncommon side effect with Trazodone is priapism which is a spontaneous erection requiring medical intervention.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of depression. Other treatments include actively therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to work within a few days but may take as long as 4-6 weeks for significant changes in mood to occur. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimal amount of medication to relieve your symptoms.

ANTI-PARKINSONIAN:

Cogentin (Benztropin)

Domnamin (Diphenhydramine)

Aricept (Donepezil)

COMMON SIDE EFFECTS: Short-term side effects may include drowsiness, dry mouth, constipation, blurred vision, dizziness, weakness, dizziness, confusion, difficulty urinating, constipation, rapid or pounding heartbeat, eye pain, and rash.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of side effects of anti-psychotic medication. Other treatments include lowering or discontinuation of anti-psychotic medication.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within a few hours. It is generally used for short lengths of time. However, an extended, long-term usage is needed. Your health care practitioner will adjust the dosage from time to time based on your symptoms. Periodic blood tests may be required to monitor the medication in your system. The practitioner will review the medication and its effects every month.

DEPRESSANTS/SEDATIVES:

Valproic acid

Depressants (Diazepam, Valium)

Trandol

COMMON SIDE EFFECTS: The most common side effects are tremor, dizziness, weakness, nausea/vomiting, slurred speech, blurred vision, decreased reflexes, and increased risk of falls.

VALPROIC ACID TOXICITY: The development of extreme unwellness, feeling slurred speech, mental confusion or disorientation on your face requires immediate medical evaluation and intervention.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of bipolar disorder. It will help alleviate the symptoms quicker than other treatments available. Other treatments include cognitive therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within a few days. Long-term usage of this medication may be required to gain maximum benefit. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimum amount of medication to relieve your symptoms. You will need periodic blood/urine/serum levels for as long as you take this medication.

LITHIUM:

Lithium Carbonate

Lithium Citrate

COMMON SIDE EFFECTS: Possible side effects may include tremor, fatigue, nausea, weight gain, increased urination, loose stools, constipation, increased thirst, thyroid disorder, and increased risk of seizure.

SYMPTOMS OF TOXICITY: When there is too much lithium in your system you can experience difficulty walking, nausea/vomiting, slurred speech, severe drowsiness, severe weakness, muscle twitching.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of bipolar disorder. It will help alleviate the symptoms quicker than other treatments available. Other treatments include cognitive therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within a few days. Long-term usage of this medication may be required to gain maximum benefit. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimum amount of medication to relieve your symptoms. You will need periodic blood/urine/serum levels for as long as you take this medication.

WELLBUTRIN:

Wellbutrin

COMMON SIDE EFFECTS: Possible side effects may include tremor, fatigue, nausea, weight gain, increased urination, loose stools, constipation, increased thirst, thyroid disorder, and increased risk of seizure.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of depression. Alternative treatments include cognitive therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: Generally, this medication will start to work in 1-2 weeks with maximum benefit in 4-6 weeks. Long-term use of this medication may be required to gain maximum benefit. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimum amount of medication needed to relieve your symptoms.

RISKS AND HAZARDS: Ongoing use of any of these medications, could alcohol or other drug use. Avoid operation of a motor vehicle or other activities that require alertness until you know how this drug affects you. Serious discontinuation of medications may cause medical problems please discuss discontinuation with the medical staff prior to stopping the medication.

I understand that I can decide to stop taking this medication at any time by telling the practitioner or my other health care staff member. If I decide to stop taking this medication, it will not affect my ability to receive other health care services. I understand that by signing this form I am agreeing to let ARMOR CHS, a contracted agent, treat me with a psychotropic drug. I have been given and have had explained information about this treatment and alternative treatments, the risks and benefits associated with this treatment, the possible side effects that may experience from this treatment, and the approximate length of time that will be taking this medication. I have been given a chance to ask questions about my treatment and have had all my questions answered. I understand that you discuss my questions I signed below about my treatment with the provider and that a copy of this form is available to me upon request.

Patient Signature: *X Felipe Alvarado*

8/22/17 Time: 3:00 P
8/22/17 Time: 3:00 P

Staff Signature: (b)(6), (b)(7)(C)

PATIENT NAME: *Almazan Ruiz, Felipe*

DOB: *6/26/66* SEX: *M* RACE: *61665*

Amazon Ruiz, Felipe

Specific Authorization for Psychotropic Medications

The undersigned, hereby authorizes the professional staff of this facility to administer treatment, limited to mental health medications, as follows:
ANODYLTICS/SEDATIVES/HYPNOTICS:

COMMON SIDE EFFECTS: The most common side effects are drowsiness, confusion, light-headedness, agitation, abnormal speech, difficulty walking, and problems with coordination.

APPROXIMATE LENGTH OF CARE: Generally, this medication will start to work in a few hours. Short-term use of this medication is recommended as dependency may develop. It is important that you take this medication as prescribed to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimum amount of medication needed to relieve your symptoms.

ATYPICAL ANTIPSYCHOTIC DRUGS:

COMMON SIDE EFFECTS: You may feel drowsy when first taking these medications. Get up slowly from sitting or lying positions as these medications may cause low blood pressure. Short-term side effects may include insomnia, weight gain, agitation, headache, upset stomach, muscle stiffness, increased prolactin levels that may lead to an increase in breast tissue and milk production. Sensitivity to sun or sun lamps may develop, therefore sensitive exposure must be avoided.

LESS COMMON SIDE EFFECTS: somnolence, stiffness, shakes, dizziness, constipation, nausea, and increased heart rate. In some people with heart problems or a slow heart beat, Geodon can cause serious and potentially fatal heart rhythm irregularities. Risperdal has been linked to diabetes. Long-term use may also potentially cause an irreversible muscular movement disorder called Tardive Dyskinesia.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of psychosis, bipolar mania, and schizophrenia. It will help alleviate the symptoms quicker than other treatments available. Other treatments include activity therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within a few days. Long-term usage of this medication may be required to gain maximum benefit. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimum amount of medication to relieve your symptoms.

TYPICAL ANTIPSYCHOTIC DRUGS:

COMMON SIDE EFFECTS: You may feel drowsy when first taking these medications. Get up slowly from sitting or lying positions as these medications may cause low blood pressure. Use of sunscreen lotion is required when outside as some people develop photosensitivity when taking these medications. Short-term side effects may include dry mouth, blurred vision, tremors, nasal congestion, constipation, drowsiness, difficulty urinating, muscle spasms, increase in appetite or weight gain, in addition or lack of menstrual periods in women, restlessness, stiffness and light-headedness. Sensitivity to sun or sun lamps may develop, therefore sensitive exposure must be avoided.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of psychosis and schizophrenia. It will help alleviate the symptoms quicker than other treatments available. Other treatments include activity therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within a few days. Long-term usage of this medication may be required to gain maximum benefit. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimum amount of medication to relieve your symptoms.

SEROTONIN ANTIDEPRESSANTS:

COMMON SIDE EFFECTS: Short-term side effects may include dry mouth, tremors, nausea, nervousness, anxiety, diarrhea, headache, drowsiness, insomnia, sedation and sexual dysfunction.

LESS COMMON SIDE EFFECTS: other side effects you may experience are constipation, heartburn, blurred vision, rash, taste changes, dizziness, and hot flashes.

ALTERNATIVE THERAPIES: It has been determined, at this time that this category of medication is effective for treatment of depression. Other treatments include activity therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within 10-14 days but may take as long as 4-6 weeks for significant changes in mood to occur. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimum amount of medication to relieve your symptoms.

TRICYCLIC OR TETRACYCLIC ANTIDEPRESSANTS:

COMMON SIDE EFFECTS: You may feel drowsy when first taking these medications. Get up slowly from sitting or lying positions as these medications may cause low blood pressure. Short-term side effects may include dry mouth, blurred vision, tremors, nasal congestion, constipation, drowsiness, difficulty urinating, and light-headedness. Sensitivity to sun or sun lamps may develop, therefore sensitive exposure must be avoided.

LESS COMMON SIDE EFFECTS: An uncommon side effect with Trazadone is priapism which is a spontaneous erection requiring medical intervention.

ALTERNATIVE THERAPIES: It has been determined, at this time, that this category of medication is effective for treatment of depression. Other treatments include activity therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within a few days but may take as long as 4-6 weeks for significant changes in mood to occur. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimum amount of medication to relieve your symptoms.

ANTI-PARASITIC:

Corgenta (Benzimidazole)

Dronedra (Dithiazolopyridine)

Arlene (Chlorocephalidol)

COMMON SIDE EFFECTS: Short-term side effects may include dizziness, dry mouth, nausea, constipation, blurred vision, dizziness, weakness, depression, confusion, difficulty urinating, constipation, rapid or pounding heartbeat, eye pain, and pain.

ALTERNATIVE THERAPIES: It has been determined, at this time that the category of medication is effective for treatment of skin effects of anti-psychotic medications. Other treatments include lowering or discontinuation of anti-psychotic medication.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within a few hours. It is generally used for short lengths of time. However, an extended, long-term usage is needed. Your health care practitioner will adjust the dosage based on your symptoms. Periodic blood tests may be ordered to ensure that the medication is safe. The practitioner will review the medication and its effects every month.

DEPRESSIVE/ANTIDEPRESSANT:

Valproic acid

Deprolin Solution (Deprolin, Deprolin)

Traxadol

COMMON SIDE EFFECTS: The most common side effects are tremor, dizziness, nausea, unsteadiness, slurred speech, loss of appetite, weight gain, abdominal pain and headache.

VALPROIC ACID TOXICITY: The development of extreme tiredness, lightheadedness, mental confusion or unsteadiness on your feet requires immediate medical evaluation and intervention.

ALTERNATIVE THERAPIES: It has been determined, at this time that the category of medication is effective for treatment of bipolar disorder. It will help alleviate the symptoms quicker than other treatments available. Other treatments include cognitive therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within a few days. Long-term usage of this medication may be required to gain maximum benefit. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimum amount of medication to relieve your symptoms. You will need periodic blood testing levels for as long as you take this medication.

LITHIUM: Lithium Carbonate

Lithium Citrate

COMMON SIDE EFFECTS: Possible side effects may include, fatigue, nausea, weight gain, increased thirst, loose stools, constipation, increased blood, thyroid disorder, and increased risk of seizure.

SYMPTOMS OF TOXICITY: When there is too much lithium in your system you can experience difficulty walking, severe dizziness, slurred speech, nausea, drowsiness, severe vomiting, muscle twitches.

ALTERNATIVE THERAPIES: It has been determined, at this time that the category of medication is effective for treatment of bipolar disorder. It will help alleviate the symptoms quicker than other treatments available. Other treatments include cognitive therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: This medication usually starts to act within a few days. Long-term usage of this medication may be required to gain maximum benefit. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimum amount of medication to relieve your symptoms. You will need periodic blood testing levels for as long as you take this medication.

WELLBUTRIN: Wellbutrin

COMMON SIDE EFFECTS: Possible side effects may include, fatigue, nausea, weight gain, increased thirst, loose stools, constipation, increased blood, thyroid disorder, and increased risk of seizure.

ALTERNATIVE THERAPIES: It has been determined, at this time that the category of medication is effective for treatment of depression. Alternative treatments include cognitive therapy and talk therapy such as counseling or behavior modification programs.

APPROXIMATE LENGTH OF CARE: Generally, this medication will start to work in 1-2 weeks with maximum benefit in 4-8 weeks. Long-term use of this medication may be required to gain maximum benefit. It is important that you take this medication regularly to get the full benefit of this treatment. Your health care practitioner will monitor you on a regular basis (usually once a month) and may adjust your medication dosage from time to time as your condition warrants. The goal of treatment is to use the minimum amount of medication needed to relieve your symptoms.

RISKS AND HAZARDS: During use of any of these medications, avoid alcohol or other drug use. Avoid operation of a motor vehicle or other activities that require alertness until you know how this drug affects you. Serious deterioration of medication may cause medical problems please discuss deterioration with the medical staff prior to stopping the medication.

I understand that you can decide to stop taking this medication at any time by telling the pharmacist or my other health care staff member. If I decide to stop taking this medication, it will not affect my ability to receive other health care services. I understand that by signing this form I am agreeing to let ARMOR CCLC, a contracted agent, deal with a psychiatric drug. I have been given and have had explained information about this treatment and alternative treatments, the risk and benefits associated with this treatment, the possible side effects that may experience from this treatment, and the approximate length of time that will be taking this medication. I have been given a chance to ask questions about my treatment and have had all my questions answered. I understand that you discuss my questions I might have about my treatment with the provider and that a copy of this form is available to me upon request.

Patient Signature: X Felipe Alvarez Date: 4/22/17 Time: 3:40 P
Staff Signature: [Redacted] Date: 4/24/17 Time: 3:00 P

PATIENT NAME: Alvarez Felipe DATE: 4/26/16 TIME: M SIGNATURE: G. Adams